

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau

(43) International Publication Date

01 October 2020 (01.10.2020)



(10) International Publication Number

WO 2020/198026 A1

(51) International Patent Classification:

C07D 261/18 (2006.01) C07D 413/10 (2006.01)

C07D 413/04 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2020/023913

(22) International Filing Date:

20 March 2020 (20.03.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/822,486 22 March 2019 (22.03.2019) US

62/934,930 13 November 2019 (13.11.2019) US

(71) Applicant: YUMANITY THERAPEUTICS, INC.

[US/US]; 790 Memorial Drive, Suite 2c, Cambridge, MA 02139 (US).

(72) Inventors: LE BOURDONNEC, Bertrand; 2 Mohi-

can Avenue, Northborough, MA 01532 (US). LUCAS,

Matthew; 48 Parker Street, Lexington, MA 02421 (US).

OZBOYA, Kerem; 11 Ellery Street Apt #1, Cambridge,

MA 02138 (US). PANDYA, Bhaumik; 325 Springs Road,

Bedford, MA 01730 (US). TARDIFF, Daniel; 48 Newland

Road, Arlington, MA 02474 (US). TIVITMAHAISOON,

Parcharee; 580 Commonwealth Ave #606, Boston, MA

02215 (US). WRONA, Iwona; 17 Harding Street, Sharon,

MA 02067 (US).

(74) Agent: BELLIVEAU, Michael, J.; CLARK & ELBING

LLP, 101 Federal Street 15th Floor, Boston, MA 02110

(US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,

HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,

KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,

MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,

OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,

TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: COMPOUNDS AND USES THEREOF

(57) Abstract: The present invention features compounds useful in the treatment of neurological disorders and primary brain cancer. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders and primary brain cancer.



WO 2020/198026 A1

COMPOUNDS AND USES THEREOF

Background

An incomplete understanding of the molecular perturbations that cause disease, as well as a limited arsenal of robust model systems, has contributed to a failure to generate successful disease-modifying therapies against common and progressive neurological disorders, such as Parkinson's Disease (PD) and Alzheimer's Disease (AD). Progress is being made on many fronts to find agents that can arrest the progress of these disorders. However, the present therapies for most, if not all, of these diseases provide very little relief. In particular, a need exists for better methods and compositions for the treatment of neurodegenerative diseases in order to improve the quality of the lives of those afflicted by such diseases.


Further, cancers of the brain and nervous system are among the most difficult to treat. Prognosis for patients with these cancers depends on the type and location of the tumor as well as its stage of development. For many types of brain cancer, average life expectancy after symptom onset may be months or a year or two. Treatment consists primarily of surgical removal and radiation therapy. Chemotherapy is also used, but the range of suitable chemotherapeutic agents is limited. Using known chemotherapeutics along with surgery and radiation rarely extends survival much beyond that produced by surgery and radiation alone.

Accordingly, a need exists to develop therapies that can alter the course of diseases of the brain including primary brain cancer and neurodegenerative diseases.

Summary of the Invention

The invention features compounds that modulate the activity of SCDs (e.g., SCD1 and/or SCD5), pharmaceutical compositions including such compounds, and methods of utilizing such compounds and compositions for modulating the activity of SCDs for the treatment of primary brain cancer and diseases and disorders related to toxicity caused by proteins such as toxicity related to misfolding and/or aggregation of proteins (e.g., a neurological disorder such as PD or AD).

In an aspect, this disclosure features a compound having the structure of **Formula I**:






Formula I,

where

R¹ is optionally substituted C₁-C₆ alkyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heteroaryl, or optionally substituted C₂-C₉ heterocyclyl;

L¹ is optionally substituted C₁-C₆ alkylene, optionally substituted C₁-C₆ heteroalkylene, optionally substituted C₂-C₆ alkenylene, optionally substituted C₂-C₆ alkynylene, optionally substituted C₃-C₆

carbocyclylene, , , , , or .

R^a is H or optionally substituted C_1 - C_6 alkyl;


L^3 is optionally substituted C_2 - C_9 heterocyclylene;

each of X^1 , X^2 , X^3 , and X^4 is, independently, N or CH;

L^2 is optionally substituted C_1 - C_6 alkylene or optionally substituted C_1 - C_6 heteroalkylene; and

- 5 R^2 is optionally substituted C_1 - C_6 heteroalkyl, optionally substituted C_3 - C_{10} carbocyclyl, optionally substituted C_2 - C_9 heterocyclyl, optionally substituted C_6 - C_{10} aryl, or optionally substituted C_2 - C_9 heteroaryl, or a pharmaceutically acceptable salt thereof.





In some embodiments, L^1 is optionally substituted C_1 - C_6 alkylene, optionally substituted C_1 - C_6 heteroalkylene, optionally substituted C_2 - C_6 alkenylene, optionally substituted C_2 - C_6 alkynylene, optionally


- 10 substituted C_3 - C_6 carbocyclylene, , , or .


In some embodiments, L^1 is optionally substituted C_1 - C_6 alkylene, optionally substituted C_2 - C_6 alkenylene, or optionally substituted C_2 - C_6 alkynylene.

- In some embodiments, L^1 is , , , , , , or . In some embodiments, L^1 is , , , , or . In some embodiments, L^1 is .
- 15

In some embodiments, L^1 is optionally substituted C_3 - C_6 carbocyclylene.


- In some embodiments, L^1 is , , , , , , , or . In some embodiments, L^1 is  or .

- In some embodiments, L^1 is . In some embodiments, L^1 is . In some
- 20 embodiments, L^1 is .

In some embodiments, L^1 is  or . In some embodiments, L^1 is .

In some embodiments, L^1 is optionally substituted C_1 - C_6 heteroalkylene.

In some embodiments, L¹ is




In some embodiments,

5 L¹ is or In some

embodiments, L¹ is or .

In some embodiments, L² is optionally substituted C₁-C₆ heteroalkyl.



10 In some embodiments, L² is or In some

embodiments, L² is or .

In some embodiments, R⁵ is H or CH₃. In some embodiments, R⁵ is H.

In some embodiments, X¹ is N. In some embodiments, X¹ is CH.


In some embodiments, X² is N. In some embodiments, X² is CH.

15 In some embodiments, X³ is N. In some embodiments, X³ is CH.

In some embodiments, X⁴ is N. In some embodiments, X⁴ is CH.

In some embodiments, at most two of X¹, X², X³, and X⁴ are N.


In some embodiments, the compound has the structure of **Formula Ia**:



Formula Ia,

or a pharmaceutically acceptable salt thereof.


5 In some embodiments, the compound has the structure of **Formula Ib**:



Formula Ib,

or a pharmaceutically acceptable salt thereof.


In some embodiments, the compound has the structure of **Formula Ic**:



Formula Ic,

or a pharmaceutically acceptable salt thereof.


In some embodiments, the compound has the structure of **Formula Id**:



Formula Id,

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound has the structure of **Formula Ie**:



Formula Ie,

or a pharmaceutically acceptable salt thereof.


In some embodiments, R^2 is optionally substituted C_3 - C_{10} carbocyclyl, optionally substituted C_2 - C_9 heterocyclyl, optionally substituted C_6 - C_{10} aryl, or optionally substituted C_2 - C_9 heteroaryl.

In some embodiments, R^2 is optionally substituted C_2 - C_9 heterocyclyl, optionally substituted C_6 - C_{10} aryl, or optionally substituted C_2 - C_9 heteroaryl.

In some embodiments, R^2 is optionally substituted C_2 - C_9 heterocyclyl or optionally substituted C_2 - C_9 heteroaryl.

In some embodiments, R^2 is optionally substituted C_2 - C_9 heterocyclyl.

In some embodiments, R^2 is optionally substituted C_2 - C_5 heterocyclyl.




where b_1 is 0, 1, 2, 3, or 4;

b_2 is 0, 1, or 2;

5 R^{6a} is H, optionally substituted C_1 - C_6 alkyl, or optionally substituted C_3 - C_6 carbocyclyl;


R^{6b} is H, optionally substituted C_1 - C_6 alkyl, or optionally substituted C_3 - C_6 carbocyclyl;

each R^7 is, independently, halo or optionally substituted C_1 - C_6 alkyl; and




In some embodiments, R^{6a} is H or optionally substituted C_1 - C_6 alkyl.

10



In some embodiments, R^{6b} is H or optionally substituted C_1 - C_6 alkyl.



In some embodiments, R^{6b} is H or



.

In some embodiments, R^8 is

.



In some embodiments, each R^7 is, independently, F, Cl, Br, I,



,









In some embodiments, b1 is 0 or 1. In some embodiments, b1 is 0. In some embodiments, b1 is 1.


In some embodiments, b2 is 0 or 1. In some embodiments, b2 is 0. In some embodiments, b2 is 1.




5 In some embodiments, R² is . In some embodiments, R² is . In


some embodiments, , . In some embodiments, R² is



10 In some embodiments, R² is . In some embodiments, R² is , , or . In some embodiments, R² is . In some

embodiments, R² is .

In some embodiments, R² is , , ,



where

15 q1 is 0, 1, 2, 3, 4, 5, or 6;




q2 is 0, 1, 2, 3, or 4;


q3 is 0, 1, or 2;

each R²¹ is, independently, hydroxyl, optionally substituted C₁-C₆ alkyl, or optionally substituted C₁-C₆ heteroalkyl; or two of the R²¹ groups, taken together with the carbon atom to which each is


attached, combine to form an optionally substituted C₃-C₁₀ carbocyclyl or optionally substituted C₂-C₉ heterocyclyl; and

R²² is H or optionally substituted C₁-C₆ alkyl.

In some embodiments, each R²¹ is, independently, , , or .




5 In some embodiments, R²² is H or .

In some embodiments, R² is



In some embodiments, R² is optionally substituted C₂-C₉ heteroaryl.

In some embodiments, R² is optionally substituted C₂-C₅ heteroaryl.


10 In some embodiments, R² is , , or , where


c is 0, 1, 2, 3, or 4; and

each R⁹ is, independently, halo, CN, NO₂, optionally substituted C₁-C₆ alkyl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₂-C₆ heteroalkenyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, SH, OH, or NH₂.

In some embodiments, each R⁹ is, independently, halo, CN, optionally substituted C₁-C₆ alkyl, optionally substituted C₂-C₆ alkene, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₂-C₆ heteroalkenyl, optionally substituted C₃-C₁₀ carbocyclyl, OH, or NH₂.


20 In some embodiments, each R⁹ is, independently, F, Cl, Br, I, CN, , ,






In some embodiments, c is 0, 1, or 2. In some embodiments, c is 0. In some embodiments, c is 1. In some embodiments, c is 2.

5 In some embodiments, R² is , , or . In some embodiments,



In some embodiments, R^2 is




where


d is 0, 1, 2, or 3; and


each R^{10} is, independently, halo, CN, NO_2 , optionally substituted C_1 - C_6 alkyl, optionally substituted C_2 - C_6 alkenyl, optionally substituted C_1 - C_6 heteroalkyl, optionally substituted C_2 - C_6 heteroalkenyl, optionally substituted C_3 - C_{10} carbocyclyl, optionally substituted C_2 - C_9 heterocyclyl, optionally substituted C_6 - C_{10} aryl, optionally substituted C_2 - C_9 heteroaryl, SH, OH, or NH_2 .

- 5 In some embodiments, each R^{10} is, independently, halo, CN, optionally substituted C_1 - C_6 alkyl, optionally substituted C_2 - C_6 alkene, optionally substituted C_1 - C_6 heteroalkyl, optionally substituted C_2 - C_6 heteroalkenyl, optionally substituted C_3 - C_{10} carbocyclyl, OH, or NH_2 .




In some embodiments, d is 0, 1, or 2. In some embodiments, d is 0. In some embodiments, d is 1. In some embodiments, d is 2.





5



where

 e is 0, 1, or 2;

each R^{11} is, independently, halo, CN, NO₂, optionally substituted C₁-C₆ alkyl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₂-C₆ heteroalkenyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, SH, OH, or NH₂.


W is CH or N;

Y is O, S, or NR^{Y1};

R^{Y1} is H, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, or optionally substituted C₂-C₉ heterocyclyl;




Z is O, S, or NR^{Z1}; and R^{Z1} is H or optionally substituted C₁-C₆ alkyl.

In some embodiments, each R^{11} is, independently, halo, CN, optionally substituted C₁-C₆ alkyl, optionally substituted C₂-C₆ alkene, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₂-C₆ heteroalkenyl, optionally substituted C₃-C₁₀ carbocyclyl, OH, or NH₂.








- 5 In some embodiments, W is CH. In some embodiments, W is N.
In some embodiments, Y is NR^{Y1} .
In some embodiments, R^{Y1} is H, optionally substituted C_1 - C_6 alkyl, or optionally substituted C_3 - C_{10} carbocyclyl.

In some embodiments, R^{Y1} is H. In some embodiments, R^{Y1} is optionally substituted C_1 - C_6 alkyl.

- 10 In some embodiments, R^{Y1} is , , , or .
- In some embodiments, R^{Y1} is optionally substituted C_3 - C_{10} carbocyclyl.
In some embodiments, R^{Y1} is optionally substituted C_3 - C_6 carbocyclyl.


In some embodiments, R^{Y1} is  or .

In some embodiments, Z is O.


- 15 In some embodiments, R^2 is , , , ,
- or .

In some embodiments, e is 0 or 1. In some embodiments, e is 0. In some embodiments, e is 1.


In some embodiments, R^2 is




In some embodiments, R^2 is




In some embodiments, R^2 is



In some embodiments, R^2



In some embodiments, R^2 is



where

R^{12a} is H, halo, CN, NO₂, optionally substituted C₁-C₆ alkyl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₂-C₆ heteroalkenyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, SH, OH, or NH₂;

each of Y^a and Y^b is, independently, O, S, or NR^{Y2};


R^{Y2} is H, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, or optionally substituted C₂-C₉ heterocyclyl;

Z^a is O, S, or NR^{Z2}; and

R^{Z2} is H or optionally substituted C₁-C₆ alkyl.

In some embodiments, R^{12a} is H.


In some embodiments, Z^a is O.




In some embodiments, R^2 is

In some embodiments, each of Y^a and Y^b is NR^{Y2} .


In some embodiments, R^{Y2} is H, optionally substituted C_1 - C_6 alkyl, or optionally substituted C_3 - C_{10} carbocyclyl.



In some embodiments, R^{Y2} is H,



In some embodiments, R^2 is



where

R^{12b} is H, halo, CN, NO_2 , optionally substituted C_1 - C_6 alkyl, optionally substituted C_2 - C_6 alkenyl, optionally substituted C_1 - C_6 heteroalkyl, optionally substituted C_2 - C_6 heteroalkenyl, optionally substituted C_3 - C_{10} carbocyclyl, optionally substituted C_2 - C_9 heterocyclyl, optionally substituted C_6 - C_{10} aryl, optionally substituted C_2 - C_9 heteroaryl, SH, OH, or NH_2 ; and


Y^c is O, S, or NR^{Y3} ;

R^{Y3} is H, optionally substituted C_1 - C_6 alkyl, optionally substituted C_1 - C_6 heteroalkyl, optionally substituted C_3 - C_{10} carbocyclyl, or optionally substituted C_2 - C_9 heterocyclyl.

In some embodiments, R^{12b} is H.


In some embodiments, Y^c is NR^{Y3} .

In some embodiments, R^{Y3} is H, optionally substituted C_1 - C_6 alkyl, or optionally substituted C_3 - C_{10} carbocyclyl.



In some embodiments, R^{Y3} is H,

In some embodiments, R^2 is



where

f is 0, 1, or 2;

- 5 each R^{13} is, independently, halo, CN, NO_2 , optionally substituted $\text{C}_1\text{-C}_6$ alkyl, optionally substituted $\text{C}_2\text{-C}_6$ alkenyl, optionally substituted $\text{C}_1\text{-C}_6$ heteroalkyl, optionally substituted $\text{C}_2\text{-C}_6$ heteroalkenyl, optionally substituted $\text{C}_3\text{-C}_{10}$ carbocyclyl, optionally substituted $\text{C}_2\text{-C}_9$ heterocyclyl, optionally substituted $\text{C}_6\text{-C}_{10}$ aryl, optionally substituted $\text{C}_2\text{-C}_9$ heteroaryl, SH, OH, or NH_2 ; and Y^d is O, S, or $\text{NR}^{\text{Y}4}$;

- 10 $\text{R}^{\text{Y}4}$ is H, optionally substituted $\text{C}_1\text{-C}_6$ alkyl, optionally substituted $\text{C}_1\text{-C}_6$ heteroalkyl, optionally substituted $\text{C}_3\text{-C}_{10}$ carbocyclyl, or optionally substituted $\text{C}_2\text{-C}_9$ heterocyclyl.


In some embodiments, each R^{13} is, independently, halo, CN, optionally substituted $\text{C}_1\text{-C}_6$ alkyl, optionally substituted $\text{C}_2\text{-C}_6$ alkene, optionally substituted $\text{C}_1\text{-C}_6$ heteroalkyl, optionally substituted $\text{C}_2\text{-C}_6$ heteroalkenyl, optionally substituted $\text{C}_3\text{-C}_{10}$ carbocyclyl, OH, or NH_2 .

- 15 In some embodiments, each R^{13} is, independently, halo, CN, or optionally substituted $\text{C}_1\text{-C}_6$ alkyl. In some embodiments, f is 0 or 1. In some embodiments, f is 0. In some embodiments, f is 1. In some embodiments, Y^d is $\text{NR}^{\text{Y}4}$.

In some embodiments, $\text{R}^{\text{Y}4}$ is H, optionally substituted $\text{C}_1\text{-C}_6$ alkyl, or optionally substituted $\text{C}_3\text{-C}_{10}$ carbocyclyl.

- 20 In some embodiments, $\text{R}^{\text{Y}4}$ is H, CH_3 , CH_2CH_3 , $\text{CH}_2\text{CH}_2\text{CH}_3$, $\text{CH}_2\text{CH}(\text{CH}_3)\text{CH}_3$, Cyclopropyl , CF_3 , or CH_2F .

In some embodiments, Y^d is O.



In some embodiments, R^2 is

where

- 25 g is 0, 1, 2, 3, or 4; each R^{14} is, independently, halo, CN, NO_2 , optionally substituted $\text{C}_1\text{-C}_6$ alkyl, optionally substituted $\text{C}_2\text{-C}_6$ alkenyl, optionally substituted $\text{C}_1\text{-C}_6$ heteroalkyl, optionally substituted $\text{C}_2\text{-C}_6$ heteroalkenyl, optionally substituted $\text{C}_3\text{-C}_{10}$ carbocyclyl, optionally substituted $\text{C}_2\text{-C}_9$ heterocyclyl, optionally substituted $\text{C}_6\text{-C}_{10}$ aryl, optionally substituted $\text{C}_2\text{-C}_9$ heteroaryl, SH, OH, or NH_2 ;

- 30 Y^e is O, S, or $\text{NR}^{\text{Y}5}$; and

R^{Y5} is H, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, or optionally substituted C₂-C₉ heterocyclyl.

In some embodiments, R¹⁴ is halo, CN, optionally substituted C₁-C₆ alkyl, optionally substituted C₂-C₆ alkene, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₂-C₆ heteroalkenyl, optionally substituted C₃-C₁₀ carbocyclyl, OH, or NH₂.

In some embodiments, R¹⁴ is halo, CN, or optionally substituted C₁-C₆ alkyl.

In some embodiments, g is 0, 1, or 2. In some embodiments, g is 0. In some embodiments, g is 1. In some embodiments, g is 2.

In some embodiments, Y^e is NR^{Y5} .

10 In some embodiments, R^{Y5} is H, optionally substituted C₁-C₆ alkyl, or optionally substituted C₃-C₁₀ carbocyclyl.


In some embodiments, R^{Y5} is , , , , , , or .

In some embodiments, Y^e is O. In some embodiments, Y^e is S.

15 In some embodiments, R² is



In some embodiments, R² is



The image shows five chemical structures representing different embodiments of R². Each structure is a pyridine ring with a wavy line at the 3-position and a substituent at the 2-position. The substituents are: 1) a 1,3-dihydro-2H-imidazol-2-ylidene group with substituents X^a, X^b, X^c, and X^d; 2) a 1,3-dihydro-2H-imidazol-2-ylidene group with substituents X^b, X^c, and X^d; 3) a 1,3-dihydro-2H-imidazol-2-ylidene group with substituents X^b, X^c, and X^d; 4) a 1,3-dihydro-2H-imidazol-2-ylidene group with substituents X^b, X^c, and X^d; 5) a 1,3-dihydro-2H-imidazol-2-ylidene group with substituents X^b, X^c, and X^d.

, or

where

20 each of X^a , X^b , X^c , and X^d is, independently, N or CR¹⁷;


each R¹⁷ is, independently, halo, CN, NO₂, optionally substituted C₁-C₆ alkyl, optionally substituted C₂-C₆ alkene, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₂-C₆ heteroalkenyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, SH, OH, or NH₂;


25 i is 0, 1, 2, or 3; and

each R^{15} is, independently, halo, CN, NO_2 , optionally substituted C_1 - C_6 alkyl, optionally substituted C_2 - C_6 alkene, optionally substituted C_1 - C_6 heteroalkyl, optionally substituted C_2 - C_6 heteroalkenyl, optionally substituted C_3 - C_{10} carbocyclyl, optionally substituted C_2 - C_9 heterocyclyl, optionally substituted C_6 - C_{10} aryl, optionally substituted C_2 - C_9 heteroaryl, SH, OH, or NH_2 .

5 In some embodiments, each R^{15} is, independently, halo, CN, optionally substituted C_1 - C_6 alkyl, optionally substituted C_2 - C_6 alkene, optionally substituted C_1 - C_6 heteroalkyl, SH, OH, or NH_2 .

In some embodiments, i is 0 or 1. In some embodiments, i is 0. In some embodiments, i is 1.

In some embodiments, R^2 is  , or

In some embodiments, R^2 is  , or

10 where

X^e is N or CR^{18} ;

R^{18} is, independently, halo, CN, NO_2 , optionally substituted C_1 - C_6 alkyl, optionally substituted C_2 - C_6 alkene, optionally substituted C_1 - C_6 heteroalkyl, optionally substituted C_2 - C_6 heteroalkenyl, optionally substituted C_3 - C_{10} carbocyclyl, optionally substituted C_2 - C_9 heterocyclyl, optionally substituted

15 C_6 - C_{10} aryl, optionally substituted C_2 - C_9 heteroaryl, SH, OH, or NH_2 ;

j is 0, 1, or 2;

each R^{16} is, independently, halo, CN, NO_2 , optionally substituted C_1 - C_6 alkyl, optionally substituted C_2 - C_6 alkene, optionally substituted C_1 - C_6 heteroalkyl, optionally substituted C_2 - C_6 heteroalkenyl, optionally substituted C_3 - C_{10} carbocyclyl, optionally substituted C_2 - C_9 heterocyclyl, optionally substituted C_6 - C_{10} aryl, optionally substituted C_2 - C_9 heteroaryl, SH, OH, or NH_2 ;

20 optionally substituted C_2 - C_9 heteroaryl, SH, OH, or NH_2 ;

each of Y^f and Y^g is, independently, O, S, or NR^{Y6} ;

R^{Y6} is H, optionally substituted C_1 - C_6 alkyl, optionally substituted C_1 - C_6 heteroalkyl, optionally substituted C_3 - C_{10} carbocyclyl, or optionally substituted C_2 - C_9 heterocyclyl;


Z^b is O, S, or NR^{Z3} ; and



25 R^{Z3} is H or optionally substituted C_1 - C_6 alkyl.

In some embodiments, each R^{16} is, independently, halo, CN, optionally substituted C_1 - C_6 alkyl, optionally substituted C_2 - C_6 alkene, optionally substituted C_1 - C_6 heteroalkyl, SH, OH, or NH_2 .

In some embodiments, j is 0 or 1. In some embodiments, j is 0. In some embodiments, j is 1.

In some embodiments, Z is O.

30 In some embodiments, R^2 is .





where

o_1 is 0, 1, 2, or 3;


o_2 is 0, 1, or 2;

each R^{23} is, independently, halo, CN, NO₂, optionally substituted C₁-C₆ alkyl, optionally substituted C₂-C₆ alkene, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₂-C₆ heteroalkenyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, SH, OH, or NH₂; and

R^{24} is H or optionally substituted C₁-C₆ alkyl.



In some embodiments, R^2 is optionally substituted C₆-C₁₀ aryl.



In some embodiments, R^2 is

where

r is 0, 1, 2, 3, or 4; and


each R^{24} is, independently, halo, CN, NO₂, optionally substituted C₁-C₆ alkyl, optionally substituted C₂-C₆ alkene, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₂-C₆ heteroalkenyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, optionally substituted sulfone, SH, OH, or NH₂.

In some embodiments, each R^{24} is, independently, halo, CN, NO₂, optionally substituted C₁-C₆ alkyl, optionally substituted C₂-C₆ alkene, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₂-C₆ heteroalkenyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, SH, OH, or NH₂.

In some embodiments, each R^{24} is, independently, halo, CN, NO₂, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, SH, OH, or NH₂.

In some embodiments, r is 0, 1, or 2. In some embodiments, r is 0. In some embodiments, r is 1. In some embodiments, r is 2.


In some embodiments, R^2 is optionally substituted C_1 - C_6 heteroalkyl.



In some embodiments, R^2 is , where R^{25} is optionally substituted C_1 - C_6 alkyl or optionally substituted C_1 - C_6 heteroalkyl.


In some embodiments, R^{25} is F_3C -.

In some embodiments, R^1 is optionally substituted C_1 - C_6 alkyl.



In some embodiments, R^1 is .

In some embodiments, R^1 is optionally substituted C_6 - C_{10} aryl.





In some embodiments, R^1 is , where

each of R^{3a} , R^{3b} , R^{3c} , R^{3d} , and R^{3e} is, independently, H, halo, CN, NO_2 , optionally substituted C_1 - C_6 alkyl, optionally substituted C_2 - C_6 alkene, optionally substituted C_1 - C_6 heteroalkyl, optionally substituted C_2 - C_6 heteroalkenyl, optionally substituted C_3 - C_{10} carbocyclyl, optionally substituted C_2 - C_9 heterocyclyl, optionally substituted C_6 - C_{10} aryl, optionally substituted C_2 - C_9 heteroaryl, SH, OH, or NH_2 ; or R^{3a} and R^{3b} , R^{3b} and R^{3c} , R^{3c} and R^{3d} , or R^{3d} and R^{3e} , together with the atoms to which each is attached, combine to form optionally substituted C_3 - C_{10} carbocyclyl or optionally substituted C_2 - C_9 heterocyclyl.

In some embodiments, each of R^{3a} , R^{3b} , R^{3c} , R^{3d} , and R^{3e} is, independently, H, halo, CN, NO_2 , optionally substituted C_1 - C_6 alkyl, optionally substituted C_1 - C_6 heteroalkyl, SH, OH, or NH_2 .

In some embodiments, each of R^{3a} , R^{3b} , R^{3c} , R^{3d} , and R^{3e} is, independently, H, F, Cl, Br, I, CN,






- 5 In some embodiments, R¹ is phenyl, 3-fluoro-phenyl, 4-fluoro-phenyl, 3-chloro-phenyl, 4-chloro-phenyl, 2-methoxy-phenyl, 3-methoxy-phenyl, 4-methoxy-phenyl, 3,4-di-fluoro-phenyl, 3,4-dichloro-phenyl, 3,5-di-fluoro-phenyl, 3,5-dichloro-phenyl, 3-chloro-4-fluoro-phenyl, 4-chloro-3-fluoro-phenyl, 3-chloro-4-nitrile-phenyl, 3-nitrile-4-fluoro-phenyl, 3-trifluoromethyl-phenyl, 4-trifluoromethyl-phenyl, 3-bromo-phenyl, 3-cyclopropyl-phenyl, 3-cyano-5-fluoro-phenyl,
- 10 3-chloro-5-fluoro-phenyl, 3-chloro-5-cyano-phenyl, 3-chloro-5-methoxy-phenyl, or 1,3-dihydroisobenzofuran.

In some embodiments, R¹ is optionally substituted C₃-C₁₀ carbocyclyl.

In some embodiments, R¹ is optionally substituted C₃-C₁₀ cycloalkyl.



15 where

n₁ is 0, 1, 2, or 3;

n₂ is 0, 1, 2, 3, or 4;


n₃ is 0, 1, 2, 3, 4, or 5;

n₄ is 0, 1, 2, 3, 4, 5, or 6; and


- 20 each R⁴ is, independently, halo, CN, NO₂, optionally substituted C₁-C₆ alkyl, optionally substituted C₂-C₆ alkene, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₂-C₆ heteroalkenyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, SH, OH, or NH₂.



In some embodiments, each R^4 is, independently, halo, CN, optionally substituted C_1 - C_6 alkyl, optionally substituted C_2 - C_6 alkene, optionally substituted C_1 - C_6 heteroalkyl, SH, OH, or NH_2 .



In some embodiments, R^1 is optionally substituted cycloalkenyl.



where



n_5 is 0, 1, 2, 3, or 4;

n_6 is 0, 1, 2, 3, 4, or 5; and

each R^4 is, independently, halo, CN, NO_2 , optionally substituted C_1 - C_6 alkyl, optionally substituted C_2 - C_6 alkene, optionally substituted C_1 - C_6 heteroalkyl, optionally substituted C_2 - C_6 heteroalkenyl, optionally substituted C_3 - C_{10} carbocyclyl, optionally substituted C_2 - C_9 heterocyclyl, optionally substituted C_6 - C_{10} aryl, optionally substituted C_2 - C_9 heteroaryl, SH, OH, or NH_2 .



In some embodiments, each R^4 is, independently, halo, CN, optionally substituted C_1 - C_6 alkyl, optionally substituted C_2 - C_6 alkene, optionally substituted C_1 - C_6 heteroalkyl, SH, OH, or NH_2 .



In some embodiments, R^1 is optionally substituted C_2 - C_6 heteroaryl.



where k is 0, 1, 2, or 3;

each R^{19} is, independently, halo, CN, NO_2 , optionally substituted C_1 - C_6 alkyl, optionally substituted C_2 - C_6 alkene, optionally substituted C_1 - C_6 heteroalkyl, optionally substituted C_2 - C_6 heteroalkenyl, optionally substituted C_3 - C_{10} carbocyclyl, optionally substituted C_2 - C_9 heterocyclyl, optionally substituted C_6 - C_{10} aryl, optionally substituted C_2 - C_9 heteroaryl, SH, OH, or NH_2 ;

5 Y^h is O, S, or NR^{Y7} ; and




R^{Y7} is H, optionally substituted C_1 - C_6 alkyl, optionally substituted C_1 - C_6 heteroalkyl, optionally substituted C_3 - C_{10} carbocyclyl, or optionally substituted C_2 - C_9 heterocyclyl.

In some embodiments, each R^{19} is, independently, halo, CN, optionally substituted C_1 - C_6 alkyl, optionally substituted C_2 - C_6 alkene, optionally substituted C_1 - C_6 heteroalkyl, SH, OH, or NH_2 .

10 In some embodiments, each R^{19} is, independently, F, Cl, Br, I, CN, or .

In some embodiments, Y^h is S.

In some embodiments, k is 0 or 1. In some embodiments, k is 0. In some embodiments, k is 1.

In some embodiments, R^1 is , , or ,


where p is 0, 1, 2, 3, or 4; and

15 each R^{20} is, independently, halo, CN, NO_2 , optionally substituted C_1 - C_6 alkyl, optionally substituted C_2 - C_6 alkene, optionally substituted C_1 - C_6 heteroalkyl, optionally substituted C_2 - C_6 heteroalkenyl, optionally substituted C_3 - C_{10} carbocyclyl, optionally substituted C_2 - C_9 heterocyclyl, optionally substituted C_6 - C_{10} aryl, optionally substituted C_2 - C_9 heteroaryl, SH, OH, or NH_2 .

In some embodiments, each R^{20} is, independently, halo, CN, optionally substituted C_1 - C_6 alkyl, 20 optionally substituted C_2 - C_6 alkene, optionally substituted C_1 - C_6 heteroalkyl, SH, OH, or NH_2 .

In some embodiments, each R^{20} is, independently, F, Cl, Br, I, CN, or .


In some embodiments, p is 0 or 1. In some embodiments, p is 0. In some embodiments, p is 1.

In some embodiments, R^1 is .

In some embodiments, R^1 is 5-chloropyridin-3-yl, 5-trifluoromethyl-pyridin-3-yl,

25 4-trifluoromethyl-pyridin-2-yl, 5-fluoropyridin-3-yl, or 5-fluoropyridin-3-yl.

In an aspect, the disclosure features a compound having the structure of **Formula II**:




Formula II,

where

30 R^1 is optionally substituted C_6 - C_{10} aryl, optionally substituted C_3 - C_{10} carbocyclyl, optionally substituted C_2 - C_9 heteroaryl, or optionally substituted C_2 - C_9 heterocyclyl;

L¹ is optionally substituted C₁-C₆ alkylene, optionally substituted C₁-C₆ heteroalkylene, optionally substituted C₂-C₆ alkenylene, optionally substituted C₂-C₆ alkynylene, optionally substituted C₃-C₆



R^a is H or optionally substituted C₁-C₆ alkyl;

5 L³ is optionally substituted C₂-C₉ heterocyclylene;

each of X⁵ and X⁶ is, independently, N or CH;


X⁷ is O, S, or NR^b;

R^b is H, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, or optionally substituted C₂-C₉ heterocyclyl;


10 L² is optionally substituted C₁-C₆ alkylene or optionally substituted C₁-C₆ heteroalkylene; and

R² is optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, or optionally substituted C₂-C₉ heteroaryl, or a pharmaceutically acceptable salt thereof.


In some embodiments, L¹ is optionally substituted C₁-C₆ alkylene, optionally substituted C₁-C₆ heteroalkylene, optionally substituted C₂-C₆ alkenylene, optionally substituted C₂-C₆ alkynylene, optionally





In some embodiments, L¹ is optionally substituted C₁-C₆ alkylene, optionally substituted C₂-C₆ alkenylene, or optionally substituted C₂-C₆ alkynylene.




In some embodiments, L¹ is optionally substituted C₃-C₆ carbocyclylene.
















25 In some embodiments, L¹ is . In some embodiments, L¹ is . In some













In some embodiments, L¹ is  or . In some embodiments, L¹ is .







In some embodiments, L¹ is optionally substituted C₁-C₆ heteroalkylene.





In some embodiments, L¹ is , , , , ,

, , , , , , , ,






, , , , , ,




, , , , or . In some embodiments,





L¹ is , , , , , or . In some



embodiments, L¹ is , , , or .

In some embodiments, L² is optionally substituted C₁-C₆ heteroalkyl.

In some embodiments, L² is , , , , or ,

, , or , where R⁵ is H or optionally substituted C₁-C₆ alkyl.

In some embodiments, L² is , , , or . In some

embodiments, L² is  or .


In some embodiments, R⁵ is H or CH₃. In some embodiments, R⁵ is H.

In some embodiments, X⁵ is CH. In some embodiments, X⁵ is N.

In some embodiments, X⁶ is CH. In some embodiments, X⁶ is N.

In some embodiments, X⁷ is S.

In some embodiments, the compound has the structure of **Formula IIa**:



Formula IIa,

or a pharmaceutically acceptable salt thereof.


In some embodiments, R^2 is optionally substituted C_3 - C_{10} carbocyclyl, optionally substituted C_2 - C_9 heterocyclyl, optionally substituted C_6 - C_{10} aryl, or optionally substituted C_2 - C_9 heteroaryl.

In some embodiments, R^2 is optionally substituted C_2 - C_9 heterocyclyl, optionally substituted C_6 - C_{10} aryl, or optionally substituted C_2 - C_9 heteroaryl.

In some embodiments, R^2 is optionally substituted C_2 - C_9 heterocyclyl or optionally substituted C_2 - C_9 heteroaryl.

In some embodiments, R^2 is optionally substituted C_2 - C_9 heterocyclyl.

In some embodiments, R^2 is optionally substituted C_2 - C_5 heterocyclyl.




where b_1 is 0, 1, 2, 3, or 4;

b_2 is 0, 1, or 2;


R^{6a} is H, optionally substituted C_1 - C_6 alkyl, or optionally substituted C_3 - C_6 carbocyclyl;

R^{6b} is H, optionally substituted C_1 - C_6 alkyl, or optionally substituted C_3 - C_6 carbocyclyl;


each R^7 is, independently, halo or optionally substituted C_1 - C_6 alkyl; and




In some embodiments, R^{6a} is H or optionally substituted C_1 - C_6 alkyl.








In some embodiments, R^{6b} is H or optionally substituted C_1 - C_6 alkyl.








In some embodiments, R^{6b} is H or .

In some embodiments, R^8 is .



In some embodiments, each R^7 is, independently, F, Cl, Br, I, , , ,



, , or . In some embodiments, each R^7 is, independently, ,


5 , , , , or .


In some embodiments, b_1 is 0 or 1. In some embodiments, b_1 is 0. In some embodiments, b_1 is 1.




In some embodiments, b_2 is 0 or 1. In some embodiments, b_2 is 0. In some embodiments, b_2 is 1.


10 In some embodiments, R^2 is . In some embodiments, R^2 is . In


some embodiments, , . In some embodiments, R^2 is

.


In some embodiments, R^2 is .

15 In some embodiments, R^2 is , , or .

In some embodiments, R^2 is .

In some embodiments, R^2 is .

In some embodiments, R^2 is



where

q_1 is 0, 1, 2, 3, 4, 5, or 6;


q_2 is 0, 1, 2, 3, or 4;

q_3 is 0, 1, or 2;

each R^{21} is, independently, hydroxyl, optionally substituted C_1 - C_6 alkyl, or optionally substituted C_1 - C_6 heteroalkyl; or two of the R^{21} groups, taken together with the carbon atom to which each is attached, combine to form an optionally substituted C_3 - C_{10} carbocyclyl or optionally substituted C_2 - C_9 heterocyclyl; and

R^{22} is H or optionally substituted C_1 - C_6 alkyl.


In some embodiments, each R^{21} is, independently,



In some embodiments, R^{22} is H or




In some embodiments, R^2 is



In some embodiments, R^2 is optionally substituted C_2 - C_9 heteroaryl.

In some embodiments, R^2 is optionally substituted C_2 - C_5 heteroaryl.

In some embodiments, R^2 is





where

c is 0, 1, 2, 3, or 4; and

each R^9 is, independently, halo, CN, NO_2 , optionally substituted C_1 - C_6 alkyl, optionally substituted C_2 - C_6 alkenyl, optionally substituted C_1 - C_6 heteroalkyl, optionally substituted C_2 - C_6 heteroalkenyl, optionally substituted C_3 - C_{10} carbocyclyl, optionally substituted C_2 - C_9 heterocyclyl, optionally substituted C_6 - C_{10} aryl, optionally substituted C_2 - C_9 heteroaryl, SH, OH, or NH_2 .




In some embodiments, each R^9 is, independently, halo, CN, optionally substituted C_1 - C_6 alkyl, optionally substituted C_2 - C_6 alkene, optionally substituted C_1 - C_6 heteroalkyl, optionally substituted C_2 - C_6 heteroalkenyl, optionally substituted C_3 - C_{10} carbocyclyl, OH, or NH_2 .



In some embodiments, each R^9 is, independently, F, Cl, Br, I, CN, , ,




In some embodiments, c is 0, 1, or 2. In some embodiments, c is 0. In some embodiments, c is

10 1. In some embodiments, c is 2.

In some embodiments, R^2 is , , or . In some embodiments,



In some embodiments, R^2 is




where

d is 0, 1, 2, or 3; and

- 5 each R^{10} is, independently, halo, CN, NO₂, optionally substituted C₁-C₆ alkyl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₂-C₆ heteroalkenyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, SH, OH, or NH₂.

- 10 In some embodiments, each R^{10} is, independently, halo, CN, optionally substituted C₁-C₆ alkyl, optionally substituted C₂-C₆ alkene, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₂-C₆ heteroalkenyl, optionally substituted C₃-C₁₀ carbocyclyl, OH, or NH₂.


In some embodiments, each R^{10} is, independently, F, Cl, Br, I, CN,







In some embodiments, d is 0, 1, or 2. In some embodiments, d is 0. In some embodiments, d is

1. In some embodiments, d is 2.

In some embodiments, R^2 is



20 In some embodiments, R^2 is



where

e is 0, 1, or 2;

each R¹¹ is, independently, halo, CN, NO₂, optionally substituted C₁-C₆ alkyl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₂-C₆

heteroalkenyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, SH, OH, or NH₂.

W is CH or N;


Y is O, S, or NR^{Y1};

- 5 R^{Y1} is H, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, or optionally substituted C₂-C₉ heterocyclyl;

Z is O, S, or NR^{Z1}; and


R^{Z1} is H or optionally substituted C₁-C₆ alkyl.

- 10 In some embodiments, each R¹¹ is, independently, halo, CN, optionally substituted C₁-C₆ alkyl, optionally substituted C₂-C₆ alkene, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₂-C₆ heteroalkenyl, optionally substituted C₃-C₁₀ carbocyclyl, OH, or NH₂.




- 15 In some embodiments, W is CH. In some embodiments, W is N.
In some embodiments, Y is NR^{Y1}.
In some embodiments, R^{Y1} is H, optionally substituted C₁-C₆ alkyl, or optionally substituted C₃-C₁₀ carbocyclyl.

- 20 In some embodiments, R^{Y1} is H. In some embodiments, R^{Y1} is optionally substituted C₁-C₆ alkyl.




In some embodiments, R^{Y1} is optionally substituted C₃-C₁₀ carbocyclyl.

In some embodiments, R^{Y1} is optionally substituted C₃-C₆ carbocyclyl.




- 25 In some embodiments, Z is O.




In some embodiments, e is 0 or 1. In some embodiments, e is 0. In some embodiments, e is 1.


In some embodiments, R² is




In some embodiments, R² is




In some embodiments, R² is



In some embodiments, R²



In some embodiments, R² is



where

R^{12a} is H, halo, CN, NO₂, optionally substituted C₁-C₆ alkyl, optionally substituted C₂-C₆ alkenyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₂-C₆ heteroalkenyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, SH, OH, or NH₂;

each of Y^a and Y^b is, independently, O, S, or NR^{Y2};


R^{Y2} is H, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, or optionally substituted C₂-C₉ heterocyclyl;

Z^a is O, S, or NR^{Z2}; and

R^{Z2} is H or optionally substituted C₁-C₆ alkyl.

In some embodiments, R^{12a} is H.


In some embodiments, Z^a is O.




In some embodiments, R^2 is

In some embodiments, each of Y^a and Y^b is NR^{Y2} .


In some embodiments, R^{Y2} is H, optionally substituted C_1 - C_6 alkyl, or optionally substituted C_3 - C_{10} carbocyclyl.



In some embodiments, R^{Y2} is H,



In some embodiments, R^2 is



where

R^{12b} is H, halo, CN, NO_2 , optionally substituted C_1 - C_6 alkyl, optionally substituted C_2 - C_6 alkenyl, optionally substituted C_1 - C_6 heteroalkyl, optionally substituted C_2 - C_6 heteroalkenyl, optionally substituted C_3 - C_{10} carbocyclyl, optionally substituted C_2 - C_9 heterocyclyl, optionally substituted C_6 - C_{10} aryl, optionally substituted C_2 - C_9 heteroaryl, SH, OH, or NH_2 ; and


Y^c is O, S, or NR^{Y3} ;

R^{Y3} is H, optionally substituted C_1 - C_6 alkyl, optionally substituted C_1 - C_6 heteroalkyl, optionally substituted C_3 - C_{10} carbocyclyl, or optionally substituted C_2 - C_9 heterocyclyl.

In some embodiments, R^{12b} is H.


In some embodiments, Y^c is NR^{Y3} .

In some embodiments, R^{Y3} is H, optionally substituted C_1 - C_6 alkyl, or optionally substituted C_3 - C_{10} carbocyclyl.



In some embodiments, R^{Y3} is H,

In some embodiments, R^2 is



where

f is 0, 1, or 2;

- 5 each R^{13} is, independently, halo, CN, NO_2 , optionally substituted C_1 - C_6 alkyl, optionally substituted C_2 - C_6 alkenyl, optionally substituted C_1 - C_6 heteroalkyl, optionally substituted C_2 - C_6 heteroalkenyl, optionally substituted C_3 - C_{10} carbocyclyl, optionally substituted C_2 - C_9 heterocyclyl, optionally substituted C_6 - C_{10} aryl, optionally substituted C_2 - C_9 heteroaryl, SH, OH, or NH_2 ; and

Y^d is O, S, or NR^{Y4} ;

- 10 R^{Y4} is H, optionally substituted C_1 - C_6 alkyl, optionally substituted C_1 - C_6 heteroalkyl, optionally substituted C_3 - C_{10} carbocyclyl, or optionally substituted C_2 - C_9 heterocyclyl.

In some embodiments, each R^{13} is, independently, halo, CN, optionally substituted C_1 - C_6 alkyl, optionally substituted C_2 - C_6 alkene, optionally substituted C_1 - C_6 heteroalkyl, optionally substituted C_2 - C_6 heteroalkenyl, optionally substituted C_3 - C_{10} carbocyclyl, OH, or NH_2 .


- 15 In some embodiments, each R^{13} is, independently, halo, CN, or optionally substituted C_1 - C_6 alkyl.

In some embodiments, f is 0 or 1. In some embodiments, f is 0. In some embodiments, f is 1.

In some embodiments, Y^d is NR^{Y4} .


In some embodiments, R^{Y4} is H, optionally substituted C_1 - C_6 alkyl, or optionally substituted C_3 - C_{10} carbocyclyl.

- 20 In some embodiments, R^{Y4} is H, ,



In some embodiments, Y^d is O.

In some embodiments, R^2 is



where

- 25 g is 0, 1, 2, 3, or 4;

each R^{14} is, independently, halo, CN, NO_2 , optionally substituted C_1 - C_6 alkyl, optionally substituted C_2 - C_6 alkenyl, optionally substituted C_1 - C_6 heteroalkyl, optionally substituted C_2 - C_6 heteroalkenyl, optionally substituted C_3 - C_{10} carbocyclyl, optionally substituted C_2 - C_9 heterocyclyl, optionally substituted C_6 - C_{10} aryl, optionally substituted C_2 - C_9 heteroaryl, SH, OH, or NH_2 ;

- 30 Y^e is O, S, or NR^{Y5} ; and

R^{Y5} is H, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, or optionally substituted C₂-C₉ heterocyclyl.

In some embodiments, R¹⁴ is halo, CN, optionally substituted C₁-C₆ alkyl, optionally substituted C₂-C₆ alkene, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₂-C₆ heteroalkenyl, optionally substituted C₃-C₁₀ carbocyclyl, OH, or NH₂.

In some embodiments, R¹⁴ is halo, CN, or optionally substituted C₁-C₆ alkyl.

In some embodiments, g is 0, 1, or 2. In some embodiments, g is 0. In some embodiments, g is 1. In some embodiments, g is 2.

In some embodiments, Y^e is NR^{Y5} .


In some embodiments, R^{Y5} is H, optionally substituted C₁-C₆ alkyl, or optionally substituted C₃-C₁₀ carbocyclyl.

In some embodiments, R^{Y5} is , , , , , , or .

In some embodiments, Y^e is O. In some embodiments, Y^e is S.

[illegible]

In some embodiments, R² is



The image shows five chemical structures representing R². The first structure is a 5-membered ring with a nitrogen atom, a wavy line at position 1, a substituent (R¹⁵)_i at position 2, and substituents X^a, X^b, and X^d at positions 3, 4, and 5 respectively. The second structure is a 6-membered ring with a nitrogen atom, a wavy line at position 1, a substituent (R¹⁵)_i at position 2, and substituents X^b and X^d at positions 3 and 4 respectively. The third structure is a 6-membered ring with a nitrogen atom, a wavy line at position 1, a substituent (R¹⁵)_i at position 2, and substituents X^b and X^d at positions 3 and 4 respectively. The fourth structure is a 6-membered ring with a nitrogen atom, a wavy line at position 1, a substituent (R¹⁵)_i at position 2, and substituents X^b and X^d at positions 3 and 4 respectively. The fifth structure is a 6-membered ring with a nitrogen atom, a wavy line at position 1, a substituent (R¹⁵)_i at position 2, and substituents X^b and X^d at positions 3 and 4 respectively.

where

each of X^a , X^b , X^c , and X^d is, independently, N or CR¹⁷:


each R¹⁷ is, independently, halo, CN, NO₂, optionally substituted C₁-C₆ alkyl, optionally substituted C₂-C₆ alkene, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₂-C₆ heteroalkenyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, SH, OH, or NH₂;


i is 0, 1, 2, or 3; and

each R^{15} is, independently, halo, CN, NO_2 , optionally substituted C_1 - C_6 alkyl, optionally substituted C_2 - C_6 alkene, optionally substituted C_1 - C_6 heteroalkyl, optionally substituted C_2 - C_6 heteroalkenyl, optionally substituted C_3 - C_{10} carbocyclyl, optionally substituted C_2 - C_9 heterocyclyl, optionally substituted C_6 - C_{10} aryl, optionally substituted C_2 - C_9 heteroaryl, SH, OH, or NH_2 .

5 In some embodiments, each R^{15} is, independently, halo, CN, optionally substituted C_1 - C_6 alkyl, optionally substituted C_2 - C_6 alkene, optionally substituted C_1 - C_6 heteroalkyl, SH, OH, or NH_2 .

In some embodiments, i is 0 or 1. In some embodiments, i is 0. In some embodiments, i is 1.

In some embodiments, R^2 is .

In some embodiments, R^2 is .

10 where

X^e is N or CR^{18} ;

R^{18} is, independently, halo, CN, NO_2 , optionally substituted C_1 - C_6 alkyl, optionally substituted C_2 - C_6 alkene, optionally substituted C_1 - C_6 heteroalkyl, optionally substituted C_2 - C_6 heteroalkenyl, optionally substituted C_3 - C_{10} carbocyclyl, optionally substituted C_2 - C_9 heterocyclyl, optionally substituted C_6 - C_{10} aryl, optionally substituted C_2 - C_9 heteroaryl, SH, OH, or NH_2 ;

j is 0, 1, or 2;

each R^{16} is, independently, halo, CN, NO_2 , optionally substituted C_1 - C_6 alkyl, optionally substituted C_2 - C_6 alkene, optionally substituted C_1 - C_6 heteroalkyl, optionally substituted C_2 - C_6 heteroalkenyl, optionally substituted C_3 - C_{10} carbocyclyl, optionally substituted C_2 - C_9 heterocyclyl, optionally substituted C_6 - C_{10} aryl, optionally substituted C_2 - C_9 heteroaryl, SH, OH, or NH_2 ;

each of Y^f and Y^g is, independently, O, S, or NR^{Y6} ;

R^{Y6} is H, optionally substituted C_1 - C_6 alkyl, optionally substituted C_1 - C_6 heteroalkyl, optionally substituted C_3 - C_{10} carbocyclyl, or optionally substituted C_2 - C_9 heterocyclyl;


Z^b is O, S, or NR^{Z3} ; and



R^{Z3} is H or optionally substituted C_1 - C_6 alkyl.

In some embodiments, each R^{16} is, independently, halo, CN, optionally substituted C_1 - C_6 alkyl, optionally substituted C_2 - C_6 alkene, optionally substituted C_1 - C_6 heteroalkyl, SH, OH, or NH_2 .

In some embodiments, j is 0 or 1. In some embodiments, j is 0. In some embodiments, j is 1.

In some embodiments, Z is O.

In some embodiments, R^2 is .





where

o_1 is 0, 1, 2, or 3;


o_2 is 0, 1, or 2;

each R^{23} is, independently, halo, CN, NO₂, optionally substituted C₁-C₆ alkyl, optionally substituted C₂-C₆ alkene, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₂-C₆ heteroalkenyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, SH, OH, or NH₂; and

R^{24} is H or optionally substituted C₁-C₆ alkyl.



In some embodiments, R^2 is optionally substituted C₆-C₁₀ aryl.



where

r is 0, 1, 2, 3, or 4; and


each R^{24} is, independently, halo, CN, NO₂, optionally substituted C₁-C₆ alkyl, optionally substituted C₂-C₆ alkene, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₂-C₆ heteroalkenyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, optionally substituted sulfone, SH, OH, or NH₂.

In some embodiments, each R^{24} is, independently, halo, CN, NO₂, optionally substituted C₁-C₆ alkyl, optionally substituted C₂-C₆ alkene, optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₂-C₆ heteroalkenyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₂-C₉ heteroaryl, SH, OH, or NH₂.

In some embodiments, each R^{24} is, independently, halo, CN, NO_2 , optionally substituted C_1 - C_6 alkyl, optionally substituted C_1 - C_6 heteroalkyl, SH, OH, or NH_2 .

In some embodiments, r is 0, 1, or 2. In some embodiments, r is 0. In some embodiments, r is 1. In some embodiments, r is 2.


5 In some embodiments, R^2 is optionally substituted C_1 - C_6 heteroalkyl.



In some embodiments, R^2 is , where R^{25} is optionally substituted C_1 - C_6 alkyl or optionally substituted C_1 - C_6 heteroalkyl.


In some embodiments, R^{25} is F_3C- .

In some embodiments, R^1 is optionally substituted C_1 - C_6 alkyl.



10 In some embodiments, R^1 is

In some embodiments, R^1 is optionally substituted C_6 - C_{10} aryl.



In some embodiments, R^1 is


where


each of R^{3a} , R^{3b} , R^{3c} , R^{3d} , and R^{3e} is, independently, H, halo, CN, NO_2 , optionally substituted

15 C_1 - C_6 alkyl, optionally substituted C_2 - C_6 alkene, optionally substituted C_1 - C_6 heteroalkyl, optionally substituted C_2 - C_6 heteroalkenyl, optionally substituted C_3 - C_{10} carbocyclyl, optionally substituted C_2 - C_9 heterocyclyl, optionally substituted C_6 - C_{10} aryl, optionally substituted C_2 - C_9 heteroaryl, SH, OH, or NH_2 ; or R^{3a} and R^{3b} , R^{3b} and R^{3c} , R^{3c} and R^{3d} , or R^{3d} and R^{3e} , together with the atoms to which each is attached, combine to form optionally substituted C_3 - C_{10} carbocyclyl or optionally substituted C_2 - C_9 heterocyclyl.

20 In some embodiments, each of R^{3a} , R^{3b} , R^{3c} , R^{3d} , and R^{3e} is, independently, H, halo, CN, NO_2 , optionally substituted C_1 - C_6 alkyl, optionally substituted C_1 - C_6 heteroalkyl, SH, OH, or NH_2 .

In some embodiments, each of R^{3a} , R^{3b} , R^{3c} , R^{3d} , and R^{3e} is, independently, H, F, Cl, Br, I, CN,






- 5 In some embodiments, R^1 is phenyl, 3-fluoro-phenyl, 4-fluoro-phenyl, 3-chloro-phenyl, 4-chloro-phenyl, 2-methoxy-phenyl, 3-methoxy-phenyl, 4-methoxy-phenyl, 3,4-di-fluoro-phenyl, 3,4-dichloro-phenyl, 3,5-di-fluoro-phenyl, 3,5-dichloro-phenyl, 3-chloro-4-fluoro-phenyl, 4-chloro-3-fluoro-phenyl, 3-chloro-4-nitrile-phenyl, 3-nitrile-4-fluoro-phenyl, 3-trifluoromethyl-phenyl, 4-trifluoromethyl-phenyl, 3-bromo-phenyl, 3-cyclopropyl-phenyl, 3-cyano-5-fluoro-phenyl,
- 10 3-chloro-5-fluoro-phenyl, 3-chloro-5-cyano-phenyl, 3-chloro-5-methoxy-phenyl, or 1,3-dihydroisobenzofuran.

In some embodiments, R^1 is optionally substituted C_3 - C_{10} carbocyclyl.

In some embodiments, R^1 is optionally substituted C_3 - C_{10} cycloalkyl.



15 where

n_1 is 0, 1, 2, or 3;

n_2 is 0, 1, 2, 3, or 4;


n_3 is 0, 1, 2, 3, 4, or 5;

n_4 is 0, 1, 2, 3, 4, 5, or 6; and


- 20 each R^4 is, independently, halo, CN, NO_2 , optionally substituted C_1 - C_6 alkyl, optionally substituted C_2 - C_6 alkene, optionally substituted C_1 - C_6 heteroalkyl, optionally substituted C_2 - C_6 heteroalkenyl, optionally substituted C_3 - C_{10} carbocyclyl, optionally substituted C_2 - C_9 heterocyclyl, optionally substituted C_6 - C_{10} aryl, optionally substituted C_2 - C_9 heteroaryl, SH, OH, or NH_2 .



In some embodiments, each R^4 is, independently, halo, CN, optionally substituted C_1 - C_6 alkyl, optionally substituted C_2 - C_6 alkene, optionally substituted C_1 - C_6 heteroalkyl, SH, OH, or NH_2 .




5 In some embodiments, R^1 is optionally substituted cycloalkenyl.




n_5 is 0, 1, 2, 3, or 4;

n_6 is 0, 1, 2, 3, 4, or 5; and

10 each R^4 is, independently, halo, CN, NO_2 , optionally substituted C_1 - C_6 alkyl, optionally substituted C_2 - C_6 alkene, optionally substituted C_1 - C_6 heteroalkyl, optionally substituted C_2 - C_6 heteroalkenyl, optionally substituted C_3 - C_{10} carbocyclyl, optionally substituted C_2 - C_9 heterocyclyl, optionally substituted C_6 - C_{10} aryl, optionally substituted C_2 - C_9 heteroaryl, SH, OH, or NH_2 .



15 In some embodiments, each R^4 is, independently, halo, CN, optionally substituted C_1 - C_6 alkyl, optionally substituted C_2 - C_6 alkene, optionally substituted C_1 - C_6 heteroalkyl, SH, OH, or NH_2 .



In some embodiments, R^1 is optionally substituted C_2 - C_6 heteroaryl.



20 each R^{19} is, independently, halo, CN, NO_2 , optionally substituted C_1 - C_6 alkyl, optionally substituted C_2 - C_6 alkene, optionally substituted C_1 - C_6 heteroalkyl, optionally substituted C_2 - C_6 heteroalkenyl, optionally substituted C_3 - C_{10} carbocyclyl, optionally substituted C_2 - C_9 heterocyclyl,
25 optionally substituted C_6 - C_{10} aryl, optionally substituted C_2 - C_9 heteroaryl, SH, OH, or NH_2 ;




Y^h is O, S, or NR^{Y7} ; and

R^{Y7} is H, optionally substituted C_1 - C_6 alkyl, optionally substituted C_1 - C_6 heteroalkyl, optionally substituted C_3 - C_{10} carbocyclyl, or optionally substituted C_2 - C_9 heterocyclyl.

In some embodiments, each R^{19} is, independently, halo, CN, optionally substituted C_1 - C_6 alkyl, optionally substituted C_2 - C_6 alkene, optionally substituted C_1 - C_6 heteroalkyl, SH, OH, or NH_2 .

- 5 In some embodiments, each R^{19} is, independently, F, Cl, Br, I, CN, or .
- In some embodiments, Y^h is S.

In some embodiments, k is 0 or 1. In some embodiments, k is 0. In some embodiments, k is 1.


In some embodiments, R^1 is , , or , where p is 0, 1, 2, 3, or 4; and

- 10 each R^{20} is, independently, halo, CN, NO_2 , optionally substituted C_1 - C_6 alkyl, optionally substituted C_2 - C_6 alkene, optionally substituted C_1 - C_6 heteroalkyl, optionally substituted C_2 - C_6 heteroalkenyl, optionally substituted C_3 - C_{10} carbocyclyl, optionally substituted C_2 - C_9 heterocyclyl, optionally substituted C_6 - C_{10} aryl, optionally substituted C_2 - C_9 heteroaryl, SH, OH, or NH_2 .

- In some embodiments, each R^{20} is, independently, halo, CN, optionally substituted C_1 - C_6 alkyl, 15 optionally substituted C_2 - C_6 alkene, optionally substituted C_1 - C_6 heteroalkyl, SH, OH, or NH_2 .

In some embodiments, each R^{20} is, independently, F, Cl, Br, I, CN, or .

In some embodiments, p is 0 or 1. In some embodiments, p is 0. In some embodiments, p is 1.

In some embodiments, R^1 is .

- In some embodiments, R^1 is 5-chloropyridin-3-yl, 5-trifluoromethyl-pyridin-3-yl, 20 4-trifluoromethyl-pyridin-2-yl, 5-fluoropyridin-3-yl, or 5-fluoropyridin-3-yl.

In another aspect, this disclosure features a compound, or pharmaceutically acceptable salt thereof, having the structure of any one of compounds 1-683 in Table 1 and Table 2. In some embodiments, the compound is any one of compounds 1-475 in Table 1. In some embodiments, the compound is any one of compounds 476-683 in Table 2.











- 25 In some embodiments, the compound is any one of compounds 40, 41, 46, 48, 53, 56, 57, 59, 66, 74-76, 79, 89, 91, 94, 95, 99, 111-114, 116, 119, 121, 122, 125, 128, 131, 132, 134, 137, 140, 142, 144, 146, 148, 149, 150, 202, 207, 216, 236, 239, 242-244, 248, 290, 292, 311, 315, 316, 321, 328-331, 366, 371, and 375 in Table 1. In some embodiments, the compound is any one of compounds 56, 76, 91, 94, 111, 112, 114, 116, 119, 122, 125, 131, 132, 137, 144, 148, 150, 236, 242-244, 290, 315, 316, 321, and 30 375 in Table 1. In some embodiments, the compound is any one of compounds 484, 494-497, 500-503, 506, 526, 528, 532, 540, 542, 543, 547, 555, 556, 559, 562, 567, 571, 572, 575, 580, 603, 616, 626, 627, 642-644, 657, 661, 668, 676, and 679 in Table 2. In some embodiments, the compound is any one of compounds 494, 497, 501, 503, 532, 559, 567, 572, 580, 603, 657, and 668 in Table 2.

















- In some embodiments, the compound is any one of compounds 1-200, 238-305, 310-316, 318- 35 321, 323-335, 337-339, 342, 344-346, 348, 349, 351, 352, 354-376, 379, 381-384, 387, 391-393, 396,

397, 401-403, 410-412, 415, 417, 418, 421, 423, 425-429, 433, 435-456, 458-460, 463, 467-472, 474, and 475 in Table 1 and 476-683 in Table 2. In some embodiments, the compound is any one of compounds 1-200, 238-305, 310-316, 318-321, 323-335, 337-339, 342, 344-346, 348, 349, 351, 352, 354-376, 379, 381-384, 387, 391-393, 396, 397, 401-403, 410-412, 415, 417, 418, 421, 423, 425-429, 433, 435-456, 458-460, 463, 467-472, 474, and 475 in Table 1. In some embodiments, the compound is any one of compounds 476-681 and 683 in Table 2. In some embodiments, the compound is any one of compounds 201-237, 317, 340, 341, 343, 345-347, 350, 353, 377, 378, 380, 385, 386, 388-390, 398-400, 404-409, 413, 414, 416, 419, 420, 422, 424, 430, 431, 461, 462, 464-466, and 473 in Table 1. In some embodiments, the compound is any one of compounds 305-309, 322, 336, 394, 432, 434, and 457 in Table 1. In some embodiments, the compound is any one of compounds 305-309 in Table 1.

















As used herein, "CMPD" refers to "compound."

















Table 1. Compounds of the Invention

CMPD No.	Structure	CMPD No.	Structure
1		239	
2		240	
3		241	
4		242	
5		243	

CMPD No.	Structure	CMPD No.	Structure
6		244	
7		245	
8		246	
9		247	
10		248	
11		249	
12		250	
13		251	

CMPD No.	Structure	CMPD No.	Structure
14		252	
15		253	
16		254	
17		255	
18		256	
19		257	
20		258	
21		259	

















CMPD No.	Structure	CMPD No.	Structure
22		260	
23		261	
24		262	
25		263	
26		264	
27		265	
28		266	
29		267	

CMPD No.	Structure	CMPD No.	Structure
30		268	
31		269	
32		270	
33		271	
34		272	
35		273	
36		274	
37		275	

CMPD No.	Structure	CMPD No.	Structure
38		276	
39		277	
40		278	
41		279	
42		280	
43		281	
44		282	
45		283	

CMPD No.	Structure	CMPD No.	Structure
46		284	
47		285	
48		286	
49		287	
50		288	
51		289	
52		290	
53		291	

















CMPD No.	Structure	CMPD No.	Structure
54		292	
55		293	
56		294	
57		295	
58		296	
59		297	
60		298	
61		299	

CMPD No.	Structure	CMPD No.	Structure
62		300	
63		301	
64		302	
65		303	
66		304	
67		305	
68		306	
69		307	

CMPD No.	Structure	CMPD No.	Structure
70		308	
71		309	
72		310	
73		311	
74		312	
75		313	
76		314	
77		315	

















CMPD No.	Structure	CMPD No.	Structure
78		316	
79		317	
80		318	
81		319	
82		320	
83		321	
84		322	
85		323	

CMPD No.	Structure	CMPD No.	Structure
86		324	
87		325	
88		326	
89		327	
90		328	
91		329	
92		330	
93		331	

CMPD No.	Structure	CMPD No.	Structure
94		332	
95		333	
96		334	
97		335	
98		336	
99		337	
100		338	
101		339	

CMPD No.	Structure	CMPD No.	Structure
102		340	
103		341	
104		342	
105		343	
106		344	
107		345	
108		346	
109		347	

CMPD No.	Structure	CMPD No.	Structure
110		348	
111		349	
112		350	
113		351	
114		352	
115		353	
116		354	
117		355	

















CMPD No.	Structure	CMPD No.	Structure
118		356	
119		357	
120		358	
121		359	
122		360	
123		361	
124		362	
125		363	

















CMPD No.	Structure	CMPD No.	Structure
126		364	
127		365	
128		366	
129		367	
130		368	
131		369	
132		370	
133		371	

CMPD No.	Structure	CMPD No.	Structure
134		372	
135		373	
136		374	
137		375	
138		376	
139		377	
140		378	
141		379	

CMPD No.	Structure	CMPD No.	Structure
142		380	
143		381	
144		382	
145		383	
146		384	
147		385	
148		386	
149		387	

CMPD No.	Structure	CMPD No.	Structure
150		388	
151		389	
152		390	
153		391	
154		392	
155		393	
156		394	
157		395	

















CMPD No.	Structure	CMPD No.	Structure
158		396	
159		397	
160		398	
161		399	
162		400	
163		401	
164		402	
165		403	

















CMPD No.	Structure	CMPD No.	Structure
166		404	
167		405	
168		406	
169		407	
170		408	
171		409	
172		410	
173		411	















CMPD No.	Structure	CMPD No.	Structure
174		412	
175		413	
176		414	
177		415	
178		416	
179		417	
180		418	
181		419	

















CMPD No.	Structure	CMPD No.	Structure
182		420	
183		421	
184		422	
185		423	
186		424	
187		425	
188		426	
189		427	

















CMPD No.	Structure	CMPD No.	Structure
190		428	
191		429	
192		430	
193		431	
194		432	
195		433	
196		434	
197		435	

CMPD No.	Structure	CMPD No.	Structure
198		436	
199		437	
200		438	
201		439	
202		440	
203		441	
204		442	
205		443	

CMPD No.	Structure	CMPD No.	Structure
206		444	
207		445	
208		446	
209		447	
210		448	
211		449	
212		450	
213		451	

CMPD No.	Structure	CMPD No.	Structure
214		452	
215		453	
216		454	
217		455	
218		456	
219		457	
220		458	

CMPD No.	Structure	CMPD No.	Structure
221		459	
222		460	
223		461	
224		462	
225		463	
226		464	
227		465	
228		466	

CMPD No.	Structure	CMPD No.	Structure
229		467	
230		468	
231		469	
232		470	
233		471	
234		472	
235		473	
236		474	






























CMPD No.	Structure	CMPD No.	Structure
237		475	
238			

Table 2. Compounds of the Invention

CMPD No.	Structure	CMPD No.	Structure
476		580	
477		581	
478		582	
479		583	
480		584	

CMPD No.	Structure	CMPD No.	Structure
481		585	
482		586	
483		587	
484		588	
485		589	
486		590	
487		591	
488		592	

CMPD No.	Structure	CMPD No.	Structure
489		593	
490		594	
491		595	
492		596	
493		597	
494		598	
495		599	
496		600	

CMPD No.	Structure	CMPD No.	Structure
497		601	
498		602	
499		603	
500		604	
501		605	
502		606	
503		607	
504		608	

CMPD No.	Structure	CMPD No.	Structure
505		609	
506		610	
507		611	
508		612	
509		613	
510		614	
511		615	
512		616	

















CMPD No.	Structure	CMPD No.	Structure
513		617	
514		618	
515		619	
516		620	
517		621	
518		622	
519		623	
520		624	

















CMPD No.	Structure	CMPD No.	Structure
521		625	
522		626	
523		627	
524		628	
525		629	
526		630	
527		631	
528		632	

















CMPD No.	Structure	CMPD No.	Structure
529		633	
530		634	
531		635	
532		636	
533		637	
534		638	
535		639	
536		640	

CMPD No.	Structure	CMPD No.	Structure
537		641	
538		642	
539		643	
540		644	
541		645	
542		646	
543		647	
544		648	

CMPD No.	Structure	CMPD No.	Structure
545		649	
546		650	
547		651	
548		652	
549		653	
550		654	
551		655	
552		656	

CMPD No.	Structure	CMPD No.	Structure
553		657	
554		658	
555		659	
556		660	
557		661	
558		662	
559		663	
560		664	

CMPD No.	Structure	CMPD No.	Structure
561		665	
562		666	
563		667	
564		668	
565		669	
566		670	
567		671	
568		672	

CMPD No.	Structure	CMPD No.	Structure
569		673	
570		674	
571		675	
572		676	
573		677	
574		678	
575		679	
576		680	

CMPD No.	Structure	CMPD No.	Structure
577		681	
578		682	
579		683	

In an aspect, this disclosure features a pharmaceutical composition comprising a compound of any of the foregoing compounds, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

5 In some embodiments, the pharmaceutical composition includes a compound of **Formula I** or **Formula II** and a pharmaceutically acceptable excipient.

In an aspect, this disclosure features a method of treating a neurological disorder in a subject in need thereof, the method comprising administering an effective amount of any of the foregoing compounds or a pharmaceutical composition thereof.

10 In an aspect, this disclosure features a method of inhibiting toxicity in a cell related to a protein, the method comprising administering an effective amount of any of the foregoing compounds or a pharmaceutical composition thereof.

In some embodiments, the toxicity is α -synuclein-related toxicity. In some embodiments, the toxicity is ApoE4-related toxicity.

15 In some embodiments, the cell is a mammalian neural cell.

In an aspect, this disclosure features a method of treating a stearyl-CoA desaturase (SCD)-associated disorder in a subject in need thereof, the method comprising administering an effective amount of any of the foregoing compounds, or pharmaceutically acceptable salts thereof, or a pharmaceutical composition thereof.

20 Non-limiting exemplary SCD-associated disorders include, but are not limited to metabolic disorders (e.g., diabetes (e.g., Type I diabetes and Type II diabetes), hyperglycemia, metabolic syndrome, obesity, lipid disorders, fatty liver, nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), and hypertension), cancer, cardiovascular diseases, cerebrovascular diseases, kidney diseases, liver diseases, skin disorders (e.g., acne (e.g., acne vulgaris)), central nervous system (CNS)

disorders, dementia, multiple sclerosis, schizophrenia, mild cognitive impairment, Alzheimer's Disease, cerebral amyloid angiopathy, and dementia associated with Down Syndrome.


In some embodiments, the SCD-associated disorder is a SCD1-associated disorder.

In some embodiments, the SCD-associated disorder is a SCD5-associated disorder.

5 In an aspect, this disclosure features a method of inhibiting SCD5, the method comprising contacting a cell with an effective amount of any of the foregoing compounds, or pharmaceutically acceptable salts thereof, or a pharmaceutical composition thereof.

In an aspect, this disclosure features a method of inhibiting SCD1, the method comprising contacting a cell with an effective amount of any of the foregoing compounds, or pharmaceutically acceptable salts thereof, or a pharmaceutical composition thereof.

10 In an aspect, this disclosure features a method of treating a primary brain cancer in a subject in need thereof, the method comprising administering an effective amount of a compound having the structure of **Formula I**:



Formula I,

wherein

R¹ is optionally substituted C₁-C₆ alkyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heteroaryl, or optionally substituted C₂-C₉ heterocyclyl;

20 L¹ is optionally substituted C₁-C₆ alkylene, optionally substituted C₁-C₆ heteroalkylene, optionally substituted C₂-C₆ alkenylene, optionally substituted C₂-C₆ alkynylene, optionally substituted C₃-C₆

carbocyclylene, , , , , or ;

R^a is H or optionally substituted C₁-C₆ alkyl;

L³ is optionally substituted C₂-C₉ heterocyclylene;

25 each of X¹, X², X³, and X⁴ is, independently, N or CH;

L² is optionally substituted C₁-C₆ alkylene or optionally substituted C₁-C₆ heteroalkylene; and

R² is optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, or optionally substituted C₂-C₉ heteroaryl,

30 or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound, or pharmaceutically acceptable salt thereof, has the structure of any one of compounds 1-475 in Table 1 or any one of compounds 476-683 in Table 2.

In some embodiments, the primary brain cancer is a glioma. In some embodiments, the glioma is an astrocytoma. In some embodiments, the astrocytoma is a glioblastoma.

In some embodiments, the cancer is determined or predicted to be resistant to one or more chemotherapeutic agents.

In some embodiments, the cancer has failed to respond to one or more chemotherapeutic agents.

In some embodiments, one or more chemotherapeutic agents is selected from the group of temozolomide, carmustine, bevacizumab, lomustine, everolimus, vincristine, or procarbazine. In some
5 embodiments, one or more chemotherapeutic agents is temozolomide.


In some embodiments, the subject is further administered one or more additional therapeutic interventions. In some embodiments, one or more additional therapeutic interventions comprises surgery, radiation, and/or one or more additional chemotherapeutic agents. In some embodiments, one or more additional therapeutic interventions is one or more chemotherapeutic agents. In some embodiments, one
10 or more chemotherapeutic agents is selected from the group of temozolomide, carmustine, bevacizumab, lomustine, everolimus, vincristine, or procarbazine. In some embodiments, one or more chemotherapeutic agents is temozolomide.

15 *Chemical Terms*

It is to be understood that the terminology employed herein is for the purpose of describing particular embodiments and is not intended to be limiting.

Those skilled in the art will appreciate that certain compounds described herein can exist in one or more different isomeric (e.g., stereoisomers, geometric isomers, tautomers) and/or isotopic (e.g., in
20 which one or more atoms has been substituted with a different isotope of the atom, such as hydrogen substituted for deuterium) forms. Unless otherwise indicated or clear from context, a depicted structure can be understood to represent any such isomeric or isotopic form, individually or in combination.

In some embodiments, one or more compounds depicted herein may exist in different tautomeric forms. As will be clear from context, unless explicitly excluded, references to such compounds
25 encompass all such tautomeric forms. In some embodiments, tautomeric forms result from the swapping of a single bond with an adjacent double bond and the concomitant migration of a proton. In certain embodiments, a tautomeric form may be a prototropic tautomer, which is an isomeric protonation states having the same empirical formula and total charge as a reference form. Examples of moieties with prototropic tautomeric forms are ketone – enol pairs, amide – imidic acid pairs, lactam – lactim pairs,
30 amide – imidic acid pairs, enamine – imine pairs, and annular forms where a proton can occupy two or more positions of a heterocyclic system, such as, 1H- and 3H-imidazole, 1H-, 2H- and 4H- 1,2,4-triazole, 1H- and 2H- isoindole, and 1H- and 2H-pyrazole. In some embodiments, tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution. In certain embodiments, tautomeric forms result from acetal interconversion, e.g., the interconversion illustrated in the scheme
35 below:



Those skilled in the art will appreciate that, in some embodiments, isotopes of compounds described herein may be prepared and/or utilized in accordance with the present invention. “Isotopes”

refers to atoms having the same atomic number but different mass numbers resulting from a different number of neutrons in the nuclei. For example, isotopes of hydrogen include tritium and deuterium. In some embodiments, an isotopic substitution (e.g., substitution of hydrogen with deuterium) may alter the physicochemical properties of the molecules, such as metabolism and/or the rate of racemization of a chiral center.

As is known in the art, many chemical entities (in particular many organic molecules and/or many small molecules) can adopt a variety of different solid forms such as, for example, amorphous forms and/or crystalline forms (e.g., polymorphs, hydrates, solvates, etc). In some embodiments, such entities may be utilized in any form, including in any solid form. In some embodiments, such entities are utilized in a particular form, for example in a particular solid form.

In some embodiments, compounds described and/or depicted herein may be provided and/or utilized in salt form.

In certain embodiments, compounds described and/or depicted herein may be provided and/or utilized in hydrate or solvate form.

At various places in the present specification, substituents of compounds of the present disclosure are disclosed in groups or in ranges. It is specifically intended that the present disclosure include each and every individual subcombination of the members of such groups and ranges. For example, the term "C₁-C₆ alkyl" is specifically intended to individually disclose methyl, ethyl, C₃ alkyl, C₄ alkyl, C₅ alkyl, and C₆ alkyl. Furthermore, where a compound includes a plurality of positions at which substitutes are disclosed in groups or in ranges, unless otherwise indicated, the present disclosure is intended to cover individual compounds and groups of compounds (e.g., genera and subgenera) containing each and every individual subcombination of members at each position.

Herein a phrase of the form "optionally substituted X" (e.g., optionally substituted alkyl) is intended to be equivalent to "X, wherein X is optionally substituted" (e.g., "alkyl, wherein said alkyl is optionally substituted"). It is not intended to mean that the feature "X" (e.g. alkyl) *per se* is optional.

The term "acyl," as used herein, represents a hydrogen or an alkyl group, as defined herein that is attached to a parent molecular group through a carbonyl group, as defined herein, and is exemplified by formyl (i.e., a carboxyaldehyde group), acetyl, trifluoroacetyl, propionyl, and butanoyl. Exemplary unsubstituted acyl groups include from 1 to 6, from 1 to 11, or from 1 to 21 carbons.

The term "alkyl," as used herein, refers to a branched or straight-chain monovalent saturated aliphatic hydrocarbon radical of 1 to 20 carbon atoms (e.g., 1 to 16 carbon atoms, 1 to 10 carbon atoms, or 1 to 6 carbon atoms). An alkylene is a divalent alkyl group.

The term "alkenyl," as used herein, alone or in combination with other groups, refers to a straight-chain or branched hydrocarbon residue having a carbon-carbon double bond and having 2 to 20 carbon atoms (e.g., 2 to 16 carbon atoms, 2 to 10 carbon atoms, 2 to 6, or 2 carbon atoms).

The term "alkynyl," as used herein, alone or in combination with other groups, refers to a straight-chain or branched hydrocarbon residue having a carbon-carbon triple bond and having 2 to 20 carbon atoms (e.g., 2 to 16 carbon atoms, 2 to 10 carbon atoms, 2 to 6, or 2 carbon atoms).

The term "amino," as used herein, represents -N(R^{N1})₂, wherein each R^{N1} is, independently, H, OH, NO₂, N(R^{N2})₂, SO₂OR^{N2}, SO₂R^{N2}, SOR^{N2}, an *N*-protecting group, alkyl, alkoxy, aryl, arylalkyl, cycloalkyl, acyl (e.g., acetyl, trifluoroacetyl, or others described herein), wherein each of these recited R^{N1}

groups can be optionally substituted; or two R^{N1} combine to form an alkylene or heteroalkylene, and wherein each R^{N2} is, independently, H, alkyl, or aryl. The amino groups of the invention can be an unsubstituted amino (i.e., $-NH_2$) or a substituted amino (i.e., $-N(R^{N1})_2$).

The term "aryl," as used herein, refers to an aromatic mono- or polycarbocyclic radical of 6 to 12 carbon atoms having at least one aromatic ring. Examples of such groups include, but are not limited to, phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, 1,2-dihydronaphthyl, indanyl, and 1*H*-indenyl.

The term "arylalkyl," as used herein, represents an alkyl group substituted with an aryl group. Exemplary unsubstituted arylalkyl groups are from 7 to 30 carbons (e.g., from 7 to 16 or from 7 to 20 carbons, such as C_1 - C_6 alkyl C_{6-10} aryl, C_1 - C_{10} alkyl C_{6-10} aryl, or C_1 - C_{20} alkyl C_{6-10} aryl), such as, benzyl and phenethyl. In some embodiments, the alkyl and the aryl each can be further substituted with 1, 2, 3, or 4 substituent groups as defined herein for the respective groups.

The term "azido," as used herein, represents a $-N_3$ group.

The term "cyano," as used herein, represents a CN group.

The terms "carbocyclyl," as used herein, refer to a non-aromatic C_3 - C_{12} monocyclic, bicyclic, or tricyclic structure in which the rings are formed by carbon atoms. Carbocyclyl structures include cycloalkyl groups and unsaturated carbocyclyl radicals.

The term "cycloalkyl," as used herein, refers to a saturated, non-aromatic, monovalent mono- or polycarbocyclic radical of three to ten, preferably three to six carbon atoms. This term is further exemplified by radicals such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, norbornyl, and adamantyl.

The term "halo," as used herein, means a fluorine (fluoro), chlorine (chloro), bromine (bromo), or iodine (iodo) radical.

The term "heteroalkyl," as used herein, refers to an alkyl group, as defined herein, in which one or more of the constituent carbon atoms have been replaced by nitrogen, oxygen, or sulfur. In some embodiments, the heteroalkyl group can be further substituted with 1, 2, 3, or 4 substituent groups as described herein for alkyl groups. Examples of heteroalkyl groups are an "alkoxy" which, as used herein, refers alkyl-O- (e.g., methoxy and ethoxy). A heteroalkylene is a divalent heteroalkyl group.

The term "heteroalkenyl," as used herein, refers to an alkenyl group, as defined herein, in which one or more of the constituent carbon atoms have been replaced by nitrogen, oxygen, or sulfur. In some embodiments, the heteroalkenyl group can be further substituted with 1, 2, 3, or 4 substituent groups as described herein for alkenyl groups. Examples of heteroalkenyl groups are an "alkenoxy" which, as used herein, refers alkenyl-O-. A heteroalkenylene is a divalent heteroalkenyl group.

The term "heteroalkynyl," as used herein, refers to an alkynyl group, as defined herein, in which one or more of the constituent carbon atoms have been replaced by nitrogen, oxygen, or sulfur. In some embodiments, the heteroalkynyl group can be further substituted with 1, 2, 3, or 4 substituent groups as described herein for alkynyl groups. Examples of heteroalkynyl groups are an "alkynoxy" which, as used herein, refers alkynyl-O-. A heteroalkynylene is a divalent heteroalkynyl group.

The term "heteroaryl," as used herein, refers to an aromatic mono- or polycyclic radical of 5 to 12 atoms having at least one aromatic ring containing one, two, or three ring heteroatoms selected from N, O, and S, with the remaining ring atoms being C. One or two ring carbon atoms of the heteroaryl group

may be replaced with a carbonyl group. Examples of heteroaryl groups are pyridyl, pyrazoyl, benzooxazolyl, benzoimidazolyl, benzothiazolyl, imidazolyl, oxazolyl, and thiazolyl.

The term "heteroarylalkyl," as used herein, represents an alkyl group substituted with a heteroaryl group. Exemplary unsubstituted heteroarylalkyl groups are from 7 to 30 carbons (e.g., from 7 to 16 or from 7 to 20 carbons, such as C₁-C₆ alkyl C₂-C₉ heteroaryl, C₁-C₁₀ alkyl C₂-C₉ heteroaryl, or C₁-C₂₀ alkyl C₂-C₉ heteroaryl). In some embodiments, the alkyl and the heteroaryl each can be further substituted with 1, 2, 3, or 4 substituent groups as defined herein for the respective groups.

The term "heterocyclyl," as used herein, denotes a mono- or polycyclic radical having 3 to 12 atoms having at least one ring containing one, two, three, or four ring heteroatoms selected from N, O or S, wherein no ring is aromatic. Examples of heterocyclyl groups include, but are not limited to, morpholinyl, thiomorpholinyl, furyl, piperazinyl, piperidinyl, pyranyl, pyrrolidinyl, tetrahydropyranyl, tetrahydrofuranlyl, and 1,3-dioxanyl.

The term "heterocyclylalkyl," as used herein, represents an alkyl group substituted with a heterocyclyl group. Exemplary unsubstituted heterocyclylalkyl groups are from 7 to 30 carbons (e.g., from 7 to 16 or from 7 to 20 carbons, such as C₁-C₆ alkyl C₂-C₉ heterocyclyl, C₁-C₁₀ alkyl C₂-C₉ heterocyclyl, or C₁-C₂₀ alkyl C₂-C₉ heterocyclyl). In some embodiments, the alkyl and the heterocyclyl each can be further substituted with 1, 2, 3, or 4 substituent groups as defined herein for the respective groups.

The term "hydroxyl," as used herein, represents an -OH group.

The term "*N*-protecting group," as used herein, represents those groups intended to protect an amino group against undesirable reactions during synthetic procedures. Commonly used *N*-protecting groups are disclosed in Greene, "Protective Groups in Organic Synthesis," 3rd Edition (John Wiley & Sons, New York, 1999). *N*-protecting groups include acyl, aryloyl, or carbamyl groups such as formyl, acetyl, propionyl, pivaloyl, t-butylacetyl, 2-chloroacetyl, 2-bromoacetyl, trifluoroacetyl, trichloroacetyl, phthalyl, o-nitrophenoxyacetyl, α-chlorobutyryl, benzoyl, 4-chlorobenzoyl, 4-bromobenzoyl, 4-nitrobenzoyl, and chiral auxiliaries such as protected or unprotected D, L or D, L-amino acids such as alanine, leucine, and phenylalanine; sulfonyl-containing groups such as benzenesulfonyl, and p-toluenesulfonyl; carbamate forming groups such as benzyloxycarbonyl, p-chlorobenzyloxycarbonyl, p-methoxybenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl, p-bromobenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, 3,5-dimethoxybenzyloxycarbonyl, 2,4-dimethoxybenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 2-nitro-4,5-dimethoxybenzyloxycarbonyl, 3,4,5-trimethoxybenzyloxycarbonyl, 1-(p-biphenyl)-1-methylethoxycarbonyl, α,α-dimethyl-3,5-dimethoxybenzyloxycarbonyl, benzhydryloxy carbonyl, t-butyloxycarbonyl, diisopropylmethoxycarbonyl, isopropylloxycarbonyl, ethoxycarbonyl, methoxycarbonyl, allyloxycarbonyl, 2,2,2-trichloroethoxycarbonyl, phenoxycarbonyl, 4-nitrophenoxy carbonyl, fluorenyl-9-methoxycarbonyl, cyclopentylloxycarbonyl, adamantylloxycarbonyl, cyclohexylloxycarbonyl, and phenylthiocarbonyl, arylalkyl groups such as benzyl, triphenylmethyl, and benzyloxymethyl, and silyl groups, such as trimethylsilyl. Preferred *N*-protecting groups are alloc, formyl, acetyl, benzoyl, pivaloyl, t-butylacetyl, alanyl, phenylsulfonyl, benzyl, t-butyloxycarbonyl (Boc), and benzyloxycarbonyl (Cbz).

The term "nitro," as used herein, represents an NO₂ group.

The term "thiol," as used herein, represents an -SH group.

The alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl (e.g., cycloalkyl), aryl, heteroaryl, and heterocyclyl groups may be substituted or unsubstituted. When substituted, there will generally be 1 to 4 substituents present, unless otherwise specified. Substituents include, for example: aryl (e.g., substituted and unsubstituted phenyl), carbocyclyl (e.g., substituted and unsubstituted cycloalkyl), halo (e.g., fluoro), hydroxyl, heteroalkyl (e.g., substituted and unsubstituted methoxy, ethoxy, or thioalkoxy), heteroaryl, heterocyclyl, amino (e.g., NH₂ or mono- or dialkyl amino), azido, cyano, nitro, or thiol. Aryl, carbocyclyl (e.g., cycloalkyl), heteroaryl, and heterocyclyl groups may also be substituted with alkyl (unsubstituted and substituted such as arylalkyl (e.g., substituted and unsubstituted benzyl)).

Compounds of the invention can have one or more asymmetric carbon atoms and can exist in the form of optically pure enantiomers, mixtures of enantiomers such as, for example, racemates, optically pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates or mixtures of diastereoisomeric racemates. The optically active forms can be obtained for example by resolution of the racemates, by asymmetric synthesis or asymmetric chromatography (chromatography with a chiral adsorbent or eluant). That is, certain of the disclosed compounds may exist in various stereoisomeric forms. Stereoisomers are compounds that differ only in their spatial arrangement. Enantiomers are pairs of stereoisomers whose mirror images are not superimposable, most commonly because they contain an asymmetrically substituted carbon atom that acts as a chiral center. "Enantiomer" means one of a pair of molecules that are mirror images of each other and are not superimposable. Diastereomers are stereoisomers that are not related as mirror images, most commonly because they contain two or more asymmetrically substituted carbon atoms and represent the configuration of substituents around one or more chiral carbon atoms. Enantiomers of a compound can be prepared, for example, by separating an enantiomer from a racemate using one or more well-known techniques and methods, such as, for example, chiral chromatography and separation methods based thereon. The appropriate technique and/or method for separating an enantiomer of a compound described herein from a racemic mixture can be readily determined by those of skill in the art. "Racemate" or "racemic mixture" means a compound containing two enantiomers, wherein such mixtures exhibit no optical activity; i.e., they do not rotate the plane of polarized light. "Geometric isomer" means isomers that differ in the orientation of substituent atoms in relationship to a carbon-carbon double bond, to a cycloalkyl ring, or to a bridged bicyclic system. Atoms (other than H) on each side of a carbon-carbon double bond may be in an E (substituents are on opposite sides of the carbon-carbon double bond) or Z (substituents are oriented on the same side) configuration. "R," "S," "S*," "R*," "E," "Z," "cis," and "trans," indicate configurations relative to the core molecule. Certain of the disclosed compounds may exist in atropisomeric forms. Atropisomers are stereoisomers resulting from hindered rotation about single bonds where the steric strain barrier to rotation is high enough to allow for the isolation of the conformers. The compounds of the invention may be prepared as individual isomers by either isomer-specific synthesis or resolved from an isomeric mixture. Conventional resolution techniques include forming the salt of a free base of each isomer of an isomeric pair using an optically active acid (followed by fractional crystallization and regeneration of the free base), forming the salt of the acid form of each isomer of an isomeric pair using an optically active amine (followed by fractional crystallization and regeneration of the free acid), forming an ester or amide of each of the isomers of an isomeric pair using an optically pure acid, amine or alcohol (followed by chromatographic separation and removal of the chiral auxiliary), or resolving an isomeric mixture of either

a starting material or a final product using various well known chromatographic methods. When the stereochemistry of a disclosed compound is named or depicted by structure, the named or depicted stereoisomer is at least 60%, 70%, 80%, 90%, 99% or 99.9%) by weight relative to the other stereoisomers. When a single enantiomer is named or depicted by structure, the depicted or named enantiomer is at least 60%, 70%, 80%, 90%, 99% or 99.9% by weight optically pure. When a single diastereomer is named or depicted by structure, the depicted or named diastereomer is at least 60%, 70%, 80%, 90%, 99% or 99.9% by weight pure. Percent optical purity is the ratio of the weight of the enantiomer or over the weight of the enantiomer plus the weight of its optical isomer. Diastereomeric purity by weight is the ratio of the weight of one diastereomer or over the weight of all the diastereomers.

When the stereochemistry of a disclosed compound is named or depicted by structure, the named or depicted stereoisomer is at least 60%, 70%, 80%, 90%, 99% or 99.9% by mole fraction pure relative to the other stereoisomers. When a single enantiomer is named or depicted by structure, the depicted or named enantiomer is at least 60%, 70%, 80%, 90%, 99% or 99.9% by mole fraction pure. When a single diastereomer is named or depicted by structure, the depicted or named diastereomer is at least 60%, 70%, 80%, 90%, 99% or 99.9% by mole fraction pure. Percent purity by mole fraction is the ratio of the moles of the enantiomer or over the moles of the enantiomer plus the moles of its optical isomer. Similarly, percent purity by moles fraction is the ratio of the moles of the diastereomer or over the moles of the diastereomer plus the moles of its isomer. When a disclosed compound is named or depicted by structure without indicating the stereochemistry, and the compound has at least one chiral center, it is to be understood that the name or structure encompasses either enantiomer of the compound free from the corresponding optical isomer, a racemic mixture of the compound or mixtures enriched in one enantiomer relative to its corresponding optical isomer. When a disclosed compound is named or depicted by structure without indicating the stereochemistry and has two or more chiral centers, it is to be understood that the name or structure encompasses a diastereomer free of other diastereomers, a number of diastereomers free from other diastereomeric pairs, mixtures of diastereomers, mixtures of diastereomeric pairs, mixtures of diastereomers in which one diastereomer is enriched relative to the other diastereomer(s) or mixtures of diastereomers in which one or more diastereomer is enriched relative to the other diastereomers. The invention embraces all of these forms.

Definitions

In this application, unless otherwise clear from context, (i) the term “a” may be understood to mean “at least one”; (ii) the term “or” may be understood to mean “and/or”; (iii) the terms “comprising” and “including” may be understood to encompass itemized components or steps whether presented by themselves or together with one or more additional components or steps; and (iv) the terms “about” and “approximately” may be understood to permit standard variation as would be understood by those of ordinary skill in the art; and (v) where ranges are provided, endpoints are included.

As used herein, the term “administration” refers to the administration of a composition (e.g., a compound, a complex or a preparation that includes a compound or complex as described herein) to a subject or system. Administration to an animal subject (e.g., to a human) may be by any appropriate route. For example, in some embodiments, administration may be bronchial (including by bronchial instillation), buccal, enteral, interdermal, intra-arterial, intradermal, intragastric, intramedullary,

intramuscular, intranasal, intraperitoneal, intrathecal, intravenous, intraventricular, mucosal, nasal, oral, rectal, subcutaneous, sublingual, topical, tracheal (including by intratracheal instillation), transdermal, vaginal and vitreal.

As used herein, the term “animal” refers to any member of the animal kingdom. In some embodiments, “animal” refers to humans, at any stage of development. In some embodiments, “animal” refers to non-human animals, at any stage of development. In some embodiments, the non-human animal is a mammal (e.g., a rodent, a mouse, a rat, a rabbit, a monkey, a dog, a cat, a sheep, cattle, a primate, and/or a pig). In some embodiments, animals include, but are not limited to, mammals, birds, reptiles, amphibians, fish, and/or worms. In some embodiments, an animal may be a transgenic animal, genetically-engineered animal, and/or a clone.

As used herein, the terms “approximately” and “about” are each intended to encompass normal statistical variation as would be understood by those of ordinary skill in the art as appropriate to the relevant context. In certain embodiments, the terms “approximately” or “about” each refer to a range of values that fall within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) of a stated value, unless otherwise stated or otherwise evident from the context (e.g., where such number would exceed 100% of a possible value).

Two events or entities are “associated” with one another, as that term is used herein, if the presence, level and/or form of one is correlated with that of the other. For example, a particular entity (e.g., polypeptide) is considered to be associated with a particular disease, disorder, or condition, if its presence, level and/or form correlates with incidence of and/or susceptibility of the disease, disorder, or condition (e.g., across a relevant population).

In the practice of the methods of the present invention, an “effective amount” of any one of the compounds of the invention or a combination of any of the compounds of the invention or a pharmaceutically acceptable salt thereof, is administered *via* any of the usual and acceptable methods known in the art, either singly or in combination.

As used herein, the term “combination therapy” refers to those situations in which a subject is simultaneously exposed to two or more therapeutic agents. In some embodiments, two or more compounds may be administered simultaneously; in some embodiments, such compounds may be administered sequentially; in some embodiments, such compounds are administered in overlapping dosing regimens.

The term “dissemination” used herein refers to spread of a tumor beyond the primary tumor site. Dissemination may be near the primary tumor site (e.g., infiltration of surrounding tissues), within the same organ as the primary tumor (e.g., intracranial dissemination of a primary glioma), or within a different organ than the primary tumor (e.g., a metastasis).

As used herein, the term “dosage form” refers to a physically discrete unit of an active compound (e.g., a therapeutic or diagnostic agent) for administration to a subject. Each unit contains a predetermined quantity of active agent. In some embodiments, such quantity is a unit dosage amount (or a whole fraction thereof) appropriate for administration in accordance with a dosing regimen that has been determined to correlate with a desired or beneficial outcome when administered to a relevant population (i.e., with a therapeutic dosing regimen). Those of ordinary skill in the art appreciate that the

total amount of a therapeutic composition or compound administered to a particular subject is determined by one or more attending physicians and may involve administration of multiple dosage forms.

As used herein, the term “dosing regimen” refers to a set of unit doses (typically more than one) that are administered individually to a subject, typically separated by periods of time. In some embodiments, a given therapeutic compound has a recommended dosing regimen, which may involve one or more doses. In some embodiments, a dosing regimen comprises a plurality of doses each of which are separated from one another by a time period of the same length; in some embodiments, a dosing regimen comprises a plurality of doses and at least two different time periods separating individual doses. In some embodiments, all doses within a dosing regimen are of the same unit dose amount. In some embodiments, different doses within a dosing regimen are of different amounts. In some embodiments, a dosing regimen comprises a first dose in a first dose amount, followed by one or more additional doses in a second dose amount different from the first dose amount. In some embodiments, a dosing regimen comprises a first dose in a first dose amount, followed by one or more additional doses in a second dose amount same as the first dose amount. In some embodiments, a dosing regimen is correlated with a desired or beneficial outcome when administered across a relevant population (i.e., is a therapeutic dosing regimen).

The term “glioma” used herein refers to a primary tumor that starts in the brain or the spinal cord and encompasses all the various types of glioma known in the art, including astrocytoma, ependymoma, oligodendroglioma, brainstem glioma, optic nerve glioma, and mixed glioma.

The terms “non-resectable tumor,” “unresectable tumor,” and “inoperable tumor” used herein refer to tumors that are unable to be surgically removed due to tumor site and/or extent of tumor dissemination.

The term “pharmaceutical composition,” as used herein, represents a composition containing a compound described herein formulated with a pharmaceutically acceptable excipient, and manufactured or sold with the approval of a governmental regulatory agency as part of a therapeutic regimen for the treatment of disease in a mammal. Pharmaceutical compositions can be formulated, for example, for oral administration in unit dosage form (e.g., a tablet, capsule, caplet, gelcap, or syrup); for topical administration (e.g., as a cream, gel, lotion, or ointment); for intravenous administration (e.g., as a sterile solution free of particulate emboli and in a solvent system suitable for intravenous use); or in any other pharmaceutically acceptable formulation.

A “pharmaceutically acceptable excipient,” as used herein, refers any ingredient other than the compounds described herein (for example, a vehicle capable of suspending or dissolving the active compound) and having the properties of being substantially nontoxic and non-inflammatory in a patient. Excipients may include, for example: antiadherents, antioxidants, binders, coatings, compression aids, disintegrants, dyes (colors), emollients, emulsifiers, fillers (diluent), film formers or coatings, flavors, fragrances, glidants (flow enhancers), lubricants, preservatives, printing inks, sorbents, suspending or dispersing agents, sweeteners, and waters of hydration. Exemplary excipients include, but are not limited to: butylated hydroxytoluene (BHT), calcium carbonate, calcium phosphate (dibasic), calcium stearate, croscarmellose, crosslinked polyvinyl pyrrolidone, citric acid, crospovidone, cysteine, ethylcellulose, gelatin, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose, magnesium stearate, maltitol, mannitol, methionine, methylcellulose, methyl paraben, microcrystalline cellulose, polyethylene glycol,

polyvinyl pyrrolidone, povidone, pregelatinized starch, propyl paraben, retinyl palmitate, shellac, silicon dioxide, sodium carboxymethyl cellulose, sodium citrate, sodium starch glycolate, sorbitol, starch (corn), stearic acid, sucrose, talc, titanium dioxide, vitamin A, vitamin E, vitamin C, and xylitol.

As used herein, the term “pharmaceutically acceptable salt” means any pharmaceutically acceptable salt of the compound of formula (I). For example pharmaceutically acceptable salts of any of the compounds described herein include those that are within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and animals without undue toxicity, irritation, allergic response and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, pharmaceutically acceptable salts are described in: Berge et al., *J. Pharmaceutical Sciences* 66:1-19, 1977 and in *Pharmaceutical Salts: Properties, Selection, and Use*, (Eds. P.H. Stahl and C.G. Wermuth), Wiley-VCH, 2008. The salts can be prepared in situ during the final isolation and purification of the compounds described herein or separately by reacting a free base group with a suitable organic acid.

The compounds of the invention may have ionizable groups so as to be capable of preparation as pharmaceutically acceptable salts. These salts may be acid addition salts involving inorganic or organic acids or the salts may, in the case of acidic forms of the compounds of the invention be prepared from inorganic or organic bases. Frequently, the compounds are prepared or used as pharmaceutically acceptable salts prepared as addition products of pharmaceutically acceptable acids or bases. Suitable pharmaceutically acceptable acids and bases and methods for preparation of the appropriate salts are well-known in the art. Salts may be prepared from pharmaceutically acceptable non-toxic acids and bases including inorganic and organic acids and bases.

The term “pure” means substantially pure or free of unwanted components (e.g., other compounds and/or other components of a cell lysate), material defilement, admixture or imperfection.

Representative acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptonate, hexanoate, hydrobromide, hydrochloride, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate, undecanoate, and valerate salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, and magnesium, as well as nontoxic ammonium, quaternary ammonium, and amine cations, including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, and ethylamine.

As used herein, the term “stearoyl-CoA desaturase (SCD)-associated disorder” refers to an undesired physiological condition, disorder, or disease that is associated with and/or mediated at least in part by an SCD protein. In some instances, SCD-associated disorders are associated with excess SCD levels and/or activity. SCDs introduce a double bond in the C9-C10 position of saturated fatty acids such as palmitoyl-CoA and stearoyl-CoA which are converted to palmitoleoyl-CoA and oleoyl-CoA, respectively. One SCD gene, SCD1, has been characterized in humans for which there are two isoforms,

SCD1 and SCD5. An SCD-associated disorder may be associated with and/or mediated at least in part by SCD1 and/or SCD5. Exemplary SCD-associated disorders include SCD-associated disorders include, but are not limited to metabolic disorders (e.g., diabetes (e.g., Type I diabetes and Type II diabetes), hyperglycemia, metabolic syndrome, obesity, lipid disorders, fatty liver, nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), and hypertension), cancer, cardiovascular diseases, cerebrovascular diseases, kidney diseases, liver diseases, skin disorders (e.g., acne (e.g., acne vulgaris)), central nervous system (CNS) disorders, dementia, multiple sclerosis, schizophrenia, mild cognitive impairment, Alzheimer's Disease, cerebral amyloid angiopathy, and dementia associated with Down Syndrome. Additional SCD-associated disorders are described herein or known in the art.

As used herein, the term "subject" refers to any organism to which a composition in accordance with the invention may be administered, e.g., for experimental, diagnostic, prophylactic, and/or therapeutic purposes. Typical subjects include any animal (e.g., mammals such as mice, rats, rabbits, non-human primates, and humans). A subject may seek or be in need of treatment, require treatment, be receiving treatment, be receiving treatment in the future, or be a human or animal who is under care by a trained professional for a particular disease or condition.

As used herein, the terms "treat," "treated," or "treating" mean both therapeutic treatment and prophylactic or preventative measures wherein the object is to prevent or slow down (lessen) an undesired physiological condition, disorder, or disease, or obtain beneficial or desired clinical results. Beneficial or desired clinical results include, but are not limited to, alleviation of symptoms; diminishment of the extent of a condition, disorder, or disease; stabilized (i.e., not worsening) state of condition, disorder, or disease; delay in onset or slowing of condition, disorder, or disease progression; amelioration of the condition, disorder, or disease state or remission (whether partial or total), whether detectable or undetectable; an amelioration of at least one measurable physical parameter, not necessarily discernible by the patient; or enhancement or improvement of condition, disorder, or disease. Treatment includes eliciting a clinically significant response without excessive levels of side effects. Treatment also includes prolonging survival as compared to expected survival if not receiving treatment.

A "therapeutic regimen" refers to a dosing regimen whose administration across a relevant population is correlated with a desired or beneficial therapeutic outcome.

The term "therapeutically effective amount" means an amount that is sufficient, when administered to a population suffering from or susceptible to a disease, disorder, and/or condition in accordance with a therapeutic dosing regimen, to treat the disease, disorder, and/or condition. In some embodiments, a therapeutically effective amount is one that reduces the incidence and/or severity of, and/or delays onset of, one or more symptoms of the disease, disorder, and/or condition. Those of ordinary skill in the art will appreciate that the term "therapeutically effective amount" does not in fact require successful treatment be achieved in a particular individual. Rather, a therapeutically effective amount may be that amount that provides a particular desired pharmacological response in a significant number of subjects when administered to patients in need of such treatment. It is specifically understood that particular subjects may, in fact, be "refractory" to a "therapeutically effective amount." To give but one example, a refractory subject may have a low bioavailability such that clinical efficacy is not obtainable. In some embodiments, reference to a therapeutically effective amount may be a reference to an amount as measured in one or more specific tissues (e.g., a tissue affected by the disease, disorder or


condition) or fluids (e.g., blood, saliva, serum, sweat, tears, urine, etc). Those of ordinary skill in the art will appreciate that, in some embodiments, a therapeutically effective amount may be formulated and/or administered in a single dose. In some embodiments, a therapeutically effective amount may be formulated and/or administered in a plurality of doses, for example, as part of a dosing regimen.

5


Detailed Description

The invention features compounds useful for the treatment of neurological disorders and primary brain cancer, e.g., by inhibiting α -synuclein toxicity in a cell such as a neural cell, or by inhibiting SCD5 and/or SCD1 in a cell such as a neural cell. Exemplary compounds described herein include compounds having a structure according to **Formula I** or **Formula II**:

10



Formula I



Formula II,

or pharmaceutically acceptable salts thereof.

In some embodiments, the compound has the structure of any one of compounds 1-475 in Table 1. In some embodiments, the compound has the structure of any one of compounds 476-683 in Table 2.

15

Other embodiments, as well as exemplary methods for the synthesis or production of these compounds, are described herein.

Pharmaceutical Uses

The compounds described herein are useful in the methods of the invention and, while not bound by theory, are believed to exert their desirable effects through their ability to inhibit toxicity caused by protein aggregation, e.g., α -synuclein aggregation, in a cell.

20

The compounds described herein are useful as inhibitors of stearoyl-CoA desaturase (SCD), including SCD1 and/or SCD5. SCD inhibitors are known in the art to be useful in methods of treating and/or preventing SCD-associated disorders. SCD-associated disorders are described, for example, in U.S. Patent No. 8,148,378, and in International Patent Application Publication Nos. WO 2011/047481, WO 2010/112520, WO 2010/045374, WO 2010/028761; WO 2009150196, and WO 2009/106991. Accordingly, another aspect of the present invention relates to methods of treating and/or preventing an SCD-associated disorder in a subject in need thereof.

25

30

Cancer

Another aspect of the present invention relates to methods of treating and/or preventing cancer, including solid tumors or hematological malignancies (e.g., esophageal cancer, pancreatic cancer, endometrial cancer, kidney cancer, hepatoma, thyroid cancer, gallbladder cancer, prostate cancer, leukemia (e.g., lymphomas and myelomas), ENT-related cancer, primary brain cancer (e.g., a glioma, such as an astrocytoma, e.g., a glioblastoma), colon cancer, rectal cancer, colorectal cancer, ovarian cancer, uterine cancer, breast cancer, skin cancer, and prostate cancer), neoplasia, malignancy, metastases, tumors (benign or malignant), carcinogenesis, and hepatomas.

35

Glioma

A glioma is a type of tumor that starts in the brain or the spinal cord and arises from glial cells. Approximately half of all brain tumors are gliomas. There are four main types of glioma: astrocytoma, ependymoma, oligodendroglioma, and mixed glioma. Gliomas can be classified according to their location: infratentorial (i.e., located in the lower part of the brain) or supratentorial (i.e., located in the upper part of the brain). Gliomas are further categorized according to their grade, which is determined by pathologic evaluation of the tumor. The World Health Organization (WHO) has developed a grading system, from Grade I gliomas, which tend to be the least aggressive, to Grade IV gliomas, which tend to be the most aggressive and malignant. Examples of low grade (i.e., Grade I or Grade II) gliomas include pilocytic astrocytoma, fibrillary astrocytoma, pleomorphic xantroastrocytoma, and desmoplastic neuroepithelial tumor. High-grade gliomas encompass Grade III gliomas (e.g., anaplastic astrocytoma, AA) and Grade IV gliomas (e.g., glioblastoma multiforme, GBM). Anaplastic astrocytoma accounts for 4% of all brain tumors. Glioblastoma multiforme, the most invasive type of glial tumor, is most common in men and women in their 50s-70s and accounts for 23% of all primary brain tumors. The prognosis is the worst for Grade IV gliomas, with an average survival time of 12 months.

Gliomas are treated with surgery, radiation therapy and chemotherapy, often in combination; however, gliomas are rarely curable. More than 95% of the patients with gliomas die within 2 years following diagnosis despite aggressive therapy. Thus, there remains a need for new methods and compositions for treating gliomas.

Treatment of primary brain cancer with SCD inhibitors

SCD1 was previously identified as a therapeutic target for the treatment of gliomas (Dai et al., doi:10.3389/fphar.2017.00960; Tracz-Gaszewska and Dobrzyn, doi.org/10.3390/cancers11070948). Accordingly, SCD inhibitors are expected to be useful for inhibiting proliferation, survival, and invasiveness of cancer cells, thereby inhibiting tumor growth and dissemination in a subject suffering from a primary brain cancer (e.g., a glioma, such as an astrocytoma, e.g., a glioblastoma). Pharmaceutical compositions (e.g., the SCD inhibitors disclosed herein) may be administered either prior to or following surgical removal of a primary tumor and/or treatment such as administration of radiotherapy or conventional chemotherapeutic drugs (e.g., temozolomide). In certain embodiments, compounds of the present invention are used for the treatment of gliomas. A patient afflicted with a glioma may be diagnosed using criteria generally accepted in the art.

SCD inhibitors can be used alone or in combination with one or more therapeutic interventions (e.g., surgery, radiotherapy, chemotherapy) for use in treating a subject suffering from a primary brain cancer (e.g., a glioma, such as an astrocytoma, e.g., a glioblastoma). In some embodiments, an SCD inhibitor can be used prior (e.g., about 1 minute, 5 minutes, 10 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 10 hours, 12 hours, 16 hours, 20 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 4 weeks, 8 weeks, 12 weeks, 4 months, 5 months, 6 months, 8 months, 10 months, or 12 months) to one or more therapeutic interventions (e.g., surgery, radiotherapy, chemotherapy). In some embodiments, an SCD inhibitor can be used concurrently with one or more therapeutic interventions (e.g., surgery, radiotherapy, chemotherapy). In some embodiments, an SCD inhibitor can be used after (e.g., about 1 minute, 5

minutes, 10 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 8 hours, 10 hours, 12 hours, 16 hours, 20 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 2 weeks, 4 weeks, 8 weeks, 12 weeks, 4 months, 5 months, 6 months, 8 months, 10 months, or 12 months) one or more therapeutic interventions (e.g., surgery, radiotherapy, chemotherapy).

For example, SCD inhibitors can be used concurrently with surgical resection of the tumor and prior to radiotherapy and chemotherapy. SCD inhibitors can also be used prior to surgical resection of the tumor, radiotherapy, and chemotherapy. SCD inhibitors can also be used concurrently with surgical resection of the tumor, radiotherapy, and chemotherapy. SCD inhibitors can also be used after surgical resection of the tumor, radiotherapy, and chemotherapy. SCD inhibitors can also be used concurrently with radiotherapy and prior to surgical resection of the tumor and chemotherapy. SCD inhibitors can also be used concurrently with post-resection radiotherapy and prior to chemotherapy. SCD inhibitors can also be used concurrently with chemotherapy and after surgical resection of the tumor and radiotherapy.

When SCD inhibitors, are used to treat a subject suffering from a glioma in combination with one or more appropriate therapeutics, the compounds within the combination can be administered as a combination product or can be administered substantially simultaneously or sequentially.

In one embodiment, an SCD inhibitor can be used in combination with one or more additional agents to treat glioblastoma multiforme. Examples of such agents include those selected from the group consisting of abarelix, actinomycin D, adriamycin, aldesleukin, alemtuzumab, alitretinoin, allopurinol, altretamine, amifostine, anakinra, anastrozole, arsenic trioxide, asparaginase, azacitidine, BCG Live, bevacuzimab, bexarotene, bleomycin, bortezomib, busulfan, calusterone, capecitabine, carboplatin, carmustine, celecoxib, cetuximab, chlorambucil, cisplatin, cladribine, clofarabine, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, dalteparin (e.g., sodium), darbepoetin alfa, dasatinib, daunorubicin, daunomycin, decitabine, denileukin, denileukin difitox, dexrazoxane, docetaxel, doxorubicin, dromostanolone propionate, eculizumab, epirubicin (e.g., HCl), epoetin alfa, erlotinib, estramustine, etoposide (e.g., phosphate), everolimus, exemestane, fentanyl (e.g., citrate), filgrastim, floxuridine, fludarabine, fluorouracil, 5-FU, fulvestrant, gefitinib, gemcitabine (e.g., HCl), gemtuzumab, ozogamicin, goserelin (e.g., acetate), histrelin (e.g., acetate), hydroxyurea, ibritumomab tiuxetan, idarubicin, ifosfamide, imatinib (e.g., mesylate), interferon alfa-2b, irinotecan, lapatinib ditosylate, lenalidomide, letrozole, leucovorin, leuprolide (e.g., acetate), levamisole, lomustine, CCNU, meclorethamine (nitrogen mustard), megestrol, melphalan (L-PAM), mercaptopurine (6-MP), mesna, methotrexate, methoxsalen, mitomycin C, mitotane, mitoxantrone, nandrolone phenpropionate, nelarabine, nofetumomab, oprelvekin, oxaliplatin, paclitaxel, palifermin, pamidronate, panitumumab, pegademase, pegaspargase, pegfilgrastim, peginterferon alfa-2b, pemetrexed (e.g., disodium), pentostatin, pipobroman, plicamycin (mithramycin), porfimer (e.g., sodium), procarbazine, quinacrine, rasburicase, rituximab, sargramostim, sorafenib, streptozocin, sunitinib (e.g., maleate), talc, tamoxifen, temozolomide, teniposide (VM-26), testolactone, thalidomide, thioguanine (6-TG), thiotepa, thiotepa, thiotepa, topotecan (e.g., hcl), toremifene, Tositumomab/I-131 (tositumomab), trastuzumab, tretinoin (ATRA), uracil mustard, valrubicin, vinblastine, vincristine, vinorelbine, vorinostat, zoledronate, and zoledronic acid. In some embodiments, an SCD inhibitor is used in combination with one or more of temozolomide, carmustine, bevacizumab, lomustine, everolimus, vincristine, and procarbazine, or biologically active variants, salts, and derivatives of any of the above.

In some embodiments, an SCD inhibitor when co-administered with a chemotherapeutic agent to a subject who has glioma, decreases the dosage of chemotherapeutic agent required for a therapeutic effect by, e.g., decreasing cancer cell growth rate, decreasing tumor size, decreasing survival of cancer cells, or increasing apoptosis by cancer cells. In one embodiment, the chemotherapeutic agent is temozolomide.

Treating primary brain cancer can result in a reduction in size or volume of a tumor. For example, after treatment, tumor size is reduced by about 5% or greater (e.g., about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or greater) relative to its size prior to treatment. Size of a tumor may be measured by any reproducible means of measurement. For example, the size of a tumor may be measured as a diameter of the tumor.

Treating primary brain cancer may further result in a decrease in number of tumors. For example, after treatment, tumor number is reduced by about 5% or greater (e.g., about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or greater) relative to number prior to treatment. Number of tumors may be measured by any reproducible means of measurement, e.g., the number of tumors may be measured by counting tumors visible to the naked eye or at a specified magnification (e.g., 2x, 3x, 4x, 5x, 10x, or 50x).

Treating primary brain cancer can result in a decrease in number of metastatic nodules in other tissues or organs distant from the primary tumor site. For example, after treatment, the number of metastatic nodules is reduced by about 5% or greater (e.g., about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or greater) relative to number prior to treatment. The number of metastatic nodules may be measured by any reproducible means of measurement. For example, the number of metastatic nodules may be measured by counting metastatic nodules visible to the naked eye or at a specified magnification (e.g., 2x, 10x, or 50x).

Treating primary brain cancer can result in an increase in average survival time of a population of subjects treated according to the present invention in comparison to a population of untreated subjects. For example, the average survival time is increased by more than about 30 days (more than about 60 days, 90 days, or 120 days). An increase in average survival time of a population may be measured by any reproducible means. An increase in average survival time of a population may be measured, for example, by calculating for a population the average length of survival following initiation of treatment with the compound of the invention. An increase in average survival time of a population may also be measured, for example, by calculating for a population the average length of survival following completion of a first round of treatment with a pharmaceutically acceptable salt of the invention.

Treating primary brain cancer can also result in a decrease in the mortality rate of a population of treated subjects in comparison to an untreated population. For example, the mortality rate is decreased by more than about 2% (e.g., more than about 5%, 10%, or 25%). A decrease in the mortality rate of a population of treated subjects may be measured by any reproducible means, for example, by calculating for a population the average number of disease-related deaths per unit time following initiation of treatment with a pharmaceutically acceptable salt of the invention. A decrease in the mortality rate of a population may also be measured, for example, by calculating for a population the average number of disease-related deaths per unit time following completion of a first round of treatment with a pharmaceutically acceptable salt of the invention.

Treating primary brain cancer can result in a decrease in recurrence of tumors in treated subjects in comparison to an untreated population. For example, after treatment, the time to tumor recurrence may be reduced by about 5% or greater (e.g., about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or greater) relative to the rate in the untreated population. The rate of recurrence may be measured, for example, by calculating for a population the average length of time from when the tumor could not be detected (e.g., after resection) to when a new tumor can be detected.

Treating primary brain cancer can result in a decrease in dissemination of cancer cells in treated subjects in comparison to an untreated population. For example, after treatment, the number of recurrent tumors at sites other than the original site of the tumor is reduced by about 5% or greater (e.g., about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or greater) relative to number present in the untreated population. A reduction in the number of recurrent tumors at sites other than the original site of the tumor can be measured by comparing the number of recurrent tumors at sites other than the original site in a treated population relative to the number in an untreated population.

Neurological disorders

Another aspect of the present invention relates to methods of treating and/or preventing neurological disorders such as neurodegenerative diseases in a subject in need thereof. The pathology of neurodegenerative disease may be characterized by the presence of inclusion bodies in brain tissue of affected patients.

In certain embodiments, neurological disorders that may be treated and/or prevented by the inventive methods include, but are not limited to, Alexander disease, Alper's disease, AD, amyotrophic lateral sclerosis, ataxia telangiectasia, Canavan disease, Cockayne syndrome, corticobasal degeneration, Creutzfeldt-Jakob disease, Huntington disease, Kennedy's disease, Krabbe disease, Lewy body dementia, Machado-Joseph disease, multiple sclerosis, PD, Pelizaeus-Merzbacher disease, Pick's disease, primary lateral sclerosis, Ref sum's disease, Sandhoff disease, Schilder's disease, Steele-RichardsonOlszewski disease, tabes dorsalis, and Guillain-Barre Syndrome.

Metabolic disorders

Another aspect of the present invention relates to methods of treating and/or preventing metabolic disorders in a subject in need thereof. Metabolic disorders include, e.g., insulin resistance, diabetes mellitus (e.g., Type I diabetes, Type II diabetes, non-insulin-dependent diabetes mellitus, gestational diabetes, and diabetic complications (e.g., diabetic peripheral neuropathy, diabetic nephropathy diseases, diabetic retinopathy, diabetic macroangiopathy, vascular complications of diabetes, and diabetic arteriosclerosis)), hyperglycemia, metabolic syndrome, hyperinsulinemia, glucose intolerance, impaired glucose tolerance, body weight disorders (e.g., obesity (e.g., abdominal obesity), overweight, cachexia, body mass index, and anorexia), lipid disorders (e.g., abnormal lipid levels (e.g., elevated lipid levels, for example, in plasma), dyslipidemia (e.g., diabetic dyslipidemia), mixed dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypoalphalipoproteinemia, hyperbetalipoproteinemia, atherosclerosis, hypercholesterolemia (e.g., familial hypercholesterolemia), low HDL, high LDL, diseases related to accumulation of lipids in liver, familial histiocytic reticulosis, lipoprotein lipase deficiency, polyunsaturated fatty acid (PUFA) disorder, fatty acid desaturation index (e.g. the ratio of 18:1/18:0 fatty

acids, or other fatty acids), and abnormal lipid metabolism disorders), disorders of abnormal plasma lipoprotein, disorders of pancreatic beta cell regeneration, fatty liver, nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), hypertension, and microalbuminemia, leptin related diseases, hyperleptinaemia, appetite disorder, essential fatty acid deficiency, and adverse weight gain associated with a drug therapy.

Other SCD-associated disorders

Further SCD-associated disorders include cardiovascular disease (e.g., heart disease, atherosclerosis, hypertension, lipidemia, dyslipidemia, elevated blood pressure, microalbuminemia, hyperuricaemia, hypercholesterolemia, hyperlipidemias, hypertriglyceridemias, arteriosclerosis, coronary artery disease, myocardial infarction, vascular complications of diabetes, and diabetic arteriosclerosis), inflammation, sinusitis, asthma, pancreatitis, osteoarthritis, rheumatoid arthritis, hepatitis (e.g., sexual hepatitis), meibomitis, cystic fibrosis, pre-menstrual syndrome, osteoporosis, thrombosis, cardiovascular risks, weight loss, angina, high blood pressure, ischemia, cardiac ischemia, reperfusion injury, angioplastic restenosis, infertility, liver disease (e.g., fatty liver, cirrhosis, nonalcoholic steatohepatitis, liver fibrosis, and hepatitis C related steatosis), kidney disease (e.g., tubulointerstitial fibrosis, kidney lipid accumulation, glomerular sclerosis, and proteinuria), osteoarthritis (e.g., osteoarthritis of the knee), gastro-esophageal disease, sleep apnea, secondary hyperparathyroidism of renal osteodystrophy, peripheral vascular disease, cerebrovascular disease (e.g., stroke, ischemic stroke and transient ischemic attack (TIA), and ischemic retinopathy), hyperandrogenism, malignant syndrome, extrapyramidal symptoms, hyperuricemia, hypercoagulability, syndrome X, cataract, polycystic ovary syndrome, breathing abnormalities, sleep-disordered breathing, low back pain, gout, gallstone disease, myopathies, lipid myopathies (e.g., carnitine palmitoyltransferase deficiency (CPT I or CPT II)), autoimmune diseases (e.g., lupus, host versus graft rejection, and rejection of organ transplants), asthma, inflammatory bowel diseases, nephropathy, retinopathy, erythrohepatic protoporphyria, iron overload disorders, and hereditary hemochromatosis.

Still further SCD-associated disorders include central nervous system (CNS) disorders, dementia, schizophrenia, mild cognitive impairment, Alzheimer's Disease, cerebral amyloid angiopathy, dementia associated with Down Syndrome, other neurodegenerative diseases, psychiatric disorders, eye diseases, immune disorders, multiple sclerosis, neuropathy, and depression.

Additional SCD-associated disorders include skin disorders (e.g., acne (e.g., acne vulgaris), psoriasis, hirsutism, rosacea, seborrheic skin, oily skin (syn seborrhea), seborrheic dermatitis, hyperseborrhea, eczema, keloid scar, skin ageing, diseases related to production or secretions from mucous membranes, wrinkles, lack of adequate skin firmness, lack of adequate dermal hydration, insufficient sebum secretion, oily hair, shiny skin, greasy-looking skin, greasy-looking hair, and other skin conditions caused by lipid imbalance).

An SCD-associated disorder can also include a disease or condition which is, or is related to, viral diseases or infections.

In some embodiments, the SCD-associated disorder is acne (e.g., acne vulgaris). In some embodiments, the SCD-associated disorder is diabetes (e.g., type II diabetes, including diabetes with inadequate glycemic control). In some embodiments, the SCD-associated disorder is nonalcoholic fatty

liver disease (NAFLD). In some embodiments, the SCD-associated disorder is nonalcoholic steatohepatitis (NASH). In some embodiments, the SCD-associated disorder is cancer. In some embodiments, the SCD-associated disorder is obesity. In some embodiments, the SCD-associated disorder is metabolic syndrome (e.g., dyslipidemia, obesity, insulin resistance, hypertension, microalbuminemia, hyperuricaemia, and hypercoagulability), syndrome X, diabetes, insulin resistance, decreased glucose tolerance, non-insulin-dependent diabetes mellitus, Type II diabetes, Type I diabetes, diabetic complications, body weight disorders (e.g., obesity, overweight, cachexia, and anorexia), weight loss, body mass index, leptin related diseases, or a skin disorder (e.g., eczema, acne, psoriasis, and keloid scar). In some embodiments, the SCD-associated disorder is diabetes, metabolic syndrome, insulin resistance, obesity, a cardiovascular disorder, a CNS disorder, schizophrenia, or Alzheimer's disease.

Combination Formulations and Uses Thereof

The compounds of the invention can be combined with one or more therapeutic agents. In particular, the therapeutic agent can be one that treats or prophylactically treats any neurological disorder described herein.

Combination Therapies

A compound of the invention can be used alone or in combination with other agents that treat neurological disorders or symptoms associated therewith, or in combination with other types of treatment to treat, prevent, and/or reduce the risk of any neurological disorders. In combination treatments, the dosages of one or more of the therapeutic compounds may be reduced from standard dosages when administered alone. For example, doses may be determined empirically from drug combinations and permutations or may be deduced by isobolographic analysis (e.g., Black et al., *Neurology* 65:S3-S6, 2005). In this case, dosages of the compounds when combined should provide a therapeutic effect.

Pharmaceutical Compositions

The compounds of the invention are preferably formulated into pharmaceutical compositions for administration to human subjects in a biologically compatible form suitable for administration *in vivo*. Accordingly, in another aspect, the present invention provides a pharmaceutical composition comprising a compound of the invention in admixture with a suitable diluent, carrier, or excipient.

The compounds of the invention may be used in the form of the free base, in the form of salts, solvates, and as prodrugs. All forms are within the scope of the invention. In accordance with the methods of the invention, the described compounds or salts, solvates, or prodrugs thereof may be administered to a patient in a variety of forms depending on the selected route of administration, as will be understood by those skilled in the art. The compounds of the invention may be administered, for example, by oral, parenteral, buccal, sublingual, nasal, rectal, patch, pump, or transdermal administration and the pharmaceutical compositions formulated accordingly. Parenteral administration includes intravenous, intraperitoneal, subcutaneous, intramuscular, transepithelial, nasal, intrapulmonary,

intrathecal, rectal, and topical modes of administration. Parenteral administration may be by continuous infusion over a selected period of time.

A compound of the invention may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or it may be enclosed in hard or soft shell gelatin capsules, or it may be compressed into tablets, or it may be incorporated directly with the food of the diet. For oral therapeutic administration, a compound of the invention may be incorporated with an excipient and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, and wafers.

A compound of the invention may also be administered parenterally. Solutions of a compound of the invention can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, DMSO and mixtures thereof with or without alcohol, and in oils. Under ordinary conditions of storage and use, these preparations may contain a preservative to prevent the growth of microorganisms. Conventional procedures and ingredients for the selection and preparation of suitable formulations are described, for example, in Remington's Pharmaceutical Sciences (2003, 20th ed.) and in The United States Pharmacopeia: The National Formulary (USP 24 NF19), published in 1999.

The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases the form must be sterile and must be fluid to the extent that may be easily administered *via* syringe.

Compositions for nasal administration may conveniently be formulated as aerosols, drops, gels, and powders. Aerosol formulations typically include a solution or fine suspension of the active substance in a physiologically acceptable aqueous or non-aqueous solvent and are usually presented in single or multidose quantities in sterile form in a sealed container, which can take the form of a cartridge or refill for use with an atomizing device. Alternatively, the sealed container may be a unitary dispensing device, such as a single dose nasal inhaler or an aerosol dispenser fitted with a metering valve which is intended for disposal after use. Where the dosage form comprises an aerosol dispenser, it will contain a propellant, which can be a compressed gas, such as compressed air or an organic propellant, such as fluorochlorohydrocarbon. The aerosol dosage forms can also take the form of a pump-atomizer. Compositions suitable for buccal or sublingual administration include tablets, lozenges, and pastilles, where the active ingredient is formulated with a carrier, such as sugar, acacia, tragacanth, gelatin, and glycerine. Compositions for rectal administration are conveniently in the form of suppositories containing a conventional suppository base, such as cocoa butter.

The compounds of the invention may be administered to an animal, e.g., a human, alone or in combination with pharmaceutically acceptable carriers, as noted herein, the proportion of which is determined by the solubility and chemical nature of the compound, chosen route of administration, and standard pharmaceutical practice.

Dosages

The dosage of the compounds of the invention, and/or compositions comprising a compound of the invention, can vary depending on many factors, such as the pharmacodynamic properties of the compound; the mode of administration; the age, health, and weight of the recipient; the nature and extent


of the symptoms; the frequency of the treatment, and the type of concurrent treatment, if any; and the clearance rate of the compound in the animal to be treated. One of skill in the art can determine the appropriate dosage based on the above factors. The compounds of the invention may be administered initially in a suitable dosage that may be adjusted as required, depending on the clinical response. In general, satisfactory results may be obtained when the compounds of the invention are administered to a human at a daily dosage of, for example, between 0.05 mg and 3000 mg (measured as the solid form). Dose ranges include, for example, between 10-1000 mg (e.g., 50-800 mg). In some embodiments, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, or 1000 mg of the compound is administered. Preferred dose ranges include, for example, between 0.05-15 mg/kg or between 0.5-15 mg/kg.

Alternatively, the dosage amount can be calculated using the body weight of the patient. For example, the dose of a compound, or pharmaceutical composition thereof, administered to a patient may range from 0.1-50 mg/kg (e.g., 0.25-25 mg/kg). In exemplary, non-limiting embodiments, the dose may range from 0.5-5.0 mg/kg (e.g., 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, or 5.0 mg/kg) or from 5.0-20 mg/kg (e.g., 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 mg/kg).

EXAMPLES


The synthesis of compounds of this invention can be synthesized according to one or more of the general schemes of 1-13 shown below. The variables recited in the general schemes below are as defined for Formulae I, II, III, and IV.

General Scheme 1




An appropriately substituted alpha-halo aldehyde I (X^a is a halo, such as Cl or Br) can be condensed with urea or thiourea II to give appropriate 5-membered heterocycle III, where Y is either an O or S. This amine can be coupled with acid IV under a variety of conditions to provide the desired amide V.

General Scheme 2




An appropriately substituted alcohol I can be reacted with a haloated heterocycle such as II under basic conditions (eg cesium carbonate) to give ether intermediate III. Coupling of amine 3 with acid IV affords the desired heterocyclic compound V.

General Scheme 3




Coupling of amine I with acid II under a variety of coupling conditions affords the desired adduct III.

General Scheme 4




Appropriately substituted aldehyde or ketone I can be alkylated with heterocycle II (where X^c is H or halide, usually bromide) under basic conditions (e.g. n-butyllithium) to give alcohol intermediate III. Deprotection of III under a variety of acidic conditions (e.g. trifluoroacetic acid) gives amine IV. Coupling of this amine IV to acid V under a variety of coupling conditions affords desired compound VI. Alternatively, deoxygenation of IV strong under acidic conditions gives intermediate VII which can be coupled with acid V under a variety of coupling conditions to give amide VIII.

General Scheme 5




Appropriately substituted halide **I** can be reacted under metal catalysis conditions with appropriately substituted boronic ester **II** or acid **III** to give amine intermediate **IV**. Coupling of amine **IV** with appropriately substituted acid **V** under a variety of coupling conditions gives amide **VI**.

General Scheme 6




Condensation of di-acid **I** with appropriately substituted hydrazine **II** gives substituted acid **III**. Coupling with appropriately substituted amine **IV** under a variety of coupling conditions (e.g. HATU) gives amide **V**.

General Scheme 7



Condensation of appropriately substituted acid **I** with aminothiurea **II** gives appropriately substituted thiadiazole isomer **III**. Reaction of amine **III** with appropriately substituted acid **IV** under a variety of coupling conditions (e.g. HATU) yields amide **V**.


General Scheme 8



Pyridine I is alkylated with alkyl halide under basic conditions (e.g. potassium carbonate) to give two regioisomers II and III. The alkylated amide III is hydrolyzed under various conditions to give acid IV.

5 Subsequent coupling with appropriately substituted amine V under various coupling conditions (e.g. HATU) affords amide VI.


General Scheme 9



An appropriately substituted phenol II is alkylated under basic conditions with pyridine I to give ether III. Reduction of nitro group in presence of iron affords amine intermediate IV. Coupling of IV with appropriately substituted acid V under a variety of coupling conditions gives VI.

10

General Scheme 10




Appropriately substituted halide I can be reacted under metal catalysis conditions with appropriately substituted boronic ester II to give amine intermediate III. Protection of amine III with a carbamate group (e.g. Boc) under standard conditions affords amine intermediate IV. Displacement of mesylate V with amine IV affords product VI which can be deprotected under standard acidic conditions to give amine VII.

15

20


General Scheme 11





General Scheme 12



General Scheme 13




Example 1. Preparation of***N*-(4-(3-fluorobenzyl)phenyl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (1)****Step 1: Preparation of 4-(3-fluorobenzyl)aniline**

5

To a solution of 1-(bromomethyl)-3-fluorobenzene (2.0 g, 10.6 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (2.33 g, 10.4 mmol), potassium carbonate (2.93 g, 21.3 mmol) acetonitrile (60 mL) and water (10 mL) was added [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II)-dichloromethane (0.868 g, 1.06 mmol) under nitrogen. The mixture was heated to 90 °C and stirred for 2 h. The volatiles were removed under reduced pressure. Aqueous layer was acidified to pH = 1-3 with 1 N hydrogen chloride and extracted with ethyl acetate (50 mL). The aqueous layer was then re-adjusted to pH = 8-10 with aqueous sodium bicarbonate and extracted with dichloromethane (50 mL x 2). The combined dichloromethane layers were dried over sodium sulfate, filtered and concentrated. Purification by column chromatography (silica gel, (petroleum ether/ethyl acetate= 4/1) yields 4-(3-fluorobenzyl)aniline (0.800 g, 3.98 mmol, 38.3%) as a red oil. LCMS (ESI) *m/z*: 202.1 [M+H]⁺.

15



Step 2: Preparation of***N*-(4-(3-fluorobenzyl)phenyl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide**

20

To a solution of 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.100 g, 0.641 mmol), *N,N*-diisopropylethylamine (0.248 g, 1.92 mmol) in tetrahydrofuran (5 mL) at room temperature, was added [bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (366 mg, 0.962 mmol). The reaction was stirred for 20 minutes before a solution of 4-(3-fluorobenzyl)aniline (0.129 g, 0.641 mmol) in tetrahydrofuran (1.0 mL) was added. The reaction mixture was stirred at 20 °C for 16 h. The volatiles were removed under reduced pressure and the crude material was added to a mixture of dichloromethane (50 mL) and water (50 mL). The organic layer was collected, dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μm column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give *N*-(4-(3-fluorobenzyl)phenyl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.0643 g, 0.192 mmol, 30%) as a white solid. ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 9.95 (s, 1H), 7.66 (d, *J* = 8.5Hz, 1H), 7.33 (t, *J* = 3.8Hz, 1H), 7.21 (d, *J* = 8.5Hz, 2H), 6.99-7.08 (m, a3H), 3.92 (s, 2H), 3.36 (s, 3H), 2.82 (t, *J* = 8.5Hz, 1H), 2.48-2.50 (m, 2H); LCMS (ESI) *m/z*: 340.1 [M+H]⁺.


25

30

Example 2. Preparation of***N*-(4-(3-chlorobenzyl)phenyl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (2)****5 Step 1: Preparation of 4-(3-chlorobenzyl)aniline**

To a solution of 1-(bromomethyl)-3-chlorobenzene (2.0 g, 9.81 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (2.15 g, 9.81 mmol), potassium carbonate (2.71 g, 19.6 mmol) in acetonitrile (16 mL) and water (4 mL) was added

10 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane (0.800 g, 0.981 mmol) under nitrogen. The mixture was heated to 90 °C and stirred for 2 h. The volatiles were removed under reduced pressure and the slurry was acidified to pH = 1-3 with aqueous 1 N hydrogen chloride and extracted with ethyl acetate (50 mL). The aqueous layer was then adjusted to pH = 8-10 with aqueous sodium bicarbonate and extracted with dichloromethane (50 mL x 2). The combined dichloromethane
15 layers were dried over sodium sulfate, filtered and concentrated to give 4-(3-chlorobenzyl)aniline as a yellow oil (0.800 g, crude). LCMS (ESI) *m/z*: 239.1 [M+H]⁺.


Step 2: Preparation of***N*-(4-(3-chlorobenzyl)phenyl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide**

20 At 20 °C 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.366 g, 0.962 mmol) was added to mixture of 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.100 g, 0.641 mmol), *N,N*-diisopropylethylamine (0.248 g, 1.92 mmol) and tetrahydrofuran (5 mL). The reaction was stirred for
25 20 minutes before a solution of 4-(3-chlorobenzyl)aniline (0.139 g, 0.641 mmol) in tetrahydrofuran (1.0 mL) was added. The reaction solution was stirred at 20 °C for 16 h. The volatiles were removed under reduced pressure and the residue was added to a mixture of dichloromethane (50 mL) and water (50 mL). The organic layer was collected, dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10
30 μm column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give *N*-(4-(3-chlorobenzyl)phenyl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide as a white solid (0.0812 g, 0.231 mmol, 36%). ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 9.94 (s, 1H), 7.66 (d, *J* = 8Hz,


1H), 7.20-7.32 (m, 6H), 3.91 (s, 2H), 3.36 (s, 3H), 2.82 (t, $J = 8.7$ Hz, 2H), 2.48-2.52 (m, 2H). LCMS (ESI) m/z : 356.1 $[M+H]^+$.

Example 3. Preparation of

5 *N*-(4-(3-chlorobenzyl)phenyl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (3)




Step 1: Preparation of 4-(3-chlorobenzyl)aniline




To a solution of 1-(bromomethyl)-3-chlorobenzene (2.0 g, 9.81 mmol),
 10 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (2.15 g, 9.81 mmol), potassium carbonate (2.71 g, 19.6 mmol) in acetonitrile (16 mL) and water (4 mL) was added
 1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II)dichloromethane complex (0.800 g, 0.981 mmol) under nitrogen. The mixture was heated to 90 °C and stirred for 2 h. The volatiles were removed under reduced pressure and the slurry was acidified to pH = 1~3 with aqueous 1 N hydrogen chloride and
 15 extracted with ethyl acetate (50 mL). The aqueous layer was then adjusted to pH = 8-10 with aqueous sodium bicarbonate and extracted with dichloromethane (50 mL x 2). The combined dichloromethane layers were dried over sodium sulfate, filtered and concentrated to give 4-(3-chlorobenzyl)aniline (0.800 g, crude) as a yellow oil. LCMS (ESI) m/z : 239.1 $[M+H]^+$.

20 Step 2: Preparation of 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid



To a solution of methyl 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylate (0.350 g, 2.08 mmol) in water (3 mL) was added sodium hydroxide (166 mg, 4.16 mmol). The reaction mixture was heated to 60 °C and stirred for 1 h. The volatiles were removed under reduced pressure to offer the crude
 25 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid as a white solid (0.330 g, crude). LCMS (ESI) m/z : 155.1 $[M+H]^+$.

Step 3: Preparation of *N*-(4-(3-chlorobenzyl)phenyl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide




30 To a solution of 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (0.100 g, 0.649 mmol), *N,N*-diisopropylethylamine (0.252 g, 1.947 mmol) in tetrahydrofuran (5 mL) at 20 °C was added 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.370 g,


0.974 mmol). The reaction was stirred for 20 minutes before a solution of 4-(3-chlorobenzyl)aniline (0.141 g, 0.649 mmol) in tetrahydrofuran (1.0 mL) was added. The reaction solution was stirred at 20 °C for 16 h. The volatiles were removed under reduced pressure and the residue was added to a mixture of dichloromethane (50 mL) and water (50 mL). The organic layer was collected, dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 µm column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give *N*-(4-(3-chlorobenzyl)phenyl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide as a white solid (0.0899 g, 0.247 mmol, 38%). ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 10.23 (s, 1H), 7.92 (d, *J* = 10 Hz, 1H), 7.70 (d, *J* = 8 Hz, 2H), 7.21-7.32 (m, 6H), 7.06 (d, *J* = 9.5 Hz, 1H), 3.93 (s, 2H), 3.79 (s, 3H), 3.32 (s, 2H); LCMS (ESI) *m/z*: 354.1 [M+H]⁺.

Example 4. Preparation of


N-(4-(3-fluorobenzyl)phenyl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (4)




Step 1: Preparation of *N*-(4-(3-fluorobenzyl)phenyl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide



To a solution of 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (0.100 g, 0.649 mmol), *N,N*-diisopropylethylamine (0.252 g, 1.95 mmol) in tetrahydrofuran (5 mL) at 20 °C was added 1-[*bis*(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.370 g, 0.974 mmol). The reaction was stirred for 20 minutes before a solution of 4-(3-fluorobenzyl)aniline (0.130 g, 0.649 mmol) in tetrahydrofuran (1.0 mL) was added. The solution was stirred at 20 °C for 16 h. The volatiles were removed under reduced pressure and the resulting slurry was added to a mixture of dichloromethane (50 mL) and water (50 mL). The organic layer was collected, dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 µm column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 µm column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give *N*-(4-(3-fluorobenzyl)phenyl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide as a white solid (0.195 g, 0.571 mmol, 88%). ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 10.23 (s, 1H), 7.92 (d, *J* = 9 Hz, 1H), 7.70 (d, *J* = 8.5 Hz, 2H), 7.33 (m, 1H), 7.24 (d, *J* = 10.4 Hz, 2H), 7.01 (m, 4H), 3.94 (s, 2H), 3.79 (s, 3H); LCMS (ESI) *m/z*: 338.1 [M+H]⁺.

Example 5. Preparation of***N*-(4-(3-fluorobenzyl)phenyl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (5)**

Step 1: Preparation of *N*-(4-(3-fluorobenzyl)phenyl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide




5


To a solution of 1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (0.150 g, 0.98 mmol), 4-(3-fluorobenzyl)aniline (0.197 g, 0.98 mmol) in pyridine (5 mL) at 20 °C was added phosphorus(V) oxychloride (0.446 g, 2.94 mmol). The reaction mixture was stirred at room temperature for 1 h. Volatiles were removed under reduced pressure and the resulting solid was dissolved in dichloromethane (10.0 mL) and added to a mixture of dichloromethane (50 mL) and water (50 mL). The organic layer was collected, dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 µm column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give *N*-(4-(3-fluorobenzyl)phenyl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide as a white solid (90.2 mg, 27%). ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 9.92 (s, 1H), 8.49 (d, *J* = 2.5 Hz, 1H), 7.95-7.97 (m, 1H), 7.61 (d, *J* = 8.5 Hz, 2H), 7.31-7.48 (m, 1H), 7.21 (d, *J* = 8.5 Hz, 2H), 6.99-7.06 (m, 3H), 6.45 (d, *J* = 9 Hz, 1H), 3.93 (s, 2H), 3.51 (s, 3H); LCMS (ESI) *m/z*: 337.1 [*M*+*H*]⁺.

10

15

Example 6. Preparation of***N*-(5-(3-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydro-3-carboxamide (6)**

Step 1: Preparation of 5-(3-fluorobenzyl)pyridin-2-amine




A mixture of 1-(bromomethyl)-3-fluorobenzene (0.400 g, 2.12 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (0.467 g, 2.12 mmol), [1,1'-*bis*(diphenylphosphino)ferrocene]dichloropalladium(II) (0.154 g, 0.21 mmol) and potassium carbonate (0.586 g, 4.24 mmol) in acetonitrile (40 mL) and water (10 mL) under nitrogen atmosphere was heated 80 °C for 3 h. The mixture was cooled to room temperature and concentrated under reduced pressure. The resulting residue was purified by column chromatography (silica gel, petroleum ether/ethyl

25

acetate = 1/1) to give 5-(3-fluorobenzyl)pyridin-2-amine (0.256 g, 1.27 mmol, 60%) as a yellow solid. LCMS (ESI) m/z : 203.2 $[M+H]^+$.

Step 2: Preparation of

5 *N*-(5-(3-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide



The synthesis of


N-(5-(3-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide followed synthetic procedure reported for **Example 19** The crude sample was dissolved in minimal

10 *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μ M column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give


N-(5-(3-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.0649 mg, 0.19 mmol, 45.4%) as a white solid. ^1H NMR (500 MHz, Dimethylsulfoxide- d_6) δ 9.98 (s, 1H), 8.32 (d, J = 2.0 Hz, 1H), 8.03 (d, J = 8.5 Hz, 1H), 7.82 (dd, J = 8.5 Hz 2.0 Hz, 1H), 7.37-7.33 (m, 1H),
15 7.13-7.11 (m, 2H), 7.06-7.02 (m, 1H), 3.99 (s, 2H), 3.36 (s, 3H), 2.85 (t, J = 8.5 Hz, 2H), 2.53 (t, J = 8.5 Hz, 2H); LCMS (ESI) m/z : 341.2 $[M+H]^+$.

Example 7. Preparation of

20 *N*-(5-(4-chloro-3-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (7)




Step 1: Preparation of 5-(4-chloro-3-fluorobenzyl)pyridin-2-amine



The synthesis of 5-(4-chloro-3-fluorobenzyl)pyridin-2-amine followed synthetic procedure
25 reported for **Example 6**. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μ M column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give 5-(4-chloro-3-fluorobenzyl)pyridin-2-amine (0.230 g, 0.97 mmol, 55%) as a yellow solid. LCMS (ESI) m/z : 237.1 $[M+H]^+$.

Step 2: Preparation of

N-(5-(4-chloro-3-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide




The synthesis of


- 5 *N*-(5-(4-chloro-3-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide followed synthetic procedure reported for **Example 19**. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μ m column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give
- 10 *N*-(5-(4-chloro-3-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.0606 g, 0.16 mmol, 38.1%,) as a white solid. ^1H NMR (500 MHz, Dimethylsulfoxide- d_6) δ 9.87 (s, 1H), 8.32 (d, J = 2.0 Hz, 1H), 8.03 (d, J = 8.5 Hz, 1H), 7.82 (dd, J = 8.5 Hz 2.5 Hz, 1H), 7.52 (dd, J = 7.5 Hz 2.0 Hz, 1H), 7.37-7.33 (m, 1H), 7.30-7.27 (m, 1H), 3.97 (s, 2H), 3.36 (s, 3H), 2.85 (t, J = 8.5 Hz, 2H), 2.53 (t, J = 8.5 Hz, 2H); LCMS (ESI) m/z : 375.1 $[\text{M}+\text{H}]^+$.

15 **Example 8. Preparation of**

N-(5-(3-cyanobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (**8**)




Step 1: Preparation of 3-((6-aminopyridin-3-yl)methyl)benzonitrile



- 20 To a mixture of 3-(chloromethyl)benzonitrile (0.500 g, 3.31 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (0.948 g, 4.30 mmol) and potassium carbonate (0.913 g, 6.62 mmol) in tetrahydrofuran (8 mL) and water (2 mL) under nitrogen was added
- 25 tetrakis(triphenylphosphine)palladium(0) (0.382 g, 0.331 mmol). Reaction was then heated to 80 °C and stirred for 2 h. The volatiles were removed under reduced pressure and the aqueous phase was adjusted to pH = 1~3 with 1 *N* hydrogen chloride solution. The water layer was then extracted with ethyl acetate (50 mL) and discarded. The aqueous phase was then adjusted to pH = 8~10 with aqueous sodium bicarbonate solution and extracted with dichloromethane (50 mL x 2). The organic layers were dried over
- 30 sodium sulfate, filtered and concentrated to yield 3-((6-aminopyridin-3-yl)methyl)benzonitrile (0.400 g, crude) as a yellow oil. LCMS (ESI) m/z : 210.2 $[\text{M}+\text{H}]^+$.


Step 2: Preparation of

N-(5-(3-cyanobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide


To a solution of 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.150 g, 0.961 mmol) in dichloromethane (2 mL) at 20 °C was added oxalyl chloride (1 mL). The reaction was stirred at room temperature for 0.5 h and concentrated *in vacuo*. The crude solid was dissolved in dichloromethane (4.0 mL) and added to a mixture of 3-((6-aminopyridin-3-yl)methyl)benzonitrile (0.201 g, 0.961 mmol), triethylamine (0.291 g, 2.883 mmol) in dichloromethane (5.0 mL) dropwise. The mixture was stirred for another 0.5 h and the solvent was removed under reduced pressure. The residue was added to a mixture of dichloromethane (50 mL) and water (50 mL). The organic layer was collected, dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 µm column; the mobile phase acetonitrile/0.01% aqueous trifluoroacetic acid) to give

N-(5-(3-cyanobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.0162 g, 0.048 mmol, 5%) as a white solid. ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 9.74 (s, 1H), 8.32-8.32 (d, *J* = 1.2 Hz, 1H), 8.02-8.04 (d, *J* = 6.8 Hz, 1H), 7.62-7.79 (m, 4H), 7.51-7.54 (t, *J* = 6.2 Hz, 1H), 4.02 (s, 2H), 3.36 (s, 3H), 2.83-2.86 (t, *J* = 6.8 Hz, 2H), 2.52-2.54 (m, 2H); LCMS (ESI) *m/z*: 348.1 [M+H]⁺.

Example 9. Preparation of

1-methyl-6-oxo-*N*-(5-(4-(trifluoromethyl)benzyl)pyridin-2-yl)-1,4,5,6-tetrahydropyridazine-3-carboxamide (9)

Step 1: Preparation of 5-(4-(trifluoromethyl)benzyl)pyridin-2-amine




To a solution of 1-(bromomethyl)-4-(trifluoromethyl)benzene (0.500 g, 2.1 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (0.463 g, 2.1 mmol), potassium carbonate (0.579 g, 4.2 mmol) in tetrahydrofuran (8 mL) and water (2 mL) was added tetrakis(triphenylphosphine)palladium(0) (0.242 g, 0.21 mmol) under nitrogen. The mixture was heated to 90 °C and stirred for 2 h. The volatiles were removed under reduced pressure. Aqueous layer was acidified to pH = 1-3 with 1 N hydrogen chloride and extracted with ethyl acetate (50 mL). The aqueous layer was then adjusted to pH = 8-10 with aqueous sodium bicarbonate and extracted with dichloromethane (50 mL x 2). The combined dichloromethane layers were dried over sodium sulfate,

filtered and concentrated to give 5-(4-(trifluoromethyl)benzyl)pyridin-2-amine (0.310 g, crude) as a yellow oil. LCMS (ESI) m/z : 253.1 $[M+H]^+$.

Step 2: Preparation of


5 1-methyl-6-oxo-*N*-(5-(4-(trifluoromethyl)benzyl)pyridin-2-yl)-1,4,5,6-tetrahydropyridazine-3-carboxamide




To a solution of 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.100 g, 0.641 mmol) in dichloromethane (2 mL) at 20 °C was added oxalyl chloride (1 mL). The reaction was stirred at 20 °C for 0.5 h and concentrated *in vacuo*. The crude solid was dissolved in dichloromethane (4 mL) and added to a mixture of 5-(4-(trifluoromethyl)benzyl)pyridin-2-amine (0.162 g, 0.641 mmol) and triethylamine (0.194 g, 1.92 mmol) in dichloromethane (5.0 mL) dropwise. The reaction was stirred at 20 °C for 20 minutes and was concentrated, *in vacuo*. The crude sample was purified by prep-TLC (petroleum ether/ethyl acetate = 2:1) to afford 1-methyl-6-oxo-*N*-(5-(4-(trifluoromethyl)benzyl)pyridin-2-yl)-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.0308 g, 0.0769 mmol, 12%) as a white solid. ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 9.73 (s, 1H), 8.32 (d, J = 2.0 Hz, 1H), 8.04 (d, J = 6.8 Hz, 1H), 7.72-7.74 (m, 1H), 7.67 (d, J = 6.4 Hz, 2H), 7.49 (d, J = 6.8 Hz, 2H), 4.06 (s, 2H), 3.36 (s, 3H), 2.84 (t, J = 7.0 Hz, 2H), 2.52-2.54 (m, 2H); LCMS (ESI) m/z : 391.0 $[M+H]^+$.

20 **Example 10. Preparation of**

***N*-(5-(3-cyano-4-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (10)**



Step 1: Preparation of 5-((6-aminopyridin-3-yl)methyl)-2-fluorobenzonitrile




To a solution of 5-(bromomethyl)-2-fluorobenzonitrile (0.500 g, 2.35 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (0.517 g, 2.35 mmol), potassium carbonate (0.648 g, 4.70 mmol) in tetrahydrofuran (8 mL) and water (2 mL) was added tetrakis(triphenylphosphine)palladium(0) (0.271 g, 0.234 mmol) under nitrogen. The reaction mixture was heated to 90 °C and stirred for 2 h. The volatiles were removed under reduced pressure. Aqueous layer was acidified to pH = 1-3 with 1 N hydrogen chloride and extracted with ethyl acetate (50 mL). The aqueous layer was then adjusted to pH = 8-10 with aqueous sodium bicarbonate and extracted with dichloromethane (50 mL x 2). The combined dichloromethane layers were dried over sodium sulfate,

filtered and concentrated to give 5-((6-aminopyridin-3-yl)methyl)-2-fluorobenzonitrile (430 mg, crude) as a yellow oil. LCMS (ESI) m/z 228.1 $[M+H]^+$.

Step 2: Preparation of


5 *N*-(5-(3-cyano-4-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide




To a solution of 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.150 g, 0.961 mmol), *N,N*-diisopropylethylamine (0.373 g, 2.88 mmol) in tetrahydrofuran (5 mL) at 20 °C was added 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.548 g, 1.44 mmol). The reaction was stirred for 20 minutes before a solution of 5-((6-aminopyridin-3-yl)methyl)-2-fluorobenzonitrile (0.218 g, 0.961 mmol) in tetrahydrofuran (1.0 mL) was added. The solution was stirred at 20 °C for 16 h. The volatiles were removed under reduced pressure and the residue was added to a mixture of dichloromethane (50 mL) and water (50 mL). The organic layer was separated, dried over sodium sulfate, filtered and concentrated. Purification by prep-TLC (dichloromethane) afforded the desired product as a white solid (0.0672 g, 0.183 mmol, 19%). ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 9.73 (s, 1H), 8.32 (s, 1H), 8.03 (d, J = 7.2 Hz, 1H), 7.89 (d, J = 4.4 Hz, 1H), 7.68-7.75 (m, 2H), 7.47 (t, J = 7.2 Hz, 1H), 4.00 (s, 2H), 3.36 (s, 3H), 2.85 (t, J = 6.6 Hz, 2H), 2.52-2.54 (m, 2H); LCMS (ESI) m/z : 366.1 $[M+H]^+$.

20 **Example 11. Preparation of**

N-(5-(4-chloro-3-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (11)



Step 1: Preparation of 5-(4-chloro-3-fluorobenzyl)pyridin-2-amine




To a solution of 4-(bromomethyl)-1-chloro-2-fluorobenzene (0.500 g, 2.25 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (0.496 g, 2.25 mmol), potassium carbonate (0.621 g, 4.51 mmol) in tetrahydrofuran (8 mL) and water (2 mL) under nitrogen was added tetrakis(triphenylphosphine)palladium(0) (0.260 g, 0.225 mmol). The mixture was heated to 90 °C and stirred for 2 h. The volatiles were removed under reduced pressure. Aqueous layer was acidified to pH = 1-3 with 1 N hydrogen chloride and extracted with ethyl acetate (50 mL). The aqueous layer was then adjusted to pH = 8-10 with aqueous sodium bicarbonate and extracted with dichloromethane (50 mL x 2).

The combined dichloromethane layers were dried over sodium sulfate, filtered and concentrated to give 5-(4-chloro-3-fluorobenzyl)pyridin-2-amine (0.250 g, crude) as a yellow oil. LCMS (ESI) m/z : 237.1 $[M+H]^+$. Used in the next step without further purification.

5 Step 2: Preparation of


N-(5-(4-chloro-3-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide




To a mixture of 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.150 g, 0.961 mmol), *N,N*-diisopropylethylamine (0.373 g, 2.88 mmol) in tetrahydrofuran (5 mL) at 20 °C was added 1-[*bis*(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.548 g, 1.44 mmol). The mixture was stirred for 20 minutes before a solution of 5-(4-chloro-3-fluorobenzyl)pyridin-2-amine (0.227 g, 0.961 mmol) in tetrahydrofuran (1.0 mL) was added. The solution was stirred at 20 °C for 16 h. The volatiles were removed under reduced pressure and the residue was added to a mixture of dichloromethane (50 mL) and water (50 mL). The organic layer was separated, dried over sodium sulfate, filtered and concentrated. Purification by prep-TLC (dichloromethane) gives the desired product as a white solid (0.0515 g, 0.137 mmol, 14.3%). ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 9.72 (s, 1H), 8.30-8.30 (d, J = 1.2 Hz, 1H), 8.03 (d, J = 6.8 Hz, 1H), 7.72-7.74 (m, 1H), 7.50-7.53 (t, J = 6.6 Hz, 1H), 7.35-7.37 (m, 1H), 7.14 (d, J = 6.4 Hz, 1H), 3.97 (s, 2H), 3.36 (s, 3H), 2.83 (t, J = 10.8 Hz, 2H), 2.52-2.54 (m, 2H); LCMS (ESI) m/z : 375.1 $[M+H]^+$.

Example 12. Preparation of

N-(5-(4-chlorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (12)



Step 1: Preparation of 5-(4-chlorobenzyl)pyridin-2-amine




To a solution of 1-(bromomethyl)-4-chlorobenzene (0.410 g, 2 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (0.528 g, 2.4 mmol), potassium carbonate (0.552 g, 4 mmol) in acetonitrile (10 mL) and water (2.5 mL) was added [1,1'-*bis*(diphenylphosphino)ferrocene]dichloropalladium(II)dichloromethane (0.163 g, 0.2 mmol) under nitrogen. The reaction mixture was stirred at 80 °C for 1 h. The reaction mixture was filtered, and the filtrate was extracted with ethyl acetate (50 mL x 2), washed with 1 N hydrogen chloride (10 mL x 3). The aqueous phase was then neutralized to pH = 7 with aqueous sodium bicarbonate solution and extracted

with ethyl acetate (30 mL x 2), washed with brine, dried with sodium sulfate, filtered and concentrated to give 5-(4-chlorobenzyl)pyridin-2-amine (250 mg, crude) as a yellow oil. LCMS (ESI) m/z : 218.9 $[M+H]^+$. Used in the next step directly without additional purification.

5 Step 2: Preparation of


N-(5-(4-chlorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide




To a solution of 1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (0.100 g, 0.65 mmol),
 5-(4-chlorobenzyl)pyridin-2-amine (0.170 g, 0.78 mmol),
 10 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.371 g, 0.975 mmol) in *N,N*-dimethylformamide (4 mL) was added *N,N*-diisopropylethylamine (252 mg, 1.95 mmol). The reaction mixture was stirred at room temperature for 2 h. The reaction solution was added to ice water slowly and the precipitate was filtered. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μ m column;
 15 acetonitrile/0.01% aqueous trifluoroacetic acid) to give
N-(5-(4-chlorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide as a white solid (0.0613 g, 0.172 mmol 26.5%). ^1H NMR (400 MHz, Dimethylsulfoxide- d_6) δ 9.87 (s, 1H), 8.29 (d, J = 1.6 Hz, 1H), 8.02 (d, J = 6.8 Hz, 1H), 7.75, 7.74 (dd, J = 3.4, 3.4 Hz, 1H), 7.37 (t, J = 3.2 Hz, 2H), 7.28 (d, J = 5.6 Hz, 2H), 3.96 (s, 2H), 3.36 (s, 3H), 2.84 (t, J = 6.8 Hz, 2H), 2.52 (t, J = 6.8 Hz, 2H); LCMS (ESI)
 20 m/z : 357.1 $[M+H]^+$.

Example 13. Preparation of

N-(5-benzylpyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (13)



25 Step 1: Preparation of 5-benzylpyridin-2-amine




To a solution of benzyl bromide (0.471 g, 2.76 mmol),
 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (0.728 g, 3.31 mmol), potassium carbonate (0.762 g, 5.52 mmol) in acetonitrile (15 mL) and water (4 mL) at room temperature was added
 30 [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II)dichloromethane (0.225 g, 0.276 mmol) under nitrogen. The mixture was then stirred at 80 °C for 2 h. The reaction was filtered and the filtrate was

extracted with ethyl acetate (50 mL x 2) and washed with aqueous 1 *N* hydrogen chloride solution (10 mL x 3). The aqueous phase was then neutralized to pH = 7 with aqueous sodium bicarbonate solution and extracted with ethyl acetate (30 mL x 2), washed with brine, dried with sodium sulfate, filtered and concentrated to give 5-benzylpyridin-2-amine as a yellow oil (0.200 g, crude); LCMS (ESI) *m/z*: 185.0 [M+H]⁺. Used in the next step directly without additional purification.

Step 2: Preparation of


N-(5-benzylpyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide




To a solution of 1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (0.100 g, 0.65 mmol), 5-benzylpyridin-2-amine (0.144 g, 0.78 mmol), 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.371 g, 0.975 mmol) in *N,N*-dimethylformamide (3 mL) was added *N,N*-diisopropylethylamine (0.251 g, 1.95 mmol). The reaction mixture was stirred at room temperature for 3 h. The reaction solution was poured into ice water slowly and the resulting precipitate was filtered. The crude solid was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μ m column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give (0.0545 g, 0.169 mmol, 26%). ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 9.75 (s, 1H), 8.28 (d, *J* = 1.6 Hz, 1H), 8.02 (d, *J* = 8.4 Hz, 1H), 7.21, 7.01 (dd, *J* = 4.2, 4.4 Hz, 1H), 7.32-7.28 (m, 2H), 7.26 (t, *J* = 4.0 Hz, 2H), 7.22 (t, *J* = 8.4 Hz, 1H), 3.95 (s, 2H), 3.35 (s, 3H), 2.84 (t, *J* = 8.2 Hz, 2H), 2.52 (t, *J* = 5.6 Hz, 2H); LCMS (ESI) *m/z*: 323.2. [M+H]⁺.

Example 14. Preparation of

1-methyl-6-oxo-*N*-(5-((4-(trifluoromethyl)pyridin-2-yl)methyl)pyridin-2-yl)-1,4,5,6-tetrahydropyridazine-3-carboxamide (14)




Step 1: Preparation of (4-(trifluoromethyl)pyridin-2-yl)methanol




To a solution of 2-bromo-4-(trifluoromethyl)pyridine (1.5 g, 6.64 mmol) in dry toluene (20 mL),
 5 at -78 °C, was added n-butyllithium (3.3 mL, 8.30 mmol, 2.5 M) dropwise under nitrogen. After the
 addition, the reaction was stirred at -78 °C for 10 minutes and *N,N*-dimethylformamide (0.77 mL, 9.95
 mmol) was added dropwise at -78 °C and stirred for 10 minutes at -78 °C before sodium borohydride (0.5
 g, 13.3 mmol) and methanol (3.75 mL) were added. The reaction was warmed to room temperature and
 stirred for 1 h. The reaction was quenched with aqueous ammonium chloride solution and extracted with
 10 ethyl acetate (30 mL x 2). The combined organic phases were washed with brine (30 mL), dried over
 sodium sulfate, filtered and concentrated to give (4-(trifluoromethyl)pyridin-2-yl)methanol (1.1 g, 6.21
 mmol, 94%) as a white solid. LCMS (ESI) 178.1 [M+H]⁺.

Step 2: Preparation of 2-(chloromethyl)-4-(trifluoromethyl)pyridine



15 To a solution of (4-(trifluoromethyl)pyridin-2-yl)methanol (1.1 g, 6.21 mmol) in dichloromethane
 (25 mL) was added thionyl chloride (2 mL) dropwise at room temperature. The reaction was stirred at 60
 °C for 2 h and was concentrated. The residue was diluted with dichloromethane/water (20 mL/20 mL),
 neutralized with aqueous sodium bicarbonate solution, and extracted with dichloromethane (20 mL x 2).
 20 The combined organic phases were washed with brine (30 mL), dried over sodium sulfate, filtered and
 concentrated to provide 2-(chloromethyl)-4-(trifluoromethyl)pyridine (0.64 g, 3.28 mmol, 53%) as a yellow
 oil. ¹H NMR (500 MHz, Chloroform-*d*) δ 8.78 (d, *J* = 5 Hz, 1H), 7.75 (s, 1H), 7.50 (d, *J* = 4.5 Hz, 1H), 4.77
 (s, 2H); LCMS (ESI) *m/z*: 196.1 [M+H]⁺.

25 Step 3: Preparation of 5-((4-(trifluoromethyl)pyridin-2-yl)methyl)pyridin-2-amine




A mixture of 2-(chloromethyl)-4-(trifluoromethyl)pyridine (0.34 g, 1.74 mmol),
 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (0.46 g, 2.09 mmol),
 [1,1'-*bis*(diphenylphosphino)ferrocene]dichloropalladium(II) (0.13 g, 0.17 mmol) and cesium carbonate
 30 (1.1 g, 3.48 mmol) in 1,4-dioxane (12 mL) was stirred at 100 °C in a microwave for 45 minutes. The
 volatiles were removed under reduced pressure. The residue was diluted with ethyl acetate/water (20

mL/20 mL), extracted with ethyl acetate (30 mL x 2). The combined organic phases were washed with brine (30 mL), dried over sodium sulfate, filtered and concentrated. The crude sample was purified by column chromatography (Biotage, 40 g silica gel, eluted with methanol/dichloromethane = 1:8, containing 0.5% 7 N ammonia in methanol, in dichloromethane from 30% to 40%) to afford

- 5 5-((4-(trifluoromethyl)pyridin-2-yl)methyl)pyridin-2-amine (0.17 g, 0.67 mmol, 38.6%) as a yellow solid. LCMS (ESI) m/z : 254.1 $[M+H]^+$.

Step 4: Preparation of

- 10 1-methyl-6-oxo-*N*-(5-((4-(trifluoromethyl)pyridin-2-yl)methyl)pyridin-2-yl)-1,4,5,6-tetrahydropyridazine-3-carboxamide




Followed the same procedure as for **Example 213** using


- 15 5-((4-(trifluoromethyl)pyridin-2-yl)methyl)pyridin-2-amine (0.15 g, 0.59 mmol). The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified by prep-HPLC (Boston C18 21*250 mm 10 μ m column. The mobile phase was acetonitrile/10 mM ammonium acetate aqueous solution) to give
1-methyl-6-oxo-*N*-(5-((4-(trifluoromethyl)pyridin-2-yl)methyl)pyridin-2-yl)-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.090 g, 0.23 mmol, 39%) as a white solid. ^1H NMR (500 MHz, Dimethylsulfoxide- d_6) δ 9.73 (s, 1H), 8.78 (d, J = 5 Hz, 1H), 8.35 (d, J = 2 Hz, 1H), 8.03 (d, J = 8.5 Hz, 1H), 7.65-7.80 (m, 2H), 7.63 (d, J = 4.5 Hz, 1H), 4.24 (s, 2H), 3.36 (s, 3H), 2.85 (t, J = 8.5 Hz, 2H), 2.53 (t, J = 8.5 Hz, 2H); LCMS (ESI)
20 m/z : 392.1 $[M+H]^+$.

Example 15. Preparation of

N-(5-(3-chlorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (15)




- 25 Step 1: Preparation of 5-(3-chlorobenzyl)pyridin-2-amine



- A mixture of 1-(bromomethyl)-3-chlorobenzene (0.157 g, 0.77 mmol),
5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (0.220 g, 1.00 mmol),
[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II)-dichloromethane (0.063 g, 0.077 mmol) and
30 potassium carbonate (0.213 g, 1.54 mmol) in acetonitrile (4.00 mL) and water (1.00 mL) under nitrogen
atmosphere was heated to 80 °C for 1 h. The mixture was concentrated, under reduced pressure and the
residue was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 1/1) to yield
5-(3-chlorobenzyl)pyridin-2-amine (0.137 g, 0.63 mmol, 81.6%) as a pale-yellow solid. LCMS (ESI) m/z :
219.1 $[M+H]^+$.

Step 2: Preparation of


N-(5-(3-chlorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide




To a stirred solution of 5-(3-chlorobenzyl)pyridin-2-amine (0.130 g, 0.60 mmol),
 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.113 g, 0.72 mmol) and
 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.274 g,
 0.72 mmol) in *N,N*-dimethylformamide (5.00 mL) was added *N,N*-diisopropylethylamine (0.232 g, 1.80
 mmol). After addition, the reaction mixture was stirred at room temperature for 2 h. The crude sample was
 dissolved in minimal *N,N*-dimethylformamide and purified via prep-HPLC (Sunfire prep C18 10 μ m OBD
 19*250 mm; mobile phase: [water (0.05% trifluoroacetic acid)-acetonitrile]; B%: 60%-88%, 15 minutes) to
 give *N*-(5-(3-chlorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.040
 g, 0.11 mmol, 18.7%) as a grey solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 9.71 (s, 1H), 8.30 (d, *J*
 = 1.9 Hz, 1H), 8.03 (d, *J* = 8.5 Hz, 1H), 7.73 (dd, *J* = 8.5, 2.2 Hz, 1H), 7.40 - 7.07 (m, 4H), 3.96 (s, 2H),
 3.36 (s, 3H), 2.85 (t, *J* = 8.5 Hz, 2H), 2.53 (d, *J* = 8.5 Hz, 2H); LCMS (ESI) *m/z*: 357.1. [M+H]⁺.

Example 16. Preparation of

N-(4-(3-chlorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (16)




Step 1: Preparation of *tert*-butyl 4-(3-chlorobenzyl)pyridin-2-ylcarbamate



A mixture of *tert*-butyl 4-bromopyridin-2-ylcarbamate (0.301 g, 1.10 mmol),
 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (0.309 g, 1.22 mmol), potassium acetate (0.356
 g, 3.36 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II)-dichloromethane (0.048 g,
 0.066 mmol) in dry *N,N*-dimethylformamide (7.5 mL) was stirred at 80 °C for 3 h under nitrogen. After
 being cooled to room temperature, 1-(bromomethyl)-3-chlorobenzene (0.150 g, 0.73 mmol,
 [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II)-dichloromethane (0.048 g, 0.066 mmol),
 sodium carbonate (0.0583 g, 5.5 mmol) and water (2.5 mL) were added. The mixture was stirred at 85 °C
 for 2 h under nitrogen atmosphere. The reaction was concentrated, under reduced pressure, and the
 residue was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 1/1) to obtain

tert-butyl 4-(3-chlorobenzyl)pyridin-2-ylcarbamate (0.036 g, 0.11 mmol, 10.3% for 2 steps) as a white solid. LCMS (ESI) *m/z*: 319.1 [M+H]⁺.


Step 2: Preparation of 4-(3-chlorobenzyl)pyridin-2-ammonium chloride



A solution of *tert*-butyl 4-(3-chlorobenzyl)pyridin-2-ylcarbamate (0.036 g, 0.11 mmol) in hydrogen chloride (2 mL, 4 M in 1,4-dioxane) was stirred at 50 °C for 2 h. After being concentrated, compound 4-(3-chlorobenzyl)pyridin-2-ammonium chloride (0.027 g, 0.106 mmol, 96.4%) was obtained as a white solid which was used in next step without further purification. LCMS (ESI) for *m/z*: 219.1 [M+H]⁺.

Step 3: Preparation of


N-(4-(3-chlorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide




To a stirred solution of 4-(3-chlorobenzyl)pyridin-2-ammonium chloride (0.027 g, 0.106 mmol), 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.020 g, 0.127 mmol) and 1-[*bis*(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.048 g, 0.127 mmol) in *N,N*-dimethylformamide (1.50 mL) was added *N,N*-diisopropylethylamine (0.041 g, 0.318 mmol). After addition, the reaction mixture was stirred at room temperature for 2 h. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Sunfire prep C18 10 μm OBD 19*250 mm; mobile phase: [water (0.05% trifluoroacetic acid)-acetonitrile]; B%: 60%-88%, 15 minutes) to give *N*-(4-(3-chlorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.011 g, 0.03 mmol, 29.2%) as a white solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 9.77 (s, 1H), 8.27 (d, *J* = 5.1 Hz, 1H), 7.99 (s, 1H), 7.36 (t, *J* = 7.7 Hz, 2H), 7.33 - 7.27 (m, 1H), 7.24 (d, *J* = 7.5 Hz, 1H), 7.10 (dd, *J* = 5.1, 1.3 Hz, 1H), 4.03 (s, 2H), 2.84 (t, *J* = 8.5 Hz, 2H), 2.65 - 2.38 (m, 5H); LCMS (ESI) *m/z*: 357.1 [M+H]⁺.

Example 17. Preparation of

N-(5-(4-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (17)




Step 1: Preparation of 5-(4-fluorobenzyl)pyridin-2-amine





To a mixture of 1-(bromomethyl)-4-fluorobenzene (0.378 g, 2 mmol),
 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (0.528 g, 2.4 mmol) and potassium
 5 carbonate (0.552 g, 4 mmol) in acetonitrile (10 mL) and water (2.5 mL) was added
 [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II)dichloromethane (0.163 g, 0.2 mmol) under
 nitrogen. The mixture was stirred at 80 °C for 2 h before it was filtered. The filtrate was extracted with
 ethyl acetate (50 mL x 2) and washed with aqueous 1 *N* hydrogen chloride (10 mL x 3). The aqueous
 phase was then neutralized with aqueous sodium bicarbonate solution and extracted with ethyl acetate
 10 (30 mL x 2). Combined organic layers were washed with brine, dried over sodium sulfate, filtered and
 concentrated to give 5-(4-fluorobenzyl)pyridin-2-amine (0.250 g, crude) as a brown oil. LCMS (ESI) *m/z*:
 203.0 [M+H]⁺. Use in the next step without additional purification.

Step 2: Preparation of


15 *N*-(5-(4-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide



To a solution of 1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (0.100 g, 0.65 mmol),
 5-(4-fluorobenzyl)pyridin-2-amine (0.158 g, 0.78 mmol),
 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.371 g,
 20 0.975 mol) in *N,N*-dimethylformamide (3 mL) was added *N,N*-diisopropylethylamine (0.251 g, 1.95 mmol).
 The reaction mixture was stirred at room temperature for 3 h. The reaction mixture was added to ice
 water slowly and resulting precipitate was filtered. The crude solid was dissolved in minimal
N,N-dimethylformamide and purified *via* prep-HPLC (Sunfire prep C18 10 μm OBD 19*250 mm; mobile
 phase: [water (0.05% trifluoroacetic acid)-acetonitrile]; B%: 60%-88%, 15 minutes) to give
 25 *N*-(5-(4-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.0777 g,
 0.229 mmol, 35.2%) as a white solid. ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 9.76 (s, 1H), 8.28 (d, *J* =
 2.0 Hz, 1H), 8.02 (d, *J* = 8.4 Hz, 1H), 7.70 (dd, *J* = 4.4, 4.2 Hz, 1H), 7.37-7.27 (m, 2H), 7.15-7.09 (m, 2H),
 3.94 (s, 2H), 3.35 (s, 3H), 2.84 (t, *J* = 8.6 Hz, 2H), 2.52 (t, *J* = 8.5 Hz, 2H); LCMS (ESI) *m/z*: 341.2 [M+H]⁺.

Example 18. Preparation of**1-methyl-6-oxo-*N*-(5-(3-(trifluoromethyl)benzyl)pyridin-2-yl)-1,4,5,6-tetrahydropyridazine-3-carboxamide (18)****5 Step 1: Preparation of 5-(3-(trifluoromethyl)benzyl)pyridin-2-amine**

To a solution of 1-(bromomethyl)-3-(trifluoromethyl)benzene (0.406 g, 1.7 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (0.411 g, 1.87 mmol), potassium carbonate (0.469 g, 3.4 mmol) in acetonitrile (9 mL) and water (3 mL) at room temperature was added
 10 [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II)dichloromethane (0.139 g, 0.17 mmol) under nitrogen. The reaction mixture was stirred at 80 °C for 1.5 h. The reaction mixture was filtered and the filtrate was extracted with ethyl acetate (50 mL x 2). The combined organic layers were washed with 1 N hydrogen chloride (30 mL x 2). Aqueous layer was then neutralized with aqueous sodium bicarbonate solution and then extracted with ethyl acetate (50 mL x 2). The combined organic layers were washed
 15 with brine, dried over sodium sulfate, filtered and concentrated to provide 5-(3-(trifluoromethyl)benzyl)pyridin-2-amine as an oil (0.230 g, crude); LCMS (ESI) *m/z*: 253.1 [M+H]⁺. Used in the next step without additional purification.


Step 2: Preparation of**20 1-methyl-6-oxo-*N*-(5-(3-(trifluoromethyl)benzyl)pyridin-2-yl)-1,4,5,6-tetrahydropyridazine-3-carboxamide**

A solution of 1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (0.100 g, 0.65 mmol), 5-(3-(trifluoromethyl)benzyl)pyridin-2-amine (0.144 g, 0.78 mmol), 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.371 g, 0.975 mmol) and *N,N*-diisopropylethylamine (0.252 g, 1.95 mmol) in *N,N*-dimethylformamide (3 mL) was
 25 stirred at room temperature for 2 h. The reaction mixture was poured into ice water and the precipitate was filtered. The crude solid was dissolved in minimal *N,N*-dimethylformamide and purified via prep-HPLC (Sunfire prep C18 10 μm OBD 19*250 mm; mobile phase: [water (0.05% trifluoroacetic acid)-acetonitrile]; B%: 60%-88%, 15 minutes) to give
 30 1-methyl-6-oxo-*N*-(5-(3-(trifluoromethyl)benzyl)pyridin-2-yl)-1,4,5,6-tetrahydropyridazine-3-carboxamide as a white solid (0.0665 g, 25.2%). ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 9.80 (s, 1H), 8.33 (d, *J* =


2.0 Hz, 1H), 8.03 (d, J = 6.8 Hz, 1H), 7.7 (dd, J = 3.4, 3.6 Hz, 1H), 7.65 (s, 1H), 7.59-7.54 (m, 3H), 4.07 (s, 2H), 3.35 (s, 3H), 2.84 (t, J = 6.8 Hz, 2H), 2.52 (t, J = 6.6 Hz, 2H); LCMS (ESI) m/z : 391.1. $[M+H]^+$.

Example 19. Preparation of

5 *N*-(5-((1,3-dihydroisobenzofuran-5-yl)methyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (19)




Step 1: Preparation of 5-(bromomethyl)-1,3-dihydroisobenzofuran



10 To a solution of (1,3-dihydroisobenzofuran-5-yl)methanol (0.900 g, 6 mmol) in dichloromethane (36 mL) was added carbon tetrabromide (2.78 g, 8.4 mmol) and triphenylphosphine (2.2 g, 8.4 mmol). The reaction mixture was stirred at room temperature for 2 h. Concentration and purification with column chromatography (silica gel, petroleum ether/ethyl acetate = 4/1) affords 5-(bromomethyl)-1,3-dihydroisobenzofuran as a white solid (1.1 g, 86.6%); LCMS (ESI) for m/z : 215.1 $[M+H]^+$. Used directly in the next step.

Step 2: Preparation of 5-((1,3-dihydroisobenzofuran-5-yl)methyl)pyridin-2-amine




20 To a solution of 5-(bromomethyl)-1,3-dihydroisobenzofuran (0.530 g, 2.5 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (0.660 g, 3 mmol) and potassium carbonate (0.690 g, 5 mmol) at 80 °C in acetonitrile (12 mL) and water (3 mL) was added [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II)dichloromethane (0.204 g, 0.25 mmol). Reaction was stirred for 2 h at 80 °C before it was extracted with ethyl acetate (50 mL x 2). Combined organic layers were washed with brine (50 mL), dried over sodium sulfate, filtered and concentrated.

25 Purification with column chromatography (silica gel, petroleum ether/ethyl acetate = 1 : 2) affords 5-((1,3-dihydroisobenzofuran-5-yl)methyl)pyridin-2-amine (0.370 g, 1.64 mmol, 65.5%) as a white solid; LCMS (ESI) m/z : 227.1 $[M+H]^+$.

Step 3: Preparation of


30 *N*-(5-((1,3-dihydroisobenzofuran-5-yl)methyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide




A solution of 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.100 g, 0.64 mmol), 5-((1,3-dihydroisobenzofuran-5-yl)methyl)pyridin-2-amine (0.159 g, 0.704 mmol), 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.365 g, 0.96 mmol) and *N,N*-diisopropylethylamine (0.248 mg, 1.92 mmol) in *N,N*-dimethylformamide (3 mL) was stirred at room temperature for 17 h. Resulting precipitate was filtered and with washed with methanol and water followed by freeze drying to offer *N*-(5-((1,3-dihydroisobenzofuran-5-yl)methyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.0757 g, 0.208 mmol, 32.5%) as a white solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 9.70 (s, 1H), 8.2 (d, *J* = 1.9 Hz, 1H), 8.01 (d, *J* = 8.5 Hz, 1H), 7.70 (dd, *J* = 8.5, 2.2 Hz, 1H), 7.23 (d, *J* = 7.5 Hz, 1H), 7.17 (d, *J* = 8.0 Hz, 2H), 4.95 (s, 4H), 3.96 (s, 2H), 3.36 (s, 3H), 2.84 (t, *J* = 8.5 Hz, 2H), 2.52 (t, *J* = 7.3 Hz, 2H); LCMS (ESI) *m/z*: 354.1 [*M*+*H*]⁺.

Example 20. Preparation of

N-(5-(3,4-dichlorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (20)




Step 1: Preparation of 5-(3,4-dichlorobenzyl)pyridin-2-amine



To a solution of 4-(bromomethyl)-1,2-dichlorobenzene (0.720 g, 3 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (0.726 mg, 3.3 mmol), potassium carbonate (0.828 mg, 6 mmol) in acetonitrile (15 mL) and water (4 mL) was added [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II)dichloromethane (0.245 mg, 0.3 mmol). Reaction mixture was stirred at 80 °C for 2 h. The reaction mixture was filtered, extracted with ethyl acetate (100 mL x 2). The combined organics layers was washed with brine (100 mL), dried over sodium sulfate, filtered and concentrated to offer 5-(3,4-dichlorobenzyl)pyridin-2-amine as a brown oil (0.380 g, 1.5 mmol, 50%); LCMS (ESI) *m/z*: 253.0 [*M*+*H*]⁺.

Step 2: Preparation of

N-(5-(3,4-dichlorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide




A solution of 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.100 g, 0.64 mmol), 5-(3,4-dichlorobenzyl)pyridin-2-amine (0.178 g, 0.7 mmol), 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.365 g, 0.96 mmol) and *N,N*-diisopropylethylamine (0.248 g, 1.92 mmol) in tetrahydrofuran (5 mL) was stirred at


room temperature for 17 h. Volatiles were removed under reduced pressure. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified via prep-HPLC (Sunfire prep C18 10 µm OBD 19*250 mm; mobile phase: [water (0.05% trifluoroacetic acid)-acetonitrile]; B%: 60%-88%, 15 minutes) to yield *N*-(5-(3,4-dichlorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.128 g, 0.326 mmol, 51%) as a white solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 9.82 (s, 1H), 8.31 (d, *J* = 1.5 Hz, 1H), 8.04 (d, *J* = 8.5 Hz, 1H), 7.77 (dd, *J* = 8.5, 2.2 Hz, 1H), 7.56 (d, *J* = 5.8 Hz, 2H), 7.26 (dd, *J* = 8.3, 1.9 Hz, 1H), 3.96 (s, 2H), 3.36 (s, 3H), 2.84 (t, *J* = 8.5 Hz, 2H), 2.52 (d, *J* = 9.0 Hz, 2H); LCMS (ESI) *m/z*: 391.0 [M+H]⁺.

Example 21. Preparation of

N-(5-((5-chlorothiophen-2-yl)methyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (21)



Step 1: Preparation of 5-((5-chlorothiophen-2-yl)methyl)pyridin-2-amine




To a solution of 2-chloro-5-(chloromethyl)thiophene (0.830 g, 5 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (1.21 g, 5.5 mmol) and potassium carbonate (1.38 g, 10 mmol) in acetonitrile (24 mL) and water (6 mL) was added [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II)dichloromethane (0.408 g, 0.5 mmol).

Reaction mixture was stirred at 80 °C for 2 h and then it was extracted with ethyl acetate (100 mL x 2). The combined organic layers were washed with brine (80 mL), dried over sodium sulfate, filtered and concentrated. The crude residue was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 2/1) to give 5-((5-chlorothiophen-2-yl)methyl)pyridin-2-amine as a brown solid (0.600 g, 2.24 mmol, 44.8%); LCMS (ESI) *m/z*: 225.1 [M+H]⁺.

Step 2: Preparation of

N-(5-((5-chlorothiophen-2-yl)methyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide




A solution of 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.173 g, 0.77 mmol), 5-((5-chlorothiophen-2-yl)methyl)pyridin-2-amine (0.100 g, 0.64 mmol), 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.365 g, 0.96 mmol) and *N,N*-diisopropylethylamine (0.248 g, 1.92 mmol) in *N,N*-dimethylformamide (3 mL) was stirred at room temperature for 17 h. Volatiles were removed under reduced pressure. The crude sample

was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Sunfire prep C18 10 μ m OBD 19*250 mm; mobile phase: [water (0.05% trifluoroacetic acid)-acetonitrile]; B%: 60%-88%, 15 minutes) to yield

N-(5-((5-chlorothiophen-2-yl)methyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.0787 g, 0.218 mmol, 34%) as a white solid. ^1H NMR (500 MHz, Dimethylsulfoxide- d_6) δ 9.79 (s, 1H), 8.30 (d, J = 2.0 Hz, 1H), 8.06 (d, J = 8.5 Hz, 1H), 7.76 (dd, J = 8.5, 2.2 Hz, 1H), 6.96 (d, J = 3.7 Hz, 1H), 6.81 (d, J = 3.7 Hz, 1H), 4.12 (s, 2H), 3.36 (s, 3H), 2.85 (t, J = 8.5 Hz, 2H), 2.52 (d, J = 9.3 Hz, 2H); LCMS (ESI) m/z : 363.1 $[\text{M}+\text{H}]^+$.

Example 22. Preparation of

N-(5-(3,5-difluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (22)




Step 1: Preparation of 5-(3,5-difluorobenzyl)pyridin-2-amine

To a solution of 1-(bromomethyl)-3,5-difluorobenzene (1.0 g, 4.83 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (1.28 g, 5.8 mmol), potassium carbonate (1.33 g, 9.66 mmol) in acetonitrile (24 mL) and water (6 mL) at room temperature was added [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II)dichloromethane (0.394 g, 0.483 mmol). The reaction mixture was stirred at 80 °C for 2 h before it was extracted with ethyl acetate (50 mL x 2). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate, filtered and concentrated. Purification by column chromatography (silica gel, petroleum ether/ethyl acetate = 1/1) gives 5-(3,5-difluorobenzyl)pyridin-2-amine (0.700 g, 3.19 mmol, 66%) as a brown oil. LCMS (ESI) m/z : 211.1 $[\text{M}+\text{H}]^+$.

Step 2: Preparation of

N-(5-(3,5-difluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide




A solution of 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.125 g, 0.8 mmol), 5-(3,5-difluorobenzyl)pyridin-2-amine (0.211 g, 0.96 mmol), 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.456 g, 1.2 mol) and *N,N*-diisopropylethylamine (0.310 g, 2.4 mmol) in *N,N*-dimethylformamide (3.5 mL) was stirred at room temperature for 2 h. The crude sample was dissolved in minimal *N,N*-dimethylformamide

and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μ m column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give


N-(5-(3,5-difluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide as a white solid (0.120 g, 0.336 mmol, 42%). ^1H NMR (500 MHz, Dimethylsulfoxide- d_6) δ 9.72 (s, 1H), 8.32 (d, J = 2.0 Hz, 1H), 8.03 (d, J = 8.5 Hz, 1H), 7.75 (dd, J = 8.5, 2.3 Hz, 1H), 7.08 - 7.02 (m, 3H), 3.97 (s, 2H), 3.36 (s, 3H), 2.85 (t, J = 8.5 Hz, 2H), 2.52 (d, J = 9.0 Hz, 2H); LCMS (ESI) m/z : 359.0 $[\text{M}+\text{H}]^+$.

Example 23. Preparation of

N-(5-(3-cyclopropylbenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (23)




Step 1: Preparation of 5-(3-bromobenzyl)pyridin-2-amine



A mixture of 1-bromo-3-(bromomethyl)benzene (2.2 g, 8.87 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (2.2 g, 10.0 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II)-dichloromethane complex (0.361 g, 0.44 mmol), potassium carbonate (2.45 g, 17.7 mmol), acetonitrile (80 mL) and water (16 mL) was stirred at 80 $^{\circ}\text{C}$ under nitrogen for 2 h. The mixture was poured into water, extracted with ethyl acetate (150 mL x 2). The combined organic phase was concentrated. The residue was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 1/1) to afford compound 5-(3-bromobenzyl)pyridin-2-amine (1.6 g, 6.10 mmol, 68.8%) as a light-yellow oil. LCMS (ESI) m/z : 263.0/265.0 $[\text{M}+\text{H}]^+$.

Step 2: Preparation of 5-(3-cyclopropylbenzyl)pyridin-2-amine




A mixture of 5-(3-bromobenzyl)pyridin-2-amine (0.800 g, 3.05 mmol), cyclopropylboronic acid (0.787 g, 9.15 mmol), palladium(II) acetate (0.067 g, 0.3 mmol), tricyclohexylphosphine tetrafluoroborate (0.220 g, 0.6 mmol), potassium phosphate (1.3 g, 6.1 mmol) in toluene (60 mL) and water (15 mL) was stirred at 110 $^{\circ}\text{C}$ under nitrogen for 16 h. The mixture was poured into water and extracted with ethyl acetate (150 mL x 2). The combined organic phases were concentrated. The crude residue was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 1/2) to afford

5-(3-cyclopropylbenzyl)pyridin-2-amine (0.350 g, 0.156 mmol, 51%) as a grey solid. LCMS (ESI) m/z : 225.2 $[M+H]^+$.

Step 3: Preparation of


5 *N*-(5-(3-cyclopropylbenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide




A mixture of 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.208 g, 1.33 mmol), 5-(3-cyclopropylbenzyl)pyridin-2-amine (0.298 g, 1.33 mmol), 1-[*bis*(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.760 g, 2.0 mmol), *N,N*-diisopropylethylamine (0.516 g, 3.99 mmol) in *N,N*-dimethylformamide (6 mL) was stirred at room temperature 16 h. The mixture was poured into water and extracted with ethyl acetate (80 mL x 3). The combined organic phases were concentrated. The residue was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 3/1) to afford *N*-(5-(3-cyclopropylbenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.134 g, 0.371 mmol, 27.9%) as a white solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ : 9.69 (s, 1H), 8.27 (d, *J* = 2.0 Hz, 1H), 8.02 (d, *J* = 8.5 Hz, 1H), 7.69 (dd, *J* = 2.0, 8.5 Hz, 1H), 7.16 (t, *J* = 8.0 Hz, 1H), 6.99 (m, 2H), 6.88 (d, *J* = 7.5 Hz, 1H), 3.89 (s, 2H), 3.36 (s, 3H), 2.85 (t, *J* = 8.5 Hz, 2H), 2.52 (t, *J* = 8.5 Hz, 2H), 1.89-1.84 (m, 1H), 0.93-0.90 (m, 2H), 0.65-0.62 (m, 2H); LCMS (ESI) m/z : 363.2 $[M+H]^+$.

20 **Example 24. Preparation of**

***N*-(5-(3-chloro-5-methoxybenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (24)**



Step 1: Preparation of 1-(bromomethyl)-3-chloro-5-methoxybenzene




25

To a solution of (3-chloro-5-methoxyphenyl)methanol (2.0 g, 11.6 mmol) in diethyl ether (20 mL) at 0 °C was added phosphorus tribromide (0.5 mL). The reaction mixture was stirred at 0 °C for 2 h. Reaction was poured into saturated aqueous sodium bicarbonate (150 mL) and extracted with ethyl acetate (200 mL x 2). The combined organic phases were dried over sodium sulfate, filtered and concentrated to afford 1-(bromomethyl)-3-chloro-5-methoxybenzene (2.15 g, 9.16 mmol, 79%) as a light-yellow solid. Used in the next step directly without additional purification.

30


Step 2: Preparation of 5-(3-chloro-5-methoxybenzyl)pyridin-2-amine



The synthesis of 5-(3-chloro-5-methoxybenzyl)pyridin-2-amine was followed similar procedure as for **Example 23** to give 5-(3-chloro-5-methoxybenzyl)pyridin-2-amine (1.1 g, 4.4 mmol, 79%) as an orange solid. LCMS (ESI) m/z : 249.1 $[M+H]^+$.

Step 3: Preparation of


N-(5-(3-chloro-5-methoxybenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide




A solution of 5-(3-chloro-5-methoxybenzyl)pyridin-2-amine (0.300 mg, 1.2 mmol), 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.188 g, 1.2 mmol), 1-[*bis*(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.684 g, 1.8 mmol), *N,N*-diisopropylethylamine (0.465 g, 3.6 mmol) in *N,N*-dimethylformamide (10 mL) was stirred at room temperature for 1 h. The mixture was poured into water. The formed precipitate was filtered, washed with ethyl acetate (25 mL) and dried *in vacuo* to afford *N*-(5-(3-chloro-5-methoxybenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.0638 g, 0.165 mmol, 13.7%) as an off-white solid. ^1H NMR (500 MHz, Dimethylsulfoxide- d_6) δ : 9.72 (s, 1H), 8.31 (d, J = 1.5 Hz, 1H), 9.03 (d, J = 8.5 Hz, 1H), 7.74 (dd, J = 2.0, 8.5 Hz, 1H), 6.90-6.84 (m, 3H), 3.91 (s, 2H), 3.75 (s, 3H), 3.36 (s, 3H), 2.85 (t, J = 8.5 Hz, 2H), 2.52 (t, J = 8.5 Hz, 2H); LCMS (ESI) m/z : 387.1 $[M+H]^+$.

Example 25. Preparation of

N-(5-(3-cyano-5-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (25)




Step 1: Preparation of 3-(bromomethyl)-5-fluorobenzonitrile



A mixture of 3-fluoro-5-methylbenzonitrile (2.0 g, 14.8 mmol), *N*-bromosuccinimide (2.85 g, 16.3 mmol), 2,2'-azobis(2-methylpropionitrile) (242 mg, 1.48 mmol) in acetonitrile (20 mL) was stirred at reflux for 3 h. The mixture was concentrated. The residue was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 10/1) to afford 3-(bromomethyl)-5-fluorobenzonitrile (1.55 g, 6.96 mmol,

47%) as a light-yellow oil. ^1H NMR (500 MHz, Chloroform- d) δ 7.51 (s, 1H), 7.40 (dt, J = 2.0, 9.0 Hz, 1H), 7.33 (dt, J = 1.5, 8.0 Hz, 1H), 4.45 (s, 2H).


Step 2: Preparation of 3-((6-aminopyridin-3-yl)methyl)-5-fluorobenzonitrile





5 A mixture of 3-(bromomethyl)-5-fluorobenzonitrile (1.0 g, 4.68 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (1.03 g, 4.68 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II)·dichloromethane complex (0.380 g, 0.468 mmol), cesium carbonate (3.04 g, 9.36 mmol) in 1,4-dioxane (40 mL) was stirred at 100 °C for 3 h. The mixture was concentrated, and the crude material was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 1/1) to afford 3-((6-aminopyridin-3-yl)methyl)-5-fluorobenzonitrile (0.720 g, 3.14 mmol, 67%) as a brown oil. LCMS (ESI) m/z : 228.1 $[\text{M}+\text{H}]^+$.

Step 3: Preparation of


15 *N*-(5-(3-cyano-5-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide




To a solution of 3-((6-aminopyridin-3-yl)methyl)-5-fluorobenzonitrile (0.350 g, 1.54 mmol), 1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (0.170 g, 1.11 mmol) in pyridine (10 mL) at 0 °C was added phosphorus(V) oxychloride (0.4 mL) dropwise. The reaction mixture was stirred at room temperature for 2 h. The mixture was poured into crushed ice and extracted with ethyl acetate (100 mL x 2). The combined organic phases were concentrated. The residue was purified by column chromatography (silica gel, 10% methanol in ethyl acetate) and the obtained solid was washed with methanol (4 mL). The gray solid (0.070 g) was dissolved in minimal *N,N*-dimethylformamide and purified by prep-HPLC (Boston C18 21*250 mm 10 μm column. The mobile phase was acetonitrile/10 mM ammonium acetate aqueous solution) to give *N*-(5-(3-cyano-5-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (0.019 g, 0.052 mmol, 3.4%) as a white solid. ^1H NMR (500 MHz, Dimethylsulfoxide- d_6) δ 10.55 (s, 1H), 8.67 (d, J = 2.5 Hz, 1H), 8.35 (d, J = 2.0 Hz, 1H), 8.06 (d, J = 8.0 Hz, 1H), 7.98 (dd, J = 3.0, 9.5 Hz, 1H), 7.75-7.68 (m, 3H), 7.58 (d, J = 9.5 Hz, 1H), 6.43 (d, J = 9.5 Hz, 1H), 4.03 (s, 2H), 3.50 (s, 3H); LCMS (ESI) m/z : 363.1 $[\text{M}+\text{H}]^+$.

Example 26. Preparation of***N*-(5-(3-cyano-5-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (26)****5 Step 1: Preparation of 3-(bromomethyl)-5-fluorobenzonitrile**

A mixture of 3-fluoro-5-methylbenzonitrile (2.0 g, 14.8 mmol), *N*-bromosuccinimide (2.85 g, 16.3 mmol), 2,2'-azobis(2-methylpropionitrile) (0.242 g, 1.48 mmol) in acetonitrile (20 mL) was stirred at reflux for 3 h. The mixture was concentrated. The crude sample was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 10/1) to give 3-(bromomethyl)-5-fluorobenzonitrile (1.55 g, 6.96 mmol, 47%) as a light-yellow oil. ¹H NMR (500 MHz, Chloroform-*d*) δ. 7.51 (s, 1H), 7.40 (dt, *J* = 2.0, 9.0 Hz, 1H), 7.33 (dt, *J* = 1.5, 8.0 Hz, 1H), 4.45 (s, 2H).

Step 2: Preparation of 3-((6-aminopyridin-3-yl)methyl)-5-fluorobenzonitrile

A mixture of 3-(bromomethyl)-5-fluorobenzonitrile (1.0 g, 4.68 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (1.03 g, 4.68 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane complex (0.380 g, 0.468 mmol), cesium carbonate (3.04 g, 9.36 mmol) in 1,4-dioxane (40 mL) was stirred at 100 °C under nitrogen for 3 h. The mixture was concentrated. The residue was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 1/1) to afford compound 3-((6-aminopyridin-3-yl)methyl)-5-fluorobenzonitrile (0.720 g, 0.314 mmol, 67%) as a brown oil. LCMS (ESI) *m/z*: 228.1 [M+H]⁺.

25 Step 3: Preparation of***N*-(5-(3-cyano-5-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide**


A mixture of 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.210 g, 1.34 mmol), 3-((6-aminopyridin-3-yl)methyl)-5-fluorobenzonitrile (0.300 g, 1.32 mmol), 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.750 g, 1.97 mmol), *N,N*-diisopropylethylamine (0.510 g, 3.95 mmol) in *N,N*-dimethylformamide (5 mL) was

stirred at room temperature for 1 h. The mixture was poured into water and extracted with ethyl acetate (80 mL x 2). The combined organic phases were concentrated. The residue was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 1/1) to afford 130 mg of a white solid. This sample was dissolved in minimal *N,N*-dimethylformamide and purified via prep-HPLC (Boston C18


21*250 mm 10 μ m column; acetonitrile/0.01% aqueous trifluoroacetic acid) to yield *N*-(5-(3-cyano-5-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.0755 g, 0.206 mmol, 13.4%) as a white solid. ^1H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ : 9.73 (s, 1H), 8.34 (d, *J* = 1.5 Hz, 1H), 8.04 (d, *J* = 8.5 Hz, 1H), 7.77 (dd, *J* = 1.5, 8.5 Hz, 1H), 7.71-6.68 (m, 2H), 7.57 (d, *J* = 9.5 Hz, 1H), 4.03 (s, 2H), 3.35 (s, 3H), 2.85 (t, *J* = 8.5 Hz, 2H), 2.52 (t, *J* = 8.5 Hz, 2H); LCMS (ESI) *m/z*: 366.1 [*M*+*H*]⁺.

Example 27. Preparation of

N-(5-(3-bromobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (27)




Step 1: Preparation of 5-(3-bromobenzyl)pyridin-2-amine



The synthesis of 5-(3-bromobenzyl)pyridin-2-amine was following similar procedures as **Example 25**. Compound 5-(3-bromobenzyl)pyridin-2-amine (0.500 g, 1.9 mmol, 37%) was obtained as a brown oil. LCMS (ESI) *m/z*: 263.0/265.0 [*M*+*H*]⁺.

Step 2: Preparation of

N-(5-(3-bromobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide




A mixture of 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.200 g, 1.28 mmol) 5-(3-bromobenzyl)pyridin-2-amine (0.400 g, 1.52 mmol), 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (0.447 g, 1.52 mmol), 4-methylmorpholine (0.460 g, 4.56 mmol) in tetrahydrofuran (8 mL) was stirred at room temperature for 1 h. The mixture was poured into water and extracted with ethyl acetate (150 mL x 2). The combined organic phases were concentrated. The residue was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 1/1) and then 100 mg was dissolved in minimal *N,N*-dimethylformamide and purified by prep-HPLC (Boston C18 21*250 mm 10 μ m column. The mobile phase was acetonitrile/10 mM ammonium acetate aqueous solution) to give *N*-(5-(3-bromobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.0347 g,

0.086 mmol, 5.7%) as a white solid. ^1H NMR (500 MHz, Dimethylsulfoxide- d_6) δ : 9.72 (s, 1H), 8.31 (d, J = 2.5 Hz, 1H), 8.03 (d, J = 8.5 Hz, 1H), 7.73 (dd, J = 2.0, 8.5 Hz, 1H), 7.49 (s, 1H), 7.42-7.40 (m, 1H), 7.28-7.27 (m, 2H), 3.96 (s, 2H), 3.36 (s, 3H), 2.85 (t, J = 8.5 Hz, 2H), 2.52 (t, J = 8.5 Hz, 2H); LCMS (ESI) m/z : 401.0/403.0 $[\text{M}+\text{H}]^+$.


5

Example 28. Preparation of

N-(5-(3-chloro-5-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (28)



10 Step 1: Preparation of 5-(3-chloro-5-fluorobenzyl)pyridin-2-amine




To a solution of 1-(bromomethyl)-3-chloro-5-fluorobenzene (3.0 g, 13.4 mmol) and 5-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)pyridin-2-amine (3.54 g, 16.1 mmol), potassium carbonate (3.71 g, 26.8 mmol) in 1,4-dioxane (72 mL) and water (24 mL) was added

15 [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (1.10 g, 1.34 mmol) under nitrogen. The mixture was stirred at 100 °C for 3 h. Reaction was quenched with water (200 mL) and the mixture was extracted with ethyl acetate (150 mL x 3). The combined organic layers were dried with sodium sulfate, filtered and concentrated. The crude material was purified by column chromatography (petroleum ether/ethyl acetate from 100/0 to 60/100) to give 5-(3-chloro-5-fluorobenzyl)pyridin-2-amine (2.5 g, 10.6 mmol, 79%) as a yellow oil. LCMS (ESI) m/z : 237.1 $[\text{M}+\text{H}]^+$:

20

Step 2: Preparation of

N-(5-(3-chloro-5-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide



25 To a solution of 5-(3-chloro-5-fluorobenzyl)pyridin-2-amine (2.3 g, 9.72 mmol), 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (2.28 g, 14.6 mmol) and 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (7.39 g, 19.4 mmol) in *N,N*-dimethylformamide (30 mL) at 0 °C was added *N,N*-diisopropylethylamine (5.02 g, 38.9 mmol) dropwise under nitrogen. The mixture was stirred at room temperature for 2 h before it was poured into water and filtered to obtain a crude product. The crude residue was recrystallized from ethanol (220 mL) to obtain

30


N-(5-(3-chloro-5-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide

(2.2 g, 5.93 mmol, 61%) as a white solid. ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 9.73 (s, 1H), 8.36-8.33 (m, 1H), 8.04 (d, *J* = 8.5 Hz, 1H), 7.77 (dd, *J*₁ = 2.4 Hz, *J*₂ = 8.5 Hz 1H), 7.24-7.28 (m, 2H), 7.17 (d, *J* = 10.0 Hz, 1H), 3.98 (s, 2H), 3.36 (s, 3H), 2.85 (t, *J* = 8.5 Hz, 2H), 2.54-2.51 (m, 2H); LCMS (ESI) *m/z*: 375.1 [M+H]⁺.


5

Example 29. Preparation of

1-methyl-6-oxo-*N*-(5-(3,4,5-trifluorobenzyl)pyridin-2-yl)-1,4,5,6-tetrahydropyridazine-3-carboxamide (29)



10 Step 1: Preparation of 5-(3,4,5-trifluorobenzyl)pyridin-2-amine




To a solution of 5-(bromomethyl)-1,2,3-trifluorobenzene (1.0 g, 4.47 mmol), 6-aminopyridin-3-ylboronic acid (0.617 g, 4.47 mmol), potassium carbonate (1.23 g, 8.94 mmol) in tetrahydrofuran (12 mL) and water (3 mL) was added tetrakis(triphenylphosphine)palladium(0) (0.516 g, 0.447 mmol) under nitrogen. The reaction mixture was heated to 90 °C and stirred for 2 h. The volatiles were removed under reduced pressure. Aqueous layer was acidified to pH = 1-3 with 1 N hydrogen chloride and extracted with ethyl acetate (50 mL). The aqueous layer was then adjusted to pH = 8-10 with aqueous sodium bicarbonate and extracted with dichloromethane (50 mL x 2). The combined dichloromethane layers were dried over sodium sulfate, filtered and concentrated to give as a yellow oil (0.300 g, crude); LCMS (ESI) *m/z*: 239.1 [M+H]⁺.

20

Step 2: Preparation of

1-methyl-6-oxo-*N*-(5-(3,4,5-trifluorobenzyl)pyridin-2-yl)-1,4,5,6-tetrahydropyridazine-3-carboxamide



To a solution of 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.100 g, 0.641 mmol), *N,N*-diisopropylethylamine (0.248 g, 1.92 mmol) in tetrahydrofuran (5 mL) at 20 °C was added 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.366 g, 0.962 mmol). The reaction was stirred for 20 minutes before a solution of 5-(3,4,5-trifluorobenzyl)pyridin-2-amine (0.153 g, 0.641 mmol) in tetrahydrofuran (1.0 mL) was added. The reaction mixture was stirred at 20 °C for 16 h. The volatiles were removed under reduced pressure and the crude residue was added to a mixture of dichloromethane (50 mL) and water (50 mL). The organic layer was collected, dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 μm column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give


30

1-methyl-6-oxo-*N*-(5-(3,4,5-trifluorobenzyl)pyridin-2-yl)-1,4,5,6-tetrahydropyridazine-3-carboxamide as a white solid (0.126 g, 0.333 mmol, 52%). ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 9.75 (s, 1H), 8.32 (d, *J* = 2.5 Hz, 1H), 8.03 (d, *J* = 8.5 Hz, 1H), 7.74-7.77 (m, 1H), 7.26-7.30 (m, 2H), 3.95 (s, 2H), 3.36 (s, 3H), 2.85 (t, *J* = 8.5 Hz, 2H), 2.52 (t, *J* = 8.5 Hz, 2H); LCMS (ESI) *m/z*: 377.0 [M+H]⁺.


5

Example 30. Preparation of

N-(5-(3-methoxybenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (30)



Step 1: Preparation of 5-(3-methoxybenzyl)pyridin-2-amine




To a solution of 1-(bromomethyl)-3-methoxybenzene (0.362 g, 1.8 mmol) and 5-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)pyridin-2-amine (0.480 g, 2.16 mmol) and potassium carbonate (0.498 g, 3.6 mmol) in 1,4-dioxane (9 mL) and water (3 mL) was added

[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (132 mg, 0.18 mmol) under nitrogen. The reaction mixture was stirred in the microwave at 100 °C for 30 minutes. After the reaction was completed, water (50 mL) was added, the mixture was extracted with ethyl acetate (80 mL x 3). The organic layers were dried with sodium sulfate, filtered and concentrated. The crude product was purified by silica gel column (petroleum ether/ethyl acetate from 1/1 to 0/1) to give 5-(3-methoxybenzyl)pyridin-2-amine (0.285 g, 1.33 mmol, 74%) as a brown solid. LCMS (ESI) *m/z*: 215.1 [M+H]⁺.

Step 2: Preparation of

N-(5-(3-methoxybenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide




To a solution of 5-(3-methoxybenzyl)pyridin-2-amine (0.086 g, 0.4 mmol), 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.063 g, 0.4 mmol) and triethylamine (0.404 g, 4 mmol) in dichloromethane (30 mL) at 0 °C was added propylphosphonic anhydride (1.27 g, 2 mmol) slowly under nitrogen. Reaction was diluted with dichloromethane (50 mL) and washed with water (30 mL x 2). The organic layer was dried over sodium sulfate, filtered and concentrated. The crude product was purified by prep-TLC (dichloromethane: 7 *N* ammonia in methanol = 30/1) to give *N*-(5-(3-methoxybenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.0857 g, 0.244 mmol, 61%) as a white solid. ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 9.70 (s, 1H), 8.28-8.29

(m, 1H), 8.02 (d, $J = 8.4$ Hz, 1H), 7.71 (dd, $J_1 = 2.0$ Hz, $J_2 = 8.4$ Hz, 1H), 7.22 (t, $J = 9.2$ Hz, 1H), 6.76-6.84 (m, 3H), 3.91 (s, 2H), 3.73 (s, 3H), 3.36 (s, 3H), 2.85 (t, $J = 8.4$ Hz, 2H), 2.50-2.55 (m, 2H); LCMS (ESI) m/z : 353.1 $[M+H]^+$.


5 Example 31. Preparation of

N-(5-(3-methoxybenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (31)



Step 1: Preparation of


10 *N*-(5-(3-methoxybenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide 5-(3,5-dichlorobenzyl)pyridin-2-amine



To a solution of 1-(bromomethyl)-3,5-dichlorobenzene (0.480 g, 2.0 mmol),
5-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)pyridin-2-amine (0.534 g, 2.4 mmol) and potassium carbonate
15 (0.553 g, 4.0 mmol) in 1,4-dioxane (9 mL) and water (3 mL) was added
[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.147 g, 0.2 mmol) under nitrogen. The
reaction mixture was stirred in the microwave at 100 °C for 0.5 h. Water (50 mL) was added and the
mixture was extracted with ethyl acetate (80 mL x 3). The combined organic layers were dried with
sodium sulfate, filtered and concentrated. Purification by column chromatography (silica gel, petroleum
20 ether/ethyl acetate from 1/1 to 1/2) gives
N-(5-(3-methoxybenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide
5-(3,5-dichlorobenzyl)pyridin-2-amine (0.458 g, 1.8 mmol, 90%) as a brown solid. LCMS (ESI) m/z : 253.0
 $[M+H]^+$.

25 Step 2: Preparation of

N-(5-(3-methoxybenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide



To a solution of 5-(3,5-dichlorobenzyl)pyridin-2-amine (0.076 g, 0.3 mmol),
1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.047 g, 0.3 mmol) and triethylamine
30 (0.303 g, 3 mmol) in dichloromethane (15 mL) at 0 °C was added propylphosphonic anhydride (0.955 g,
1.5 mmol) under nitrogen. Reaction was diluted with dichloromethane (50 mL) and washed with water (30


mL x 2). The organic layer was dried with sodium sulfate, filtered and concentrated. Purification by prep-TLC (dichloromethane: 7 N ammonia in methanol = 30/1) gives

N-(5-(3-methoxybenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide as a white solid (0.0547 g, 0.141 mmol, 47%). ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 9.73 (s, 1H), 8.33


(s, 1H), 8.04 (d, *J* = 8.8 Hz, 1H), 7.76 (dd, *J*₁ = 1.6 Hz, *J*₂ = 8.4 Hz, 1H), 7.46 (s, 1H), 7.38 (s, 2H), 3.97 (s, 2H), 3.36 (s, 3H), 2.85 (t, *J* = 8.4 Hz, 2H), 2.51-2.55 (m, 2H); LCMS (ESI) *m/z*: 390.9 [M+H]⁺.

Example 32. Preparation of

N-(5-(3-(difluoromethyl)benzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (32)




Step 1: Preparation of 2-chloro-5-(3-(difluoromethyl)benzyl)pyridine



To a solution of (3-(difluoromethyl)phenyl)boronic acid (0.405 g, 2.5 mmol) and 2-chloro-5-(chloromethyl)pyridine (0.430 g, 2.5 mmol) and potassium carbonate (0.691 g, 5 mmol) in acetonitrile (70 mL) and water (10 mL) was added [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane (0.204 g, 0.25 mmol) under argon. The mixture was stirred at 50 °C for 1 h. Volatiles were removed under reduced pressure and water (50 mL) was added. The aqueous layer was extracted with ethyl acetate (80 mL x 3), dried with sodium sulfate, filtered and concentrated. The crude material was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 12/1) to give 2-chloro-5-(3-(difluoromethyl)benzyl)pyridine (0.397 g, 1.45 mmol, 58%) as a colorless oil. LCMS (ESI) *m/z*: 254.1 [M+H]⁺.

Step 2: Preparation of 5-(3-(difluoromethyl)benzyl)pyridin-2-amine




To a solution of 2-chloro-5-(3-(difluoromethyl)benzyl)pyridine (0.319 g, 1.26 mmol) in tetrahydrofuran (40 mL) was added sequentially *tris*(dibenzylideneacetone)dipalladium(0) (0.115 g, 0.126 mmol) and X-Phos (0.120 g, 0.252 mmol) followed by lithium *bis*(trimethylsilyl)amide (3.8 mL, 3.8 mmol). Reaction vessel was heated to 70 °C and stirred for 1 h before it was quenched with water and extracted

with dichloromethane (50 mL x 3). The combined organic layers were dried with sodium sulfate, filtered and concentrated. The crude product was purified by column chromatography (silica gel, dichloromethane/ammonia in methanol (7 M) = 40/1) to give 5-(3-(difluoromethyl)benzyl)pyridin-2-amine (0.410 g, 0.781 mmol, 62%) as a yellow oil. (LCMS (ESI) 235.2 [M+H]⁺).

5

Step 3: Preparation of


N-(5-(3-(difluoromethyl)benzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide




To a solution of 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.125 g, 0.8 mmol) and 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.228 g, 0.6 mmol) in *N,N*-dimethylformamide (15 mL) at room temperature was added *N,N*-diisopropylethylamine (0.155 g, 1.2 mmol) under nitrogen. The mixture was stirred at room temperature for 30 minutes before 5-(3-(difluoromethyl)benzyl)pyridin-2-amine (0.188 g, 0.4 mmol) was added. The reaction mixture was stirred at 50 °C for 16 h. Reaction mixture was cooled to room temperature and diluted with ethyl acetate (100 mL). The combined organic layers were washed with brine (30 mL x 3), dried with sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 μm column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give *N*-(5-(3-(difluoromethyl)benzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide as a white solid (0.102 g, 0.22 mmol, 55 %). ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 9.73 (s, 1H), 8.31 (d, *J* = 2 Hz, 1H), 8.04 (d, *J* = 8.5 Hz, 1H), 7.73 (dd, *J*₁ = 2.0 Hz, *J*₂ = 7 Hz, 1H), 7.41-7.47 (m, 4H), 7.00 (t, *J* = 56 Hz, 1H), 4.03 (s, 2H), 3.362 (s, 3H), 2.85 (t, *J* = 8.5 Hz, 2H), 2.51-2.54 (m, 2H); LCMS (ESI) *m/z*: 373.1 [M+H]⁺.

25 Example 33. Preparation of

N-(5-(3-chloro-4-cyanobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (33)




Step 1: Preparation of 4-(bromomethyl)-2-chlorobenzonitrile



To a solution of 2-chloro-4-methylbenzonitrile (1.06 g, 7 mmol) and *N*-bromosuccinimide (1.37 g, 7.7 mmol) in acetonitrile (70 mL) was added 2,2-azobis(2-methylpropionitrile) (0.230 g, 1.4 mmol) under argon. The mixture was stirred at 80 °C for 20 h. The reaction mixture was filtered and washed with ethyl acetate (80 mL). The filtrate was concentrated, and the resulting crude material was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 10/1) to give 4-(bromomethyl)-2-chlorobenzonitrile as a light-yellow solid (0.661 g, 2.87 mmol, 41%). ¹H NMR (400 MHz, Chloroform-*d*) δ 7.67-7.69 (m, 1H), 7.57-7.58 (m, 1H), 7.41 (dd, *J*₁ = 1.5 Hz, *J*₂ = 8.0 Hz, 1H), 4.454 (s, 2H).


Step 2: Preparation of 4-((6-aminopyridin-3-yl)methyl)-2-chlorobenzonitrile



To a solution of 4-(bromomethyl)-2-chlorobenzonitrile (0.461 g, 2 mmol) and 5-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)pyridin-2-amine (0.534 g, 2.4 mmol) and potassium carbonate (0.563 g, 4 mmol) in 1,4-dioxane (9 mL) and water (3 mL) was added [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.147 g, 0.2 mmol) under nitrogen. The reaction mixture was stirred at 100 °C for 40 min in the microwave. Reaction was diluted with water (50 mL) and the aqueous layer was extracted with ethyl acetate (80 mL x 3). The combined organic layers were dried with sodium sulfate, filtered and concentrated. The crude residue was purified by column chromatography (silica gel, petroleum ether/ethyl acetate from 1:1 to 0:1) to give 4-((6-aminopyridin-3-yl)methyl)-2-chlorobenzonitrile as a yellow solid (0.263 g, 1.08 mmol, 54%). LCMS (ESI) *m/z*: 244.1 [M+H]⁺.

Step 3: Preparation of

N-(5-(3-chloro-4-cyanobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide




To a solution of 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.052 g, 0.33 mmol) and 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.171 g, 0.45 mmol) in *N,N*-dimethylformamide (3 mL) was added *N,N*-diisopropylethylamine (0.116 g, 0.9 mmol) at room temperature under nitrogen. The mixture was stirred at room temperature for 30 minutes before 4-((6-aminopyridin-3-yl)methyl)-2-chlorobenzonitrile (0.073 g, 0.3 mmol) was added. The reaction mixture was stirred at room temperature for 16 h. The reaction mixture was diluted with ethyl acetate (80 mL) and washed with brine (40 mL x 3). The combined

organic layers were dried with sodium sulfate, filtered and concentrated. The crude material was purified by Prep-TLC (dichloromethane: ammonia in methanol (7 M) = 40/1) to give


N-(5-(3-chloro-4-cyanobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide as a white solid (0.0736 g, 0.106 mmol, 32%). ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 9.75 (s, 1H), 8.34 (d, *J* = 1.5 Hz, 1H), 8.04 (d, *J* = 8.5 Hz, 1H), 7.92 (d, *J* = 8.0 Hz, 1H), 7.76 (dd, *J*₁ = 2.0 Hz, *J*₂ = 8.5 Hz, 1H), 7.72 (s, 1H), 7.46 (d, *J* = 8.0 Hz, 1H), 4.07 (s, 2H), 3.36 (s, 3H), 2.85 (t, *J* = 8.0 Hz, 2H), 2.51-2.54 (m, 2H); LCMS (ESI) *m/z*: 382.1 [M+H]⁺.

Example 34. Preparation of

N-(5-(cyclohexenylmethyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (34)




Step 1: Preparation of 2-chloro-5-(cyclohexenylmethyl)pyridine



To a solution of 2-chloro-5-(chloromethyl)pyridine (6.38 g, 39.65 mmol), cyclohexenylboronic acid (5 g, 39.65 mmol) and potassium carbonate (11 g, 79.3 mmol) in water (30 mL) and acetonitrile (120 mL) was added [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (3.23 g, 3.97 mmol) under nitrogen. The reaction mixture was heated to 50 °C and stirred for 1 h before volatiles were removed under reduced pressure. The aqueous layer was extracted with dichloromethane (50 mL). The combined organic layers were collected, dried over sodium sulfate, filtered and concentrated. The residue was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 10/1) to offer 2-chloro-5-(cyclohexenylmethyl)pyridine (5.3 g, 25.6 mmol, 65%) as a white solid. LCMS (ESI) *m/z*: 208.1 [M+H]⁺.


Step 2: Preparation of *tert*-butyl 5-(cyclohexenylmethyl)pyridin-2-ylcarbamate



To a solution of 2-chloro-5-(cyclohexenylmethyl)pyridine (0.9 g, 4.35 mmol), *tert*-butyl carbamate (509 mg, 4.35 mmol), XantPhos (377 mg, 0.653 mmol) and cesium carbonate (2.83 g, 8.7 mmol) in 1,4-dioxane (10 mL) was added *tris*(dibenzylideneacetone)dipalladium(0) (401 mg, 0.435 mmol) under nitrogen. The reaction mixture was heated to 100 °C and stirred for 3 h. The solid was filtered and the

filtrate was concentrated, and purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 10/1) to offer *tert*-butyl 5-(cyclohexenylmethyl)pyridin-2-ylcarbamate (0.6 g, 2.08 mmol, 48%) as a white solid. LCMS (ESI) *m/z*: 289.1 [M+H]⁺.


5 Step 3: Preparation of 5-(cyclohexenylmethyl)pyridin-2-ammonium chloride




A solution of *tert*-butyl 5-(cyclohexenylmethyl)pyridin-2-ylcarbamate (0.3 g, 1.04 mmol) in hydrochloric acid/1,4-dioxane (5 mL) was heated to 60 °C and stirred for 1 h. The volatiles were removed under the reduced pressure to give 5-(cyclohexenylmethyl)pyridin-2-amine as its hydrochloride salt (0.2 g, 0.9 mmol, 86%, crude) as a white solid which was used in the next step without purification. LCMS (ESI) *m/z*: 189.1 [M+H]⁺.

Step 4: Preparation of


N-(5-(cyclohexenylmethyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide



To a solution of 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (100 mg, 0.641 mmol) and diisopropylethylamine (249 mg, 1.923 mmol) in tetrahydrofuran (5 mL) at 20 °C was added 1-[*bis*(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (366 mg, 0.962 mmol). The reaction mixture was stirred for 20 minutes before a solution of 5-(cyclohexenylmethyl)pyridin-2-ammonium chloride (144 mg, 0.641 mmol) in tetrahydrofuran (1.0 mL) was added. The reaction solution was heated to 90 °C and stirred for 1 h. The volatiles were removed under reduced pressure and the residue was added to a mixture of dichloromethane (50 mL) and water (50 mL). The organic layer was collected, dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified by prep-HPLC (Boston C18 21*250 mm 10 μm column. The mobile phase was acetonitrile/10 mM ammonium acetate aqueous solution) to give *N*-(5-(cyclohexenylmethyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (13.6 mg, 0.042 mmol, 6%) as a white solid. ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 9.70 (s, 1H), 8.16 (d, *J* = 4.0 Hz, 1H), 8.03 (d, *J* = 8.0 Hz, 1H), 7.64 (q, *J* = 4.0 Hz, 1H), 5.44 (s, 1H), 3.36 (s, 3H), 3.21 (s, 2H), 2.86 (t, *J* = 10.0 Hz, 2H), 2.53-2.55 (m, 2H), 1.97 (s, 2H), 1.82 (s, 2H), 1.48-1.54 (m, 4H); LCMS (ESI) *m/z*: 327.1 [M+H]⁺.


Example 35. Preparation of***N*-(5-(3,4-difluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (35)**

5

Step 1: Preparation of 5-(3,4-difluorobenzyl)pyridin-2-amine

To a solution of 4-(bromomethyl)-1,2-difluorobenzene (2.0 g, 9.71 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (2.14 g, 9.71 mmol) and potassium carbonate (2.7 g, 19.42 mmol) in tetrahydrofuran (20 mL) and water (5 mL) was added tetrakis(triphenylphosphine)palladium(0) (1.12 g, 0.971 mmol) under nitrogen. The reaction mixture was heated to 90 °C and stirred for 2 h. The volatiles were removed under reduced pressure and the aqueous layer was adjusted to pH = 1 with ~1 *N* hydrochloric acid. The aqueous layer was extracted with ethyl acetate (50 mL) before aqueous sodium bicarbonate added to adjust the pH = 8~10. The aqueous layer was extracted with dichloromethane (50 mL x 2). The combined dichloromethane layers were collected, dried over sodium sulfate, filtered and concentrated. The crude sample was purified by column chromatography (silica gel, dichloromethane/methanol = 20/1) to offer 5-(3,4-difluorobenzyl)pyridin-2-amine as a yellow oil (800 mg, 3.64 mmol, 37%); LCMS (ESI) *m/z*: 221.1 [M+H]⁺.


20

Step 2: Preparation of 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid


To a solution of methyl 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylate (0.150 g, 0.892 mmol) in water (3 mL) was added sodium hydroxide (71 mg, 1.785 mmol). The reaction mixture was heated to 60 °C and stirred for 1 h. The reaction solution was treated with 1 *N* hydrochloric acid to adjust the pH value to 3~5 before all volatiles were removed to yield 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid as a white solid (110 mg, crude); LCMS (ESI) *m/z*: 155.1 [M+H]⁺.

25


Step 3: Preparation of

N-(5-(3,4-difluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide

To a solution of 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (100 mg, 0.649 mmol) and diisopropylethylamine (252 mg, 1.947 mmol) in tetrahydrofuran (4 mL) at 20°C was added 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (370 mg, 0.974 mmol). The reaction mixture was stirred for 20 minutes before a solution of 5-(3,4-difluorobenzyl)pyridin-2-amine (143 mg, 0.649 mmol) in tetrahydrofuran (1.0 mL) was added. The reaction solution was stirred at 20 °C for 4 h. The volatiles were removed under reduced pressure and the residue was added to a mixture of dichloromethane (50 mL) and water (50 mL). The organic layer was collected, dried over sodium sulfate, filtered and concentrated. The crude sample was purified by column chromatography (silica gel, dichloromethane/methanol = 20/1) to offer *N*-(5-(3,4-difluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (130.3 mg, 0.36 mmol, 55%) as a white solid. ¹H NMR (400 MHz, trifluoroacetic acid-*d*) δ 8.75-8.84 (m, 3H), 8.30 (d, *J* = 7.2 Hz, 1H), 7.95 (d, *J* = 7.6 Hz, 1H), 7.65-7.67 (m, 1H), 7.47-7.52 (m, 2H), 4.64 (s, 2H), 4.54 (s, 3H); LCMS (ESI) *m/z*: 357.1 [*M*+*H*]⁺.

Example 36. Preparation of***N*-(5-(4-chlorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (36)**

Step 1: Preparation of 5-(4-chlorobenzyl)pyridin-2-amine




To a solution of 1-(bromomethyl)-4-chlorobenzene (1.0 g, 4.90 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (1.08 g, 4.90 mmol), potassium carbonate (1.35 g, 9.80 mmol), in tetrahydrofuran (12 mL) and water (3 mL) was added tetrakis(triphenylphosphine)palladium(0) (0.566 g, 0.49 mmol) under nitrogen. The reaction mixture was heated to 90 °C and stirred for 2 h. The volatiles were removed under reduced pressure and the aqueous phase was acidified to pH = 1-3 with 1 N hydrogen chloride and extracted with ethyl acetate (50 mL). The aqueous layer was then adjusted to pH = 8-10 with aqueous sodium bicarbonate and extracted with dichloromethane (50 mL x 2). The combined dichloromethane layers were dried over sodium sulfate, filtered and concentrated. The crude material was purified by column chromatography (silica gel,

petroleum ether/ethyl acetate = 1/1) to offer 5-(4-chlorobenzyl)pyridin-2-amine (0.55 g, 2.52 mmol, 51%) as a yellow solid. LCMS (ESI) m/z : 219.1 $[M+H]^+$.

Step 2: Preparation of


5 *N*-(6-(3-chlorobenzyl)pyridazin-3-yl)-6-oxo-1,6-dihydropyridazine-3-carboxamide



To a solution of 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (0.100 g, 0.649 mmol), diisopropylethylamine (0.168 g, 1.298 mmol) in tetrahydrofuran (5 mL) at 20 °C, was added 1-*bis*(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (370 mg, 0.974 mmol). The reaction mixture was stirred for 20 minutes before a solution of 10 5-(4-chlorobenzyl)pyridin-2-amine (0.142 g, 0.649 mmol) in tetrahydrofuran (1.0 mL) was added. The reaction solution was stirred at 20 °C for 4 h. The volatiles were removed under the reduced pressure and the crude residue was added to a mixture of dichloromethane (50 mL) and water (50 mL). The organic layer was collected, dried over sodium sulfate, filtered and concentrated. The crude sample was 15 dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μ m column. The mobile phase was acetonitrile/10 mM ammonium acetate aqueous solution) to offer *N*-(5-(4-chlorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (94.2 mg, 0.27 mmol, 41%) as a white solid. ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 10.11 (s, 1H), 8.31 (s, 1H), 8.07-8.09 (d, *J* = 8.4 Hz, 1H), 7.93-7.95 (d, *J* = 9.6 Hz, 1H), 7.71-7.73 (d, *J* = 8.4 Hz, 1H), 7.28-7.37 (m, 20 4H), 7.06-7.08 (d, *J* = 9.6 Hz, 1H), 3.96 (s, 2H), 3.78 (s, 3H); LCMS (ESI) m/z : 355.1 $[M+H]^+$.

Example 37. Preparation of


N-(5-(3,5-difluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (37)



25

Step 1: Preparation of

N-(5-(3,5-difluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide




A mixture of 5-(3,5-difluorobenzyl)pyridin-2-amine (200 mg, 0.9 mmol), 30 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (139 mg, 0.9 mmol), 2-(7-azabenzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate (513 mg, 1.35 mmol) and

N,N-diisopropylethylamine (349 mg, 2.7 mmol) in *N,N*-dimethylformamide (8 mL) was stirred at room temperature for 1 h. The mixture was poured into water. The formed precipitate was collected by filtration and the obtained solid was washed with methanol (20 mL) to give


N-(5-(3,5-difluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (0.134 g, 0.38 mmol, 42%) as a grey solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 10.12 (s, 1H), 8.34 (d, *J* = 2.0 Hz, 1H), 8.07 (d, *J* = 10.5 Hz, 1H), 7.93 (d, *J* = 12.5 Hz, 1H), 7.76 (dd, *J* = 10.5, 3.0 Hz, 1H), 7.08-7.02 (m, 4H), 3.97 (s, 2H), 3.77 (s, 3H); LCMS (ESI) *m/z*: 357.1 [M+H]⁺.

Example 38. Preparation of

N-(5-(cyclohexylmethyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (38)




Step 1: Preparation of 2-chloro-5-(cyclohexenylmethyl)pyridine



To a solution of 2-chloro-5-(chloromethyl)pyridine (6.38 g, 39.7 mmol), cyclohexenylboronic acid (5 g, 39.7 mmol) and potassium carbonate (11 g, 79.3 mmol) in water (30 mL) and acetonitrile (120 mL) was added [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane adduct (3.23 g, 3.97 mmol) under nitrogen. The reaction mixture was heated to 50 °C and stirred for 1 h before volatiles were removed under reduced pressure. The aqueous layer was extracted with dichloromethane (50 mL x 2). The combined organic layers were collected, dried over sodium sulfate, filtered and concentrated. The crude product was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 10/1) to offer 2-chloro-5-(cyclohexenylmethyl)pyridine (5.3 g, 25.6 mmol, 65%) as a white solid. LCMS (ESI) *m/z*: 208.1 [M+H]⁺.


Step 2: Preparation of *tert*-butyl 5-(cyclohexenylmethyl)pyridin-2-ylcarbamate



To a solution of 2-chloro-5-(cyclohexenylmethyl)pyridine (5.2 g, 25.1 mmol), *tert*-butyl carbamate (2.94 g, 25.1 mmol), XantPhos (2.2 g, 3.77 mmol) and cesium carbonate (16.4 g, 50.2 mmol) in 1,4-dioxane (60 mL) was added tris(dibenzylideneacetone)dipalladium(0) (2.3 g, 2.51 mmol) under nitrogen. The reaction mixture was heated to 100 °C and stirred for 3 h. The solid was filtered and the filtrate was concentrated, and purified by column chromatography (silica gel, petroleum ether/ethyl

acetate = 10/1) to offer *tert*-butyl 5-(cyclohexenylmethyl)pyridin-2-ylcarbamate (2.4 g, 8.32 mmol, 33%) as a white solid. LCMS (ESI) *m/z*: 289.1 [M+H]⁺.


Step 3: Preparation of 5-(cyclohexenylmethyl)pyridin-2-ammonium chloride



A solution of *tert*-butyl 5-(cyclohexenylmethyl)pyridin-2-ylcarbamate (2.4 g, 8.32 mmol) in hydrochloric acid in 1,4-dioxane (20 mL) was heated to 60 °C and stirred for 1 h. The volatiles were removed under reduced pressure to offer 5-(cyclohexenylmethyl)pyridin-2-ammonium chloride (1.5 g, 6.69 mmol, 80%, crude) as a white solid which was used in the next step without further purification.

LCMS (ESI) *m/z*: 189.1 [M+H]⁺.


Step 4: Preparation of 5-(cyclohexylmethyl)pyridin-2-ammonium chloride



To a solution of 5-(cyclohexenylmethyl)pyridin-2-ammonium chloride (1.5 g, 6.69 mmol) in methanol (10 mL) was added palladium on activated carbon (450 mg) under nitrogen. Reaction mixture was heated to 40 °C under hydrogen and stirred for 12 h. The solid was filtered off and the filtrate was concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified by prep-HPLC (Boston C18 21*250 mm 10 μm column. The mobile phase was acetonitrile/10 mM ammonium acetate aqueous solution) to give 5-(cyclohexylmethyl)pyridin-2-amine as the hydrochloride salt (0.400 g, 1.77 mmol, 26%, crude) as a brown solid. LCMS (ESI) *m/z*: 191.3 [M+H]⁺.

Step 5: Preparation of

N-(5-(cyclohexylmethyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide




To a solution of 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (69 mg, 0.446 mmol) and diisopropylethylamine (173 mg, 1.34 mmol) in tetrahydrofuran (4 mL) at 20 °C was added 1-[*bis*(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (254 mg, 0.669 mmol). The reaction mixture was stirred for 20 minutes before a solution of 5-(cyclohexylmethyl)pyridin-2-ammonium chloride (100 mg, 0.446 mmol) in tetrahydrofuran (1.0 mL) was added. The reaction solution was heated to 90 °C and stirred for 1 h. The volatiles were removed under reduced pressure and the residue was added to a mixture of dichloromethane (50 mL) and water (50 mL). The organic layer was collected, dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified by prep-HPLC (Boston C18 21*250 mm 10 μm column. The mobile phase was acetonitrile/10 mM ammonium acetate aqueous solution) to give *N*-(5-(cyclohexylmethyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (35.8 mg, 0.11 mmol, 25%) as a white solid. ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 10.08 (s, 1H), 8.18 (d, *J* = 4.0


Hz, 1H), 8.07 (d, $J = 8.0$ Hz, 1H), 7.96 (d, $J = 8.0$ Hz, 1H), 7.68 (q, $J = 4.0$ Hz, 1H), 7.08 (d, $J = 8.0$ Hz, 1H), 3.79 (s, 3H), 2.46-2.48 (m, 2H), 1.59-1.67 (m, 5H), 1.48-1.51 (m, 1H), 1.10-1.23 (m, 3H), 0.88-0.97 (m, 2H); LCMS (ESI) m/z : 327.1 $[M+H]^+$.

5 Example 39. Preparation of

1-methyl-6-oxo-*N*-(5-(4-(trifluoromethyl)benzyl)pyridin-2-yl)-1,6-dihydropyridazine-3-carboxamide (39)




Step 1: Preparation of 5-(4-(trifluoromethyl)benzyl)pyridin-2-amine





To a solution of 1-(bromomethyl)-4-(trifluoromethyl)benzene (1.6 g, 6.7 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (1.77 g, 8 mmol) and potassium carbonate (1.85 g, 13.4 mmol) in acetonitrile (32 mL) and water (8 mL) was added 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (0.147 g, 0.67 mmol) under argon. The reaction mixture was stirred at 80 °C for 2 h. The reaction solution was extracted with ethyl acetate (50 mL x 2). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate, filtered and concentrated. The crude residue was purified by column chromatography (silica gel, dichloromethane/methanol = 100/1) to give 5-(4-(trifluoromethyl)benzyl)pyridin-2-amine (1.2 g, 4.8 mmol, 71 %) as a color oil. LCMS (ESI) m/z : 253.1 $[M+H]^+$.

Step 2: Preparation of

1-methyl-6-oxo-*N*-(5-(4-(trifluoromethyl)benzyl)pyridin-2-yl)-1,6-dihydropyridazine-3-carboxamide




A solution of 5-(4-(trifluoromethyl)benzyl)pyridin-2-amine (0.194 g, 0.77 mmol), 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (0.154 g, 0.64 mmol), 2-(7-azabenzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate (0.365 g, 0.96 mmol) and ethyldiisopropylamine (0.248 g, 1.92 mmol) in *N,N*-dimethylformamide (3.5 mL) was stirred at room temperature for 2 h. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 μ m column. The mobile phase was acetonitrile/0.01% aqueous trifluoroacetic acid) to give 1-methyl-6-oxo-*N*-(5-(4-(trifluoromethyl)benzyl)pyridin-2-yl)-1,6-dihydropyridazine-3-carboxamide (0.0912 g, 0.24 mmol, 37.2%) as a white solid. ^1H NMR (500 MHz, Dimethylsulfoxide- d_6) δ 10.15 (s, 1H), 8.35 (d, $J = 2.5$ Hz, 1H), 8.09 (d, $J = 8.5$ Hz, 1H), 7.94 (d, $J = 9.1$ Hz, 1H), 7.76 (dd, $J = 8.5, 2.0$ Hz, 1H), 7.67 (d, $J = 8.5$ Hz, 2H), 7.49 (d, $J = 8.0$ Hz, 2H), 7.07 (d, $J = 9.5$ Hz, 1H), 4.07 (s, 2H), 3.76 (s, 3H); LCMS (ESI) m/z : 389.0 $[M+H]^+$.

Example 40. Preparation of***N*-(5-(3-chloro-5-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (40)****5 Step 1: Preparation of 5-(3-chloro-5-fluorobenzyl)pyridin-2-amine**

To a solution of 1-(bromomethyl)-3-chloro-5-fluorobenzene (2.23 g, 10 mmol), 5-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)pyridin-2-amine (2.67 g, 12 mmol) and potassium carbonate (2.76 g, 20 mmol) in 1,4-dioxane (45 mL) and water (15 mL) was added

10 [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.732 g, 1.0 mmol) under nitrogen. The reaction mixture was stirred at 100 °C for 2 h. The volatiles were concentrated and water (50 mL) was added. The aqueous layer was extracted with ethyl acetate (80 mL x 3). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The crude product was purified by column chromatography (silica gel, petroleum ether/ethyl acetate from 1:1 to 0:1) to give

15 5-(3-chloro-5-fluorobenzyl)pyridin-2-amine (1.9 g, 8.1 mmol, 81%) as a brown solid. LCMS (ESI) *m/z*: 237.1 [M+H]⁺.

Step 2: Preparation of***N*-(5-(3-chloro-5-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide**

20 To a solution of 5-(3-chloro-5-fluorobenzyl)pyridin-2-amine (0.285 g, 1.2 mmol) in toluene (5 mL) at room temperature was added trimethylaluminum (0.6 mL, 1.2 mmol, 2 M in toluene) slowly under argon. The reaction mixture was stirred at room temperature for 1 h before methyl 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylate (0.168 g, 1.0 mmol) in toluene (5 mL) was added.

25 The resulting solution was heated to 100 °C and stirred for 2 h. The reaction mixture was quenched with methanol and aqueous 2 N hydrochloric acid. The volatiles were removed under pressure and water (20 mL) was added. The aqueous layer was extracted with dichloromethane (50 mL x 3). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μm column.


30 The mobile phase was acetonitrile/10 mM ammonium acetate aqueous solution) to give *N*-(5-(3-chloro-5-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (0.151 g,

0.41 mmol, 41%) as a white solid. ^1H NMR (400 MHz, Dimethylsulfoxide- d_6) δ 10.13 (s, 1H), 8.35 (d, J = 2.0 Hz, 1H), 8.08 (d, J = 8.8 Hz, 1H), 7.94 (d, J = 10.0 Hz, 1H), 7.77 (dd, J_1 = 2.0 Hz, J_2 = 8.4 Hz, 1H), 7.24-7.28 (m, 2H), 7.15-7.18 (m, 1H), 7.06 (d, J = 10.0 Hz, 1H), 3.98 (s, 2H), 3.78 (s, 3H); LCMS (ESI) m/z : 373.1 $[\text{M}+\text{H}]^+$.


5

Example 41. Preparation of

1-methyl-6-oxo-*N*-(5-(3,4,5-trifluorobenzyl)pyridin-2-yl)-1,6-dihydropyridazine-3-carboxamide (41)



Step 1: Preparation of 5-(3,4,5-trifluorobenzyl)pyridin-2-amine




10

To a solution of 5-(bromomethyl)-1,2,3-trifluorobenzene (1.0 g, 4.47 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (0.983 g, 4.47 mmol), potassium carbonate (1.23 g, 8.94 mmol) in tetrahydrofuran (16 mL) and water (4 mL) under nitrogen was added tetrakis(triphenylphosphine)palladium(0) (0.516 g, 0.447 mmol). The reaction mixture was heated to 90 °C and stirred for 2 h. The volatiles were removed under reduced pressure. Aqueous layer was acidified to pH = 1-3 with 1 N hydrogen chloride and extracted with ethyl acetate (50 mL). The aqueous layer was then adjusted to pH = 8-10 with aqueous sodium bicarbonate and extracted with dichloromethane (50 mL x 2). The combined dichloromethane layers were dried over sodium sulfate, filtered and concentrated to give 5-(3,4,5-trifluorobenzyl)pyridin-2-amine (0.750 g, crude) as a yellow oil. LCMS (ESI) m/z : 239.1 $[\text{M}+\text{H}]^+$. Used in the next step without further purification.

20


Step 2: Preparation of 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid



To a solution of methyl 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylate (0.200 g, 1.19 mmol) in water (2 mL) was added sodium hydroxide (0.095 g, 2.38 mmol). The reaction was heated to 60 °C and stirred for 1 h. The aqueous layer was adjusted to pH = 3~5 with aqueous 1 N hydrogen chloride. Solution mixture was concentrated, down to dryness to afford 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid as a white solid (0.130 g, crude); LCMS (ESI) m/z : 155.1 $[\text{M}+\text{H}]^+$.


25

Step 3: Preparation of


1-methyl-6-oxo-*N*-(5-(3,4,5-trifluorobenzyl)pyridin-2-yl)-1,6-dihydropyridazine-3-carboxamide

To a solution of 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (0.100 g, 0.649 mmol),
 5 *N,N*-diisopropylethylamine (0.252 g, 1.95 mmol) in tetrahydrofuran (4 mL) at 20 °C was added
 1-[*bis*(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.370 g,
 0.974 mmol). The reaction was stirred for 20 minutes before a solution of
 5-(3,4,5-trifluorobenzyl)pyridin-2-amine (0.154 g, 0.649 mmol) in tetrahydrofuran (1.0 mL) was added. The
 solution was stirred at 20 °C 16 h and the volatiles were removed under reduced pressure. The crude
 10 residue was added to a mixture of dichloromethane (50 mL) and water (50 mL). The organic layer was
 collected, dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in
 minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 µm column;
 acetonitrile/0.01% aqueous trifluoroacetic acid) to give
 1-methyl-6-oxo-*N*-(5-(3,4,5-trifluorobenzyl)pyridin-2-yl)-1,6-dihydropyridazine-3-carboxamide as a white
 15 solid (0.064 g, 0.169 mmol, 26%). ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 10.13 (s, 1H), 8.35 (s, 1H),
 8.08 (d, *J* = 6 Hz, 1H), 7.95 (d, *J* = 7.5 Hz, 1H), 7.76-7.79 (m, 1H), 7.27-7.31 (m, 2H), 7.06-7.09 (d, *J* = 12
 Hz, 1H), 3.96 (s, 2H), 3.79 (s, 3H); LCMS (ESI) *m/z*: 375.1 [*M*+*H*]⁺.

Example 42. Preparation of


 20 *N*-(5-(3-cyano-5-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (42)


Step 1: Preparation of 3-(bromomethyl)-5-fluorobenzonitrile



The synthesis of 3-(bromomethyl)-5-fluorobenzonitrile followed similar procedures as for
 25 **Example 25.** Compound 3-(bromomethyl)-5-fluorobenzonitrile (17.0 g, 79.4 mmol, 107%) was obtained
 as a colorless oil. ¹H NMR (500 MHz, Chloroform-*d*) δ 7.51 (s, 1H), 7.38 (dt, *J* = 2.5, 11.0 Hz, 1H), 7.32
 (dt, *J* = 1.5, 10.0 Hz, 1H), 4.45 (s, 2H).


Step 2: Preparation of 3-((6-aminopyridin-3-yl)methyl)-5-fluorobenzonitrile



The synthesis of 3-((6-aminopyridin-3-yl)methyl)-5-fluorobenzonitrile was followed with similar procedures as for **Example 23**. Compound 3-((6-aminopyridin-3-yl)methyl)-5-fluorobenzonitrile (0.800 g, 3.50 mmol, 50%) was obtained as a light-yellow oil. LCMS (ESI) for m/z : 228.1 $[M+H]^+$.

Step 3: Preparation of


N-(5-(3-cyano-5-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide




A mixture of 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (0.203 g, 1.32 mmol), 3-((6-aminopyridin-3-yl)methyl)-5-fluorobenzonitrile (0.300 g, 1.32 mmol), 1-*bis*(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.752 g, 1.98 mmol), *N,N*-diisopropylethylamine (0.511 g, 3.96 mmol) in *N,N*-dimethylformamide (10 mL) was stirred at room temperature for 2 h. The mixture was poured into water. The formed precipitate was collected by filtration and washed with methanol (25 mL) to afford *N*-(5-(3-cyano-5-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (0.198 g, 0.545 mmol, 41%) as an off-white solid. ^1H NMR (500 MHz, Trifluoroacetic acid-*d*) δ : 8.91-8.88 (m, 2H), 8.78 (d, J = 9.5 Hz, 1H), 8.39 (d, J = 4.0 Hz, 1H), 7.99-7.94 (m, 3H), 7.86 (d, J = 8.5 Hz, 1H), 4.80 (s, 2H), 4.57 (s, 3H); LCMS (ESI) m/z : 364.0 $[M+H]^+$.

Example 43. Preparation of

N-(5-(3-cyanobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (**43**)



Step 1: Preparation of 3-((6-aminopyridin-3-yl)methyl)benzonitrile



To a solution of 3-(bromomethyl)benzonitrile (0.980 g, 5 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (1.21 g, 5.5 mmol), potassium carbonate (1.38 g, 10 mmol) in acetonitrile (24 mL) and water (6 mL) was added


[1,1'-*bis*(diphenylphosphino)ferrocene]dichloropalladium(II)dichloromethane (0.408 g, 0.5 mmol).

Reaction was stirred at 80 °C for 2 h. The reaction mixture was extracted with ethyl acetate (50 mL x 2), washed with brine (50 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified

by column chromatography (silica gel, (dichloromethane: methanol = 13/1) to give 3-((6-aminopyridin-3-yl)methyl)benzonitrile (0.900 g, 4.31 mmol, 86.1%) as a brown liquid. LCMS (ESI) m/z : 210.1 $[M+H]^+$.

5 Step 2: Preparation of

N-(5-(3-cyanobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide



A solution of 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (0.100 g, 0.65 mmol), 3-((6-aminopyridin-3-yl)methyl)benzonitrile (0.163 g, 0.78 mmol),


10 1-[*bis*(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.371 g, 0.975 mol) and *N,N*-diisopropylethylamine (0.252 g, 1.95 mmol) in *N,N*-dimethylformamide (3 mL) was stirred at room temperature for 17 h. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μ m column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give

15 *N*-(5-(3-cyanobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (0.0738 g, 0.174 mmol, 26.7%) as a white solid. ^1H NMR (400 MHz, Dimethylsulfoxide- d_6) δ 10.10 (s, 1H), 8.36 (d, J = 2.0 Hz, 1H), 8.09 (d, J = 8.5 Hz, 1H), 7.95 (d, J = 9.7 Hz, 1H), 7.78 - 7.73 (m, 2H), 7.70 (d, J = 7.6 Hz, 1H), 7.63 (d, J = 7.9 Hz, 1H), 7.53 (t, J = 7.7 Hz, 1H), 7.08 (d, J = 9.7 Hz, 1H), 4.03 (s, 2H), 3.78 (s, 3H); LCMS (ESI) m/z : 346.1 $[M+H]^+$.


20

Example 44. Preparation of

N-(5-(3-methoxybenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (44)



25 Step 1: Preparation of 5-(3-methoxybenzyl)pyridin-2-amine



To a solution of 1-(bromomethyl)-3-methoxybenzene (1.00 g, 5.00 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (1.21 g, 5.50 mmol), potassium carbonate (1.38 g, 10.0 mmol) in acetonitrile (24 mL) and water (6 mL) at room temperature was added


30 [1,1'-*bis*(diphenylphosphino)ferrocene]dichloropalladium(II)dichloromethane (0.408 g, 0.500 mmol).

Reaction was stirred at 80 °C for 2 h. The reaction mixture was extracted with ethyl acetate (50 mL x 2), washed with brine (50 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by column chromatography (silica gel, (dichloromethane/methanol = 13/ 1) to yield

5-(3-methoxybenzyl)pyridin-2-amine as a brown liquid (0.740 g, 3.46 mmol, 69.2%). LCMS (ESI) m/z : 215.1 $[M+H]^+$.

Step 2: Preparation of


5 *N*-(5-(3-methoxybenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide



A solution of 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (0.100 g, 0.65 mmol), 5-(3-methoxybenzyl)pyridin-2-amine (0.167 g, 0.78 mmol), 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.371 g, 0.975 mmol) and *N,N*-diisopropylethylamine (0.252 g, 1.95 mmol) in *N,N*-dimethylformamide (3 mL) was stirred at room temperature for 2 h. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μ m column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give *N*-(5-(3-methoxybenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (0.0787 g, 0.221 mmol, 34%) as a white solid. ^1H NMR (500 MHz, Dimethylsulfoxide- d_6) δ 8.31 (s, 1H), 8.07 (d, J = 8.4 Hz, 1H), 7.94 (d, J = 9.7 Hz, 1H), 7.73 (d, J = 8.4 Hz, 1H), 7.22 (t, J = 7.8 Hz, 1H), 7.07 (d, J = 9.7 Hz, 1H), 6.84 - 6.77 (m, 3H), 3.93 (s, 2H), 3.78 (s, 3H), 3.72 (s, 3H); LCMS (ESI) for m/z : 351.1 $[M+H]^+$.


Example 45. Preparation of

20 *N*-(5-(3-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (45)



Step 1: Preparation of

N-(5-(3-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide



The synthesis of


N-(5-(3-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide followed synthetic procedure reported for **Example 43**. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μ m column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give

N-(5-(3-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (0.0206 g, 0.06 mmol, 14.3%) as a white solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 10.21 (s, 1H), 8.34 (d, *J* = 2.0 Hz, 1H), 8.08 (d, *J* = 8.5 Hz, 1H), 7.95 (d, *J* = 9.0 Hz, 1H), 7.78 (dd, *J* = 8.5 Hz 2.0 Hz, 1H), 7.38-7.33 (m, 1H), 7.14-7.02 (m, 3H), 3.99 (s, 2H), 3.79 (s, 3H); LCMS (ESI) *m/z*: 339.1 [*M*+*H*]⁺.

5


Example 46. Preparation of

N-(5-(3-chloro-4-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (46)



10


Step 1: Preparation of 5-(3-chloro-4-fluorobenzyl)pyridin-2-amine



To a solution of 4-(bromomethyl)-1-chloro-2-fluorobenzene (0.500 g, 2.25 mmol), 6-aminopyridin-3-ylboronic acid (0.311 g, 2.25 mmol), potassium carbonate (0.621 g, 4.51 mmol) in tetrahydrofuran (8 mL) and water (2 mL) was added tetrakis(triphenylphosphine)palladium(0) (0.260 g, 0.225 mmol) under nitrogen. The mixture was heated to 90 °C and stirred for 2 h. The volatiles were removed under reduced pressure. Aqueous layer was acidified to pH = 1-3 with 1 N hydrogen chloride and extracted with ethyl acetate (50 mL). The aqueous layer was then adjusted to pH = 8-10 with aqueous sodium bicarbonate and extracted with dichloromethane (50 mL x 2). The combined dichloromethane layers were dried over sodium sulfate, filtered and concentrated to give 5-(3-chloro-4-fluorobenzyl)pyridin-2-amine as a yellow oil (0.300 g, crude); LCMS (ESI) *m/z*: 237.1 [*M*+*H*]⁺. Used in the next step without additional purification.

20

Step 2: Preparation of 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid




25

To a solution of methyl 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylate (0.200 g, 1.19 mmol) in water (1.5 mL) was added sodium hydroxide (0.095 g, 2.38 mmol). The reaction was heated to 60 °C and stirred for 1 h. The aqueous layer was then adjusted to pH = 8-10 with aqueous sodium bicarbonate and all volatiles were removed to afford 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (0.130 g, crude) as a white solid. LCMS (ESI) *m/z*: 155.1 [*M*+*H*]⁺. Used in the next step without further purification.

30

Step 3: Preparation of


N-(5-(3-chloro-4-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide




To a solution of 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (0.130 g, 0.844 mmol),
 5 *N,N*-diisopropylethylamine (0.327 g, 2.53 mmol) in tetrahydrofuran (5 mL) at 20 °C was added
 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.481 g,
 1.23 mmol). The reaction was stirred for 20 minutes before a solution of
 5-(3-chloro-4-fluorobenzyl)pyridin-2-amine (0.199 g, 0.844 mmol) in tetrahydrofuran (1.0 mL) was added.
 The reaction mixture was stirred at 20 °C for 16 h. The volatiles were removed under reduced pressure
 10 and the residue was added to a mixture of dichloromethane (50 mL) and water (50 mL). The organic layer
 was separated, dried over sodium sulfate, filtered and concentrated. Purification by prep-HPLC gives
N-(5-(3-chloro-4-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide as a
 white solid (0.0262 g, 0.070 mmol, 8.3%). ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 10.14 (s, 1H), 8.34
 (d, *J* = 1.6 Hz, 1H), 8.08 (d, *J* = 6.8 Hz, 1H), 7.95(d, *J* = 7.6 Hz, 1H), 7.75-7.77 (m, 1H), 7.52-7.54 (m, 1H),
 15 7.33-7.35 (m, 2H), 7.08 (d, *J* = 8.0 Hz, 1H), 3.97 (s, 2H), 3.79 (s, 3H); LCMS (ESI) *m/z*: 373.0 [M+H]⁺.

Example 47. Preparation of

N-(5-(3-chlorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (47)




Step 1: Preparation of 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid



To a solution of methyl 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylate (0.100 g, 0.60 mmol)
 in water (1.2 mL) was added sodium hydroxide (0.048 g, 1.20 mmol). The mixture was stirred at 60 °C for
 25 1 h. After being cooled to room temperature, hydrogen chloride (1*N*, 1.2 mL) was added and the aqueous
 phase was extracted with ethyl acetate (20 mL x 5). The combined organic layers were washed with brine
 (20 mL), dried with sodium sulfate, filtered and concentrated to afford
 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (0.045 g, 0.29 mmol, 48.7%) as a white solid.
 LCMS (ESI) *m/z*: 155.1 [M+H]⁺. Used in the next step directly without additional purification.

Step 2: Preparation of

N-(5-(3-chlorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide



To a stirred solution of 5-(3-chlorobenzyl)pyridin-2-amine (0.076 g, 0.35 mmol),

1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (0.045 g, 0.29 mmol) and

1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.133 g, 0.35 mmol) in *N,N*-dimethylformamide (2.00 mL) was added *N,N*-diisopropylethylamine (0.112 g, 0.87 mmol). After addition, the reaction mixture was stirred at room temperature for 2 h. The crude sample was

dissolved in minimal *N,N*-dimethylformamide and purified via prep-HPLC (Sunfire prep C18 10 μ m OBD


19*250 mm; mobile phase: [water (0.05% trifluoroacetic acid)-acetonitrile]; B%: 60%-88%, 15 minutes) to

give *N*-(5-(3-chlorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (0.010 g, 0.028 mmol, 9.74%) as a white solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 10.15 (s, 1H), 8.34 (d, *J* = 1.7 Hz, 1H), 8.09 (d, *J* = 8.5 Hz, 1H), 7.95 (d, *J* = 9.7 Hz, 1H), 7.76 (dd, *J* = 8.5, 2.1 Hz, 1H), 7.44 - 7.31 (m, 2H), 7.26 (dd, *J* = 16.1, 7.9 Hz, 2H), 7.08 (d, *J* = 9.7 Hz, 1H), 3.98 (s, 2H), 3.79 (s, 3H); LCMS (ESI)

m/z: 355.0 [M+H]⁺.


Example 48. Preparation of

N-(5-(3-chlorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (48)



Step 1: Preparation of

N-(5-(3-chlorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide



To a solution of 1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (0.153 g, 1 mmol) in

dichloromethane (30 mL) at 0 °C was added *N,N*-dimethylformamide (2 drops) and oxalyl chloride (0.635 g, 5 mmol) dropwise. Reaction was warmed to room temperature over 2 h before it was concentrated.

The crude solid was dissolved in dichloromethane (5 mL) and added to a solution of

5-(3-chlorobenzyl)pyridin-2-amine (0.262 g, 1.2 mmol) in pyridine (6 mL) at 0 °C Reaction mixture was


warmed to room temperature over 2 h. Reaction was poured into ice water and extracted with ethyl acetate (50 mL x 2). The combined organic layers were washed with brine (60 mL), dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide

and purified *via* prep-HPLC (Sunfire prep C18 10 μ m OBD 19*250 mm; mobile phase: [water (0.05% trifluoroacetic acid)-acetonitrile]; B%: 60%-88%, 15 minutes) to yield


N-(5-(3-chlorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide as a white solid (0.046 g, 0.13 mmol, 13%). ^1H NMR (400 MHz, Dimethylsulfoxide- d_6) δ 10.59 (s, 1H), 8.67 (d, J = 2.6 Hz, 1H), 8.31 (d, J = 2.1 Hz, 1H), 8.04 (d, J = 8.8 Hz, 1H), 7.98 (dd, J = 4.8 Hz, 4.8 Hz, 1H), 7.72 (dd, J = 8.6, 2.3 Hz, 1H), 7.35 (t, J = 6.0 Hz, 2H), 7.28-7.23 (m, 2H), 6.43 (d, J = 9.5 Hz, 1H), 3.97 (s, 2H), 3.50 (s, 3H); LCMS (ESI) m/z : 354.1 $[\text{M}+\text{H}]^+$.

Example 49. Preparation of

N-(5-(3-fluoro-4-methoxybenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (49)




Step 1: Preparation of 5-(3-fluoro-4-methoxybenzyl)pyridin-2-amine



To a solution of 4-(bromomethyl)-2-fluoro-1-methoxybenzene (0.767 g, 3.50 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (0.847 g, 3.68 mmol), potassium carbonate (0.966 g, 7.00 mmol) in acetonitrile (17 mL) and water (4.2 mL) was added [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II)dichloromethane (0.286 g, 0.35 mmol). Reaction mixture was stirred at 80 °C for 3 h before it was filtered and extracted with ethyl acetate (80 mL x 2). The combined organic layers were washed with brine (80 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 2/3) to give 5-(3-fluoro-4-methoxybenzyl)pyridin-2-amine as a brown oil (0.380 g, 1.27 mmol, 36.4%); LCMS (ESI) m/z : 233.2 $[\text{M}+\text{H}]^+$.

Step 2: Preparation of

N-(5-(3-fluoro-4-methoxybenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide




To a solution of 1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (0.086 g, 0.56 mmol) and 5-(3-fluoro-4-methoxybenzyl)pyridin-2-amine (0.130 g, 0.56 mmol) in pyridine (4.3 mL) at 0 °C was added phosphorus(V) oxychloride (0.257 g, 1.68 mmol). The reaction mixture was warmed to room temperature over 2 h. The reaction mixture was poured into ice water and extracted with ethyl acetate (30 mL x 2). The combined organic layers were washed with brine (30 mL), dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via*


prep-HPLC (Boston C18 21*250 mm 10 μ m column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give *N*-(5-(3-fluoro-4-methoxybenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (0.0058 g, 0.0123 mmol, 2.2%) as a white solid. ^1H NMR (400 MHz, Dimethylsulfoxide- d_6) δ 10.52 (s, 1H), 8.66 (d, J = 2.6 Hz, 1H), 8.27 (d, J = 2.1 Hz, 1H), 8.04 (d, J = 8.5 Hz, 1H), 7.98 (dd, J = 9.5, 2.6 Hz, 1H), 7.66 (dd, J = 8.6, 2.3 Hz, 1H), 7.14 - 7.07 (m, 2H), 7.02 (d, J = 8.5 Hz, 1H), 6.43 (d, J = 9.5 Hz, 1H), 3.88 (s, 2H), 3.79 (s, 3H), 3.50 (s, 3H); LCMS (ESI) m/z : 368.2 $[\text{M}+\text{H}]^+$.

Example 50. Preparation of

N-(5-(3-chloro-5-methoxybenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (50)




Step 1: Preparation of 1-(bromomethyl)-3-chloro-5-methoxybenzene




To a solution of (3-chloro-5-methoxyphenyl)methanol (2.0 g, 11.6 mmol) in diethyl ether (20 mL) at 0 °C was added phosphorus tribromide (0.5 mL). The mixture was stirred for 2 h at 0 °C. Reaction mixture was poured into saturated aqueous sodium bicarbonate solution (150 mL) and extracted with ethyl acetate (200 mL x 2). The combined organic phases were dried over sodium sulfate, filtered and concentrated to afford 1-(bromomethyl)-3-chloro-5-methoxybenzene (2.15 g, 9.16 mmol, 79%) as a light-yellow solid. Used in the next step directly without additional purification.

Step 2: Preparation of 5-(3-chloro-5-methoxybenzyl)pyridin-2-amine




The synthesis of 5-(3-chloro-5-methoxybenzyl)pyridin-2-amine was following a similar procedure as for **Example 23** to yield 5-(3-chloro-5-methoxybenzyl)pyridin-2-amine (1.1 g, 4.40 mmol, 79%) as an orange solid. LCMS (ESI) m/z : 249.1 $[\text{M}+\text{H}]^+$.

Step 3: Preparation of


N-(5-(3-chloro-5-methoxybenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide

A solution of 1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (0.200 g, 1.3 mmol) in thionyl chloride (15 mL) was stirred at 80 °C for 1 h. Once the suspension went clear volatiles were removed under reduced pressure. The crude residue was dissolved in dichloromethane (5 mL) and added slowly to a solution of 5-(3-chloro-5-methoxybenzyl)pyridin-2-amine (0.248 g, 1.0 mmol) and pyridine (0.240 g, 3.0 mmol) in dichloromethane (5 mL) at 0 °C. The resulting mixture was stirred at room temperature for another 2 h. The mixture was poured into water and extracted with dichloromethane (50 mL x 2). The combined organic phases were concentrated. The residue was purified by column chromatography (silica gel, 10% methanol in ethyl acetate) to afford 250 mg of brown oil. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified by prep-HPLC (Boston C18 21*250 mm 10 µm column. The mobile phase was acetonitrile/10 mM ammonium acetate aqueous solution) to give *N*-(5-(3-chloro-5-methoxybenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (0.148 g, 0.386 mmol, 38.6%) as a white solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ. 10.59 (s, 1H), 8.67 (d, *J* = 2.5 Hz, 1H), 8.32 (d, *J* = 2.0 Hz, 1H), 8.04 (d, *J* = 8.5 Hz, 1H), 7.98 (dd, *J* = 3.0, 9.5 Hz, 1H), 7.73 (dd, *J* = 2.5, 8.5 Hz, 1H), 6.90-6.84 (m, 3H), 6.43 (d, *J* = 9.5 Hz, 1H), 3.92 (s, 2H), 3.75 (s, 3H), 3.50 (s, 3H); LCMS (ESI) *m/z*: 384.1 [M+H]⁺.

Example 51. Preparation of

N-(5-(3-chloro-5-cyanobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (51)


Step 1: Preparation of 3-chloro-5-methylbenzonitrile



A mixture of 1-bromo-3-chloro-5-methylbenzene (2.0 g, 10.0 mmol), zinc cyanide (0.700 g, 6.0 mmol), 1,1'-ferrocenediyl-*bis*(diphenylphosphine) (1.1 g, 2.0 mmol),


tris(dibenzylideneacetone)dipalladium(0) (0.900 g, 1.0 mmol) in *N,N*-dimethylformamide (15 mL) was stirred at 110 °C under nitrogen for 5 h. The reaction was poured into water and the aqueous layer was extracted with ethyl acetate (200 mL x 2). The combined organic phases were concentrated. The residue was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 60/1) to afford 3-chloro-5-methylbenzonitrile (1.4 g, 9.2 mmol, 92%) as a yellow solid. ¹H NMR (500 MHz, Chloroform-*d*) δ. 7.46 (s, 1H), 7.42 (s, 1H), 7.37 (m, 1H), 2.40 (s, 3H).

Step 2: Preparation of 3-(bromomethyl)-5-chlorobenzonitrile




The synthesis of 3-(bromomethyl)-5-chlorobenzonitrile was following a similar procedure to **Example 25**. Product 3-(bromomethyl)-5-chlorobenzonitrile (0.800 g, 3.47 mmol, 48%) was obtained as a yellow solid. ¹H NMR (500 MHz, Chloroform-*d*) δ. 7.64 (m, 1H), 7.59 (m, 2H), 4.44 (s, 2H).

Step 3: Preparation of 3-((6-aminopyridin-3-yl)methyl)-5-chlorobenzonitrile





The synthesis of 3-((6-aminopyridin-3-yl)methyl)-5-chlorobenzonitrile was followed similar procedure to **Example 23**. Product 3-((6-aminopyridin-3-yl)methyl)-5-chlorobenzonitrile (0.190 g, 56% purity; 260 mg, 79% purity) was obtained as a yellow oil. LCMS (ESI) *m/z*: 244.1 [M+H]⁺.


Step 4: Preparation of *N*-(5-(3-chloro-5-cyanobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide



A solution of 3-((6-aminopyridin-3-yl)methyl)-5-chlorobenzonitrile (0.190 g (56% purity), 0.43 mmol), 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.122 g, 0.78 mmol), 1-[*bis*(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.445 g, 1.17 mmol), *N,N*-diisopropylethylamine (0.302 g, 2.34 mmol) in *N,N*-dimethylformamide (5 mL) was stirred at room temperature 16 h. The mixture was poured into water. The formed precipitate was collected by filtration and purified by chiral prep-HPLC to afford compound *N*-(5-(3-chloro-5-cyanobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.0794 g, 0.208 mmol, 45%) as a white solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ. 9.73 (s, 1H), 8.35 (d, *J* = 2.0 Hz, 1H), 8.04 (d, *J* = 8.5 Hz, 1H), 7.89 (s, 1H), 7.80-7.76 (m, 3H), 4.02 (s, 2H), 3.36 (s, 3H), 2.85 (t, *J* = 8.5 Hz, 2H), 2.52 (t, *J* = 8.5 Hz, 2H); LCMS (ESI) *m/z*: 382.0 [M+H]⁺.


Example 52. Preparation of***N*-(5-(3-fluoro-5-methoxybenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (52)****5 Step 1: Preparation of 1-(bromomethyl)-3-fluoro-5-methoxybenzene**

A solution of (3-fluoro-5-methoxyphenyl)methanol (1.5 g, 6.88 mmol), 40% hydrogen bromide (6 mL) and toluene (10 mL) was stirred at room temperature for 3 days. The reaction mixture was poured into water and extracted with ethyl acetate (160 mL x 3). The combined organic phases were concentrated. The crude residue was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 16/1) to afford 1-(bromomethyl)-3-fluoro-5-methoxybenzene (1.7 g, 5.57 mmol, 81%) as a light-yellow oil. ¹H NMR (500 MHz, Chloroform-*d*) δ 6.74-6.71 (m, 2H), 6.58-6.55 (m, 1H), 4.42 (s, 2H), 3.82 (s, 3H).

15 Step 2: Preparation of 5-(3-fluoro-5-methoxybenzyl)pyridin-2-amine

The synthesis of 5-(3-fluoro-5-methoxybenzyl)pyridin-2-amine was following similar procedure to **Example 25**. Product 5-(3-fluoro-5-methoxybenzyl)pyridin-2-amine (0.600 g, 2.57 mmol, 70%) was obtained as a brown oil. LCMS (ESI) *m/z*: 233.1 [M+H]⁺.

20

Step 3: Preparation of***N*-(5-(3-fluoro-5-methoxybenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide**

The synthesis of


25 *N*-(5-(3-fluoro-5-methoxybenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide was following a similar procedure for **Example 25**. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified by prep-HPLC (Boston C18 21*250 mm 10 μm column. The mobile

phase was acetonitrile/10 mM ammonium acetate aqueous solution) to give


N-(5-(3-fluoro-5-methoxybenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (0.0704 g, 0.191 mmol, 12.8%) as a white solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 10.60 (s, 1H), 8.67 (s, 1H), 8.31 (d, *J* = 2.5 Hz, 1H), 8.04-7.97 (m, 2H), 7.73 (d, *J* = 8.0 Hz, 1H), 6.71-6.68 (m, 3H), 6.43 (d, *J* = 9.5 Hz, 1H), 3.92 (s, 2H), 3.74 (s, 3H), 3.50 (s, 3H); LCMS (ESI) *m/z*: 368.2 [M+H]⁺.

Example 53. Preparation of

N-(5-(4-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (53)




Step 1: Preparation of 5-(4-fluorobenzyl)pyridin-2-amine



To a solution of 1-(bromomethyl)-4-fluorobenzene (3.0 g, 16.0 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (3.51 g, 16.0 mmol), potassium carbonate (4.4 g, 31.9 mmol) in tetrahydrofuran (48 mL) and water (12 mL) was added tetrakis(triphenylphosphine)palladium(0) (1.84 g, 1.60 mmol) under nitrogen. The reaction mixture was heated to 90 °C and stirred for 2 h. The volatiles were removed under reduced pressure. Aqueous layer was acidified to pH = 1-3 with 1 N hydrogen chloride and extracted with ethyl acetate (50 mL). The aqueous layer was then adjusted to pH = 8-10 with aqueous sodium bicarbonate and extracted with dichloromethane (50 mL x 2). The combined dichloromethane layers were dried over sodium sulfate, filtered and concentrated. Purification by column chromatography (silica gel, petroleum ether/ethyl acetate = 1/1) affords 5-(4-fluorobenzyl)pyridin-2-amine (1.8 g, 8.96 mmol, 56%) as a yellow solid. LCMS (ESI) *m/z*: 203.1 [M+H]⁺.

Step 2: Preparation of

N-(5-(4-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide




To a solution of 1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (0.200 g, 1.31 mmol), 5-(4-fluorobenzyl)pyridin-2-amine (0.264 g, 1.31 mmol) in pyridine (8 mL) at 20 °C was added phosphorus(V) oxychloride (0.595 g, 3.921 mmol). The reaction mixture was stirred at room temperature for 3 h. The solvent was removed under reduced pressure and the crude solid was dissolved in dichloromethane (10.0 mL) and added to a mixture of dichloromethane (50 mL) and water (50 mL). The organic layer was collected, dried over sodium sulfate, filtered and concentrated. The crude sample was

dissolved in minimal *N,N*-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 μ m column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give


N-(5-(4-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide as a light-yellow solid (0.170 g, 0.503 mmol, 38.4%). ^1H NMR (400 MHz, Dimethylsulfoxide- d_6) δ 10.62 (s, 1H), 8.67 (s, 1H), 8.29 (s, 1H), 8.02 (d, J = 8 Hz, 1H), 7.98 (d, J = 9.5 Hz, 1H), 7.71 (d, J = 8.5 Hz, 1H), 7.30 (t, J = 6 Hz, 2H), 7.12 (t, J = 8.3 Hz, 2H), 6.44 (t, J = 9.5 Hz, 2H), 3.95 (s, 2H), 3.50 (s, 3H); LCMS (ESI) m/z : 338.1 $[\text{M}+\text{H}]^+$.

Example 54. Preparation of

N-(5-(4-fluoro-3-methoxybenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (54)




Step 1: Preparation of 5-(4-fluoro-3-methoxybenzyl)pyridin-2-amine



A mixture of 4-(bromomethyl)-1-fluoro-2-methoxybenzene (0.5 g, 2.29 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (0.56 g, 2.52 mmol), potassium carbonate (0.63 g, 4.59 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.19 g, 0.23 mmol) in acetonitrile (20.0 mL) and water (5.00 mL) was stirred at 80 °C under nitrogen atmosphere for 2 h. The reaction mixture was cooled down to room temperature and filtered. The filtrate was concentrated, under reduced pressure and the residue was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 1/1) to give 5-(4-fluoro-3-methoxybenzyl)pyridin-2-amine (0.30 g, 1.29 mmol, 56.3%) as a yellow solid. LCMS (ESI) m/z : 233.1 $[\text{M}+\text{H}]^+$.

Step 2: Preparation of

N-(5-(4-fluoro-3-methoxybenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide




To a solution of 5-(4-fluoro-3-methoxybenzyl)pyridin-2-amine (0.20 g, 0.86 mmol), 1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (0.15 g, 0.95 mmol) in pyridine (4.0 mL) was added phosphorus(V) oxychloride (0.0681 g, 0.86 mmol) at 0 °C dropwise. The reaction mixture was warmed to room temperature and stirred for 1 h. The reaction mixture was quenched with water (20 mL) and the aqueous layer was extracted with ethyl acetate (20 mL). The combined organic layers were washed with water (10 mL x 2) and brine (10 mL x 2), dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo*. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 μ m column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give


N-(5-(4-fluoro-3-methoxybenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (0.0324 g, 0.09 mmol, 10.5%) as a white solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 10.55 (s, 1H), 8.66 (d, *J* = 2.6 Hz, 1H), 8.30 (d, *J* = 2.6 Hz, 1H), 8.07 - 7.92 (m, 2H), 7.70 (dd, *J* = 8.6, 2.3 Hz, 1H), 7.17 - 7.02 (m, 2H), 6.83 - 6.71 (m, 1H), 6.43 (d, *J* = 9.5 Hz, 1H), 3.92 (s, 2H), 3.82 (s, 3H), 3.50 (s, 3H); LCMS (ESI) *m/z*: 368.2 [M+H]⁺.

Example 55. Preparation of

N-(5-(3-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (55)




Step 1: Preparation of 5-(3-Fluorobenzyl)pyridin-2-amine



To a solution of 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (5.0 g, 22.72 mmol) in tetrahydrofuran (75 mL) and water (19 mL) at room temperature was added 1-(bromomethyl)-3-fluorobenzene (4.30 g, 22.7 mmol), tetrakis(triphenylphosphine)palladium(0) (2.63 g, 2.27 mmol) and potassium carbonate (6.27 g, 45.4 mmol) under nitrogen. The reaction mixture was stirred at 80 °C for 2 h, then cooled to room temperature and diluted with water (100 mL). Volatiles were removed under reduced pressure. Aqueous layer was acidified to pH = 2-3 with 4 N hydrogen chloride and extracted with ethyl acetate (80 mL x 2). The aqueous layer was then adjusted to pH = 9-10 with aqueous sodium carbonate and extracted with dichloromethane (80 mL x 2). The combined dichloromethane layers were dried over sodium sulfate, filtered and concentrated to give 5-(3-fluorobenzyl)pyridin-2-amine (4.4 g, 21.8 mmol, 95.7 %) as a pale yellow solid. LCMS (ESI) *m/z*: 203.2 [M+H]⁺.

Step 2: Preparation of

N-(5-(3-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide




A suspension of 1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (6.00 g, 39.2 mmol) in thionyl chloride (30 mL) was heated to 80 °C for 1 h. After being concentrated and dried *in vacuo*, the

residue was dissolved in dry tetrahydrofuran (60 mL). This solution was added dropwise to a mixture of 5-(3-fluorobenzyl)pyridin-2-amine (6.00 g, 30.2 mmol) and pyridine (7.20 mL, 90.5 mmol) in dry tetrahydrofuran (60 mL) at 0 °C over 15 minutes. The reaction mixture was warmed to room temperature and stirred for 2 h. The white solid precipitate was collected by filtration and the filter cake was washed with ethanol (60 mL) and *tert*-butyl methyl ether (60 mL). The filtrate was concentrated, and the resulting solid was washed with ethanol (60 mL) and *tert*-butyl methyl ether (60 mL). Combined solids were dried *in vacuo* to give crude *N*-(5-(3-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (7.3 g). The crude material (7.3 g) was dissolved in ethanol (1.10 L) at 80 °C. After being filtered, the filtrate was concentrated, to about 300 mL and cooled down to room temperature. The solid was collected by filtration and the filter cake was washed with ethanol (50 mL) and *tert*-butyl methyl ether (50 mL). The white solid was dried *in vacuo* to obtain

N-(5-(3-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (5.05 g, 15.0 mmol, 49.7%). ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 11.47 (s, 1H), 8.91 (d, *J* = 2.4 Hz, 1H), 8.36 (d, *J* = 1.8 Hz, 1H), 8.12 (d, *J* = 8.7 Hz, 1H), 8.06 - 7.94 (m, 2H), 7.42 - 7.28 (m, 1H), 7.14 (t, *J* = 8.6 Hz, 2H), 7.05 (dd, *J* = 9.0, 2.0 Hz, 1H), 6.47 (d, *J* = 9.6 Hz, 1H), 4.04 (s, 2H), 3.52 (s, 3H); LCMS (ESI) *m/z*: 338.0 [M+H]⁺.


Example 56. Preparation of

1-methyl-6-oxo-*N*-(5-(3,4,5-trifluorobenzyl)pyridin-2-yl)-1,6-dihydropyridine-3-carboxamide (56)




Step 1: Preparation of


1-methyl-6-oxo-*N*-(5-(3,4,5-trifluorobenzyl)pyridin-2-yl)-1,6-dihydropyridine-3-carboxamide



To a solution of 1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (0.100 g, 0.653 mmol), 5-(3,4,5-trifluorobenzyl)pyridin-2-amine (0.155 g, 0.653 mmol) in pyridine (4 mL) at 20 °C was added phosphorus(V) oxychloride (0.297 g, 1.96 mmol). The reaction mixture was stirred at room temperature for 1 h. The solvent was removed under reduced pressure and the solid was dissolved in dichloromethane (10.0 mL). The resulting solution was added to a mixture of dichloromethane (50 mL) and water (50 mL). The organic layer was collected, dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μm column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give 1-methyl-6-oxo-*N*-(5-(3,4,5-trifluorobenzyl)pyridin-2-yl)-1,6-dihydropyridine-3-carboxamide as a light-yellow solid (0.0286 g, mmol, 0.078 mmol, 12%). ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 10.56 (s, 1H), 8.67 (d, *J* = 2.5 Hz, 1H), 8.32 (d, *J* = 2 Hz, 1H), 7.97-8.06 (m, 2H), 7.71-7.73 (m, 1H), 7.27-7.30 (m, 2H), 6.42-6.44 (d, *J* = 10 Hz, 1H), 3.95 (s, 2H), 3.50 (s, 3H). LCMS (ESI) *m/z*: 374.0 [M+H]⁺.

Example 57. Preparation of**5-(3-chlorobenzyl)-*N*-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)picolinamide (57)**

Step 1: Preparation of methyl 5-(3-chlorobenzyl)picolinate




5

To a solution of 1-(bromomethyl)-3-chlorobenzene (1.56 g, 7.60 mmol) in acetonitrile (80.0 mL) and water (20 mL) at room temperature, was added potassium carbonate (2.10 g, 15.2 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.434 g, 0.532 mmol) and methyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)picolinate (2.0 g, 7.60 mmol) under nitrogen. The reaction mixture was stirred at 80 °C for 3 h, cooled to room temperature and diluted with water (200 mL). The aqueous layer was extracted with ethyl acetate (80 mL × 3). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The crude residue was purified by column chromatography (silica gel, ethyl acetate/petroleum ether = 1/3) to afford methyl 5-(3-chlorobenzyl)picolinate (1.3 g, 4.97 mmol, 65.4%) as a brown oil. LCMS (ESI) *m/z*: 262.1 [M+H]⁺.

15

Step 2: Preparation of 5-(3-chlorobenzyl)-*N*-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)picolinamide



To a solution of 5-amino-1-methylpyridin-2(1H)-one (0.200 g, 1.66 mmol) in anhydrous 1,4-dioxane (8 mL) was added trimethylaluminum (0.81 mL, 1.62 mmol, 2 *M* in toluene) under nitrogen. The reaction mixture was stirred at room temperature for 1 h before methyl 5-(3-chlorobenzyl)picolinate (0.106 g, 0.404 mmol) in 1,4-dioxane (3.0 mL) was added and stirred at 100 °C for 16 h. The mixture was cooled to room temperature and quenched with water (100 mL). The aqueous layer was extracted with ethyl acetate (50 mL × 3). The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Sunfire prep C18 10 μm OBD 19*250 mm; mobile phase: [water (0.05% trifluoroacetic acid)-acetonitrile]; B%: 60%-88%, 15 minutes) to give 5-(3-chlorobenzyl)-*N*-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)picolinamide (0.101 g, 0.285 mmol, 70.5%) as a white solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 10.47 (s, 1H), 8.67 (s, 1H), 8.34 (d, *J* = 2.5


20

25


Hz, 1H), 8.04 (d, $J = 8.5$ Hz, 1H), 7.90 (dd, $J = 8.0, 2.0$ Hz, 1H), 7.77 (dd, $J = 9.5, 3.0$ Hz, 1H), 7.40 (s, 1H), 7.35 (t, $J = 7.5$ Hz, 1H), 7.30-7.27 (m, 2H), 6.42 (d, $J = 9.0$ Hz, 1H), 4.12 (s, 2H), 3.44 (s, 3H); LCMS (ESI) m/z : 354.1 $[M+H]^+$.

5 Example 58. Preparation of

N-(5-((6-methoxypyridin-3-yl)methyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (58)




10 Step 1: Preparation of 2-chloro-5-((6-methoxypyridin-3-yl)methyl)pyridine



A mixture of 2-chloro-5-(chloromethyl)pyridine (1 g, 6.21 mmol), 6-methoxypyridin-3-ylboronic acid (1.12 g, 7.45 mmol), tris(dibenzylideneacetone)dipalladium(0) (0.28 g, 0.31 mmol), 1,3-bis(2,4,6-trimethylphenyl)imidazolium chloride (0.21 g, 0.62 mmol) and cesium carbonate (4 g, 12.42 mmol) in 1,4-dioxane (50 mL) was evacuated and refilled with argon (3 x) and stirred at 90 °C for 16 h. The reaction was cooled down, diluted with ethyl acetate (30 mL), filtered through a pad of silica gel and concentrated. The residue was purified by Combi-Flash (Biotage, 40 g silica gel, eluted with ethyl acetate in petroleum ether from 20% to 30%) to give 2-chloro-5-((6-methoxypyridin-3-yl)methyl)pyridine (0.85 g, 3.63 mmol, 58.6%) as a yellow oil. LCMS (ESI) m/z : 235.1 $[M+H]^+$.

20

Step 2: Preparation of 5-((6-methoxypyridin-3-yl)methyl)pyridin-2-amine




A solution of 2-chloro-5-((6-methoxypyridin-3-yl)methyl)pyridine (0.5 g, 2.13 mmol) in dry-tetrahydrofuran (20 mL) was evacuated and refilled with nitrogen (2 x) and was charged with tris(dibenzylideneacetone)dipalladium(0) (0.19 g, 0.21 mmol), X-Phos (0.2 g, 0.42 mmol) and 1 *M* lithium bis(trimethylsilyl)amide tetrahydrofuran solution (6.4 mL, 6.4 mmol). The mixture was again evacuated and refilled with nitrogen (2 x) and stirred at 70 °C for 16 h. The volatiles were concentrated and the crude residue was purified by Combi-Flash (Biotage, 40 g silica gel, eluted with methanol/dichloromethane = 1/10, containing 0.5% 7 N ammonia in methanol, in from 30% to 40%) to give

25

5-((6-methoxypyridin-3-yl)methyl)pyridin-2-amine (0.22 g, 1.02 mmol, 48%) as a yellow oil. LCMS (ESI) m/z : 216.2 $[M+H]^+$.


Step 3: Preparation of 1-methyl-6-oxo-1,6-dihydropyridine-3-carbonyl chloride



A mixture of 1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (0.6 g, 3.92 mmol) and thionyl chloride (5 mL) was stirred at 80 °C for 1 h. The reaction mixture was concentrated, to afford 1-methyl-6-oxo-1,6-dihydropyridine-3-carbonyl chloride (0.6 g, crude) as a white solid. Used directly in next step without further purification.

Step 4: Preparation of



N-(5-((6-methoxypyridin-3-yl)methyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide




To a solution of 5-((6-methoxypyridin-3-yl)methyl)pyridin-2-amine (0.17 g, 0.79 mmol) in tetrahydrofuran (20 mL) at 0 °C was added pyridine (0.2 mL, 2.37 mL) followed by 1-methyl-6-oxo-1,6-dihydropyridine-3-carbonyl chloride (0.2 g, 1.19 mmol) in small portions. The reaction mixture was stirred at room temperature for 16 h. Another portion of 1-methyl-6-oxo-1,6-dihydropyridine-3-carbonyl chloride (0.1 g, 0.79 mmol) was added and the reaction was stirred at 30 °C for 5 h. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (30 mL x 3). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified by prep-HPLC (Boston C18 21*250 mm 10 μ m column. The mobile phase was acetonitrile/10 mM ammonium acetate aqueous solution) to give

N-(5-((6-methoxypyridin-3-yl)methyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carbox-amide

(0.088 g, 0.25 mmol, 32%) as a white solid. ^1H NMR (400 MHz, Dimethylsulfoxide- d_6) δ 10.50 (s, 1H), 8.65 (d, 1H, J = 2.8 Hz), 8.27 (d, 1H, J = 2 Hz), 8.10 (d, 1H, J = 2 Hz), 8.04 (d, 1H, J = 8.8 Hz), 7.97 (dd, 1H, J = 2.8 Hz, 9.6 Hz), 7.65 (dd, 1H, J = 2.4 Hz, 8.4 Hz), 7.56 (dd, 1H, J = 2.4 Hz, 8.4 Hz), 6.75 (d, 1H, J = 8.4 Hz, 6.42 (d, 1H, J = 9.6 Hz), 3.88 (s, 2H), 3.00 (s, 3H), 3.48 (s, 3H); LCMS (ESI) m/z : 351.1 $[M+H]^+$.

Example 59. Preparation of***N*-(5-(3,5-difluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (59)****5 Step 1: Preparation of 5-(3,5-difluorobenzyl)pyridin-2-amine**

To a solution of 1-(bromomethyl)-3,5-difluorobenzene (10.4 g, 50.2 mmol) and 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (12.2 g, 55.26 mmol) in 1,4-dioxane (240 mL) was added a solution of potassium carbonate (13.9 g, 100 mmol) in water (80 mL). The reaction mixture was degassed with nitrogen for 1 minute before 1,1'-bis(diphenylphosphino)ferrocene-palladium(II) dichloride dichloromethane complex (2.04 g, 2.50 mmol) was added and the mixture was degassed with nitrogen for 1 minute. The reaction mixture was stirred at 90 °C for 2 h and was concentrated and diluted with water (250 mL). The aqueous layer was extracted with ethyl acetate (300 mL x 3). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The residue was purified by column chromatography (silica gel, ethyl acetate then dichloromethane: ethyl acetate=2:1) to afford compound 5-(3,5-difluorobenzyl)pyridin-2-amine (8.02 g, 36.4 mmol, 72%) as a pale yellow solid. The pale yellow solid (4.6 g) was re-purified by column chromatography (silica gel, dichloromethane: ammonia in methanol (7 N) = 20/1) to afford 5-(3,5-difluorobenzyl)pyridin-2-amine (4.4 g, 20 mmol, 95%) as a pale yellow solid. LCMS (ESI) *m/z*: 221.1 [M+H]⁺.

Step 2: Preparation of***N*-(5-(3,5-difluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide**

A suspension of 1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (4.0 g, 26 mmol) in thionyl chloride (40 mL) was heated to 80 °C for 1 h. After being concentrated and dried *in vacuo*, the residue was dissolved in dry tetrahydrofuran (100 mL) and added to a mixture of

5-(3,5-difluorobenzyl)pyridin-2-amine (4.4 g, 20 mmol) and pyridine (8.0 g, 100 mmol) in dry tetrahydrofuran (50 mL) at room temperature over 1 h. The reaction mixture was stirred at room temperature for 20 h. The yellow solid precipitated out of the reaction solution and was collected by filtration. The filter cake was washed with ethanol (50 mL) and *tert*-butyl methyl ether (50 mL). The filtrate was concentrated, and the residue was washed with ethanol (20 mL) and *tert*-butyl methyl ether (20 mL).


Combined both solids and dried *in vacuo* to give crude

N-(5-(3,5-difluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (4.1 g) which was dissolved in ethanol (500 mL) at 110 °C. After being filtered, the filtrate was cooled to room temperature. The solid was collected by filtration and the cake was washed with ethanol (50 mL) and *tert*-butyl methyl ether (50 mL). The off-white solid was slurring in water for 3 h before filtered and dried over *vacuo* to give


N-(5-(3,5-difluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (2.9 g, 8.17 mmol, 41%) as an off-white solid. ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 10.55 (s, 1H), 8.66 (d, *J* = 2.4 Hz, 1H), 8.31 (d, *J* = 1.6 Hz, 1H), 8.05 (d, *J* = 8.8 Hz, 1H), 7.97 (dd, *J*₁ = 2.4 Hz, *J*₂ = 9.6 Hz, 1H), 7.71 (dd, *J*₁ = 2.4 Hz, *J*₂ = 8.8 Hz, 1H), 7.02-7.08 (m, 3H), 6.42 (d, *J* = 9.6 Hz, 1H), 3.96 (s, 2H), 3.49 (s, 3H); LCMS (ESI) *m/z*: 356.0 [M+H]⁺.

Example 60. Preparation of

N-(5-(3-chloro-4-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (60)




Step 1: Preparation of 5-(3-chloro-4-fluorobenzyl)pyridin-2-amine



To a solution of 4-(bromomethyl)-2-chloro-1-fluorobenzene (1.12 g, 5 mmol), 5-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)pyridin-2-amine (1.34 g, 6 mmol) and potassium carbonate (1.38 g, 10 mmol) in 1,4-dioxane (30 mL) and water (10 mL) was added [1,1'-*bis*(diphenylphosphino)ferrocene]dichloropalladium(II) (0.366 g, 0.5 mmol) under nitrogen. The reaction mixture was stirred at 100 °C for 2 h. The reaction mixture was concentrated, and water (50 mL) was added. The aqueous phase was extracted with ethyl acetate (80 mL x 3). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The crude product was purified by column chromatography (silica gel, petroleum ether/ethyl acetate from 1/1 - 0/1) to give 5-(3-chloro-4-fluorobenzyl)pyridin-2-amine (870 mg, 74%) as a yellow solid. LCMS (ESI) *m/z*: 237.1 [M+H]⁺.

Step 2: Preparation of


N-(5-(3-chloro-4-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide



To a solution of 5-(3-chloro-4-fluorobenzyl)pyridin-2-amine (0.142 g, 0.6 mmol) and
 5 1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (0.092 g, 0.6 mmol) in pyridine (4 mL) at room
 temperature was added phosphorus oxychloride (0.276 g, 1.8 mmol) slowly under argon. The reaction
 mixture was stirred at room temperature for 1.5 h. The reaction mixture was concentrated, and water (30
 mL) was added. The aqueous layer was extracted with dichloromethane (30 mL x 2). The combined
 organic layers were dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved
 10 in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (BostonC18 21*250 mm 10 μ m column.
 The mobile phase was acetonitrile/10 mM ammonium acetate aqueous solution) to give
N-(5-(3-chloro-4-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (14.3 mg,
 0.04 mmol, 6.5%) as a white solid. ^1H NMR (400 MHz, Dimethylsulfoxide- d_6) δ 10.53 (s, 1H), 8.65 (d, J
 =2.8 Hz, 1H), 8.30 (d, J = 2.0 Hz, 1H), 8.05 (d, J = 8.8 Hz, 1H), 7.96 (dd, J_1 = 2.8 Hz, J_2 = 9.6 Hz, 1H),
 15 7.68 (dd, J_1 = 2.4 Hz, J_2 = 8.4 Hz, 1H), 7.51 (dd, J_1 = 2.0 Hz, J_2 = 6.8 Hz, 1H), 7.32 - 7.36 (m, 1H),
 7.25 - 7.29 (m, 1H), 6.42 (d, J = 9.2 Hz, 1H), 3.94 (s, 2H), 3.48 (s, 3H); LCMS (ESI) m/z : 372.0 $[\text{M}+\text{H}]^+$.


Example 61. Preparation of

N-(5-(3-cyanobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (61)



Step 1: Preparation of

N-(5-(3-cyanobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide




A suspension of 1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (0.184 g, 1.2 mmol) in
 25 thionyl chloride (4 mL) was stirred at 85 °C for 1 h. The reaction mixture was concentrated, dissolved in
 dichloromethane (6 mL) and added to a solution of 3-((6-aminopyridin-3-yl)methyl)benzonitrile (0.209 g, 1
 mmol) in pyridine (6 mL) at 0 °C. The reaction mixture was stirred at 0 °C ~ room temperature for 2 h and
 was poured into ice water. The aqueous layer was extracted with dichloromethane (20 mL x 2). The
 30 combined organic layers washed with brine (20 mL) were dried over sodium sulfate, filtered and
 concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via*
 prep-HPLC (Boston C18 21*250 mm 10 μ m column. The mobile phase was acetonitrile/0.01% aqueous
 trifluoroacetic acid) to give

N-(5-(3-cyanobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (0.159 g, 0.46 mmol, 46%) as a white solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 10.61 (s, 1H), 8.67 (d, *J* = 3.0 Hz, 1H), 8.33 (d, *J* = 2.0 Hz, 1H), 8.04 (d, *J* = 8.5 Hz, 1H), 7.98 (dd, *J* = 9.5, 2.5 Hz, 1H), 7.78 (s, 1H), 7.74 (dd, *J* = 8.5, 2.5 Hz, 1H), 7.69 (d, *J* = 7.5 Hz, 1H), 7.63 (d, *J* = 8.5 Hz, 1H), 7.52 (t, *J* = 7.5 Hz, 1H), 6.43 (d, *J* = 9.5 Hz, 1H), 4.02 (s, 2H), 3.50 (s, 3H); LCMS (ESI) *m/z*: 345.1 [M+H]⁺.


Example 62. Preparation of

N-(5-((1,3-dihydroisobenzofuran-5-yl)methyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (62)




Step 1: Preparation of


N-(5-((1,3-dihydroisobenzofuran-5-yl)methyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide



A suspension of 1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (0.081 g, 0.531 mmol) in thionyl chloride (3 mL) was stirred at 80 °C for 0.5 h under nitrogen. The reaction mixture was concentrated, dissolved in dichloromethane (3 mL) and added to a solution of 5-((1,3-dihydroisobenzofuran-5-yl)methyl)pyridin-2-amine (0.100 g, 0.442 mmol) in pyridine (3 mL) at 0 °C. The reaction mixture was then stirred at 0 °C ~ room temperature for 2 h. The reaction solution was poured into ice water and extracted with dichloromethane (20 mL x 2). The combined organic layers were washed with brine (20 mL), dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μm column. The mobile phase was acetonitrile/10 mM ammonium acetate aqueous solution) to give *N*-(5-((1,3-dihydroisobenzofuran-5-yl)methyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (0.0885 g, 0.245 mmol, 55.3%) as a white solid. ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 10.61 (s, 1H), 8.66 (d, *J* = 2.8 Hz, 1H), 8.29 (d, *J* = 1.6 Hz, 1H), 8.01 (d, *J* = 8.4 Hz, 1H), 7.97 (dd, *J* = 9.6, 2.8 Hz, 1H), 7.70 (dd, *J* = 8.8, 2.4 Hz, 1H), 7.23 (d, *J* = 8.4 Hz, 1H), 7.17 (d, *J* = 6.8 Hz, 2H), 6.43 (d, *J* = 9.6 Hz, 1H), 4.95 (s, 4H), 3.97 (s, 2H), 3.50 (s, 3H); LCMS (ESI) *m/z*: 362.1 [M+H]⁺.

Example 63. Preparation of**1-methyl-6-oxo-*N*-(5-(4-(trifluoromethyl)benzyl)pyridin-2-yl)-1,6-dihydropyridine-3-carboxamide (63)**



5

Step 1: Preparation of**1-methyl-6-oxo-*N*-(5-(4-(trifluoromethyl)benzyl)pyridin-2-yl)-1,6-dihydropyridine-3-carboxamide**

10 A suspension of 1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (0.184 g, 1.2 mmol) in thionyl chloride (4 mL) was stirred at 80 °C for 0.5 h under nitrogen. The reaction mixture was concentrated, dissolved in dichloromethane (6 mL) and added to a solution of 5-(4-(trifluoromethyl)benzyl)pyridin-2-amine (0.252 g, 1 mmol) in pyridine (6 mL) at 0 °C. The reaction mixture was stirred at room temperature for 2 h and was poured into ice water. The aqueous layer was

15 extracted with dichloromethane (20 mL x 2). The combined organic layers were washed with brine (20 mL), dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 µm column. The mobile phase was acetonitrile/0.01% aqueous trifluoroacetic acid) to give

20 1-methyl-6-oxo-*N*-(5-(4-(trifluoromethyl)benzyl)pyridin-2-yl)-1,6-dihydropyridine-3-carboxamide (0.1955 g, 0.51 mmol, 50.5%) as a white solid. ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 10.60 (s, 1H), 8.67 (d, *J* = 2.4 Hz, 1H), 8.32 (d, *J* = 2.0 Hz, 1H), 8.04 (d, *J* = 8.8 Hz, 1H), 7.97 (dd, *J* = 9.6, 2.8 Hz, 1H), 7.72 (dd, *J* = 8.8, 2.8 Hz, 1H), 7.67 (d, *J* = 8.4 Hz, 2H), 7.49 (d, *J* = 8.0 Hz, 2H), 6.43 (d, *J* = 9.6 Hz, 1H), 4.07 (s, 2H), 3.50 (s, 3H); LCMS (ESI) *m/z*: 388.1 [M+H]⁺.

Example 64. Preparation of***N*-(5-(4-chlorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (64)****Step 1: Preparation of*****N*-(5-(4-chlorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide**

30

To a solution of 1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (0.100 g, 0.653 mmol), 5-(4-chlorobenzyl)pyridin-2-amine (0.142 g, 0.653 mmol) in pyridine (4 mL) at 20 °C was added


phosphorus oxychloride (0.297 g, 1.96 mmol). The reaction mixture was stirred at 20 °C for 2 h. The volatiles were removed under reduced pressure. The crude solid was dissolved in dichloromethane (10.0 mL) and added to a mixture of dichloromethane (50 mL) and water (50 mL). The organic layer was collected, dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 µm column. The mobile phase was acetonitrile/0.01% aqueous trifluoroacetic acid) to offer

5 *N*-(5-(4-chlorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (29.6 mg, 0.084 mmol, 13%) as a white solid. ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 10.55 (s, 1H), 8.66-8.67 (d, *J* = 2.4 Hz, 1H), 8.28 (s, 1H), 7.96-8.05 (m, 2H), 7.66-7.69 (q, *J* = 3.6 Hz, 1H), 7.27-7.38 (m, 4H), 6.42-6.44

10 (d, *J* = 9.6 Hz, 1H), 3.95 (s, 2H), 3.50 (s, 3H); LCMS (ESI) *m/z*: 354.1 [M+H]⁺.


Example 65. Preparation of

N-(5-(cyclohexylmethyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (65)



15 Step 1: Preparation of

N-(5-(cyclohexylmethyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide



To a solution of 1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (80 mg, 0.526 mmol) in dichloromethane (5 mL) at 20 °C was added thionyl chloride (5 mL). The reaction mixture was heated to


20 90 °C and refluxed for 0.5 h. The volatiles were removed under reduced pressure and the solid was dissolved in dichloromethane (2 mL) and was added to a solution of 5-(cyclohexylmethyl)pyridin-2-amine (50 mg, 0.263 mmol) and pyridine (62 mg, 0.789 mmol) in dichloromethane (5 mL). The reaction solution was stirred at 20 °C for 2 h. The reaction mixture was portioned between dichloromethane (50 mL) and water (50 mL). The organic layer was collected, dried over sodium sulfate, filtered and concentrated. The

25 crude sample was dissolved in minimal *N,N*-dimethylformamide and purified by prep-HPLC (Boston C18 21*250 mm 10 µm column. The mobile phase was acetonitrile/10 mM ammonium acetate aqueous solution) to give *N*-(5-(cyclohexylmethyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (25.6 mg, 0.079 mmol, 30%) as a white solid. ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 10.56 (s, 1H), 8.68 (d, *J* = 4.0 Hz, 1H), 8.16 (s, 2H), 8.02 (t, *J* = 8.0 Hz, 1H), 7.64-7.67 (m, 1H), 6.44 (d, *J* = 8.0 Hz, 1H),

30 3.50 (s, 3H), 2.46 (d, *J* = 8.0 Hz, 2H), 1.59-1.67 (m, 5H), 1.49-1.51 (m, 1H), 1.10-1.29 (m, 3H), 0.88-0.96 (m, 2H) ; LCMS (ESI) *m/z*: 326.2 [M+H]⁺.


Example 66. Preparation of

N-(5-(3,4-difluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (66)



Step 1: Preparation of

N-(5-(3,4-difluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide




5


To a solution of 1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (100 mg, 0.653 mmol) and 5-(3,4-difluorobenzyl)pyridin-2-amine (144 mg, 0.653 mmol) in pyridine (4 mL) at 20 °C, was added phosphorus oxychloride (297 mg, 1.96 mmol). The reaction mixture was stirred at 20 °C for 4 h. The volatiles were removed under reduced pressure, and the resulting crude solid was dissolved in dichloromethane (10.0 mL) and added to a mixture of dichloromethane (50 mL) and water (50 mL). The organic layer was collected, dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 μm column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give *N*-(5-(3,4-difluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (39.8 mg, 0.11 mmol, 17%) as a light-yellow solid. ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 10.56 (s, 1H), 8.67 (d, *J* = 2.0 Hz, 1H), 8.30 (s, 1H), 8.05 (d, *J* = 8.4 Hz, 1H), 7.99 (d, *J* = 2.8 Hz, 1H), 7.69-7.72 (m, 1H), 7.33-7.40 (m, 2H), 7.10-7.13 (m, 1H), 6.43 (d, *J* = 9.6 Hz, 1H), 3.95 (s, 2H), 3.50 (s, 3H); LCMS (ESI) *m/z*: 356.0 [M+H]⁺.

20 Example 67. Preparation of

N-(5-(3-chlorobenzyl)pyridin-2-yl)-1-ethyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (67)



25 Step 1: Preparation of 1-ethyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid




To a solution of methyl 1-ethyl-6-oxo-1,6-dihydropyridazine-3-carboxylate (0.637 g, 3.5 mmol) in tetrahydrofuran (5 mL) and water (1.5 mL) was added sodium hydroxide (0.280 g, 7 mmol). The reaction mixture was stirred at room temperature for 3 h before it was neutralized to pH = 6 with aqueous 1 *N* hydrogen chloride. The mixture was concentrated, to 1-ethyl-6-oxo-1,6-dihydropyridazine-3-carboxylic

30

acid as a white solid (0.900 g, crude); LCMS (ESI) m/z : 169.1 $[M+H]^+$. Used in the next step without additional purification.

Step 2: Preparation of


5 *N*-(5-(3-chlorobenzyl)pyridin-2-yl)-1-ethyl-6-oxo-1,6-dihydropyridazine-3-carboxamide



A solution of 1-ethyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (0.100 g, 0.6 mmol), 5-(3-chlorobenzyl)pyridin-2-amine (0.157 g, 0.75 mmol), 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.342 g, 0.9 mmol) and *N,N*-diisopropylethylamine (0.232 mg, 1.8 mmol) in tetrahydrofuran (4 mL) was stirred at room temperature for 2 h. Volatiles were removed under reduced pressure. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified via prep-HPLC (Sunfire prep C18 10 μ m OBD 19*250 mm; mobile phase: [water (0.05% trifluoroacetic acid)-acetonitrile]; B%: 60%-88%, 15 minutes) to yield *N*-(5-(3-chlorobenzyl)pyridin-2-yl)-1-ethyl-6-oxo-1,6-dihydropyridazine-3-carboxamide as a white solid (0.050 g, 0.136 mmol, 22.6%). ^1H NMR (400 MHz, Dimethylsulfoxide- d_6) δ 10.23 (s, 1H), 8.35 (d, J = 2.0 Hz, 1H), 8.08 (d, J = 8.4 Hz, 1H), 7.93 (d, J = 4.8 Hz, 1H), 7.78 (dd, J = 4.2, 4.0 Hz, 1H), 7.36-7.32 (m, 2H), 7.28-7.23 (m, 2H), 7.07 (d, J = 9.2 Hz, 1H), 4.24-4.18 (m, 2H), 3.99 (s, 2H), 1.35 (t, J = 7.2 Hz, 3H); LCMS (ESI) 369.1 $[M+H]^+$.


20 **Example 68. Preparation of**

1-ethyl-*N*-(5-(3-fluorobenzyl)pyridin-2-yl)-6-oxo-1,6-dihydropyridazine-3-carboxamide (68)



Step 1: Preparation of

1-ethyl-*N*-(5-(3-fluorobenzyl)pyridin-2-yl)-6-oxo-1,6-dihydropyridazine-3-carboxamide




A solution of 1-ethyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (120 mg, 0.71 mmol), 5-(3-fluorobenzyl)pyridin-2-amine (162 mg, 0.86 mmol), 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (405 mg, 1.065 mol) and *N,N,N*-diisopropylethylamine (275 mg, 2.13 mmol) in tetrahydrofuran (4 mL) was stirred at room temperature for 2 h. Volatiles were removed under reduced pressure. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified via prep-HPLC (Sunfire prep C18 10 μ m OBD


19*250 mm; mobile phase: [water (0.05% trifluoroacetic acid)-acetonitrile]; B%: 60%-88%, 15 minutes) to yield 1-ethyl-*N*-(5-(3-fluorobenzyl)pyridin-2-yl)-6-oxo-1,6-dihydropyridazine-3-carboxamide as a white solid (0.0973 g, 0.275 mmol, 38.8%). ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 10.21 (s, 1H), 8.34 (d, *J* = 2.0 Hz, 1H), 8.08 (d, *J* = 8.8 Hz, 1H), 7.93 (d, *J* = 10.0 Hz, 1H), 7.77 (dd, *J* = 4.2, 4.2 Hz, 1H), 7.37-7.32 (m, 1H), 7.13-7.01 (m, 4H), 4.23-4.18 (m, 2H), 3.99 (s, 2H), 1.34 (t, *J* = 7.2 Hz, 3H); LCMS (ESI) *m/z*: 353.1 [M+H]⁺.

Example 69. Preparation of

N-(5-(3-cyano-5-fluorobenzyl)pyridin-2-yl)-1-ethyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (69)




Step 1: Preparation of 3-(bromomethyl)-5-fluorobenzonitrile



The synthesis of 3-(bromomethyl)-5-fluorobenzonitrile was followed using similar procedure to

Example 25. Product 3-(bromomethyl)-5-fluorobenzonitrile (17.0 g, 79.4 mmol, 107%) was obtained as a colorless oil. ¹H NMR (500 MHz, Chloroform-*d*) δ 7.51 (s, 1H), 7.38 (dt, *J* = 2.5, 11.0 Hz, 1H), 7.32 (dt, *J* = 1.5, 10.0 Hz, 1H), 4.45 (s, 2H).


Step 2: Preparation of 3-((6-aminopyridin-3-yl)methyl)-5-fluorobenzonitrile



The synthesis of 3-((6-aminopyridin-3-yl)methyl)-5-fluorobenzonitrile was following similar procedures to **Example 23**. Product 3-((6-aminopyridin-3-yl)methyl)-5-fluorobenzonitrile (800 mg, 3.5 mmol, 50%) was obtained as a light-yellow oil. LCMS (ESI) *m/z*: 228.1 [M+H]⁺.

Step 3: Preparation of

N-(5-(3-cyano-5-fluorobenzyl)pyridin-2-yl)-1-ethyl-6-oxo-1,6-dihydropyridazine-3-carboxamide




The synthesis of

N-(5-(3-cyano-5-fluorobenzyl)pyridin-2-yl)-1-ethyl-6-oxo-1,6-dihydropyridazine-3-carboxamide followed similar procedures as for **Example 42**. Compound

N-(5-(3-cyano-5-fluorobenzyl)pyridin-2-yl)-1-ethyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (0.180 g, 0.478 mmol, 43.4%) was obtained as an off-white solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 10.19 (s, 1H), 8.38 (d, *J* = 2.0 Hz, 1H), 8.09 (d, *J* = 9.0 Hz, 1H), 7.94 (d, *J* = 9.5 Hz, 1H), 7.80 (dd, *J* = 2.5, 9.0 Hz, 1H), 7.72-7.69 (m, 2H), 7.58 (d, *J* = 10.0 Hz, 1H), 7.07 (d, *J* = 9.5 Hz, 1H), 4.20 (q, *J* = 7.0 Hz, 2H), 4.05 (s, 2H), 1.35 (t, *J* = 7.0 Hz, 3H); LCMS (ESI) *m/z*: 378.1 [M+H]⁺.


Example 70. Preparation of

N-(5-(3,4-dichlorobenzyl)pyridin-2-yl)-1-ethyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (**70**)




Step 1: Preparation of

N-(5-(3,4-dichlorobenzyl)pyridin-2-yl)-1-ethyl-6-oxo-1,6-dihydropyridazine-3-carboxamide




A solution of 1-ethyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (0.127 g, 0.75 mmol), 5-(3,4-dichlorobenzyl)pyridin-2-amine (0.230 g, 0.90 mmol), 1-*bis*(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.427 g, 1.125 mmol) and *N,N*-diisopropylethylamine (0.290 g, 2.25 mmol) in tetrahydrofuran (4 mL) was stirred at room temperature for 16 h. Then the reaction mixture was concentrated, and the crude sample was dissolved in minimal *N,N*-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 μm column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give *N*-(5-(3,4-dichlorobenzyl)pyridin-2-yl)-1-ethyl-6-oxo-1,6-dihydropyridazine-3-carboxamide as a white solid (0.0679 g, 0.141 mmol, 18.8%). ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 10.20 (s, 1H), 8.35 (d, *J* = 2.0 Hz, 1H), 8.09 (d, *J* = 8.5 Hz, 1H), 7.94 (d, *J* = 9.7 Hz, 1H), 7.76 (dd, *J* = 8.5, 2.3 Hz, 1H), 7.57 (t, *J* = 5.4 Hz, 2H), 7.27 (dd, *J* = 8.3, 2.0 Hz, 1H), 7.07 (d, *J* = 9.7 Hz, 1H), 4.21 (t, *J* = 7.2 Hz, 2H), 3.99 (s, 2H), 1.34 (t, *J* = 7.2 Hz, 3H); LCMS (ESI) *m/z*: 403.0 [M+H]⁺.

Example 71. Preparation of***N*-(5-(3-fluorobenzyl)pyridin-2-yl)-6-oxo-1-propyl-1,6-dihydropyridazine-3-carboxamide (71)**

5

Step 1: Preparation of methyl 6-oxo-1-propyl-1,6-dihydropyridazine-3-carboxylate




10

To a solution of methyl 6-oxo-1,6-dihydropyridazine-3-carboxylate (1.0 g, 6.49 mmol), potassium carbonate (2.68 g, 19.5 mmol) in *N,N*-dimethylformamide (15.0 mL) was added 1-iodopropane (1.65 g, 9.74 mmol). The reaction mixture was heated to 60 °C and stirred for 3 h. The reaction solution was dissolved in ethyl acetate (50 mL) and washed with water (50 mL), dried over sodium sulfate, filtered and concentrated. The crude material was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 1/1) to afford methyl 6-oxo-1-propyl-1,6-dihydropyridazine-3-carboxylate (0.700 g, 3.57 mmol, 55%) as a white solid. LCMS (ESI) *m/z*: 197.2 [*M*+*H*]⁺.

15

Step 2: Preparation of 6-oxo-1-propyl-1,6-dihydropyridazine-3-carboxylic acid




20

Sodium hydroxide (81.6 mg, 2.04 mmol) was added to a mixture of methyl 6-oxo-1-propyl-1,6-dihydropyridazine-3-carboxylate (200 mg, 1.02 mmol), tetrahydrofuran (4 mL) and water (2 mL) before the reaction was heated to 60 °C and stirred for 1 h. 1 *N* hydrochloric acid was added to adjust the pH value to 3~5 before all the solvent was removed to offer crude 6-oxo-1-propyl-1,6-dihydropyridazine-3-carboxylic acid (200 mg, crude).

Step 3: Preparation of

N-(5-(3-fluorobenzyl)pyridin-2-yl)-6-oxo-1-propyl-1,6-dihydropyridazine-3-carboxamide




25

To a mixture of 6-oxo-1-propyl-1,6-dihydropyridazine-3-carboxylic acid (0.120 g, 0.659 mmol), diisopropylethylamine (0.255 g, 1.977 mmol) and tetrahydrofuran (5 mL) at 20°C was added 1-[*bis*(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.376 g,


0.659 mmol). The reaction solution was stirred for 20 minutes before a solution of 6-(3-chlorobenzyl)pyridazin-3-amine (0.144 g, 0.659 mmol) in tetrahydrofuran (1.0 mL) was added. The reaction solution was stirred at 20 °C for 16 h. The solvent was removed under reduced pressure and the residue was added to a mixture of dichloromethane (50 mL) and water (50 mL). The organic layer was collected, dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 µm column. The mobile phase was acetonitrile/0.01% aqueous trifluoroacetic acid) to offer *N*-(5-(3-fluorobenzyl)pyridin-2-yl)-6-oxo-1-propyl-1,6-dihydropyridazine-3-carboxamide (178.0 mg, 0.49 mmol, 74%) as a white solid. ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 10.16 (s, 1H), 8.34 (s, 1H), 8.08-8.10 (d, *J* = 8.4 Hz, 1H), 7.92-7.95 (d, *J* = 9.6 Hz, 1H), 7.75-7.78 (m, 1H), 7.32-7.36 (m, 1H), 7.04-7.14 (m, 4H), 4.12-4.16 (t, *J* = 7.2 Hz, 2H), 3.99 (s, 2H), 1.78-1.84 (q, *J* = 7.4 Hz, 2H), 0.90-0.94 (t, *J* = 7.4 Hz, 3H); LCMS (ESI) *m/z*: 367.1 [*M*+*H*]⁺.

Example 72. Preparation of

N-(5-(3-fluorobenzyl)pyridin-2-yl)-1-isopropyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (72)




Step 1: Preparation of methyl 1-isopropyl-6-oxo-1,6-dihydropyridazine-3-carboxylate



To a solution of methyl 6-oxo-1,6-dihydropyridazine-3-carboxylate (1.0 g, 6.49 mmol) and potassium carbonate (2.68 g, 19.47 mmol) in *N,N*-dimethylformamide (15.0 mL) at room temperature was added 2-iodopropane (1.65 g, 9.74 mmol). The reaction mixture was heated to 60 °C and stirred for 1 h. The reaction mixture was dissolved in ethyl acetate (50 mL) and washed with water (50 mL), dried over sodium sulfate, filtered and concentrated. The crude product was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 1/1) to offer methyl 1-isopropyl-6-oxo-1,6-dihydropyridazine-3-carboxylate as a white solid (0.500 g, 2.55 mmol, 39%) as a white solid. LCMS (ESI) *m/z*: 197.1 [*M*+*H*]⁺.

Step 2: Preparation of


N-(5-(3-fluorobenzyl)pyridin-2-yl)-1-isopropyl-6-oxo-1,6-dihydropyridazine-3-carboxamide



To a solution of 5-(3-fluorobenzyl)pyridin-2-amine (0.206 g, 1.02 mmol) in toluene (10 mL) at 20 °C was added trimethylaluminum (0.5 mL, 1.02 mmol, 2 M in toluene) under argon. The reaction mixture was stirred at 20 °C for 1 h before a solution of methyl 1-isopropyl-6-oxo-1,6-dihydropyridazine-3-carboxylate (0.100 g, 0.51 mmol) in toluene (5 mL) was added. The reaction solution was stirred at 100 °C for 2 h. The solvent was removed under reduced pressure and the residue was treated with a mixture of 1 *N* hydrochloric acid (5 mL) and methanol (20 mL). The volatiles were removed under reduced pressure and the crude product was dissolved in dichloromethane (50 mL) and water (50 mL). The organic layer was separated, dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 µm column. The mobile phase was acetonitrile/0.01% aqueous trifluoroacetic acid) to offer *N*-(5-(3-fluorobenzyl)pyridin-2-yl)-1-isopropyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (0.0832 g, 0.23 mmol, 45%) as a white solid. ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 10.12 (s, 1H), 8.35 (s, 1H), 8.07-8.09 (d, *J* = 8.4 Hz, 1H), 7.91-7.94 (d, *J* = 9.6 Hz, 1H), 7.74-7.77 (m, 1H), 7.32-7.38 (m, 1H), 7.01-7.13 (m, 4H), 5.15-5.19 (t, *J* = 6.6 Hz, 1H), 3.99 (s, 2H), 1.38-1.40 (d, *J* = 6.4 Hz, 6H); LCMS (ESI) *m/z*: 367.1 [M+H]⁺.


Example 73. Preparation of

N-(5-(3-chlorobenzyl)pyridin-2-yl)-1-isopropyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (73)



Step 1: Preparation of

N-(5-(3-chlorobenzyl)pyridin-2-yl)-1-isopropyl-6-oxo-1,6-dihydropyridazine-3-carboxamide




To a solution of 5-(3-chlorobenzyl)pyridin-2-amine (0.222 g, 1.02 mmol) in toluene (15 mL) at 20 °C was added trimethylaluminum (0.5 mL, 1.02 mmol, 2 M in toluene) under argon. The reaction mixture was stirred at 20 °C for 1 h before a solution of methyl 1-isopropyl-6-oxo-1,6-dihydropyridazine-3-carboxylate (0.100 g, 0.51 mmol) in toluene (15 mL) was added. The reaction solution was stirred at 100 °C for 2 h. The volatiles were removed under reduced pressure and the residue was quenched with water (50 mL) and extracted with dichloromethane (50 mL). The organic layer was dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 µm column. The mobile phase was acetonitrile/0.01% aqueous trifluoroacetic acid) to offer *N*-(5-(3-chlorobenzyl)pyridin-2-yl)-1-isopropyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (107.8 mg, 0.28 mmol, 55%) as a white solid. ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 10.11 (s, 1H), 8.36 (s, 1H), 8.07-8.09 (d, *J* = 8.0 Hz, 1H), 7.92-7.94 (d, *J* = 9.6 Hz, 1H), 7.75-7.77 (d, *J* = 8.0 Hz, 1H), 7.23-7.35 (m,

4H), 7.05-7.07 (d, $J = 9.6$ Hz, 1H), 5.16-5.19 (t, $J = 6.6$ Hz, 1H), 3.99 (s, 2H), 1.39-1.40 (d, $J = 6.8$ Hz, 6H); LCMS (ESI) m/z : 383.1 $[M+H]^+$.


Example 74. Preparation of

5 *N*-(5-(3-chloro-5-fluorobenzyl)pyridin-2-yl)-1-cyclopropyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (74)



Step 1: Preparation of


N-(5-(3-chloro-5-fluorobenzyl)pyridin-2-yl)-1-cyclopropyl-6-oxo-1,6-dihydropyridazine-3-carboxamide




10 A solution of 1-cyclopropyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (0.126 g, 0.7 mmol), 5-(3-chloro-5-fluorobenzyl)pyridin-2-amine (0.198 g, 0.84 mmol), 1-[*bis*(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.400 g, 1.05 mmol) and *N,N*-diisopropylethylamine (0.271 g, 2.1 mmol) in *N,N*-dimethylformamide (3.5 mL) was stirred at room temperature for 2 h. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μ m column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give

15 *N*-(5-(3-chloro-5-fluorobenzyl)pyridin-2-yl)-1-cyclopropyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (0.104 g, 0.262 mmol, 37.4%) as a white solid. ^1H NMR (500 MHz, Dimethylsulfoxide- d_6) δ 10.12 (s, 1H), 8.37 (d, $J = 2.0$ Hz, 1H), 8.06 (d, $J = 8.5$ Hz, 1H), 7.91 (d, $J = 9.7$ Hz, 1H), 7.78 (dd, $J = 8.5, 2.3$ Hz, 1H), 7.30 - 7.22 (m, 2H), 7.17 (d, $J = 9.5$ Hz, 1H), 7.06 (d, $J = 9.7$ Hz, 1H), 4.10 - 4.06 (m, 1H), 4.00 (s, 2H), 1.28 - 1.24 (m, 2H), 1.04 - 1.00 (m, 2H); LCMS (ESI) m/z : 399.1 $[M+H]^+$.

20

Example 75. Preparation of**1-cyclopropyl-*N*-(5-(3-fluorobenzyl)pyridin-2-yl)-6-oxo-1,6-dihydropyridazine-3-carboxamide (75)**

Step 1: Preparation of methyl 1-cyclopropyl-6-oxo-1,6-dihydropyridazine-3-carboxylate




5

Combined methyl 6-oxo-1,6-dihydropyridazine-3-carboxylate (0.400 g, 2.59 mmol) with cyclopropylboronic acid (0.444 g, 5.18 mmol) and copper(II) acetate (0.940 g, 5.18 mmol) and suspended in 1,2-dichloroethane (8.63 mL). Added triethylamine (1.43 mL, 10.3 mmol) and pyridine (1.04 mL, 12.9 mmol). The reaction was degassed by cycling with vacuum and nitrogen gas for 3 cycles. Stirred for 16 h at 80 °C. Cooled to room temperature and quenched with saturated aqueous ammonium chloride (15 mL). Extracted with dichloromethane (10 mL x 3). The combined organic layers were dried over sodium sulfate, filtered, and concentrated. Purified reaction by column chromatography (eluting with 0-100% ethyl acetate/hexanes through 40 g of silica gel) to give methyl 1-cyclopropyl-6-oxo-1,6-dihydropyridazine-3-carboxylate as a yellow solid (155 mg, 0.798 mmol, 31%). ¹H NMR (300 MHz, Chloroform-*d*) δ 7.99 (d, *J* = 9.7 Hz, 1H), 7.10 (d, *J* = 9.7 Hz, 1H), 4.43 - 4.26 (m, 1H), 4.11 (s, 3H), 1.49 - 1.19 (m, 4H).

10

15

Step 2: Preparation of 1-cyclopropyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid




20

Dissolved methyl 1-cyclopropyl-6-oxo-1,6-dihydropyridazine-3-carboxylate (0.135 g, 0.6951 mmol) in tetrahydrofuran (2.0 mL) and added lithium hydroxide hydrate (0.087 g, 2.08 mmol) and water (0.5 mL). Stirred at room temperature 16 h. Monitored reaction by LC/MS. Upon completion, quenched with 10% aqueous hydrochloric acid (7 mL) until acidic (pH ~3). Extracted with ethyl acetate (15 mL). Washed with brine (10 mL), then dried over sodium sulfate, filtered, and concentrated to give 1-cyclopropyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid, as a beige solid (80 mg, 0.444 mmol, 64%). ¹H NMR (300 MHz, Chloroform-*d*) δ 7.90 (d, *J* = 9.7 Hz, 1H), 7.03 (d, *J* = 9.7 Hz, 1H), 4.24 - 4.08 (m, 1H), 1.26 - 1.09 (m, 4H).

25

Step 3: Preparation of


1-cyclopropyl-*N*-{5-[(3-fluorophenyl)methyl]pyridin-2-yl}-6-oxo-1,6-dihydropyridazine-3-carboxamide

Combined 5-[(3-fluorophenyl)methyl]pyridin-2-amine (0.076 g, 0.3758 mmol) with


1-cyclopropyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (0.068 g, 0.3758 mmol) and

1-[Bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.121 g, 0.3758 mmol) in a 25mL round bottom flask. Suspended in dichloromethane (4 mL) and added ethylbis(propan-2-yl)amine (98.1 μ L, 0.5637 mmol). Stirred 16 h at room temperature. Concentrated

reaction to remove solvent. Purified reaction by column chromatography (eluting with 0-100% ethyl acetate/hexanes through 24 g of silica gel) to give

1-cyclopropyl-*N*-{5-[(3-fluorophenyl)methyl]pyridin-2-yl}-6-oxo-1,6-dihydropyridazine-3-carboxamide (48 mg, 0.132 mmol, 35%) as a white solid. ^1H NMR (300 MHz, Chloroform-*d*) δ 9.27 (s, 1H), 8.30 - 8.20 (m, 2H), 8.03 (d, J = 9.7 Hz, 1H), 7.57 (dd, J = 8.6, 2.5 Hz, 1H), 7.30 (d, J = 2.0 Hz, 1H), 7.14 - 6.85 (m, 4H), 4.20 - 4.04 (m, 1H), 3.99 (s, 2H), 1.27 - 1.10 (m, 4H); LCMS (ESI) m/z : 365.5 $[\text{M}+\text{H}]^+$.**Example 76. Preparation of*****N*-(5-(3-chloro-4-fluorobenzyl)pyridin-2-yl)-1-cyclopropyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (76)**

Step 1: Preparation of 5-(3-chloro-4-fluorobenzyl)pyridin-2-amine



To a solution of 4-(bromomethyl)-2-chloro-1-fluorobenzene (1.12 g, 5 mmol),

5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (1.32 g, 6 mmol) and potassium carbonate (1.38 g, 10 mmol) in acetonitrile (24 mL) and water (6 mL) at room temperature was added


1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (0.408 g, 0.5

mmol) under argon. The reaction mixture was stirred at 80 °C for 2 h. The reaction mixture was extracted with ethyl acetate (50 mL x 2). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate, filtered and concentrated. The crude residue was purified by column chromatography

(silica gel, petroleum ether/ethyl acetate = 2/3) to give 5-(3-chloro-4-fluorobenzyl)pyridin-2-amine (0.8 g, 3.4 mmol, 67.8%) as a brown solid. LCMS (ESI) m/z : 237.1 $[M+H]^+$.

Step 2: Preparation of

5 *N*-(5-(3-chloro-4-fluorobenzyl)pyridin-2-yl)-1-cyclopropyl-6-oxo-1,6-dihydropyridazine-3-carboxamide




A solution of 5-(3-chloro-4-fluorobenzyl)pyridin-2-amine (0.198 g, 0.84 mmol), 1-cyclopropyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (0.126 g, 0.7 mmol), 2-(7-azabenzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate (400 mg, 1.05 mmol) and ethyldiisopropylamine (271 mg, 2.1 mmol) in *N,N*-dimethylformamide (3.5 mL) was stirred at room temperature for 2 h. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 μ m column. The mobile phase was acetonitrile/0.01% aqueous trifluoroacetic acid) to give


10 *N*-(5-(3-chloro-4-fluorobenzyl)pyridin-2-yl)-1-cyclopropyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (71.4 mg, 0.18 mmol, 25.7%) as a white solid. ^1H NMR (500 MHz, Dimethylsulfoxide- d_6) δ 10.11 (s, 1H), 8.35 (d, J = 2.0 Hz, 1H), 8.05 (d, J = 8.5 Hz, 1H), 7.90 (d, J = 10.0 Hz, 1H), 7.74 (dd, J = 8.5, 2.5 Hz, 1H), 7.51 (dd, J = 7.5, 2.0 Hz, 1H), 7.35 (t, J = 8.8 Hz, 1H), 7.29 - 7.26 (m, 1H), 7.06 (d, J = 10.0 Hz, 1H), 4.10 - 4.07 (m, 1H), 3.97 (s, 2H), 1.28 - 1.23 (m, 2H), 1.04 - 1.00 (m, 2H); LCMS (ESI) m/z : 399.0 $[M+H]^+$.

20 **Example 77. Preparation of**

1-(cyclopropylmethyl)-*N*-(5-(3-fluorobenzyl)pyridin-2-yl)-6-oxo-1,6-dihydropyridazine-3-carboxamide (77)



25 Step 1: Preparation of 5-[(3-fluorophenyl)methyl]pyridin-2-amine




In a 40 mL reaction vial, combined 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (0.500 g, 2.27 mmol), tripotassium phosphate (0.721 g, 3.40 mmol) and bis(triphenylphosphine)palladium(II) dichloride (0.080 g, 0.1135 mmol). Added tetrahydrofuran (3.0 mL) and water (1.0 mL) and added 1-(bromomethyl)-3-fluorobenzene (278 μ L, 2.27 mmol). The reaction was degassed by cycling with vacuum and nitrogen gas for 3 cycles. The reaction was heated at 75 $^{\circ}\text{C}$ for 16 h. Cooled the reaction to room temperature and diluted with ethyl acetate (15 mL). Washed the organic

layer with water (10 mL), then brine (10 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated. Purified reaction by column chromatography (eluting with 0-100% ethyl acetate/hexanes through 24 g of silica gel) to give 5-[(3-fluorophenyl)methyl]pyridin-2-amine (33 mg, 0.163 mmol, 7%) as a yellow oil. ¹H NMR (300 MHz, Chloroform-*d*) δ 8.31 - 8.17 (m, 2H), 8.04 (d, *J* = 9.7 Hz, 1H), 7.04 (d, *J* = 9.7 Hz, 1H), 7.02 - 6.87 (m, 2H), 3.99 (s, 2H).

Step 2: Preparation of

1-(cyclopropylmethyl)-*N*-{5-[(3-fluorophenyl)methyl]pyridin-2-yl}-6-oxo-1,6-dihydropyridazine-3-carboxamide




Dissolved 5-[(3-fluorophenyl)methyl]pyridin-2-amine (0.033 g, 0.1631 mmol) in methylene chloride (2.0 mL) and added 1-(cyclopropylmethyl)-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (0.032 g, 0.1631 mmol), [bis(dimethylamino)methylidene]({3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl})oxidanium; tetrafluoroboranuide (0.053 mg, 0.1631 mmol) and ethylbis(propan-2-yl)amine (42.5 μL, 0.2446 mmol).


Stirred at room temperature 16 h. Directly purified reaction by column chromatography (eluting with 0-100% ethyl acetate/hexanes through 12 g of silica gel) to give 1-(cyclopropylmethyl)-*N*-{5-[(3-fluorophenyl)methyl]pyridin-2-yl}-6-oxo-1,6-dihydropyridazine-3-carboxamide (29 mg, 0.077 mmol, 47%) as a white solid. ¹H NMR (300 MHz, Chloroform-*d*) δ 8.38 - 8.21 (m, 2H), 8.06 (d, *J* = 9.7 Hz, 1H), 7.63 - 7.50 (m, 1H), 7.28 (s, 2H), 7.05 (d, *J* = 9.7 Hz, 1H), 6.97 (t, *J* = 8.1 Hz, 3H), 4.13 (d, *J* = 7.3 Hz, 2H), 3.99 (s, 2H), 1.43 (t, *J* = 8.0 Hz, 1H), 0.61 (d, *J* = 7.7 Hz, 2H), 0.50 (d, *J* = 5.1 Hz, 2H); LCMS (ESI) *m/z*: 379.3 [M+H]⁺.

Example 78. Preparation of

1-ethyl-*N*-(5-(3-fluoro-5-methoxybenzyl)pyridin-2-yl)-6-oxo-1,6-dihydropyridine-3-carboxamide (78)




Step 1: Preparation of 1-(bromomethyl)-3-fluoro-5-methoxybenzene



To a solution of (3-fluoro-5-methoxyphenyl)methanol (2.0 g, 12.8 mmol) in ethyl ether (30 mL) at 0 °C was added phosphorus tribromide (1.0 mL) slowly. The reaction mixture was stirred at room


temperature for 2 h. The mixture was quenched with saturated aqueous sodium bicarbonate (150 mL). The aqueous layer was extracted with ethyl acetate (200 mL x 2). The combined organic phases were dried over sodium sulfate, filtered and concentrated to afford 1-(bromomethyl)-3-fluoro-5-methoxybenzene (1.5 g, 6.88 mmol, 53%, crude) as a light-yellow oil. Used in the next step directly without additional purification.

Step 2: Preparation of 5-(3-fluoro-5-methoxybenzyl)pyridin-2-amine




To a stirred solution of 1-(bromomethyl)-3-fluoro-5-methoxybenzene (1.5 g, 6.88 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (1.51 g, 6.88 mmol) in acetonitrile (60 mL) was added a solution of potassium carbonate (1.9 g, 13.76 mmol) in water (20 mL), followed by the addition of 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (280 mg, 0.34 mmol) under nitrogen. The mixture was stirred at 80 °C for 2 h. The reaction solution was poured into water and extracted with ethyl acetate (150 mL x 2). The combined organic phases were concentrated and the crude residue was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 1/2) to give 5-(3-fluoro-5-methoxybenzyl)pyridin-2-amine (0.9 g, 3.88 mmol, 56%) as a red oil. LCMS (ESI) m/z: 233.2 [M+H]⁺.

Step 3: Preparation of methyl 1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxylate



A mixture of methyl 6-hydroxynicotinate (10.0 g, 65.3 mmol), iodoethane (10.1 g, 65.3 mmol), potassium carbonate (18.0 g, 130.6 mmol) in acetonitrile (400 mL) was stirred at 80 °C for 16 h. The precipitate was filtered off and the filtrate was concentrated. The crude residue was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 4/1 to 1/1) to give methyl 1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxylate (8.7 g, 48.1 mmol, 73%) as a light-yellow solid. ¹H NMR (500 MHz, Chloroform-*d*) δ 8.19 (d, *J* = 2.5 Hz, 1H), 7.82 (dd, *J* = 9.5, 2.0 Hz, 1H), 6.52 (d, *J* = 9.0 Hz, 1H), 4.03 (q, *J* = 7.0 Hz, 2H), 3.86 (s, 3H), 1.39 (t, *J* = 7.0 Hz, 3H); LCMS (ESI) m/z: 182.1 [M+H]⁺.

Step 4: Preparation of 1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid




A mixture of methyl 1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxylate (5.4 g, 29.8 mmol), lithium hydroxide hydrate (6.26 g, 149.1 mmol) in tetrahydrofuran (100 mL) and water (30 mL) was stirred at

room temperature for 2 h. The mixture was acidified to pH 1-2 with dilute hydrogen chloride acid and extracted with ethyl acetate/tetrahydrofuran (200 mL/50 mL x 3). The combined organic phases were dried over sodium sulfate, filtered and concentrated to afford

1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (4.7 g, 28.14 mmol, 94%) as an off-white solid. LCMS (ESI) m/z : 168.1 $[M+H]^+$. Used in the next step directly without additional purification.

Step 5: Preparation of


1-ethyl-*N*-(5-(3-fluoro-5-methoxybenzyl)pyridin-2-yl)-6-oxo-1,6-dihydropyridine-3-carboxamide




A mixture of 5-(3-fluoro-5-methoxybenzyl)pyridin-2-amine (232 mg, 1.0 mmol), 1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (167 mg, 1.0 mmol), 2-(7-azabenzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate (570 mg, 1.5 mmol), *N,N*-diisopropylethyl amine (390 mg, 3.0 mmol) in *N,N*-dimethylformamide (8 mL) was stirred at room temperature for 0.5 h and at 90 °C for 2 h. The mixture was poured into water and extracted with ethyl acetate (200 mL x 3). The combined organic phases were concentrated. The crude residue was purified first by column chromatography (silica gel, petroleum ether/ethyl acetate = 1/1) and second by prep-HPLC (Boston C18 21*250 mm 10 μ m column. The mobile phase was acetonitrile/10 mM ammonium acetate aqueous solution) to give 1-ethyl-*N*-(5-(3-fluoro-5-methoxybenzyl)pyridin-2-yl)-6-oxo-1,6-dihydropyridine-3-carboxamide (0.0594 g, 0.16 mmol, 16%) as a white solid. ^1H NMR (500 MHz, Dimethylsulfoxide- d_6) δ 10.61 (s, 1H), 8.64 (d, J = 2.5 Hz, 1H), 8.31 (d, J = 2.0 Hz, 1H), 8.06 (d, J = 8.5 Hz, 1H), 7.94 (dd, J = 9.0, 2.5 Hz, 1H), 7.70 (dd, J = 9.0, 2.5 Hz, 1H), 6.71-6.65 (m, 3H), 6.43 (d, J = 9.5 Hz, 1H), 3.97 (q, J = 7.0 Hz, 2H), 3.91 (s, 2H), 3.74 (s, 3H), 1.28 (t, J = 7.0 Hz, 3H); LCMS (ESI) m/z : 382.1 $[M+H]^+$.

Example 79. Preparation of

5-(3-Chloro-5-fluorobenzyl)-*N*-(1-ethyl-6-oxo-1,6-dihydropyridin-3-yl)picolinamide (79)




Step 1: Preparation of methyl 5-(3-chloro-5-fluorobenzyl)picolinate



To a solution of methyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)picolinate (1.0 g, 3.8 mmol) in acetonitrile (20 mL) and water (5 mL) at room temperature was added potassium carbonate (1.05 g,


7.6 mmol), 1,1'-bis(diphenylphosphino)ferrocene palladium(II)dichloride (0.310 g, 0.38 mmol) and 1-(bromomethyl)-3-chloro-5-fluorobenzene (0.850 g, 3.8 mmol) under nitrogen. The reaction mixture was stirred at 80 °C for 3 h. The reaction solution was cooled to room temperature and diluted with water (200 mL). The aqueous layer was extracted with ethyl acetate (100 mL × 3). The combined organic layers were washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 3/1) to give methyl 5-(3-chloro-5-fluorobenzyl)picolinate (0.550 g, 1.97 mmol, 52%) as a yellow solid. LCMS (ESI) m/z : 280.0 $[M+H]^+$.

10 Step 2: Preparation of lithium 5-(3-chloro-5-fluorobenzyl)picolinate




To a solution of methyl 5-(3-chloro-5-fluorobenzyl)picolinate (0.550 g, 1.97 mmol) in a mixture of tetrahydrofuran (2.0 mL), methanol (2.0 mL) and water (1.0 mL) at room temperature was added lithium hydroxide (0.083 g, 1.97 mmol). The reaction mixture was stirred at room temperature for 3 h before it was concentrated, to afford lithium 5-(3-chloro-5-fluorobenzyl)picolinate (0.610 g, 1.97 mmol, crude) as a white solid. LCMS (ESI) m/z : 266.1 $[M+H]^+$. Used in the next step directly without additional purification.

Step 3: Preparation of 1-ethyl-5-nitropyridin-2(1H)-one



To a solution of 5-nitropyridin-2(1H)-one (3.0 g, 21.41 mmol) in *N,N*-dimethylformamide (60 mL) at room temperature was added potassium carbonate (5.91 g, 42.8 mmol) and iodoethane (4.35 g, 27.8 mmol). The reaction mixture was stirred at room temperature for 5 h before it was diluted with water (200 mL). The aqueous phase was extracted with ethyl acetate (100 mL × 3). The combined organic layers were washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude sample was purified by column chromatography (petroleum ether/ethyl acetate = 2/1) to give 1-ethyl-5-nitropyridin-2(1H)-one (2.3 g, 13.7 mmol, 64%) as a yellow solid. LCMS (ESI) m/z : 169.1 $[M+H]^+$.

Step 4: Preparation of 5-amino-1-ethylpyridin-2(1H)-one




To a solution of 1-ethyl-5-nitropyridin-2(1H)-one (1.0 g, 5.95 mmol) in ethanol (15 mL) and tetrahydrofuran (15 mL) at room temperature was added acetic acid (5.0 mL) and iron (1.67 g, 29.8 mmol). The reaction mixture was refluxed for 2 h before it was cooled to room temperature and concentrated to give a residue. The residue was treated with aqueous saturated sodium carbonate solution (10 mL) and extracted with ethanol (80 mL × 3). The combined organic layers were dried over

sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μ m column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give 5-amino-1-ethylpyridin-2(1H)-one (0.320 g, 2.31 mmol, 39%) as a colorless oil. LCMS (ESI) *m/z*: 139.1 [M+H]⁺.

5

Step 5: Preparation of 5-(3-chloro-5-fluorobenzyl)-*N*-(1-ethyl-6-oxo-1,6-dihydropyridin-3-yl)picolinamide




To a solution of lithium 5-(3-chloro-5-fluorobenzyl)picolinate (0.200 g, 0.74 mmol) in *N,N*-dimethylformamide (6 mL) at room temperature was added 5-amino-1-ethylpyridin-2(1H)-one (0.129 g, 0.74 mmol), 2-(7-aza-1*H*-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (0.364 g, 0.96 mmol) and pyridine (0.291 g, 3.68 mmol). The reaction mixture was stirred at room temperature for 16 h. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μ m column. The mobile phase was acetonitrile/10 mM ammonium acetate aqueous solution) to afford

5-(3-chloro-5-fluorobenzyl)-*N*-(1-ethyl-6-oxo-1,6-dihydropyridin-3-yl)picolinamide (0.065 g, 0.17 mmol, 23%) as a white solid. ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 10.49 (s, 1H), 8.70 (s, 1H), 8.33 (d, *J* = 2.4 Hz, 1H), 8.04 (d, *J* = 8.0 Hz, 1H), 7.92 (dd, *J*₁ = 1.6 Hz, *J*₂ = 8.0 Hz, 1H), 7.77 (dd, *J*₁ = 2.8 Hz, *J*₂ = 10.0 Hz, 1H), 7.30 (d, *J* = 4.8 Hz, 2H), 7.22 (d, *J* = 9.2 Hz, 1H), 6.41 (d, *J* = 9.6 Hz, 1H), 4.13 (s, 2H) 3.92 (q, *J* = 7.2 Hz, 2H), 1.22 (t, *J* = 7.2 Hz, 4H); LCMS (ESI) *m/z*: 386.1 [M+H]⁺.


20

Example 80. Preparation of

1-ethyl-*N*-(5-(3-fluorobenzyl)pyridin-2-yl)-6-oxo-1,6-dihydropyridine-3-carboxamide (80)



Step 1: Preparation of 5-(3-fluorobenzyl)pyridin-2-amine




25

To a solution of 1-(bromomethyl)-3-fluorobenzene (1.0 g, 5.32 mmol), 6-aminopyridin-3-ylboronic acid (0.734 g, 5.32 mmol), potassium carbonate (1.47 g, 10.6 mmol) in tetrahydrofuran (12 mL) and water (3 mL) under nitrogen was added tetrakis(triphenylphosphine)palladium(0) (0.614 g, 0.532 mmol). The reaction mixture was heated to 90 °C and stirred for 2 h. The volatiles were removed under reduced pressure. Aqueous layer was acidified to pH = 1-3 with 1 N hydrogen chloride and extracted with ethyl acetate (50 mL). The aqueous layer was then adjusted to pH = 8-10 with aqueous sodium bicarbonate and extracted with dichloromethane (50 mL x 2). The combined dichloromethane layers were dried over

30

sodium sulfate, filtered and concentrated to give 5-(3-fluorobenzyl)pyridin-2-amine as a yellow oil (0.55 g); LCMS (ESI) m/z : 203.1 $[M+H]^+$.


Step 2: Preparation of 1-ethyl-*N*-(5-(3-fluorobenzyl)pyridin-2-yl)-6-oxo-1,6-dihydropyridine-3-carboxamide




5

To a solution of 1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (0.150 g, 0.899 mmol), 5-(3-fluorobenzyl)pyridin-2-amine (0.181 g, 0.899 mmol) in pyridine (4 mL) at 20 °C was added phosphorus(V) oxychloride (0.410 g, 2.70 mmol). The reaction mixture was stirred at room temperature for 3 h. The solvent was removed under reduced pressure. The resulting solid was dissolved in dichloromethane (10.0 mL) and added to a mixture of dichloromethane (50 mL) and water (50 mL). The organic layer was collected, dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 μ m column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give 1-ethyl-*N*-(5-(3-fluorobenzyl)pyridin-2-yl)-6-oxo-1,6-dihydropyridine-3-carboxamide (0.0750 g, 0.216 mmol, 24%) as a light-yellow solid. ^1H NMR (400 MHz, Dimethylsulfoxide- d_6) δ 10.65 (s, 1H), 8.64 (d, J = 2.5 Hz, 1H), 8.31 (d, J = 2.5 Hz, 1H), 8.05 (d, J = 8.5 Hz, 1H), 7.93-7.95 (m, 1H), 7.70-7.73 (m, 1H), 7.35 (d, J = 6.5 Hz, 1H), 7.04-7.13 (m, 3H), 6.43 (d, J = 9.5 Hz, 1H), 3.95-3.99 (m, 4H), 1.27 (t, J = 7.2 Hz, 3H); LCMS (ESI) m/z : 352.1 $[M+H]^+$.

20 Example 81. Preparation of 1-ethyl-*N*-(5-(4-fluorobenzyl)pyridin-2-yl)-6-oxo-1,6-dihydropyridine-3-carboxamide (81)




Step 1: Preparation of 5-(4-fluorobenzyl)pyridin-2-amine



25

To a solution of 1-(bromomethyl)-4-fluorobenzene (1.0 g, 5.32 mmol), 6-aminopyridin-3-ylboronic acid (0.735 g, 5.32 mmol), potassium carbonate (1.47 g, 10.6 mmol) in tetrahydrofuran (12 mL) and water (3 mL) under nitrogen was added tetrakis(triphenylphosphine)palladium(0) (0.614 g, 0.532 mmol). The reaction mixture was heated to 90 °C and stirred for 2 h. The volatiles were removed under reduced pressure. Aqueous layer was acidified to pH = 1-3 with 1 N hydrogen chloride and extracted with ethyl acetate (50 mL). The aqueous layer was then adjusted to pH = 8-10 with aqueous sodium bicarbonate and extracted with dichloromethane (50 mL x 2). The combined dichloromethane layers were dried over sodium sulfate, filtered and concentrated to give 5-(4-fluorobenzyl)pyridin-2-amine (0.35 g, crude) as a yellow oil. LCMS (ESI) m/z : 203.1 $[M+H]^+$. Used in the next step without further purification.

Step 2: Preparation of 1-ethyl-*N*-(5-(4-fluorobenzyl)pyridin-2-yl)-6-oxo-1,6-dihydropyridine-3-carboxamide




To a solution of 1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (0.150 g, 0.899 mmol), 5-(3-fluorobenzyl)pyridin-2-amine (0.181 g, 0.899 mmol) in pyridine (4 mL) at 20 °C was added, phosphorus(V) oxychloride (410 mg, 2.697 mmol). The reaction mixture was stirred at room temperature for 3 h. Volatiles were removed under reduced pressure and the solid was dissolved in dichloromethane (10.0 mL) and added to a mixture of dichloromethane (50 mL) and water (50 mL). The organic layer was collected, dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 µm column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give


1-ethyl-*N*-(5-(4-fluorobenzyl)pyridin-2-yl)-6-oxo-1,6-dihydropyridine-3-carboxamide as a light-yellow solid (0.0340 g, 0.099 mmol, 11%). ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 10.59 (s, 1H), 8.64 (d, *J* = 2.5 Hz, 1H), 8.28 (d, *J* = 2 Hz, 1H), 8.05 (d, *J* = 8.5 Hz, 1H), 7.93-7.95 (m, 1H), 7.65-7.67 (m, 1H), 7.28-7.31 (m, 2H), 7.11-7.15 (m, 2H), 6.42 (d, *J* = 9.5 Hz, 1H), 3.94-3.99 (m, 4H), 1.27 (t, *J* = 7.0 Hz, 3H); LCMS (ESI) *m/z*: 352.1 [M+H]⁺.

Example 82. Preparation of

N-(5-(3-chloro-4-fluorobenzyl)pyridin-2-yl)-1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxamide (82)



Step 1: Preparation of *N*-(5-(3-chloro-4-fluorobenzyl)pyridin-2-yl)-1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxamide




To a solution of 5-(3-chloro-4-fluorobenzyl)pyridin-2-amine (0.2 g, 0.85 mmol), 1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (0.17 g, 1.02 mmol) and 1-[*bis*(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.39 g, 1.02 mmol) in *N,N*-dimethylformamide (3 mL) was added triethylamine (0.26 g, 2.53 mmol). The mixture was stirred at 90 °C for 2 h and then cooled to room temperature. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 µm column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give

N-(5-(3-chloro-4-fluorobenzyl)pyridin-2-yl)-1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxamide (0.0733 g, 0.19 mmol, 22.4%) as a white solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 10.68 (s, 1H), 8.64 (d, *J* =


2.6 Hz, 1H), 8.32 (d, $J = 2.6$ Hz, 1H), 8.04 (d, $J = 8.5$ Hz, 1H), 7.94 (dd, $J = 8.5, 2.6$ Hz, 1H), 7.73 (dd, $J = 8.5, 2.6$ Hz, 1H), 7.52 (dd, $J = 7.2, 2.1$ Hz, 1H), 7.40 - 7.23 (m, 2H), 6.43 (d, $J = 9.5$ Hz, 1H), 4.03 - 3.90 (m, 4H), 1.28 (t, $J = 7.1$ Hz, 3H); LCMS (ESI) m/z : 386.0 $[M+H]^+$.

5 Example 83. Preparation of

N-(5-(3-chlorobenzyl)pyridin-2-yl)-1-isopropyl-6-oxo-1,6-dihydropyridine-3-carboxamide (83)




Step 1: Preparation of methyl 1-isopropyl-6-oxo-1,6-dihydropyridine-3-carboxylate



A mixture of methyl 6-hydroxynicotinate (10.0 g, 65.3 mmol), 2-iodopropane (11.1 g, 65.3 mmol), potassium carbonate (18.0 g, 130.6 mmol) in acetonitrile (450 mL) was stirred at 80 °C for 16 h. The precipitate was filtered and the filtrate was concentrated. The crude residue was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 4/1 to 1/1) to give methyl


1-isopropyl-6-oxo-1,6-dihydropyridine-3-carboxylate (6.5 g, 33.3 mmol, 51%) as a white solid. ^1H NMR (500 MHz, Chloroform- d) δ 8.23 (d, $J = 3.0$ Hz, 1H), 7.82 (dd, $J = 9.0, 3.0$ Hz, 1H), 6.54 (d, $J = 9.0$ Hz, 1H), 5.28-5.23 (m, 1H), 3.88 (s, 3H), 1.41 (d, $J = 6.5$ Hz, 6H); LCMS (ESI) m/z : 196.2 $[M+H]^+$.

Step 2: Preparation of 1-isopropyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid





A mixture of methyl 1-isopropyl-6-oxo-1,6-dihydropyridine-3-carboxylate (4.0 g, 20.5 mmol), lithium hydroxide hydrate (4.3 g, 102.5 mmol) in tetrahydrofuran (100 mL) and water (25 mL) was stirred at room temperature for 2 h. The reaction solution was acidified to pH 1-2 with dilute hydrochloric acid and the aqueous layer was extracted with ethyl acetate/tetrahydrofuran (200 mL/50 mL x 3). The combined organic phases were dried over sodium sulfate, filtered and concentrated to afford 1-isopropyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (3.5 g, 19.3 mmol, 94.3%) as an off-white solid. LCMS (ESI) m/z : 182.2 $[M+H]^+$. Used in the next step directly without additional purification.

Step 3: Preparation of

N-(5-(3-chlorobenzyl)pyridin-2-yl)-1-isopropyl-6-oxo-1,6-dihydropyridine-3-carboxamide

A mixture of 5-(3-chlorobenzyl)pyridin-2-amine (218 mg, 1.0 mmol),
 1-isopropyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (181 mg, 1.0 mmol),
 2-(7-azabenzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate (570 mg, 1.5 mmol),
N,N,N-diisopropylethyl amine (390 mg, 3.0 mmol) in *N,N*-dimethylformamide (10 mL) was stirred at room
 temperature for 0.5 h and at 90 °C for 2 h. The mixture was poured into water and the aqueous layer was
 extracted with ethyl acetate (150 mL x 2). The combined organic phases were concentrated. The crude
 residue was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 1/1) and
 prep-HPLC (the crude sample was dissolved in minimal *N,N,N*-dimethylformamide and loaded onto
 Boston C18 21*250 mm 10 µm column. The mobile phase was acetonitrile/10 mM ammonium acetate
 aqueous solution) to afford

N-(5-(3-chlorobenzyl)pyridin-2-yl)-1-isopropyl-6-oxo-1,6-dihydropyridine-3-carboxamide (0.056 g, 0.15
 mmol, 14.6%) as a white solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 10.83 (s, 1H), 8.58 (d, *J* = 2.5
 Hz, 1H), 8.32 (d, *J* = 2.0 Hz, 1H), 8.07 (d, *J* = 8.0 Hz, 1H), 7.92 (dd, *J* = 9.0, 2.5 Hz, 1H), 7.69 (dd, *J* = 9.0,
 2.5 Hz, 1H), 7.36-7.33 (m, 2H), 7.28-7.23 (m, 2H), 6.44 (d, *J* = 9.5 Hz, 1H), 5.09-5.03 (m, 1H), 3.97 (s,
 2H), 1.37 (d, *J* = 7.0 Hz, 6H); LCMS (ESI) *m/z*: 382.1 [*M*+*H*]⁺.


Example 84. Preparation of***N*-(5-(3-chlorobenzyl)pyridin-2-yl)-1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxamide (84)**Step 1: Preparation of *N*-(5-(3-chlorobenzyl)pyridin-2-yl)-1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxamide

A solution of 1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (0.100 g, 0.60 mmol),
 5-(3-chlorobenzyl)pyridin-2-amine (0.157 g, 0.72 mmol),
 1-[*bis*(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.342 g,
 0.9 mmol) and *N,N*-diisopropylethylamine (0.232 g, 1.8 mmol) in *N,N*-dimethylformamide (3 mL) was
 stirred at 90 °C for 1 h. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified
 via prep-HPLC (Boston C18 21*250 mm 10 µm column; acetonitrile/0.01% aqueous trifluoroacetic acid) to
 give *N*-(5-(3-chlorobenzyl)pyridin-2-yl)-1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxamide a white solid
 (0.056 g, 0.153 mmol, 25.5%). ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 10.70 (s, 1H), 8.65 (d, *J* = 2.5
 Hz, 1H), 8.32 (d, *J* = 1.8 Hz, 1H), 8.05 (d, *J* = 8.5 Hz, 1H), 7.95 (dd, *J* = 9.5, 2.5 Hz, 1H), 7.73 (dd, *J* = 8.6,


2.1 Hz, 1H), 7.34-7.32 (m, 2H), 7.28-7.23 (m, 2H), 6.44 (d, $J = 9.5$ Hz, 1H), 3.99 - 3.95 (m, 4H), 1.28 (t, $J = 7.1$ Hz, 3H); LCMS (ESI) m/z : 368.0 $[M+H]^+$.

Example 85. Preparation of

5 1-ethyl-*N*-(5-(3-fluorobenzyl)pyridin-2-yl)-6-oxo-1,6-dihydropyridine-3-carboxamide (85)




Step 1: Preparation of methyl 1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxylate




A mixture of methyl 6-hydroxynicotinate (15.3 g, 100 mmol), potassium carbonate (27.6 g, 200 mmol) in *N,N*-dimethylformamide (150 mL) was stirred at room temperature for 10 minutes, before iodoethane (17.2 g, 110 mmol) was added. The reaction mixture was stirred at room temperature for another 4 h and quenched with water (500 mL) and extracted with ethyl acetate (400 mL x 3). The combined organic phases were washed with brine, dried over sodium sulfate, filtered and concentrated. The residue was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 9/1 to 1/1) to afford methyl 1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxylate (6.0 g, contained residual *N,N*-dimethylformamide) as an orange oil. ^1H NMR (500 MHz, Chloroform- d) δ 8.22 (d, $J = 3.0$ Hz, 1H), 7.83 (dd, $J = 12.0, 3.5$ Hz, 1H), 6.52 (d, $J = 12.0$ Hz, 1H), 4.04 (q, $J = 9.0$ Hz, 2H), 3.86 (s, 3H), 1.38 (t, $J = 9.0$ Hz, 3H); LCMS (ESI) 182.1 $[M+H]^+$.

Step 2: Preparation of 1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid



A mixture of methyl 1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxylate (5.8 g, 32.0 mmol), lithium hydroxide (6.72 g, 160.0 mmol) in tetrahydrofuran (60 mL) and water (15 mL) was stirred at room temperature for 2 h. The organics were removed under reduced pressure. The water phase was acidified to pH = 1-2 with dilute aqueous hydrogen chloride and extracted with 2-methylfuran (200 mL x 3). The combined organic phases were dried over sodium sulfate, filtered and concentrated to afford 1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (2.8 g, 52.3%) as a light-yellow solid. ^1H NMR (500 MHz, Dimethylsulfoxide- d_6) δ 12.80 (bs, 1H), 8.47 (d, $J = 2.5$ Hz, 1H), 7.77 (dd, $J = 9.5, 2.5$ Hz, 1H), 6.40 (d, $J = 9.5$ Hz, 1H), 3.99 (q, $J = 7.0$ Hz, 2H), 1.23 (d, $J = 7.0$ Hz, 3H); LCMS (ESI) m/z : 168.1 $[M+H]^+$.

Step 3: Preparation of 1-ethyl-*N*-(5-(3-fluorobenzyl)pyridin-2-yl)-6-oxo-1,6-dihydropyridine-3-carboxamide



A mixture of 1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (0.098 g, 0.59 mmol), 5-(3-fluorobenzyl)pyridin-2-amine (0.120 g, 0.59 mmol),


5 1-[*bis*(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.342 g, 0.900 mmol) and *N,N*-diisopropylethylamine (0.155 g, 1.2 mmol) in *N,N*-dimethylformamide (3 mL) was stirred at room temperature for 1 h and then at 90 °C for 1 h. The mixture was poured into water and extracted with ethyl acetate (50 mL x 3). The combined organic phases were concentrated. The residue was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 1/4) and then by
10 prep-HPLC twice (first by: sample was dissolved in minimal *N,N*-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 µm column; acetonitrile/0.01% aqueous trifluoroacetic acid). Second by: sample was dissolved in minimal *N,N*-dimethylformamide and purified by prep-HPLC (Boston C18 21*250 mm 10 µm column. The mobile phase was acetonitrile/10 mM ammonium acetate aqueous solution) to afford compound

15 1-ethyl-*N*-(5-(3-fluorobenzyl)pyridin-2-yl)-6-oxo-1,6-dihydropyridine-3-carboxamide (0.0179 g, 0.0507 mmol, 8.6%) as a grey solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 10.65 (s, 1H), 8.65 (d, *J* = 2.5 Hz, 1H), 8.31 (d, *J* = 2.5 Hz, 1H), 8.05 (d, *J* = 8.5 Hz, 1H), 7.94 (dd, *J* = 9.5, 3.0 Hz, 1H), 7.71 (dd, *J* = 8.5, 2.0 Hz, 1H), 7.35 (dd, *J* = 14.0, 8.5 Hz, 1H), 7.13-7.10 (m, 2H), 7.04 (td, *J* = 8.5, 2.0 Hz, 1H), 6.43 (d, *J* = 9.5 Hz, 1H), 3.99-3.95 (m, 4H), 1.28 (t, *J* = 7.5 Hz, 3H); LCMS (ESI) *m/z*: 352.2 [*M*+*H*]⁺.


20

Example 86. Preparation of

5-(3-Chlorobenzyl)-*N*-(1-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)picolinamide (86)




25 Step 1: Preparation of 5-(3-Chlorobenzyl)-*N*-(1-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)picolinamide



To a solution of 6-amino-2-methyl-4,5-dihydropyridazin-3(2H)-one (0.127 g, 1.0 mmol) in anhydrous toluene (8 mL) at room temperature was added trimethylaluminum (0.50 mL, 1.0 mmol, 2 M in toluene) under nitrogen. The reaction mixture was stirred at room temperature for 1 h before methyl 5-(3-chlorobenzyl)picolinate (0.130 g, 0.50 mmol) was added. Reaction mixture was stirred at 100 °C for 16 h. Reaction solution was cooled to room temperature and quenched with water (100 mL). The aqueous layer was extracted with ethyl acetate (50 mL × 3). The combined organic layers were washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μm column. The mobile phase was acetonitrile/10 mM ammonium acetate aqueous solution) to give 5-(3-chlorobenzyl)-*N*-(1-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)picolinamide (35.0 mg, 0.1 mmol, 20%) as a white solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 10.15 (s, 1H), 8.66 (d, *J* = 1.5 Hz, 1H), 8.05 (d, *J* = 8.0 Hz, 1H), 7.92 (dd, *J*₁ = 2.0 Hz, *J*₂ = 8.0 Hz, 1H), 7.40 (s, 1H), 7.37-7.33 (m, 1H), 7.30-7.26 (m, 2H), 4.12 (s, 2H), 3.21 (t, *J* = 8.0 Hz, 2H), 3.17 (s, 3H), 2.48 (t, *J* = 8.0 Hz, 2H); LCMS (ESI) *m/z*: 357.1 [M+H]⁺.

Example 87. Preparation of


5-(3,4-Difluorobenzyl)-*N*-(1-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)picolinamide (87)



To a solution of methyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)picolinate (1.0 g, 3.8 mmol) in acetonitrile (20 mL) and water (5 mL) at room temperature was added potassium carbonate (1.04 g, 7.6 mmol), 1,1'-bis(diphenylphosphino)ferrocene palladium(II)dichloride (0.310 g, 0.38 mmol) and 4-(bromomethyl)-1,2-difluorobenzene (0.787 g, 3.8 mmol) under nitrogen. The reaction mixture was stirred at 80 °C for 3 h. The reaction solution was cooled to room temperature and diluted with water (200 mL). The aqueous layer was extracted with ethyl acetate (80 mL × 3). The combined organic layers were washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude sample was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 3/1) to give methyl 5-(3,4-difluorobenzyl)picolinate (0.610 g, 2.31 mmol, 61%) as a yellow solid. LCMS (ESI) *m/z*: 264.1 [M+H]⁺.

Step 2: Preparation of


5-(3,4-difluorobenzyl)-*N*-(1-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)picolinamide




To a solution of 6-amino-2-methyl-4,5-dihydropyridazin-3(2H)-one (0.204 g, 1.6 mmol) in anhydrous toluene (12 mL) at room temperature was added trimethylaluminum (0.8 mL, 1.6 mmol, 2 M in toluene) under nitrogen. The reaction mixture was stirred at room temperature for 1 h before methyl 5-(3-fluorobenzyl)picolinate (0.210 g, 0.80 mmol) was added. The reaction mixture was stirred at 100 °C for 16 h. The reaction solution was cooled to room temperature and diluted with water (200 mL). The aqueous layer was extracted with ethyl acetate (50 mL × 3). The combined organic layers were washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μm column. The mobile phase was acetonitrile/10 mM ammonium acetate aqueous solution) to give 5-(3,4-difluorobenzyl)-*N*-(1-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)picolinamide (32 mg, 0.09 mmol, 11%) as a white solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 10.17 (s, 1H), 8.65 (d, *J* = 1.5 Hz, 1H), 8.04 (d, *J* = 8.0 Hz, 1H), 7.92 (dd, *J*₁ = 2.0 Hz, *J*₂ = 8.5 Hz, 1H), 7.44-7.35 (m, 2H), 7.16-7.14 (m, 1H), 4.10 (s, 2H) 3.21 (t, *J* = 7.5 Hz, 2H), 3.17 (s, 3H), 2.48 (t, *J* = 8.0 Hz, 2H); LCMS (ESI) *m/z*: 359.1 [M+H]⁺.

Example 88. Preparation of

5-(3-Fluorobenzyl)-*N*-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)picolinamide (88)



Step 1: Preparation of 5-(3-fluorobenzyl)-*N*-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)picolinamide




To a solution of 6-amino-2-methylpyridazin-3(2H)-one (0.133 g, 1.06 mmol) in anhydrous toluene (8 mL) at room temperature was added trimethylaluminum (0.53 mL, 1.0 mmol, 2 M in toluene) under nitrogen. The reaction mixture was stirred at room temperature for 1 h before methyl 5-(3-fluorobenzyl)picolinate (0.130 g, 0.53 mmol) was added and stirred at 100 °C for 16 h. The reaction solution was cooled to room temperature and quenched with water (100 mL). The aqueous layer was extracted with ethyl acetate (50 mL × 3). The combined organic layers were washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μm column. The mobile phase was acetonitrile/10 mM ammonium acetate aqueous solution) to give

5-(3-fluorobenzyl)-*N*-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)picolinamide (0.087 g, 0.26 mmol, 49%) as a white solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 10.37 (s, 1H), 8.68 (d, *J* = 1.0 Hz, 1H), 8.09-8.06 (m, 2H), 7.93 (dd, *J*₁ = 2.0 Hz, *J*₂ = 8.0 Hz, 1H), 7.39-7.34 (m, 1H), 7.19-7.08 (m, 2H), 7.07-7.04 (m, 2H), 4.13 (s, 2H), 3.61 (s, 3H); LCMS (ESI) *m/z*: 339.1 [M+H]⁺.


5

Example 89. Preparation of

5-(3-Chlorobenzyl)-*N*-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)picolinamide (89)



10 Step 1: Preparation of 5-(3-chlorobenzyl)-*N*-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)picolinamide



To a solution of 6-amino-2-methylpyridazin-3(2H)-one (0.125 g, 1.0 mmol) in anhydrous toluene (8 mL) at room temperature was added trimethylaluminum (0.5 mL, 1.0 mmol, 2 *M* in toluene) under nitrogen. The reaction mixture was stirred at room temperature for 1 h before methyl


15 5-(3-fluorobenzyl)picolinate (0.130 g, 0.50 mmol) was added and stirred at 100 °C for 16 h. The reaction mixture was cooled to room temperature and quenched with water (100 mL). The aqueous layer was extracted with ethyl acetate (50 mL × 3). The combined organic layers were washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μm column. The mobile phase was acetonitrile/10 mM ammonium acetate aqueous solution) to give

20 5-(3-chlorobenzyl)-*N*-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)picolinamide (0.050 g, 0.14 mmol, 28%) as a white solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 10.03 (s, 1H), 8.69 (d, *J* = 1.5 Hz, 1H), 8.09-8.06 (m, 2H), 7.93 (dd, *J*₁ = 2.0 Hz, *J*₂ = 8.0 Hz, 1H), 7.41 (s, 1H), 7.35 (t, *J* = 8.0 Hz, 1H), 7.30-7.27 (m, 2H), 7.05 (d, *J* = 10.0 Hz, 1H), 4.13 (s, 2H), 3.61 (s, 3H). LCMS (ESI) *m/z*: 355.0 [M+H]⁺.


25

Example 90. Preparation of

5-(3-Fluorobenzyl)-*N*-(1-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)picolinamide (90)




Step 1: Preparation of *tert*-butyl (1-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)carbamate




To a solution of 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (6.0 g, 38.4 mmol) in toluene (150 mL) at room temperature was added sequentially 2-methylpropan-2-ol (28.5 g, 384 mmol), diphenyl phosphoryl azide (12.7 g, 46.1 mmol) and triethylamine (4.3 g, 42.3 mmol). The reaction mixture was stirred at 100 °C for 16 h, cooled to room temperature and concentrated. Purification over column chromatography (silica gel, petroleum ether/ethyl acetate = 3/1) affords *tert*-butyl (1-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)carbamate (6.1 g, 26.8 mmol, 69.9%) as a white solid. LCMS (ESI) *m/z*: 228.1 [M+H]⁺.

Step 2: Preparation of 6-amino-2-methyl-4,5-dihydropyridazin-3(2H)-one





To a solution of *tert*-butyl (1-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)carbamate (0.500 g, 2.20 mmol) in dichloromethane (10 mL) at room temperature was added trifluoroacetic acid (10 mL). The reaction mixture was stirred at room temperature for 5 h. The mixture was concentrated, and the residue was diluted with water (200 mL) and extracted with dichloromethane (50 mL × 3). The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated to afford 6-amino-2-methyl-4,5-dihydropyridazin-3(2H)-one (0.200 g, 1.57 mmol, 71.4%) as a white solid. LCMS (ESI) *m/z*: 128.1 [M+H]⁺.

Step 3: Preparation of 5-(3-fluorobenzyl)-*N*-(1-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)picolinamide




To a solution of 6-amino-2-methyl-4,5-dihydropyridazin-3(2H)-one (0.166 g, 1.3 mmol) in anhydrous toluene (15 mL) at 0 °C was added trimethylaluminum (0.65 mL, 2 M in toluene) under nitrogen. The mixture was stirred at room temperature for 2 h before methyl 5-(3-fluorobenzyl)picolinate (0.245 g, 1.0 mmol) was added. Reaction was stirred at 100 °C for 16 h. The reaction mixture was quenched with ice water (30 mL) and extracted with ethyl acetate (50 mL × 3). The combined organic layer was washed with brine (100 mL), dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μm column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give 5-(3-fluorobenzyl)-*N*-(1-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)picolinamide (0.170 g, 0.50 mmol, 50.0%) as a white solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 10.17 (s, 1H), 8.66 (s, 1H), 8.05 (d, *J* = 8.0 Hz, 1H), 7.93 (dd, *J* = 8.0, 1.8 Hz, 1H), 7.38-7.34 (m, 1H), 7.18-7.13 (m, 2H), 7.07-7.04 (m, 1H), 4.13 (s, 2H), 3.21 (t, *J* = 8.2 Hz, 2H), 3.17 (s, 3H), 2.48 (d, *J* = 8.2 Hz, 2H); LCMS (ESI) *m/z*: 341.1 [M+H]⁺.

Example 91. Preparation of *N*-(5-(3-chlorobenzyl)pyridin-2-yl)-1-methyl-1*H*-pyrazole-3-carboxamide (91)**Step 1: Preparation of 5-(3-chlorobenzyl)pyridin-2-amine**

5

To a solution of 1-(bromomethyl)-3-chlorobenzene (10.0 g, 49.0 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (10.8 g, 49.0 mmol), potassium carbonate (13.5 g, 98.1 mmol) in tetrahydrofuran (40 mL) and water (10 mL) was added tetrakis(triphenylphosphine)palladium(0) (5.65 g, 4.9 mmol) under nitrogen. The reaction mixture was heated to 90 °C and stirred for 2 h. The volatiles were removed under reduced pressure. Aqueous layer was acidified to pH = 1-3 with 1 N hydrogen chloride and extracted with ethyl acetate (50 mL). The aqueous layer was then adjusted to pH = 8-10 with aqueous sodium bicarbonate and extracted with dichloromethane (50 mL x 2). The combined dichloromethane layers were dried over sodium sulfate, filtered and concentrated to give 5-(3-chlorobenzyl)pyridin-2-amine as a yellow oil (8.0 g, crude); LCMS (ESI) *m/z*: 219.1 [M+H]⁺.

15

Step 2: Preparation of *N*-(5-(3-chlorobenzyl)pyridin-2-yl)-1-methyl-1*H*-pyrazole-3-carboxamide

To a solution of 1-methyl-1*H*-pyrazole-3-carboxylic acid (0.100 g, 0.793 mmol), *N,N*-diisopropylethylamine (0.307 g, 2.38 mmol) in tetrahydrofuran (4 mL) at 20 °C was added 1-[*bis*(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.452 g, 1.19 mmol). The reaction was stirred for 20 minutes before a solution of 5-(3-chlorobenzyl)pyridin-2-amine (0.173 g, 0.793 mmol) in tetrahydrofuran (1.0 mL) was added. The solution was stirred at 20 °C for 16 h. The volatiles were removed under reduced pressure and the residue was added to a mixture of dichloromethane (50 mL) and water (50 mL). The organic layer was collected, dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μm column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give *N*-(5-(3-chlorobenzyl)pyridin-2-yl)-1-methyl-1*H*-pyrazole-3-carboxamide (0.0927 g, 0.285 mmol, 36%) as a white solid. ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 9.51 (s, 1H), 8.29 (s, 1H), 8.10 (d, *J* = 10.5 Hz,


25

30


1H), 7.88 (d, $J = 2.5$ Hz, 1H), 7.71-7.74 (m, 1H), 7.23-7.35 (m, 4H), 6.84 (d, $J = 2.5$ Hz, 1H), 3.96 (s, 5H); LCMS (ESI) m/z : 327.1 $[M+H]^+$.

Example 92. Preparation of

5 *N*-(5-(3,4-difluorobenzyl)pyridin-2-yl)-1-methyl-1*H*-pyrazole-3-carboxamide (92)




Step 1: Preparation of *N*-(5-(3,4-difluorobenzyl)pyridin-2-yl)-1-methyl-1*H*-pyrazole-3-carboxamide




- 10 A mixture of 5-(3,4-difluorobenzyl)pyridin-2-amine (0.100 g, 0.45 mmol),
1-methyl-1*H*-pyrazole-3-carboxylic acid (0.048 g, 0.38 mmol),
1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.173 g,
0.45 mmol) and *N,N*-diisopropylethylamine (0.147 g, 1.14 mmol) in anhydrous *N,N*-dimethylformamide
(4.00 mL) was stirred at 20 °C for 2 h. The reaction mixture was extracted with ethyl acetate (20 mL x 2).
15 The combined organic layers were washed with water (50 mL), brine (50 mL), dried over anhydrous
sodium sulfate, filtered and concentrated *in vacuo*. The crude sample was dissolved in minimal
N,N-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μ m column;
acetonitrile/0.01% aqueous trifluoroacetic acid) to give
N-(5-(3,4-difluorobenzyl)pyridin-2-yl)-1-methyl-1*H*-pyrazole-3-carboxamide (0.0258 g, 0.08 mmol, 21%)
20 as a white solid. $[M+H]^+$. ^1H NMR (400 MHz, Dimethylsulfoxide- d_6) δ 10.03 (s, 1H), 8.32 (d, $J = 1.5$ Hz,
1H), 8.09 (d, $J = 8.6$ Hz, 1H), 7.88 (dd, $J = 24.1, 5.4$ Hz, 1H), 7.56 - 7.23 (m, 2H), 7.23 - 7.01 (m, 1H),
6.87 (d, $J = 2.3$ Hz, 1H), 4.14 - 3.77 (m, 5H) ; LCMS (ESI) m/z : 329.1

Example 93. Preparation of *N*-(5-(4-fluorobenzyl)pyridin-2-yl)-1-methyl-1*H*-pyrazole-3-carboxamide (93)



Step 1: Preparation of *N*-(5-(4-fluorobenzyl)pyridin-2-yl)-1-methyl-1*H*-pyrazole-3-carboxamide




- A mixture of 5-(4-fluorobenzyl)pyridin-2-amine (0.100 g, 0.50 mmol),
30 1-methyl-1*H*-pyrazole-3-carboxylic acid (0.069 g, 0.55 mmol),
1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.232 g,
0.61 mmol) and *N,N*-diisopropylethylamine (213 mg, 1.65 mmol) in anhydrous *N,N*-dimethylformamide
(4.00 mL) was stirred at 20 °C for 2 h. The reaction was diluted with water and extracted with ethyl


acetate (20 mL x 2). The combined organic layers were washed with water (50 mL) and brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified by prep-HPLC (Boston C18 21*250 mm 10 μ m column. The mobile phase was acetonitrile/10 mM ammonium acetate aqueous solution) to give

- 5 *N*-(5-(4-fluorobenzyl)pyridin-2-yl)-1-methyl-1*H*-pyrazole-3-carboxamide (0.0437 g, 0.14 mmol, 28%) as a white solid. ^1H NMR (400 MHz, Dimethylsulfoxide- d_6) δ 9.50 (s, 1H), 8.26 (d, J = 2.1 Hz, 1H), 8.09 (d, J = 8.5 Hz, 1H), 7.88 (d, J = 2.3 Hz, 1H), 7.69 (dd, J = 8.5, 2.3 Hz, 1H), 7.30 (dd, J = 8.5, 5.6 Hz, 2H), 7.22 - 7.04 (m, 2H), 6.84 (d, J = 2.3 Hz, 1H), 4.10 - 3.73 (m, 5H); LCMS (ESI) m/z : 311.1 $[\text{M}+\text{H}]^+$.

10 **Example 94. Preparation of *N*-(5-(3-chlorobenzyl)pyridin-2-yl)-1-methyl-1*H*-pyrazole-4-carboxamide (94)**




- 15 Step 1: Preparation of *N*-(5-(3-chlorobenzyl)pyridin-2-yl)-1-methyl-1*H*-pyrazole-4-carboxamide




- To a solution of 1-methyl-1*H*-pyrazole-4-carboxylic acid (0.100 g, 0.793 mmol), 5-(3-chlorobenzyl)pyridin-2-amine (0.173 g, 0.793 mmol) in pyridine (4 mL) at 20 °C was added phosphorus oxychloride (0.361 g, 2.38 mmol). The reaction mixture was stirred at room temperature for 1 h. The volatiles were removed under reduced pressure and the solid was dissolved in dichloromethane (10.0 mL). The resulting solution was added to a mixture of dichloromethane (50 mL) and water (50 mL). The organic layer was collected, dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μ m column. The mobile was acetonitrile/0.01% aqueous trifluoroacetic acid) to offer
- 20 *N*-(5-(3-chlorobenzyl)pyridin-2-yl)-1-methyl-1*H*-pyrazole-4-carboxamide (0.0504 g, 0.15 mmol, 19%) as a white solid. ^1H NMR (400 MHz, Dimethylsulfoxide- d_6) δ 10.53 (s, 1H), 8.42 (s, 1H), 8.29-8.29 (d, J = 2.5 Hz, 1H), 8.12 (s, 1H), 8.06-8.08 (d, J = 9.0 Hz, 1H), 7.69-7.72 (q, J = 3.6 Hz, 1H), 7.23-7.35 (m, 4H), 3.96 (s, 2H), 3.88 (s, 3H); LCMS (ESI) m/z : 327.1 $[\text{M}+\text{H}]^+$.
- 25

30 **Example 95. Preparation of 5-(3-fluorobenzyl)-*N*-(1-methyl-1*H*-pyrazol-3-yl)picolinamide (95)**



Step 1: Preparation of 5-(3-fluorobenzyl)-*N*-(1-methyl-1*H*-pyrazol-3-yl)picolinamide




To a solution of 1-methyl-1*H*-pyrazol-3-amine (0.159 g, 1.63 mmol) in anhydrous toluene (12 mL) at room temperature was added trimethylaluminum (0.82 mL, 1.63 mmol, 2 *M* in toluene) under nitrogen.

The reaction mixture was stirred at room temperature for 1 h before methyl 5-(3-fluorobenzyl)picolinate (0.200 g, 0.82 mmol) was added and stirred at 100 °C for 16 h. The reaction mixture was cooled to room temperature diluted with water (200 mL). The aqueous phase was extracted with ethyl acetate (50 mL × 3). The combined organic layers were washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μm column. The mobile phase was acetonitrile/10 mM ammonium acetate aqueous solution) to give


5-(3-fluorobenzyl)-*N*-(1-methyl-1*H*-pyrazol-3-yl)picolinamide (95.0 mg, 0.31 mmol, 37%) as a white solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 10.33 (s, 1H), 8.65 (d, *J* = 2.0 Hz, 1H), 8.06 (d, *J* = 8.0 Hz, 1H), 7.91 (dd, *J*₁ = 2.5 Hz, *J*₂ = 8.5 Hz, 1H), 7.64 (d, *J* = 2.0 Hz, 1H), 7.38-7.34 (m, 1H), 7.19-7.14 (m, 2H), 7.07-7.02 (m, 1H), 6.60 (d, *J* = 2.0 Hz, 1H), 4.11 (s, 2H), 3.77 (s, 3H); LCMS (ESI) *m/z*: 311.1 [*M*+*H*]⁺.

Example 96. Preparation of

N-(5-(3-cyano-5-fluorobenzyl)pyridin-2-yl)-1-methyl-1*H*-pyrazole-3-carboxamide (96)



Step 1: Preparation of *N*-(5-(3-cyano-5-fluorobenzyl)pyridin-2-yl)-1-methyl-1*H*-pyrazole-3-carboxamide



To a solution of 1-methyl-1*H*-pyrazole-3-carboxylic acid (50 mg, 0.397 mmol) and diisopropylethylamine (154 mg, 1.19 mmol) in tetrahydrofuran (4.0 mL) at 20 °C was added 1-[*bis*(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (226 mg, 0.595 mmol). The reaction mixture was stirred for 20 minutes before a solution of 3-((6-aminopyridin-3-yl)methyl)-5-fluorobenzonitrile (90 mg, 0.397 mmol) in tetrahydrofuran (1.0 mL) was added. The reaction solution was stirred at 20 °C for 16 h. The volatiles were removed under reduced pressure and the crude residue was added to a mixture of dichloromethane (50 mL) and water (50 mL). The combined organic layers were collected, dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μm column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give *N*-(5-(3-cyano-5-fluorobenzyl)pyridin-2-yl)-1-methyl-1*H*-pyrazole-3-carboxamide as a white solid (29.3 mg, 0.087 mmol, 22%). ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 10.48 (s, 1H), 8.41 (s, 1H), 8.32 (d, *J*


= 1.8 Hz, 1H), 8.10 (d, J = 8.9 Hz, 2H), 7.77 - 7.66 (m, 2H), 7.57 (d, J = 9.4 Hz, 1H), 4.02 (s, 2H), 3.87 (s, 2H); LCMS (ESI) m/z : 336.1 $[M+H]^+$.

Example 97. Preparation of

5 *N*-(5-(3,5-difluorobenzyl)pyridin-2-yl)-1-ethyl-1*H*-pyrazole-3-carboxamide (97)




Step 1: Preparation of *N*-(5-(3,5-difluorobenzyl)pyridin-2-yl)-1-ethyl-1*H*-pyrazole-3-carboxamide




A mixture of 5-(3,5-difluorobenzyl)pyridin-2-amine (0.100 g, 0.45 mmol),
 1-ethyl-1*H*-pyrazole-3-carboxylic acid (0.053 g, 0.38 mmol),
 1-*bis*(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.173 g, 0.45 mmol) and *N,N*-diisopropylethylamine (0.147 g, 1.14 mmol) in anhydrous *N,N*-dimethylformamide (4.00 mL) was stirred at 20 °C for 2 h. The reaction solution was extracted with ethyl acetate (20 mL x 20). The combined organic layers were washed with water (50 mL) and brine (50 mL) were dried over
 anhydrous sodium sulfate, filtered and concentrated *in vacuo*. The crude sample was dissolved in
 minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μ m column;
 acetonitrile/0.01% aqueous trifluoroacetic acid) to give
N-(5-(3,5-difluorobenzyl)pyridin-2-yl)-1-ethyl-1*H*-pyrazole-3-carboxamide (0.0304 g, 0.09 mmol, 23%) as
 a white solid. ^1H NMR (400 MHz, Dimethylsulfoxide- d_6) δ 9.68 (s, 1H), 8.32 (d, J = 1.8 Hz, 1H), 8.10 (d, J
 = 8.5 Hz, 1H), 7.94 (s, 1H), 7.79 (dd, J = 8.5, 2.2 Hz, 1H), 7.13 - 6.95 (m, 3H), 6.85 (d, J = 2.3 Hz, 1H),
 4.26 (q, J = 7.3 Hz, 2H), 3.98 (s, 2H), 1.44 (t, J = 7.3 Hz, 3H); LCMS (ESI) m/z : 343.1 $[M+H]^+$.

Example 98. Preparation of

25 *N*-(5-(3,4-difluorobenzyl)pyridin-2-yl)-1-ethyl-1*H*-pyrazole-3-carboxamide (98)



Step 1: Preparation of *N*-(5-(3,4-difluorobenzyl)pyridin-2-yl)-1-ethyl-1*H*-pyrazole-3-carboxamide



A mixture of 5-(3,4-difluorobenzyl)pyridin-2-amine (0.100 g, 0.45 mmol),
 1-ethyl-1*H*-pyrazole-3-carboxylic acid (0.053 g, 0.38 mmol),
 1-*bis*(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.173 g, 0.45 mmol) and *N,N*-diisopropylethylamine (0.147 g, 1.14 mmol) in anhydrous *N,N*-dimethylformamide


(4.00 mL) was stirred at 20 °C for 2 h. The reaction was extracted with ethyl acetate (20 mL x 2). The combined organic layers were washed with water (50 mL) and brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo*. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 µm column;

acetonitrile/0.01% aqueous trifluoroacetic acid) to give


N-(5-(3,4-difluorobenzyl)pyridin-2-yl)-1-ethyl-1*H*-pyrazole-3-carboxamide (28.7 mg, 0.08 mmol, 22%) as a white solid. ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 10.00 (s, 1H), 8.32 (d, *J* = 1.7 Hz, 1H), 8.09 (d, *J* = 8.6 Hz, 1H), 7.96 (d, *J* = 2.3 Hz, 1H), 7.85 (dd, *J* = 8.6, 1.9 Hz, 1H), 7.38 (ddd, *J* = 17.0, 9.3, 5.4 Hz, 2H), 7.21 - 7.06 (m, 1H), 6.87 (d, *J* = 2.3 Hz, 1H), 4.27 (q, *J* = 7.3 Hz, 2H), 3.98 (s, 2H), 1.62 - 1.23 (m, 3H); LCMS (ESI) *m/z*: 343.2 [M+H]⁺.

Example 99. Preparation

N-(5-(3-chloro-5-fluorobenzyl)pyridin-2-yl)-1-ethyl-1*H*-pyrazole-3-carboxamide (99)




Step 1: Preparation of *N*-(5-(3-chloro-5-fluorobenzyl)pyridin-2-yl)-1-ethyl-1*H*-pyrazole-3-carboxamide




To a solution of 5-(3-chloro-5-fluorobenzyl)pyridin-2-amine (0.189 g, 0.8 mmol), 1-ethyl-1*H*-pyrazole-3-carboxylic acid (0.168 g, 1.2 mmol) and *N,N*-diisopropylethylamine (0.310 g, 2.4 mmol) in *N,N*-dimethylformamide (5 mL) at room temperature was added 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.456 g, 1.2 mmol) under nitrogen. The reaction mixture was stirred at 90 °C for 3 h. The reaction mixture was diluted with ethyl acetate (80 mL) and washed with brine (30 mL x 3). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 µm column. The mobile phase was acetonitrile/10 mM ammonium acetate aqueous solution) to give

N-(5-(3-chloro-5-fluorobenzyl)pyridin-2-yl)-1-ethyl-1*H*-pyrazole-3-carboxamide (44.7 mg, 0.13 mmol, 26%) as a pale white solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 9.55 (s, 1H), 8.32 (s, 1H), 8.11 (d, *J* = 8.5 Hz, 1H), 7.94 (d, *J* = 2.0 Hz, 1H), 7.76 (dd, *J*₁ = 1.5 Hz, *J*₂ = 8.0 Hz, 1H), 7.25-7.28 (m, 2H), 7.17 (d, *J* = 9.5 Hz, 1H), 6.85 (d, *J* = 2.0 Hz, 1H), 4.25 (dd, *J*₁ = 7.0 Hz, *J*₂ = 14.5 Hz, 2H), 3.97 (s, 2H), 1.43 (t, *J* = 7.0 Hz, 3H); LCMS (ESI) *m/z*: 359.1 [M+H]⁺.

Example 100. Preparation *N*-(5-(3-chlorobenzyl)pyridin-2-yl)-1-ethyl-1*H*-pyrazole-3-carboxamide (100)

Step 1: Preparation of *N*-(5-(3-chlorobenzyl)pyridin-2-yl)-1-ethyl-1*H*-pyrazole-3-carboxamide




5

To a solution of 5-(3-chlorobenzyl)pyridin-2-amine (0.110 g, 0.5 mmol), 1-ethyl-1*H*-pyrazole-3-carboxylic acid (0.105 g, 0.75 mmol) and *N,N*-diisopropylethylamine (0.194 g, 1.5 mmol) in *N,N*-dimethylformamide (3 mL) at room temperature was added 1-[*bis*(dimethylamino) methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.285 g, 0.75 mmol) under nitrogen. The reaction mixture was stirred at 90 °C for 3 h before it was diluted with ethyl acetate (80 mL) and washed with brine (30 mL x 3). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified via prep-HPLC (BostonC18 21*250 mm 10 µm column. The mobile phase was acetonitrile/10 mM ammonium acetate aqueous solution) to give *N*-(5-(3-chlorobenzyl)pyridin-2-yl)-1-ethyl-1*H*-pyrazole-3-carboxamide (44.7 mg, 0.13 mmol, 26%) as a white solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 9.54 (s, 1H), 8.30 (d, *J* = 2.0 Hz, 1H), 8.10 (d, *J* = 8.5 Hz, 1H), 7.94 (d, *J* = 2.0 Hz, 1H), 7.73 (dd, *J*₁ = 3.0 Hz, *J*₂ = 8.5 Hz, 1H), 7.33-7.36 (m, 2H), 7.24-7.29 (m, 2H), 6.85 (d, *J* = 2.5 Hz, 1H), 4.25 (dd, *J*₁ = 7.5 Hz, *J*₂ = 14.5 Hz, 2H), 3.97 (s, 2H), 1.44 (t, *J* = 7.0 Hz, 3H); LCMS (ESI) *m/z*: 341.1 [M+H]⁺.


10

15

20

Example 101. Preparation of 1-ethyl-*N*-(5-(3-fluorobenzyl)pyridin-2-yl)-1*H*-pyrazole-3-carboxamide (101)

Step 1: Preparation of 1-ethyl-*N*-(5-(3-fluorobenzyl)pyridin-2-yl)-1*H*-pyrazole-3-carboxamide




To a solution of 1-ethyl-1*H*-pyrazole-3-carboxylic acid (111 mg, 0.793 mmol) and diisopropylethylamine (307 mg, 2.379 mmol) in tetrahydrofuran (4.0 mL) at 20 °C was added


25

1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (452 mg, 1.19 mmol). The reaction mixture was stirred for 20 minutes before a solution of 5-(3-fluorobenzyl)pyridin-2-amine (160 mg, 0.793 mmol) in tetrahydrofuran (1.0 mL) was added. The solution mixture was stirred at 20 °C for 16 h. The volatiles were removed under reduced pressure and the residue was added to a mixture of dichloromethane (50 mL) and water (50 mL). The combined organic layers were collected, dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 µm column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give 1-ethyl-*N*-(5-(3-fluorobenzyl)pyridin-2-yl)-1*H*-pyrazole-3-carboxamide (43.0 mg, 0.132 mmol, 16.7%) as a white solid. ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 9.51 (s, 1H), 8.27 (d, *J* = 2.0 Hz, 1H), 8.08 (d, *J* = 8.5 Hz, 1H), 7.92 (d, *J* = 2.3 Hz, 1H), 7.71 - 7.70 (dd, *J* = 8.5, 2.2 Hz, 1H), 7.33 - 7.30 (dd, *J* = 14.3, 8.0 Hz, 1H), 7.10 - 7.08 (t, *J* = 7.0 Hz, 2H), 7.02 - 7.01 (dd, *J* = 11.9, 5.3 Hz, 1H), 6.82 (d, *J* = 2.3 Hz, 1H), 4.23 - 4.21 (q, *J* = 7.3 Hz, 2H), 3.95 (s, 2H), 1.41 - 1.40 (t, *J* = 7.3 Hz, 3H); LCMS (ESI) *m/z*: 325.1 [M+H]⁺.


Example 102. Preparation of *N*-(5-(3-fluorobenzyl)pyridin-2-yl)-5-methylpyrimidine-2-carboxamide (102)




Step 1: Preparation of 1-ethyl-*N*-(5-(4-fluorobenzyl)pyridin-2-yl)-1*H*-pyrazole-3-carboxamide



To solution of 1-ethyl-1*H*-pyrazole-3-carboxylic acid (104 mg, 0.742 mmol) and diisopropylethylamine (288 mg, 2.226 mmol) in tetrahydrofuran (4 mL) at 20 °C was added 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (423 mg, 1.113 mmol). The reaction mixture was stirred for 20 minutes before a solution of 5-(4-fluorobenzyl)pyridin-2-amine (150 mg, 0.742 mmol) in tetrahydrofuran (1.0 mL) was added. The reaction solution was heated to 90 °C and stirred for 2 h. The volatiles were removed under the reduced pressure and the residue was added to a mixture of dichloromethane (50 mL) and water (50 mL). The organic layer was collected, dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified by prep-HPLC (Boston C18 21*250 mm 10 µm column. The mobile phase was acetonitrile/10 mM ammonium acetate aqueous solution) to give 1-ethyl-*N*-(5-(4-fluorobenzyl)pyridin-2-yl)-1*H*-pyrazole-3-carboxamide (89.9 mg, 0.28 mmol, 37%) as a white solid. ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 9.51 (s, 1H), 8.27 (d, *J* = 4.0 Hz, 1H), 8.09 (d, *J* = 8.0 Hz, 1H), 7.94 (d, *J* = 4.0 Hz, 1H), 7.70 (q, *J* = 2.6 Hz, 1H), 7.30 (q, *J* = 2.6 Hz, 2H), 7.13 (t, *J* = 10.0 Hz, 2H), 6.84 (s, 1H), 4.25 (q, *J* = 8.0 Hz, 1H), 3.94 (s, 2H), 1.43 (t, *J* = 8.0 Hz, 3H); LCMS (ESI) *m/z*: 325.1 [M+H]⁺.

Example 103. Preparation of***N*-(5-(3-chlorobenzyl)pyridin-2-yl)-5-methyl-1,3,4-thiadiazole-2-carboxamide (103)**

Step 1: Preparation of *N*-(5-(3-chlorobenzyl)pyridin-2-yl)-5-methyl-1,3,4-thiadiazole-2-carboxamide




5


To a solution of 5-(3-chlorobenzyl)pyridin-2-amine (0.253 g, 1.16 mmol) in toluene (10 mL) at 20 °C was added trimethylaluminum (0.58 mL, 1.16 mmol, 2 M in toluene) under argon. The reaction mixture was stirred at 20 °C for 1 h before a solution of ethyl 5-methyl-1,3,4-thiadiazole-2-carboxylate (0.100 g, 0.581 mmol) in toluene (15 mL) was added. The reaction solution was stirred at 100 °C for 2 h. The volatiles were removed under reduced pressure and reaction was diluted with water (50 mL) and dichloromethane (50 mL). The organic layer was collected, dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 μm column. The mobile was acetonitrile/0.01% aqueous trifluoroacetic acid) to offer *N*-(5-(3-chlorobenzyl)pyridin-2-yl)-5-methyl-1,3,4-thiadiazole-2-carboxamide (0.0731 g, 0.21 mmol, 37%) as a white solid. ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 10.66 (s, 1H), 8.37 (s, 1H), 7.96-7.98 (d, *J* = 8.8 Hz, 1H), 7.75-7.78 (m, 1H), 7.24-7.36 (m, 4H), 3.99 (s, 2H), 2.83 (s, 3H); LCMS (ESI) *m/z*: 345.1 [*M*+*H*]⁺.

10

15

Example 104. Preparation of***N*-(5-(3-chlorobenzyl)pyridin-2-yl)-1-isopropyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (104)**

Step 1: Preparation of *N*-(5-(3-chlorobenzyl)pyridin-2-yl)-5-methyl-1,3,4-oxadiazole-2-carboxamide




To a solution of 5-(3-chlorobenzyl)pyridin-2-amine (0.279 g, 1.28 mmol) in toluene (10 mL) at 20 °C was added trimethylaluminum (0.64 mL, 1.02 mmol, 2 M in toluene) under argon. The reaction mixture was stirred at 20 °C for 1 h before a solution of ethyl 5-methyl-1,3,4-oxadiazole-2-carboxylate (100 mg, 0.641 mmol) in toluene (15 mL) was added. The reaction solution was stirred at 100 °C for 1 h. The volatiles were removed under reduced pressure and the residue was quenched with water (50 mL) and

25


extracted with dichloromethane (50 mL). The organic layer was dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 μ m column. The mobile phase was acetonitrile/0.01% aqueous trifluoroacetic acid) to offer *N*-(5-(3-chlorobenzyl)pyridin-2-yl)-5-methyl-1,3,4-oxadiazole-2-carboxamide (0.109 g, 0.33 mmol, 51%) as a white solid. ^1H NMR (400 MHz, Dimethylsulfoxide- d_6) δ 11.05 (s, 1H), 8.37 (s, 1H), 7.93-7.95 (d, J = 8.4 Hz, 1H), 7.75-7.78 (m, 1H), 7.23-7.36 (m, 4H), 3.99 (s, 2H), 2.62 (s, 3H); LCMS (ESI) m/z : 329.0 $[\text{M}+\text{H}]^+$.

Example 105. Preparation of

N-(5-(3-chlorobenzyl)pyridin-2-yl)-1-methyl-5-oxo-4,5-dihydro-1*H*-pyrazole-3-carboxamide (105)




Step 1: Preparation of ethyl 5-hydroxy-1-methyl-1*H*-pyrazole-3-carboxylate



A mixture of methylhydrazine sulfate (7.2 g, 50.0 mmol), diethyl oxalacetate sodium salt (10.5 g, 50.0 mmol) in acetic acid (50 mL) and ethanol (100 mL) was stirred at 80 °C for 7 h. Ethanol was removed under reduced pressure and the residue was poured into water. The aqueous layers were extracted with ethyl acetate (200 mL x 3). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The crude material was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 1/1) to give ethyl 5-hydroxy-1-methyl-1*H*-pyrazole-3-carboxylate (5.20 g, 30.6 mmol, 61%) as a light-yellow solid. ^1H NMR (500 MHz, Dimethylsulfoxide- d_6) δ 11.40 (s, 1H), 5.76 (s, 1H), 4.20 (q, J = 7.0 Hz, 2H), 3.59 (s, 3H), 1.25 (t, J = 7.0 Hz, 3H); LCMS (ESI) m/z : 171.1 $[\text{M}+\text{H}]^+$.

Step 2: Preparation of *N*-(5-(3-chlorobenzyl)pyridin-2-yl)-5-hydroxy-1-methyl-1*H*-pyrazole-3-carboxamide




To a stirred solution of 5-(3-chlorobenzyl)pyridin-2-amine (218 mg, 1.0 mmol) in 1,4-dioxane (5 mL) under nitrogen at room temperature was added trimethylaluminum (2 M in toluene, 1.0 mL). The reaction mixture was stirred for 0.5 h before ethyl 5-hydroxy-1-methyl-1*H*-pyrazole-3-carboxylate (170 mg, 1.0 mmol) in 1,4-dioxane (5 mL) was added. The reaction solution was stirred at 80 °C for 2 h. The mixture was quenched with water and pH was adjusted to 1-2 with dilute hydrochloric acid. The solution mixture was concentrated, and the crude residue was purified by prep-HPLC x 2 (Boston C18 21*250 mm 10 μ m column. The mobile phase was acetonitrile/10 mM ammonium acetate aqueous solution) to afford

N-(5-(3-chlorobenzyl)pyridin-2-yl)-5-hydroxy-1-methyl-1*H*-pyrazole-3-carboxamide (0.0164 g, 0.05 mmol, 4.8%) as an off-white solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 9.23 (s, 1H), 8.24(d, *J* = 2.0 Hz, 1H), 8.08 (d, *J* = 8.5 Hz, 1H), 7.68 (dd, *J* = 8.5, 2.0 Hz, 1H), 7.35 (d, *J* = 2.0 Hz, 1H), 7.32 (d, *J* = 8.0 Hz, 1H), 7.27-7.22 (m, 2H), 5.45 (s, 1H), 3.94 (s, 2H), 3.50 (s, 3H); LCMS (ESI) *m/z*: 343.1/345.1 [*M*+*H*]⁺.


5

Example 106. Preparation of

N-(5-(3-fluorobenzyl)pyridin-2-yl)-5-hydroxy-1-methyl-1*H*-pyrazole-3-carboxamide (106)



Step 1: Preparation of ethyl 5-hydroxy-1-methyl-1*H*-pyrazole-3-carboxylate




10

A mixture of methylhydrazine sulfate (7.2 g, 50.0 mmol), diethyl oxalacetate sodium salt (10.5 g, 50.0 mmol) in acetic acid (50 mL) and ethanol (100 mL) was stirred at 80 °C for 7 h. Ethanol was removed under reduced pressure and the residue was poured into water. The aqueous layer was extracted with ethyl acetate (200 mL x 3). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The crude residue was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 1/1) to give ethyl 5-hydroxy-1-methyl-1*H*-pyrazole-3-carboxylate (5.20 g, 30.6 mmol, 61%) as a light-yellow solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 11.40 (s, 1H), 5.76 (s, 1H), 4.20 (q, *J* = 7.0 Hz, 2H), 3.59 (s, 3H), 1.25 (t, *J* = 7.0 Hz, 3H); LCMS (ESI) *m/z*: 171.1 [*M*+*H*]⁺.

15

Step 2: Preparation of *N*-(5-(3-fluorobenzyl)pyridin-2-yl)-5-hydroxy-1-methyl-1*H*-pyrazole-3-carboxamide



20

To a stirred solution of 5-(3-fluorobenzyl)pyridin-2-amine (202 mg, 1.0 mmol) in 1,4-dioxane (5 mL) at room temperature under nitrogen was added trimethylaluminum (1.0 mL, 2 M in toluene) dropwise. The reaction mixture was stirred for 0.5 h, before ethyl

5-hydroxy-1-methyl-1*H*-pyrazole-3-carboxylate (170 mg, 1.0 mmol) in 1,4-dioxane (5 mL) was added. The reaction solution was stirred at 80 °C for 2 h. The reaction mixture was quenched with water and pH was adjusted to ~1-2 with dilute hydrochloric acid and concentrated to dryness. The crude residue was purified by prep-HPLC x 2 (the crude sample was dissolved in minimal *N,N*-dimethylformamide and loaded onto Boston C18 21*250 mm 10 μm column. The mobile phase was acetonitrile/10 mM ammonium acetate aqueous solution) to afford


25

N-(5-(3-chlorobenzyl)pyridin-2-yl)-5-hydroxy-1-methyl-1*H*-pyrazole-3-carboxamide (0.052 g, 0.16 mmol, 16%) as an off-white solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 9.26 (s, 1H), 8.25 (d, *J* = 2.5 Hz,

30


1H), 8.07 (d, $J = 8.5$ Hz, 1H), 7.69 (dd, $J = 8.5, 2.5$ Hz, 1H), 7.36-7.31 (m, 1H), 7.12-7.09 (m, 2H), 7.03 (td, $J = 8.5, 2.0$ Hz, 1H), 5.61 (s, 1H), 3.95 (s, 2H), 3.56 (s, 3H); LCMS (ESI) m/z : 327.1 $[M+H]^+$.

Example 107. Preparation of *N*-(5-(3-fluorobenzyl)pyridin-2-yl)-5-methylisoxazole-3-carboxamide (107)



Step 1: Preparation of


N-(5-(3-fluorobenzyl)pyridin-2-yl)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide




To a solution of 5-methylisoxazole-3-carboxylic acid (100 mg, 0.787 mmol) and diisopropylethylamine (305 mg, 2.36 mmol) in tetrahydrofuran (5 mL) at 20 °C was added 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (449 mg, 1.18 mmol). The reaction mixture was stirred for 20 minutes before a solution of 5-(3-fluorobenzyl)pyridin-2-amine (159 mg, 0.787 mmol) in tetrahydrofuran (1.0 mL) was added. The reaction solution was stirred at 20 °C for 4 h. The volatiles were removed under reduced pressure and the residue was added to a mixture of dichloromethane (50 mL) and water (50 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The residue was purified by HPLC (the crude sample was dissolved in minimal *N,N*-dimethylformamide and loaded onto Boston C18 21*250 mm 10 μ m column. The mobile phase was acetonitrile/10 mM ammonium acetate aqueous solution) to give to offer *N*-(5-(3-fluorobenzyl)pyridin-2-yl)-5-methylisoxazole-3-carboxamide (42.8 mg, 0.14 mmol, 17%) as a white solid. ^1H NMR (400 MHz, Dimethylsulfoxide- d_6) δ 10.57 (s, 1H), 8.34 (s, 1H), 8.02 (d, $J = 12.0$ Hz, 1H), 7.75 (q, $J = 5.2$ Hz, 1H), 7.35 (q, $J = 8.0$ Hz, 1H), 7.01-7.14 (m, 3H), 6.74 (s, 1H), 3.99 (s, 2H), 3.45 (s, 3H); LCMS (ESI) m/z : 312.1 $[M+H]^+$.

Example 108. Preparation of

N-(5-(3-chlorobenzyl)pyridin-2-yl)-4-methyl-5-oxo-4,5-dihydropyrazine-2-carboxamide (108)




Step 1: Preparation of methyl 4-methyl-5-oxo-4,5-dihydropyrazine-2-carboxylate



A solution of methyl 5-oxo-4,5-dihydropyrazine-2-carboxylate (1.00 g, 6.5 mmol), iodomethane (0.767 g, 5.4 mmol) and potassium carbonate (1.49 g, 10.8 mmol) in acetonitrile (27 mL) was stirred at 85 °C for 4 h. The reaction mixture was extracted with ethyl acetate (50 mL x 2). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate, filtered and concentrated. Purification by column chromatography (silica gel, petroleum ether/ethyl acetate = 1/1) gives methyl 4-methyl-5-oxo-4,5-dihydropyrazine-2-carboxylate (0.480 g, 2.97 mmol, 45.7%) as a white solid. LCMS (ESI) m/z : 169.1 $[M+H]^+$.


Step 2: Preparation of 4-methyl-5-oxo-4,5-dihydropyrazine-2-carboxylic acid





To a solution of methyl 4-methyl-5-oxo-4,5-dihydropyrazine-2-carboxylate (0.430 g, 2.56 mmol) in methanol (9 mL) and water (3 mL) was added sodium hydroxide (0.205 g, 5.12 mmol). The reaction mixture was stirred at room temperature for 1 h before aqueous 1 *N* hydrogen chloride was added and the pH was adjusted to 6. Concentration under reduced pressure gives 4-methyl-5-oxo-4,5-dihydropyrazine-2-carboxylic acid (0.660 g, crude) as a white solid. LCMS (ESI) m/z : 155.1 $[M+H]^+$.

Step 3: Preparation of


N-(5-(3-chlorobenzyl)pyridin-2-yl)-4-methyl-5-oxo-4,5-dihydropyrazine-2-carboxamide




A solution of 4-methyl-5-oxo-4,5-dihydropyrazine-2-carboxylic acid (0.154 g, 1.0 mmol), 5-(3-chlorobenzyl)pyridin-2-amine (0.260 g, 1.2 mmol), 1-[*bis*(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.570 g, 1.5 mmol) and *N,N*-diisopropylethylamine (0.387 g, 3 mmol) in *N,N*-dimethylformamide (4 mL) was stirred at room temperature for 2 h and then at 90 °C for 1 h. The reaction mixture was cooled to room temperature and the resulting precipitate was filtered and washed with water. Freeze drying yields *N*-(5-(3-chlorobenzyl)pyridin-2-yl)-4-methyl-5-oxo-4,5-dihydropyrazine-2-carboxamide (0.0756 g, 0.214 mmol, 21.4%) as a white solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 9.78 (s, 1H), 8.61 (s, 1H), 8.30 (d, *J* = 1.5 Hz, 1H), 8.13 (d, *J* = 8.5 Hz, 1H), 8.04 (s, 1H), 7.75 (dd, *J* = 8.4, 2.0 Hz, 1H), 7.35 - 7.32 (m, 2H), 7.28-7.23 (m, 2H), 3.97 (s, 2H), 3.55 (s, 3H); LCMS (ESI) m/z : 355.1 $[M+H]^+$.

Example 109. Preparation of**5-(3-fluorobenzyl)-*N*-(2-methyl-3-oxo-2,3-dihydropyridazin-4-yl)picolinamide (109)****5 Step 1: Preparation of 5-(3-fluorobenzyl)picolinic acid**

To a solution of methyl 5-(3-fluorobenzyl)picolinate (0.5 g, 2.04 mmol) in tetrahydrofuran (6 mL), at 0 °C was added aqueous sodium hydroxide solution (10 mL, 10 mmol, 1 *M*) dropwise. The reaction mixture was stirred at room temperature for 16 h before it was diluted with ethyl acetate/water (20 mL/ 20 mL) mixture and separated. The aqueous layer was acidified with 1 *M* hydrochloric acid aqueous solution (pH 2~3) and extracted with ethyl acetate (20 mL x 2). The combined organic extracts were washed with brine (20 mL), dried over sodium sulfate, filtered and concentrated to give 5-(3-fluorobenzyl)picolinic acid (0.41 g, 1.77 mmol, 87%) as a white solid. LCMS (ESI) *m/z*: 232.1 [*M*+*H*]⁺.

15 Step 2: Preparation of 4-amino-2-methylpyridazin-3(2H)-one

To a solution of 4,5-dichloro-2-methylpyridazin-3(2H)-one (1.5 g, 8.38 mmol) in ethanol (55 mL) at 85 °C was added hydrazine hydrate (4.2 g, 83.8 mmol). The reaction mixture was stirred for 16 h. The volatiles were removed and the crude residue was purified by Combi-Flash (Biotage, 40 g silica gel, eluted with ethyl acetate in petroleum ether from 40% to 60%) to give 4-amino-2-methylpyridazin-3(2H)-one (0.63 g, 5.04 mmol, 60.2%) as a yellow solid. LCMS (ESI) *m/z*: 126.2 [*M*+*H*]⁺.

Step 3: Preparation of 5-(3-fluorobenzyl)-*N*-(2-methyl-3-oxo-2,3-dihydropyridazin-4-yl)picolinamide

To a mixture of 5-(3-fluorobenzyl)picolinic acid (0.2 g, 0.86 mmol) and 4-amino-2-methylpyridazin-3(2H)-one (0.1 g, 0.86 mmol) in dry pyridine (8 mL) was added phosphorus oxychloride (0.24 mL, 2.60 mmol) dropwise. The reaction mixture was stirred at room temperature for 2 h.


The volatiles were removed and the crude residue was diluted with dichloromethane/water (20 mL/20 mL) mixture and extracted with dichloromethane (20 mL x 2) twice. The combined organic layers were dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal

N,N-dimethylformamide and purified by prep-HPLC (Boston C18 21*250 mm 10 µm column. The mobile phase was acetonitrile/10 mM ammonium acetate aqueous solution) to give


5-(3-fluorobenzyl)-*N*-(2-methyl-3-oxo-2,3-dihydropyridazin-4-yl)picolinamide (0.095 g, 0.28 mmol, 32%) as a white solid. ¹H NMR (500 MHz, trifluoroacetic acid-*d*) δ 9.42 (s, 1H), 9.31 (d, 1H, *J* = 8.5 Hz), 9.13 (d, 1H, *J* = 8 Hz), 9.08 (d, 1H, *J* = 5 Hz), 8.80 (d, 1H, *J* = 5 Hz), 7.87-7.96 (m, 1H), 7.52-7.61 (m, 2H), 7.46 (d, 1H, *J* = 9 Hz), 4.89 (s, 2H), 4.60 (s, 3H); LCMS (ESI) *m/z*: 339.1 [M+H]⁺.

Example 110. Preparation of

N-(5-(3-chlorobenzyl)pyridin-2-yl)-4-methoxy-2-(methoxymethyl)pyrimidine-5-carboxamide (110)




Step 1: Preparation of ethyl 4-hydroxy-2-(methoxymethyl)pyrimidine-5-carboxylate



A mixture of diethyl 2-(ethoxymethylene)malonate (5 g, 23.2 mmol), 2-methoxyacetimidamide hydrochloride (2.88 g, 23.2 mmol) and sodium ethoxide (3.15 g, 46.3 mmol) in anhydrous ethanol (200 mL) was stirred at 90 °C for 17 h. The reaction mixture was concentrated, to give ethyl

4-hydroxy-2-(methoxymethyl)pyrimidine-5-carboxylate (4 g, 18.8 mmol, 81%) as a white solid. LCMS (ESI) *m/z*: 213.1 [M+H]⁺.

Step 2: Preparation of ethyl 4-methoxy-2-(methoxymethyl)pyrimidine-5-carboxylate




A mixture of ethyl 4-hydroxy-2-(methoxymethyl)pyrimidine-5-carboxylate (1.6 g, 7.55 mmol), iodomethane (1.61 g, 11.32 mmol) and potassium carbonate (2.08 g, 15.1 mmol) in anhydrous *N,N*-dimethylformamide (30 mL) was stirred at 20 °C for 17 h. The reaction mixture was diluted with water and extracted with ethyl acetate (100 mL x 2). The combined organic layers were washed with water (200 mL) and brine (200 mL), dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo*. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 µm column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give ethyl

4-methoxy-2-(methoxymethyl)pyrimidine-5-carboxylate (0.380 g, 1.67 mmol, 22%) as a white solid. LCMS (ESI) m/z : 227.1 $[M+H]^+$.

Step 3: Preparation of

5 *N*-(5-(3-chlorobenzyl)pyridin-2-yl)-4-methoxy-2-(methoxymethyl)pyrimidine-5-carboxamide




To a mixture of 5-(3-chlorobenzyl)pyridin-2-amine (0.194 g, 0.88 mmol) in dry 1,4-dioxane (2 mL) was added trimethylaluminum (0.44 mL, 0.88 mmol, 2 M in toluene). The mixture was stirred at 20 °C for 0.5 h before a solution of ethyl 4-methoxy-2-(methoxymethyl)pyrimidine-5-carboxylate (0.050 g, 0.22 mmol) in dry 1,4-dioxane (2 mL) was added. The reaction mixture and stirred at 100 °C for 17 h. The reaction solution was extracted with ethyl acetate (20 mL x 2). The combined organic layers were washed with water (50 mL) and brine (50 mL) dried over anhydrous sodium sulfate, filtered and concentrated *in vacuo*. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μ m column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give


15 *N*-(5-(3-chlorobenzyl)pyridin-2-yl)-4-methoxy-2-(methoxymethyl)pyrimidine-5-carboxamide (2.0 mg, 0.005 mmol, 2.2%) as a white solid. ^1H NMR (500 MHz, Dimethylsulfoxide- d_6) δ 11.68 (s, 1H), 8.80 (s, 1H), 8.31 (d, J = 1.8 Hz, 1H), 8.18 (d, J = 8.5 Hz, 1H), 7.73 (dd, J = 8.5, 2.2 Hz, 1H), 7.42 - 7.17 (m, 4H), 4.63 (s, 2H), 3.98 (s, 2H), 3.58 (s, 3H), 3.39 (s, 3H); LCMS (ESI) m/z : 399.1 $[M+H]^+$.

20 **Example 111. Preparation of**

N-(5-(3-chloro-5-fluorobenzyl)pyridin-2-yl)-6-(hydroxymethyl)nicotinamide (111)



Step 1: Preparation of *N*-(5-(3-chloro-5-fluorobenzyl)pyridin-2-yl)-6-(hydroxymethyl)nicotinamide



25 To a solution of 5-(3-chloro-5-fluorobenzyl)pyridin-2-amine (0.227 g, 0.96 mmol) in toluene (5 mL at room temperature) was added trimethylaluminum (0.5 mL, 1.0 mmol, 2 M in toluene) slowly under argon. The reaction mixture was stirred at room temperature for 1 h before methyl

6-((*tert*-butyldimethylsilyloxy)methyl)nicotinate (0.225 g, 0.8 mmol) in toluene (5 mL) was added. The resulting mixture was heated to 100 °C and stirred for 3 h. Reaction was quenched with methanol and

30 aqueous 2 N hydrochloric acid. The volatiles were removed *in vacuo*. Water (20 mL) was added and the mixture was extracted with dichloromethane (50 mL x 3). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal


N,N-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μ m column. The mobile phase was acetonitrile/0.01% aqueous trifluoroacetic acid.) to give

N-(5-(3-chloro-5-fluorobenzyl)pyridin-2-yl)-6-(hydroxymethyl)nicotinamide (0.113 g, 0.30 mmol, 38%) as a white solid. ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 11.11 (s, 1H), 9.07 (s, 1H), 8.41 (dd, *J*₁ = 2.0 Hz, *J*₂ = 8.4 Hz, 1H), 8.36 (d, *J* = 2.0 Hz, 1H), 8.11 (d, *J* = 11.0 Hz, 1H), 7.77 (dd, *J*₁ = 2.4 Hz, *J*₂ = 8.4 Hz, 1H), 7.63 (d, *J* = 8.0 Hz, 1H), 7.24-7.28 (m, 2H), 7.16 (d, *J* = 9.6 Hz, 1H), 4.66 (s, 2H), 3.99 (s, 2H);

5 LCMS (ESI) *m/z*: 372.1 [M+H]⁺.


Example 112. Preparation of

N-(5-(3-chloro-4-fluorobenzyl)pyridin-2-yl)-6-(hydroxymethyl)nicotinamide (112)



10

Step 1: Preparation of *N*-(5-(3-chloro-4-fluorobenzyl)pyridin-2-yl)-6-(hydroxymethyl)nicotinamide



To a solution of methyl 5-(3-chloro-4-fluorobenzyl)pyridin-2-amine (0.227 g, 0.96 mmol) in toluene (5 mL) at room temperature was added trimethylaluminum (0.5 mL, 1.0 mmol, 2 M in toluene) slowly under argon. The reaction mixture was stirred at room temperature for 1 h before methyl 6-((*tert*-butyldimethylsilyloxy)methyl)nicotinate (0.225 g, 0.8 mmol) in toluene (5 mL) was added. The resulting mixture was heated to 100 °C and stirred for 3 h. Reaction was cooled to room temperature and quenched with methanol and aqueous 2 N hydrochloric acid. The volatiles were concentrated *in vacuo* and water (20 mL) was added. The aqueous layer were extracted with dichloromethane (50 mL x 3). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (BostonC18 21*250 mm 10 μm column. The mobile phase was acetonitrile/0.01% aqueous trifluoroacetic acid) to give *N*-(5-(3-chloro-4-fluorobenzyl)pyridin-2-yl)-6-(hydroxymethyl)nicotinamide (0.159 g, 0.42 mmol, 53%) as a light-yellow solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 11.15 (s, 1H), 9.09 (d, *J* = 1.5 Hz, 1H), 8.45 (dd, *J*₁ = 2.0 Hz, *J*₂ = 8.0 Hz, 1H), 8.36 (d, *J* = 1.5 Hz, 1H), 8.11 (d, *J* = 8.5 Hz, 1H), 7.77 (dd, *J*₁ = 2.0 Hz, *J*₂ = 8.5 Hz, 1H), 7.67 (d, *J* = 8.5 Hz, 1H), 7.53 (dd, *J*₁ = 2.0 Hz, *J*₂ = 7.5 Hz, 1H), 7.36 (t, *J* = 9.0 Hz, 1H), 7.28-7.31 (m, 1H), 4.69 (s, 2H), 3.98 (s, 2H); LCMS (ESI) *m/z*: 372.1 [M+H]⁺.


15

20

25


Example 113. Preparation of

N-(5-(3-cyano-4-fluorobenzyl)pyridin-2-yl)-2-methylpyrimidine-4-carboxamide (113)




30

Step 1: Preparation of 5-((6-aminopyridin-3-yl)methyl)-2-fluorobenzonitrile





To a solution of 5-(bromomethyl)-2-fluorobenzonitrile (1.07 g, 5 mmol) and 5-(4,4,5,5-tetramethyl-1,3-dioxolan-2-yl)pyridin-2-amine (1.34 g, 6 mmol) and potassium carbonate (1.38 g, 10 mmol) in 1,4-dioxane (30 mL) and water (10 mL) was added [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride (0.366 g, 0.5 mmol) under argon. The reaction mixture was stirred at 100 °C for 2 h. The volatiles were concentrated and water (50 mL) was added. The aqueous layer was extracted with ethyl acetate (80 mL x 3). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The crude product was purified by column chromatography (silica gel, petroleum ether/ethyl acetate from 1/1 to 0/1) to give 5-((6-aminopyridin-3-yl)methyl)-2-fluorobenzonitrile (1.01 g, 4.4 mmol, 89%) as a yellow solid. LCMS (ESI) m/z : 228.1 $[M+H]^+$.



Step 2: Preparation of *N*-(5-(3-cyano-4-fluorobenzyl)pyridin-2-yl)-2-methylpyrimidine-4-carboxamide



To a solution of 5-((6-aminopyridin-3-yl)methyl)-2-fluorobenzonitrile (0.227 mg, 1.0 mmol), 2-methylpyrimidine-4-carboxylic acid (276 mg, 2.0 mmol) and *N,N*-diisopropylethylamine (388 mg, 3.0 mmol) in *N,N*-dimethylformamide (10 mL) at room temperature was added 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.570 g, 1.5 mmol) under nitrogen. The reaction mixture was stirred at room temperature for 16 h. The reaction mixture was diluted with ethyl acetate (100 mL) and washed with brine (30 mL x 3). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (BostonC18 21*250 mm 10 μ m column. The mobile phase was acetonitrile/10 mM ammonium acetate aqueous solution) to give *N*-(5-(3-cyano-4-fluorobenzyl)pyridin-2-yl)-2-methylpyrimidine-4-carboxamide (0.133 g, 0.38 mmol, 38%) as a white solid. ^1H NMR (400 MHz, Dimethylsulfoxide- d_6) δ 10.37 (s, 1H), 9.03 (d, J = 5.2 Hz, 1H), 8.36 (d, J = 1.6 Hz, 1H), 8.17 (d, J = 8.4 Hz, 1H), 7.94 (d, J = 4.8 Hz, 1H), 7.88 (dd, J_1 = 2.0 Hz, J_2 = 7.6 Hz, 1H), 7.79 (dd, J_1 = 2.0 Hz, J_2 = 8.4 Hz, 1H), 7.68 - 7.72 (m, 1H), 7.46 (t, J = 8.8 Hz, 1H), 4.02 (s, 2H), 2.77 (s, 3H); LCMS (ESI) m/z : 348.1 $[M+H]^+$.

Example 114. Preparation *N*-(5-(3-chlorobenzyl)pyridin-2-yl)-2-methylpyrimidine-4-carboxamide (114)**5 Step 1: Preparation of *N*-(5-(3-chlorobenzyl)pyridin-2-yl)-2-methylpyrimidine-4-carboxamide**


To a solution of 5-(3-chlorobenzyl)pyridin-2-amine (0.132 g, 0.6 mmol), 2-methylpyrimidine-4-carboxylic acid (0.166 g, 1.2 mmol) and *N,N*-diisopropylethylamine (0.233 g, 1.8 mmol) in *N,N*-dimethylformamide (10 mL) at room temperature was added 1-*bis*(dimethylamino) methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.342 g, 0.9 mmol) under nitrogen. The reaction mixture was stirred at room temperature for 16 h. The reaction mixture was, the mixture was diluted with ethyl acetate (100 mL) and washed with brine (30 mL x 3). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (BostonC18 21*250 mm 10 μ m column). The mobile phase was acetonitrile/10 mM ammonium acetate aqueous solution) to give *N*-(5-(3-chlorobenzyl)pyridin-2-yl)-2-methylpyrimidine-4-carboxamide (0.0496 g, 0.15 mmol, 24%) as a yellow solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 10.39 (s, 1H), 9.05 (d, *J* = 5.0 Hz, 1H), 8.37 (d, *J* = 2.0 Hz, 1H), 8.19 (d, *J* = 9.0 Hz, 1H), 7.97 (d, *J* = 5.0 Hz, 1H), 7.81 (dd, *J*₁ = 2.5 Hz, *J*₂ = 8.5 Hz, 1H), 7.33 - 7.37 (m, 2H), 7.25 - 7.29 (m, 2H), 4.00 (s, 2H), 2.79 (s, 3H); LCMS (ESI) *m/z*: 339.1 [*M*+*H*]⁺.

Example 115. Preparation of 5-(3-Fluorobenzyl)-*N*-(2-methylpyrimidin-4-yl)picolinamide (115)**Step 1: Preparation of 5-(3-fluorobenzyl)-*N*-(2-methylpyrimidin-4-yl)picolinamide**


To a solution of 2-methylpyrimidin-4-amine (0.178 g, 1.63 mmol) in anhydrous toluene (12 mL) at room temperature was added trimethylaluminum (0.81 mL, 1.63 mmol, 2 M in toluene). The reaction

mixture was stirred at room temperature for 1 h before methyl 5-(3-fluorobenzyl)picolinate (0.200 g, 0.82 mmol) was added. The reaction mixture was stirred at 100 °C for 16 h. The reaction solution was cooled to room temperature and diluted with water (200 mL). The aqueous layer was extracted with ethyl acetate (80 mL × 3). The combined organic layers were washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC Boston C18 21*250 mm 10 µm column. The mobile phase was acetonitrile/10 mM ammonium acetate aqueous solution) to give 5-(3-fluorobenzyl)-*N*-(2-methylpyrimidin-4-yl)picolinamide (0.099 g, 0.31 mmol, 37%) as a white solid. ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 10.43 (s, 1H), 8.72 (d, *J* = 1.6 Hz, 1H), 8.66 (d, *J* = 1.6 Hz, 1H), 8.14 (d, *J* = 8.0 Hz, 1H), 8.04 (d, *J* = 2.0 Hz, 1H), 7.97 (dd, *J*₁ = 2.0 Hz, *J*₂ = 8.0 Hz, 1H), 7.40-7.35 (m, 1H), 7.20-7.15 (m, 2H), 7.09-7.04 (m, 1H), 4.15 (s, 2H), 2.56 (s, 3H); LCMS (ESI) *m/z*: 323.0 [M+H]⁺.



Example 116. Preparation of *N*-(5-(4-fluorobenzyl)pyridin-2-yl)-6-(hydroxymethyl)nicotinamide (116)



Step 1: Preparation of *N*-(5-(4-fluorobenzyl)pyridin-2-yl)-6-(hydroxymethyl)nicotinamide



To a solution of 5-(4-fluorobenzyl)pyridin-2-amine (0.194 g, 0.96 mmol) in toluene (5 mL) at room temperature was added trimethylaluminum (0.5 mL, 1.0 mmol, 2 M in toluene) slowly under argon. The reaction mixture was stirred at room temperature for 1 h before methyl 6-((*tert*-butyldimethylsilyloxy)methyl)nicotinate (0.225 g, 0.8 mmol) in toluene (5 mL) was added. The resulting solution was heated to 100 °C and stirred for 3 h. The reaction mixture was quenched with methanol and aqueous 2 N hydrochloric acid. The volatiles were removed *in vacuo* and water (20 mL) was added. The aqueous layer was extracted with dichloromethane (50 mL × 3). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (BostonC18 21*250 mm 10 µm column. The mobile phase was acetonitrile/0.01% aqueous trifluoroacetic acid) to give *N*-(5-(4-fluorobenzyl)pyridin-2-yl)-6-(hydroxymethyl)nicotinamide (176.2 mg, 0.52 mmol, 65%) as a yellow solid. ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 11.12 (s, 1H), 9.07 (s, 1H), 8.44 (dd, *J*₁ = 2.0 Hz, *J*₂ = 8.0 Hz, 1H), 8.32 (d, *J* = 2.0 Hz, 1H), 8.09 (d, *J* = 8.8 Hz, 1H), 7.72 (dd, *J*₁ = 2.0 Hz, *J*₂ = 8.4 Hz, 1H), 7.65 (d, *J* = 8.0 Hz, 1H), 7.28-7.31 (m, 2H), 7.10-7.15 (m, 2H), 4.67 (s, 2H), 3.96 (s, 2H); LCMS (ESI) *m/z*: 338.0 [M+H]⁺.

Example 117. Preparation of**5-fluoro-*N*-(5-(3-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (117)****5 Step 1: Preparation of****5-fluoro-*N*-(5-(3-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide**


To a solution of 5-(3-fluorobenzyl)pyridin-2-amine (300 mg, 1.48 mmol) in 1,4-dioxane (6 mL) was added trimethylaluminum (0.72 mL, 1.44 mmol, 2 M in toluene) slowly at room temperature under argon.

10 The mixture was stirred at room temperature for 30 minutes before methyl

5-fluoro-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate (67 mg, 0.36 mmol) in 1,4-dioxane (2 mL) was added. The resulting mixture was heated to 100 °C and stirred for 16 h. The reaction solution was cooled to room temperature and was quenched with hydrochloric acid (0.5 *N*, 25 mL) and ethyl acetate (50 mL). The organic was washed with hydrochloric acid (0.5 *N*, 25 mL x 2), and brine (25 mL), dried over sodium


15 sulfate, filtered and concentrated. The residue was purified by column chromatography (silica gel, ethyl acetate/petroleum ether = 2/1). The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Sunfire prep C18 10 μm OBD 19*250 mm; mobile phase: [water (0.05% trifluoroacetic acid)-acetonitrile]; B%: 60%-88%, 15 minutes) to give

20 5-fluoro-*N*-(5-(3-fluorobenzyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (70 mg, 0.20 mmol, 54.8%) as a white solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 10.66 (s, 1H), 8.57 (s, 1H), 8.32 (d, *J* = 1.8 Hz, 1H), 8.04 (d, *J* = 8.5 Hz, 1H), 7.96 (dd, *J* = 11.0, 2.2 Hz, 1H), 7.73 (dd, *J* = 8.6, 2.2 Hz, 1H), 7.35 (d, *J* = 6.4 Hz, 1H), 7.21 - 7.08 (m, 2H), 7.04 (s, 1H), 3.98 (s, 2H), 3.58 (s, 3H); LCMS (ESI) *m/z*: 356.0 [M+H]⁺.

Example 118. Preparation of***N*-(5-(3-fluorobenzyl)pyridin-2-yl)-1,5-dimethyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (118)**

5


Step 1: Preparation of (*E*)-1-*tert*-butyl 5-methyl 2-(diphenylmethyleamino)pent-2-enedioate



To a solution of *tert*-butyl 2-(diphenylmethyleamino)acetate (5.00 g, 16.9 mmol) in tetrahydrofuran (100 mL) at -78 °C was added potassium *tert*-butoxide (2.10 g, 18.7 mmol). The reaction mixture was stirred for 10 minutes before methyl propiolate (1.57 g, 18.7 mmol) was added under nitrogen. The reaction mixture was stirred for 2 h before it was warmed to room temperature and diluted with ice-water (100 mL). The aqueous phases were extracted with ethyl acetate (200 mL x 3). The combined organic layers were washed with water (200 mL x 3) and brine (200 mL x 3), dried over sodium sulfate, filtered and concentrated *in vacuo*. The residue was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 20/1) to offer (*E*)-1-*tert*-butyl 5-methyl 2-(diphenylmethyleamino)pent-2-enedioate (4.90 g, 12.93 mmol, 76%) as a yellow oil. LCMS (ESI) *m/z*: 380.2 [M+H]⁺.

15

Step 2: Preparation of (*E*)-1-*tert*-butyl 5-methyl 2-(diphenylmethyleamino)-4-methylpent-2-enedioate




20

To a solution of (*E*)-1-*tert*-butyl 5-methyl 2-(diphenylmethyleamino)pent-2-enedioate (3.00 g, 7.92 mmol) in acetonitrile (75 mL) at room temperature was added sequentially sodium hydroxide (0.38 g, 9.50 mmol), triethylbenzyl ammonium chloride (0.22 g, 0.95 mmol) and iodomethane (1.35 g, 9.50 mmol). The reaction mixture was stirred at this temperature for 2 h before it was filtered. The filtrate was concentrated, and the residue was purified by column chromatography (silica gel, petroleum ether/ethyl

25


acetate = 50/1) to offer (*E*)-1-*tert*-butyl 5-methyl 2-(diphenylmethyleamino)-4-methylpent-2-enedioate (1.2 g, 3.05 mmol, 38.5%) as a yellow oil. LCMS (ESI) m/z : 394.1 $[M+H]^+$.

Step 3: Preparation of *tert*-butyl 5-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylate




To a solution of (*E*)-1-*tert*-butyl 5-methyl 2-(diphenylmethyleamino)-4-methylpent-2-enedioate (2.64 g, 6.72 mmol) in ethanol (350 mL) at room temperature was added hydrazine monohydrochloride (1.83 g, 26.87 mmol) and sodium acetate (2.20 g, 26.87 mmol). The reaction mixture was stirred at 80 °C for 3 h. The reaction mixture was cooled to room temperature and concentrated. The residue was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 6/1) to offer *tert*-butyl 5-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylate (1.00 g, 4.72 mmol, 70.2%) as a white solid. LCMS (ESI) m/z : 213.3 $[M+H]^+$.

Step 4: Preparation of *tert*-butyl 1,5-dimethyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylate



A mixture of *tert*-butyl 5-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylate (462 mg, 2.18 mmol), iodomethane (618 mg, 4.36 mmol) and potassium carbonate (903 mg, 6.54 mmol) in *N,N*-dimethylformamide (10 mL) was stirred at 50 °C for 5 h. The reaction mixture was cooled to room temperature and it was diluted with ethyl acetate (100 mL). The combined organic layers were washed with water (50 mL) and brine (50 mL), dried over sodium sulfate, filtered and concentrated to afford *tert*-butyl 1,5-dimethyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylate (478 mg, 2.12 mmol, crude) as a pale-yellow solid. LCMS (ESI) m/z : 227.2 $[M+H]^+$.


Step 5: Preparation of methyl 1,5-dimethyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylate



A solution of *tert*-butyl 1,5-dimethyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylate (478 mg, 2.12 mmol) in hydrochloric acid (3 *M* in methanol, 20 mL) was stirred room temperature for 18 h. The reaction mixture was concentrated, and the residue was purified by column chromatography (silica gel, ethyl acetate/petroleum ether = 1/1) to offer 1,5-dimethyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylate (258 mg, 1.40 mmol, 64.3%) as a pale-yellow solid. LCMS (ESI) m/z : 185.2 $[M+H]^+$.

Step 6: Preparation of

N-(5-(3-fluorobenzyl)pyridin-2-yl)-1,5-dimethyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide



To a solution of 5-(3-fluorobenzyl)pyridin-2-amine (152 mg, 0.75 mmol) in 1,4-dioxane (4 mL) was added trimethylaluminum (0.38 mL, 0.75 mmol, 2 M in toluene) slowly at room temperature under argon.


The mixture was stirred at room temperature for 30 minutes before

methyl-1,5-dimethyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylate (92 mg, 0.5 mmol) in 1,4-dioxane (1 mL) was added. The resulting mixture was heated to 100 °C and stirred for 18 h. The reaction mixture was cooled to room temperature, the mixture was quenched with aqueous hydrochloric acid (0.5 N, 25


mL) and ethyl acetate (50 mL). The combined organic layers were washed with hydrochloric acid (0.5 N, 25 mL x 2), and brine (25 mL), dried over sodium sulfate, filtered and concentrated. The residue was first purified by column chromatography (silica gel, ethyl acetate/petroleum ether = 2/1) and by prep-HPLC (Sunfire prep C18 10 µm OBD 19*250 mm; mobile phase: [water (0.05% trifluoroacetic acid)-acetonitrile]; B%: 60%-88%, 15 minutes) to offer

N-(5-(3-fluorobenzyl)pyridin-2-yl)-1,5-dimethyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (11 mg, 0.031 mmol, 6.21 %) as a white solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 9.76 (s, 1H), 8.30 (d, *J* = 2.0 Hz, 1H), 8.03 (d, *J* = 8.5 Hz, 1H), 7.74 (dd, *J* = 8.5, 2.2 Hz, 1H), 7.42 - 7.26 (m, 1H), 7.12 (dd, *J* = 10.5, 4.3 Hz, 2H), 7.04 (d, *J* = 2.3 Hz, 1H), 3.97 (s, 2H), 3.37 (s, 3H), 3.08 (dd, *J* = 17.3, 6.9 Hz, 1H), 2.59 (d, *J* = 6.6 Hz, 1H), 2.49 - 2.39 (m, 1H), 1.13 (d, *J* = 6.9 Hz, 3H); LCMS (ESI) *m/z*: 355.1 [M+H]⁺.

Example 119. Preparation of *N*-(5-(3-fluorobenzyl)pyridin-2-yl)-6-(hydroxymethyl)nicotinamide (119)



Step 1: Preparation of *N*-(5-(3-fluorobenzyl)pyridin-2-yl)-6-(hydroxymethyl)nicotinamide




To a solution of methyl 5-(3-fluorobenzyl)pyridin-2-amine (0.194 g, 0.96 mmol) in toluene (5 mL) at room temperature was added trimethylaluminum (0.5 mL, 1.0 mmol, 2 M in toluene) slowly under argon. The reaction mixture was stirred at room temperature for 1 h before methyl


6-((*tert*-butyldimethylsilyloxy)methyl)nicotinate (0.225 g, 0.8 mmol) in toluene (5 mL) was added. The reaction solution was heated to 100 °C and stirred for 3 h. The reaction mixture was cooled to room temperature and quenched with methanol and aqueous 2 N hydrochloric acid and the solvent was removed *in vacuo*. Water (20 mL) was added and the mixture was extracted with dichloromethane (50 mL x 3). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The crude

sample was dissolved in minimal *N,N,N*-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 μ m column. The mobile phase was acetonitrile/0.01% aqueous trifluoroacetic acid.) to give *N*-(5-(3-fluorobenzyl)pyridin-2-yl)-6-(hydroxymethyl)nicotinamide (76 mg, 0.23 mmol, 28%) as a colorless oil. ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 11.24 (s, 1H), 9.11 (s, 1H), 8.52 (dd, *J*₁ = 1.6 Hz, *J*₂ = 8.0 Hz, 1H), 8.35 (d, *J* = 2.0 Hz, 1H), 8.09 (d, *J* = 8.4 Hz, 1H), 7.77 (dd, *J*₁ = 2.4 Hz, *J*₂ = 8.4 Hz, 1H), 7.72 (d, *J* = 8.4 Hz, 1H), 7.34 (dd, *J*₁ = 8.0 Hz, *J*₂ = 14.4 Hz, 1H), 7.10 - 7.13 (m, 2H), 7.00 - 7.05 (m, 1H), 4.72 (s, 2H), 3.99 (s, 2H); LCMS (ESI) *m/z*: 338.0 [M+H]⁺.

Example 120. Preparation of *N*-(5-(3-chlorobenzyl)pyridin-2-yl)-6-cyanonicotinamide (120)




Step 1: Preparation of *N*-(5-(3-chlorobenzyl)pyridin-2-yl)-6-cyanonicotinamide




To a solution of methyl 5-(3-chlorobenzyl)pyridin-2-amine (0.262 g, 1.2 mmol) in toluene (7 mL) was added trimethylaluminum (0.6 mL, 1.2 mmol, 2 M in toluene) at room temperature under argon. The reaction mixture was stirred at room temperature for 1 h before a solution of methyl 6-cyanonicotinate (0.162 g, 1 mmol) in toluene (2 mL) was added. Reaction mixture was stirred at 100 °C for 2 h under argon. The reaction solution was cooled to room temperature and quenched with methanol (5 mL) and 1 *N* hydrochloric acid aqueous (5 mL). The volatiles were concentrated, and the aqueous phase was extracted with dichloromethane (100 mL x 2). The combined organic layers were washed with brine (100 mL), dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 μ m column. The mobile phase was acetonitrile/0.01% aqueous trifluoroacetic acid) to give *N*-(5-(3-chlorobenzyl)pyridin-2-yl)-6-cyanonicotinamide (70 mg, 0.20 mmol, 20.8%) as a white solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 11.33 (s, 1H), 9.22 (d, *J* = 1.3 Hz, 1H), 8.53 (dd, *J* = 4.3, 2.5 Hz, 1H), 8.36 (d, *J* = 2.0 Hz, 1H), 8.20 (d, *J* = 8.0 Hz, 1H), 8.12 (d, *J* = 8.5 Hz, 1H), 7.75 (dd, *J* = 4.3, 2.5 Hz, 1H), 7.35 - 7.32 (m, 2H), 7.28-7.23 (m, 2H), 3.99 (s, 2H); LCMS (ESI) *m/z*: 349.0 [M+H]⁺.

Example 121. Preparation of 6-(aminomethyl)-*N*-(5-(3-chlorobenzyl)pyridin-2-yl)nicotinamide 2,2,2-trifluoroacetate (121)




Step 1: Preparation of 6-(aminomethyl)-*N*-(5-(3-chlorobenzyl)pyridin-2-yl)nicotinamide trifluoroacetic acid




To a solution of *N*-(5-(3-chlorobenzyl)pyridin-2-yl)-6-cyanonicotinamide (0.174 g, 0.5 mmol) in methanol (20 mL) at room temperature under hydrogen was added Raney nickel (0.200 g). The reaction mixture was stirred at room temperature for 4 h. The reaction mixture was filtered and the filtrate was concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 μ m column. The mobile phase was acetonitrile/0.01% aqueous trifluoroacetic acid) to give 6-(aminomethyl)-*N*-(5-(3-chlorobenzyl)pyridin-2-yl)nicotinamide trifluoroacetic acid (36.7 mg, 0.10 mmol, 20.9%) as a white solid. ^1H NMR (400 MHz, Dimethylsulfoxide- d_6) δ 11.18 (s, 1H), 9.18 (d, J = 2.0 Hz, 1H), 8.43 - 8.36 (m, 5H), 8.13 (d, J = 8.4 Hz, 1H), 7.75 (dd, J = 8.8, 2.0 Hz, 1H), 7.61 (d, J = 8.0 Hz, 1H), 7.37-7.33 (m, 2H), 7.29-7.24 (m, 2H), 4.33-4.29 (m, 2H), 3.99 (s, 2H) ; LCMS (ESI) m/z : 353.0 $[\text{M}+\text{H}]^+$.

Example 122. Preparation of

N-(5-(3-chlorobenzyl)pyridin-2-yl)-6-(hydroxymethyl)pyridazine-3-carboxamide (122)




Step 1: Preparation of dimethyl pyridazine-3,6-dicarboxylate




To a solution of pyridazine-3,6-dicarboxylic acid (2.52 g, 15 mmol) in methanol (125 mL) was added thionyl chloride (7.14 g, 6.0 mmol) dropwise at 0 °C under nitrogen. The reaction mixture was warmed to room temperature and stirred for 2 h. The volatiles were concentrated and water (50 mL) was added. The aqueous layer was extracted with ethyl acetate (80 mL x 3). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The crude product was purified by column chromatography (silica gel, dichloromethane/methanol = 20/1) to give dimethyl pyridazine-3,6-dicarboxylate (1.12 g, 5.7 mmol, 38 %) as a yellow solid. LCMS (ESI) m/z : 197.1 $[\text{M}+\text{H}]^+$.

Step 2: Preparation of methyl 6-(5-(3-chlorobenzyl)pyridin-2-ylcarbamoyl)pyridazine-3-carboxylate




To a solution of 5-(3-chlorobenzyl)pyridin-2-amine (0.218 g, 1.0 mmol) in toluene (5 mL) at room temperature was added trimethylaluminum (0.5 mL, 1.0 mmol, 2 M in toluene) slowly under argon. The reaction mixture was stirred at room temperature for 1 h before dimethyl pyridazine-3,6-dicarboxylate (0.196 g, 1.0 mmol) in toluene (5 mL) was added and the resulting mixture was heated to 100 °C and stirred for 3 h. Reaction vessel was cooled to room temperature and reaction was quenched with methanol and aqueous 2 N hydrochloric acid. The volatiles were removed *in vacuo* and water (20 mL) was added to the residue. The aqueous layer was extracted with dichloromethane (50 mL x 3). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The crude material was purified by column chromatography (silica gel, petroleum ether/ethyl acetate from 1/1 to 0/1) to give methyl 6-(5-(3-chlorobenzyl)pyridin-2-ylcarbamoyl)pyridazine-3-carboxylate (0.150 g, 0.39 mmol, 39%) as a white solid. LCMS (ESI) *m/z*: 383.2 [M+H]⁺.


Step 3: Preparation of *N*-(5-(3-chlorobenzyl)pyridin-2-yl)-6-(hydroxymethyl)pyridazine-3-carboxamide



To a solution of methyl 6-(5-(3-chlorobenzyl)pyridin-2-ylcarbamoyl)pyridazine-3-carboxylate (0.148 g, 0.39 mmol) and calcium chloride (0.173 g, 1.56 mmol) in methanol (20 mL) and tetrahydrofuran (10 mL) at 0 °C was added sodium borohydride (0.072 g, 1.94 mmol) slowly under nitrogen. The reaction mixture was stirred at 0 °C for 1 h before it was quenched with water. The aqueous layer was extracted with dichloromethane (50 mL x 2). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μm column. The mobile phase was acetonitrile/0.01% aqueous trifluoroacetic acid) to give *N*-(5-(3-chlorobenzyl)pyridin-2-yl)-6-(hydroxymethyl)pyridazine-3-carboxamide (0.0628 g, 0.18 mmol, 46%) as a white solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 8.37-8.38 (m, 2H), 8.19 (d, *J* = 8.5 Hz, 1H), 8.01 (d, *J* = 8.0 Hz, 1H), 7.81 (dd, *J*₁ = 2.5 Hz, *J*₂ = 8.5 Hz, 1H), 7.33-7.38 (m, 2H), 7.25-7.29 (m, 2H), 5.86 (s, 1H), 4.91 (s, 2H), 4.00 (s, 2H); LCMS (ESI) *m/z*: 355.1 [M+H]⁺.

Example 123. Preparation of***N*-(5-(3-chlorobenzyl)-4-methylpyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (123)**

5


Step 1: Preparation of *tert*-butyl 5-bromo-4-methylpyridin-2-ylcarbamate

To a solution of 5-bromo-4-methylpyridin-2-amine (5.0 g, 27.0 mmol) and triethylamine (5.44 g, 53.8 mmol) in tetrahydrofuran (30 mL) was added di-*tert*-butyl dicarbonate (5.86 g, 27.0 mmol) slowly.

10 Reaction was stirred at 60 °C for 2 h. The precipitated solid was filtered and collected to give *tert*-butyl 5-bromo-4-methylpyridin-2-ylcarbamate (4.2 g, 14.6 mmol, 54%) as a light-yellow solid. LCMS (ESI) *m/z*: 289.0 [M+H]⁺.

Step 2: Preparation of *tert*-butyl

15 4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-ylcarbamate




To a solution of *tert*-butyl 5-bromo-4-methylpyridin-2-ylcarbamate (1.5 g, 5.24 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (1.6 g, 6.29 mmol) and potassium acetate (1.03 g, 10.5 mmol) in 1,4-dioxane (8.0 mL) was added

20 [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.081 g, 0.10mmol) under nitrogen. The

reaction was heated to 80 °C and stirred for 12 h. The volatiles were removed under reduced pressure and the residue was added to a mixture of dichloromethane (100 mL) and water (100 mL). The organic layer was collected, dried over sodium sulfate, filtered and purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 4/1) to give *tert*-butyl

- 5 4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-ylcarbamate (0.150 g, 0.472 mmol, 9%) as a white solid. LCMS (ESI) *m/z*: 335.2 [M+H]⁺.


Step 3: Preparation of *tert*-butyl 5-(3-chlorobenzyl)-4-methylpyridin-2-ylcarbamate



- 10 To a solution of *tert*-butyl
4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-ylcarbamate (0.140 g, 0.419 mmol),
1-(bromomethyl)-3-chlorobenzene (0.103 g, 0.503 mmol), potassium carbonate (0.116 g, 0.838 mmol) in
tetrahydrofuran (4 mL) and water (2 mL) was added tetrakis(triphenylphosphine)palladium(0) (0.034 g,
0.04 mmol) under nitrogen. The mixture was then heated to 80 °C and stirred for 2 h. The volatiles were
15 removed under reduced pressure and the resulting residue was diluted with ethyl acetate (100 mL),
washed with water (100 mL), brine (100 mL), dried over sodium sulfate, filtered and concentrated.
Purification by column chromatography (silica gel, petroleum ether/ethyl acetate = 10/1) affords *tert*-butyl
5-(3-chlorobenzyl)-4-methylpyridin-2-ylcarbamates (0.120 g, 0.360 mmol, 86%) as a white solid. LCMS
(ESI) *m/z*: 333.1 [M+H]⁺.

20


Step 4: Preparation of 5-(3-chlorobenzyl)-4-methylpyridin-2-amine



- Trifluoroacetic acid (1.0 mL) was slowly added to *tert*-butyl
5-(3-chlorobenzyl)-4-methylpyridin-2-ylcarbamate (0.070 mg, 0.211 mmol). Reaction mixture was stirred
25 at 20 °C for 0.5 h before trifluoroacetic acid was removed under reduced pressure. The residue was
dissolved in dichloromethane (50 mL) and washed with water (50 mL), sodium bicarbonate aqueous (50
mL) and brine (50 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure to
yield 5-(3-chlorobenzyl)-4-methylpyridin-2-amine (0.050 g, crude) as a yellow solid. Used directly in the
next step. LCMS (ESI) *m/z*: 233.1 [M+H]⁺.

Step 5: Preparation of

N-(5-(3-chlorobenzyl)-4-methylpyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide




To a solution of 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.034 g, 0.215 mmol) in dichloromethane (2 mL) at 20 °C was added oxalyl chloride (1 mL). The reaction was stirred at 0 °C for 0.5 h and concentrated *in vacuo*. The crude residue was dissolved in dichloromethane (2 mL) and added to a mixture of 5-(3-chlorobenzyl)-4-methylpyridin-2-amine (0.050 g, 0.215 mmol) and triethylamine (0.065 g, 0.645 mmol) in dichloromethane (3.0 mL) dropwise. The reaction was stirred for another 0.5 h and volatiles were removed under reduced pressure. The residue was added to a mixture of dichloromethane (50 mL) and water (50 mL) and the organic layer was collected, dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 µm column; the mobile phase acetonitrile/0.01% aqueous trifluoroacetic acid) to give

N-(5-(3-chlorobenzyl)-4-methylpyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.0515 g, 0.138 mmol, 64%) as a white solid. ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 9.88 (s, 1H), 8.19 (s, 1H), 7.95 (s, 1H), 7.32-7.35 (m, 1H), 7.13-7.29 (m, 3H), 4.02 (s, 2H), 3.37 (s, 3H), 2.84-2.87 (t, *J* = 6.8 Hz, 2H), 2.52-2.55 (m, 2H), 2.23 (s, 3H); LCMS (ESI) *m/z*: 371.1 [M+H]⁺.


Example 124. Preparation of

N-(5-(3-chlorobenzyl)-3-fluoropyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (124)



Step 1: Preparation of

N-(5-(3-chlorobenzyl)-3-fluoropyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide




To an ice-cooled solution of 5-(3-chlorobenzyl)-3-fluoropyridin-2-amine (0.100 g, 0.42 mmol) and 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.066 mg, 0.42 mmol) in dry pyridine (5.00 mL) was added phosphorus(V) oxychloride (0.193 g, 1.27mmol) dropwise. The mixture was stirred at 0 °C for 1 h. The mixture was diluted with ethyl acetate (50 mL) and washed with aqueous saturated sodium bicarbonate solution (25 mL) and brine (25 mL). The organic layer was dried with sodium sulfate, filtered


and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified via prep-HPLC (Sunfire prep C18 10 μ m OBD 19*250 mm; mobile phase: [water (0.05% trifluoroacetic acid)-acetonitrile]; B%: 60%-88%, 15 minutes) to give

N-(5-(3-chlorobenzyl)-3-fluoropyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.060 g, 0.16 mmol, 38.2) as a white solid. ^1H NMR (500 MHz, Dimethylsulfoxide- d_6) δ 10.25 (s, 1H), 8.27 (s, 1H), 7.75 (dd, J = 10.6, 1.5 Hz, 1H), 7.42 (s, 1H), 7.34 (d, J = 7.6 Hz, 1H), 7.29 (d, J = 8.0 Hz, 2H), 4.03 (s, 2H), 3.34 (s, 3H), 2.81 (t, J = 8.5 Hz, 2H), 2.57 - 2.51 (m, 2H); LCMS (ESI) m/z : 375.1 $[\text{M}+\text{H}]^+$.

Example 125. Preparation of 5-(3-Fluorobenzyl)-*N*-(6-(hydroxymethyl)pyridin-3-yl)picolinamide (125)




Step 1: Preparation of methyl 5-aminopicolinate




Thionyl chloride (12.9 g, 109 mmol) was added to methanol (60 mL) at 0 °C. The reaction mixture was stirred at 0 °C for 1 h before 5-aminopicolinic acid (3.0 g, 21.7 mmol) was added. The reaction solution was refluxed for 4 h. The reaction solution was cooled to room temperature and concentrated. The crude residue was dissolved in water (100 mL) and treated with saturated aqueous of sodium bicarbonate (30 mL). The aqueous layer was extracted with ethyl acetate (100 mL $\times$ 3). The combined organic layers were washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated to give methyl 5-aminopicolinate (2.6 g, 17.1 mmol, 78%) as a yellow oil. LCMS (ESI) m/z : 153.0 $[\text{M}+\text{H}]^+$. Used in the next step directly without additional purification.

Step 2: Preparation of (5-aminopyridin-2-yl)methanol




To a solution of methyl 5-aminopicolinate (1.0 g, 6.57 mmol) in anhydrous tetrahydrofuran (20 mL) was added lithium aluminum hydride (499 mg, 13.14 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 16 h before it was quenched with water (150 mL). The aqueous layer was extracted with 2-methyltetrahydrofuran (80 mL $\times$ 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated to afford methyl (5-aminopyridin-2-yl)methanol (0.750 g, 17.1 mmol, 92%) as a yellow oil. LCMS (ESI) m/z : 125.1 $[\text{M}+\text{H}]^+$.


Step 3: Preparation of 5-(3-fluorobenzyl)-*N*-(6-(hydroxymethyl)pyridin-3-yl)picolinamide

To a solution of (5-aminopyridin-2-yl)methanol (0.248 g, 2.0 mmol) in anhydrous toluene (15 mL) at room temperature was added trimethylaluminum (1.0 mL, 2.0 mmol, 2 M in toluene) under nitrogen.

- 5 The reaction mixture was stirred at room temperature for 1 h before methyl 5-(3-fluorobenzyl)picolinate (0.245 g, 1.0 mmol) was added and stirred at 100 °C for 16 h. The reaction mixture was cooled to room temperature and diluted with water (200 mL). The aqueous layer was extracted with ethyl acetate (80 mL × 3). The combined organic layers were washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide
- 10 and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μm column. The mobile phase was acetonitrile/10 mM ammonium acetate aqueous solution) to give
- 5-(3-fluorobenzyl)-*N*-(6-(hydroxymethyl)pyridin-3-yl)picolinamide (38 mg, 0.11 mmol, 11%) as a white solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 11.21 (s, 1H), 9.18 (s, 1H), 8.73 (d, *J* = 1.0 Hz, 1H), 8.61 (dd, *J*₁ = 2.0 Hz, *J*₂ = 8.5 Hz, 1H), 8.12 (d, *J* = 8.5 Hz, 1H), 7.94 (dd, *J*₁ = 2.0 Hz, *J*₂ = 8.0 Hz, 1H), 7.74 (d, *J* = 8.5 Hz, 1H), 7.39-7.35 (m, 1H), 7.18-7.14 (m, 2H), 7.08-7.04 (m, 1H), 4.70 (s, 2H), 4.15 (s, 2H);
- 15 LCMS (ESI) *m/z*: 338.1 [M+H]⁺.

Example 126. Preparation of 5-(3-Fluorobenzyl)-*N*-(6-methylpyridazin-3-yl)picolinamide (126)


20

Step 1: Preparation of 5-(3-fluorobenzyl)-*N*-(6-methylpyridazin-3-yl)picolinamide


- At room temperature to a solution of 6-methylpyridazin-3-amine (178.0 mg, 1.63 mmol) in anhydrous toluene (10 mL) was added trimethylaluminum (0.82 mL, 1.63 mmol, 2 M in toluene) under
- 25 nitrogen. The reaction mixture was stirred at room temperature for 1 h before methyl 5-(3-fluorobenzyl)picolinate (0.200 g, 0.82 mmol) was added. The reaction mixture was stirred at 100 °C for 5 h. The reaction mixture was cooled to room temperature then diluted with water (200 mL) and extracted with ethyl acetate (80 mL × 3). The combined organic layers were washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude sample was dissolved in
- 30 minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μm column. The mobile phase was acetonitrile/10 mM ammonium acetate aqueous solution) to give
- 5-(3-fluorobenzyl)-*N*-(6-methylpyridazin-3-yl)picolinamide (0.062 g, 0.19 mmol, 23%) as a white solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 10.79 (s, 1H), 8.74 (d, *J* = 2.0 Hz, 1H), 8.39 (d, *J* = 9.5 Hz, 1H),

8.14 (d, $J = 7.5$ Hz, 1H), 7.97 (dd, $J_1 = 2.0$ Hz, $J_2 = 8.5$ Hz, 1H), 7.68 (d, $J = 9.0$ Hz, 1H), 7.39-7.35 (m, 1H), 7.20-7.15 (m, 2H), 7.08-7.04 (m, 1H), 4.15 (s, 2H), 2.60 (s, 3H); LCMS (ESI) m/z : 323.1 $[M+H]^+$.

Example 127. Preparation of *N*-(5-(3-chlorobenzyl)pyridin-2-yl)-6-(hydroxymethyl)nicotinamide (127)




Step 1: Preparation of methyl 5-bromo-6-oxo-1,6-dihydropyridazine-3-carboxylate



To a solution of methyl 6-oxo-1,6-dihydropyridazine-3-carboxylate (9.0 g, 58.4 mmol) in acetic acid (100 mL) at room temperature was added potassium acetate (17.2 g, 175 mmol) and bromine (18.66 g, 117 mmol). The resulting solution was stirred for 6 h at 80 °C. The reaction mixture was quenched with aqueous sodium bisulfate solution (100 mL, 3 mol/L). The aqueous layer was extracted with ethyl acetate (100 mL x 3). The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated to yield methyl 5-bromo-6-oxo-1,6-dihydropyridazine-3-carboxylate (11.1 g, 47.9 mmol, 82%, crude) as a light-yellow solid. LCMS (ESI) m/z : 233.0 $[M+H]^+$. Used in the next step directly without additional purification.


Step 2: Preparation of methyl 5-bromo-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylate



To a solution of methyl 6-oxo-1,6-dihydropyridazine-3-carboxylate (2.0 g, 8.58 mmol), potassium carbonate (2.38 g, 17.16 mmol) in *N,N'*-dimethylformamide (10.0 mL) was added 1-iodomethane (0.73 g, 5.15 mmol). The reaction mixture was stirred at room temperature for 3 h. The solution was dissolved in the ethyl acetate (50 mL). The combined organic layers were separated, washed with water (50 mL), dried over sodium sulfate, filtered and concentrated. The crude sample was purified by column

chromatography (silica gel, petroleum ether/ethyl acetate = 1/1) to offer methyl 5-bromo-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylate (1.60 g, 6.50 mmol, 76.2%) as a white solid. LCMS (ESI) m/z : 247.0 $[M+H]^+$.

5 Step 3: Preparation of 5-methoxy-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid




To a solution of methyl 5-bromo-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylate (300 mg, 1.22 mmol) in methanol (4.0 mL), tetrahydrofuran (4.0 mL) and water (1.0 mL) mixture was added lithium hydroxide hydrate (102 mg, 2.44 mmol). The reaction solution was stirred at room temperature for 1 h before 1 *N* aqueous hydrochloric acid was added to adjust the pH value to 3~5. The volatiles were removed to give 5-methoxy-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (200 mg, 1.09 mmol, 89%, crude) as a white solid. ^1H NMR (400 MHz, Dimethylsulfoxide- d_6) δ 13.66 (s, 1H), 8.26 (s, 1H), 3.88 (s, 3H), 3.78 (s, 3H); LCMS (ESI) m/z : 185.1 $[M+H]^+$. Used in the next step directly without additional purification.

15


Step 4: Preparation of

N-(5-(3-fluorobenzyl)pyridin-2-yl)-5-methoxy-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide




To a solution of 5-methoxy-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (121 mg, 0.659 mmol) and diisopropylethylamine (255 mg, 1.98 mmol) in tetrahydrofuran (5.0 mL) at 20 °C was added 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (376 mg, 0.659 mmol). The reaction solution was stirred for 20 minutes before a solution of 5-(3-fluorobenzyl)pyridin-2-amine (144 mg, 0.659 mmol) in tetrahydrofuran (1.0 mL) was added. The reaction mixture was stirred at 20 °C for 16 h. The volatiles were removed under reduced pressure and the crude material was added to a mixture of dichloromethane (50 mL) and water (50 mL). The combined organic layers were collected, dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μm column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give *N*-(5-(3-fluorobenzyl)pyridin-2-yl)-6-oxo-1-propyl-1,6-dihydropyridazine-3-carboxamide (43.0 mg, 0.117 mmol, 22%) as a white solid. ^1H NMR (500 MHz, Dimethylsulfoxide- d_6) δ 10.05 (s, 1H), 8.33 (d, J = 2.0 Hz, 1H), 8.09 (d, J = 8.5 Hz, 1H), 7.75 (dd, J = 8.5, 2.3 Hz, 1H), 7.34 (dd, J = 14.3, 8.0 Hz, 1H), 7.26 (s, 1H), 7.11 (t, J = 7.7 Hz, 2H), 7.04 (t, J = 7.4 Hz, 1H), 3.99 (s, 2H), 3.93 (s, 3H), 3.78 (s, 3H); LCMS (ESI) m/z : 369.1 $[M+H]^+$.

30

Example 128. Preparation of***N*-(5-(3-chlorobenzyl)pyridin-2-yl)-5-fluoro-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (128)**

5


Step 1: Preparation of 3-fluoro-5-(methoxycarbonyl)pyridine 1-oxide



To a solution of methyl 5-fluoronicotinate (3.54 g, 22.8 mmol) and urea hydrogen peroxide (4.64 g, 47.88 mmol) in dichloromethane (50 mL) at 0 °C was added trifluoroacetic anhydride (6.4 mL, 118 mmol) dropwise under nitrogen. The reaction mixture was stirred at room temperature for 17 h. The reaction vessel was cooled to 0 °C and saturated aqueous sodium *bisulfate* was added. The aqueous layer extracted with dichloromethane (100 mL x 3). The combined organic layers were washed with saturated aqueous sodium *bisulfate* (50 mL), dried over sodium sulfate, filtered and concentrated to give 3-fluoro-5-(methoxycarbonyl)pyridine 1-oxide as a light-yellow solid (3.78 g, 22.1 mmol, 97 %); LCMS (ESI) *m/z*: 172.1 [M+H]⁺.

15


Step 2: Preparation of methyl 5-fluoro-6-oxo-1,6-dihydropyridine-3-carboxylate



3-fluoro-5-(methoxycarbonyl)pyridine 1-oxide (2.5 g, 14.6 mmol) in acetic anhydride (75 mL) was stirred at 140 °C for 5 h under nitrogen. The reaction was cooled to room temperature and was concentrated. The residue was heated to 50 °C for 15 minutes and concentrated. The crude brown solid was suspended in dichloromethane and filtered, the product was then dried *in vacuo* to give methyl 5-fluoro-6-oxo-1,6-dihydropyridine-3-carboxylate as a yellow solid (880 mg, 5.15 mmol, 35%); LCMS (ESI) *m/z*: 172.1 [M+H]⁺.

25


Step 3: Preparation of methyl 5-fluoro-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate



To a solution of methyl 5-fluoro-6-oxo-1,6-dihydropyridine-3-carboxylate (838 mg, 4.9 mmol) and potassium carbonate (1.36 g, 9.8 mmol) in *N,N*-dimethylformamide (20 mL) was added iodomethane (1.04 g, 7.35 mmol) at room temperature under nitrogen. The mixture was stirred at room temperature for 2 h. The volatiles were removed *in vacuo* and the crude product was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 1/1) to give methyl 5-fluoro-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate as a yellow solid (830 mg, 4.5 mmol, 91 %); LCMS (ESI) *m/z*: 186.1 [M+H]⁺.


Step 4: Preparation of

N-(5-(3-chlorobenzyl)pyridin-2-yl)-5-fluoro-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide




To a solution of 5-(3-chlorobenzyl)pyridin-2-amine (323 mg, 1.48 mmol) in 1,4-dioxane (6 mL) at room temperature was added trimethylaluminum (0.72 mL, 1.44 mmol, 2 M in toluene) slowly under argon. The mixture was stirred at room temperature for 30 minutes before methyl 5-fluoro-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate (67 mg, 0.36 mmol) in 1,4-dioxane (2 mL) was added. The resulting solution was heated to 100 °C and stirred for 16 h. The reaction mixture was cooled to room temperature and was quenched with hydrochloric acid (0.5 *N*, 25 mL) and ethyl acetate (50 mL). The combined organic layers were washed with hydrochloric acid (0.5 *N*, 25 mL x 2) and brine (25 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified first by column chromatography (silica gel, ethyl acetate/petroleum ether= 2/1) and by prep-HPLC (Sunfire prep C18 10 μm OBD 19*250 mm; mobile phase: [water (0.05% trifluoroacetic acid)-acetonitrile]; B%: 60%-88%, 15 minutes) to offer


N-(5-(3-chlorobenzyl)pyridin-2-yl)-5-fluoro-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (70 mg, 0.19 mmol, 52.4%) as a white solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 10.66 (s, 1H), 8.57 (d, *J* = 1.7 Hz, 1H), 8.33 (d, *J* = 2.0 Hz, 1H), 8.05 (d, *J* = 8.5 Hz, 1H), 7.96 (dd, *J* = 11.0, 2.3 Hz, 1H), 7.73 (dd, *J* = 8.6, 2.3 Hz, 1H), 7.37 - 7.31 (m, 2H), 7.30 - 7.18 (m, 2H), 3.97 (s, 2H), 3.58 (s, 3H); LCMS (ESI) *m/z*: 372.0 [M+H]⁺.

Example 129. Preparation of *N*-(5-(3-chlorobenzyl)pyridin-2-yl)-5-cyanopicolinamide (129)


Step 1: Preparation of *N*-(5-(3-chlorobenzyl)pyridin-2-yl)-5-cyanopicolinamide



- 5 A mixture of 5-(3-chlorobenzyl)pyridin-2-amine (109 mg, 0.5 mmol), 5-cyanopicolinic acid (74 mg, 0.5 mmol), 2-(7-azabenzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate (285 mg, 0.75 mmol), *N,N*-diisopropylethylamine (194 mg, 1.5 mmol) in *N,N*-dimethylformamide (4 mL) was stirred at room temperature for 1 h. The mixture was poured into water and the formed precipitate was collected by filtration. The obtained solid was washed with methanol (20 mL) to afford
- 10 *N*-(5-(3-chlorobenzyl)pyridin-2-yl)-5-cyanopicolinamide (0.144 g, 0.41 mmol, 82%) as a grey solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 10.39 (s, 1H), 9.21 (d, *J* = 1.5 Hz, 1H), 8.61 (dd, *J* = 8.0, 1.5 Hz, 1H), 8.36 (d, *J* = 1.0 Hz, 1H), 8.32 (d, *J* = 8.0 Hz, 1H), 8.18 (d, *J* = 8.0 Hz, 1H), 7.79 (dd, *J* = 8.5, 2.0 Hz, 1H), 7.36-7.32 (m, 2H), 7.28-7.24 (m, 2H), 3.99 (s, 2H); LCMS (ESI) *m/z*: 349.1 [*M*+*H*]⁺.

Example 130. Preparation of *N*-(5-(3-chloro-4-fluorobenzyl)pyridin-2-yl)-5-cyanopicolinamide (130)


Step 1: Preparation of *N*-(5-(3-chloro-4-fluorobenzyl)pyridin-2-yl)-5-cyanopicolinamide




- 20 A mixture of 5-(3-chloro-4-fluorobenzyl)pyridin-2-amine (118 mg, 0.5 mmol), 5-cyanopicolinic acid (74 mg, 0.5 mmol), 2-(7-azabenzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate (285 mg, 0.75 mmol) and *N,N*-diisopropylethylamine (194 mg, 1.5 mmol) in *N,N*-dimethylformamide (4 mL) was stirred at room temperature for 1 h. The mixture was purified directly by prep-HPLC (Boston C18 21*250 mm 10 μm column. The mobile phase was acetonitrile/10 mM ammonium acetate aqueous
- 25 solution) to afford *N*-(5-(3-chloro-4-fluorobenzyl)pyridin-2-yl)-5-cyanopicolinamide (0.0514 g, 0.14 mmol, 28%) as a grey solid. ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 10.41 (s, 1H), 9.22 (d, *J* = 1.2 Hz, 1H), 8.62 (dd, *J* = 8.0, 2.0 Hz, 1H), 8.37 (d, *J* = 1.6 Hz, 1H), 8.32 (d, *J* = 8.0 Hz, 1H), 8.18 (d, *J* = 8.4 Hz, 1H),

7.80 (dd, $J = 8.4, 2.0$ Hz, 1H), 7.54 (dd, $J = 7.6, 2.0$ Hz, 1H), 7.38-7.28 (m, 2H), 3.98 (s, 2H); LCMS (ESI) m/z : 367.0 $[M+H]^+$.

Example 131. Preparation of *N*-(5-(3-chlorobenzyl)pyridin-2-yl)-6-(hydroxymethyl)nicotinamide (131)




Step 1: Preparation of methyl 6-((*tert*-butyldimethylsilyloxy)methyl)nicotinate



To a solution of methyl 6-(hydroxymethyl)nicotinate (2 g, 12 mmol), imidazole (2.44 g, 36 mmol) and 4-dimethylaminepyridine (0.020 g, 0.16 mmol) in dry *N,N*-dimethylformamide (30 mL) was added dimethyl-*tert*-butylchlorosilane (2.17 g, 14.4 mmol) under argon. The reaction mixture was stirred at room temperature for 16 h and diluted with ethyl acetate (150 mL). The organic layer was washed with brine (50 mL x 3). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The crude sample was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 10/1) to give methyl 6-((*tert*-butyldimethylsilyloxy)methyl)nicotinate (3.37 g, 1.19 mmol, 99%) as a colorless oil. LCMS (ESI) m/z : 282.1 $[M+H]^+$.


Step 2: Preparation of *N*-(5-(3-chlorobenzyl)pyridin-2-yl)-6-(hydroxymethyl)nicotinamide




To a solution of methyl 5-(3-chlorobenzyl)pyridin-2-amine (0.218 g, 1.0 mmol) in toluene (10 mL) at room temperature was added trimethylaluminum (0.5 mL, 1.0 mmol, 2 M in toluene) slowly under argon. The reaction mixture was stirred at room temperature for 30 minutes before methyl 6-((*tert*-butyldimethylsilyloxy)methyl)nicotinate (0.141 g, 0.5 mmol) in toluene (2 mL) was added. The reaction vessel was heated to 100 °C and stirred for 3 h. Reaction was cooled to room temperature and quenched by addition of methanol and aqueous 2 *N* hydrochloric acid. The volatiles were removed *in vacuo* and water (20 mL) was added to the slurry mixture. The aqueous phase was extracted with dichloromethane (50 mL x 3). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 μ m column. The mobile phase was acetonitrile/0.01% aqueous trifluoroacetic acid) to give *N*-(5-(3-chlorobenzyl)pyridin-2-yl)-6-(hydroxymethyl)nicotinamide (39.3 mg, 0.11 mmol, 22%) as a white solid. ^1H NMR (500 MHz, Dimethylsulfoxide- d_6) δ 11.08 (s, 1H), 9.07 (d, $J = 2.0$ Hz, 1H), 8.42 (dd, $J_1 = 2.5$ Hz, $J_2 = 8.5$ Hz, 1H), 8.35 (d, $J = 2.0$ Hz, 1H), 8.12 (d, $J = 8.5$ Hz, 1H),

7.75 (dd, $J_1 = 2.5$ Hz, $J_2 = 8.5$ Hz, 1H), 7.64 (d, $J = 8.0$ Hz, 1H), 7.34 - 7.37 (m, 2H), 7.25 - 7.29 (m, 2H), 4.67 (s, 2H), 3.99 (s, 2H); LCMS (ESI) m/z : 354.1 $[M+H]^+$.

Example 132. Preparation of 5-(3-Chlorobenzyl)-*N*-(6-(hydroxymethyl)pyridin-3-yl)picolinamide (132)




Step 1: Preparation of 5-(3-Chlorobenzyl)-*N*-(6-(hydroxymethyl)pyridin-3-yl)picolinamide




To a solution of (5-aminopyridin-2-yl)methanol (0.249 g, 2.0 mmol) in anhydrous toluene (15 mL) at room temperature was added trimethylaluminum (1.0 mL, 2.0 mmol, 2 M in toluene) under nitrogen. The reaction mixture was stirred at room temperature for 1 h before methyl 5-(3-chlorobenzyl)picolinate (0.261 g, 1.0 mmol) was added. The reaction mixture was stirred at 100 °C for 16 h. The reaction solution was cooled to room temperature and diluted with water (200 mL). The aqueous layer was extracted with ethyl acetate (80 mL $\times$ 3). The combined organic layers were washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21 $\times$ 250 mm 10 μ m column. The mobile phase was acetonitrile/10 mM ammonium acetate aqueous solution) to give 5-(3-chlorobenzyl)-*N*-(6-(hydroxymethyl)pyridin-3-yl)picolinamide (0.047 g, 0.13 mmol, 13%) as a white solid. ^1H NMR (500 MHz, Dimethylsulfoxide- d_6) δ 10.83 (s, 1H), 8.96 (s, 1H), 8.72 (s, 1H), 8.29 (d, $J = 7.5$ Hz, 1H), 8.10 (d, $J = 7.5$ Hz, 1H), 7.92 (d, $J = 7.5$ Hz, 1H), 7.45-7.41 (m, 2H), 7.37-7.27 (m, 3H), 5.38 (t, $J = 6.0$ Hz, 1H), 4.54 (d, $J = 5.0$ Hz, 2H), 4.14 (s, 2H); LCMS (ESI) m/z : 354.1 $[M+H]^+$.

Example 133. Preparation of 4-cyano-*N*-(5-(3-fluorobenzyl)pyridin-2-yl)benzamide (133)



Step 1: Preparation of 4-cyano-*N*-(5-(3-fluorobenzyl)pyridin-2-yl)benzamide




A mixture of 5-(3-fluorobenzyl)pyridin-2-amine (80 mg, 0.4 mmol), 4-cyanobenzoic acid (59 mg, 0.5 mmol), 2-(7-azabenzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate (228 mg, 0.6


mmol) and diisopropylethylamine (155 mg, 1.2 mmol) in *N,N*-dimethylformamide (4 mL) was stirred at room temperature for 4 h and at 80 °C for 1.5 h. The mixture was purified directly by prep-HPLC (Boston C18 21*250 mm 10 µm column. The mobile phase was acetonitrile/10 mM ammonium acetate aqueous solution) to afford 4-cyano-*N*-(5-(3-fluorobenzyl)pyridin-2-yl)benzamide (0.0565 g, 0.17 mmol, 42.5%) as a grey solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 11.09 (s, 1H), 9.35 (d, *J* = 1.5 Hz, 1H), 8.14-8.10 (m, 3H), 7.99 (d, *J* = 8.0 Hz, 2H), 7.74 (dd, *J* = 8.5, 2.0 Hz, 1H), 7.35 (dd, *J* = 9.0, 2.5 Hz, 1H), 7.14-7.11 (m, 2H), 7.06-7.02 (m, 1H), 3.99 (s, 2H); LCMS (ESI) *m/z*: 332.1 [M+H]⁺.

Example 134. Preparation of

N-(5-(3-cyano-5-fluorobenzyl)pyridin-2-yl)-2-methylpyrimidine-4-carboxamide (134)




Step 1: Preparation of *N*-(5-(3-cyano-5-fluorobenzyl)pyridin-2-yl)-2-methylpyrimidine-4-carboxamide




A mixture of 3-((6-aminopyridin-3-yl)methyl)-5-fluorobenzonitrile (227 mg, 1.0 mmol), 2-methylpyrimidine-4-carboxylic acid (138 mg, 1.0 mmol), 2-(7-azabenzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate (570 mg, 1.5 mmol) and diisopropylethylamine (390 mg, 3.0 mmol) in *N,N*-dimethylformamide (4 mL) was stirred at room temperature for 1 h. The mixture was poured into water. The formed precipitate was collected by filtration and the obtained solid was washed with methanol (15 mL) to afford *N*-(5-(3-cyano-5-fluorobenzyl)pyridin-2-yl)-2-methylpyrimidine-4-carboxamide (0.228 g, 0.66 mmol, 66%) as a grey solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 10.40 (s, 1H), 9.05 (d, *J* = 5.0 Hz, 1H), 8.40 (d, *J* = 2.0 Hz, 1H), 8.19 (d, *J* = 8.5 Hz, 1H), 7.96 (d, *J* = 5.5 Hz, 1H), 7.84 (dd, *J* = 8.5, 2.5 Hz, 1H), 7.72-7.70 (m, 2H), 7.60 (d, *J* = 5.5 Hz, 1H), 4.06 (s, 2H), 2.78 (s, 3H); LCMS (ESI) *m/z*: 348.1 [M+H]⁺.

Example 135. Preparation of 5-cyano-*N*-(5-(3-fluorobenzyl)pyridin-2-yl)picolinamide (135)




Step 1: Preparation of 5-cyano-*N*-(5-(3-fluorobenzyl)pyridin-2-yl)picolinamide




A mixture of 5-(3-fluorobenzyl)pyridin-2-amine (80 mg, 0.4 mmol), 5-cyanopicolinic acid (74 mg, 0.5 mmol), 2-(7-azabenzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate (228 mg, 0.6 mmol) and diisopropylethylamine (155 mg, 1.2 mmol) in *N,N*-dimethylformamide (4 mL) was stirred at room temperature 1 h. The mixture was purified directly by prep-HPLC (Boston C18 21*250 mm 10 μ m column. The mobile phase was acetonitrile/10 mM ammonium acetate aqueous solution) to afford 5-cyano-*N*-(5-(3-fluorobenzyl)pyridin-2-yl)picolinamide (0.0317 g, 0.095 mmol, 23.8%) as an off-white solid. ^1H NMR (400 MHz, Dimethylsulfoxide- d_6) δ 10.34 (bs, 1H), 9.22 (d, J = 1.2 Hz, 1H), 8.62 (dd, J = 8.4, 2.0 Hz, 1H), 8.36 (d, J = 1.6 Hz, 1H), 8.32 (d, J = 8.4 Hz, 1H), 8.18 (d, J = 8.4 Hz, 1H), 7.80 (dd, J = 8.4, 2.4 Hz, 1H), 7.38-7.32 (m, 1H), 7.15-7.11 (m, 2H), 7.04 (td, dd, J = 8.8, 2.0 Hz, 1H), 4.00 (s, 2H); LCMS (ESI) m/z : 333.1 $[\text{M}+\text{H}]^+$.

Example 136. Preparation of *N*-(5-(3-chlorobenzyl)pyridin-2-yl)-6-(methoxymethyl)nicotinamide (136)




Step 1: Preparation of methyl 6-(methoxymethyl)nicotinate




To a solution of methyl 6-(hydroxymethyl)nicotinate (500 mg, 2.99 mmol) in dichloromethane (5 mL) at 20 °C was added thionyl chloride (529 mg, 4.49 mmol). The residue was stirred for 1 h before solvent was removed under reduced pressure. The crude material was dissolved in methanol (15 mL) and sodium methoxide (1 mL) was added. The reaction solution was stirred at 75 °C for 1 h. The volatiles were removed under reduced pressure and the crude product was purified by column chromatography (petroleum ether/ethyl acetate = 4/1) to offer methyl 6-(methoxymethyl)nicotinate (250 mg, 1.38 mmol, 46%) as a yellow solid. LCMS (ESI) m/z : 182.1 $[\text{M}+\text{H}]^+$.

Step 2: Preparation of *N*-(5-(3-chlorobenzyl)pyridin-2-yl)-6-(methoxymethyl)nicotinamide




To a solution of 5-(3-chlorobenzyl)pyridin-2-amine (300 mg, 1.376 mmol) in toluene (10 mL) at 20 °C was added trimethylaluminum (0.7 mL, 1.376 mmol, 2 M in toluene) under argon. The reaction mixture was stirred at 20 °C for 1 h before a solution of methyl 6-(methoxymethyl)nicotinate (125 mg, 0.688 mmol) in toluene (2 mL) was added. The reaction solution was stirred at 90 °C for 2 h. The volatiles were removed under reduced pressure and the residue was quenched with water (50 mL). The aqueous layer was extracted with dichloromethane (50 mL x 2). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The crude sample was purified by prep-HPLC (dissolved in minimal *N,N*-dimethylformamide and loaded onto Boston C18 21*250 mm 10 µm column; eluted with acetonitrile/0.01% aqueous trifluoroacetic acid) to give *N*-(5-(3-chlorobenzyl)pyridin-2-yl)-6-(methoxymethyl)nicotinamide (35.5 mg, 0.097 mmol, 14%) as a light-yellow solid. ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 11.05 (s, 1H), 9.08 (s, 1H), 8.35-8.37 (m, 2H), 8.13 (d, *J* = 12.0 Hz, 1H), 7.72-7.75 (m, 1H), 7.53 (d, *J* = 8.0 Hz, 1H), 7.24-7.36 (m, 4H), 4.58 (s, 2H), 3.98 (s, 2H), 3.40 (s, 3H); LCMS (ESI) *m/z*: 368.0 [M+H]⁺.

Example 137. Preparation of *N*-(5-(3-chlorobenzyl)pyridin-2-yl)-5-(hydroxymethyl)picolinamide (137)




Step 1: Preparation of methyl 6-(5-(3-chlorobenzyl)pyridin-2-ylcarbamoyl)nicotinate



To a mixture of 5-(methoxycarbonyl)picolinic acid (300 mg, 1.657 mmol) and diisopropylethylamine (643 mg, 4.971 mmol) in tetrahydrofuran (10 mL) at 20 °C was added 1-[*bis*(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (945 mg, 2.486 mmol). The reaction solution was stirred for 20 minutes before a solution of 5-(3-chlorobenzyl)pyridin-2-amine (300 mg, 1.657 mmol) in tetrahydrofuran (1.0 mL) was added. The

reaction vessel was heated to 90 °C and stirred for 2 h. The volatiles were removed under reduced pressure and the residue was added to a mixture of dichloromethane (50 mL) and water (50 mL). The organic layer was separated, dried over sodium sulfate, filtered and concentrated. The crude product was purified by column chromatography (silica gel, dichloromethane/methanol = 20/1) to offer methyl 6-(5-(3-chlorobenzyl)pyridin-2-ylcarbamoyl)nicotinate (410 mg, 1.08 mmol, 65%) as a white solid. LCMS (ESI) m/z : 382.0 $[M+H]^+$.


Step 2: Preparation of *N*-(5-(3-chlorobenzyl)pyridin-2-yl)-5-(hydroxymethyl)picolinamide




To a solution of methyl 6-(5-(3-chlorobenzyl)pyridin-2-ylcarbamoyl)nicotinate (200 mg, 0.525 mmol) in methanol (15 mL) was added sodium borohydride (100 mg, 2.624 mmol). The reaction mixture was heated to 60 °C for 1 h. The reaction solution was quenched with aqueous sodium bicarbonate (10 mL). The aqueous layer was extracted with dichloromethane (50 mL x 2). The combined organic layers were collected, dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 μ m column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give *N*-(5-(3-chlorobenzyl)pyridin-2-yl)-5-(hydroxymethyl)picolinamide (58.1 mg, 0.16 mmol, 31%) as a white solid. ^1H NMR (400 MHz, Dimethylsulfoxide- d_6) δ 10.39 (s, 1H), 8.68 (s, 1H), 8.34 (s, 1H), 8.20 (q, J = 6.6 Hz, 1H), 8.02 (d, J = 8.0 Hz, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.32-7.37 (m, 4H), 5.55 (t, J = 4.0 Hz, 1H), 4.68 (d, J = 4.0 Hz, 2H), 3.98 (s, 2H); LCMS (ESI) m/z : 354.1 $[M+H]^+$.

Example 138. Preparation of

N-(5-(3-chloro-4-fluorobenzyl)pyridin-2-yl)-5-methylpyrazine-2-carboxamide (138)



Step 1: Preparation of *N*-(5-(3-chloro-4-fluorobenzyl)pyridin-2-yl)-5-methylpyrazine-2-carboxamide




To a solution of 5-methylpyrazine-2-carboxylic acid (100 mg, 0.635 mmol) and diisopropylethylamine (246 mg, 1.905 mmol) in tetrahydrofuran (4 mL) at 20 °C was added 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (362 mg, 0.953 mmol). The reaction mixture was stirred for 20 minutes before a solution of 5-(3-chloro-4-fluorobenzyl)pyridin-2-amine (150 mg, 0.635 mmol) in tetrahydrofuran (1.0 mL) was added.


The reaction solution was heated to 90 °C and stirred for 1 h. The volatiles were removed under reduced pressure and the residue was added to a mixture of dichloromethane (50 mL) and water (50 mL). The organic layer was collected, dried over sodium sulfate, filtered and concentrated. The crude material was purified by column chromatography (silica gel, dichloromethane/methanol = 20/1) to offer

- 5 *N*-(5-(3-chloro-4-fluorobenzyl)pyridin-2-yl)-5-methylpyrazine-2-carboxamide (120.0 mg, 0.34 mmol, 54%) as a white solid. ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 10.23 (s, 1H), 9.19 (s, 1H), 8.71 (s, 1H), 8.35 (s, 1H), 8.17 (d, *J* = 8.0 Hz, 1H), 7.79 (q, *J* = 2.6 Hz, 1H), 7.53 (q, *J* = 2.6 Hz, 1H), 7.29-7.37 (m, 2H), 3.98 (s, 2H), 2.64 (s, 3H); LCMS (ESI) *m/z*: 357.1 [M+H]⁺.

10 **Example 139. Preparation of *N*-(5-(3-fluorobenzyl)pyridin-2-yl)-5-methylpyrimidine-2-carboxamide (139)**



Step 1: Preparation of *N*-(5-(3-fluorobenzyl)pyridin-2-yl)-5-methylpyrimidine-2-carboxamide




- 15 To a solution of 5-methylpyrimidine-2-carboxylic acid (102 mg, 0.742 mmol) and diisopropylethylamine (288 mg, 2.226 mmol) in tetrahydrofuran (4 mL) at 20 °C was added 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (423 mg, 1.113 mmol). The reaction mixture was stirred for 20 minutes before a solution of
- 20 5-(3-fluorobenzyl)pyridin-2-amine (150 mg, 0.742 mmol) in tetrahydrofuran (1.0 mL) was added. The reaction solution was heated to 90 °C and stirred for 1 h. The volatiles were removed under reduced pressure and the residue was added to a mixture of dichloromethane (50 mL) and water (50 mL). The organic layer was collected, dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified by prep-HPLC (Boston C18 21*250 mm 10 μm
- 25 column. The mobile phase was acetonitrile/10 mM ammonium acetate aqueous solution) to give *N*-(5-(3-fluorobenzyl)pyridin-2-yl)-5-methylpyrimidine-2-carboxamide (150 mg, 0.47 mmol, 63%) as a white solid. ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 10.44 (s, 1H), 8.90 (s, 2H), 8.34 (s, 1H), 8.19 (d, *J* = 8.0 Hz, 1H), 7.79 (q, *J* = 2.6 Hz, 1H), 7.34 (q, *J* = 2.6 Hz, 1H), 7.01-7.14 (m, 3H), 3.99 (s, 2H), 2.40 (s, 3H); LCMS (ESI) *m/z*: 323.0 [M+H]⁺.

30


Example 140. Preparation of

***N*-(5-(3-fluorobenzyl)pyridin-2-yl)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide (140)**




Step 1: Preparation of

N-(5-(3-fluorobenzyl)pyridin-2-yl)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide




To a mixture of 1-methyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid (100 mg, 0.653 mmol), and diisopropylethylamine (253 mg, 1.959 mmol) in tetrahydrofuran (5 mL) at 20 °C was added 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (372 mg, 0.98 mmol). The reaction solution was stirred for 20 minutes before a solution of 5-(3-fluorobenzyl)pyridin-2-amine (132 mg, 0.653 mmol) in tetrahydrofuran (1.0 mL) was added. The reaction mixture was stirred at 20 °C for 4 h. The volatiles were removed under reduced pressure and the residue was added to a mixture of dichloromethane (50 mL) and water (50 mL). The organic layer was collected, dried over sodium sulfate, filtered and concentrated. The residue was purified by column chromatography (silica gel, dichloromethane/methanol = 20/1) to offer *N*-(5-(3-fluorobenzyl)pyridin-2-yl)-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide (89.6 mg, 0.27 mmol, 41%) as a white solid. ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 12.48 (s, 1H), 8.45-8.47 (m, 1H), 8.29 (s, 1H), 8.21 (s, 1H), 8.17-8.19 (m, 1H), 7.69-7.72 (m, 1H), 7.35 (q, *J* = 6.6 Hz, 1H), 7.10-7.13 (m, 2H), 7.03 (t, *J* = 8.0 Hz, 1H), 6.60 (t, *J* = 8.0 Hz, 1H), 3.96 (s, 2H), 3.63 (s, 3H); LCMS (ESI) *m/z*: 338.0 [M+H]⁺.

Example 141. Preparation of *N*-(5-(3-fluorobenzyl)pyridin-2-yl)-2-methylpyrimidine-5-carboxamide (141)



Step 1: Preparation of *N*-(5-(3-fluorobenzyl)pyridin-2-yl)-2-methylpyrimidine-5-carboxamide




To a solution of 2-methylpyrimidine-5-carboxylic acid (100 mg, 0.724 mmol) and diisopropylethylamine (281 mg, 2.17 mmol) in tetrahydrofuran (4 mL) at 20 °C was added 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (413 mg, 1.09 mmol). The reaction mixture was stirred for 20 minutes before a solution of 5-(3-fluorobenzyl)pyridin-2-amine (146 mg, 0.724 mmol) in tetrahydrofuran (1.0 mL) was added. The reaction solution was heated to 90 °C and stirred at 90 °C for 1 h. The volatiles were removed under reduced pressure and the residue was added to a mixture of dichloromethane (50 mL) and water (50 mL). The organic layer was collected, dried over sodium sulfate, filtered and concentrated. The residue was purified by column chromatography (silica gel, dichloromethane/methanol = 20/1) to offer


N-(5-(3-fluorobenzyl)pyridin-2-yl)-2-methylpyrimidine-5-carboxamide (93.1 mg, 0.29 mmol, 40%) as a white solid. ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 11.19 (s, 1H), 9.18 (s, 2H), 8.34 (d, *J* = 2.0 Hz, 1H), 8.12 (d, *J* = 8.8 Hz, 1H), 7.73-7.76 (m, 1H), 7.33-7.38 (m, 1H), 7.02-7.14 (m, 3H), 3.99 (s, 2H), 2.70 (s, 3H); LCMS (ESI) *m/z*: 323.1 [M+H]⁺.

5

Example 142. Preparation of 5-cyano-*N*-(5-(3-fluorobenzyl)pyridin-2-yl)picolinamide (142)



Step 1: Preparation of 5-[(3-fluorophenyl)methyl]pyridin-2-amine




10

In a 40 mL reaction vial, combined 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (1 g, 4.54 mmol), tripotassium phosphate (0.963 g, 4.54 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.165 g, 0.227 mmol). Reagents were suspended in 1,4-dioxane (6 mL) and water (2 mL) and 1-(bromomethyl)-3-fluorobenzene (556 μL, 4.54 mmol) was added. The reaction was degassed by cycling with vacuum and nitrogen for 3 cycles. The reaction was stirred at 80 °C for 16 h. After cooling to room temperature, the reaction was diluted with ethyl acetate (15 mL) and washed with water (10 mL) and brine (10 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated. Purified reaction by column chromatography (eluting with 0-100% ethyl acetate/hexanes through 12 g of silica gel) to give 5-[(3-fluorophenyl)methyl]pyridin-2-amine (90 mg, 0.445 mmol, 10%) as a brown oil. ¹H NMR (300 MHz, Chloroform-*d*) δ 8.01 - 7.94 (m, 1H), 7.31 - 7.19 (m, 2H), 7.07 - 6.83 (m, 3H), 6.47 (dd, *J* = 8.4, 0.8 Hz, 1H), 4.36 (s, 2H), 3.84 (s, 2H).

15

20

Step 2: Preparation of 5-cyano-*N*-(5-(3-fluorophenyl)methyl)pyridin-2-yl)pyridine-2-carboxamide



25


In a 25 mL round bottom flask, combined 5-[(3-fluorophenyl)methyl]pyridin-2-amine (90 mg, 0.445 mmol) with 5-cyanopyridine-2-carboxylic acid (0.065 g, 0.445 mmol) and 1-[(dimethylamino)(dimethyliminium)methyl]-3-oxo-1H,2H,3H-3λ⁵-[1,2,3]triazolo[5,4-b]pyridin-3-ylum-2-ide; hexafluoro-λ⁵-phosphanuide (0.169 g, 0.445 mmol). Reagents were suspended in *N,N*-dimethylformamide (2 mL) and ethylbis(propan-2-yl)amine (116 μL, 0.6675 mmol) was added. Reaction mixture was stirred at room temperature 16 h. Diluted with ethyl acetate (20 mL) and washed with water (10 mL x 3) and with brine (15 mL). The combined organic layers were dried over sodium

30


sulfate, filtered, and concentrated. Purified reaction by column chromatography (eluting with 0-100% ethyl acetate/hexanes through 24 g of silica gel) to give

5-cyano-*N*-{5-[(3-fluorophenyl)methyl]pyridin-2-yl}pyridine-2-carboxamide (41 mg, 0.123 mmol, 28%) a white solid. ¹H NMR (300 MHz, Chloroform-*d*) δ 10.36 (s, 1H), 8.94 (dd, *J* = 2.0, 0.9 Hz, 1H), 8.44 (dd, *J* = 8.1, 0.9 Hz, 1H), 8.39 - 8.31 (m, 1H), 8.29 - 8.15 (m, 2H), 7.60 (dd, *J* = 8.4, 2.4 Hz, 1H), 7.38 - 7.24 (m, 1H), 7.12 - 6.84 (m, 3H), 3.99 (s, 2H); LCMS (ESI) *m/z*: 333.4 [M+H]⁺.

Example 143. Preparation of *N*-(5-(3-fluorobenzyl)pyridin-2-yl)pyridazine-4-carboxamide (143)




Step 1: Preparation of 5-[(3-fluorophenyl)methyl]pyridin-2-amine



In a 40 mL reaction vial, combined 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (0.5 g, 2.27 mmol), dipotassium carbonate (0.627 g, 4.54 mmol) and tetrakis(triphenylphosphane) palladium (0.131 g, 0.1135 mmol) and added a stir bar. Added 1,4-dioxane (6 mL) and water (2 mL) and 1-(bromomethyl)-3-fluorobenzene (278 μL, 2.27 mmol). The reaction was degassed by cycling with vacuum and nitrogen for 3 cycles. The reaction was stirred at 90 °C for 16 h. Diluted with ethyl acetate (15 mL) and washed with water (10 mL), then brine (10 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated. Purified reaction by column chromatography (eluting with 0-100% ethyl acetate/hexanes through 24 g of silica gel) to give 5-[(3-fluorophenyl)methyl]pyridin-2-amine (203 mg, 1.00 mmol, 44%) as an orange solid. ¹H NMR (300 MHz, Chloroform-*d*) δ 7.96 (dd, *J* = 2.4, 0.8 Hz, 1H), 7.75 - 7.60 (m, 1H), 7.60 - 7.43 (m, 1H), 7.41 - 7.13 (m, 2H), 7.04 - 6.79 (m, 3H), 6.47 (dd, *J* = 8.4, 0.8 Hz, 1H), 4.37 (s, 2H), 3.84 (s, 2H).


Step 2: Preparation of *N*-(5-(3-fluorophenyl)methyl)pyridin-2-yl}pyridazine-4-carboxamide



Combined pyridazine-4-carboxylic acid (0.061 g, 0.4943 mmol) and 1-*bis*(dimethylamino)methanidyl]-3-oxo-1*H*,2*H*,3*H*-λ⁵-[1,2,3]triazolo[5,4-*b*]pyridine-1,4-diium-3-ylid-ium-2-ide, hexafluoro-λ⁵-phosphanuide (0.188 g, 0.4943 mmol) in a 40 mL reaction vial and added a solution of 5-[(3-fluorophenyl)methyl]pyridin-2-amine (0.100 g, 0.4944 mmol) in 4 mL of *N,N,N'*-dimethylformamide. Added ethyl*bis*(propan-2-yl)amine (129 μL, 0.7416 mmol), then stirred at room temperature 16 h. Diluted with ethyl acetate (15 mL), then washed with water (3 X 10 mL), then once with brine (10 mL). The combined organic layers were dried over sodium sulfate, filtered, and


concentrated. Purified reaction by column chromatography (eluting with 0-100% ethyl acetate/hexanes through 12 g of silica gel) to give *N*-{5-[(3-fluorophenyl)methyl]pyridin-2-yl}pyridazine-4-carboxamide (24 mg, 0.078 mmol, 16%) as a white solid. ¹H NMR (300 MHz, Chloroform-*d*) δ 9.72 (dd, *J* = 2.4, 1.2 Hz, 1H), 9.46 (dd, *J* = 5.3, 1.2 Hz, 1H), 8.45 - 8.30 (m, 1H), 8.15 (s, 1H), 8.14 - 7.97 (m, 1H), 7.75 - 7.61 (m, 1H), 7.60 - 7.41 (m, 1H), 7.28 (d, *J* = 5.5 Hz, 2H), 7.04 - 6.91 (m, 2H), 6.87 (d, *J* = 9.7 Hz, 1H), 4.00 (s, 2H); LCMS (ESI) *m/z*: 309.3 [M+H]⁺.

Example 144. Preparation of *N*-(5-(3-fluorobenzyl)pyridin-2-yl)-2-methylpyrimidine-4-carboxamide (144)



In a 40 mL reaction vial, combined 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (0.500 g, 2.27 mmol), dipotassium carbonate (0.375 g, 2.72 mmol) and λ²-iron(2+) *bis*((cyclopenta-2,4-dien-1-yl)diphenyl-λ⁴-phosphane) palladium dichloride (0.082 g, 0.1135 mmol). Added 1,4-dioxane (6 mL) and water (2 mL) and added 1-(bromomethyl)-3-fluorobenzene (278 μL, 2.27 mmol). The reaction was degassed by cycling with vacuum and nitrogen gas for 3 cycles. Stirred the reaction at 80 °C for 16 h. Cooled to room temperature and diluted with ethyl acetate (15 mL), then washed with water (10 mL), then brine (10 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated. Purified reaction by column chromatography (eluting with 0-100% ethyl acetate/hexanes through 24 g of silica gel) to give 5-(3-fluorophenyl)methylpyridin-2-amine as a brown solid (131 mg, 0.648 mmol, 28%). ¹H NMR (300 MHz, Chloroform-*d*) δ 8.02 - 7.94 (m, 1H), 7.33 - 7.18 (m, 2H), 7.06 - 6.80 (m, 3H), 6.47 (dd, *J* = 8.4, 0.9 Hz, 1H), 4.36 (s, 2H), 3.84 (s, 2H).


Step 2: Preparation of *N*-{5-[(3-fluorophenyl)methyl]pyridin-2-yl}-2-methylpyrimidine-4-carboxamide




In a 40 mL reaction vial, combined 5-(3-fluorophenyl)methylpyridin-2-amine (0.131 g, 0.6477 mmol) with 2-methylpyrimidine-4-carboxylic acid (0.089 g, 0.6477 mmol) and [bis(dimethylamino)methylidene]({3H-[1,2,3]triazolo[4,5-*b*]pyridin-3-yl})oxidanium; tetrafluoroboranuide (0.208 g, 0.6477 mmol). Dissolved in *N,N'*-dimethylformamide (3 mL) and added ethylbis(propan-2-yl)amine (168 μL, 0.9715 mmol). Stirred for 16 h at room temperature. Diluted with ethyl acetate (15 mL) and washed 3 times with water (10 mL), then once with brine (10 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated. Purified reaction by

column chromatography (eluting with 0-100% ethyl acetate/hexanes through 24 g of silica gel) to give *N*-{5-[(3-fluorophenyl)methyl]pyridin-2-yl}-2-methylpyrimidine-4-carboxamide as a white solid (88 mg, 0.273 mmol, 42%). ¹H NMR (300 MHz, Chloroform-*d*) δ 8.95 (d, *J* = 5.0 Hz, 1H), 8.41 - 8.32 (m, 1H), 8.27 (dd, *J* = 2.4, 0.8 Hz, 1H), 8.01 (m, 1H), 7.66 - 7.52 (m, 1H), 7.28 (s, 2H), 7.05 - 6.84 (m, 2H), 4.00 (s, 2H), 2.85 (s, 3H); LCMS (ESI) *m/z*: 323.4 [M+H]⁺.

Example 145. Preparation of *N*-(5-(3-fluorobenzyl)pyridin-2-yl)-6-methylpyridazine-3-carboxamide (145)




Step 1: Preparation of 5-[(3-fluorophenyl)methyl]pyridin-2-amine



In a 40 mL reaction vial, combined 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (0.500 g, 2.27 mmol), dipotassium carbonate (0.375 mg, 2.72 mmol) and tetrakis(triphenylphosphane) palladium (0.052 g, 0.0454 mmol). Added 1,4-dioxane (6.0 mL) and water (2.0 mL) and added 1-(bromomethyl)-3-fluorobenzene (278 μL, 2.27 mmol). The reaction was degassed by cycling with vacuum and nitrogen gas for 3 cycles. Stirred at 80 °C for 16 h. Diluted with ethyl acetate (15 mL) and washed with water (10 mL), then brine (10 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated. Purified reaction by column chromatography (eluting with 0-100% ethyl acetate/hexanes through 24 g of silica gel) to give 5-[(3-fluorophenyl)methyl]pyridin-2-amine as a brown solid (102 mg, 0.504 mmol, 22%). ¹H NMR (300 MHz, Chloroform-*d*) δ 7.81 (s, 1H), 7.34 (d, *J* = 16.4 Hz, 2H), 7.11 - 6.78 (m, 3H), 6.64 (s, 1H), 3.85 (s, 2H).

Step 2: Preparation of *N*-(5-[(3-fluorophenyl)methyl]pyridin-2-yl)-6-methylpyridazine-3-carboxamide




In a 25mL round bottom flask, combined 5-[(3-fluorophenyl)methyl]pyridin-2-amine (0.102 g, 0.504 mmol) with 6-methylpyridazine-3-carboxylic acid (0.070 g, 0.504 mmol) and 1-[Bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.162 g, 0.504 mmol). Dissolved in 3.0 mL *N,N'*-dimethylformamide and added *N,N*-diisopropylethylamine (131 μL, 0.756 mmol). Stirred at room temperature 16 h. Diluted with ethyl acetate (15 mL) and washed 3 times with water (10 mL), then once with brine (15 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated. Purified reaction by column chromatography (eluting with 0-100% ethyl acetate/hexanes through 24 g of silica gel) to give

N-{5-[(3-fluorophenyl)methyl]pyridin-2-yl}-6-methylpyridazine-3-carboxamide as a white solid (71 mg, 0.220 mmol, 44%). ¹H NMR (300 MHz, Chloroform-*d*) δ 10.54 (s, 1H), 8.39 - 8.20 (m, 3H), 7.63 - 7.51 (m, 2H), 7.30 (s, 1H), 6.96 (dd, *J* = 18.6, 7.2 Hz, 3H), 3.99 (s, 2H), 2.86 (s, 3H); LCMS (ESI) *m/z*: 323.4 [M+H]⁺.


5

Example 146. Preparation of

N-(5-(3-chlorobenzyl)pyridin-2-yl)-[1,2,4]triazolo[4,3-*a*]pyridine-6-carboxamide (146)



Step 1: Preparation of *N*-(5-(3-chlorobenzyl)pyridin-2-yl)-[1,2,4]triazolo[4,3-*a*]pyridine-6-carboxamide




To a solution of [1,2,4]triazolo[4,3-*a*]pyridine-6-carboxylic acid (100 mg, 0.613 mmol) and 5-(3-chlorobenzyl)pyridin-2-amine (134 mg, 0.613 mmol) in pyridine (4 mL) at 20 °C was added phosphorus oxychloride (279 mg, 1.839 mmol). The reaction mixture was stirred at room temperature for 1 h before solvent was removed under reduced pressure. The resulting solid was dissolved in dichloromethane (10.0 mL) and added to a mixture of dichloromethane (50 mL) and water (50 mL). The combined organic layers were collected, dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 μm column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give


N-(5-(3-chlorobenzyl)pyridin-2-yl)-[1,2,4]triazolo[4,3-*a*]pyridine-6-carboxamide (34.0 mg, 0.09 mmol, 15%) as a yellow solid. ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 11.03 (s, 1H), 9.38 (s, 1H), 9.30 (s, 1H), 8.33 (d, *J* = 2.0 Hz, 1H), 8.09 (d, *J* = 8.4 Hz, 1H), 7.83 (s, 2H), 7.72-7.74 (m, 1H), 7.22-7.35 (m, 4H), 3.97 (s, 2H); LCMS (ESI) *m/z*: 364.0 [M+H]⁺.

Example 147. Preparation of

N-(5-(3,4-difluorobenzyl)pyridin-2-yl)-[1,2,4]triazolo[4,3-*a*]pyridine-6-carboxamide (147)




Step 1: Preparation of 5-(3,4-difluorobenzyl)pyridin-2-amine




To a solution of 4-(bromomethyl)-1,2-difluorobenzene (2.0 g, 9.71 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (2.14 g, 9.71 mmol) and potassium carbonate (2.7 g, 19.42 mmol) in tetrahydrofuran (20 mL) and water (5 mL) was added tetrakis(triphenylphosphine)palladium(0) (1.12 g, 0.971 mmol) under nitrogen. The reaction mixture was heated to 90 °C and stirred for 2 h. The volatiles were removed under reduced pressure. The aqueous layer was treated with 1 *N* hydrochloric acid to adjust the pH value to 1~3. The aqueous layer was extracted with ethyl acetate (50 mL) before aqueous sodium bicarbonate was added to adjust the pH value to 8~10. The aqueous layer was extracted with dichloromethane (50 mL x 2). The combined organic layers were collected, dried over sodium sulfate, filtered and concentrated. The crude material was purified by column chromatography (silica gel, dichloromethane/methanol = 20/1) to offer 5-(3,4-difluorobenzyl)pyridin-2-amine as a yellow oil (800 mg, 3.64 mmol, 37%); LCMS (ESI) *m/z*: 221.1 [M+H]⁺.

Step 2: Preparation of *N*-(5-(3,4-difluorobenzyl)pyridin-2-yl)-[1,2,4]triazolo[4,3-*a*]pyridine-6-carboxamide




To a solution of [1,2,4]triazolo[4,3-*a*]pyridine-6-carboxylic acid (100 mg, 0.613 mmol) and 5-(3,4-difluorobenzyl)pyridin-2-amine (135 mg, 0.613 mmol) in pyridine (4 mL) at 20 °C was added phosphorus oxychloride (279 mg, 1.839 mmol). The reaction mixture was stirred at room temperature for 2 h. The volatiles were removed under reduced pressure and the solid was dissolved in dichloromethane (10.0 mL) and added to a mixture of dichloromethane (50 mL) and water (50 mL). The organic layer was collected, dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 μm column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give *N*-(5-(3,4-difluorobenzyl)pyridin-2-yl)-[1,2,4]triazolo[4,3-*a*]pyridine-6-carboxamide (23.7 mg, 0.06 mmol, 10%) as a light-yellow solid. ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 11.12 (s, 1H), 9.46 (s, 1H), 9.38 (s, 1H), 8.41 (d, *J* = 2.4 Hz, 1H), 8.17 (d, *J* = 8.4 Hz, 1H), 7.91 (s, 2H), 7.80-7.82 (m, 1H), 7.40-7.48 (m, 2H), 7.18-7.22 (m, 1H), 4.03 (s, 2H); LCMS (ESI) *m/z*: 366.1 [M+H]⁺.

Example 148. Preparation of***N*-(5-(3-chloro-4-fluorobenzyl)pyridin-2-yl)-[1,2,4]triazolo[4,3-*a*]pyridine-6-carboxamide (148)**

Step 1: Preparation of


5 ***N*-(5-(3-chloro-4-fluorobenzyl)pyridin-2-yl)-[1,2,4]triazolo[4,3-*a*]pyridine-6-carboxamide**




To a solution of [1,2,4]triazolo[4,3-*a*]pyridine-6-carboxylic acid (100 mg, 0.613 mmol) and 5-(3-chloro-4-fluorobenzyl)pyridin-2-amine (135 mg, 0.613 mmol) in pyridine (4 mL) at 20 °C was added phosphorus oxychloride (279 mg, 1.84 mmol). The reaction mixture was stirred at room temperature for 2 h. The volatiles were removed under reduced pressure and the solid was dissolved in dichloromethane (10.0 mL) and added to a mixture of dichloromethane (50 mL) and water (50 mL). The organic layer was collected, dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 μm column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give

10 *N*-(5-(3-chloro-4-fluorobenzyl)pyridin-2-yl)-[1,2,4]triazolo[4,3-*a*]pyridine-6-carboxamide (21.8 mg, 0.06 mmol, 9%) as a light-yellow solid. ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 11.03 (s, 1H), 9.38 (s, 1H), 9.30 (s, 1H), 8.33 (d, *J* = 2.0 Hz, 1H), 8.09 (d, *J* = 8.4 Hz, 1H), 7.83 (s, 2H), 7.72-7.74 (m, 1H), 7.50-7.54 (m, 1H), 7.26-7.36 (m, 2H), 3.96 (s, 2H); LCMS (ESI) *m/z*: 382.0 [M+H]⁺.

20 **Example 149. Preparation of**


***N*-(5-(3,5-difluorobenzyl)pyridin-2-yl)-[1,2,4]triazolo[4,3-*a*]pyridine-6-carboxamide (149)**

Step 1: Preparation of [1,2,4]triazolo[4,3-*a*]pyridine-6-carboxylic acid




25 A solution of 6-hydrazinylpyridine-3-carboxylic acid (1.0 g, 6.53 mmol) in formic acid (10 mL) was heated to 100 °C and refluxed for 3 h. The volatiles were removed to offer [1,2,4]triazolo[4,3-*a*]pyridine-6-carboxylic acid (1.0 g, 6.13 mmol, 94%, crude) as a white solid which was used in the next step without further purification. LCMS (ESI) *m/z*: 164.1 [M+H]⁺.

Step 2: Preparation of *N*-(5-(3,5-difluorobenzyl)pyridin-2-yl)-[1,2,4]triazolo[4,3-*a*]pyridine-6-carboxamide




To a solution of 1-methyl-1*H*-pyrazole-4-carboxylic acid (100 mg, 0.613 mmol), 5-(3,5-difluorobenzyl)pyridin-2-amine (135 mg, 0.613 mmol) in pyridine (5 mL) at 20 °C was added, phosphorus oxychloride (279 mg, 1.839 mmol). The reaction mixture was stirred at 20 °C for 1 h. The volatiles were removed under reduced pressure and the solid was dissolved in dichloromethane (10.0 mL) and added to a mixture of dichloromethane (50 mL) and water (50 mL). The organic layer was collected, dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μm column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give *N*-(5-(3,5-difluorobenzyl)pyridin-2-yl)-[1,2,4]triazolo[4,3-*a*]pyridine-6-carboxamide (23.6 mg, 0.064 mmol, 10%) as a light-yellow solid. ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 11.07 (s, 1H), 9.40 (s, 1H), 9.32 (s, 1H), 8.37 (s, 1H), 8.11 (d, *J* = 8.0 Hz, 1H), 7.85 (s, 2H), 7.78 (q, *J* = 4.0 Hz, 1H), 7.04-7.10 (m, 3H), 4.00 (s, 2H); LCMS (ESI) *m/z*: 366.1 [M+H]⁺.

Example 150. Preparation of *N*-[1,2,4]triazolo[4,3-*a*]pyridin-6-yl)-5-(3-chlorobenzyl)picolinamide trifluoroacetic acid (150 TFA)




Step 1: Preparation of lithium 5-(3-chlorobenzyl)picolinate



To a solution of methyl 5-(3-chlorobenzyl)picolinate (0.300 g, 1.15 mmol) in tetrahydrofuran (10 mL) and water (1.0 mL) at room temperature was added lithium hydroxide monohydrate (51.0 mg, 1.21 mmol). The reaction mixture was stirred at room temperature for 5 h. The volatiles were removed to reveal lithium 5-(3-chlorobenzyl)picolinate (0.365 g, 1.15 mmol, crude) as a white solid. LCMS (ESI) *m/z*: 248.1 [M+H]⁺.

Step 2: Preparation of 5-(3-chlorobenzyl)-*N*-(6-(hydroxymethyl)pyridin-3-yl)picolinamide trifluoroacetate



To a solution of lithium 5-(3-chlorobenzyl)picolinate (0.300 g, 1.18 mmol) in *N,N*-dimethylformamide (6 mL) at room temperature was added [1,2,4]triazolo[4,3-*a*]pyridin-6-amine


(0.174 g, 1.30 mmol), 2-(7-aza-1*H*-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (0.673 g, 1.77 mmol) and *N,N*-diisopropylethylamine (0.762 g, 5.9 mmol). The reaction mixture was stirred at room temperature for 16 h. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μ m column. The mobile phase was

acetonitrile/0.01% aqueous trifluoroacetic acid) to afford


5-(3-chlorobenzyl)-*N*-(6-(hydroxymethyl)pyridin-3-yl)picolinamide trifluoroacetate (0.102 g, 0.21 mmol, 18%) as a white solid. ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 11.09 (s, 1H), 9.62 (s, 1H), 9.48 (s, 1H), 8.75 (s, 1H), 8.12 (d, *J* = 8.0 Hz, 1H), 8.02-7.92 (m, 3H), 7.42 (s, 1H), 7.38-7.27 (m, 3H), 4.15 (s, 2H); LCMS (ESI) *m/z*: 364.0 [M+H]⁺.

Example 151. Preparation of

N-(5-(3-fluorobenzyl)pyridin-2-yl)-[1,2,4]triazolo[4,3-*a*]pyridine-6-carboxamide (151)




Step 1: Preparation of 6-hydrazinylnicotinic acid




Hydrazine hydrate (8 mL) was added to 6-chloronicotinic acid (3.0 g, 19.1 mmol). The reaction mixture was heated to 100 °C and stirred 16 h. The volatiles were removed under reduced pressure and ethanol (50 mL) was added. The resulting precipitate was filtered and collected to give 6-hydrazinylnicotinic acid (2.8 g, crude) as a white solid. Used directly in the next step without further purification. LCMS (ESI) *m/z*: 154.1 [M+H]⁺.

Step 2: Preparation of [1,2,4]triazolo[4,3-*a*]pyridine-6-carboxylic acid



A solution of 6-hydrazinylnicotinic acid (1.0 g, 6.53 mmol) in formic acid (13 mL) was heated to 105 °C and stirred 16 h. The solution was cooled to room temperature and volatiles were removed to offer [1,2,4]triazolo[4,3-*a*]pyridine-6-carboxylic acid (1.1 g, crude) as a white solid. LCMS (ESI) *m/z*: 164.1. [M+H]⁺. Used in the next step without further purification.


Step 3: Preparation of *N*-(5-(3-fluorobenzyl)pyridin-2-yl)-[1,2,4]triazolo[4,3-*a*]pyridine-6-carboxamide




To a solution of [1,2,4]triazolo[4,3-a]pyridine-6-carboxylic acid (0.100 g, 0.613 mmol), 5-(3-fluorobenzyl)pyridin-2-amine (0.124 g, 0.613 mmol) and pyridine (5 mL) at 20 °C was added phosphorus(V) oxychloride (0.279 g, 1.84 mmol). The reaction mixture was stirred at room temperature for 1 h. The solvent was removed under reduced pressure. The crude solid was dissolved in dichloromethane (10.0 mL) and added to a mixture of dichloromethane (50 mL) and water (50 mL). The organic layer was collected, dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 µm column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give *N*-(5-(3-fluorobenzyl)pyridin-2-yl)-[1,2,4]triazolo[4,3-a]pyridine-6-carboxamide light-yellow solid (0.0281 g, 0.0797 mmol, 13%). ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 11.06 (s, 1H), 9.41 (s, 1H), 9.33 (s, 1H), 8.35 (d, *J* = 2 Hz, 1H), 8.10 (d, *J* = 8.5 Hz, 1H), 7.86 (d, *J* = 1.5 Hz, 2H), 7.74-7.76 (m, 1H), 7.34-7.38 (m, 1H), 7.06-7.14 (m, 2H), 7.02-7.05 (m, 1H), 4.0 (s, 2H). LCMS (ESI) *m/z*: 348.1 [M+H]⁺.

Example 152. Preparation of

N-(5-(3-fluorobenzyl)pyridin-2-yl)-3-methyl-[1,2,4]triazolo[4,3-a]pyridine-6-carboxamide (152)




Step 1: Preparation of 6-hydrazinylnicotinic acid



A solution of hydrazine hydrate (8 mL) and 6-chloronicotinic acid (3.0 g, 19.1 mmol) was heated to 100 °C and stirred 16 h. The volatiles were removed under reduced pressure. The crude material was treated with ethanol (50 mL) to precipitate solid. Filtration affords crude 6-hydrazinylnicotinic acid (2.8 g, crude) as a white solid. LCMS (ESI) *m/z*: 154.1 [M+H]⁺. Used in the next step without further purification.


Step 2: Preparation of 3-methyl-[1,2,4]triazolo[4,3-a]pyridine-6-carboxylic acid



A solution of 6-hydrazinylnicotinic acid (1.0 g, 6.53 mmol) in acetic acid (13 mL) was heated to 120 °C and stirred 16 h. The solution was cooled to room temperature. The solid was filtered and collected to offer 3-methyl-[1,2,4]triazolo[4,3-a]pyridine-6-carboxylic acid as a white solid (0.48 g, crude). LCMS (ESI) *m/z*: 178.1 [M+H]⁺. Used in the next step without further purification.


Step 3: Preparation of

N-(5-(3-fluorobenzyl)pyridin-2-yl)-3-methyl-[1,2,4]triazolo[4,3-*a*]pyridine-6-carboxamide




To a solution of 3-methyl-[1,2,4]triazolo[4,3-*a*]pyridine-6-carboxylic acid (0.100 g, 0.565 mmol),
 5-(3-fluorobenzyl)pyridin-2-amine (0.114 g, 0.565 mmol) in pyridine (4 mL) at 20 °C was added
 phosphorus(V) oxychloride (0.257 g, 1.70 mmol). The reaction mixture was stirred at room temperature
 for 1 h and volatiles were removed under reduced pressure. The resulting crude material was dissolved
 in dichloromethane (10.0 mL) and added to a mixture of dichloromethane (50 mL) and water (50 mL). The
 organic layer was collected, dried over sodium sulfate, filtered and concentrated. The crude sample was
 dissolved in minimal *N,N*-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 µm
 column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give
N-(5-(3-fluorobenzyl)pyridin-2-yl)-3-methyl-[1,2,4]triazolo[4,3-*a*]pyridine-6-carboxamide as a light red solid
 (0.067 g, 0.186 mmol, 33%). ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 11.08 (s, 1H), 9.29 (s, 1H), 8.36
 (d, *J* = 2.0 Hz, 1H), 8.14 (d, *J* = 8.5 Hz, 1H), 7.74-7.88 (m, 3H), 7.34-7.38 (m, 1H), 7.03-7.14 (m, 3H),
 4.00 (s, 2H), 2.78 (s, 3H); LCMS (ESI) *m/z*: 362.1 [*M*+*H*]⁺.

Example 153. Preparation of 5-(5-(3-fluorobenzyl)pyridin-2-yl)-1-methyl-1*H*-indazole (153)




Step 1: Preparation of 2-chloro-5-(3-fluorobenzyl)pyridine



A mixture of 2-chloro-5-(chloromethyl)pyridine (1.0 g, 6.17 mmol), 3-fluorophenylboronic acid
 (1.30 g, 9.26 mmol), tris(dibenzylideneacetone)dipalladium(0) (0.16 g, 0.31 mmol),
 1,3-dimesityl-1*H*-imidazol-3-ium chloride (0.10 g, 0.31 mmol) and cesium carbonate (4.0 g, 12.3 mmol) in
 1,4-dioxane (30.0 mL) was stirred under nitrogen atmosphere at 100 °C for 17 h. The reaction mixture
 was cooled down to room temperature and filtered. The filtrate was concentrated, under reduced
 pressure and the crude solid was purified by column chromatography (silica gel, petroleum ether/ethyl
 acetate = 1/1) to afford 2-chloro-5-(3-fluorobenzyl)pyridine (0.85 g, 3.85 mmol, 62.0%) as a yellow solid.
 LCMS (ESI) *m/z*: 222.1 [*M*+*H*]⁺.


Step 2: Preparation of 5-(5-(3-fluorobenzyl)pyridin-2-yl)-1-methyl-1*H*-indazole




A mixture of 2-chloro-5-(3-fluorobenzyl)pyridine (0.2 g, 0.90 mmol), 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1*H*-indazole (0.26 g, 0.99 mmol), potassium carbonate (0.25 g, 1.81 mmol) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.074 g, 0.09 mmol) in acetonitrile (8.0 mL) and water (2.0 mL) under nitrogen atmosphere was stirred at 80 °C for 2 h. The reaction mixture was cooled down to room temperature and filtered. The filtrate was concentrated, under reduced pressure. The crude sample was dissolved in minimal *N,N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 µm column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give 5-(5-(3-fluorobenzyl)pyridin-2-yl)-1-methyl-1*H*-indazole (0.0655 g, 0.21 mmol, 23.3%) as a white solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 8.63 (s, 1H), 8.45 (s, 1H), 8.14 (d, *J* = 9.8 Hz, 2H), 7.99 (d, *J* = 9.8 Hz, 1H), 7.84 - 7.68 (m, 2H), 7.37 (dd, *J* = 14.3, 7.9 Hz, 1H), 7.21 - 7.00 (m, 3H), 4.08 (s, 3H) 4.05 (s, 2H); LCMS (ESI) *m/z*: 318.1 [M+H]⁺.

Example 154. Preparation of


N-(5-(3-fluorobenzyl)pyridin-2-yl)imidazo[1,2-*a*]pyridine-6-carboxamide (154)




Step 1: Preparation of *N*-(5-(3-fluorobenzyl)pyridin-2-yl)imidazo[1,2-*a*]pyridine-6-carboxamide




To a solution of imidazo[1,2-*a*]pyridine-6-carboxylic acid (0.151 g, 0.75 mmol) and 5-(3-fluorobenzyl)pyridin-2-amine (0.120 g, 0.75 mmol) in pyridine (4 mL) at 0 °C was added phosphorus(V) oxychloride (1.5 mL). Reaction was stirred at room temperature for 1 h. The reaction mixture was poured into ice water and extracted with ethyl acetate (100 mL x 2). Combined organic layers were washed with brine (50 mL), dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 µm column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give *N*-(5-(3-fluorobenzyl)pyridin-2-yl)imidazo[1,2-*a*]pyridine-6-carboxamide (0.0314 g, 0.0908 mmol, 12.1%) as a yellow solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 11.27 (s, 1H), 9.58 (s, 1H), 8.43 (d, *J* = 1.7 Hz, 1H), 8.36 (d, *J* = 9.7 Hz, 2H), 8.24 (d, *J* = 1.7 Hz, 1H), 8.13 (d, *J* = 8.5 Hz, 1H), 8.03 (d, *J* = 9.4 Hz, 1H), 7.78 (dd, *J* = 8.5, 2.2 Hz, 1H), 7.38-7.34 (m, 1H), 7.185- 7.12 (m, 2H), 7.07-7.03 (m, 1H), 4.01 (s, 2H); LCMS (ESI) *m/z*: 347.1 [M+H]⁺.

Example 155. Preparation of***N*-(5-(3-chlorobenzyl)pyridin-2-yl)imidazo[1,2-*a*]pyridine-6-carboxamide (155)**


Step 1: Preparation of *N*-(5-(3-chlorobenzyl)pyridin-2-yl)imidazo[1,2-*a*]pyridine-6-carboxamide



5 A solution of imidazo[1,2-*a*]pyridine-6-carboxylic acid (0.100 g, 0.62 mmol),
 5-(3-chlorobenzyl)pyridin-2-amine (0.161 g, 0.74 mmol),
 1-[*bis*(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.353 g,
 0.93 mmol) and *N,N,N*-diisopropylethylamine (0.240 g, 1.86 mmol) in *N,N*-dimethylformamide (3 mL) was
 10 stirred at room temperature for 2 h. The crude sample was dissolved in minimal *N,N*-dimethylformamide
 and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μ m column; acetonitrile/0.01% aqueous
 trifluoroacetic acid) to give *N*-(5-(3-chlorobenzyl)pyridin-2-yl)imidazo[1,2-*a*]pyridine-6-carboxamide (0.048
 g, 0.112 mmol, 18.0%) as a faint yellow solid. ^1H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 11.26 (s, 1H),
 9.57 (s, 1H), 8.41 (d, *J* = 1.8 Hz, 1H), 8.37 (d, *J* = 2.5 Hz, 1H), 8.34 (dd, *J* = 4.8, 4.8 Hz, 1H), 8.22 (d, *J* =
 15 2.0 Hz, 1H), 8.12 (d, *J* = 8.5 Hz, 1H), 8.02 (d, *J* = 9.4 Hz, 1H), 7.77 (dd, *J* = 8.5, 2.3 Hz, 1H), 7.36- 7.33
 (m, 2H), 7.29-7.25 (m, 2H), 4.00 (s, 2H); LCMS (ESI) *m/z*: 363.0 [*M*+*H*]⁺.

Example 156. Preparation of***N*-(5-(2-chlorophenoxy)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (156)**


Step 1: Preparation of 5-(2-chlorophenoxy)-2-nitropyridine



25 To a solution of 5-bromo-2-nitropyridine (1.0 g, 4.95 mmol), cesium carbonate (4.84 g, 14.9
 mmol) in acetonitrile (10 mL) at 70 °C was added 2-chlorophenol (0.824 g, 6.44 mmol) dropwise. The
 mixture was stirred at 70 °C for 2 h. The volatiles were removed under reduced pressure and the crude
 material was diluted with water (100 mL). The aqueous phase was extracted with dichloromethane (100

mL). The organic layer was dried over sodium sulfate, filtered and concentrated to give 5-(2-chlorophenoxy)-2-nitropyridine (1.10 g, crude) as a white oil. LCMS (ESI) m/z : 251.1 $[M+H]^+$. Used directly in the next step.

5 Step 2: Preparation of 5-(2-chlorophenoxy)pyridin-2-amine




To a mixture of 5-(2-chlorophenoxy)-2-nitropyridine (1.1 g, 4.4 mmol), ammonium chloride (0.466 g, 8.8 mmol) in ethanol (15 mL) and water (5 mL) was added iron powder (0.738 g, 13.2 mmol). Reaction mixture was heated to 90 °C and stirred for 1 h before it was filtered to remove iron powder. The filtrate was concentrated, under reduced pressure and dichloromethane (50 mL) was added to the residue. The resulting precipitate was filtered and the organic layer was concentrated. Purification *via* column chromatography (silica gel, petroleum ether/ethyl acetate = 4/1) affords 5-(2-chlorophenoxy)pyridin-2-amine (0.500 g, 2.29 mmol, 52%) as a red oil. LCMS (ESI) m/z : 221.2 $[M+H]^+$.

15



Step 3: Preparation of

N-(5-(2-chlorophenoxy)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide




To a solution of 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.150 g, 0.961 mmol) in dichloromethane (2 mL) at 20 °C was added oxalyl chloride (2 mL). The reaction was stirred at 0 °C for 0.5 h and concentrated *in vacuo*. The crude solid was dissolved in dichloromethane (2 mL) and added to a mixture of 5-(2-chlorophenoxy)pyridin-2-amine (0.275 g, 1.25 mmol) and triethylamine (0.291 g, 2.88 mmol) in dichloromethane (5.0 mL) dropwise. The reaction was stirred at 0 °C for 20 minutes and was concentrated, *in vacuo*. The crude residue was purified *via* column chromatography (silica gel, petroleum ether/ethyl acetate = 1/1) to yield *N*-(5-(2-chlorophenoxy)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide as a white solid (0.0275 g, 0.0769 mmol, 8%). ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 9.85 (s, 1H), 8.11-8.16 (m, 2H), 7.52-7.63 (m, 1H), 7.38 (s, 1H), 7.14-7.24 (m, 2H), 3.36 (s, 3H), 2.86 (s, 2H), 2.51-2.53 (m, 2H); LCMS (ESI) m/z : 359.1 $[M+H]^+$.

30

Example 157. Preparation of***N*-(5-(3-chlorophenoxy)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (157)****5 Step 1: Preparation of 5-(3-chlorophenoxy)-2-nitropyridine**


To a solution of 5-bromo-2-nitropyridine (1.0 g, 4.95 mmol), cesium carbonate (4.84 g, 14.9 mmol) in acetonitrile (10 mL) at 70 °C was added 3-chlorophenol (0.825 g, 6.44 mmol) dropwise. The mixture was stirred at 70 °C for 2 h. The solvent was removed under reduced pressure and the crude material was portioned with water (100 mL) and dichloromethane (100 mL). The organic layer was dried over sodium sulfate, filtered and concentrated to give 5-(3-chlorophenoxy)-2-nitropyridine (1.0 g, crude) as a white oil. LCMS (ESI) *m/z*: 251.1 [M+H]⁺. Used directly in the next step.

Step 2: Preparation of 5-(3-chlorophenoxy)pyridin-2-amine

To a mixture of 5-(3-chlorophenoxy)-2-nitropyridine (1.0 g, 4.0 mmol), ammonium chloride (0.424 g, 8.0 mmol) in ethanol (15 mL) and water (5 mL) at 90 °C was added iron powder (0.671 g, 12 mmol). Reaction mixture was stirred at 90 °C for 1 h. Reaction was filtered and the filtrate was concentrated, under reduced pressure. The crude material was treated with dichloromethane (50 mL) and the resulting precipitate was filtered off. The organic layer was then concentrated and purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 4/1) to afford 5-(3-chlorophenoxy)pyridin-2-amine (0.400 g, 1.8 mmol, 45%) as a green solid. LCMS (ESI) *m/z*: 221.1 [M+H]⁺.

Step 3: Preparation of

N-(5-(3-chlorophenoxy)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide




To a solution of 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.150 g, 0.961 mmol) in dichloromethane (2 mL) at 20 °C was added oxalyl chloride (2 mL). The reaction was stirred at 20 °C for 0.5 h and concentrated *in vacuo*. The crude solid was dissolved in dichloromethane (4 mL) and added to a mixture of 5-(3-chlorophenoxy)pyridin-2-amine (0.275 g, 1.25 mmol) and triethylamine (0.291 g, 2.88 mmol) in dichloromethane (5.0 mL) dropwise. The reaction was stirred at 20 °C for 20 minutes and was concentrated, *in vacuo*. The crude sample was purified by prep-TLC (silica gel, petroleum ether/ethyl acetate = 1/1) to yield

N-(5-(3-chlorophenoxy)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.0119 g, 0.0336 mmol, 3.5%) as a white solid. ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 9.88 (s, 1H), 8.24 (d, *J* = 2.4 Hz, 1H), 8.15 (d, *J* = 7.6 Hz, 1H), 7.65-7.67 (m, 1H), 7.41-7.44 (m, 1H), 7.22-7.23 (m, 1H), 7.13 (s, 1H), 7.00-7.02 (m, 1H), 3.37 (s, 3H), 2.87 (t, *J* = 6.8 Hz, 2H), 2.54 (d, *J* = 6.4 Hz, 2H); LCMS (ESI) *m/z*: 359.1 [M+H]⁺.


Example 158. Preparation of

N-(4-(4-chlorophenoxy)phenyl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (158)



Step 1: Preparation of

N-(4-(4-chlorophenoxy)phenyl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide




To a mixture of 4-(4-chlorophenoxy)aniline (0.100 g, 0.457 mmol) and 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.072 mg, 0.457 mmol) in tetrahydrofuran (2 mL) was added 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.208 g, 0.548 mmol) and *N,N*-diisopropylethylamine (0.118 g, 0.914 mmol). The reaction was stirred at room temperature 16 h. Mixture was combined with another batch (0.1 g) and diluted with water (20 mL). The aqueous layer was extracted with ethyl acetate (10 mL x 3). The combined organic layers were washed with brine (10 mL), dried over sodium sulfate, filtered and concentrated *in vacuo*. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μm column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give *N*-(4-(4-chlorophenoxy)phenyl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (122.2 mg, 0.342 mmol, 68%,) as a light-yellow solid. ¹H NMR (500 MHz, Chloroform-*d*) δ 8.75 (s, 1H), 7.62 (dd,

$J = 7.0, 2.0$ Hz, 2H), 7.30 (td, $J = 6.5, 2.5$ Hz, 2H), 7.06-6.99 (m, 2H), 6.96 (dd, $J = 6.0, 4.0$ Hz, 2H), 3.49 (s, 3H), 3.01 (t, $J = 8.5$ Hz, 2H), 2.61 (t, $J = 8.5$ Hz, 2H); LCMS (ESI) m/z : 358.0 $[M+H]^+$.


Example 159. Preparation of

5 *N*-(4-(3-chlorophenoxy)phenyl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (159)



Step 1: Preparation of

N-(4-(3-chlorophenoxy)phenyl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide




10 To a mixture of 4-(3-chlorophenoxy)aniline (0.100 g, 0.457 mmol) and 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.072 g, 0.457 mmol) in tetrahydrofuran (2 mL) was added 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.208 g, 0.548 mmol) and *N,N*-diisopropylethylamine (0.118 g, 0.914 mmol). The reaction was stirred at room temperature 16 h. Mixture was combined with another batch (0.100 g) and

15 diluted with water (20 mL). The aqueous layer was extracted with ethyl acetate (10 mL x 3). The combined organic layers were washed with brine (10 mL), dried over sodium sulfate, filtered and concentrated *in vacuo*. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μ m column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give *N*-(4-(3-chlorophenoxy)phenyl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.125 g,


20 0.350 mmol, 70%) as a light-yellow solid. ^1H NMR (500 MHz, Dimethylsulfoxide- d_6) δ 10.10 (s, 1H), 7.84-7.76 (m, 2H), 7.40 (t, $J = 8.0$ Hz, 1H), 7.18 (ddd, $J = 8.0, 2.0, 0.5$ Hz, 1H), 7.12-7.05 (m, 2H), 7.02 (t, $J = 2.0$ Hz, 1H), 6.95 (ddd, $J = 8.0, 2.5, 0.5$ Hz, 1H), 3.38 (s, 3H), 2.85 (t, $J = 8.5$ Hz, 2H), 2.56-2.50 (m, 2H); LCMS (ESI) m/z : 358.1 $[M+H]^+$.

25 Example 160. Preparation of

N-[5-(3-fluorophenoxy)pyridin-2-yl]-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (160)



Step 1: Preparation of 5-(3-fluorophenoxy)-2-nitropyridine




To a sealed tube was added 3-fluorophenol (0.551 g, 4.92 mmol), 5-bromo-2-nitropyridine (1.0 g, 4.92 mmol), and cesium carbonate (2.40 g, 7.37 mmol) and suspended in acetonitrile (10 mL).

- 5 Reaction was heated to 70 °C for 2 h. Reaction was cooled to room temperature and concentrated. The crude product was purified over silica gel (ISCO, 40 g, 0-15% ethyl acetate/hexanes, over 25 minutes) to give 5-(3-fluorophenoxy)-2-nitropyridine (644 mg, 2.74 mmol, 56%) as a yellow solid. ¹H NMR (300 MHz, Chloroform-*d*) δ 8.37 (d, *J* = 2.8 Hz, 1H), 8.29 (d, *J* = 8.9 Hz, 1H), 7.53 - 7.35 (m, 2H), 7.03 (tdd, *J* = 8.3, 2.4, 0.9 Hz, 1H), 6.97 - 6.78 (m, 2H); LCMS (ESI) *m/z*: 235.1 [M+H]⁺.

10


Step 2: Preparation of 5-(3-fluorophenoxy)pyridin-2-amine



- 15 To a hot solution of 5-(3-fluorophenoxy)-2-nitropyridine (0.300 g, 1.28 mmol) and ammonium chloride (0.273 g, 5.12 mmol) in methanol (3.45 mL) and water (0.86 mL) at 70 °C was added iron (0.285 g, 5.12 mmol) in one portion. The reaction was stir heated at 70 °C for 16 h, after which the reaction was cooled to room temperature and diluted with saturated solution of sodium bicarbonate (40 mL). The reaction mixture volume was diluted with ethyl acetate (50 mL) and filtered through a pad of Celite® and washed with ethyl acetate (20 mL x 3). Layers were separated and the aqueous layer was extracted with ethyl acetate (50 mL x 2). The combined organic layers were dried over magnesium sulfate, filtered and
- 20 concentrated to give the 5-(3-fluorophenoxy)pyridin-2-amine (0.261 g, 1.27 mmol, 100%) as a crude red solid. The crude material is used without further purification.

Step 3: Preparation of

N-[5-(3-fluorophenoxy)pyridin-2-yl]-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide



25

- To a solution of 1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (0.050 g, 0.327 mmol), 5-(3-fluorophenoxy)pyridin-2-amine (0.0666 g, 0.327 mmol) and [*bis*(dimethylamino)methylidene]({3H-[1,2,3]triazolo[4,5-*b*]pyridin-3-yl})oxidanium; hexafluoro-λ⁵-phosphanuide (0.124 g, 0.327 mmol) in tetrahydrofuran (1.1 mL) at room temperature was
- 30 added diisopropylethylamine (0.113 mL, 0.653 mmol) dropwise. Reaction was stir at room temperature for 16 h. Reaction solution was quenched with water (1 mL). The aqueous layer was extracted with ethyl acetate (5 mL x 3). The combined organic layers were washed with brine, dried over magnesium sulfate, filtered and concentrated. The crude residue was purified over silica gel chromatography (ISCO, 12 g,

eluting with 0-80% ethyl acetate/hexanes for 20 minutes) to


afford *N*-[5-(3-fluorophenoxy)pyridin-2-yl]-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (27.7

mg, 0.0817 mmol, 21%) as a yellow solid. ¹H NMR (300 MHz, Dimethylsulfoxide-*d*₆) δ 10.67 (s, 1H), 8.68 (d, *J* = 2.7 Hz, 1H), 8.31 - 8.12 (m, 2H), 8.00 (dd, *J* = 9.6, 2.7 Hz, 1H), 7.64 (dd, *J* = 9.1, 3.0 Hz, 1H), 7.43

5 (td, *J* = 8.3, 6.9 Hz, 1H), 7.05 - 6.82 (m, 3H), 6.44 (d, *J* = 9.5 Hz, 1H); LCMS (ESI) *m/z*: 340.3 [M+H]⁺.


Example 161. Preparation of

N-[5-(3-chlorophenoxy)pyridin-2-yl]-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (161)



10

Step 1: Preparation of 5-(3-chlorophenoxy)-2-nitropyridine



A sealed tube was charged with 3-chlorophenol (0.632 g, 4.92

mmol), 5-bromo-2-nitropyridine (1.0 g, 4.92 mmol), cesium carbonate (2.40 g, 7.37 mmol) and


15 acetonitrile (9.84 mL). Reaction was heated to 70 °C for 2 h. Reaction was cooled to room temperature and concentrated. The crude product was purified over silica gel chromatography (ISCO, 40 g, 0-15%

ethyl acetate/hexanes, over 25 minutes) to give 5-(3-chlorophenoxy)-2-nitropyridine (0.807 g, 3.21 mmol,

65%) as a white solid. ¹H NMR (300 MHz, Chloroform-*d*) δ 8.36 (d, *J* = 2.8 Hz, 1H), 8.29 (d, *J* = 8.9 Hz, 1H), 7.53 - 7.38 (m, 2H), 7.38 - 7.22 (m, 1H), 7.15 (t, *J* = 2.1 Hz, 1H), 7.03 (ddd, *J* = 8.2, 2.4, 1.0 Hz,

20 1H); LCMS (ESI) *m/z*: 251.0 [M+H]⁺.

Step 2: Preparation of 5-(3-chlorophenoxy)pyridin-2-amine



To a heated 70 °C solution of 5-(3-chlorophenoxy)-2-nitropyridine (0.300 g, 1.19 mmol)

25 and ammonium chloride (0.254 g, 4.76 mmol) in a 4:1 mixture of methanol (3.2 mL) and water (0.80

mL) was added iron (0.265 g, 4.76 mmol) in one portion. The reaction was stir at 70 °C for 16 h, after

which the reaction was cooled to room temperature and saturated bicarbonate (8 mL) was added. The reaction mixture volume was diluted with ethyl acetate (50 mL) and filtered through a pad of Celite® and

washed with ethyl acetate (20 mL x 3). Layers were separated and the aqueous layer was extracted with


30 ethyl acetate (50 mL x 2). The organic layer was dried over magnesium sulfate, filtered and concentrated

to give 5-(3-chlorophenoxy)pyridin-2-amine (0.254 g, 1.15 mmol) as a crude a brown oil. ^1H NMR (300 MHz, Chloroform- d) δ 7.93 (dd, J = 2.9, 0.7 Hz, 1H), 7.31 - 7.12 (m, 2H), 7.03 (ddd, J = 8.0, 2.0, 0.9 Hz, 1H), 6.91 (t, J = 2.2 Hz, 1H), 6.89 - 6.79 (m, 1H), 6.55 (dd, J = 8.8, 0.7 Hz, 1H), 4.45 (s, 2H).; LCMS (ESI) m/z : 221.2 $[\text{M}+\text{H}]^+$. Used without further purification in the next step.

5

Step 3: Preparation of

N-[5-(3-chlorophenoxy)pyridin-2-yl]-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide



To a solution of 1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (0.050 g, 0.327

10 mmol), 5-(3-chlorophenoxy)pyridin-2-amine (0.072 g, 0.327 mmol)

and [*bis*(dimethylamino)methylidene]({3H-[1,2,3]triazolo[4,5-*b*]pyridin-3-yl})oxidanium;

hexafluoro- λ^5 -phosphanuide (0.124 g, 0.327 mmol) in tetrahydrofuran (1.1 mL) at room temperature was added diisopropylethylamine (0.113 mL, 0.653 mmol) dropwise. Reaction was stir at room temperature for 16 h. Reaction solution was quenched with water (1 mL). The aqueous layer was extracted with ethyl acetate (5 mL x 3). The combined organic layers were washed with brine, dried over magnesium sulfate, filtered and concentrated. The crude residue was purified over silica gel *via* column chromatography (ISCO, 12 g, eluting with 0-80% ethyl acetate/hexanes for 20 minutes) to

15

afford *N*-[5-(3-chlorophenoxy)pyridin-2-yl]-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (24.0


mg, 0.0675 mmol, 20.6%) as a yellow solid. ^1H NMR (300 MHz, Dimethylsulfoxide- d_6) δ 10.68 (s, 1H),

20


8.68 (d, J = 2.7 Hz, 1H), 8.25 (d, J = 3.0 Hz, 1H), 8.19 (d, J = 9.0 Hz, 1H), 7.99 (dd, J = 9.5, 2.7 Hz, 1H), 7.64 (dd, J = 9.1, 2.9 Hz, 1H), 7.42 (t, J = 8.2 Hz, 1H), 7.21 (ddd, J = 8.0, 2.0, 0.9 Hz, 1H), 7.12 (t, J = 2.2 Hz, 1H), 7.00 (ddd, J = 8.3, 2.4, 1.0 Hz, 1H), 6.44 (d, J = 9.5 Hz, 1H); LCMS (ESI) m/z : 356. $[\text{M}+\text{H}]^+$.

Example 162. Preparation of

25 *N*-[5-(3-fluorophenoxy)pyridin-2-yl]-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (162)



Step 1: Preparation of 5-(3-fluorophenoxy)-2-nitropyridine




To a sealed tube was added 3-fluorophenol (0.551 g, 4.92 mmol), 5-bromo-2-nitropyridine (1.0 g, 4.92 mmol), and cesium carbonate (2.40 g, 7.37 mmol) and suspended in acetonitrile (10 mL).

- 5 Reaction was heated to 70 °C for 2 h. Reaction was cooled to room temperature and concentrated. The crude product was purified over silica gel chromatography (ISCO, 40 g, 0-15% ethyl acetate/hexanes, over 25 minutes) to give 5-(3-fluorophenoxy)-2-nitropyridine (0.644 g, 2.74 mmol, 56%) as a yellow solid. ¹H NMR (300 MHz, Chloroform-*d*) δ 8.37 (d, *J* = 2.8 Hz, 1H), 8.29 (d, *J* = 8.9 Hz, 1H), 7.53 - 7.35 (m, 2H), 7.03 (tdd, *J* = 8.3, 2.4, 0.9 Hz, 1H), 6.97 - 6.78 (m, 2H); LCMS (ESI) *m/z*: 235.1 [M+H]⁺.

10

Step 2: Preparation of 5-(3-fluorophenoxy)pyridin-2-amine




To a hot solution of 5-(3-fluorophenoxy)-2-nitropyridine (0.300 g, 1.28 mmol) and ammonium chloride (0.273 g, 5.12 mmol) in methanol (3.45 mL) and water (0.864 mL) at 70 °C was

- 15 added iron (0.285 g, 5.12 mmol) in one portion. The reaction was stir heated at 70 °C for 16 h, after which the reaction was cool to room temperature and diluted with saturated solution of sodium bicarbonate (40 mL). The reaction mixture volume was diluted with ethyl acetate (50 mL) and filtered through a pad of Celite® and washed with ethyl acetate (20 mL x 3). Layers were separated and the aqueous layer was extracted with ethyl acetate (50 mL x 2). The combined organic layers were dried over magnesium
- 20 sulfate, filtered and concentrated to give the 5-(3-fluorophenoxy)pyridin-2-amine (0.261 g, 1.27 mmol, 100%) as a crude red solid. Used directly in the step without further purification.

Step 3: Preparation of

N-[5-(3-fluorophenoxy)pyridin-2-yl]-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide



25

To a solution of 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (0.050 g, 0.324 mmol), 5-(3-fluorophenoxy)pyridin-2-amine (0.0662 g, 0.324 mmol)

and [*bis*(dimethylamino)methylidene]({3H-[1,2,3]triazolo[4,5-*b*]pyridin-3-yl})oxidanium;


hexafluoro-λ⁵-phosphanuide (0.123 g, 0.3244 mmol) in tetrahydrofuran (1.1 mL) at room temperature

- 30 was added diisopropylethylamine (0.112 mL, 0.649 mmol) dropwise. Reaction was stir at room temperature for 16 h. Reaction solution was quenched with water (1 mL). The aqueous layer was extracted with ethyl acetate (5 mL x 3). The combined organic layers were washed with brine, dried over


magnesium sulfate, filtered and concentrated. The crude residue was purified over silica gel chromatography (ISCO, 12 g, eluting with 0-80% ethyl acetate/hexanes for 20 minutes) to afford *N*-[5-(3-fluorophenoxy)pyridin-2-yl]-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (59.8 mg, 0.176 mmol, 54.3%) as a yellow solid. ¹H NMR (300 MHz, Chloroform-*d*) δ 9.49 (s, 1H), 8.36 (dt, *J* = 9.1, 0.7 Hz, 1H), 8.18 (dt, *J* = 2.9, 0.7 Hz, 1H), 8.08 (d, *J* = 9.9 Hz, 1H), 7.48 (dd, *J* = 9.0, 2.9 Hz, 1H), 7.39 - 7.28 (m, 1H), 7.07 (dt, *J* = 9.6, 0.7 Hz, 1H), 6.93 - 6.67 (m, 3H), 3.91 (d, *J* = 0.5 Hz, 3H); LCMS (ESI) *m/z*: 341.4 [M+H]⁺.

Example 163. Preparation

of *N*-[5-(3-chlorophenoxy)pyridin-2-yl]-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (163)




Step 1: Preparation of 5-(3-chlorophenoxy)-2-nitropyridine



To a sealed tube was added 3-chlorophenol (0.632 g, 4.92 mmol), 5-bromo-2-nitropyridine (1.0 g, 4.92 mmol), and cesium carbonate (2.40 g, 7.37 mmol) and suspended in acetonitrile (9.84 mL). Reaction was heated to 70 °C for 2 h. Reaction was cooled to room temperature and concentrated. The crude product was purified over silica gel chromatography (ISCO, 40 g, 0-15% ethyl acetate/hexanes, over 25 minutes) to give 5-(3-chlorophenoxy)-2-nitropyridine (0.807 g, 3.21 mmol, 65%) as a white solid. ¹H NMR (300 MHz, Chloroform-*d*) δ 8.36 (d, *J* = 2.8 Hz, 1H), 8.29 (d, *J* = 8.9 Hz, 1H), 7.53 - 7.38 (m, 2H), 7.38 - 7.22 (m, 1H), 7.15 (t, *J* = 2.1 Hz, 1H), 7.03 (ddd, *J* = 8.2, 2.4, 1.0 Hz, 1H); LCMS (ESI) *m/z*: 251.0 [M+H]⁺.

Step 2: Preparation of 5-(3-chlorophenoxy)pyridin-2-amine




To a heated 70 °C solution of 5-(3-chlorophenoxy)-2-nitropyridine (0.300 g, 1.19 mmol) and ammonium chloride (0.254 g, 4.76 mmol) in a 4:1 mixture of methanol (3.21 mL) and water (0.80 mL) was added iron (0.265 g, 4.76 mmol) in one portion. The reaction was stirred at 70 °C for 16 h, after which the reaction was cooled to room temperature and 8 mL of saturated bicarbonate was added. The

reaction mixture volume was diluted with ethyl acetate (50 mL) and filtered through a pad of Celite® and washed with ethyl acetate (20 mL x 3). Layers were separated and the aqueous layer was extracted with ethyl acetate (50 mL x 2). The organic layer was dried over magnesium sulfate, filtered and concentrated to give 5-(3-chlorophenoxy)pyridin-2-amine (0.254 g, 1.15 mmol) as a crude a brown oil. ¹H NMR (300 MHz, Chloroform-*d*) δ 7.93 (dd, *J* = 2.9, 0.7 Hz, 1H), 7.31 - 7.12 (m, 2H), 7.03 (ddd, *J* = 8.0, 2.0, 0.9 Hz, 1H), 6.91 (t, *J* = 2.2 Hz, 1H), 6.89 - 6.79 (m, 1H), 6.55 (dd, *J* = 8.8, 0.7 Hz, 1H), 4.45 (s, 2H).; LCMS (ESI) *m/z*: 221.2 [M+H]⁺. The crude material is used without further purification in the next step.

Step 3: Preparation of

N-[5-(3-chlorophenoxy)pyridin-2-yl]-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide




To a solution of 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (0.050 g, 0.3244 mmol), 5-(3-chlorophenoxy)pyridin-2-amine (0.0712 g, 0.324 mmol) and [bis(dimethylamino)methylidene]({3H-[1,2,3]triazolo[4,5-*b*]pyridin-3-yl})oxidanium;

hexafluoro-λ⁵-phosphanuide (0.123 g, 0.324 mmol) in tetrahydrofuran (1.1 mL) at room temperature was added diisopropylethylamine (0.112 mL, 0.649 mmol) dropwise. Reaction was stir at room temperature for 16 h. Reaction solution was quenched with water (1 mL). The aqueous layer was extracted with ethyl acetate (5 mL x 3). The combined organic layers were washed with brine, dried over magnesium sulfate, filtered and concentrated. The crude residue was purified over silica gel chromatography (ISCO, 12 g, eluting with 0-80% ethyl acetate/hexanes for 20 minutes) to afford


N-[5-(3-chlorophenoxy)pyridin-2-yl]-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (85.4 mg, 0.239 mmol, 77%) as a yellow solid. ¹H NMR (300 MHz, Chloroform-*d*) δ 9.52 (s, 1H), 8.37 (d, *J* = 9.0 Hz, 1H), 8.17 (dd, *J* = 2.9, 0.7 Hz, 1H), 8.08 (d, *J* = 9.7 Hz, 1H), 7.48 (dd, *J* = 9.0, 2.9 Hz, 1H), 7.31 (d, *J* = 8.2 Hz, 1H), 7.18 - 6.83 (m, 4H), 3.91 (s, 3H); LCMS (ESI) *m/z*: 357.5 [M+H]⁺.

Example 164. Preparation of

1-ethyl-*N*-[5-(3-fluorophenoxy)pyridin-2-yl]-6-oxo-1,6-dihydropyridine-3-carboxamide (164)



Step 1: Preparation of 5-(3-fluorophenoxy)-2-nitropyridine




To a sealed tube was added 3-fluorophenol (0.551 g, 4.92 mmol), 5-bromo-2-nitropyridine (1.0 g, 4.92 mmol), and cesium carbonate (2.40 g, 7.37 mmol) and suspended in acetonitrile (10 mL).

- 5 Reaction was heated to 70 °C for 2 h. Reaction was cooled to room temperature and concentrated. The crude product was purified over silica gel chromatography (ISCO, 40 g, 0-15% ethyl acetate/hexanes, over 25 minutes) to give 5-(3-fluorophenoxy)-2-nitropyridine (0.644 g, 2.74 mmol, 56%) as a yellow solid. ¹H NMR (300 MHz, Chloroform-*d*) δ 8.37 (d, *J* = 2.8 Hz, 1H), 8.29 (d, *J* = 8.9 Hz, 1H), 7.53 - 7.35 (m, 2H), 7.03 (tdd, *J* = 8.3, 2.4, 0.9 Hz, 1H), 6.97 - 6.78 (m, 2H); LCMS (ESI) *m/z*: 235.1 [M+H]⁺.

10


Step 2: Preparation of 5-(3-fluorophenoxy)pyridin-2-amine



To a hot solution of 5-(3-fluorophenoxy)-2-nitropyridine (0.300 g, 1.28 mmol) and ammonium chloride (0.273 g, 5.12 mmol) in methanol (3.45 mL) and water (0.864 mL) at 70 °C was


- 15 added iron (0.285 g, 5.12 mmol) in one portion. The reaction was stir heated at 70 °C for 16 h, after which the reaction was cool to room temperature and diluted with saturated solution of sodium bicarbonate (40 mL) was added. The reaction mixture volume was diluted with ethyl acetate (50 mL) and filtered through a pad of Celite®. The pad was washed with ethyl acetate (20 mL x 3) and the aqueous layer was extracted with ethyl acetate (50 mL x 2). The combined organic layers were dried over magnesium sulfate, filtered
- 20 and concentrated to give the 5-(3-fluorophenoxy)pyridin-2-amine (0.261 g, 1.27 mmol, 100%) as a crude red solid. The crude material is used without further purification.

Step 3: Preparation of methyl 1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxylate



- 25 A solution of methyl 2-oxo-2H-pyran-5-carboxylate (0.500 g, 3.24 mmol) was added. in methanol (10.8 mL) at room temperature was treated with ethanamine (2.02 mL, 4.05 mmol) and triethylamine (0.796 mL, 5.67 mmol). Reaction mixture stirred for 1 h before it was concentrated, and purified by silica gel chromatography (ISCO, ethyl acetate/hexanes, 3:1, over 20 minutes) to give methyl 1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxylate (0.380 g, 2.09 mmol, 64% as a brown oil. ¹H NMR
- 30 (300 MHz, Chloroform-*d*) δ 8.20 (dd, *J* = 2.5, 0.6 Hz, 1H), 7.84 (dd, *J* = 9.5, 2.5 Hz, 1H), 6.58 - 6.46 (m, 1H), 4.05 (q, *J* = 7.2 Hz, 2H), 3.87 (s, 3H), 1.40 (t, *J* = 7.2 Hz, 3H).; LCMS (ESI) *m/z*: 182.2 [M+H]⁺.

Step 4: Preparation of 1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid




To a solution of methyl 1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxylate (0.180 g, 0.9934 mmol) in tetrahydrofuran (3.31 mL) and water (0.83 mL) at 25 °C was added lithium hydrate hydroxide (0.0625 g, 1.49 mmol) in one portion. The reaction mixture was stirred at room temperature 3 h before it was evaporated to dryness, diluted with water (15 mL) and adjusted to pH = 2 with 1N hydrogen chloride solution. The reaction mixture was extracted with ethyl acetate (20 mL x 3). The combined organic layers were dried over magnesium sulfate, filtered and concentrated *in vacuo* to give 1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (0.066 g, 0.407 mmol, 40.9%) as a yellow solid.

¹H NMR (300 MHz, Dimethylsulfoxide-*d*₆) δ 12.80 (s, 1H), 8.46 (d, *J* = 2.6 Hz, 1H), 7.77 (dt, *J* = 9.5, 1.8 Hz, 1H), 6.39 (d, *J* = 9.5 Hz, 1H), 3.98 (q, *J* = 7.1 Hz, 2H), 1.20 (q, *J* = 6.7 Hz, 4H); LCMS (ESI) *m/z*: 168.2 [M+H]⁺. Used in the next step without further purification.

Step 5: Preparation of



1-ethyl-*N*-[5-(3-fluorophenoxy)pyridin-2-yl]-6-oxo-1,6-dihydropyridine-3-carboxamide




To a solution of 1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (0.050 g, 0.2991 mmol), 5-(3-fluorophenoxy)pyridin-2-amine (0.061 g, 0.299 mmol) and [*bis*(dimethylamino)methylidene]({3H-[1,2,3]triazolo[4,5-*b*]pyridin-3-yl})oxidanium;

hexafluoro-λ⁵-phosphanuide (0.113 g, 0.2991 mmol) in tetrahydrofuran (1 mL) at room temperature was added *N,N*-diisopropylethylamine (0.1 mL, 0.5982 mmol) dropwise. Reaction was stirred at room temperature for 16 h. Reaction solution was quenched with water (1 mL). The aqueous layer was extracted with ethyl acetate (5 mL x 3). The combined organic layers were washed with brine, dried over magnesium sulfate, filtered and concentrated. The crude residue was purified over silica gel

chromatography (ISCO, 12 g, eluting with 0-80% ethyl acetate/hexanes for 20 minutes) to afford 1-ethyl-*N*-[5-(3-fluorophenoxy)pyridin-2-yl]-6-oxo-1,6-dihydropyridine-3-carboxamide (32.6 mg, 0.0924 mmol, 31%). ¹H NMR (300 MHz, Chloroform-*d*) δ 8.32 (dd, *J* = 9.0, 0.7 Hz, 1H), 8.24 (d, *J* = 2.5 Hz, 2H), 8.13 (dd, *J* = 2.9, 0.7 Hz, 1H), 7.74 (dd, *J* = 9.6, 2.7 Hz, 1H), 7.47 (dd, *J* = 9.0, 2.9 Hz, 1H), 7.36 - 7.28 (m, 1H), 6.92 - 6.67 (m, 3H), 6.63 (d, *J* = 9.5 Hz, 1H), 4.10 (q, *J* = 7.2 Hz, 2H), 1.44 (t, *J* = 7.2 Hz, 3H); LCMS (ESI) *m/z*: 354.4 [M+H]⁺.


Example 165. Preparation of***N*-[5-(3-chlorophenoxy)pyridin-2-yl]-1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxamide (165)****5 Step 1: Preparation of 5-(3-chlorophenoxy)-2-nitropyridine**

To a sealed tube was added 3-chlorophenol (0.632 g, 4.92 mmol), 5-bromo-2-nitropyridine (1.0 g, 4.92 mmol), and cesium carbonate (2.40 g, 7.37 mmol) and suspended in acetonitrile (9.84 mL). Reaction was heated to 70 °C for 2 h. Reaction was cooled to room temperature and concentrated. The crude product was purified over silica gel (ISCO, 40 g, 0-15% ethyl acetate/hexanes, over 25 minutes) to give 5-(3-chlorophenoxy)-2-nitropyridine (0.807 g, 3.21 mmol, 65%) as a white solid. ¹H NMR (300 MHz, Chloroform-*d*) δ 8.36 (d, *J* = 2.8 Hz, 1H), 8.29 (d, *J* = 8.9 Hz, 1H), 7.53 - 7.38 (m, 2H), 7.38 - 7.22 (m, 1H), 7.15 (t, *J* = 2.1 Hz, 1H), 7.03 (ddd, *J* = 8.2, 2.4, 1.0 Hz, 1H); LCMS (ESI) *m/z*: 251.0 [M+H]⁺.

15 Step 2: Preparation of 5-(3-chlorophenoxy)pyridin-2-amine


To a heated 70 °C solution of 5-(3-chlorophenoxy)-2-nitropyridine (0.300 g, 1.19 mmol) and ammonium chloride (0.254 g, 4.76 mmol) in a 4:1 mixture of methanol (3.21 mL) and water (0.80 mL) was added iron (0.265 g, 4.76 mmol) in one portion. The reaction was stirred at 70 °C for 16 h, after which the reaction was cooled to room temperature and 8 mL of saturated bicarbonate was added. The reaction mixture volume was diluted with ethyl acetate (50 mL) and filtered through a pad of Celite® and washed with ethyl acetate (20 mL x 3). Layers were separated and the aqueous layer was extracted with ethyl acetate (50 mL x 2). The organic layer was dried over magnesium sulfate, filtered and concentrated to give 5-(3-chlorophenoxy)pyridin-2-amine (0.254 g, 1.15 mmol) as a crude brown oil. The crude material is used without further purification in the next step. ¹H NMR (300 MHz, Chloroform-*d*) δ 7.93 (dd, *J* = 2.9, 0.7 Hz, 1H), 7.31 - 7.12 (m, 2H), 7.03 (ddd, *J* = 8.0, 2.0, 0.9 Hz, 1H), 6.91 (t, *J* = 2.2 Hz, 1H), 6.89 - 6.79 (m, 1H), 6.55 (dd, *J* = 8.8, 0.7 Hz, 1H), 4.45 (s, 2H); LCMS (ESI) *m/z*: 221.2 [M+H]⁺.

Step 3: Preparation of methyl 1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxylate



A solution of methyl 2-oxo-2H-pyran-5-carboxylate (0.500 g, 3.24 mmol) in methanol (10.8 mL) at room temperature was treated with ethanamine (2.0 mL, 4.05 mmol) and triethylamine (0.796 mL, 5.67 mmol). Reaction mixture stirred for 1 h before it was concentrated, and purified by silica gel chromatography (ISCO, ethyl acetate/hexanes, 3:1, over 20 minutes) to give methyl 1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxylate (380 mg, 2.09 mmol, 64%) as a brown oil. ¹H NMR (300 MHz, Chloroform-*d*) δ 8.20 (dd, *J* = 2.5, 0.6 Hz, 1H), 7.84 (dd, *J* = 9.5, 2.5 Hz, 1H), 6.58 - 6.46 (m, 1H), 4.05 (q, *J* = 7.2 Hz, 2H), 3.87 (s, 3H), 1.40 (t, *J* = 7.2 Hz, 3H); LCMS (ESI) *m/z*: 182.2 [M+H]⁺.


Step 4: Preparation of 1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid



To a solution of methyl 1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxylate (0.180 g, 0.9934 mmol) in tetrahydrofuran (3.31 mL) and water (0.83 mL) at 25 °C was added lithium hydroxide hydrate (62.5 mg, 1.49 mmol) in one portion. The reaction mixture was stirred at room temperature for 3 h before it was evaporated to dryness, diluted with water (15 mL) and adjusted to pH = 2 with 1N hydrogen chloride solution. The reaction mixture was extracted with ethyl acetate (20 mL x 3). The combined organic layers were dried over magnesium sulfate, filtered and concentrated in vacuo to give 1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (0.066 g, 0.407 mmol, 40.9%) as a yellow solid. ¹H NMR (300 MHz, Dimethylsulfoxide-*d*₆) δ 12.80 (s, 1H), 8.46 (d, *J* = 2.6 Hz, 1H), 7.77 (dt, *J* = 9.5, 1.8 Hz, 1H), 6.39 (d, *J* = 9.5 Hz, 1H), 3.98 (q, *J* = 7.1 Hz, 2H), 1.20 (q, *J* = 6.7 Hz, 4H); LCMS (ESI) *m/z*: 168.2 [M+H]⁺. Used in the next step without further purification.

Step 5: Preparation of

N-[5-(3-chlorophenoxy)pyridin-2-yl]-1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxamide



To a solution of 1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (0.050 g, 0.2991 mmol), 5-(3-chlorophenoxy)pyridin-2-amine (0.066 g, 0.299 mmol) and [bis(dimethylamino)methylidene]({3H-[1,2,3]triazolo[4,5-*b*]pyridin-3-yl})oxidanium;

hexafluoro-λ⁵-phosphanuide (0.113 g, 0.299 mmol) in tetrahydrofuran (1.0 mL) at room temperature was

added diisopropylethylamine (0.10 mL, 0.598 mmol) dropwise. Reaction was stirred at room temperature for 16 h. Reaction solution was quenched with water (1 mL). The aqueous layer was extracted with ethyl acetate (5 mL x 3). The combined organic layers were washed with brine, dried over magnesium sulfate, filtered and concentrated. The crude residue was purified over silica gel chromatography (ISCO, 12 g,

eluting with 0-80% ethyl acetate/hexanes for 20 minutes) to

afford *N*-[5-(3-chlorophenoxy)pyridin-2-yl]-1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxamide (39.6

mg, 0.107 mmol, 36%). ¹H NMR (300 MHz, Chloroform-*d*) δ 8.33 (d, *J* = 9.1 Hz, 1H), 8.24 (d, *J* = 2.7


Hz, 2H), 8.13 (d, *J* = 2.8 Hz, 1H), 7.73 (dd, *J* = 9.6, 2.8 Hz, 1H), 7.46 (dd, *J* = 9.1, 2.9 Hz, 1H), 7.30 (t, *J*

= 8.2 Hz, 2H), 7.13 (d, *J* = 8.6 Hz, 1H), 7.00 (t, *J* = 2.2 Hz, 1H), 6.91 (dd, *J* = 8.4, 2.1 Hz, 1H), 6.63 (d, *J*


= 9.5 Hz, 1H), 4.10 (q, *J* = 7.3 Hz, 2H), 1.44 (t, *J* = 7.2 Hz, 3H); LCMS (ESI) *m/z*: 370.4 [M+H]⁺.

Example 166. Preparation of

N-[5-(3-chlorophenoxy)pyridin-2-yl]-6-oxo-1-(propan-2-yl)-1,6-dihydropyridine-3-carboxamide (166)




Step 1: Preparation of 5-(3-chlorophenoxy)-2-nitropyridine



To a sealed tube was added 3-chlorophenol (0.632 g, 4.92 mmol), 5-bromo-2-nitropyridine (1.0 g, 4.92 mmol), and cesium carbonate (2.40 g, 7.37 mmol) and suspended in acetonitrile (9.84 mL).

Reaction was heated to 70 °C for 2 h. Reaction was cooled to room temperature and concentrated. The crude product was purified over silica gel (ISCO, 40 g, 0-15% ethyl acetate/hexanes, over 25 minutes) to give 5-(3-chlorophenoxy)-2-nitropyridine (0.807 g, 3.21 mmol, 65%) as a white solid. ¹H NMR (300 MHz, Chloroform-*d*) δ 8.36 (d, *J* = 2.8 Hz, 1H), 8.29 (d, *J* = 8.9 Hz, 1H), 7.53 - 7.38 (m, 2H), 7.38 - 7.22 (m, 1H), 7.15 (t, *J* = 2.1 Hz, 1H), 7.03 (ddd, *J* = 8.2, 2.4, 1.0 Hz, 1H); LCMS (ESI) *m/z*: 251. [M+H]⁺.


Step 2: Preparation of 5-(3-chlorophenoxy)pyridin-2-amine



To a heated 70 °C solution of 5-(3-chlorophenoxy)-2-nitropyridine (0.300 g, 1.19 mmol) and ammonium chloride (0.254 g, 4.76 mmol) in a 4:1 mixture of methanol (3.2 mL) and water (0.80


mL) was added iron (0.265 g, 4.76 mmol) in one portion. The reaction was stirred at 70 °C for 16 h, after which the reaction was cooled to room temperature and 8 mL of saturated bicarbonate was added. The reaction mixture volume was diluted with ethyl acetate (50 mL) and filtered through a pad of Celite® and washed with ethyl acetate (20 mL x 3). Layers were separated and the aqueous layer was extracted with ethyl acetate (50 mL x 2). The organic layer was dried over magnesium sulfate, filtered and concentrated to give 5-(3-chlorophenoxy)pyridin-2-amine (0.254 g, 1.15 mmol) as a crude brown oil. The crude material is used without further purification in the next step. ¹H NMR (300 MHz, Chloroform-*d*) δ 7.93 (dd, *J* = 2.9, 0.7 Hz, 1H), 7.31 - 7.12 (m, 2H), 7.03 (ddd, *J* = 8.0, 2.0, 0.9 Hz, 1H), 6.91 (t, *J* = 2.2 Hz, 1H), 6.89 - 6.79 (m, 1H), 6.55 (dd, *J* = 8.8, 0.7 Hz, 1H), 4.45 (s, 2H).; LCMS (ESI) *m/z*: 221.2 [M+H]⁺.

Step 3: Preparation of methyl 6-oxo-1-(propan-2-yl)-1,6-dihydropyridine-3-carboxylate



A solution of methyl 2-oxo-2H-pyran-5-carboxylate (0.500 g, 3.24 mmol) in methanol (10.8 mL) at room temperature was treated with propan-2-amine (239 mg, 4.05 mmol) and triethylamine (0.80 mL, 5.67 mmol). Reaction mixture stirred for 1 h before it was concentrated, and purified by silica gel chromatography (ISCO, 12 g, ethyl acetate/hexanes, 3:1, over 20 minutes) to give methyl 6-oxo-1-(propan-2-yl)-1,6-dihydropyridine-3-carboxylate (85.9 mg, 0.441 mmol, 13%) as a brown solid. ¹H NMR (300 MHz, Dimethylsulfoxide-*d*₆) δ 8.34 (dd, *J* = 2.6, 0.6 Hz, 1H), 7.77 (dd, *J* = 9.5, 2.6 Hz, 1H), 6.44 (dd, *J* = 9.5, 0.5 Hz, 1H), 4.99 (hept, *J* = 6.8 Hz, 1H), 3.79 (s, 3H), 1.33 (d, *J* = 6.8 Hz, 6H); LCMS (ESI) *m/z*: 196.2 [M+H]⁺.


Step 4: Preparation of 6-oxo-1-(propan-2-yl)-1,6-dihydropyridine-3-carboxylic acid



To a solution of methyl 6-oxo-1-(propan-2-yl)-1,6-dihydropyridine-3-carboxylate (0.086 g, 0.440 mmol) in tetrahydrofuran (1.5 mL) and water (0.366 mL) at 25 °C was added lithium hydroxide hydrate (27.6 mg, 0.66 mmol) in one portion. The reaction mixture was stirred at room temperature 3 h before it was evaporated to dryness, diluted with water (15 mL) and adjusted to pH 2 with 1N hydrogen chloride solution. The reaction mixture was extracted with ethyl acetate (20 mL x 3). The combined organic layers were dried over magnesium sulfate, filtered and concentrated in vacuo to give 6-oxo-1-(propan-2-yl)-1,6-dihydropyridine-3-carboxylic acid (0.064 g, 0.353 mmol, 80.3%) as a yellow solid. Use as is in the next step.

Step 5: Preparation of


N-[5-(3-chlorophenoxy)pyridin-2-yl]-6-oxo-1-(propan-2-yl)-1,6-dihydropyridine-3-carboxamide




To a solution of 6-oxo-1-(propan-2-yl)-1,6-dihydropyridine-3-carboxylic acid (0.0402 g, 0.222 mmol), 5-(3-chlorophenoxy)pyridin-2-amine (0.049 g, 0.2220 mmol) and [bis(dimethylamino)methylidene]({3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl})oxidanium; hexafluoro- λ^5 -phosphanuide (0.0844 g, 0.222 mmol) in tetrahydrofuran (740 μ L) at room temperature was added *N,N*-diisopropylethylamine (77.2 μ L, 0.444 mmol) dropwise. Reaction was stirred at room temperature for 16 h. Reaction solution was quenched with water (1 mL). The aqueous layer was extracted with ethyl acetate (5 mL x 3). The combined organic layers were washed with brine, dried over magnesium sulfate, filtered and concentrated. The crude residue was purified over silica gel chromatography (ISCO, 12 g, eluting with 0-80% ethyl acetate/hexanes for 20 minutes) to afford *N*-[5-(3-chlorophenoxy)pyridin-2-yl]-6-oxo-1-(propan-2-yl)-1,6-dihydropyridine-3-carboxamide (14.7 mg, 0.0383 mmol, 17%) as a white solid. ^1H NMR (300 MHz, Chloroform-*d*) δ 8.36 - 8.18 (m, 3H), 8.13 (d, *J* = 2.9 Hz, 1H), 7.70 (dd, *J* = 9.6, 2.7 Hz, 1H), 7.46 (dd, *J* = 9.0, 3.0 Hz, 1H), 7.31 (d, *J* = 8.1 Hz, 1H), 7.13 (d, *J* = 8.0 Hz, 1H), 7.00 (t, *J* = 2.1 Hz, 1H), 6.98 - 6.88 (m, 1H), 6.63 (d, *J* = 9.5 Hz, 1H), 5.33 - 5.25 (m, 1H), 1.45 (d, *J* = 6.8 Hz, 6H); LCMS (ESI) *m/z*: 384.4 [*M*+H] $^+$.

Example 167. Preparation of

N-[5-(3-chloro-4-fluorophenoxy)pyridin-2-yl]-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (167)



Step 1: Preparation of 5-(4-chloro-3-fluorophenoxy)-2-nitropyridine




To a sealed tube was added 4-chloro-3-fluorophenol (0.597 g, 4.08 mmol), 5-bromo-2-nitropyridine (0.830 g, 4.08 mmol), and cesium carbonate (1.99 g, 6.12 mmol) and suspended in acetonitrile (10 mL). Reaction was heated to 70 °C for 2 h. Reaction was cooled to room

temperature and concentrated. The crude product was purified over silica gel (ISCO, 40 g, 0-15% ethyl acetate/hexanes, over 25 minutes) to give 5-(4-chloro-3-fluorophenoxy)-2-nitropyridine (0.760 g, 2.82 mmol, 69.7%) as a yellow solid. ¹H NMR (300 MHz, Methanol-*d*₄) δ 8.44 - 8.18 (m, 2H), 7.47 (ddt, *J* = 8.9, 2.8, 1.0 Hz, 1H), 7.26 (s, 2H), 7.16 - 6.97 (m, 1H); LCMS (ESI) *m/z*: 269.2 [M+H]⁺.

5

Step 2: Preparation of 5-(3-chloro-4-fluorophenoxy)pyridin-2-amine




To a heated 70 °C solution of 5-(3-chloro-4-fluorophenoxy)-2-nitropyridine (0.760 g, 2.82 mmol) and ammonium chloride (0.599 g, 11.2 mmol) in a 4:1 mixture of methanol (7.62 mL) and water (1.90 mL) was added iron (625 mg, 11.2 mmol) in one portion. The reaction was stirred at 70 °C for 16 h, after which the reaction was cooled to room temperature and 8 mL of saturated bicarbonate was added. The reaction mixture volume was diluted with ethyl acetate (50 mL) and filtered through a pad of Celite® and washed with ethyl acetate (20 mL x 3). Layers were separated and the aqueous layer was extracted with ethyl acetate (50 mL x 2). The organic layer was dried over magnesium sulfate, filtered and concentrated to give 5-(3-chloro-4-fluorophenoxy)pyridin-2-amine (0.254 g, 1.06 mmol, 37.7%) as a crude brown oil. The crude material is used without further purification in the next step. ¹H NMR (300 MHz, Chloroform-*d*) δ 7.91 (d, *J* = 2.9 Hz, 1H), 7.19 (dd, *J* = 8.8, 2.9 Hz, 1H), 7.08 (t, *J* = 8.8 Hz, 1H), 6.96 (dd, *J* = 6.0, 3.0 Hz, 1H), 6.82 (ddd, *J* = 9.0, 3.8, 3.0 Hz, 1H), 6.55 (d, *J* = 8.8 Hz, 1H), 4.44 (s, 2H).

20

Step 3: Preparation of

N-[5-(3-chloro-4-fluorophenoxy)pyridin-2-yl]-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide




To a solution of 1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (0.050 g, 0.327 mmol), 5-(3-chloro-4-fluorophenoxy)pyridin-2-amine (0.0779 g, 0.327 mmol) and [bis(dimethylamino)methylidene]({3H-[1,2,3]triazolo[4,5-*b*]pyridin-3-yl})oxidanium; hexafluoro-λ⁵-phosphanuide (0.124 g, 0.327 mmol) in tetrahydrofuran (1.1 mL) at room temperature was added *N,N*-diisopropylethylamine (0.113 mL, 0.653 mmol) dropwise. Reaction was stirred at room temperature for 16 h. Reaction solution was quenched with water (1 mL). The aqueous layer was extracted with ethyl acetate (5 mL x 3). The combined organic layers were washed with brine, dried over magnesium sulfate, filtered and concentrated. The crude residue was purified over silica gel chromatography (ISCO, 12 g, eluting with 0-80% ethyl acetate/hexanes for 20 minutes) to afford *N*-[5-(3-chloro-4-fluorophenoxy)pyridin-2-yl]-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (70.8 mg, 0.189 mmol, 58%) as a white solid. ¹H NMR (300 MHz, Dimethylsulfoxide-*d*₆) δ 10.66 (s, 1H), 8.67 (d, *J* = 2.7 Hz, 1H), 8.29 - 8.12 (m, 2H), 7.99 (dd, *J* = 9.5, 2.7 Hz, 1H), 7.60 (dd, *J* = 9.1, 3.1 Hz,

30


1H), 7.45 (t, $J = 9.0$ Hz, 1H), 7.36 (dd, $J = 6.2, 3.0$ Hz, 1H), 7.09 (dt, $J = 9.0, 3.5$ Hz, 1H), 6.44 (d, $J = 9.5$ Hz, 1H); LCMS (ESI) m/z : 374.4 $[M+H]^+$.

Example 168. Preparation of

5 *N*-[5-(3-chloro-4-fluorophenoxy)pyridin-2-yl]-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (168)




Step 1: Preparation of give 5-(4-chloro-3-fluorophenoxy)-2-nitropyridine



To a sealed tube was added 4-chloro-3-fluorophenol (0.597 g, 4.08 mmol), 5-bromo-2-nitropyridine (0.830 g, 4.08 mmol) and cesium carbonate (1.99 g, 6.12 mmol) and suspended in acetonitrile (10 mL). Reaction was heated to 70 °C for 2 h. Reaction was cooled to room temperature and concentrated. The crude product was purified over silica gel chromatography (ISCO, 40 g, 0-15% ethyl acetate/hexanes, over 25 minutes) to give 5-(4-chloro-3-fluorophenoxy)-2-nitropyridine (0.760 g, 2.82 mmol, 69.7%) as a yellow solid. ^1H NMR (300 MHz, Methanol- d_4) δ 8.44 - 8.18 (m, 2H), 7.47 (ddt, $J = 8.9, 2.8, 1.0$ Hz, 1H), 7.26 (s, 2H), 7.16 - 6.97 (m, 1H); LCMS (ESI) m/z : 269.2 $[M+H]^+$.

Step 2: Preparation of 5-(3-chloro-4-fluorophenoxy)pyridin-2-amine




To a heated 70 °C solution of 5-(3-chloro-4-fluorophenoxy)-2-nitropyridine (0.760 g, 2.82 mmol) and ammonium chloride (0.599 g, 11.2 mmol) in a 4:1 mixture of methanol (7.62 mL) and water (1.90 mL) was added iron (0.625 g, 11.2 mmol) in one portion. The reaction was stirred at 70 °C for 16 h, after which the reaction was cooled to room temperature and 8 mL of saturated bicarbonate was added. The reaction mixture volume was diluted with ethyl acetate (50 mL) and filtered through a pad of Celite® and washed with ethyl acetate (20 mL x 3). Layers were separated and the aqueous layer was extracted with ethyl acetate (50 mL x 2). The organic layer was dried over magnesium sulfate, filtered and concentrated to give 5-(3-chloro-4-fluorophenoxy)pyridin-2-amine (0.254 g, 1.06 mmol, 37.7%) as a crude brown oil. The crude material is used without further purification in the next step. ^1H NMR (300 MHz, Chloroform- d)

δ 7.91 (d, J = 2.9 Hz, 1H), 7.19 (dd, J = 8.8, 2.9 Hz, 1H), 7.08 (t, J = 8.8 Hz, 1H), 6.96 (dd, J = 6.0, 3.0 Hz, 1H), 6.82 (ddd, J = 9.0, 3.8, 3.0 Hz, 1H), 6.55 (d, J = 8.8 Hz, 1H), 4.44 (s, 2H).

Step 3: Preparation of

5 *N*-[5-(3-chloro-4-fluorophenoxy)pyridin-2-yl]-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide




To a solution of 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (0.050 g, 0.324 mmol), 5-(3-chloro-4-fluorophenoxy)pyridin-2-amine (0.0774 g, 0.324 mmol) and [bis(dimethylamino)methylidene]({3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl})oxidanium;

- 10 hexafluoro- λ^5 -phosphanide (0.123 g, 0.324 mmol) in tetrahydrofuran (1.1 mL) at room temperature was added diisopropylethylamine (0.112 mL, 0.649 mmol) dropwise. Reaction was stirred at room temperature for 16 h. Reaction solution was quenched with water (1 mL). The aqueous layer was extracted with ethyl acetate (5 mL x 3). The combined organic layers were washed with brine, dried over magnesium sulfate, filtered and concentrated. The crude residue was purified over silica gel
- 15 chromatography (ISCO, 12 g, eluting with 0-80% ethyl acetate/hexanes for 20 minutes) to afford *N*-[5-(3-chloro-4-fluorophenoxy)pyridin-2-yl]-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (47.5 mg, 0.127 mmol, 39.2%). ^1H NMR (300 MHz, Chloroform- d) δ 9.48 (s, 1H), 8.36 (dd, J = 9.0, 0.7 Hz, 1H), 8.15 (dd, J = 2.9, 0.7 Hz, 1H), 8.08 (d, J = 9.7 Hz, 1H), 7.43 (dd, J = 9.0, 2.9 Hz, 1H), 7.14 (d, J = 8.6 Hz, 1H), 7.11 - 7.03 (m, 2H), 6.92 (ddd, J = 9.0, 3.8, 3.0 Hz, 1H), 3.91 (s, 4H); LCMS (ESI)
- 20 m/z : 375.4 $[\text{M}+\text{H}]^+$.


Example 169. Preparation of

N-[5-(3-chloro-4-fluorophenoxy)pyridin-2-yl]-1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxamide (169)




25

Step 1: Preparation of give 5-(4-chloro-3-fluorophenoxy)-2-nitropyridine




To a sealed tube was added 4-chloro-3-fluorophenol (0.597 g, 4.08 mmol), 5-bromo-2-nitropyridine (0.830 g, 4.08 mmol), and cesium carbonate (1.99 g, 6.12 mmol) and suspended in acetonitrile (10 mL). Reaction was heated to 70 °C for 2 h. Reaction was cooled to room temperature and concentrated. The crude product was purified over silica gel chromatography (ISCO, 40 g, 0-15% ethyl acetate/hexanes, over 25 minutes) to give 5-(4-chloro-3-fluorophenoxy)-2-nitropyridine (0.760 g, 2.82 mmol, 69.7%) as a yellow solid. ¹H NMR (300 MHz, Methanol-*d*₄) δ 8.44 - 8.18 (m, 2H), 7.47 (ddt, *J* = 8.9, 2.8, 1.0 Hz, 1H), 7.26 (s, 2H), 7.16 - 6.97 (m, 1H); LCMS (ESI) *m/z*: 269.2 [M+H]⁺.

Step 2: Preparation of 5-(3-chloro-4-fluorophenoxy)pyridin-2-amine



To a heated 70 °C solution of 5-(3-chloro-4-fluorophenoxy)-2-nitropyridine (0.760 g, 2.82 mmol) and ammonium chloride (0.599 g, 11.2 mmol) in a 4:1 mixture of methanol (7.62 mL) and water (1.90 mL) was added iron (0.625 g, 11.2 mmol) in one portion. The reaction was stirred at 70 °C for 16 h, after which the reaction was cooled to room temperature and 8 mL of saturated bicarbonate was added. The reaction mixture volume was diluted with ethyl acetate (50 mL) and filtered through a pad of Celite® and washed with ethyl acetate (20 mL x 3). Layers were separated and the aqueous layer was extracted with ethyl acetate (50 mL x 2). The organic layer was dried over magnesium sulfate, filtered and concentrated to give 5-(3-chloro-4-fluorophenoxy)pyridin-2-amine (0.254 g, 1.06 mmol, 37.7%) as a crude a brown oil. The crude material is used without further purification in the next step. ¹H NMR (300 MHz, Chloroform-*d*) δ 7.91 (d, *J* = 2.9 Hz, 1H), 7.19 (dd, *J* = 8.8, 2.9 Hz, 1H), 7.08 (t, *J* = 8.8 Hz, 1H), 6.96 (dd, *J* = 6.0, 3.0 Hz, 1H), 6.82 (ddd, *J* = 9.0, 3.8, 3.0 Hz, 1H), 6.55 (d, *J* = 8.8 Hz, 1H), 4.44 (s, 2H).


Step 3: Preparation of methyl 1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxylate



A solution of methyl 2-oxo-2H-pyran-5-carboxylate (0.500 g, 3.24 mmol) in methanol (10.8 mL) at room temperature was treated with ethanamine (2.02 mL, 4.05 mmol) and triethylamine (0.796 mL, 5.67 mmol). Reaction mixture was stirred for 1 h before it was concentrated, and purified by silica gel chromatography (ISCO, ethyl acetate/hexanes, 3/1, over 20 minutes) to give methyl 1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxylate (0.380 g, 2.09 mmol, 64%) as a brown oil. ¹H NMR

(300 MHz, Chloroform-*d*) δ 8.20 (dd, $J = 2.5, 0.6$ Hz, 1H), 7.84 (dd, $J = 9.5, 2.5$ Hz, 1H), 6.58 - 6.46 (m, 1H), 4.05 (q, $J = 7.2$ Hz, 2H), 3.87 (s, 3H), 1.40 (t, $J = 7.2$ Hz, 3H).; LCMS (ESI) m/z : 182.2 $[M+H]^+$.


Step 4: Preparation of 1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid



5 To a solution of methyl 1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxylate (0.180 g, 0.993 mmol) in tetrahydrofuran (3.31 mL) and water (0.83 mL) at 25 °C was added lithium hydroxide hydrate (0.0625 g, 1.49 mmol) in one portion. The reaction mixture was stirred at room temperature 3 h before it was evaporated to dryness, diluted with water (15 mL) and adjusted to pH = 2 with 1N hydrogen chloride
10 solution. The reaction mixture was extracted with ethyl acetate (3x 20 mL). The combined organic layers were dried over magnesium sulfate, filtered and concentrated in vacuo to give 1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (0.066 g, 0.407 mmol, 40.9%) as a yellow solid. ^1H NMR (300 MHz, Dimethylsulfoxide-*d*₆) δ 12.80 (s, 1H), 8.46 (d, $J = 2.6$ Hz, 1H), 7.77 (dt, $J = 9.5, 1.8$ Hz, 1H), 6.39 (d, $J = 9.5$ Hz, 1H), 3.98 (q, $J = 7.1$ Hz, 2H), 1.20 (q, $J = 6.7$ Hz, 4H); LCMS (ESI) m/z :
15 168.2 $[M+H]^+$. Used in the next step without further purification.

Step 5: Preparation of

N-[5-(3-chloro-4-fluorophenoxy)pyridin-2-yl]-1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxamide




20 To a solution of 1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (0.060 g, 0.359 mmol), 5-(3-chloro-4-fluorophenoxy)pyridin-2-amine (0.0856 g, 0.359 mmol) and *bis*(dimethylamino)methylidene[({3H-[1,2,3]triazolo[4,5-*b*]pyridin-3-yl})oxidanium; hexafluoro- λ^5 -phosphanuide (0.136 g, 0.3589 mmol) in tetrahydrofuran (1.2 mL) at room temperature was added *N,N*-diisopropylethylamine (0.124 mL, 0.718 mmol) dropwise. Reaction was stir
25 at room temperature for 16 h. Reaction solution was quenched with water (1 mL). The aqueous layer was extracted with ethyl acetate (5 mL x 3). The combined organic layers were washed with brine, dried over magnesium sulfate, filtered and concentrated. The crude residue was purified over silica gel chromatography (ISCO, 12 g, eluting with 0-80% ethyl acetate/hexanes for 20 minutes) to afford *N*-[5-(3-chloro-4-fluorophenoxy)pyridin-2-yl]-1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxamide (45
30 .0 mg, 0.116 mmol, 32.2%). ^1H NMR (300 MHz, Dimethylsulfoxide-*d*₆) δ 10.73 (s, 1H), 8.65 (d, $J = 2.7$ Hz, 1H), 8.31 - 8.10 (m, 2H), 8.00 - 7.91 (m, 1H), 7.61 (dd, $J = 9.1, 3.0$ Hz, 1H), 7.46 (t, $J = 9.1$ Hz, 1H),


7.36 (dd, $J = 6.2, 3.0$ Hz, 1H), 7.17 - 6.95 (m, 1H), 6.43 (d, $J = 9.5$ Hz, 1H), 3.97 (q, $J = 7.2$ Hz, 2H), 1.28 (t, $J = 7.1$ Hz, 3H); LCMS (ESI) m/z 388.1 $[M+H]^+$.

Example 170. Preparation of

5 *N*-(5-(3-chlorobenzoyloxy)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (170)




Step 1: Preparation of 2-chloro-5-(3-chlorobenzoyloxy)pyridine



A suspension of 6-chloropyridin-3-ol (1.8 g, 14 mmol), 1-(bromomethyl)-3-chlorobenzene (3.18 g, 15.4 mmol) and cesium carbonate (5.02 g, 15.4 mmol) in *N,N*-dimethylformamide (10 mL) was stirred at room temperature for 6 h. The solid was filtered and the filtrate was extracted with dichloromethane (50 mL x 2). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate, filtered and concentrated. The crude residue was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 10/1) to give 2-chloro-5-(3-chlorobenzoyloxy)pyridine (2.6 g, 10.3 mmol, 73.4%) as a white solid. LCMS (ESI) m/z : 254.1 $[M+H]^+$.

Step 2: Preparation of

20 *N*-(5-(3-chlorobenzoyloxy)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide




A suspension of 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.248 g, 1.6 mmol), 2-chloro-5-(3-chlorobenzoyloxy)pyridine (0.202 g, 0.8 mmol), tris(dibenzylideneacetone)dipalladium(0) (0.073 g, 0.08 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (0.046 g, 0.08 mmol) and cesium carbonate (0.522 g, 1.6 mmol) in 1,4-dioxane (6 mL) was stirred at 90 °C for 3 h under argon. The reaction mixture was cooled and extracted with ethyl acetate (50 mL x 2). The combined organic layers were washed with brine (50 mL) dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 μ m column. The mobile phase was acetonitrile/0.01% aqueous trifluoroacetic acid) to give *N*-(5-(3-chlorobenzoyloxy)pyridin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.0686 g, 0.18 mmol, 23.1 %) as a white solid. ^1H NMR (500 MHz, Dimethylsulfoxide- d_6) δ 9.70 (s, 1H), 8.16 (d, J

= 3.5 Hz, 1H), 8.04 (d, J = 8.5 Hz, 1H), 7.58 (dd, J = 8.5, 3.0 Hz, 1H), 7.55 (s, 1H), 7.45 - 7.41 (m, 3H), 5.19 (s, 2H), 3.56 (s, 3H), 2.85 (t, J = 8.3 Hz, 2H), 2.52 (t, J = 7.0 Hz, 2H); LCMS (ESI) m/z : 373.0 $[M+H]^+$.


Example 171. Preparation of

5 *N*-(5-(3-chlorobenzyloxy)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (171)



Step 1: Preparation of

10 *N*-(5-(3-chlorobenzyloxy)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide




A suspension of 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (0.245 g, 1.6 mmol), 2-chloro-5-(3-chlorobenzyloxy) pyridine (0.202 g, 0.8 mmol), tris(dibenzylideneacetone)dipalladium(0) (0.073 g, 0.08 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (0.046 g, 0.08 mmol) and cesium carbonate (0.522 g, 1.6 mmol) in 1,4-dioxane (6 mL) was stirred at 90 °C for 6 h under argon. The reaction mixture was extracted with ethyl acetate (50 mL x 2). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate, filtered and concentrated. The crude residue was washed with methanol/ acetonitrile = 1/2 (4.5 mL) to give

15 *N*-(5-(3-chlorobenzyloxy)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (0.0574 g, 0.16 mmol, 19.4%) as a white solid. ^1H NMR (400 MHz, Dimethylsulfoxide- d_6) δ 10.10 (s, 1H), 8.19 (d, J = 1.6 Hz, 1H), 8.07 (d, J = 9.2 Hz, 1H), 7.94 (d, J = 9.6 Hz, 1H), 7.60 (dd, J = 8.8, 3.2 Hz, 1H), 7.55 (s, 1H), 7.45 - 7.41 (m, 3H), 7.07 (d, J = 9.2 Hz, 1H), 5.20 (s, 2H), 3.79 (s, 3H); LCMS (ESI) m/z : 371.0 $[M+H]^+$.


Example 172. Preparation of

25 *N*-(5-(3-chlorobenzyloxy)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (172)



Step 1: Preparation of

N-(5-((3-chlorophenoxy)methyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide



A suspension of 1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (0.243 g, 1.6 mmol),

5 2-chloro-5-((3-chlorophenoxy)methyl) pyridine (0.202 g, 0.8 mmol),

tris(dibenzylideneacetone)dipalladium(0) (0.073 g, 0.08 mmol),

4,5-*bis*(diphenylphosphino)-9,9-dimethylxanthene (0.046 g, 0.08 mmol) and cesium carbonate (0.522 g,

1.6 mmol) in 1,4-dioxane (6 mL) was stirred at 90 °C for 3 h under argon. The reaction mixture was

10 dried over sodium sulfate, filtered and concentrated. The crude residue was purified by column chromatography (silica gel, dichloromethane/methanol = 50/1) to give

N-(5-((3-chlorophenoxy)methyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (0.0565 g,

0.15 mmol, 19.2%) as a pink solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 10.65 (s, 1H), 8.69 (d, *J* =


15 2.5 Hz, 1H), 8.47 (d, *J* = 1.5 Hz, 1H), 8.17 (d, *J* = 8.0 Hz, 1H), 7.99 (dd, *J* = 9.5, 2.5 Hz, 1H), 7.91 (dd, *J* =

8.5, 2.0 Hz, 1H), 7.33 (t, *J* = 8.0 Hz, 1H), 7.14 (t, *J* = 1.8 Hz, 1H), 7.03 - 7.00 (m, 2H), 6.44 (d, *J* = 9.5 Hz,

1H), 5.14 (s, 2H), 3.51 (s, 3H); LCMS (ESI) *m/z*: 370.1 [M+H]⁺.


Example 173. Preparation of

N-(5-((3-chlorophenylamino)methyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (173)



Step 1: Preparation of

N-(5-((3-chlorophenylamino)methyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide



25 To a solution of 3-chloro-*N*-((6-chloropyridin-3-yl)methyl)aniline (0.130g, 0.51 mmol) in anhydrous 1,4-dioxane (15 mL) at room temperature was added 1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (0.078 g, 0.51 mmol), tris(dibenzylideneacetone)dipalladium(0) (24 mg, 0.03 mmol),

4,5-*bis*(diphenylphosphino)-9,9-dimethylxanthene (0.030 g, 0.05 mmol) and cesium carbonate (0.251 g, 0.77 mmol) under nitrogen. The reaction mixture was stirred at 90 °C for 5 h, cooled to room temperature

30 and diluted with water (100 mL). The aqueous layer was extracted with ethyl acetate (80 mL × 3). The


combined organic layers were washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 μ m column. The mobile phase was acetonitrile/10 mM ammonium acetate aqueous solution) to give

- 5 *N*-(5-((3-chlorophenylamino)methyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (0.127 g, 0.34 mmol, 67%) as a white solid. ^1H NMR (400 MHz, Dimethylsulfoxide- d_6) δ 10.54 (s, 1H), 8.67 (d, J = 2.4 Hz, 1H), 8.36 (d, J = 1.6 Hz, 1H), 8.09 (d, J = 8.8 Hz, 1H), 7.98 (dd, J_1 = 2.8 Hz, J_2 = 9.6 Hz, 1H), 7.78 (dd, J_1 = 2.0 Hz, J_2 = 8.4 Hz, 1H), 7.06 (t, J = 8.0 Hz, 1H), 6.61 (t, J = 2.0 Hz, 1H), 6.57-6.52 (m, 3H), 6.43 (d, J = 9.6 Hz, 1H), 4.27 (d, J = 5.6 Hz, 2H), 3.50 (s, 3H); LCMS (ESI) m/z : 369.1 $[\text{M}+\text{H}]^+$.

10


Example 174. Preparation of

N-(5-((3-Chlorophenylamino)methyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (174)



15


Step 1: Preparation of 3-chloro-*N*-((6-chloropyridin-3-yl)methyl)aniline



- To a solution of 3-chloroaniline (3.0 g, 23.5 mmol) in ethanol (60 mL) at room temperature was added 6-chloronicotinaldehyde (3.33 g, 23.5 mmol), acetic acid (0.141 g, 2.35 mmol) and sodium cyanoborohydride (4.43 g, 70.55 mmol). The reaction mixture was stirred at 50 $^{\circ}\text{C}$ for 5 h before it was cooled to room temperature and diluted with water (200 mL). The aqueous layer was extracted with ethyl acetate (100 mL $\times$ 3). The combined organic layers were washed with brine (200 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 1/1) to afford
- 20 3-chloro-*N*-((6-chloropyridin-3-yl)methyl)aniline (4.5 g, 17.8 mmol, 75%) as a white solid. LCMS (ESI) m/z : 254.1 $[\text{M}+\text{H}]^+$.
- 25

Step 2: Preparation of

N-(5-((3-chlorophenylamino)methyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide



30

To a solution of 3-chloro-*N*-((6-chloropyridin-3-yl)methyl)aniline (0.100 g, 0.40 mmol) in anhydrous 1,4-dioxane (12 mL) at room temperature was added 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (0.061 g, 0.40 mmol), tris(dibenzylideneacetone)dipalladium(0) (0.018 g, 0.02 mmol),

5 4,5-*bis*(diphenylphosphino)-9,9-dimethylxanthene (0.024.0 g, 0.04 mmol) and cesium carbonate (0.194 g, 0.60 mmol) under nitrogen. The reaction mixture was stirred at 90 °C for 5 h before it was cooled to room temperature and diluted with water (100 mL). The aqueous layer was extracted with ethyl acetate (80 mL × 3). The combined organic layers were washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide


10 and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μm column. The mobile phase was acetonitrile/10 mM ammonium acetate aqueous solution) to give

N-(5-((3-chlorophenylamino)methyl)pyridin-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (0.105 g, 0.28 mmol, 71%) as a white solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 8.38 (d, *J* = 1.5 Hz, 1H), 8.12 (d, *J* = 8.5 Hz, 1H), 7.95 (d, *J* = 9.5 Hz, 1H), 7.84 (dd, *J*₁ = 2.5 Hz, *J*₂ = 8.5 Hz, 1H),


15 7.09-7.04 (m, 2H), 6.61-6.53 (m, 4H), 4.29 (d, *J* = 5.5 Hz, 2H), 3.79 (s, 3H); LCMS (ESI) *m/z*: 370.0 [M+H]⁺.

Example 175. Preparation of

N-(5-(3-chlorobenzyl)pyrimidin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (175)



Step 1: Preparation of 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid




To a solution of 2-oxopentanedioic acid (10 g, 68 mmol) in 10% hydrogen chloride (40 mL) was added methylhydrazine sulfate (9.8 g, 68 mmol) in three portions. Reaction was stirred at 100 °C for 3 h before it was cooled to room temperature and extracted with tetrahydrofuran (100 mL × 3). The combined organic layers were washed with brine (50 mL × 2), dried over sodium sulfate, filtered and concentrated.

30 The crude solid was washed with petroleum ether (20 mL) to offer

1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid as a white solid (5.6 g, 52.8%); LCMS (ESI) *m/z*: 157.1 [M+H]⁺.


Step 2: Preparation of 5-(3-chlorobenzyl)pyrimidin-2-amine





A suspension of potassium carbonate (1.66 g, 12 mmol), tetrakis(triphenylphosphine)palladium(0) (0.277 g, 0.24 mmol) in tetrahydrofuran (6 mL) and water (6 mL) was stirred at room temperature for 0.5 h. Then a solution of 1-(bromomethyl)-3-chlorobenzene (0.812 g, 4 mmol) and 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine (0.972 g, 4.4 mmol) in tetrahydrofuran (16 mL) was added. The reaction mixture was stirred at 100 °C for 2 h before it was cooled and filtered. The filtrate was extracted with ethyl acetate (50 mL x 2), washed with aqueous 1 N hydrogen chloride (30 mL x 2) and neutralized with aqueous sodium bicarbonate. The resulting precipitate was filtered and dissolved in ethyl acetate (50 mL). The organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated to give 5-(3-chlorobenzyl)pyrimidin-2-amine (6.00 g, 3.01 mmol, 68.5%) as a white solid. LCMS (ESI) m/z: 220.1 [M+H]⁺.

Step 3: Preparation of


N-(5-(3-chlorobenzyl)pyrimidin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide




To a solution of 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.120 g, 0.75 mmol) in dichloromethane (20 mL) at 0 °C was added *N,N*-dimethylformamide (1 drop) and oxalyl chloride (0.476 g, 3.75 mmol) dropwise. Reaction was warmed to room temperature over 2 h before it was concentrated. The crude solid was re-dissolved in dichloromethane (5 mL) and added to a solution of 5-(3-chlorobenzyl)pyrimidin-2-amine (0.197 g, 0.9 mmol) in pyridine (3 mL) at 0 °C. Reaction mixture was warmed to room temperature over 2 h. Reaction was poured into ice water and extracted with ethyl acetate (50 mL x 2). The combined organic layers were washed with brine (60 mL), dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Sunfire prep C18 10 μm OBD 19*250 mm; mobile phase: [water (0.05% trifluoroacetic acid)-acetonitrile]; B%: 60%-88%, 15 minutes) to yield *N*-(5-(3-chlorobenzyl)pyrimidin-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide as a white solid (0.0656 g, 0.191 mmol, 25.4%). ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 10.08 (s, 1H), 8.66 (s, 2H), 7.41 (s, 1H), 7.35 (t, *J* = 7.5 Hz, 1H), 7.30-7.26 (m, 2H), 3.97 (s, 2H), 3.33 (s, 3H), 2.82 (t, *J* = 8.5 Hz, 2H), 2.51 (t, *J* = 6.5 Hz, 2H); LCMS (ESI) m/z: 358.1 [M+H]⁺.

Example 176. Preparation of***N*-(6-(3-fluorobenzyl)pyridazin-3-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (176)****5 Step 1: Preparation of*****N*-(6-(3-fluorobenzyl)pyridazin-3-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide**

- A mixture of 3-chloro-6-(3-fluorobenzyl)pyridazine (0.25 g, 1.13 mmol),
 1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (0.34 g, 2.25 mmol),
 10 tris(dibenzylideneacetone)dipalladium(0) (0.10 g, 0.11 mmol), XantPhos (0.10 g, 0.17 mmol) and cesium
 carbonate (0.73 g, 2.25 mmol) in 1,4-dioxane (10.0 mL) was stirred under nitrogen atmosphere at 90 °C
 for 3 h. The reaction mixture was cooled down to room temperature and filtered. The filtrate was
 concentrated, under reduced pressure and the crude sample was dissolved in minimal
N,N-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 µm column;
 15 acetonitrile/0.01% aqueous trifluoroacetic acid) to give
N-(6-(3-fluorobenzyl)pyridazin-3-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (0.0686 g, 0.20
 mmol, 17.7%) as a white solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 11.15 (s, 1H), 8.71 (d, *J* = 2.5
 Hz, 1H), 8.25 (d, *J* = 9.1 Hz, 1H), 8.00 (dd, *J* = 9.5, 2.5 Hz, 1H), 7.61 (d, *J* = 9.5 Hz, 1H), 7.36 (dd, *J* =
 14.3, 8.0 Hz, 1H), 7.16 - 7.04 (m, 3H), 6.44 (d, *J* = 9.5 Hz, 1H), 4.29 (s, 2H), 3.51 (s, 3H); LCMS (ESI) for
 20 *m/z*: 339.1 [M+H]⁺.


Example 177. Preparation of***N*-(6-(5-chloro-2-fluorobenzyl)pyridazin-3-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (177)**

Step 1: Preparation of (5-chloro-2-fluorophenyl)(6-(4-methoxybenzylamino)pyridazin-3-yl)methanol



To a solution of 2-bromo-4-chloro-1-fluorobenzene (1.03 g, 4.94 mmol) in tetrahydrofuran (20 mL) at -78 °C was added n-butyllithium (4.0 mL, 9.88 mmol) under nitrogen. The reaction mixture was stirred at -78 °C for 2 h before a solution of 6-(4-methoxybenzylamino)pyridazine-3-carbaldehyde (0.800 g, 3.29 mmol) in tetrahydrofuran (3 mL) was added dropwise. The reaction mixture was stirred for another 2 h and was warmed to 20 °C. Aqueous ammonium chloride was added to quench the reaction and the volatiles were removed under reduced pressure. The aqueous layer was extracted with dichloromethane (50 mL x 2). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The crude sample was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 4/1 to 1/1) to give (5-chloro-2-fluorophenyl)(6-(4-methoxybenzylamino)pyridazin-3-yl)methanol (0.330 g, 0.888 mmol, 27%) as a yellow solid. LCMS (ESI) m/z : 374.0 $[M+H]^+$.


Step 2: Preparation of 6-(5-chloro-2-fluorobenzyl)pyridazin-3-amine



To a solution of (5-chloro-2-fluorophenyl)(6-(4-methoxybenzylamino)pyridazin-3-yl)methanol (0.330 g, 0.885 mmol) and hypophosphorous acid (0.973 g, 7.08 mmol) in acetic acid (4.0 mL) was added iodide (0.337 g, 1.33 mmol). The reaction was heated to 100 °C and stirred for 20 h. The reaction solution was slowly added to aqueous sodium bicarbonate and was extracted with dichloromethane (50 mL x 2). The combined organic layers were collected, dried over sodium sulfate, filtered and concentrated to give 6-(5-chloro-2-fluorobenzyl)pyridazin-3-amine (0.160 g, crude) as a white solid; LCMS (ESI) m/z : 238.1 $[M+H]^+$.

Step 3: Preparation of

N-(6-(5-chloro-2-fluorobenzyl)pyridazin-3-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide




To a solution of 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.100 g, 0.641 mmol), *N,N*-diisopropylethylamine (0.249 g, 1.92 mmol) in tetrahydrofuran (5 mL) at 20 °C was added 1-[*bis*(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.366 g, 0.962 mmol). The reaction was stirred for 20 minutes before a solution of 6-(5-chloro-2-fluorobenzyl)pyridazin-3-amine (0.152 g, 0.641 mmol) in tetrahydrofuran (1.0 mL) was added. Then reaction mixture was stirred at 20 °C for 16 h. The volatiles were removed under reduced pressure and the slurry was added to a mixture of dichloromethane (50 mL) and water (50 mL). The organic layer was collected, dried over sodium sulfate, filtered and concentrated. The crude sample was

dissolved in minimal *N,N*-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 μ m column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give


N-(6-(5-chloro-2-fluorobenzyl)pyridazin-3-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.0233 g, 0.0641 mmol, 10%) as a white solid. ^1H NMR (400 MHz, Dimethylsulfoxide- d_6) δ 10.42 (s, 1 H), 8.25 (d, J = 9.0 Hz, 1 H), 7.64 (d, J = 9.0 Hz, 1 H), 7.47-7.49 (m, 1 H), 7.37-7.40 (m, 1 H), 7.24-7.28 (m, 1 H), 4.30 (s, 2 H), 3.38 (s, 3 H), 2.86 (t, J = 8.5 Hz, 1 H), 2.52-2.55 (m, 2 H); LCMS (ESI) m/z : 376.0 $[\text{M}+\text{H}]^+$.

Example 178. Preparation of

1-cyclopropyl-*N*-{6-[(3-fluorophenyl)methyl]pyridazin-3-yl}-6-oxo-1,6-dihydropyridazine-3-carboxamide (178)



Step 1: Preparation of methyl 1-cyclopropyl-6-oxo-1,6-dihydropyridazine-3-carboxylate




Combined methyl 6-oxo-1,6-dihydropyridazine-3-carboxylate (0.400 g, 2.59 mmol) with cyclopropylboronic acid (0.444 g, 5.18 mmol) and copper(II) acetate (0.940 g, 5.18 mmol) and suspended in 1,2-dichloroethane (8.63 mL). Added triethylamine (1.43 mL, 10.3 mmol) and pyridine (1.04 mL, 12.9 mmol). The reaction was degassed by cycling with vacuum and nitrogen for 3 cycles. Stirred 16 h at 80 $^{\circ}\text{C}$. Cooled to room temperature and quenched with saturated aqueous ammonium chloride (15 mL).

Extracted mixture with ethyl acetate (3 x 15 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated. Purified reaction by column chromatography (eluting with 0-100% ethyl acetate/hexanes through 24 g of silica gel) to give methyl

1-cyclopropyl-6-oxo-1,6-dihydropyridazine-3-carboxylate as a yellow solid (160 mg, 0.824 mmol, 32%). ^1H NMR (300 MHz, Chloroform- d) δ 8.01 (d, J = 9.7 Hz, 1H), 7.13 (d, J = 9.7 Hz, 1H), 4.36 (td, J = 7.5, 3.7 Hz, 1H), 4.14 (s, 3H), 1.48 - 1.36 (m, 2H), 1.36 - 1.22 (m, 2H)

Step 2: Preparation of 1-cyclopropyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid




Dissolved methyl 1-cyclopropyl-6-oxo-1,6-dihydropyridazine-3-carboxylate (0.160 g, 0.8239 mmol) in tetrahydrofuran (2.0 mL) and added lithium hydrate hydroxide (0.103 g, 2.47 mmol) and water (1.0 mL). Stirred 16 h at rt. Acidified with 10% hydrochloric acid solution (5 mL) and extracted with ethyl acetate (15 mL), then washed with brine (10 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated to give 1-cyclopropyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (83

mg, 0.461 mmol, 56%) as a yellow solid ¹H NMR (300 MHz, Chloroform-*d*) δ 7.90 (d, *J* = 9.6 Hz, 1H), 7.03 (d, *J* = 9.7 Hz, 1H), 4.30 - 4.14 (m, 1H), 1.27 - 1.00 (m, 4H).

Step 3: Preparation of

5 1-cyclopropyl-*N*-{6-[(3-fluorophenyl)methyl]pyridazin-3-yl}-6-oxo-1,6-dihydropyridazine-3-carboxamide



Dissolved 6-[(3-fluorophenyl)methyl]pyridazin-3-amine; trifluoroacetic acid (0.146 g, 0.4606 mmol) in *N,N'*-dimethylformamide (1.53 mL) and added


1-cyclopropyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (0.083 g, 0.4606 mmol) and

10 [bis(dimethylamino)methylidene]({3H-[1,2,3]triazolo[4,5-*b*]pyridin-3-yl})oxidanium; tetrafluoroboranuide (0.148 g, 0.4606 mmol). Carefully added ethylbis(propan-2-yl)amine (239 μL, 1.38 mmol) and stirred at room temperature 16 h. Diluted with ethyl acetate (15 mL) and washed 3 times with water (10 mL), then once with brine (15 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated. Purified reaction by column chromatography (eluting with 0-100% ethyl acetate/hexanes through 24 g of silica gel) to give

1-cyclopropyl-*N*-{6-[(3-fluorophenyl)methyl]pyridazin-3-yl}-6-oxo-1,6-dihydropyridazine-3-carboxamide as a beige, waxy solid (40 mg, 0.109 mmol, 24%). ¹H NMR (300 MHz, Chloroform-*d*) δ 9.73 (s, 1H), 8.47 (d, *J* = 9.1 Hz, 1H), 8.01 (d, *J* = 9.7 Hz, 1H), 7.36 (d, *J* = 9.2 Hz, 1H), 7.34 - 7.26 (m, 2H), 7.16 - 6.90 (m, 4H), 4.34 (s, 2H), 4.16 (d, *J* = 7.2 Hz, 1H), 1.31 - 1.08 (m, 4H); LCMS (ESI) *m/z*: 366.3 [M+H]⁺.


Example 179. Preparation of

N-(6-(3-chloro-4-fluorobenzyl)pyridazin-3-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (179)



Step 1: Preparation of

N-(6-(3-chloro-4-fluorobenzyl)pyridazin-3-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide




A mixture of 3-chloro-6-(3-chloro-4-fluorobenzyl)pyridazine (103 mg, 0.40 mmol), 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (122 mg, 0.80 mmol), tris(dibenzylideneacetone)dipalladium(0) (35 mg, 0.04 mmol),


4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (35 mg, 0.06 mmol) and cesium carbonate (261 mg, 0.80 mmol) in dry 1,4-dioxane (4 mL) was stirred at 90 °C for 3 h under argon. The reaction mixture was cooled to room temperature and the mixture was diluted with ethyl acetate (50 mL). The combined organic layers were washed with water (25 mL) and brine (25 mL), dried over sodium sulfate, filtered and concentrated. The residue was first purified by column chromatography (silica gel, ethyl acetate/petroleum ether = 2/1) and by prep-HPLC (Sunfire prep C18 10 µm OBD 19*250 mm; mobile phase: [water (0.05% trifluoroacetic acid)-acetonitrile]; B%: 60%-88%, 15 minutes) to offer *N*-(6-(3-chloro-4-fluorobenzyl)pyridazin-3-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (36 mg, 0.096 mmol, 24.0%) as a white solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 10.43 (s, 1H), 8.25 (d, *J* = 9.1 Hz, 1H), 7.67 (d, *J* = 9.1 Hz, 1H), 7.56 (dd, *J* = 7.2, 2.0 Hz, 1H), 7.33 (dd, *J* = 21.6, 5.7 Hz, 2H), 4.27 (s, 2H), 3.38 (s, 3H), 2.85 (t, *J* = 8.5 Hz, 2H), 2.54 (d, *J* = 8.5 Hz, 2H); LCMS (ESI) *m/z*: 376.0 [M+H]⁺.

Example 180. Preparation of

N-(6-(3-chloro-4-fluorobenzyl)pyridazin-3-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (180)



Step 1: Preparation of 3-chloro-6-(3-chloro-4-fluorobenzyl)pyridazine




A 2-neck flask equipped with a magnetic stirring bar and a condenser was charged with lithium chloride (535 mg, 12.75 mmol). The flask was heated with a heat gun (400 °C) for 10 minutes under high vacuum. After cooling to 25 °C, the flask was flushed with argon (3 x) before activated zinc dust (1815 mg, 12.75 mmol) was added followed by tetrahydrofuran (10 mL). A solution of 1,2-dibromomethane (0.14 mL, 1.57 mmol) in tetrahydrofuran (1 mL) was added dropwise over 5 minutes. The reaction mixture was heated to 60 °C for 5 minutes. After cooling to 25 °C, a solution of trimethylsilyl chloride (0.2 mL, 2.32 mmol) in tetrahydrofuran (1 mL) was added dropwise over 5 minutes. The reaction solution was heated to 60 °C for 30 minutes before a solution of 4-(bromomethyl)-2-chloro-1-fluorobenzene (2.17 g, 9.80 mmol) in tetrahydrofuran (3 mL) was added dropwise over 20 minutes. The resulting solution was stirred at 60 °C for 1 h before it was cooled to room temperature and added dropwise to a solution of 3,6-dichloropyridazine (906 mg, 6.13 mmol) and tetraphenyl palladium (304 mg, 0.29 mmol) in tetrahydrofuran (10 mL) over 5 minutes. The reaction mixture was stirred at 23 °C for 18 h. The reaction mixture was quenched with aqueous saturated ammonium chloride (25 mL). The aqueous layer was extracted with ethyl acetate (25 mL x 3). The combined organic layers were washed brine (25 mL), dried

over sodium sulfate, filtered and concentrated. The residue was purified by column chromatography (silica gel, ethyl acetate/petroleum ether = 1/1) to offer 3-chloro-6-(3-chloro-4-fluorobenzyl)pyridazine (650 mg, 2.54 mmol, 41.4%) as a yellow solid. LCMS (ESI) m/z : 257.0 $[M+H]^+$.

5 Step 2: Preparation of


N-(6-(3-chloro-4-fluorobenzyl)pyridazin-3-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide




A mixture of 3-chloro-6-(3-chloro-4-fluorobenzyl)pyridazine (103 mg, 0.40 mmol), 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (122 mg, 0.80 mmol), tris(dibenzylideneacetone)dipalladium(0) (35 mg, 0.04 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (35 mg, 0.06 mmol) and cesium carbonate (261 mg, 0.80 mmol) in dry 1,4-dioxane (4 mL) was stirred at 90 °C for 3 h under argon. The reaction mixture was cooled to room temperature and diluted with ethyl acetate (50 mL). The combined organic layers were washed with water (25 mL) and brine (25 mL), dried over sodium sulfate, filtered and concentrated. The residue was first purified by column chromatography (silica gel, ethyl acetate/petroleum ether = 2/1) and by prep-HPLC (Sunfire prep C18 10 μ m OBD 19*250 mm; mobile phase: [water (0.05% trifluoroacetic acid)-acetonitrile]; B%: 60%-88%, 15 minutes) to offer *N*-(6-(3-chloro-4-fluorobenzyl)pyridazin-3-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (35 mg, 0.094 mmol, 23.5%) as a white solid. ^1H NMR (500 MHz, Dimethylsulfoxide- d_6) δ 10.89 (s, 1H), 8.30 (d, J = 9.1 Hz, 1H), 7.95 (d, J = 9.7 Hz, 1H), 7.70 (d, J = 9.1 Hz, 1H), 7.57 (dd, J = 7.2, 1.8 Hz, 1H), 7.44 - 7.25 (m, 2H), 7.09 (d, J = 9.7 Hz, 1H), 4.29 (s, 2H), 3.81 (s, 3H); LCMS (ESI) m/z : 374.1 $[M+H]^+$.

Example 181. Preparation of

N-(6-((3-chlorophenoxy)methyl)pyridazin-3-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (181)




Step 1: Preparation of 6-((3-chlorophenoxy)methyl)-*N*-(4-methoxybenzyl)pyridazin-3-amine



A mixture of 6-(chloromethyl)-*N*-(4-methoxybenzyl)pyridazin-3-amine (0.58 g, 2.2 mmol), 3-chlorophenol (0.28 g, 2.2 mmol) and potassium carbonate (0.6 g, 4.4 mmol) in acetonitrile (45 mL) was stirred at 80 °C for 4 h. The reaction mixture was concentrated, and the residue was diluted with ethyl acetate/water (20 mL/20 mL) mixture and extracted with ethyl acetate (25 mL x 2). The combined organic layers were washed with brine (25 mL), dried over sodium sulfate, filtered and concentrated. The crude material was purified by Combi-Flash (Biotage, 40 g silica gel, eluted with methanol/ethyl acetate = 1/20 in petroleum ether from 40% to 50%) to give 6-((3-chlorophenoxy)methyl)-*N*-(4-methoxybenzyl)pyridazin-3-amine (0.33 g, 0.93 mmol, 42.3%) as a white solid. LCMS (ESI) *m/z*: 356.1 [M+H]⁺.


Step 2: Preparation of 6-((3-chlorophenoxy)methyl)pyridazin-3-amine



To a solution of 6-((3-chlorophenoxy)methyl)-*N*-(4-methoxybenzyl)pyridazin-3-amine (0.3 g, 0.84 mmol) in dry toluene (20 mL) was added *p*-toluenesulfonic acid (0.58 g, 3.38 mmol) and the reaction was stirred at 95 °C for 3 h. The reaction mixture was concentrated. The residue was diluted with ethyl acetate/water (20 mL/20 mL), neutralized with sodium bicarbonate aqueous solution and extracted with ethyl acetate (25 mL) twice. The combined organic layers were washed with brine (25 mL), dried over sodium sulfate, filtered and concentrated. The crude material was purified by Combi-Flash (Biotage, 25 g silica gel, eluted with methanol/dichloromethane (1:10, containing 0.5% 7N ammonia methanol) in dichloromethane from 40% to 50%) to yield 6-((3-chlorophenoxy)methyl)pyridazin-3-amine (0.15 g, 0.64 mmol, 75.7%) as a white solid. LCMS (ESI) *m/z*: 236.1 [M+H]⁺.

Step 3: Preparation of

N-(6-((3-chlorophenoxy)methyl)pyridazin-3-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide




To a solution of 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.044 g, 0.28 mmol), 1-[*bis*(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.117 g, 0.31 mmol) in *N,N*-dimethylformamide (8 mL) at room temperature was added

N,N-diisopropylethylamine (0.067 g, 0.52 mmol) dropwise. The reaction was stirred for 20 min and 6-((3-chlorophenoxy)methyl)pyridazin-3-amine (0.060 g, 0.26 mmol) was added in one portion. The reaction mixture was stirred at room temperature for 16 h. The reaction was diluted with ethyl acetate/water (20 mL/20 mL), separated and the aqueous layer was extracted with ethyl acetate (20 mL x 2). The combined organic layers were washed with brine (30 mL), dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified by prep-HPLC (Boston C18 21*250 mm 10 μ m column. The mobile phase was acetonitrile/10 mM ammonium acetate aqueous solution) to give


N-(6-((3-chlorophenoxy)methyl)pyridazin-3-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.030 g, 0.08 mmol, 31.5%) as a white solid. ^1H NMR (500 MHz, Dimethylsulfoxide- d_6) δ 10.58 (s, 1H), 8.38 (d, 1H, J = 9 Hz), 7.90 (d, 1H, J = 9.5 Hz), 7.35 (t, 1H, J = 8 Hz), 7.17-7.21 (m, 1H), 7.01-7.08 (m, 2H), 5.40 (s, 2H), 3.39 (s, 3H), 2.87 (t, 2H, J = 8.5 Hz), 2.55 (t, 2H, J = 8.5 Hz); LCMS (ESI) m/z : 374.1 $[\text{M}+\text{H}]^+$.

Example 182. Preparation of

N-(6-(3-methoxybenzyl)pyridazin-3-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (182)




Step 1: Preparation of 6-(3-methoxybenzyl)pyridazin-3-amine



A mixture of 6-(3-bromobenzyl)pyridazin-3-amine (0.264 g, 1.0 mmol) and copper(I) iodide (0.095 g, 0.5 mmol) in sodium methoxide (5 mL, methanol) was stirred at 80 °C for 72 h in a sealed tube. Water (30 mL) was added to quench the reaction. The aqueous layer was extracted with ethyl acetate (50 mL x 3). The combined organic layers were dried with sodium sulfate, filtered and concentrated. The crude material was purified by Prep-TLC (dichloromethane/ammonia in methanol (7N) = 15/1) to give 6-(3-methoxybenzyl)pyridazin-3-amine (0.086 g, 0.60 mmol, 40%) as a white solid. LCMS (ESI) m/z : 216.1 $[\text{M}+\text{H}]^+$.

Step 2: Preparation of

N-(6-(3-methoxybenzyl)pyridazin-3-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide




To a solution of 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.071 g, 0.45 mmol) and 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.171 g, 0.45 mmol) in *N,N*-dimethylformamide (3 mL) was added *N,N*-diisopropylethylamine (0.116 g, 0.9 mmol) at room temperature under nitrogen. The mixture was stirred at room temperature for 30 minutes before 6-(3-methoxybenzyl)pyridazin-3-amine (0.064 g, 0.3 mmol) was added. Reaction mixture was stirred at room temperature for 16 h before it was diluted with ethyl acetate (80 mL). The organic layer was washed with brine (40 mL x 3). The combined organic layers were dried with sodium sulfate, filtered and concentrated. The crude product was purified by Prep-TLC (dichloromethane/ammonia in methanol (7N) = 35/1) to give


N-(6-(3-methoxybenzyl)pyridazin-3-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.0573 g, mmol, 41%) as a white solid. ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 10.42 (s, 1H), 8.23 (d, *J* = 9.0 Hz, 1H), 7.63 (d, *J* = 9.0 Hz, 1H), 7.23 (t, *J* = 8.0 Hz, 1H), 6.88-6.89 (m, 1H), 6.85 (d, *J* = 7.5 Hz, 1H), 6.80 (dd, *J*₁ = 2.0 Hz, *J*₂ = 8.0 Hz, 1H), 4.23 (s, 2H), 3.73 (s, 3H), 3.39 (s, 3H), 2.86 (t, *J* = 7.5 Hz, 2H), 2.51-2.56 (m, 2H); LCMS (ESI) *m/z*: 354.2 [M+H]⁺.

Example 183. Preparation of

N-(6-(3-chlorobenzyl)pyridazin-3-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (183)



Step 1: Preparation of 3-chloro-6-(3-chlorobenzyl)pyridazine




A 2-neck flask equipped with a magnetic stirring bar and a condenser was charged with lithium chloride (1.07 g, 25.5 mmol). The flask was heated with a heat gun (400 °C) for 10 min under high vacuum. Reaction vessel was cooled to 25 °C and flushed with argon (3 x) and activated zinc dust (1.63 g, 25.5 mmol) followed by tetrahydrofuran (20 mL). A solution of 1,2-dibromomethane (0.27 mL, 3.13 mmol) in tetrahydrofuran (2 mL) was added dropwise over 5 min and the reaction mixture was heated to 60 °C. Reaction mixture was cooled to room temperature before a solution of trimethylsilyl chloride (0.40 mL, 4.63 mmol) in tetrahydrofuran (2 mL) was added dropwise over 5 min was added and the mixture was heated to 60 °C for 30 minutes before a solution of 1-(bromomethyl)-3-chlorobenzene (4.00 g, 19.6 mmol) in tetrahydrofuran (6 mL) was added over 20 min. The resulting mixture was stirred at 60 °C for 1 h. The mixture was cooled to room temperature, before a solution of 3,6-dichloropyridazine (1.82 g, 12.3 mmol) and tetraphenyl palladium (0.710 g, 0.62 mmol) in tetrahydrofuran (20 mL) was added and stirred at room

temperature for 18 h. Reaction mixture was quenched with aqueous saturated solution of ammonium chloride (50 mL) and extracted with ethyl acetate (50 mL x 3). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate, filtered and concentrated. The crude residue was purified by column chromatography (silica gel, ethyl acetate/petroleum ether = 1/1) to afford

5 3-chloro-6-(3-chlorobenzyl)pyridazine (1.77 g, 7.44 mmol, 60.5%) as a pale yellow solid. LCMS (ESI) m/z : 239.1 $[M+H]^+$.

Step 2: Preparation of


N-(6-(3-chlorobenzyl)pyridazin-3-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide



10 A mixture of 3-chloro-6-(3-chlorobenzyl)pyridazine (0.050 g, 0.21 mmol), 1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (0.064 g, 0.42 mmol), tris(dibenzylideneacetone)dipalladium(0) (0.019 g, 0.021 mmol), XantPhos (0.018 g, 0.0315 mmol) and cesium carbonate (0.137 g, 0.42 mmol) in dry 1,4-dioxane (2 mL) was stirred at 90 °C for 3 h under
15 argon. Reaction vessel was cooled to room temperature and diluted with ethyl acetate (50 mL). The organic layer washed with water (25 mL) and brine (25 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by column chromatography (silica gel, 100% ethyl acetate) to yield *N*-(6-(3-chlorobenzyl)pyridazin-3-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (0.020 g,
20 0.056 mmol, 26.9%) as a white solid. ^1H NMR (500 MHz, Dimethylsulfoxide- d_6) δ 11.16 (s, 1H), 8.72 (s, 1H), 8.26 (d, J = 9.1 Hz, 1H), 8.00 (dd, J = 9.5, 1.4 Hz, 1H), 7.64 (d, J = 9.1 Hz, 1H), 7.43 - 7.19 (m, 4H), 6.45 (d, J = 9.5 Hz, 1H), 4.28 (s, 2H), 3.51 (s, 3H); LCMS (ESI) m/z : 355.1 $[M+H]^+$.


Example 184. Preparation of

N-(6-(3-chlorobenzyl)pyridazin-3-yl)-1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxamide (184)



Step 1: Preparation of

N-(6-(3-chlorobenzyl)pyridazin-3-yl)-1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxamide




30 A mixture of 6-(3-chlorobenzyl)pyridazin-3-amine (0.066 g, 0.30 mmol), 1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (0.066 g, 0.39 mmol), 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.150 g,


0.39 mmol) and *N,N*-diisopropylethylamine (0.120 g, 0.90 mmol) in *N,N*-dimethylformamide (3 mL) was stirred at room temperature for 1 h and then at 90 °C for 1 h. Reaction mixture was cooled to room temperature and purified directly by prep-HPLC (column: Sunfire prep C18 10 µm OBD 19*250 mm; mobile phase: [water (0.05% trifluoroacetic acid)-acetonitrile]; B%: 60%-88%, 15 minutes) to yield *N*-(6-(3-chlorobenzyl)pyridazin-3-yl)-1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxamide (0.040 g, 0.11 mmol, 36.2%) as a white solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 11.23 (s, 1H), 8.70 (d, *J* = 2.5 Hz, 1H), 8.27 (d, *J* = 9.2 Hz, 1H), 7.96 (dd, *J* = 9.5, 2.6 Hz, 1H), 7.64 (d, *J* = 9.2 Hz, 1H), 7.32 (ddd, *J* = 42.1, 18.9, 8.9 Hz, 4H), 6.45 (d, *J* = 9.5 Hz, 1H), 4.28 (s, 2H), 3.99 (q, *J* = 7.1 Hz, 2H), 1.29 (t, *J* = 7.1 Hz, 3H); LCMS (ESI) *m/z*: 369.1 [M+H]⁺.

Example 185. Preparation of

N-(6-(3-chlorobenzyl)pyridazin-3-yl)-1-ethyl-6-oxo-1,6-dihydropyridine-3-carboxamide (185)




Step 1: Preparation of 6-(3-chlorobenzyl)pyridazin-3-amine



A mixture of 3-chloro-6-(3-chlorobenzyl)pyridazine (1.50 g, 6.30 mmol), *tert*-butyl carbamate (1.48 g, 12.6 mmol), tris(dibenzylideneacetone)dipalladium(0) (0.577 g, 0.63 mmol), XantPhos (0.547 g, 0.95 mmol) and cesium carbonate (4.46 g, 12.61 mmol) in dry 1,4-dioxane (50 mL) was stirred at 90 °C for 3 h under argon. Reaction mixture was cooled to room temperature and the mixture was diluted with ethyl acetate (300 mL). The organic layer was washed with water (100 mL) and brine (100 mL), dried over sodium sulfate, filtered and concentrated. The crude residue was taken up in methanol (30 mL) and hydrochloric acid (3 *M* in methanol, 30 mL) was added. The mixture was stirred at 60 °C for 1 h, then cooled to room temperature and concentrated *in vacuo*. The crude residue was diluted with ethyl acetate (200 mL) and washed with 0.5 *N* hydrochloric acid (50 mL x 3). The combined aqueous layers were adjusted to pH= 8 with solid potassium carbonate and extracted with ethyl acetate (50 mL x 3). The combined organics were washed with brine (50 mL), dried over sodium sulfate, filtered and concentrated to afford 6-(3-chlorobenzyl)pyridazin-3-amine (0.750 g, 3.42 mmol, 54.4%) as an off-white solid. LCMS (ESI) *m/z*: 220.1 [M+H]⁺.

Step 2: Preparation of

N-(6-(3-chlorobenzyl)pyridazin-3-yl)-1-ethyl-6-oxo-1,6-dihydropyridazine-3-carboxamide




To a solution of 6-(3-chlorobenzyl)pyridazin-3-amine (0.180 g, 0.82 mmol) in dry 1,4-dioxane (2 mL) was added trimethylaluminum (0.40 mL, 0.80 mmol, 2 M in toluene) dropwise under argon. The mixture was stirred at room temperature for 1 h before a solution of methyl 1-ethyl-6-oxo-1,6-dihydropyridazine-3-carboxylate (0.036 g, 0.2 mmol) in dry 1,4-dioxane (1 mL) was added dropwise to the above solution. The mixture was stirred at 100 °C for 3 h. After being cooled down to room temperature, the mixture was quenched with 0.5 *N* hydrochloric acid (25 mL) and ethyl acetate (50 mL). The organic layer was washed with 0.5 *N* hydrochloric acid (25 mL x 2), and brine (25 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by column chromatography (silica gel, ethyl acetate/petroleum ether = 2/1) to give


N-(6-(3-chlorobenzyl)pyridazin-3-yl)-1-ethyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (30 mg, 0.081 mmol, 40.7%) as a white solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 10.93 (s, 1H), 8.30 (d, *J* = 9.1 Hz, 1H), 7.93 (d, *J* = 9.7 Hz, 1H), 7.70 (d, *J* = 9.1 Hz, 1H), 7.45 - 7.20 (m, 4H), 7.08 (d, *J* = 9.7 Hz, 1H), 4.30 (s, 2H), 4.25 - 4.16 (m, 2H), 1.37 (t, *J* = 7.1 Hz, 3H). LCMS (ESI) *m/z*: 370.0 [M+H]⁺.

Example 186. Preparation of

N-(6-benzylpyridazin-3-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (186)




Step 1: Preparation of 6-benzylpyridazin-3-amine



To a solution of 6-(3-bromobenzyl)pyridazin-3-amine (0.264 g, 1 mmol) in methanol (30 mL) was added palladium on carbon (0.106 mg, 0.5 mmol) under hydrogen balloon at room temperature. The mixture was stirred at room temperature for 1.5 h before it was filtered through Celite® and washed with methanol (30 mL). The filtrate was concentrated, to give 6-benzylpyridazin-3-amine (0.260 g, crude) as a yellow solid. LCMS (ESI) *m/z*: 186.2 [M+H]⁺.

Step 2: Preparation of


N-(6-benzylpyridazin-3-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide

To a solution of 6-benzylpyridazin-3-amine (0.130 g crude, 0.5 mmol),


1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.094 g, 0.6 mmol) and *N*-methylmorpholine (0.152 g, 1.5 mmol) in tetrahydrofuran (15 mL) and *N,N*-dimethylformamide (15 mL) was added 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (0.147 g, 0.5 mmol) at room temperature under argon. The mixture was stirred at room temperature for 20 h before it was diluted with ethyl acetate (100 mL) and washed with brine (50 mL x 3). The organic layers were dried with sodium sulfate, filtered and concentrated. The crude product was purified by Prep-TLC (dichloromethane: ammonia in methanol (7 *N*) = 35/1) to give

N-(6-benzylpyridazin-3-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide as a white solid (0.080 g, 0.245 mmol, 49%). ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 10.42 (s, 1H), 8.24 (d, *J* = 9.5 Hz, 1H), 7.63 (d, *J* = 9.5 Hz, 1H), 7.29-7.34 (m, 4H), 7.23 (t, *J* = 7 Hz, 1H), 4.27 (s, 2H), 3.39 (s, 3H), 2.85 (t, *J* = 8.5 Hz, 2H), 2.46-2.56 (m, 2H). LCMS (ESI) *m/z*: 324.2 [M+H]⁺.

Example 187. Preparation of

N-(6-(3-cyclopropylbenzyl)pyridazin-3-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (187)


Step 1: Preparation of 6-(3-cyclopropylbenzyl)pyridazin-3-amine



To a solution of 6-(3-bromobenzyl)pyridazin-3-amine (0.264 g, 1 mmol), cyclopropylboronic acid (0.258 g, 3 mmol), tricyclohexylphosphine tetrafluoroborate (0.037 g, 0.1 mmol) and potassium phosphate (0.424 g, 2 mmol) in toluene (8 mL) and water (2 mL) was added palladium(II) acetate (0.023 g, 0.1 mmol) under argon. The mixture was stirred at 120 °C for 1.5 h in the microwave. Reaction was cooled to room temperature and diluted with ethyl acetate (100 mL). The organic layer was washed with water (30 mL x 2), dried with sodium sulfate, filtered and concentrated. The crude sample was purified by column chromatography (dichloromethane/ammonia in methanol (7 *N*) = 20/1) to give

N-(6-(3-cyclopropylbenzyl)pyridazin-3-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide as a light-yellow solid (0.110 g, 0.49 mmol, 49%); LCMS (ESI) 226.2 [M+H]⁺.


Step 2: Preparation of

N-(6-(3-cyclopropylbenzyl)pyridazin-3-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide


To a solution of 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.059 g, 0.375 mmol) and 1-[*bis*(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.143 g, 0.375 mmol) in *N,N*-dimethylformamide (3 mL) was added *N,N*-diisopropylethylamine (0.097 g, 0.75 mmol) at room temperature under nitrogen. The mixture was stirred at room temperature for 30 minutes before 6-(3-cyclopropylbenzyl)pyridazin-3-amine (0.057 g, 0.25 mmol) was added. The reaction mixture was stirred at room temperature for 20 h and diluted with ethyl acetate (80 mL). The organic layer was washed with brine (30 mL x 3), dried with sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μ m column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give

N-(6-(3-cyclopropylbenzyl)pyridazin-3-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (67.1 mg, 0.132 mmol, 53%) as a colorless oil. ^1H NMR (500 MHz, Dimethylsulfoxide- d_6) δ 10.42 (s, 1H), 8.23 (d, J = 9 Hz, 1H), 7.61 (d, J = 9 Hz, 1H), 7.18 (t, J = 7.5 Hz, 1H), 7.02-7.04 (m, 2H), 6.91 (d, J = 8.0 Hz, 1H), 4.21 (s, 2H), 3.39 (s, 3H), 2.85 (t, J = 8.5 Hz, 2H), 2.51-2.56 (m, 2H), 1.85-1.90 (m, 1H), 0.91-0.94 (m, 2H), 0.62-0.65 (m, 2H). LCMS (ESI) m/z : 364.2 $[\text{M}+\text{H}]^+$.

Example 188. Preparation of

N-(6-(3,4-dichlorobenzyl)pyridazin-3-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (188)

Step 1: Preparation of

N-(6-(3,4-dichlorobenzyl)pyridazin-3-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide


A mixture of 3-chloro-6-(3,4-dichlorobenzyl)pyridazine (0.150 g, 0.55 mmol), 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.171 g, 1.10 mmol), tris(dibenzylideneacetone)dipalladium(0) (50 mg, 0.055 mmol), XantPhos (48 mg, 0.083 mmol) and cesium carbonate (0.358 g, 1.10 mmol) in dry 1,4-dioxane (5 mL) was stirred at 90 °C for 2 h under

argon. After being cooled to room temperature, the mixture was diluted with ethyl acetate (50 mL) and washed with water (25 mL) and brine (25 mL). The organic layer was dried over sodium sulfate, filtered and concentrated. The residue was purified by column chromatography (ethyl acetate/petroleum ether = 2/1) followed by prep-HPLC (column: Sunfire prep C18 10 μ m OBD 19*250 mm; mobile phase: [water (0.05% trifluoroacetic acid)-acetonitrile]; B%: 60%-88%, 15 minutes) to give


N-(6-(3,4-dichlorobenzyl)pyridazin-3-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (45 mg, 0.12 mmol, 21.8%) as a white solid. ^1H NMR (500 MHz, Dimethylsulfoxide- d_6) δ 10.44 (s, 1H), 8.25 (d, J = 9.1 Hz, 1H), 7.68 (d, J = 9.1 Hz, 1H), 7.60 (dd, J = 16.9, 5.1 Hz, 2H), 7.29 (dd, J = 8.3, 2.0 Hz, 1H), 4.28 (s, 2H), 3.38 (s, 3H), 2.85 (t, J = 8.5 Hz, 2H), 2.54 (t, J = 8.5 Hz, 2H); LCMS (ESI) m/z : 392.0 $[\text{M}+\text{H}]^+$.

Example 189. Preparation of

6-(3-chlorobenzyl)-*N*-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)pyridazine-3-carboxamide (189)




Step 1: Preparation of methyl 6-(3-chlorobenzyl)pyridazine-3-carboxylate



A solution of (3-chlorobenzyl)zinc(II) bromide (60 mL, 39.2 mmol) was added dropwise to a solution of methyl 6-chloropyridazine-3-carboxylate (4.23 g, 24.60 mmol) and tetrakis(triphenylphosphine)palladium(0) (1.42 g, 1.23 mmol) in tetrahydrofuran (40 mL). The reaction mixture was stirred at 50 °C for 18 h before it was quenched with aqueous saturated solution of ammonium chloride (50 mL). The aqueous layer was extracted with ethyl acetate (50 mL x 3). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate, filtered and concentrated. The crude residue was taken up in methanol (100 mL) and hydrochloric acid (3.0 M, 10 mL) was added. The mixture was stirred at 60 °C for 1 h. Concentration followed by purification via column chromatography (silica gel, ethyl acetate/petroleum ether = 1/1) gives 6-(3-chlorobenzyl)pyridazine-3-carboxylate (1.78 g, 6.79 mmol, 27.6%) as a yellow solid. LCMS (ESI) m/z : 263.0 $[\text{M}+\text{H}]^+$.

Step 2: Preparation of


6-(3-chlorobenzyl)-*N*-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)pyridazine-3-carboxamide



To a solution of 5-amino-1-methylpyridin-2(1H)-one (0.194 g, 1.56 mmol) in dry 1,4-dioxane (5 mL) was added dropwise trimethylaluminum (0.76 mL, 1.52 mmol, 2 M in toluene) under argon. The mixture was stirred at room temperature for 1 h before a solution of 6-(3-chlorobenzyl)pyridazine-3-carboxylate (0.100 g, 0.38 mmol) in dry 1,4-dioxane (3 mL) was added dropwise. The mixture was stirred at 100 °C for 5 h. Reaction mixture was cooled to room temperature and quenched with 0.5 *N* hydrochloric acid (25 mL). The aqueous layer was extracted with ethyl acetate (100 mL). The organic layer was washed with 0.5 *N* hydrochloric acid (25 mL x 2), brine (50 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by column chromatography (silica gel, ethyl acetate/methanol = 20/1) and prep-HPLC (column: Sunfire prep C18 10 µm OBD 19*250 mm; mobile phase: [water (0.05% trifluoroacetic acid-acetonitrile); B%: 60%-88%, 15 minutes) to give 6-(3-chlorobenzyl)-*N*-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)pyridazine-3-carboxamide (75 mg, 0.21 mmol, 55.8%) as a yellow solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 10.92 (s, 1H), 8.36 (d, *J* = 2.7 Hz, 1H), 8.20 (d, *J* = 8.6 Hz, 1H), 7.87 (d, *J* = 8.6 Hz, 1H), 7.80 (dd, *J* = 9.7, 2.8 Hz, 1H), 7.46 (s, 1H), 7.40 - 7.24 (m, 3H), 6.44 (d, *J* = 9.7 Hz, 1H), 4.44 (s, 2H), 3.46 (s, 3H); LCMS (ESI) *m/z*: 355.1 [*M*+H]⁺.


Example 190. Preparation of

6-(3-chlorobenzyl)-*N*-(1-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)pyridazine-3-carboxamide (190)



Step 1: Preparation of

6-(3-chlorobenzyl)-*N*-(1-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)pyridazine-3-carboxamide




To a solution of 6-amino-2-methyl-4,5-dihydropyridazin-3(2H)-one (0.100 g, 0.78 mmol) in dry 1,4-dioxane (3 mL) was added trimethylaluminum (0.38 mL, 0.76 mmol, 2.0 M in toluene) dropwise under argon. The mixture was stirred at room temperature for 1 h before a solution of 6-(3-chlorobenzyl)pyridazine-3-carboxylate (0.050 g, 0.19 mmol) in dry 1,4-dioxane (1 mL) was added dropwise. The reaction mixture was stirred at 100 °C for 5 h. Reaction vessel was cooled to room temperature and quenched with 0.5 *N* hydrochloric acid (25 mL). The aqueous layer was extracted with ethyl acetate (100 mL). The organic layer was washed with 0.5 *N* hydrochloric acid (25 mL x 2), brine (50 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by column


chromatography (ethyl acetate/methanol = 20/1) and prep-HPLC (column: Sunfire prep C18 10 μ m OBD 19*250 mm; mobile phase: [water (0.05% trifluoroacetic acid)-acetonitrile]; B%: 60%-88%, 15 minutes) to give 6-(3-chlorobenzyl)-*N*-(1-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)pyridazine-3-carboxamide (13 mg, 0.036 mmol, 19.2%) as a white solid. ^1H NMR (500 MHz, Dimethylsulfoxide- d_6) δ 10.59 (s, 1H), 8.19 (d, J = 8.6 Hz, 1H), 7.88 (d, J = 8.7 Hz, 1H), 7.45 (s, 1H), 7.40 - 7.22 (m, 3H), 4.44 (s, 2H), 3.25 - 3.03 (m, 5H), 2.49 (d, J = 8.7 Hz, 2H); LCMS (ESI) m/z : 358.1 $[\text{M}+\text{H}]^+$.

Example 191. Preparation of

N-(6-(3-bromobenzyl)pyridazin-3-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (191)




Step 1: Preparation of methyl 6-(4-methoxybenzylamino)pyridazine-3-carboxylate




To a solution of (4-methoxyphenyl)methanamine (19.9 g, 145 mmol) in acetonitrile (150 mL) at room temperature was added potassium carbonate (20.0 g, 145 mmol) and methyl 6-chloropyridazine-3-carboxylate (12.5 g, 72.4 mmol). The reaction mixture was stirred at 80 °C for 16 h before it was cooled to room temperature and diluted with water (300 mL). The aqueous layer was extracted with ethyl acetate (200 mL $\times$ 3). The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated. The crude residue was purified by column chromatography (silica gel, ethyl acetate/petroleum ether = 1/3) to afford methyl 6-(4-methoxybenzylamino)pyridazine-3-carboxylate (28.0 g, crude) as a light yellow oil. (LCMS (ESI) m/z : 274.1 $[\text{M}+\text{H}]^+$). Used in the next step directly without additional purification.

Step 2: Preparation of (6-(4-Methoxybenzylamino)pyridazin-3-yl)methanol




To a solution of methyl 6-(4-methoxybenzylamino)pyridazine-3-carboxylate (9.2 g, 33.7 mmol) in methanol (336 mL) at 0 °C was added sodium borohydride (2.56 g, 67.3 mmol). The mixture was stirred at room temperature for 16 h before it was quenched with ice water (200 mL). The aqueous layer was extracted with dichloromethane (200 mL × 4). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The crude sample was purified by column chromatography (silica gel, ethyl acetate/petroleum ether = 3/1) to afford (6-(4-methoxybenzylamino)pyridazin-3-yl)methanol (4.3 g, 17.5 mmol, 52.1%) as a white solid. (LCMS (ESI) m/z : 246.1 $[M+H]^+$).

Step 3: Preparation of 6-(4-Methoxybenzylamino)pyridazine-3-carbaldehyde




To a solution of (6-(4-methoxybenzylamino)pyridazin-3-yl)methanol (4.3 g, 17.5 mmol) in dimethylsulfoxide (175 mL) at 0 °C was added 2-iodoxybenzoic acid (7.36 g, 26.3 mmol). The reaction mixture was stirred at room temperature for 5 h before it was quenched with water (300 mL). The aqueous layer was extracted with ethyl acetate (150 mL × 3). The combined organic layers were washed with aqueous solution of sodium bicarbonate (100 mL), dried over sodium sulfate, filtered and concentrated. The crude sample was purified by column chromatography (silica gel, ethyl acetate/petroleum ether = 2/1) to afford 6-(4-methoxybenzylamino)pyridazine-3-carbaldehyde (4.0 g, 16.4 mmol, 93.8%) as a white solid. LCMS (ESI) m/z : 244.1 $[M+H]^+$.

Step 4: Preparation of (3-bromophenyl)(6-(4-methoxybenzylamino)pyridazin-3-yl)methanol



To a solution of 1,3-dibromobenzene (6.11 g, 25.9 mmol) in anhydrous tetrahydrofuran (86 mL) at -78 °C, was added *n*-butyllithium (10.4 mL, 25.9 mmol, 2.5 M in hexanes) under nitrogen. The reaction mixture was stirred at -78 °C for 1 h before 6-(4-methoxybenzylamino)pyridazine-3-carbaldehyde (2.1 g, 8.63 mmol) was added. Reaction was warmed to 0 °C over 5 h before it was quenched with ice water (300 mL). The aqueous layer was extracted with ethyl acetate (100 mL × 3). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated. The crude sample was purified by column chromatography (silica gel, dichloromethane/methanol = 10/1) to afford (3-bromophenyl)(6-(4-methoxybenzylamino)pyridazin-3-yl)methanol (3.8 g, crude) as a white solid. (LCMS (ESI) m/z : 400.0 $[M+H]^+$).


Step 5: Preparation of 6-(3-Bromobenzyl)pyridazin-3-amine



To a solution of (3-bromophenyl)(6-(4-methoxybenzylamino)pyridazin-3-yl)methanol (3.3 g, 8.27 mmol) in acetic acid (82 mL) was added hypophosphorous acid (48%, 9.10 g, 66.2 mmol) and iodine (3.15 g, 12.41 mmol). The mixture was stirred at 100 °C for 32 h before it was cooled to room temperature and concentrated. The residue was diluted with water (200 mL) and aqueous solution of sodium bicarbonate (100 mL). The aqueous layer was extracted with dichloromethane (100 mL × 4). The combined organic layers were dried over sodium sulfate, filtered and concentrated. Purification by column chromatography (silica gel, dichloromethane/ methanol = 10/1) affords 6-(3-bromobenzyl)pyridazin-3-amine (2.6 g, crude) as a white solid. LCMS (ESI) m/z : 264.1 $[M+H]^+$.

Step 6: Preparation of


N-(6-(3-bromobenzyl)pyridazin-3-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide




To a solution of 6-(3-bromobenzyl)pyridazin-3-amine (0.100 g, 0.378 mmol) in *N,N*-dimethylformamide (4 mL) at room temperature was added 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.060 g, 0.454 mmol), 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (0.134 g, 0.454 mmol) and 4-methylmorpholine (0.192 g, 1.89 mmol). The reaction mixture was stirred at room temperature for 16 h before it was diluted with water (100 mL). The aqueous layer was extracted with ethyl acetate (50 mL × 3). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 μm column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give *N*-(6-(3-bromobenzyl)pyridazin-3-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (30.0 mg, 0.074 mmol, 19.6%) as a white solid. ^1H NMR (400 MHz, Dimethylsulfoxide- d_6) δ 10.44 (s, 1H), 8.25 (d, J = 9.2 Hz, 1H), 7.67 (d, J = 9.2 Hz, 1H), 7.53 (s, 1H), 7.45-7.42 (m, 1H), 7.31 - 7.26 (m, 2H), 4.27 (s, 2H), 3.38 (s, 3H), 2.85 (t, J = 20.0 Hz, 2H), 2.54 (t, J = 20.0 Hz, 2H); LCMS (ESI) m/z : 402.1 $[M+H]^+$.

Example 192. Preparation of

N-(6-(3-chloro-4-fluorobenzyl)pyridazin-3-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (192)




Step 1: Preparation of



N-(6-chloropyridazin-3-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide

In a 40 mL reaction vial, 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.5 g, 3.20 mmol) was combined with 6-chloropyridazin-3-amine (0.414 g, 3.20 mmol) and 2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (1.03 g, 3.20 mmol). To the vial *N,N'*-dimethylformamide (16.0 mL) was added followed by *N,N,N,N*-diisopropylethyl amine (0.835 mL, 4.80 mmol). The reaction is stirred 16 h at room temperature. The reaction is diluted with ethyl acetate (25 mL) and washed 3 times with water (10 mL), then once with brine (15 mL). The mixture is dried over sodium sulfate, filtered, and concentrated. Purified reaction by column chromatography (eluting with 0-100% ethyl acetate/hexanes through 24 g of silica gel) to give *N*-(6-chloropyridazin-3-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (381 mg, 1.42 mmol, 44%) as a yellow solid. ¹H NMR (300 MHz, Chloroform-*d*) δ 9.84 (s, 1H), 8.55 (d, *J* = 9.3 Hz, 1H), 7.56 (dd, *J* = 9.3, 0.7 Hz, 1H), 3.51 (s, 3H), 3.09 - 2.93 (m, 2H), 2.63 (t, *J* = 8.6 Hz, 2H).


Step 2: Preparation of

N-(6-(3-chloro-4-fluorobenzyl)pyridazin-3-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide

In a 40 mL reaction vial, suspended *bis*(triphenylphosphine)palladium(II) dichloride (0.050 mg, 0.071 mmol) in *N,N'*-dimethylformamide (5.0 mL). The reaction was degassed by cycling with vacuum and nitrogen gas for 3 cycles. Added iodine (0.018 g, 0.071 mmol) and stirred at room temperature for 5 min. Added 4-(bromomethyl)-2-chloro-1-fluorobenzene (191 μL, 1.42 mmol) and stirred at 80 °C for 3 h. Cooled to room temperature and added zinc dust (0.185 g, 2.84 mmol) and *N*-(6-chloropyridazin-3-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.381 g, 1.42 mmol) then stirred 16 h at room temperature. Diluted with ethyl acetate (15 mL) and washed with water (10 mL x 3), then with brine (10 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated. Purified by column chromatography (eluting with 0-100% ethyl acetate/hexanes through 24 g of silica gel) to give *N*-(6-(3-chloro-4-fluorobenzyl)pyridazin-3-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide as a white solid (59 mg, 0.157 mmol, 11%). ¹H NMR (300 MHz, Chloroform-*d*) δ 9.79 (s, 1H), 8.44 (d, *J* = 9.2 Hz, 1H), 7.40 - 7.25 (m, 3H), 7.25 - 7.04 (m, 2H), 4.28 (s, 2H), 3.51 (s, 3H), 2.98 (t, *J* = 8.6 Hz, 2H), 2.62 (t, *J* = 8.5 Hz, 2H); LCMS (ESI) *m/z*: 376.206 [*M*+*H*]⁺.

Example 193. Preparation of***N*-(6-(3-fluorobenzyl)pyridazin-3-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (193)****5 Step 1: Preparation of*****N*-(6-chloropyridazin-3-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide**

In a 40 mL reaction vial, 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.5 g, 3.20 mmol) was combined with 6-chloropyridazin-3-amine (0.414 g, 3.20 mmol) and
 10 2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (1.03 g, 3.20 mmol). To the vial *N,N'*-dimethylformamide (16.0 mL) was added followed by *N,N,N,N*-diisopropylethyl amine (835 μ L, 4.80 mmol). The reaction is stirred 16 h at room temperature. The reaction is diluted with ethyl acetate (20 mL) and washed with water (10 mL x 3), then once with brine (10 mL). The mixture is dried over sodium sulfate, filtered, and concentrated. Purified reaction by column chromatography (eluting with
 15 0-100% ethyl acetate/hexanes through 24 g of silica gel) to give of *N*-(6-chloropyridazin-3-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide as a yellow solid (381 mg, 1.42 mmol, 44%). ¹H NMR (300 MHz, Chloroform-*d*) δ 9.84 (s, 1H), 8.55 (d, *J* = 9.3 Hz, 1H), 7.56 (dd, *J* = 9.3, 0.7 Hz, 1H), 3.51 (s, 3H), 3.09 - 2.93 (m, 2H), 2.63 (t, *J* = 8.6 Hz, 2H).

20 Step 2: Preparation of***N*-(6-(3-fluorobenzyl)pyridazin-3-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide****Suspended**


N-(6-chloropyridazin-3-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.381 g, 1.42
 25 mmol) in tetrahydrofuran (8.0 mL) and added *bis*(triphenylphosphine)palladium(II) dichloride (0.050 mg, 0.07100 mmol). The reaction was degassed by cycling with vacuum and nitrogen gas for 3 cycles. Slowly added 3-Fluoro-benzylzinc chloride (0.5M in tetrahydrofuran, 8.52 mL, 4.26 mmol) and stirred 16 h at 65 °C. Cooled to room temperature and quenched with saturated aqueous ammonium chloride (20 mL). Diluted with ethyl acetate (20 mL), then washed with water (10 mL), then brine (10 mL). The combined
 30 organic layers were dried over sodium sulfate, filtered, and concentrated. Purified reaction by column chromatography (eluting with 0-100% ethyl acetate/hexanes through 24 g of silica gel. Purification was

repeated twice to obtain clean product. Isolated

N-(6-(3-fluorobenzyl)pyridazin-3-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide as a white solid (85 mg, 0.249 mmol, 18%). ¹H NMR (300 MHz, Chloroform-*d*) δ 9.79 (s, 1H), 8.42 (d, *J* = 9.2 Hz, 1H), 7.39 - 7.27 (m, 3H), 7.07 (d, *J* = 7.6 Hz, 1H), 6.98 (d, *J* = 10.0 Hz, 2H), 4.33 (s, 2H), 3.51 (s, 3H), 2.98 (t, *J* = 8.6 Hz, 2H), 2.62 (t, *J* = 8.5 Hz, 2H); LCMS (ESI) *m/z*: 342.2 [*M*+H]⁺.


Example 194. Preparation of

1-methyl-6-oxo-*N*-(6-(3-(trifluoromethyl)benzyl)pyridazin-3-yl)-1,4,5,6-tetrahydropyridazine-3-carboxamide (194)



Step 1: Preparation of

N-(6-chloropyridazin-3-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide




In a 40 mL reaction vial, 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.500 g, 3.20 mmol) was combined with 6-chloropyridazin-3-amine (0.414 g, 3.20 mmol) and 2-(3H-[1,2,3]triazolo[4,5-*b*]pyridin-3-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (1.03 g, 3.20 mmol). To the vial *N,N'*-dimethylformamide (16.0 mL) was added followed by *N,N,N,N*-diisopropylethyl amine (835 μL, 4.80 mmol). The reaction is stirred 16 h at room temperature. The reaction is diluted with ethyl acetate (15 mL x 3) with water (10 mL), then with brine (10 mL). The mixture is dried over sodium sulfate, filtered, and concentrated. Purified reaction by column chromatography (eluting with 0-100% ethyl acetate/hexanes through 24 g of silica gel) to give

N-(6-chloropyridazin-3-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide as a yellow solid (156 mg, 0.583 mmol, 18%). ¹H NMR (300 MHz, Chloroform-*d*) δ 9.84 (s, 1H), 8.55 (d, *J* = 9.3 Hz, 1H), 7.56 (dd, *J* = 9.3, 0.7 Hz, 1H), 3.51 (s, 3H), 3.09 - 2.93 (m, 2H), 2.63 (t, *J* = 8.6 Hz, 2H).

Step 2: Preparation of

1-methyl-6-oxo-*N*-(6-(3-(trifluoromethyl)benzyl)pyridazin-3-yl)-1,4,5,6-tetrahydropyridazine-3-carboxamide



In a 40 mL reaction vial, suspended dust zinc dust (0.121 g, 1.86 mmol) in *N,N'*-dimethylformamide (3.0 mL) and carefully added iodine (0.008 g, 0.029 mmol). Stirred at room temperature for 5 min. Slowly added 1-(bromomethyl)-3-(trifluoromethyl)benzene (269 μL, 1.74 mmol)


and stirred at 85 °C for 4 h. Cooled to room temperature and added *bis*(triphenylphosphine)palladium(II) dichloride (0.020 g, 0.02914 mmol) and

N-(6-chloropyridazin-3-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.156 g, 0.5828 mmol). The reaction was degassed by cycling with vacuum and nitrogen for 3 cycles. Stirred reaction at room temperature 16 h. Diluted with ethyl acetate (15 mL) and washed with water (10 mL x 3) and then with brine (15 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated. Purified reaction by column chromatography (eluting with 0-100% ethyl acetate/hexanes through 24 g of silica gel) to give


1-methyl-6-oxo-*N*-(6-(3-(trifluoromethyl)benzyl)pyridazin-3-yl)-1,4,5,6-tetrahydropyridazine-3-carboxamide as a pale yellow solid (25 mg, 0.064 mmol, 11%). ¹H NMR (300 MHz, Chloroform-*d*) δ 9.79 (s, 1H), 8.43 (d, *J* = 9.2 Hz, 1H), 7.63 - 7.43 (m, 4H), 7.33 (d, *J* = 9.2 Hz, 1H), 4.39 (s, 2H), 3.51 (s, 3H), 3.04 - 2.92 (m, 2H), 2.62 (t, *J* = 8.5 Hz, 2H); LCMS (ESI) *m/z*: 392.2 [*M*+*H*]⁺.

Example 195. Preparation of

N-(6-(3-fluorobenzyl)pyridazin-3-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (195)




Step 1: Preparation of 6-(3-fluorobenzyl)pyridazin-3-amine



In a 40 mL reaction vial, suspended 6-chloropyridazin-3-amine (0.200 g, 1.54 mmol) and [1,3-*bis*(diphenylphosphino)propane]dichloronickel(II) (0.166 g, 0.308 mmol) in 1,4-dioxane (7.70 mL). The reaction was degassed by cycling with vacuum and nitrogen gas for 3 cycles. Carefully added (3-fluorobenzyl)zinc(II) chloride (9.24 mL, 4.62 mmol), then stirred at 80 °C for 16 h. Cooled to room temperature and diluted with saturated aqueous ammonium chloride (15 mL). Extracted with ethyl acetate (20 mL), then washed with water (10 mL) then brine (15 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated. Purified reaction by column chromatography (eluting with 0-100% ethyl acetate/hexanes through 12 g of silica gel) to give 6-(3-fluorobenzyl)pyridazin-3-amine as a yellow oil (249 mg, 1.22 mmol, 80%). (LCMS (ESI) *m/z*: 204.1 [*M*+*H*]⁺).

Step 2: Preparation of


N-(6-(3-fluorobenzyl)pyridazin-3-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide




In a 40 mL reaction vial, combined 6-(3-fluorobenzyl)pyridazin-3-amine (0.249 g, 1.22 mmol) and 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (0.188 g, 1.22 mmol) with 2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (0.392 g, 1.22 mmol). Suspended in 5.0 mL *N,N'*-dimethylformamide and added *N,N,N,N*-diisopropylethyl amine (318 μ L, 1.83 mmol). Stirred at room temperature 16 h. Diluted with ethyl acetate (15 mL) and washed with water (10 mL x 3), then brine (15 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated. Purified reaction by column chromatography (eluting with 0-100% ethyl acetate/hexanes through 24 g of silica gel) to give *N*-(6-(3-fluorobenzyl)pyridazin-3-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide as a yellow solid (61 mg, 0.18 mmol, 15%). ¹H NMR (300 MHz, Chloroform-*d*) δ 8.50 (d, *J* = 9.2 Hz, 1H), 8.04 (d, *J* = 9.7 Hz, 1H), 7.37 (d, *J* = 9.3 Hz, 1H), 7.32 (s, 2H), 7.07 (d, *J* = 9.7 Hz, 2H), 6.99 (d, *J* = 11.7 Hz, 2H), 4.35 (s, 2H), 3.94 (s, 3H); LCMS (ESI) *m/z*: 340. 2 [M+H]⁺.

Example 196. Preparation of

N-(6-(3-chlorobenzyl)pyridazin-3-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (196)



Step 1: Preparation of *tert*-butyl *N*-(6-[(3-chlorophenyl)methyl]pyridazin-3-yl)carbamate)




In a 40 mL vial, combined *tert*-butyl *N*-(6-chloropyridazin-3-yl)carbamate (0.400 g, 1.74 mmol) with [(2-di-*tert*-butylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)-2-(2'-amino-1,1'-biphenyl)] palladium(II) methanesulfonate (0.027 g, 0.0348 mmol), then suspended in tetrahydrofuran (3.48 mL). The reaction was degassed by cycling with vacuum and nitrogen gas for 3 cycles. Slowly added 3-chlorobenzylzinc chloride (0.5 M in tetrahydrofuran, 6.96 mL, 3.48 mmol) and stirred 16 h at 60 °C.

Dibromo[1,1-*bis*(diphenylphosphino)ferrocene]palladium(II) (0.025 g, 0.030 mmol) was added and stirred at 70 °C for 16 h. Cooled to room temperature and diluted with ethyl acetate (20 mL). Washed with saturated aqueous ammonium chloride (15 mL), water (10 mL), then brine (15 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated. Purified reaction by column chromatography (eluting with 0-100% ethyl acetate/hexanes through 24 g of silica gel) to give *tert*-butyl

N-{6-[(3-chlorophenyl)methyl]pyridazin-3-yl}carbamate) as a white solid (162 mg, 0.506 mmol, 29%). ¹H NMR (300 MHz, Chloroform-*d*) δ 8.16 (d, *J* = 9.2 Hz, 1H), 7.32 - 7.20 (m, 3H), 4.26 (s, 2H), 1.54 (s, 9H).


Step 2: Preparation of 6-[(3-chlorophenyl)methyl]pyridazin-3-amine



Dissolved *tert*-butyl *N*-{6-[(3-chlorophenyl)methyl]pyridazin-3-yl}carbamate (162 mg, 0.5065 mmol) in dichloromethane and added 2,2,2-trifluoroacetic acid (0.25 mL, 0.507 mmol). Stirred at room temperature 16 h. Reaction is concentrated *in vacuo* and is taken crude to next reaction.

Step 3: Preparation of


N-{6-[(3-chlorophenyl)methyl]pyridazin-3-yl}-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide




Combined 6-[(3-chlorophenyl)methyl]pyridazin-3-amine (0.111 g, 0.5053 mmol), 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (0.078 g, 0.5053 mmol), and [bis(dimethylamino)methylidene]({3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl})oxidanium; tetrafluoroboranuide (0.162 g, 0.5053 mmol) in a 25 mL round bottom flask and dissolved in 2.0 mL *N,N'*-dimethylformamide. Added ethylbis(propan-2-yl)amine (131 μL, 0.7579 mmol) and stirred at room temperature 16 h. Diluted with ethyl acetate (15 mL), then washed with water (10 mL x 3) and brine (10 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated. Purified reaction by column chromatography (eluting with 0-100% ethyl acetate/hexanes through 24 g of silica gel) to give *N*-{6-[(3-chlorophenyl)methyl]pyridazin-3-yl}-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide as a white solid (57 mg, 0.16 mmol, 32%). ¹H NMR (300 MHz, Chloroform-*d*) δ 8.56 (d, *J* = 9.2 Hz, 1H), 8.03 (d, *J* = 9.7 Hz, 1H), 7.41 (d, *J* = 9.3 Hz, 1H), 7.19 (s, 4H), 7.07 (d, *J* = 9.8 Hz, 1H), 4.33 (s, 2H), 3.95 (d, *J* = 0.8 Hz, 3H); LCMS (ESI) *m/z*: 356.2 [*M*+H]⁺.

Example 197. Preparation of

***N*-(6-(3-chlorobenzyl)pyridazin-3-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (197)**




Step 1: Preparation of


N-(6-chloropyridazin-3-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide

In a 40 mL reaction vial, 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.5 g, 3.20 mmol) was combined with 6-chloropyridazin-3-amine (0.414 g, 3.20 mmol) and 2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (1.03 g, 3.20 mmol). To the vial *N,N'*-dimethylformamide (16.0 mL) was added followed by *N,N,N,N*-diisopropylethyl amine (835 μ L, 4.80 mmol). The reaction is stirred 16 h at room temperature. The reaction is diluted with ethyl acetate (20 mL) and washed with water (10 mL x 3), then with brine (15 mL). The mixture is dried over sodium sulfate, filtered, and concentrated. Purified reaction by column chromatography (eluting with 0-100% ethyl acetate/hexanes through 24 g of silica gel) to give *N*-(6-chloropyridazin-3-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide as a white solid (140 mg, 0.523 mmol, 16%). ^1H NMR (300 MHz, Chloroform-*d*) δ 8.55 (d, J = 9.3 Hz, 1H), 7.56 (dd, J = 9.3, 0.7 Hz, 1H), 3.51 (s, 3H), 2.99 (m, 2H), 2.63 (t, J = 8.5 Hz, 2H).


Step 2: Preparation of

N-(6-(3-chlorobenzyl)pyridazin-3-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide

Suspend zinc dust (0.048 g, 0.7322 mmol) in tetrahydrofuran (2.61 mL) and added 1,2-dibromoethane (18.0 μ L, 0.2092 mmol). Heated to 65 $^{\circ}\text{C}$ for 5 minutes. Cooled to 0 $^{\circ}\text{C}$ and added 1-(bromomethyl)-3-chlorobenzene (81.7 μ L, 0.6275 mmol). Stirred at 0 $^{\circ}\text{C}$ for 1 hour. Add [1,1'-*bis*(diphenylphosphino)ferrocene]dibromopalladium(II) (0.021 mg, 0.02615 mmol) and stirred at room temperature for 30 minutes. Add *N*-(6-chloropyridazin-3-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.140 g, 0.523 mmol) and stirred at 80 $^{\circ}\text{C}$ for 16 h. Cooled to room temperature and diluted with ethyl acetate (15 mL). Washed with 1 N aqueous sodium hydroxide (10 mL), water (10 mL), then brine (10 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated. Purified reaction by column chromatography (eluting with 0-100% ethyl acetate/hexanes through 24 g of silica gel) to give *N*-(6-(3-chlorobenzyl)pyridazin-3-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide as a white solid (17 mg, 0.047 mmol, 9%). ^1H NMR (300 MHz, Chloroform-*d*) δ 9.80 (s, 1H), 8.43 (d, J = 9.1 Hz, 1H), 7.37 - 7.27 (m, 3H), 4.31 (s, 2H), 3.51 (s, 3H), 2.98 (t, J = 8.5 Hz, 2H), 2.62 (t, J = 8.6 Hz, 2H); LCMS (ESI) m/z 358.4 $[\text{M}+\text{H}]^+$.

Example 198. Preparation of***N*-(6-(cyclohexylmethyl)pyridazin-3-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (198)**


5

Step 1: Preparation of *tert*-butyl *N*-[6-(cyclohexylmethyl)pyridazin-3-yl]carbamate

Combined *tert*-butyl *N*-(6-chloropyridazin-3-yl)carbamate (0.200 g, 0.8708 mmol) and [1,1'-*bis*(diphenylphosphino)ferrocene]dibromopalladium(II) (0.036 g, 0.04354 mmol) in a 40 mL reaction vial and suspended in tetrahydrofuran (2.0 mL). The reaction was degassed by cycling with vacuum and nitrogen gas for 3 cycles. Carefully added chloro(cyclohexylmethyl)zinc dust (0.5M in tetrahydrofuran, 5.22 mL, 2.61 mmol) by syringe, then stirred 16 h at 80 °C. The reaction was cooled to room temperature and quenched with saturated aqueous ammonium chloride (15 mL). The mixture was extracted with ethyl acetate (20 mL), then washed with water (10 mL), then brine (10 mL). The reaction was dried over sodium sulfate, filtered, and concentrated. Purified reaction by column chromatography (eluting with 0-100% ethyl acetate/hexanes through 24 g of silica gel) to give *tert*-butyl *N*-[6-(cyclohexylmethyl)pyridazin-3-yl]carbamate as a white solid (170 mg, 0.583 mmol, 67%). ¹H NMR (300 MHz, Chloroform-*d*) δ 8.12 (d, *J* = 9.1 Hz, 1H), 7.25 (s, 1H), 2.79 (d, *J* = 7.0 Hz, 2H), 1.92 - 1.58 (m, 6H), 1.55 (s, 9H), 1.19 (m, 3H), 1.02 (m, 3H).

20


Step 2: Preparation of 6-(cyclohexylmethyl)pyridazin-3-amine



Reaction was dissolved in dichloromethane (5.0 mL) and cooled to 0 °C. Slowly added 2,2,2-trifluoroacetic acid (0.4 mL, 0.5834 mmol) and stirred at 0 °C to room temperature over 3 h. Concentrated *in vacuo*, and reaction was taken crude to next step. ¹H NMR (300 MHz, Chloroform-*d*) δ 7.49 (d, *J* = 9.4 Hz, 1H), 7.28 (d, *J* = 5.2 Hz, 2H), 2.65 (d, *J* = 6.9 Hz, 2H), 1.70 (d, *J* = 10.8 Hz, 8H), 1.21 (d, *J* = 9.7 Hz, 4H), 1.01 (d, *J* = 12.0 Hz, 3H).

25


Step 3: Preparation of

N-[6-(cyclohexylmethyl)pyridazin-3-yl]-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide

Combined 6-(cyclohexylmethyl)pyridazin-3-amine (0.111 g, 0.5803 mmol),


- 5 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.091 g, 0.5803 mmol) and 1-[Bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.186 g, 0.5803 mmol) in a 25 mL round bottom flask and dissolved in *N,N'*-dimethylformamide (3.0 mL). Added ethylbis(propan-2-yl)amine (150 μ L, 0.8704 mmol) and stirred 16 h at room temperature. Diluted with ethyl acetate (15 mL) and washed 3 times with water (10 mL), then once with brine (10 mL). The
- 10 combined organic layers were dried over sodium sulfate, filtered, and concentrated. Purified reaction by column chromatography (eluting with 0-100% ethyl acetate/hexanes through 24 g of silica gel) to give *N*-[6-(cyclohexylmethyl)pyridazin-3-yl]-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide as a white solid (27 mg, 0.082 mmol, 14%). ¹H NMR (300 MHz, Chloroform-*d*) δ 8.58 (d, *J* = 8.9 Hz, 1H), 7.48 (d, *J* = 9.2 Hz, 1H), 3.53 (s, 3H), 2.99 (t, *J* = 8.5 Hz, 2H), 2.89 (d, *J* = 7.1 Hz, 2H), 2.63 (t, *J* = 8.5 Hz, 2H),
- 15 1.69 (d, *J* = 13.5 Hz, 8H), 1.21 (d, *J* = 9.4 Hz, 3H); LCMS (ESI) *m/z*: 330.2 [*M*+*H*]⁺

Example 199. Preparation of

1-ethyl-*N*-(6-(3-fluorobenzyl)pyridazin-3-yl)-6-oxo-1,6-dihydropyridazine-3-carboxamide (199)

20


Step 1: Preparation of methyl 1-ethyl-6-oxo-1,6-dihydropyridazine-3-carboxylate



- 25 Dissolved methyl 6-oxo-1,6-dihydropyridazine-3-carboxylate (0.500 g, 3.24 mmol) in *N,N'*-dimethylformamide (5.0 mL) and added potassium carbonate (0.671 g, 4.86 mmol) and iodoethane (390 μ L, 4.86 mmol). Stirred at 75 $^{\circ}$ C for 16 h. Cooled to room temperature and diluted with ethyl acetate (20 mL). Washed with water (10 mL $\times$ 3), then with brine (15 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated. Purified reaction by column chromatography (eluting with 0-50% ethyl acetate/hexanes through 24 g of silica gel) to give methyl
- 1-ethyl-6-oxo-1,6-dihydropyridazine-3-carboxylate (211 mg, 1.15 mmol, 36%) as a pale yellow solid. ¹H

NMR (300 MHz, Chloroform-*d*) δ 7.86 (d, *J* = 9.7 Hz, 1H), 6.96 (d, *J* = 9.7 Hz, 1H), 4.33 (q, *J* = 7.2 Hz, 2H), 3.98 (s, 3H), 1.43 (t, *J* = 7.2 Hz, 3H).


Step 2: Preparation of 1-ethyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid





5 Dissolved methyl 1-ethyl-6-oxo-1,6-dihydropyridazine-3-carboxylate (0.211 g, 1.15 mmol) in tetrahydrofuran (2.0 mL) and water (1.0 mL). Added lithium hydroxide hydrate (0.144 g, 3.44 mmol) and stirred at room temperature 16 h. Acidified with 10% hydrochloric acid solution (6 mL), then extracted with ethyl acetate (15 mL). Washed organic layer with brine (10 mL), then dried over sodium sulfate. Filtered
10 and concentrated to yield 1-ethyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (106 mg, 0.630 mmol, 55%) as a white solid. ¹H NMR (300 MHz, Chloroform-*d*) δ 7.93 (d, *J* = 9.7 Hz, 1H), 7.04 (d, *J* = 9.6 Hz, 1H), 4.32 (q, *J* = 7.2 Hz, 2H), 1.46 (t, *J* = 7.2 Hz, 3H).

Step 3: Preparation of


15 1-ethyl-*N*-{6-[(3-fluorophenyl)methyl]pyridazin-3-yl}-6-oxo-1,6-dihydropyridazine-3-carboxamide



Combined 6-[(3-fluorophenyl)methyl]pyridazin-3-amine; trifluoroacetic acid (0.100 g, 0.3152 mmol) and 1-ethyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (0.053 g, 0.3152 mmol) with
20 [*bis*(dimethylamino)methylidene]({3H-[1,2,3]triazolo[4,5-*b*]pyridin-3-yl})oxidanium; tetrafluoroboranuide (0.101 g, 0.3152 mmol). Dissolved in methylene chloride (2.0 mL) and added ethyl*bis*(propan-2-yl)amine (136 μ L, 0.7879 mmol). Stirred at room temperature 16 h. Directly purified reaction by column chromatography (eluting with 0-100% ethyl acetate/hexanes through 12 g of silica gel) to give
1-ethyl-*N*-{6-[(3-fluorophenyl)methyl]pyridazin-3-yl}-6-oxo-1,6-dihydropyridazine-3-carboxamide (18 mg, 0.051 mmol, 16%) as a yellow solid. ¹H NMR (300 MHz, Chloroform-*d*) δ 8.57 (d, *J* = 9.7 Hz, 1H), 8.01
25 (dd, *J* = 9.7, 0.6 Hz, 1H), 7.42 (d, *J* = 9.2 Hz, 1H), 7.39 - 7.28 (m, 1H), 7.14 - 6.92 (m, 4H), 4.37 (d, *J* = 5.1 Hz, 4H), 1.49 (t, *J* = 7.2 Hz, 3H); LCMS (ESI) *m/z*: 354.2 [*M*+*H*]⁺.


Example 200. Preparation of***N*-(6-(3-fluorobenzyl)pyridazin-3-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (200)****5 Step 1: Preparation of 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid**

In a 40 mL reaction vial, dissolved 2-oxopentanedioic acid (3.0 g, 20.5 mmol) in 15.0 mL of 10% hydrochloric acid. Stirred until completely dissolved. Carefully added methylhydrazine (1.07 mL, 20.5 mmol) to the reaction, then stirred at 95 °C for 3 h. Cooled to room temperature and diluted with water (15 mL). Extracted twice with dichloromethane (30 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated to give 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid as a white solid (1.47g, 9.41 mmol, 46%). ¹H NMR (300 MHz, Chloroform-*d*) δ 3.48 (s, 3H), 2.95 (d, *J* = 8.6, 2H), 2.62 (t, *J* = 8.6 Hz, 2H).

15 Step 2: Preparation of 6-(3-fluorobenzyl)pyridazin-3-amine

Dissolved [1,3-*bis*(diphenylphosphino)propane]dichloronickel(II) (0.166 g, 0.3080 mmol) in 1,4-dioxane (8.0 mL) in a 40 mL reaction vial and introduced an atmosphere of nitrogen. Carefully added diethylzinc dust (1.0M in tetrahydrofuran, 7.70 mL, 7.70 mmol) and stirred at room temperature for 10 min. Slowly added 1-(bromomethyl)-3-fluorobenzene (1.12 mL, 9.24 mmol) and stirred at 100 °C for 4 h. Added a solution of 6-chloropyridazin-3-amine (0.2 g, 1.54 mmol) in 2.0 mL of tetrahydrofuran *via* syringe and stirred at 100 °C for 2 h. Cooled to room temperature and quenched with methanol (5 mL) and concentrated hydrochloric acid (2 mL). Basified (pH ~ 10) with 1M aqueous sodium hydroxide (15 mL), then extracted with ethyl acetate (20 mL), then washed with brine (10 mL x 2). The combined organic layers were dried over sodium sulfate, filtered, and concentrated. Purified reaction by column chromatography (eluting with 0-100% ethyl acetate/hexanes through 12 g of silica gel) to give 6-(3-fluorobenzyl)pyridazin-3-amine as a white solid (86 mg, 0.423 mmol, 27%). ¹H NMR (300 MHz, Chloroform-*d*) δ 7.24 (d, *J* = 6.2 Hz, 1H), 7.18 - 6.85 (m, 4H), 6.69 (d, *J* = 9.0 Hz, 1H), 4.64 (s, 2H), 4.20 (s, 2H).

Step 3: Preparation of

N-(6-(3-fluorobenzyl)pyridazin-3-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide

Combined 6-(3-fluorobenzyl)pyridazin-3-amine (0.086 g, 0.4231 mmol) and


5 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.066 g, 0.4231 mmol) and added

2-(1*H*-benzo[d][1,2,3]triazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (0.135 g, 0.4231 mmol).Added 1.0 mL dichloromethane, followed by 0.50 mL *N,N'*-dimethylformamide. Stirred reaction at room temperature 16 h. Diluted with ethyl acetate (15 mL) and washed 3 times with water (10 mL) and once with brine (10 mL). The combined organic layers were dried over sodium sulfate, filtered, and


10 concentrated. Purified reaction by column chromatography (eluting with 0-50% ethyl acetate/dichloromethane through 12 g of silica gel) to give

N-(6-(3-fluorobenzyl)pyridazin-3-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide as awhite solid (22 mg, 0.064 mmol, 15%). ¹H NMR (300 MHz, Chloroform-*d*) δ 8.43 (d, *J* = 9.1 Hz, 1H), 7.33(d, *J* = 9.1 Hz, 2H), 7.14 - 6.87 (m, 2H), 4.33 (s, 2H), 3.51 (s, 3H), 2.98 (t, *J* = 8.5 Hz, 2H), 2.62 (t, *J* = 8.515 Hz, 2H); LCMS (ESI) *m/z*: 342.3 [M+H]⁺.

Example 201. Preparation of


N-(5-benzylthiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (201)

Step 1: Preparation of 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid




To a solution of 2-oxopentanedioic acid (4.99 g, 34.1 mmol) in aqueous hydrogen chloride solution (50 mL, 10%) was added methylhydrazine (3.93 g, 34.1 mmol, 50% in water) dropwise. The mixture was stirred at 100 °C for 3 h. The mixture was extracted with dichloromethane (10 x 30 mL). The combined organic layers were dried and concentrated *in vacuo* to give a residue. The residue was re-crystallized from ethanol (20 mL) and filtered to give 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (2.5 g, 16.0 mmol, 47%) as white solid. ¹H NMR (400 MHz, Chloroform-*d*) δ 9.63 (br. s, 1H), 3.46 (s, 3H), 2.98 - 2.83 (m, 2H), 2.67 - 2.54 (m, 2H).

Step 2: Preparation of 2-chloro-3-phenyl-propanal




To a mixture of aniline (2.61 g, 28 mmol) in water (15 mL) at 0 °C was added hydrogen chloride (4 mL, 12M) followed by a solution of sodium nitrate (2.13 g, 30.8 mmol) in water (4 mL) drop wise. After addition, the mixture was stirred for 30 minutes at 0-15 °C and the mixture was treated with solid sodium bicarbonate to adjust pH=6 at 0 °C. In another three-neck bottom, copper(II) chloride (1.51 g, 11.2 mmol), magnesium oxide (0.282 g, 7.00 mmol) and prop-2-enal (1.57 g, 28.0 mmol) in acetone (10 mL) were stirred. To the above solution was added dropwise the former solution at 0 °C. After addition, the mixture was warmed slowly to 15 °C and stirred for 15 h. The mixture was concentrated, *in vacuo* to give 2-chloro-3-phenyl-propanal (5.0 g, crude) as a yellow oil. Used directly in the next step without additional purification.

Step 3: Preparation of 5-benzylthiazol-2-amine



To a mixture of 2-chloro-3-phenyl-propanal (4 g, 7.12 mmol) in ethanol (100 mL) at 85°C was added isothiurea (2 g, 26.3 mmol). The reaction mixture was stirred at 85 °C for 4 h. The mixture was concentrated *in vacuo* to give a residue. The crude product was purified by column chromatography (ISCO, 40 g silica, 0-20% ethyl acetate in petroleum ether, gradient over 30 minutes) to give 5-benzylthiazol-2-amine (0.4 g, 2.10 mmol, 30%) as a thick red solid.


Step 4: Preparation of

N-(5-benzylthiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide

To a solution of 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.150 g, 0.961 mmol) and 5-benzylthiazol-2-amine (0.365 g, 1.92 mmol) in dichloromethane (15 mL) was added triethylamine (0.291 g, 2.88 mmol) and propylphosphonic anhydride solution in ethyl acetate (1.22 g, 1.92 mmol, 50% purity). The mixture was stirred at 25 °C for 12 h. The mixture was poured into ice-water (10 mL) and extracted with dichloromethane (10 mL x 2). The combined organic layers were dried over sodium sulfate, filtered and concentrated *in vacuo* to give a residue. The crude material was purified by prep-HPLC ((Waters X bridge 150*25 5 uM column; 45-65 % acetonitrile in a 10 mM ammonium acetate solution in water, 12 min gradient) to give



N-(5-benzylthiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.190 g, 0.558 mmol, 58%) as a yellow solid. ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 11.80 (br. s, 1H), 7.37-7.13 (m, 6H), 4.09 (s, 2H), 3.31 (s, 3H), 2.85-2.74 (m, 2H), 2.52-2.49 (m, 2H). ¹H NMR (400 MHz, Chloroform-*d*) δ = 9.97 (br. s, 1H), 7.34 - 7.28 (m, 2H), 7.27 - 7.21 (m, 3H), 7.18 (s, 1H), 4.10 (s, 2H), 3.44 (s, 3H), 3.00-2.89 (m, 2H), 2.63-2.51 (m, 2H); LCMS (ESI) *m/z*: 329.1 [M+H]⁺.

Example 202. Preparation of


N-(5-(3-fluorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (202)

Compound **202** was synthesized according to the synthetic procedure reported for the preparation of compound **201**.


N-(5-(3-fluorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (0.033 g, 0.094 mmol, 10%) was obtained as a yellow solid. ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 11.19 (br. s, 1H), 7.90 (d, *J* = 9.7 Hz, 1H), 7.43 - 7.33 (m, 2H), 7.17 - 7.11 (m, 2H), 7.10 - 7.02 (m, 2H), 4.15 (s, 2H), 3.77 (s, 3H); LCMS (ESI) *m/z*: 345.0 [M+H]⁺.

Example 203. Preparation of***N*-(5-(3-fluorophenoxy)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (203)****Step 1: Preparation of 5-(3-fluorophenoxy)thiazol-2-amine**

To a mixture of 5-bromothiazol-2-amine (0.100 g, 0.562 mmol) and cesium carbonate (0.275 g, 0.843 mmol) in acetonitrile (2 mL) at 70 °C was added a solution of 3-fluorophenol (0.082 g, 0.731 mmol) in acetonitrile (1 mL) dropwise. Then the reaction was stirred at 70 °C for 1 h. The reaction was cooled to room temperature and diluted with water (30 mL). The aqueous layer was extracted with ethyl acetate (20 mL x 3). The combined organic layers were washed with brine (30 mL), dried over sodium sulfate, filtered and concentrated *in vacuo* to give 5-(3-fluorophenoxy)thiazol-2-amine (0.100 g, crude) as a brown oil which was used directly in the next step. LCMS (ESI) *m/z*: 211.1 [M+H]⁺.


Step 2: Preparation of***N*-(5-(3-fluorophenoxy)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide**

To a mixture of 5-(3-fluorophenoxy)thiazol-2-amine (0.090 g, 0.428 mmol) and 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.067 g, 0.428 mmol) in tetrahydrofuran (1 mL) at room temperature was added 1-[*bis*(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.195 g, 0.514 mmol) and diisopropylethylamine (0.110 g, 0.856 mmol). The reaction was stirred at room temperature 16 h and was combined with another batch (90 mg). Reaction mixture was diluted with water (20 mL) and the aqueous layer was extracted with ethyl acetate (10 mL X 3). The combined organic layers were washed with brine (10 mL), dried over sodium sulfate, filtered and concentrated *in vacuo*. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μm column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give *N*-(5-(3-fluorophenoxy)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3 carboxamide (20.1 mg, 0.058 mmol, 12%,) as a light-yellow solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 12.10 (s, 1H), 7.45 (dd, *J* = 15.0, 8.0 Hz, 1H), 7.39 (s, 1H), 7.09-6.93 (m, 3H), 3.37 (s, 3H), 2.84 (t, *J* = 8.5 Hz, 2 H), 2.59-2.57 (m, 2H); LCMS (ESI) *m/z*: 349.0 [M+H]⁺.

Example 204. Preparation of***N*-(5-((3-fluorophenyl)(methoxy)methyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (204)**

5

Step 1: Preparation of 5-((3-fluorophenyl)(methoxy)methyl)thiazol-2-amine



A mixture of *tert*-butyl 5-((3-fluorophenyl)(hydroxy)methyl)thiazol-2-ylcarbamate (0.200 g, 0.62 mmol) and trifluoroacetic acid (2 mL) in dichloromethane (2 mL) was stirred at room temperature for 1 h. Methanol (2 mL) was added and the reaction continued to stir for an additional 1 h at room temperature. The reaction mixture was concentrated, and the residue was dissolved in ethyl acetate (60 mL). The organic layer was washed with saturated sodium bicarbonate aqueous solution (60 mL) and brine (60 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude residue was purified by column chromatography (silica gel, petroleum ether/ethyl acetate =1/1) to afford 5-((3-fluorophenyl)(methoxy)methyl)thiazol-2-amine (0.120 g, 0.50 mmol, 81%,) as a yellow solid. LCMS (ESI) *m/z*: 239.1 [M+H]⁺.


10

15

Step 2: Preparation of

N-(5-((3-fluorophenyl)(methoxy)methyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide

20



To a stirred solution of 5-((3-fluorophenyl)(methoxy)methyl)thiazol-2-amine (0.110 g, 0.46 mmol), 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.108 g, 0.69 mmol) and *N,N*-diisopropylethylamine (0.297 g, 2.30 mmol) in *N,N*-dimethylformamide (5 mL) was added 1-[*bis*(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.262 g, 0.69 mmol). The mixture was stirred for 16 h at room temperature and heated to 50 °C for another 16 h. The reaction mixture was poured into water (60 mL) and extracted with ethyl acetate (40 mL x 2). The combined organics were washed with brine (80 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified by prep-HPLC (Boston C18 21*250 mm 10 μm column. The mobile phase was acetonitrile/10 mM ammonium acetate aqueous solution) to give

25


30

N-(5-((3-fluorophenyl)(methoxy)methyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carbox


amide (0.085 g, 0.23 mmol, 49%,) as a white solid. ^1H NMR (400 MHz, Dimethylsulfoxide- d_6) δ 12.01 (s, 1H), 7.50 - 7.38 (m, 2H), 7.28 - 7.10 (m, 3H), 5.67 (s, 1H), 3.32 (s, 3H), 3.29 (s, 3H), 2.89 - 2.77 (m, 2H), 2.53 - 2.47 (m, 2H); LCMS (ESI) m/z : 377.0 $[\text{M}+\text{H}]^+$.

5 Example 205. Preparation of

N-(5-((3-fluorophenyl)(hydroxy)methyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (205)




10 Step 1: Preparation of (2-aminothiazol-5-yl)(3-fluorophenyl)methanol



The mixture of *tert*-butyl 5-((3-fluorophenyl)(hydroxy)methyl)thiazol-2-ylcarbamate (0.300 g, 0.93 mmol) and trifluoroacetic acid (1 mL) in dichloromethane (3 mL) was stirred at room temperature for 1 h. The reaction mixture was concentrated, and the residue was dissolved in ethyl acetate (100 mL), washed with saturated sodium bicarbonate aqueous solution (60 mL) and brine (100 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure to yield (2-aminothiazol-5-yl)(3-fluorophenyl)methanol (0.207 g, 0.93 mmol, 100%) as a yellow solid. LCMS (ESI) m/z : 225.1 $[\text{M}+\text{H}]^+$.

20 Step 2: Preparation of

N-(5-((3-fluorophenyl)(hydroxy)methyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide




To a stirred solution of (2-aminothiazol-5-yl)(3-fluorophenyl)methanol (0.207 g, 0.93 mmol), 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (145 mg, 0.93 mmol) and *N,N*-diisopropylethylamine (0.361 g, 2.79 mmol) in *N,N*-dimethylformamide (5 mL) was added 1-[*bis*(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.389 g, 1.02 mmol). The mixture was stirred at room temperature for 16 h. The reaction mixture was poured into water (60 mL) and extracted with ethyl acetate (40 mL x 2). The combined organics were washed with brine (80 mL), dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μm column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give

N-(5-((3-fluorophenyl)(hydroxy)methyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (40 mg, 0.11 mmol, 12%) as a white solid. ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 11.93 (s, 1H), 7.40 (td, *J* = 8.1, 6.2 Hz, 1H), 7.32 - 7.19 (m, 3H), 7.15 - 7.05 (m, 1H), 6.39 (d, *J* = 4.4 Hz, 1H), 5.99 (d, *J* = 3.6 Hz, 1H), 3.34 (s, 3H), 2.89 - 2.78 (m, 2H), 2.53 - 2.48 (m, 2H); LCMS (ESI) *m/z*: 363.1 [M+H]⁺.

5


Example 206. Preparation of

N-(5-(2-fluorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (206)



Step 1: Preparation of

N-(5-(2-fluorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide




N-(5-(2-fluorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide was synthesized according to the synthetic procedure reported for the preparation of compound **201**.

Compound *N*-(5-(2-fluorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.177 g, 0.505 mmol, 61%) was obtained as a pale yellow solid. ¹H NMR (400 MHz, Chloroform-*d*) δ 10.12 (br. s, 1H), 7.27 - 7.19 (m, 3H), 7.12 - 7.02 (m, 2H), 4.13 (s, 2H), 3.43 (s, 3H), 2.97 (t, *J* = 8.6 Hz, 2H), 2.59 (t, *J* = 8.8 Hz, 2H); LCMS (ESI) *m/z*: 347.0 [M+H]⁺.


Example 207. Preparation of

N-(5-(3-chlorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (207)



Step 1: Preparation of

N-(5-(3-chlorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide




N-(5-(3-chlorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide

- 5 was synthesized according to the synthetic procedure reported for the preparation of compound **201**. Compound *N*-(5-(3-chlorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.231 g, 0.631 mmol, 66%) was obtained as a yellow solid. ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 11.87 (br. s, 1H), 7.37 - 7.31 (m, 3H), 7.30 - 7.21 (m, 2H), 4.12 (s, 2H), 3.33 (s, 3H), 2.85 - 2.75 (m, 2H), 2.51 (s, 2H); LCMS (ESI) *m/z*: 363.0 [M+H]⁺.

10

Example 208. Preparation of

N-(5-(4-fluorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (**208**)



Step 1: Preparation of

- 15 *N*-(5-(4-fluorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide


N-(5-(4-fluorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide was synthesized according to the synthetic procedure reported for the preparation of compound **201**.

Compound *N*-(5-(4-fluorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.113 g, 0.322 mmol, 33%) was obtained as a yellow solid. ¹H NMR (400 MHz, Chloroform-*d*) δ 10.10

- 20 (br. s, 1H), 7.23 - 7.17 (m, 3H), 7.02 - 6.98 (m, 2H), 4.07 (s, 2H), 3.43 (s, 3H), 3.01 - 2.92 (m, 2H), 2.66 - 2.54 (m, 2H); LCMS (ESI) *m/z*: 347.0 [M+H]⁺.

Example 209. Preparation of


N-(5-(3-cyanobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (**209**)



25

Step 1: Preparation of

N-(5-(3-cyanobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide




N-(5-(3-cyanobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide

- 5 was synthesized according to the synthetic procedure reported for the preparation of compound **201**. Compound *N*-(5-(3-cyanobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.206 g, 0.563 mmol, 73%) was obtained as a white solid. ¹H NMR (400 MHz, Chloroform-*d*) δ 10.05 (br. s, 1H), 7.57 - 7.52 (m, 2H), 7.52 - 7.48 (m, 1H), 7.46 - 7.40 (m, 1H), 7.22 (s, 1H), 4.15 (s, 2H), 3.45 (s, 3H), 2.97 (t, *J* = 8.6 Hz, 2H), 2.60 (t, *J* = 8.8 Hz, 2H); LCMS (ESI) *m/z*: 354.1 [M+H]⁺.

10

Example 210. Preparation of


N-(5-(3-methoxybenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (**210**)



15


Step 1: Preparation of

N-(5-(3-methoxybenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide




Compound

- 20 *N*-(5-(3-methoxybenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide was synthesized according to the synthetic procedure reported for the preparation of compound **201**. *N*-(5-(3-methoxybenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.162 g, 0.452 mmol, 54%) was obtained as a yellow solid. ¹H NMR (400 MHz, Chloroform-*d*) δ 10.06 (br. s, 1H), 7.26 - 7.18 (m, 2H), 6.85 (d, *J* = 7.5 Hz, 1H), 6.82 - 6.75 (m, 2H), 4.08 (s, 2H), 3.79 (s, 3H), 3.44 (s, 3H), 2.97 (t, *J* = 8.6 Hz, 2H), 2.59 (t, *J* = 8.4 Hz, 2H); LCMS (ESI) *m/z*: 359.0 [M+H]⁺.
- 25

Example 211. Preparation of***N*-(5-(3-fluorobenzyl)-1,3,4-thiadiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (211)**

5

Step 1: Preparation of 5-[(3-fluorophenyl)methyl]-1,3,4-thiadiazol-2-amine




A mixture of 2-(3-fluorophenyl)acetic acid (2.00 g, 13.0 mmol) and aminothiurea (1.18 g, 13.0 mmol) in phosphorus(V) oxychloride (3 mL) was stirred and heated to 75 °C for 0.5 h. The mixture was cooled to 15 °C and water (10 mL) was added dropwise. The mixture was then stirred at 100 °C for 4 h. The reaction was then cooled to 15 °C and basified to pH = 8 with 50% sodium hydroxide aqueous solution. The precipitate was filtered and the cake was dried *in vacuo* to give 5-[(3-fluorophenyl)methyl]-1,3,4-thiadiazol-2-amine (2.0 g, 7.46 mmol, 57%) as a white solid. The solid was used directly in the next step. ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 7.43 - 7.32 (m, 1H), 7.21 - 7.02 (m, 5H), 4.19 (s, 2H).

15

Step 2: Preparation of

N-(5-(3-fluorobenzyl)-1,3,4-thiadiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide





To a solution of 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.15 g, 0.961 mmol) and 5-[(3-fluorophenyl)methyl]-1,3,4-thiadiazol-2-amine (0.201 g, 0.961 mmol) in dichloromethane (15 mL) at 25 °C was added sequentially triethylamine (0.194 g, 1.92 mmol) and propylphosphonic anhydride in ethyl acetate (0.917 g, 1.44 mmol, 50% purity). The mixture was stirred at 25 °C for 12 h. The reaction was poured into ice-water (10 mL) and extracted with dichloromethane (10 mL x 2). The combined organic layers were dried over sodium sulfate, filtered and concentrated *in vacuo*. The residue was purified *via* prep-HPLC (Waters X bridge 150*25 5 uM column; 15-45 % acetonitrile in a 10 mM ammonium bicarbonate solution in water, 12 minutes gradient) to give *N*-(5-(3-fluorobenzyl)-1,3,4-thiadiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.240 g, 0.676 mmol, 70%) as a white solid. ¹H NMR (400 MHz, Chloroform-*d*) δ 10.55 (br. s, 1H), 7.31 (dt, *J* = 6.1, 7.9 Hz, 1H), 7.09 (d, *J* = 7.7 Hz, 1H), 7.05 - 6.95 (m, 2H), 4.36 (s, 2H), 3.43 (s, 3H), 2.96 (t, *J* = 8.6 Hz, 2H), 2.66 - 2.57 (m, 2H); LCMS (ESI) *m/z*: 348.0 [*M*+*H*]⁺.


20

25

30


Example 212. Preparation of***N*-(5-(3-methoxybenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (212)****5 Step 1: Preparation of *tert*-butyl thiazol-2-ylcarbamate**

Di-*tert*-butyl dicarbonate (6.54 g, 30.0 mmol) was slowly added to a mixture of thiazol-2-amine (3.0 g, 30.0 mmol) and triethylamine (6.07 g, 60.0 mmol) in tetrahydrofuran (20 mL). The mixture was heated to 60 °C and stirred for 2 h. The volatiles were removed under reduced pressure. The crude residue was added to a mixture of petroleum ether/ethyl acetate = 50:1 and the mixture was stirred for 2 h. Filtration afforded crude *tert*-butyl thiazol-2-ylcarbamate (4.4 g, crude) as a yellow solid. LCMS (ESI) m/z : 201.1 $[M+H]^+$.

Step 2: Preparation of *tert*-butyl 5-(hydroxy(3-methoxyphenyl)methyl)thiazol-2-ylcarbamate


A solution of *tert*-butyl thiazol-2-ylcarbamate (1.2 g, 6.0 mmol) in tetrahydrofuran (20 mL) at -70 °C, was treated slowly with *n*-butyllithium (5.3 mL, 13.2 mmol). The reaction was stirred at -70 °C for 2 h before a solution of 3-methoxybenzaldehyde (1.22 g, 9.0 mmol) in tetrahydrofuran (5 mL) was slowly added to the reaction mixture. Water was added to quench the reaction. The volatiles were removed under reduced pressure. The aqueous layer was extracted with dichloromethane (100 mL) and the organic phase was then washed with brine (50 mL), dried over sodium sulfate, filtered, concentrated. The crude residue was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 1/1) to yield *tert*-butyl 5-(hydroxy(3-methoxyphenyl)methyl)thiazol-2-ylcarbamate (1.22 g, 61%) as a yellow solid. LCMS (ESI) m/z : 337.1 $[M+H]^+$.

Step 3: Preparation of 5-(3-methoxybenzyl)thiazol-2-amine



A solution of *tert*-butyl 5-(hydroxy(3-methoxyphenyl)methyl)thiazol-2-ylcarbamate (1.2 g, 3.57 mmol) in trifluoroacetic acid (10.0 mL) was treated with triethylsilane (1.66 g, 14.28 mmol) and was heated to 90 °C for 1 h. Trifluoroacetic acid was removed under reduced pressure and the crude residue was dissolved in dichloromethane (50 mL). The organic layer was washed with sodium bicarbonate (50 mL), brine (50 mL x1), dried over sodium sulfate, filtered and concentrated *in vacuo*. The crude sample was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 1/1) to afford 5-(3-methoxybenzyl)thiazol-2-amine (0.700 g, 3.18 mmol, 89%) as a yellow solid. LCMS (ESI) *m/z*: 221.1 [M+H]⁺.


Step 4: Preparation of 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid



To a solution of methyl 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylate (0.15 g, 0.892 mmol) in water (1.5 mL) was added sodium hydroxide (0.071 g, 1.79 mmol). The mixture was heated to 60 °C and stirred for 1 h. Solution was acidified to pH value to 1~3 with 1N hydrogen chloride and then all volatiles were removed to afford 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (0.100 g, crude) as a white solid. LCMS (ESI) *m/z*: 155.1 [M+H]⁺.

Step 5: Preparation of

N-(5-(3-methoxybenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide




To a solution of 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (0.100 g, 0.649 mmol) in dichloromethane (2 mL) at 20 °C was added oxalyl chloride (1 mL). Reaction mixture was stirred at 20 °C for 0.5 h and concentrated *in vacuo*. The crude solid was dissolved in dichloromethane (4.0 mL) and added to a mixture of 5-(3-methoxybenzyl)thiazol-2-amine (0.186 g, 0.844 mmol) and triethylamine (0.256 g, 2.53 mmol) in dichloromethane (5.0 mL) dropwise. The reaction was stirred at 0 °C for 20 minutes and was concentrated, *in vacuo*. The residue was added to a mixture of dichloromethane (50 mL) and water (50 mL). The organic layer was collected, dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μm column; the mobile phase acetonitrile/0.01% aqueous trifluoroacetic acid) to give

N-(5-(3-methoxybenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide as a white solid


(0.0692 g, 0.195 mmol, 30%). ^1H NMR (400 MHz, Dimethylsulfoxide- d_6) δ 12.28 (s, 1H), 7.89-7.91 (d, J = 7.6 Hz, 1H), 7.35 (s, 1H), 7.24-7.26 (t, J = 6.2 Hz, 1H), 7.04-7.06 (d, J = 7.6 Hz, 1H), 6.80-6.86 (m, 3H), 4.09 (s, 2H), 3.77 (s, 3H), 3.745 (s, 3H); LCMS (ESI) m/z : 357.1 $[\text{M}+\text{H}]^+$.

5 Example 213. Preparation of

N-(5-(4-chlorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (213)




Step 1: Preparation of *tert*-butyl 5-((4-chlorophenyl)(hydroxy)methyl)thiazol-2-ylcarbamate




To a solution of *tert*-butyl thiazol-2-ylcarbamate (1.00 g, 5.00 mmol) in tetrahydrofuran (40 mL) at -78 °C was added *n*-butyllithium (4.4 mL, 11 mmol, 2.5 M in hexanes) dropwise under nitrogen. The reaction was stirred at -78 °C for 1 h and a solution of 4-chlorobenzaldehyde (0.66 g, 4.75 mmol) in tetrahydrofuran (10 mL) was added dropwise at -78 °C. The reaction mixture was then stirred at -78 °C for 30 minutes and warmed to room temperature 16 h. The reaction was quenched with aqueous ammonium chloride solution, extracted with ethyl acetate (40 mL x 2). The combined organic phases were washed with brine (40 mL), dried over sodium sulfate, filtered and concentrated. The residue was purified by column chromatography (Biotage, 40 g silica gel, eluted with ethyl acetate in petroleum ether from 40% to 50%) to yield *tert*-butyl 5-((4-chlorophenyl)(hydroxy)methyl)thiazol-2-ylcarbamate (0.6 g, 1.76 mmol, 35%) as an off-white solid. LCMS (ESI) m/z : 341.1 $[\text{M}+\text{H}]^+$.

Step 2: Preparation of 5-(4-chlorobenzyl)thiazol-2-amine



To a solution of *tert*-butyl 5-((4-chlorophenyl)(hydroxy)methyl)thiazol-2-ylcarbamate (0.55 g, 1.62 mmol) in dichloromethane (20 mL) at room temperature was added triethylsilane (2 mL, 12.9 mmol). Reaction mixture was cooled to 0 °C and then trifluoroacetic acid (1.65 mL, 21.8 mmol) was added dropwise. After the addition, the reaction was stirred at room temperature 16 h. The volatiles were removed under reduced pressure and the residue was diluted with dichloromethane (10 mL), neutralized with aqueous sodium bicarbonate solution and extracted with dichloromethane (20 mL x 2). The combined organic layers were washed with brine (20 mL), dried over sodium sulfate, filtered and concentrated. The crude sample was purified by Combi-Flash (Biotage, 40 g silica gel, eluted with methanol : dichloromethane = 1:15) to afford 5-(4-chlorobenzyl)thiazol-2-amine (0.17 g, 0.76 mmol, 47%) as a white solid. LCMS (ESI) m/z : 225.1 $[\text{M}+\text{H}]^+$.



Step 3: Preparation of

N-(5-(4-chlorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide

A solution of 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.110 g, 0.72 mmol),
 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.3 g,
 0.08 mmol) and *N,N*-diisopropylethylamine (0.22 mL, 1.33 mmol) in *N,N*-dimethylformamide (10 mL) was
 stirred at room temperature for 30 minutes. Then the 5-(4-chlorobenzyl)thiazol-2-amine (0.15 g,
 0.67 mmol) was added and the reaction mixture was stirred at room temperature 16 h. The reaction
 solution was diluted with ethyl acetate/water (20 mL/20 mL) and extracted with ethyl acetate (20 mL x 2).
 The combined organic phases were washed with brine (20 mL), dried over sodium sulfate, filtered and
 concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified by
 prep-HPLC (Boston C18 21*250 mm 10 μ m column. The mobile phase was acetonitrile/10 mM
 ammonium acetate aqueous solution) to yield

N-(5-(4-chlorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.140 g,
 0.38 mmol, 57.8%) as a white solid. ¹H NMR (500 MHz, Methanol-*d*₄) δ 7.25-7.35 (m, 4H), 7.24 (s, 1H),
 4.13 (s, 2H), 3.46 (s, 3H), 2.94 (t, *J* = 8.5 Hz, 2H), 2.60 (t, *J* = 8.5 Hz, 2H); LCMS (ESI) *m/z*: 363.0 [*M*+*H*]⁺.


Example 214. Preparation of

N-(5-(1-(3-fluorophenyl)ethyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (214)Step 1: Preparation of *tert*-butyl thiazol-2-ylcarbamate

To a solution of thiazol-2-amine (10.0 g, 100 mmol) in tetrahydrofuran (30 mL) at room
 temperature was added a solution of di-*tert*-butyl dicarbonate (26.2 g, 120 mmol) in tetrahydrofuran (10
 mL) slowly. After the addition, the reaction was stirred at room temperature 16 h. The reaction was
 concentrated, and the resulting residue was dispersed in a solution mixture of petroleum ether/ethyl
 acetate = 100 mL/2mL, filtered and dried *in vacuo* to give *tert*-butyl thiazol-2-ylcarbamate (18 g, 90 mmol,

90%) as a yellow solid. ^1H NMR (500 MHz, Dimethylsulfoxide- d_6): δ 11.41 (s, 1H), 7.35 (d, J = 3.5 Hz, 1H), 7.14 (d, J = 4 Hz, 1H), 1.48 (s, 9H); LCMS (ESI) m/z : 145.0 $[\text{M}-55]^+$. Used in the next step directly without additional purification.


5 Step 2: Preparation of *tert*-butyl 5-(1-(3-fluorophenyl)-1-hydroxyethyl)thiazol-2-ylcarbamate



Used the same procedure as for synthesis of compound **213**. Compound *tert*-butyl 5-(1-(3-fluorophenyl)-1-hydroxyethyl)thiazol-2-ylcarbamate (0.9 g, 2.66 mmol, 53%) was obtained as a yellow solid. LCMS (ESI) m/z : 339.1 $[\text{M}+\text{H}]^+$. Used in the next step directly without additional purification.

10

Step 3: Preparation of 5-(1-(3-fluorophenyl)ethyl)thiazol-2-amine




Used the same procedure as for synthesis of compound **213** 5-(4-chlorobenzyl)thiazol-2-amine using *tert*-butyl 5-(1-(3-fluorophenyl)-1-hydroxyethyl)thiazol-2-ylcarbamate (0.4 g, 1.18 mmol).

15 Compound 5-(1-(3-fluorophenyl)ethyl)thiazol-2-amine (0.15 g, 0.67 mmol, 57%) was obtained as a white solid. LCMS (ESI) m/z : 223.1 $[\text{M}+\text{H}]^+$. Used in the next step directly without additional purification.

Step 4: Preparation of

N-(5-(1-(3-fluorophenyl)ethyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide





20

Used the same procedure as for synthesis of compound **213**


N-(5-(4-chlorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide using 5-(1-(3-fluorophenyl)ethyl)thiazol-2-amine (0.13 g, 0.58 mmol). Compound

N-(5-(1-(3-fluorophenyl)ethyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide


25 (0.131 g, 0.36 mmol, 62%) as a white solid. ^1H NMR (500 MHz, Methanol- d_4) δ 7.36 (m, 1H), 7.25 (s, 1H), 7.14 (d, J = 8 Hz, 1H), 7.04 (m, 1H), 6.98 (m, 1H), 4.40 (m, 1H), 3.46 (s, 3H), 2.94 (t, J = 9 Hz, 2H), 2.60 (t, J = 9 Hz, 2H), 1.71 (d, J = 7.5 Hz, 3H); LCMS (ESI) m/z : 361.1 $[\text{M}+\text{H}]^+$.

Example 215. Preparation of***N*-(1-(3-chlorobenzyl)-1*H*-pyrazol-4-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (215)****5 Step 1: Preparation of*****N*-(1-(3-chlorobenzyl)-1*H*-pyrazol-4-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide**

To a stirred solution of 1-(3-chlorobenzyl)-1*H*-pyrazol-4-amine (0.090 g, 0.44 mmol), 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (0.080 g, 0.52 mmol) and 10 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.198 g, 0.52 mmol) in *N,N*-dimethylformamide (5.00 mL) was added *N,N*-diisopropylethylamine (0.168 g, 1.31 mmol). After addition, the reaction mixture was stirred at room temperature for 2 h. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified via prep-HPLC Sunfire prep C18 10 μ m OBD 19*250 mm; mobile phase: [water (0.05% trifluoroacetic acid)-acetonitrile]; B%: 60%-88%, 15 minutes) to 15 give *N*-(1-(3-chlorobenzyl)-1*H*-pyrazol-4-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (0.040 g, 0.12 mmol, 26.8%) as a white solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 10.60 (s, 1H), 8.19 (s, 1H), 7.91 (d, *J* = 9.7 Hz, 1H), 7.72 (s, 1H), 7.38 (d, *J* = 7.4 Hz, 2H), 7.28 (s, 1H), 7.20 (d, *J* = 6.7 Hz, 1H), 7.05 (d, *J* = 9.7 Hz, 1H), 5.34 (s, 2H), 3.78 (s, 3H); LCMS (ESI) *m/z*: 344.0 [*M*+*H*]⁺.


20 Example 216. Preparation of***N*-(5-(3-chloro-5-fluorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (216)**

Step 1: Preparation of *tert*-butyl (5-((3-chloro-5-fluorophenyl)(hydroxy)methyl)thiazol-2-yl)carbamate



Dissolved *tert*-butyl (5-bromothiazol-2-yl)carbamate (0.5 g, 2.49 mmol) in tetrahydrofuran (12.4 mL) and cooled to -78 °C. Carefully added *n*-butyllithium (1.6M in hexanes, 1.59 mL, 3.98 mmol) and stirred for 10 minutes, followed by 3-chloro-5-fluorobenzaldehyde (424 μ L, 3.48 mmol). Quenched with saturated aqueous ammonium chloride (15 mL) and extracted with ethyl acetate (20 mL). Washed with brine (15 mL), then dried over sodium sulfate. Filtered, then concentrated *in vacuo*. Purified reaction by column chromatography (eluting with 0-50% ethyl acetate/hexanes through 40g of silica gel) to give *tert*-butyl (5-((3-chloro-5-fluorophenyl)(hydroxy)methyl)thiazol-2-yl)carbamate as an orange oil (138mg, 0.384 mmol, 15%). ¹H NMR (300 MHz, Chloroform-*d*) δ 7.25 - 6.95 (m, 4H), 5.99 (s, 1H), 1.54 (s, 9H).


Step 2: Preparation of 5-(3-chloro-5-fluorobenzyl)thiazol-2-amine



Dissolved *tert*-butyl (5-((3-chloro-5-fluorophenyl)(hydroxy)methyl)thiazol-2-yl)carbamate (0.138 g, 0.3845 mmol) in methylene chloride (1.92 mL) and added triethylsilane (306 μ L, 1.92 mmol) and 2,2,2-trifluoroacetic acid (235 μ L, 3.07 mmol). Stirred 16 h at room temperature. Concentrated to remove solvent. Diluted with ethyl acetate (15 mL), then washed with saturated aqueous sodium bicarbonate (10 mL), and then brine (10 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated. Material is taken crude to next step.

Step 3: Preparation of

N-(5-(3-chloro-5-fluorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamidecarboxamide




Combined 5-(3-chloro-5-fluorobenzyl)thiazol-2-amine (0.093 g, 0.383 mmol) and 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.060 g, 0.383 mmol) in a 25 mL round bottom flask and added 2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (0.123 g, 0.3831 mmol). Dissolved in *N,N'*-dimethylformamide (1.91 mL) and added *N,N,N,N*-diisopropylethyl amine (100 μ L, 0.5746 mmol). Stirred at room temperature 16 h. Diluted with

ethyl acetate (15 mL) and washed 3 times with water (10 mL), then brine (10 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated. Purified reaction by column chromatography (eluting with 0-100% ethyl acetate/hexanes through 24 g of silica gel) to give *N*-(5-(3-chloro-5-fluorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamidecarboxamide as a pale yellow solid (29 mg, 0.076 mmol, 20%). ¹H NMR (300 MHz, Chloroform-*d*) δ 7.24 (s, 1H), 7.05 (s, 1H), 7.00 (d, *J* = 8.3 Hz, 1H), 6.87 (d, *J* = 9.0 Hz, 1H), 4.09 (s, 2H), 3.47 (s, 3H), 2.99 (t, *J* = 8.6 Hz, 2H), 2.61 (t, *J* = 8.6 Hz, 2H); LCMS (ESI) *m/z* 381.4 [M+H]⁺.


Example 217. Preparation of

N-(5-(3-fluorobenzyl)thiazol-2-yl)-1-methyl-1,4,5,6-tetrahydropyridazine-3-carboxamide (217)



Step 1: Preparation of


N-(5-(3-fluorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide



To a stirred solution of 5-(3-fluorobenzyl)thiazol-2-amine (0.208 g, 1.00 mmol), 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.172 g, 1.10 mmol) and 1-[*bis*(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.418 g, 1.10 mmol) in *N,N*-dimethylformamide (5.00 mL) was added *N,N*-diisopropylethylamine (0.387 g, 3.00 mmol). After addition, the reaction mixture was stirred at room temperature for 2 h. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Sunfire prep C18 10 μm OBD 19*250 mm; mobile phase: [water (0.05% trifluoroacetic acid)-acetonitrile]; B%: 60%-88%, 15 minutes) to give (5-(3-fluorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.240 g, 0.69 mmol, 69.4%) as an off-white solid. LCMS (ESI) *m/z*: 347.0 [M+H]⁺.

Step 2: Preparation of

N-(5-(3-fluorobenzyl)thiazol-2-yl)-1-methyl-1,4,5,6-tetrahydropyridazine-3-carboxamide




To a solution of (5-(3-fluorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.140 g, 0.40 mmol) in tetrahydrofuran (10.0 mL) was added borane-tetrahydrofuran (4.00 mL, 4.00 mmol, 1 *M*). The mixture was stirred at 80 °C for 0.5 h. After being cooled to 0 °C, the mixture was quenched with


methanol (10.0 mL) and adjusted to pH 2 with aqueous 1 *N* hydrogen chloride solution. The resulting mixture was stirred at 80 °C for 30 minutes. After being concentrated, the residue was dissolved in ethyl acetate (50 mL), washed with aqueous saturated sodium bicarbonate solution (25 mL) and brine (25 mL), dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified via prep-HPLC (Sunfire prep C18 10 µm OBD 19*250 mm; mobile phase: [water (0.05% trifluoroacetic acid)-acetonitrile]; B%: 60%-88%, 15 minutes) to give *N*-(5-(3-fluorobenzyl)thiazol-2-yl)-1-methyl-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.070 g, 0.21 mmol, 52.7%) as a white solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 10.79 (s, 1H), 7.36 (td, *J* = 8.0, 6.4 Hz, 1H), 7.23 (s, 1H), 7.17 - 6.99 (m, 3H), 4.10 (s, 2H), 3.18 - 2.96 (m, 5H), 2.26 (t, *J* = 6.6 Hz, 2H), 1.86 - 1.70 (m, 2H); LCMS (ESI) *m/z*: 333.1 [M+H]⁺.

Example 218. Preparation of

N-(4-chloro-5-(3-fluorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (218)




Step 1: Preparation of *tert*-butyl 4-chloro-5-formylthiazol-2-ylcarbamate



A solution of 2-amino-4-chloro-5-formylthiazole (1.00 g, 6.17 mmol), di-*tert*-butyl dicarbonate (1.6 g, 7.40 mmol) and 4-(dimethylamino)pyridine (0.076 g, 0.62 mmol) in dry 1,4-dioxane (15 mL) was stirred at 60 °C for 2 h. After being concentrated, the residue was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 4/1). Compound *tert*-butyl 4-chloro-5-formylthiazol-2-ylcarbamate (1.30 g, 4.96 mmol, 80.4%) was obtained as a brown solid. LCMS (ESI) *m/z*: 263.0 [M+H]⁺.

Step 2: Preparation of *tert*-butyl 4-chloro-5-((3-fluorophenyl)(hydroxy)methyl)thiazol-2-ylcarbamate




To an ice-cooled solution of *tert*-butyl 4-chloro-5-formylthiazol-2-ylcarbamate (1.12 g, 4.27 mmol) in tetrahydrofuran (20 mL) was added a solution of 3-fluorophenylmagnesium bromide (8.55 mL, 8.55 mmol, 1 M in tetrahydrofuran) dropwise. The mixture was stirred at 0 °C for 1 h. The reaction was quenched with aqueous saturated ammonium chloride solution (10 mL) and extracted with ethyl acetate

(50 mL x 3). The combined organic layers were washed with brine (50 mL), dried with sodium sulfate, filtered and concentrated. The residue was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 4/1) to afford *tert-butyl*

4-chloro-5-((3-fluorophenyl)(hydroxy)methyl)thiazol-2-ylcarbamate (1.01 g, 2.82 mmol, 66.1%) as a yellow solid. LCMS (ESI) m/z : 359.0 $[M+H]^+$.

Step 3: Preparation of 4-chloro-5-(3-fluorobenzyl)thiazol-2-amine




To an ice-cooled solution of *tert-butyl*

4-chloro-5-((3-fluorophenyl)(hydroxy)methyl)thiazol-2-ylcarbamate (1.00 g, 2.79 mmol) and triethylsilane (3.60 mL, 22.32 mmol) in dichloromethane (10.0 mL) was added trifluoroacetic acid (2.90 mL, 39.1 mmol) dropwise. The mixture was warmed to room temperature and stirred for 18 h. The volatiles were removed under reduced pressure and the resulting residue was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 3/1) to yield 4-chloro-5-(3-fluorobenzyl)thiazol-2-amine (0.650 g, 2.69 mmol, 96.3%) as a yellow solid. LCMS (ESI) m/z : 243.1 $[M+H]^+$.

Step 4: Preparation of

N-(4-chloro-5-(3-fluorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide




To a solution of 4-chloro-5-(3-fluorobenzyl)thiazol-2-amine (0.557 g, 2.30 mmol) in methanol (5.00 mL) was added hydrogen chloride (1.15 mL, 3.45 mmol, 3.0 M in methanol). The mixture was stirred at room temperature for 2 h. The volatiles were removed under reduced pressure and the resulting residue was dissolved in dry toluene (5.00 mL). Trimethylaluminum (1.15 mL, 2.30 mmol, 2.0 M in toluene) was added dropwise at 0 °C. The reaction mixture was warmed to room temperature and stirred for 4 h. This solution was added dropwise to a solution of methyl 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylate (0.326 g, 1.92 mmol) in toluene (1.00 mL). The mixture was stirred at 90 °C for 18 h in a sealed tube. After being cooled to room temperature, the mixture was quenched with water (25 mL) and extracted with ethyl acetate (50 mL x 3). The combined organic layers were washed with aqueous 1 N hydrogen chloride (50 mL) and brine (50 mL), dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μ m column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give *N*-(4-chloro-5-(3-fluorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.100 g, 0.26 mmol, 31.3%) was obtained as a white solid. ^1H NMR (500 MHz, Dimethylsulfoxide- d_6) δ


12.38 (s, 1H), 7.39 (d, $J = 6.3$ Hz, 1H), 7.20 - 6.95 (m, 3H), 4.11 (s, 2H), 3.35 (s, 3H), 2.81 (t, $J = 8.5$ Hz, 2H), 2.53 (d, $J = 8.5$ Hz, 2H); LCMS (ESI) m/z : 381.0 $[M+H]^+$.

Example 219. Preparation of

5 *N*-(5-(3-fluorobenzyl)-4-methylthiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (219)




Step 1: Preparation of *tert*-butyl 4-methylthiazol-2-ylcarbamate



10 A solution of 4-methylthiazol-2-amine (2.50 g, 21.9 mmol), di-*tert*-butyl dicarbonate (5.26 g, 24.1 mmol), 4-(dimethylamino)pyridine (0.025 g, 10 wt. %) and triethylamine (3.95 mL, 28.5 mmol) in dry tetrahydrofuran (50 mL) was stirred at room temperature for 18 h. After being filtered, the filtrate was concentrated, and purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 10/1) to give *tert*-butyl 4-methylthiazol-2-ylcarbamate (2.70 g, 12.6 mmol, 57.6%) as a white solid. LCMS (ESI) m/z : 215.1 $[M+H]^+$.

15

Step 2: Preparation of *tert*-butyl 5-((3-fluorophenyl)(hydroxy)methyl)-4-methylthiazol-2-ylcarbamate




To a solution of *tert*-butyl 4-methylthiazol-2-ylcarbamate (1.07g, 5.00 mmol) in tetrahydrofuran (15 mL) was added lithium diisopropylamide (6.25 mL, 12.5 mmol, 2.0 M) dropwise at -78°C . The mixture was stirred at -78°C for 30 minutes before a solution of 3-fluorobenzaldehyde (0.744 g, 6.00 mmol) was added dropwise. The mixture was stirred for another 1 h at -78°C and it was quenched with aqueous saturated ammonium chloride (50 mL). The mixture was extracted with ethyl acetate (50 mL x 3). The combined organic layers were washed with brine (50 mL), dried with sodium sulfate, filtered and concentrated. The residue was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 1/1) to give *tert*-butyl 5-((3-fluorophenyl)(hydroxy)methyl)-4-methylthiazol-2-ylcarbamate (1.30 g, 3.85 mmol, 76.9%) as a colorless oil. LCMS (ESI) m/z : 339.1 $[M+H]^+$.

20

25

Step 3: Preparation of 5-(3-fluorobenzyl)-4-methylthiazol-2-amine




To an ice-cooled solution of *tert-butyl*

5-((3-fluorophenyl)(hydroxy)methyl)-4-methylthiazol-2-ylcarbamate (0.338 g, 1.00 mmol) and triethylsilane (0.930 g, 8.00 mmol) in dichloromethane (5.00 mL) was added trifluoroacetic acid (1.60 g, 14.0 mmol) dropwise. The mixture was warmed to room temperature and stirred for 18 h. The volatiles were removed under reduced pressure and the residue was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 1/1) to give 5-(3-fluorobenzyl)-4-methylthiazol-2-amine (0.206 g, 0.93 mmol, 92.8%) as a white solid. LCMS (ESI) *m/z*: 223/1 [M+H]⁺.

Step 4: Preparation of


N-(5-(3-fluorobenzyl)-4-methylthiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide




To a stirred solution of 5-(3-fluorobenzyl)-4-methylthiazol-2-amine (0.180 g, 0.81 mmol), 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.151 g, 0.97 mmol) and 1-[*bis*(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.369 g, 0.97 mmol) in *N,N*-dimethylformamide (5.00 mL) was added *N,N*-diisopropylethylamine (0.313 g, 2.43 mmol). After addition, the reaction mixture was stirred at room temperature for 2 h. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μm column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give *N*-(5-(3-fluorobenzyl)-4-methylthiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.066 mg, 0.18 mmol, 22.6%) as a white solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 11.83 (s, 1H), 7.36 (dd, *J* = 14.9, 7.4 Hz, 1H), 7.06 (dd, *J* = 18.6, 8.6 Hz, 3H), 4.07 (s, 2H), 2.81 (t, *J* = 8.5 Hz, 2H), 2.59 - 2.41 (m, 6H), 2.27 (s, 3H); LCMS (ESI) *m/z*: 361.1 [M+H]⁺.

Example 220. Preparation of

***N*-(5-(3-fluorobenzyl)thiazol-2-yl)-*N*,1-dimethyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (220)**




Step 1: Preparation of *tert*-butyl 5-((3-fluorophenyl)(hydroxy)methyl)thiazol-2-ylcarbamate



To a stirred solution of *tert*-butyl thiazol-2-ylcarbamate (5.0 g, 25.0 mmol) in tetrahydrofuran (100 mL) at -78 °C was added n-butyllithium (22 mL, 55 mmol, 2.5 M) dropwise over 5 minutes under nitrogen.

- 5 After stirring for 30 minutes, 3-fluorobenzaldehyde (4.65 g, 37.5 mmol) was added. The solution was warmed to room temperature over 2 h, and then poured into ice-water (100 mL). The solution was adjusted to pH = 6-7 with 1 M hydrogen chloride (20 mL), extracted with ethyl acetate (100 mL × 2), washed with brine (100 mL), dried over sodium sulfate, filtered and concentrated *in vacuo*. The crude sample was treated with *tert*-butyl methyl ether (50 mL to afford *tert*-butyl
- 10 5-((3-fluorophenyl)(hydroxy)methyl)thiazol-2-ylcarbamate (6.5 g, 20.0 mmol, 80%) as a brown solid. LCMS (ESI) *m/z*: 325.1 [M+H]⁺.


Step 2: Preparation of 5-(3-fluorobenzyl)thiazol-2-amine



- 15 To a stirred solution of *tert*-butyl 5-((3-fluorophenyl)(hydroxy)methyl)thiazol-2-ylcarbamate (1.0 g, 3.1 mmol) in trifluoroacetic acid (15.0 mL) at 0 °C was added triethylsilane (1.39 g, 12.4 mmol). The solution was stirred at room temperature for 17 h. The volatiles were removed under reduced pressure and the crude sample was diluted with aqueous saturated sodium bicarbonate (100 mL) and extracted with ethyl acetate (50 mL × 2). The combined organic layers were washed with brine (50 mL), dried over
- 20 sodium sulfate, filtered and concentrated *in vacuo*. The crude sample was treated with *tert*-butyl methyl ether (10 mL) to afford 5-(3-fluorobenzyl)thiazol-2-amine (0.6 g, 2.88 mmol, 93%) as a brown solid. LCMS (ESI) *m/z*: 209.1 [M+H]⁺.

Step 3: Preparation of

- 25 *N*-(5-(3-fluorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide




- A solution of 5-(3-fluorobenzyl)thiazol-2-amine (0.3 g, 1.44 mmol), 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.270 g, 1.73 mmol), 1-[*bis*(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.657 g, 1.73 mmol) and triethylamine (0.727 g, 7.2 mmol) in *N,N*-dimethylformamide (5.00 mL) was stirred at
- 30 room temperature for 17 h. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified via prep-HPLC (Sunfire prep C18 10 μm OBD 19*250 mm; mobile phase: [water (0.05% sodium bicarbonate)-acetonitrile]; B%: 40%-50%, 7 minutes) to give

N-(5-(3-fluorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.300 g, 0.87 mmol, 60%) as a white solid. ¹H NMR (400 MHz, Chloroform-*d*) δ 9.98 (s, 1H), 7.25-7.31 (m, 1H), 7.21 (s, 1H), 7.04 (d, *J* = 8.0 Hz, 1H), 6.94 (t, *J* = 6.0 Hz, 2H), 4.10 (s, 2H), 3.45 (s, 3H), 2.97 (t, *J* = 8.8 Hz, 2H), 2.59 (t, *J* = 8.8 Hz, 2H); LCMS (ESI) *m/z*: 347.0 [*M*+H]⁺.

5


Example 221. Preparation of

N-(5-(3-fluorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (221)



Step 1: Preparation of

N-(5-(3-fluorobenzyl)thiazol-2-yl)-N,1-dimethyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide




To a stirred solution of

N-(5-(3-fluorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.200 g, 0.58 mmol) and potassium carbonate (0.120 g, 0.87 mmol) in *N,N*-dimethylformamide (5.0 mL) was added iodomethane (0.246 g, 1.73 mmol) at room temperature for 17 h. The reaction mixture was filtered, and the filtrate was concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Sunfire prep C18 10 μm OBD 19*250 mm; mobile phase: [water (0.05% sodium bicarbonate)-acetonitrile]; B%: 40%-50%, 7 minutes) to afford


N-(5-(3-fluorobenzyl)thiazol-2-yl)-N,1-dimethyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.0625 g, 0.17 mmol, 30%) as a white solid. LCMS (ESI) *m/z*: 361.1 [*M*+H]⁺. ¹H NMR (500 MHz, Chloroform-*d*) δ 7.32 (s, 1H), 7.24-7.28 (m, 2H), 7.02 (d, *J* = 8.0 Hz, 1H), 6.93 (dd, *J* = 9.0 Hz, *J* = 2.0 Hz, 2H), 4.10 (s, 2H), 3.82 (s, 3H), 3.40 (s, 3H), 2.92 (t, *J* = 8.5 Hz, 2H), 2.61 (t, *J* = 8.5 Hz, 2H).

Example 222. Preparation of

N-(5-(3-Chlorobenzyl)thiazol-2-yl)-1-isopropyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (222)




Step 1: Preparation of *tert*-butyl (5-((3-chlorophenyl)(hydroxy)methyl)thiazol-2-yl)carbamate



To a solution of *tert*-butyl thiazol-2-ylcarbamate (2.8 g, 14.0 mmol) in anhydrous tetrahydrofuran (80 mL) was added *n*-butyllithium (8.4 mL, 21.0 mmol, 2.5 M in tetrahydrofuran) at -78 °C under nitrogen.

- 5 The reaction mixture was stirred at -78 °C for 1 h before 3-chlorobenzaldehyde (2.95 g, 21.0 mmol) was added. Reaction was warmed to 0 °C for 3 h, quenched with aqueous solution of ammonium chloride (20 mL) and extracted with ethyl acetate (80 mL × 3). The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated *in vacuo*. The residue was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 2:1) to afford *tert*-butyl
- 10 (5-((3-chlorophenyl)(hydroxy)methyl)thiazol-2-yl)carbamate (2.8 g, 8.2 mmol, 58.6%) as a brown solid. LCMS (ESI) *m/z*: 341.1 [M+H]⁺.


Step 2: Preparation of 5-(3-chlorobenzyl)thiazol-2-amine



- 15 To a solution of *tert*-butyl (5-((3-chlorophenyl)(hydroxy)methyl)thiazol-2-yl)carbamate (1.0 g, 2.93 mmol) in triethylsilane (10 mL) at room temperature was added trifluoroacetic acid (1.67 g, 14.7 mmol). The reaction mixture was stirred at room temperature for 16 h before it was concentrated, and purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 1/1) to afford
- 5-(3-chlorobenzyl)thiazol-2-amine (580 mg, 2.58 mmol, 88%) as a brown solid. LCMS (ESI) *m/z*: 225.1
- 20 [M+H]⁺.

Step 3: Preparation of

N-(5-(3-chlorobenzyl)thiazol-2-yl)-1-isopropyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide




- 25 To a solution of 5-(3-chlorobenzyl)thiazol-2-amine (0.098 g, 0.53 mmol), 1-isopropyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.120 g, 0.53 mmol) and 1-[*bis*(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.263 g, 0.69 mmol) in *N,N*-dimethylformamide (6 mL) was added *N,N*-diisopropylethylamine (0.276 g, 2.14 mmol). The mixture was stirred at room temperature for 16 h and concentrated. The crude sample was
- 30 dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μm column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give
- N*-(5-(3-chlorobenzyl)thiazol-2-yl)-1-isopropyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.098 g, 0.25 mmol, 47.2%) as a white solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 12.07 (s, 1H),


7.44 - 7.16 (m, 5H), 4.84 (dt, $J = 13.3, 6.6$ Hz, 1H), 4.15 (s, 2H), 2.86 - 2.70 (m, 2H), 2.48 (d, $J = 8.5$ Hz, 2H), 1.24 (d, $J = 6.6$ Hz, 6H); LCMS (ESI) m/z : 391.1 $[M+H]^+$.

Example 223. Preparation of

5 *N*-(5-(3-fluorobenzyl)thiazol-2-yl)-1-methyl-6-oxopiperidine-3-carboxamide (223)




Step 1: Preparation of 1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid



10 To a solution of methyl 1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate (1.5 g, 8.97 mmol) in tetrahydrofuran (10.0 mL) at room temperature was added sodium hydroxide (1.44 g, 35.9 mmol) and water (10.0 mL). The reaction mixture was stirred at room temperature for 16 h, diluted with water (100 mL), adjusted to pH = 3-4 with aqueous 2 M hydrogen chloride and extracted with ethyl acetate (80 mL × 3). The combined organic layers were washed with brine, dried over sodium sulfate, filtered and
15 concentrated to afford 1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (1.1 g, 7.18 mmol, 80.0 %) as a white solid. LCMS (ESI) m/z : 154.1 $[M+H]^+$.


Step 2: Preparation of 1-methyl-6-oxopiperidine-3-carboxylic acid



20 To a solution of 1-methyl-6-oxopiperidine-3-carboxylic acid (0.130 g, 0.85 mmol) in methanol (8 mL) and acetic acid (2.0 mL) at room temperature was added platinum(IV) oxide (0.100 g). The reaction mixture was stirred at room temperature for 16 h under hydrogen atmosphere. The reaction solution was filtered and concentrated to afford 1-methyl-6-oxopiperidine-3-carboxylic acid (0.135 g, crude) as a white solid. LCMS (ESI) m/z : 158.2 $[M+H]^+$.

25

Step 3: Preparation of *N*-(5-(3-Fluorobenzyl)thiazol-2-yl)-1-methyl-6-oxopiperidine-3-carboxamide




To a solution of 1-methyl-6-oxopiperidine-3-carboxylic acid (0.135 g, 0.85 mmol), 5-(3-fluorobenzyl)thiazol-2-amine (0.177 g, 0.85 mmol) and


1-[*bis*(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.422.0 g, 1.11 mmol) in *N,N*-dimethylformamide (6 mL) at room temperature was added *N,N*-diisopropylethylamine (0.440 g, 3.4 mmol). The mixture was stirred at room temperature for 16 h. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μ m column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give *N*-(5-(3-fluorobenzyl)thiazol-2-yl)-1-methyl-6-oxopiperidine-3-carboxamide (0.135 g, 0.388 mmol, 45.6%) as a white solid. ^1H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 12.15 (s, 1H), 7.39 - 7.32 (m, 1H), 7.28 (s, 1H), 7.11-7.03(m, 3H), 4.11 (s, 3H), 3.43 (dd, *J* = 11.9, 9.0 Hz, 2H), 3.07 - 2.96 (m, 1H), 2.82 (d, *J* = 16.3 Hz, 3H), 2.31 - 2.17 (m, 2H), 2.05 - 1.94 (m, 1H), 1.93 - 1.81 (m, 1H); LCMS (ESI) *m/z*: 348.1 [*M*+*H*]⁺.

Example 224. Preparation of

N-(5-(3-fluorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (214)




Step 1: Preparation of 1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid



To a solution of methyl 1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate (1.5 g, 8.97 mmol) in tetrahydrofuran (10 mL) and water (10 mL) at room temperature was added sodium hydroxide (1.44 g, 35.9 mmol). The reaction mixture was stirred at room temperature for 3 h. The mixture was diluted with water (100 mL), pH was adjusted to ~3-4 with aqueous 2 M hydrogen chloride and extracted with ethyl acetate (80 mL $\times$ 3). The combined organic layers were dried over sodium sulfate, filtered and concentrated to afford 1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (1.1 g, 7.18 mmol, 80.0 %) as a white solid. LCMS (ESI) *m/z*: 154.1 [*M*+*H*]⁺.

Step 2: Preparation of

N-(5-(3-fluorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide




To a solution of 1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid (0.367 g, 2.4 mmol), 5-(3-fluorobenzyl)thiazol-2-amine (0.500 mg, 2.4 mmol) and 1-[*bis*(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (1.19 g,

3.12 mmol) in *N,N*-dimethylformamide (6 mL) was added *N,N*-diisopropylethylamine (1.24 g, 9.6 mmol). The mixture was stirred at room temperature for 16 h. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μ m column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give


- 5 *N*-(5-(3-fluorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide (0.450 g, 1.31 mmol, 54.6%) as a white solid. ^1H NMR (500 MHz, Dimethylsulfoxide- d_6) δ 12.22 (s, 1H), 8.68 (d, J = 2.4 Hz, 1H), 7.99 (dd, J = 9.5, 2.7 Hz, 1H), 7.40 - 7.32 (m, 2H), 7.14 - 7.04 (m, 3H), 6.44 (d, J = 9.6 Hz, 1H), 4.13 (s, 2H), 3.50 (s, 3H); LCMS (ESI) m/z : 334.0 $[\text{M}+\text{H}]^+$.

10 **Example 225. Preparation of**

***N*-(5-(3-chlorobenzyl)thiazol-2-yl)-1-(oxetan-3-yl)-6-oxo-1,6-dihydropyridazine-3-carboxamide (225)**




Step 1: Preparation of methyl 1-(oxetan-3-yl)-6-oxo-1,6-dihydropyridazine-3-carboxylate



- 15 To a solution of methyl 6-oxo-1,6-dihydropyridazine-3-carboxylate (2.0 g, 13.0 mmol) in *N,N*-dimethylformamide (60 mL) at room temperature was added 3-iodooxetane (4.77 g, 26.0 mmol) and potassium carbonate (3.58 g, 26.0 mmol). The reaction mixture was stirred at 100 °C for 16 h, cooled to room temperature, diluted with water (300 mL) and extracted with ethyl acetate (80 mL $\times$ 3). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated *in vacuo*. The residue was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 3:1) to afford methyl 1-(oxetan-3-yl)-6-oxo-1,6-dihydropyridazine-3-carboxylate (1.5 g, 7.14 mmol, 55%) as a white solid. LCMS (ESI) m/z : 211.1 $[\text{M}+\text{H}]^+$.

- 25 Step 2: Preparation of 1-(oxetan-3-yl)-6-oxo-1,6-dihydropyridazine-3-carboxylic acid




To a solution of methyl 1-(oxetan-3-yl)-6-oxo-1,6-dihydropyridazine-3-carboxylate (0.200 g, 0.95 mmol) in tetrahydrofuran (8 mL) and water (8 mL) was added sodium hydroxide (0.152 g, 3.80 mmol) at room temperature. The reaction mixture was stirred at room temperature for 3 h. Concentration affords

1-(oxetan-3-yl)-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (0.370 g, crude) as a white solid. LCMS (ESI) m/z : 197.1 $[M+H]^+$.

Step 3: Preparation of


5 *N*-(5-(3-chlorobenzyl)thiazol-2-yl)-1-(oxetan-3-yl)-6-oxo-1,6-dihydropyridazine-3-carboxamide




To a solution of 1-(oxetan-3-yl)-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (0.370 g, 0.95 mmol), 5-(3-chlorobenzyl)thiazol-2-amine (0.213 g, 0.95 mmol) and 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.471 g, 1.24 mmol) in *N,N*-dimethylformamide (8 mL) at room temperature was added *N,N*-diisopropylethylamine (0.491 g, 3.80 mmol). The mixture was stirred at room temperature for 3 h. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μ m column; acetonitrile/0.01% aqueous trifluoroacetic acid) to afford *N*-(5-(3-chlorobenzyl)thiazol-2-yl)-1-(oxetan-3-yl)-6-oxo-1,6-dihydropyridazine-3-carboxamide (0.042 g, 0.10 mmol, 10.5%) as a white solid. ^1H NMR (500 MHz, Dimethylsulfoxide- d_6) δ 12.61 (s, 1H), 7.93 (d, J = 9.7 Hz, 1H), 7.40 - 7.35 (m, 3H), 7.29 (dd, J = 15.5, 7.9 Hz, 2H), 7.08 (d, J = 9.7 Hz, 1H), 5.85-5.79 (m, 1H), 5.10 (t, J = 6.7 Hz, 2H), 4.83 (t, J = 7.3 Hz, 2H), 4.17 (s, 2H); LCMS (ESI) m/z : 403.0 $[M+H]^+$.

Example 226. Preparation of

20 *N*-(5-(3-fluorobenzyl)thiazol-2-yl)-1-(2-fluoroethyl)-6-oxo-1,6-dihydropyridazine-3-carboxamide (226)




Step 1: Preparation of methyl 1-(2-fluoroethyl)-6-oxo-1,6-dihydropyridazine-3-carboxylate



To a solution of methyl 6-oxo-1,6-dihydropyridazine-3-carboxylate (2.5 g, 16.2 mmol) in *N,N*-dimethylformamide (60.0 mL) was added 1-bromo-2-fluoroethane (4.12 g, 32.4 mmol) and potassium carbonate (4.48 g, 32.4 mmol). The reaction mixture was stirred at 100 °C for 16 h, cooled to room temperature, diluted with water (300 mL) and extracted with ethyl acetate (80 mL $\times$ 3). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated *in vacuo*. The residue was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 2/1) to

afford methyl 1-(2-fluoroethyl)-6-oxo-1,6-dihydropyridazine-3-carboxylate (2.2 g, 11.0 mmol, 67.8%) as a white solid. LCMS (ESI) m/z : 201.1 $[M+H]^+$.


Step 2: Preparation of 1-(2-Fluoroethyl)-6-oxo-1,6-dihydropyridazine-3-carboxylic acid



To a solution of methyl 1-(2-fluoroethyl)-6-oxo-1,6-dihydropyridazine-3-carboxylate (0.200 g, 1.0 mmol) in tetrahydrofuran (8 mL) and water (8 mL) was added sodium hydroxide (0.016 g, 4.0 mmol). The reaction mixture was stirred at room temperature for 3 h. Concentration affords 1-(2-fluoroethyl)-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (0.400 g, crude) as a white solid. LCMS (ESI) m/z : 187.1 $[M+H]^+$.

Step 3: Preparation of


N-(5-(3-fluorobenzyl)thiazol-2-yl)-1-(2-fluoroethyl)-6-oxo-1,6-dihydropyridazine-3-carboxamide




To a solution of 1-(2-fluoroethyl)-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (0.400 g, crude) in *N,N*-dimethylformamide (6 mL) at room temperature was added 5-(3-fluorobenzyl)thiazol-2-amine (0.208 g, 1.0 mmol), 1-[*bis*(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.494 g, 1.3 mmol) and *N,N*-diisopropylethylamine (0.517 g, 4.0 mmol). The mixture was stirred at room temperature for 16 h. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μ m column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give *N*-(5-(3-fluorobenzyl)thiazol-2-yl)-1-(2-fluoroethyl)-6-oxo-1,6-dihydropyridazine-3-carboxamide (0.230 g, 0.227 mmol, 22.7%) as a white solid. ^1H NMR (500 MHz, Dimethylsulfoxide- d_6) δ 12.42 (s, 1H), 7.91 (d, J = 9.7 Hz, 1H), 7.40 - 7.35 (m, 2H), 7.15 - 7.12 (m, 2H), 7.10 - 7.04 (m, 2H), 4.99 (t, J = 4.9 Hz, 1H), 4.90 (t, J = 4.9 Hz, 1H), 4.51 (t, J = 4.9 Hz, 1H), 4.46 (t, J = 4.9 Hz, 1H), 4.16 (s, 2H); LCMS (ESI) m/z : 377.0 $[M+H]^+$.

Example 227. Preparation of

1-ethyl-*N*-(5-(3-fluorobenzyl)thiazol-2-yl)-6-oxo-1,6-dihydropyridazine-3-carboxamide (227)




Step 1: Preparation of methyl 1-ethyl-6-oxo-1,6-dihydropyridazine-3-carboxylate



To a solution of methyl 6-oxo-1,6-dihydropyridazine-3-carboxylate (1.1 g, 7.14 mmol) in *N,N*-dimethylformamide (20 mL) at room temperature was added potassium carbonate (1.97 g, 14.3 mmol) and iodoethane (2.23 g, 14.3 mmol). The reaction mixture was stirred at 70 °C for 16 h, cooled to room temperature, diluted with water (300 mL) and extracted with ethyl acetate (80 mL × 3). The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated to afford methyl 1-ethyl-6-oxo-1,6-dihydropyridazine-3-carboxylate (1.0 g, 5.49 mmol, 76.9%) as a white solid. LCMS (ESI) *m/z*: 183.1 [M+H]⁺.


Step 2: Preparation of 1-ethyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid



To a solution of methyl 1-ethyl-6-oxo-1,6-dihydropyridazine-3-carboxylate (0.410 g, 2.25 mmol) in tetrahydrofuran (15 mL) and water (2 mL) at room temperature was added sodium hydroxide (0.180 g, 4.5 mmol). The reaction mixture was stirred at room temperature for 3 h and adjusted to pH = 6 - 7 with aqueous 2 M hydrogen chloride. The mixture was concentrated, to afford 1-ethyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (0.660 g, crude) as a white solid. LCMS (ESI) *m/z*: 169.1 [M+H]⁺.

Step 3: Preparation of

1-ethyl-*N*-(5-(3-fluorobenzyl)thiazol-2-yl)-6-oxo-1,6-dihydropyridazine-3-carboxamide




To a solution of 1-ethyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (0.660 mg, 2.25 mmol), 5-(3-fluorobenzyl)thiazol-2-amine (0.360 g, 1.73 mmol) and 1-[*bis*(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.921 g, 2.42 mmol) in *N,N*-dimethylformamide (8 mL) was added *N,N*-diisopropylethylamine (0.894 g, 6.92 mmol). The reaction mixture was stirred at room temperature for 16 h. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified via prep-HPLC (Boston C18 21*250 mm 10 μm column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give 1-ethyl-*N*-(5-(3-fluorobenzyl)thiazol-2-yl)-6-oxo-1,6-dihydropyridazine-3-carboxamide (0.201 g, 0.56 mmol, 32.4%) as a white solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 12.37 (s, 1H), 7.88 (d, *J* = 9.7


Hz, 1H), 7.44 - 7.32 (m, 2H), 7.18 - 7.11 (m, 2H), 7.10 - 7.00 (m, 2H), 4.22 - 4.13 (m, 4H), 1.35 (t, $J = 7.2$ Hz, 3H); LCMS (ESI) m/z : 359.0 $[M+H]^+$.

Example 228. Preparation of

5 *N*-(5-(3,4-difluorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (228)




Step 1: Preparation of *tert*-butyl 5-((3,4-difluorophenyl)(hydroxy)methyl)thiazol-2-ylcarbamate



To a solution of *tert*-butyl thiazol-2-ylcarbamate (1.5 g, 7.5 mmol) in tetrahydrofuran (30 mL) at -75 °C was added *n*-butyllithium (6.6 mL, 16.5 mmol) dropwise. Reaction mixture was stirred for 30 minutes before 3,4-difluorobenzaldehyde (1.6 g, 11.3 mmol) was added slowly. Reaction was warmed to room temperature over 2 h. The reaction solution was poured into ice water (50 mL) and pH was adjusted to 6~7 with aqueous 1 N hydrogen chloride. The aqueous layer was extracted with ethyl acetate (50 mL x 2). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate, filtered and concentrated. Treatment of crude residue with *tert*-butyl methyl ether (5 mL) provides *tert*-butyl 5-((3,4-difluorophenyl)(hydroxy)methyl)thiazol-2-ylcarbamate (0.930 g, 2.72 mmol, 36.3%) as a white solid. LCMS (ESI) m/z : 343.1 $[M+H]^+$. Used in the next step directly without additional purification.


Step 2: Preparation of 5-(3,4-difluorobenzyl)thiazol-2-amine



To a solution of *tert*-butyl 5-((3,4-difluorophenyl)(hydroxy)methyl)thiazol-2-ylcarbamate (0.830 g, 2.43 mmol) in trifluoroacetic acid (12 mL) at 0 °C was added triethylsilane (1.13 g, 9.7 mmol). Reaction was warmed to room temperature and stirred for 5 h. The reaction mixture was concentrated and diluted with aqueous saturated sodium bicarbonate solution (50 mL). The aqueous phase was extracted with ethyl acetate (30 mL x 2). Combined organic layers were washed with brine (30 mL), dried over sodium sulfate, filtered and concentrated. Treatment of the crude residue with *tert*-butyl methyl ether (2 mL) gives 5-(3,4-difluorobenzyl)thiazol-2-amine (0.250 g, 1.11 mmol, 45.5%) as a white solid. LCMS (ESI) m/z : 227.1 $[M+H]^+$.

Step 3: Preparation of

N-(5-(3,4-difluorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide




A solution of 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.070 g, 0.448 mmol), 5-(3,4-difluorobenzyl)thiazol-2-amine (0.121 g, 0.54 mmol),

1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.255 g, 0.67 mmol) and *N,N*-diisopropylethylamine (0.173 g, 1.34 mmol) in *N,N*-dimethylformamide (3 mL) was stirred at room temperature for 2 h. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μ m column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give


N-(5-(3,4-difluorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.119 g, 0.327 mmol, 73%) as a white solid. ^1H NMR (500 MHz, Dimethylsulfoxide- d_6) δ 11.90 (s, 1H), 7.45 - 7.35 (m, 2H), 7.33 (s, 1H), 7.14 - 7.12 (m, 1H), 4.24 (s, 2H), 3.35 (s, 3H), 2.82 (t, J = 8.5 Hz, 2H), 2.51 (t, J = 5.75 Hz, 2H); LCMS (ESI) m/z : 364.37 $[\text{M}+\text{H}]^+$.

Example 229. Preparation of

***N*-(5-(3,5-difluorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (229)**




Step 1: Preparation of *tert*-butyl 5-((3,5-difluorophenyl)(hydroxy)methyl)thiazol-2-ylcarbamate



To a solution of *tert*-butyl thiazol-2-ylcarbamate (1.5 g, 7.5 mmol) in tetrahydrofuran (30 mL) at -78 °C was added *n*-butyllithium (6.6 mL, 16.5 mmol) dropwise. Reaction was stirred at this temperature for 30 minutes before 3,4-difluorobenzaldehyde (1.6 g, 11.3 mmol) was added. Reaction was warmed to room temperature over 2 h. Reaction solution was poured into ice water (50 mL) and pH was adjusted to 6~7 with aqueous 1 N hydrogen chloride. The aqueous layer was extracted with ethyl acetate (50 mL x 2). Combined organic phases were washed with brine (50 mL), dried over sodium sulfate, filtered and concentrated. Treatment of crude residue with *tert*-butyl methyl ether (5 mL) affords *tert*-butyl

5-((3,5-difluorophenyl)(hydroxy)methyl)thiazol-2-ylcarbamate (0.650 g, 1.90 mmol, 25.3%) as a brown solid. LCMS (ESI) m/z : 343.1 $[M+H]^+$. Used in the next step directly without additional purification.


Step 2: Preparation of 5-(3,5-difluorobenzyl)thiazol-2-amine





To a solution of *tert*-butyl 5-((3,5-difluorophenyl)(hydroxy)methyl)thiazol-2-ylcarbamate (0.590 g, 1.73 mmol) in trifluoroacetic acid (8 mL) at 0 °C was added triethylsilane (0.8 g, 6.9 mmol). Reaction was warmed to room temperature and stirred for 5 h. Volatiles were removed and the crude residue was diluted with aqueous saturated sodium bicarbonate solution (50 mL) and extracted with ethyl acetate (30 mL x 2). Combined organic layers were washed with brine (30 mL), dried over sodium sulfate, filtered and concentrated. Treatment of the crude material with *tert*-butyl methyl ether (2 mL) gives 5-(3,5-difluorobenzyl)thiazol-2-amine (0.340 g, 0.513 mmol, 87%) as a yellow solid. LCMS (ESI) 227.1 $[M+H]^+$.

Step 3: Preparation of


N-(5-(3,5-difluorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide



A solution of 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.100 g, 0.464 mmol), 5-(3,5-difluorobenzyl)thiazol-2-amine (0.174 g, 0.77 mmol), 1-[*bis*(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.365 g, 0.96 mmol) and *N,N*-diisopropylethylamine (0.248 g, 1.92 mmol) in *N,N*-dimethylformamide (5 mL) was stirred at room temperature for 2 h. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μ m column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give *N*-(5-(3,5-difluorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.132 g, 0.263 mmol, 56.6%) as a white solid. ^1H NMR (500 MHz, Dimethylsulfoxide- d_6) δ 11.92 (s, 1H), 7.36 (s, 1H), 7.12-7.08 (m, 1H), 7.04 (d, J = 6.5 Hz, 2H), 4.15 (s, 2H), 3.35 (s, 3H), 2.82 (t, J = 8.5 Hz, 2H), 2.51 (t, J = 6.5 Hz, 2H); LCMS (ESI) m/z : 364.4 $[M+H]^+$.


Example 230. Preparation of***N*-(5-(2-chlorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (230)****5 Step 1: Preparation of *tert*-butyl thiazol-2-ylcarbamate**

To a solution of thiazol-2-amine (11 g, 100 mmol) in tetrahydrofuran (5 mL) at 0 °C was added di-*tert*-butyl dicarbonate (26.2 g, 120 mmol). Reaction was stirred at room temperature for 17 h. Concentration followed by treatment of the resulting solid with petroleum ether/ethyl acetate = 100:2 (100 mL) affords *tert*-butyl thiazol-2-ylcarbamate as a faint yellow solid (16.9 g, 84.5 mmol, 84.5%). LCMS (ESI) *m/z*: 145.1 [M-56]⁺. Used in the next step directly without additional purification.

Step 2: Preparation of *tert*-butyl 5-((2-chlorophenyl)(hydroxy)methyl)thiazol-2-ylcarbamate

To a solution of *tert*-butyl thiazol-2-ylcarbamate (1 g, 5.00 mmol) in tetrahydrofuran (20 mL) at -78 °C was added *n*-butyllithium (4.4 mL, 11.0 mmol) dropwise. Reaction was stirred for 30 minutes, before 2-chlorobenzaldehyde (1.05 g, 7.50 mmol) was added at -78 °C. Reaction mixture was warmed to room temperature over 2 h. The solution was poured into ice water (50 mL) and neutralized with aqueous 1 N hydrogen chloride and extracted with ethyl acetate (50 mL x 2). The combined organic layers were washed with brine (50 mL), dried over sodium sulfate, filtered and concentrated. Treatment of the crude sample with *tert*-butyl methyl ether (5 mL) gives *tert*-butyl 5-((2-chlorophenyl)(hydroxy)methyl)thiazol-2-ylcarbamate as a white solid (0.340 g, 1.00 mmol, 20%); LCMS (ESI) *m/z*: 341.1 [M+H]⁺.


Step 3: Preparation of 5-(2-chlorobenzyl)thiazol-2-amine




To a solution of *tert*-butyl 5-((2-chlorophenyl)(hydroxy)methyl)thiazol-2-ylcarbamate (0.300 g, 0.88 mmol) in tetrahydrofuran (6 mL) at 0 °C was added triethylsilane (0.409 g, 3.56 mmol). Reaction mixture was warmed to room temperature and stirred for 17 h. Then the reaction mixture was concentrated, diluted with saturated sodium bicarbonate solution (20 mL), and extracted with ethyl acetate (30 mL x 2). The combined organic layers were washed with brine (30 mL), dried over sodium sulfate, concentrated and triturated with *tert*-butyl methyl ether (1 mL) to offer 5-(2-chlorobenzyl)thiazol-2-amine (0.140 g, 0.412 mmol, 46.8%) as a white solid. LCMS (ESI) *m/z*: 225.1 [M+H]⁺.

Step 4: Preparation of

N-(5-(2-chlorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide




A solution of 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.070 g, 0.35 mmol), 5-(2-chlorobenzyl)thiazol-2-amine (0.120 g, 0.54 mmol), 1-[*bis*(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.257 g, 0.675 mmol) and *N,N*-diisopropylethylamine (0.174 g, 1.35 mmol) in *N,N*-dimethylformamide (3 mL) was stirred at room temperature for 2 h. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μm column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give *N*-(5-(2-chlorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.160 g, 0.343 mmol, 98%) as a white solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 11.89 (s, 1H), 7.47-7.42 (m, 2H), 7.34 - 7.27 (m, 3H), 4.22 (s, 2H), 3.34 (s, 3H), 2.82 (t, *J* = 8.5 Hz, 2H), 2.51 - 2.49 (m, 2H); LCMS (ESI) *m/z*: 363.0 [M+H]⁺.

Example 231. Preparation of***N*-(5-((5-chloropyridin-3-yl)methyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (231)**


5

Step 1: Preparation of *tert*-butyl 5-((5-chloropyridin-3-yl)(hydroxy)methyl)thiazol-2-ylcarbamate



To a solution of *tert*-butyl thiazol-2-ylcarbamate (1.8 g, 9 mmol) in tetrahydrofuran (54 mL) at -78 °C was added *n*-butyllithium (7.9 mL, 19.8 mmol) dropwise. Reaction was stirred for 1 h at -78 °C for 1 h before a solution of 5-chloronicotinaldehyde (1.9 g, 13.5 mmol) in tetrahydrofuran (5 mL) was added. Reaction mixture was warmed to room temperature over 2 h. The mixture was poured into ice water (50 mL), pH was adjusted to 6~7 with aqueous 1 N hydrogen chloride and extracted with ethyl acetate (100 mL x 2). Combined organic layers were washed with brine (100 mL), dried over sodium sulfate, filtered and concentrated. Purification by column chromatography (silica gel, petroleum ether/ethyl acetate = 1:10~1/2) affords *tert*-butyl 5-((5-chloropyridin-3-yl)(hydroxy)methyl)thiazol-2-ylcarbamate (1.7 g, 55.4%) as a white solid. LCMS (ESI) *m/z*: 342.1 [M+H]⁺.


Step 2: Preparation of 5-((5-chloropyridin-3-yl)methyl)thiazol-2-amine



To a solution of *tert*-butyl 5-((5-chloropyridin-3-yl)(hydroxy)methyl)thiazol-2-ylcarbamate (1.5 g, 4.4 mmol) in trifluoroacetic acid (22 mL) at 0 °C was added triethylsilane (2.04 g, 17.6 mmol). Reaction was stirred at 60 °C for 24 h. The reaction mixture was concentrated, and diluted with saturated aqueous sodium bicarbonate solution to form a precipitate. The precipitate was filtered and washed with petroleum ether to give 5-((5-chloropyridin-3-yl)methyl)thiazol-2-amine (0.900 g, 3.54 mmol, 80.4%) as a yellow solid. LCMS (ESI) *m/z*: 226.0 [M+H]⁺.

Step 3: Preparation of



N-(5-((5-chloropyridin-3-yl)methyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide



- 5 A solution of 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.080 g, 0.51 mmol), 5-((5-chloropyridin-3-yl)methyl)thiazol-2-amine (0.138 g, 0.62 mmol), 1-*bis*(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.291 g, 0.765 mmol) and *N,N*-diisopropylethylamine (0.197 g, 1.53 mmol) in *N,N*-dimethylformamide (3 mL) was stirred at room temperature for 8 h. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μ m column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give
- 10 *N*-(5-((5-chloropyridin-3-yl)methyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide as a yellow solid (0.0697 g, 0.158 mmol, 31%). ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 11.94 (s, 1H), 8.52 (t, *J* = 2.3 Hz, 2H), 7.88 (t, *J* = 2.1 Hz, 1H), 7.37 (s, 1H), 4.19 (s, 2H), 3.35 (s, 3H), 2.82 (t, *J* = 8.5 Hz, 2H), 2.51 (t, *J* = 5.3 Hz, 2H); LCMS (ESI) *m/z*: 363.8 [M+H]⁺.
- 15


Example 232. Preparation of

N-(4-chloro-5-(3-fluorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (232)

Step 1: Preparation of *tert*-butyl 4-chloro-5-formylthiazol-2-ylcarbamate


To a solution of 2-amino-4-chlorothiazole-5-carbaldehyde (0.838 g, 5.15 mmol) and di-*tert*-butyl dicarbonate (1.35 g, 6.18 mmol) in 1,4-dioxane (25 mL) at room temperature was added 4-dimethylaminopyridine (0.063 g, 0.52 mmol) under nitrogen. The reaction mixture was stirred at 60 °C for 2 h. The reaction mixture was diluted with ethyl acetate (150 mL) and washed with aqueous 1 *N* hydrochloric acid solution (30 mL x 2). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The crude product was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 4/1) to give *tert*-butyl 4-chloro-5-formylthiazol-2-ylcarbamate (1.17 g, 4.45 mmol, 87 %) as a yellow solid. (LCMS (ESI) *m/z*: 207.1 [M-56+H]⁺).

Step 2: Preparation of *tert*-butyl 4-chloro-5-((3-fluorophenyl)(hydroxy)methyl)thiazol-2-ylcarbamate




To a solution of *tert*-butyl 4-chloro-5-formylthiazol-2-ylcarbamate (1.14 g, 4.3 mmol) in tetrahydrofuran (40 mL) at 0 °C was added (3-fluorophenyl)magnesium bromide (5.4 mL, 10.8 mmol) dropwise under argon. The reaction mixture was stirred at 0 °C for 2 h. Reaction was quenched with aqueous ammonium chloride solution (20 mL) and extracted with ethyl acetate (100 mL x 3). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The crude product was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 3/1) to give *tert*-butyl 4-chloro-5-((3-fluorophenyl)(hydroxy)methyl)thiazol-2-ylcarbamate (1.51 g, 4.2 mmol, 97%) as a yellow solid. LCMS (ESI) *m/z*: 303.0 [M-56+H]⁺.

Step 3: Preparation of 4-chloro-5-(3-fluorobenzyl)thiazol-2-amine



To a solution of *tert*-butyl 4-chloro-5-((3-fluorophenyl)(hydroxy)methyl)thiazol-2-ylcarbamate (1.49 g, 4.16 mmol) and triethoxysilane (5.46 g, 58.24 mmol) in dichloromethane (50 mL) was added trifluoroacetic acid (6.64 g, 58.2 mmol) at room temperature under nitrogen. The reaction mixture was stirred at 35 °C for 8 h. The volatiles were concentrated and the slurry was adjusted to pH 9 with saturated sodium bicarbonate aqueous. The aqueous layer was extracted with dichloromethane (80 mL x 3). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The crude product was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 3/1) to give 4-chloro-5-(3-fluorobenzyl)thiazol-2-amine (800 mg, 3.3 mmol, 80%) as a light-yellow solid. LCMS (ESI) *m/z*: 243.1 [M+H]⁺.

Step 4: Preparation of

N-(4-chloro-5-(3-fluorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide

To a solution of 4-chloro-5-(3-fluorobenzyl)thiazol-2-amine (0.291 g, 1.2 mmol) in toluene (5 mL)

at room temperature was added trimethylaluminum (0.6 mL, 1.2 mmol, 2 M in toluene) slowly under argon. The reaction mixture was stirred at room temperature for 1 h before methyl



1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylate (0.168 g, 1.0 mmol) in toluene (5 mL) was added.

The resulting solution was heated to 100 °C and stirred for 3 h. Reaction mixture was cooled to room temperature and quenched with methanol and aqueous 2 N hydrochloric acid. The volatiles were

removed *in vacuo* and water (20 mL) was added. The aqueous layer was extracted with dichloromethane (50 mL x 3). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (BostonC18 21*250 mm 10 µm column. The mobile phase was acetonitrile/10 mM ammonium acetate aqueous solution) to give

N-(4-chloro-5-(3-fluorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (0.200 g, 0.53 mmol, 53%) as a white solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 12.75 (s, 1H), 7.89 (d, *J* = 9.5 Hz, 1H), 7.37-7.42 (m, 1H), 7.10-7.14 (m, 3H), 7.05-7.08 (m, 1H), 4.13 (s, 2H), 3.78 (s, 3H); LCMS (ESI) *m/z*: 379.0 [M+H]⁺.


Example 233. Preparation of

N-(4-cyano-5-(3-fluorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (233)Step 1: Preparation of *tert*-butyl 5-bromothiazol-2-ylcarbamate

To a solution of 5-bromothiazol-2-amine (4.46 g, 24.9 mmol), di-*tert*-butyl dicarbonate (6.52 g, 30 mmol) and 4-dimethylaminopyridine (0.304 g, 2.5 mmol) in dichloromethane (120 mL) at room temperature was added triethylamine (6.3 g, 62.3 mmol) dropwise under nitrogen. The reaction mixture


was stirred at room temperature for 2 h. The reaction mixture was diluted with dichloromethane (200 mL) and washed with 1N hydrochloric acid solution (50 mL x 2). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The crude product was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 10/1) to give *tert*-butyl 5-bromothiazol-2-ylcarbamate as a white solid (4.04 g, 18.1 mmol, 73%); LCMS (ESI) *m/z*: 223.0 [M+H]⁺.

Step 2: Preparation of methyl *tert*-butyl 4-bromo-5-((3-fluorophenyl)(hydroxy)methyl)thiazol-2-ylcarbamate




To a solution of lithium diisopropylamide (16.5 mL, 33 mmol) in tetrahydrofuran (20 mL) at 0 °C was added *tert*-butyl 5-bromothiazol-2-ylcarbamate (2.8 g, 10.0 mmol) slowly under argon. The reaction mixture was stirred at 0 °C for 30 minutes before a solution of 3-fluorobenzaldehyde (4.1 g, 33.0 mmol) in tetrahydrofuran (10 mL) was added. The reaction solution was warmed to room temperature and stirred for 20 h. The reaction mixture was diluted with water (30 mL) and extracted with ethyl acetate (150 mL x 3). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The crude product was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 4/1) to give *tert*-butyl 4-bromo-5-((3-fluorophenyl)(hydroxy)methyl)thiazol-2-ylcarbamate as a yellow solid (2.5 g, 6.2 mmol, 62%). LCMS (ESI) *m/z*: 346.9 [M-56+H]⁺.

Step 3: Preparation of 4-bromo-5-(3-fluorobenzyl)thiazol-2-amine



To a solution of *tert*-butyl 4-bromo-5-((3-fluorophenyl)(hydroxy)methyl)thiazol-2-ylcarbamate (2.0 g, 5 mmol) and triethylsilane (6.57 g, 40 mmol) in dichloromethane (20 mL) at room temperature was added trifluoroacetic acid (8 g, 70 mmol) under nitrogen. The reaction mixture was stirred at 35 °C for 18 h. The volatiles were concentrated and the slurry was adjusted to pH 9 with aqueous saturated sodium bicarbonate. The aqueous layer was extracted with dichloromethane (100 mL x 3). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The crude product was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 3/1) to give 4-bromo-5-(3-fluorobenzyl)thiazol-2-amine (1.09 g, 3.8 mmol, 76%) as a light-yellow solid. LCMS (ESI) *m/z*: 287.0 [M+H]⁺.

Step 4: Preparation of 2-amino-5-(3-fluorobenzyl)thiazole-4-carbonitrile




To a solution of 4-bromo-5-(3-fluorobenzyl)thiazol-2-amine (0.824 g, 2.87 mmol) and zinc cyanide (0.253 g, 2.15 mmol) and 1,1'-bis(diphenylphosphino)ferrocene (0.078 g, 0.14 mmol) in

- 5 *N,N*-dimethylformamide (10 mL) at room temperature was added tris(dibenzylideneacetone) dipalladium(0) (0.082 g, 0.14 mmol) under nitrogen. The reaction mixture was stirred at 130 °C in the microwave for 1 h. The reaction mixture was cooled to room temperature and diluted with ethyl acetate (150 mL). The combined organic layers were washed with brine (50 mL x 3), dried over sodium sulfate, filtered and concentrated. The crude product was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 3/1) to give 2-amino-5-(3-fluorobenzyl)thiazole-4-carbonitrile as a brown solid (0.210 g, 0.9 mmol, 30%); LCMS (ESI) *m/z*: 234.1 [M+H]⁺.


Step 5: Preparation of

N-(4-cyano-5-(3-fluorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide




- 15 To a solution of 2-amino-5-(3-fluorobenzyl)thiazole-4-carbonitrile (0.100 g, 0.43 mmol) in toluene (5 mL) at room temperature was added trimethylaluminum (0.25 mL, 0.5 mmol, 2 M in toluene) slowly under argon. The reaction mixture was stirred at room temperature for 1 h before methyl 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylate (0.072 mg, 0.43 mmol) in toluene (5 mL) was added.
- 20 The reaction mixture was heated to 100 °C and stirred for 3 h before it was cooled to room temperature and quenched with methanol and aqueous 2 N hydrochloric acid. The volatiles were removed and water (20 mL) was added. The aqueous layer was extracted with dichloromethane (50 mL x 3). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (BostonC18 21*250 mm 10 μm column.
- 25 The mobile phase was acetonitrile/10 mM ammonium acetate aqueous solution) to give *N*-(4-cyano-5-(3-fluorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (3.1 mg, 0.01 mmol, 2%) as a white solid. ¹H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 12.93 (s, 1H), 7.90 (d, *J* = 9.6 Hz, 1H), 7.42 (dd, *J*₁ = 6.4 Hz, *J*₂ = 7.6 Hz, 1H), 7.14 - 7.23 (m, 3H), 7.07 (d, *J* = 9.6 Hz, 1H), 4.37 (s, 2H), 3.78 (s, 3H); LCMS (ESI) *m/z*: 370.0 [M+H]⁺.

30


Example 234. Preparation of***N*-(5-(2,4-difluorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (234)**

5 Step 1: Preparation of *tert*-butyl (5-((2,4-difluorophenyl)(hydroxy)methyl)thiazol-2-yl)carbamate



Dissolved *tert*-butyl thiazol-2-ylcarbamate (0.5 g, 2.49 mmol) in tetrahydrofuran (12.4 mL) and cooled to -78 °C. Carefully added *n*-butyllithium (1.6 M in hexanes, 1.39 mL, 3.48 mmol) and stirred for 10 minutes, followed by 2,4-difluorobenzaldehyde (325 μ L, 2.98 mmol). Quenched with saturated aqueous ammonium chloride (15 mL) and extracted with ethyl acetate (20 mL). Washed with brine (10 mL), then dried over sodium sulfate. Filtered and concentrated *in vacuo*. Purified reaction by column chromatography (eluting with 0-50% ethyl acetate/hexanes through 24 g of silica gel) to give *tert*-butyl (5-((2,4-difluorophenyl)(hydroxy)methyl)thiazol-2-yl)carbamate as an orange solid (165 mg, 0.482 mmol, 19%). ¹H NMR (300 MHz, Chloroform-*d*) δ 7.62 (d, *J* = 6.4 Hz, 1H), 7.15 (s, 1H), 6.96 (d, *J* = 10.0 Hz, 2H), 6.88 - 6.75 (m, 1H), 6.26 (s, 1H), 1.53 (s, 9H).


Step 2: Preparation of 5-(2,4-difluorobenzyl)thiazol-2-amine



Dissolved *tert*-butyl (5-((2,4-difluorophenyl)(hydroxy)methyl)thiazol-2-yl)carbamate (0.165 g, 0.4819 mmol) in methylene chloride (2.40 mL) and added triethylsilane (383 μ L, 2.40 mmol) and 2,2,2-trifluoroacetic acid (294 μ L, 3.85 mmol) in a 50mL round bottom flask. Stirred 16 h at room temperature. After 9 h, added 0.1 mL more of 2,2,2-trifluoroacetic acid and stirred 16 h again. Concentrated to remove solvent, then diluted with ethyl acetate (15 mL) and washed with saturated aqueous sodium bicarbonate (10 mL), then brine (15 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated. 5-(2,4-Difluorobenzyl)thiazol-2-amine is taken crude to next step. ¹H NMR (300 MHz, Chloroform-*d*) δ 7.18 (d, *J* = 6.4 Hz, 1H), 6.91 - 6.82 (m, 2H), 6.80 (d, *J* = 1.1 Hz, 1H), 3.95 (s, 2H).

Step 3: Preparation of

N-(5-(2,4-difluorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide




Combined 5-(2,4-difluorobenzyl)thiazol-2-amine (0.158 g, 0.6983 mmol) and

- 5 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.109 g, 0.6983 mmol) in a 25 mL round bottom flask and added 2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (0.224 g, 0.6983 mmol). Dissolved in *N,N'*-dimethylformamide (3.49 mL) and added *N,N,N,N*-diisopropylethyl amine (180 μ L, 1.04 mmol). Stirred at room temperature 16 h. Diluted with ethyl acetate (15 mL) and washed 3 times with water (10 mL), then brine (15 mL). The combined organic
- 10 layers were dried over sodium sulfate, filtered, and concentrated. Purified reaction by column chromatography (eluting with 0-100% ethyl acetate/hexanes through 24 g of silica gel) to give *N*-(5-(2,4-difluorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide as a pale yellow solid (93 mg, 0.255 mmol, 37%). ^1H NMR (300 MHz, Chloroform-*d*) δ 7.26 - 7.15 (m, 2H), 6.84 (t, J = 9.3 Hz, 2H), 4.10 (s, 2H), 3.46 (s, 3H), 2.98 (t, J = 8.6 Hz, 2H), 2.61 (t, J = 8.6 Hz, 2H); LCMS
- 15 (ESI) m/z 365.4 $[\text{M}+\text{H}]^+$.


Example 235. Preparation of

N-(5-(2,5-difluorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (235)



20

Step 1: Preparation of *tert*-butyl (5-((2,5-difluorophenyl)(hydroxy)methyl)thiazol-2-yl)carbamate




25

Dissolved *tert*-butyl (5-bromothiazol-2-yl)carbamate (0.5 g, 1.79 mmol) in tetrahydrofuran (8.95 mL) and cooled to -78 °C. Carefully added *n*-butyllithium (1.6M in hexanes, 1.14 mL, 2.86 mmol) and stirred for 10 minutes, followed by 2,5-difluorobenzaldehyde (271 μ L, 2.50 mmol). Stirred at -78 °C for 3 h. Warmed to room temperature and quenched with saturated aqueous ammonium chloride (15 mL). Extracted with ethyl acetate (20 mL) and washed with brine (15 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated. Purified reaction by column chromatography (eluting with 0-50% ethyl acetate/hexanes through 24 g of silica gel) to give *tert*-butyl

(5-((2,5-difluorophenyl)(hydroxy)methyl)thiazol-2-yl)carbamate as a yellow solid (150 mg, 0.438 mmol, 24%). ¹H NMR (300 MHz, Chloroform-*d*) δ 7.37 (d, *J* = 3.0 Hz, 1H), 7.17 (s, 1H), 7.10 - 6.92 (m, 2H), 6.27 (s, 1H), 1.53 (s, 9H).


5 Step 2: Preparation of 5-(2,5-difluorobenzyl)thiazol-2-amine




Dissolved *tert*-butyl (5-((2,5-difluorophenyl)(hydroxy)methyl)thiazol-2-yl)carbamate (0.150 g, 0.4381 mmol) in 5 mL dichloromethane and added 2,2,2-trifluoroacetic acid (267 μL, 3.50 mmol) and triethylsilane (348 μL, 2.19 mmol). Stirred 16 h at room temperature. A second load of
 10 2,2,2-trifluoroacetic acid (267 μL, 3.50 mmol) and triethylsilane (348 μL, 2.19 mmol) was added. Reaction was stirred for another night at room temperature. Concentrated to remove solvent and 2,2,2-trifluoroacetic acid, then diluted in dichloromethane (20 mL) and washed with saturated aqueous sodium bicarbonate (15 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated. Crude product is taken to the next step. ¹H NMR (300 MHz, Chloroform-*d*) δ 6.99 - 6.84 (m,
 15 2H), 6.84 - 6.74 (m, 1H), 6.70 (s, 1H), 3.83 (s, 2H).

Step 3: Preparation of


N-(5-(2,5-difluorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide




20 Combined 5-(2,5-difluorobenzyl)thiazol-2-amine (0.088 g, 0.3889 mmol) and 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (60.7 mg, 0.3889 mmol) with 2-(3H-[1,2,3]triazolo[4,5-*b*]pyridin-3-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (0.137 g, 0.4277 mmol) in a 25mL round bottom flask and dissolved in *N,N'*-dimethylformamide (2.0 mL). Added *N,N,N,N*-diisopropylethyl amine (101 μL, 0.5833 mmol) and stirred 16 h at room temperature. Diluted with
 25 ethyl acetate (15 mL) and washed 3 times with water (10 mL) and once with brine (10 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated. Purified reaction by column chromatography (eluting with 0-100% ethyl acetate/hexanes through 24 g of silica gel) to give *N*-(5-(2,5-difluorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide as a slightly yellow solid (32 mg, 0.088 mmol, 23%). ¹H NMR (300 MHz, Chloroform-*d*) δ 7.28 (s, 1H), 7.04 (s,
 30 1H), 6.94 (d, *J* = 7.7 Hz, 2H), 4.12 (s, 2H), 3.46 (d, *J* = 0.9 Hz, 3H), 2.99 (t, *J* = 8.6 Hz, 2H), 2.61 (t, *J* = 8.6 Hz, 2H); LCMS (ESI) *m/z* 365.5 [*M*+*H*]⁺.

Example 236. Preparation of***N*-(5-(3-chlorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (236)**


Step 1: Preparation of

5 ***N*-(5-(3-chlorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide**

To a stirred solution of 5-(3-chlorobenzyl)thiazol-2-amine (0.100 g, 0.45 mmol), 1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxylic acid (0.083 g, 0.54 mmol) and 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.200 g, 0.54 mmol) in *N,N*-dimethylformamide (5.00 mL) was added *N,N*-diisopropylethylamine (0.170 g, 1.34 mmol). After addition, the reaction mixture was stirred at room temperature for 2 h. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Sunfire prep C18 10 μ m OBD 19*250 mm; mobile phase: [water (0.05% trifluoroacetic acid)-acetonitrile]; B%: 60%-88%, 15 minutes) to give *N*-(5-(3-chlorobenzyl)thiazol-2-yl)-1-methyl-6-oxo-1,6-dihydropyridazine-3-carboxamide (0.070 g, 0.19 mmol, 43.2%) as a white solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 12.30 (s, 1H), 7.90 (d, *J* = 9.7 Hz, 1H), 7.45 - 7.33 (m, 3H), 7.29 (dd, *J* = 16.6, 7.9 Hz, 2H), 7.05 (d, *J* = 9.7 Hz, 1H), 4.15 (s, 2H), 3.77 (s, 3H); LCMS (ESI) *m/z*: 361.0 [M+H]⁺.

Example 237. Preparation of20 ***N*-(5-((3-fluorophenyl)(methyl)amino)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (237)**


Step 1: Preparation of *N*-(3-fluorophenyl)-*N*-methylthiazole-2,5-diamine



To a stirred solution of 5-bromothiazol-2-amine (0.30 g, 1.68 mmol) in acetone (10.0 mL) at room temperature was added 3-fluoro-*N*-methylbenzenamine (0.31 g, 2.51 mmol) and cesium carbonate (0.66 g, 2.01 mmol). The reaction mixture was heated to 55 °C and stirred at this temperature for 2 h. The reaction mixture was cooled to room temperature and filtered. The filtrate was concentrated. The residue was diluted with water (20 mL) and extracted with ethyl acetate (30 mL x 2). The combined organic layers were washed with brine (20 mL x 2), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel, petroleum ether/ethyl acetate = 4/1) to give *N*-(3-fluorophenyl)-*N*-methylthiazole-2,5-diamine (0.26 g, 1.17 mmol, 69.6%) as a yellow solid. LCMS (ESI) *m/z*: 224.1 [*M*+*H*]⁺.

Step 2: Preparation of

N-(5-((3-fluorophenyl)(methyl)amino)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide



To a solution of *N*-(3-fluorophenyl)-*N*-methylthiazole-2,5-diamine (0.25 g, 1.12 mmol), 1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid (0.21 g, 1.35 mmol) and 1-[*bis*(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (0.51 g, 1.35 mmol) in *N,N*-dimethylformamide (5 mL) was added triethylamine (0.34 g, 3.36 mmol). The mixture was stirred at room temperature for 2 h. The crude sample was dissolved in minimal *N,N*-dimethylformamide and purified *via* prep-HPLC (Boston C18 21*250 mm 10 μm column; acetonitrile/0.01% aqueous trifluoroacetic acid) to give *N*-(5-((3-fluorophenyl)(methyl)amino)thiazol-2-yl)-1-methyl-6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxamide (0.228 g, 0.63 mmol, 56.2%) as a white solid. ¹H NMR (500 MHz, Dimethylsulfoxide-*d*₆) δ 11.99 (s, 1H), 7.38 (s, 1H), 7.24 (dd, *J* = 15.2, 9.0 Hz, 1H), 6.66 - 6.60 (m, 3H), 3.37 (s, 3H), 3.27 (s, 3H), 2.83 (t, *J* = 8.5 Hz, 2H), 2.53 (t, *J* = 8.5 Hz, 2H); LCMS (ESI) *m/z*: 362.0 [*M*+*H*]⁺.

Example 238. Characterization Data of Compounds of the Invention

The following compounds were synthesized by methods similar to those described above.

Compound **238**: ^1H NMR (300 MHz, Chloroform-*d*) δ 8.57 (d, J = 9.1 Hz, 1H), 8.17 (d, J = 3.7 Hz, 2H), 8.09 – 7.93 (m, 2H), 7.41 (s, 1H), 7.09 (d, J = 7.6 Hz, 1H), 6.99 (d, J = 5.3 Hz, 2H), 4.37 (s, 2H);

5 LCMS (ESI) m/z : 349.2 $[\text{M}+\text{H}]^+$.

Compound **239**: ^1H NMR (300 MHz, Chloroform-*d*) δ 10.45 (s, 1H), 8.36 (d, J = 8.4 Hz, 1H), 8.33 – 8.20 (m, 1H), 7.87 (s, 1H), 7.59 (dd, J = 8.5, 2.4 Hz, 1H), 7.30 (s, 1H), 7.10 – 6.84 (m, 3H), 3.99 (s, 2H), 2.80 (s, 3H), 2.64 (s, 3H); LCMS (ESI) m/z : 337.4 $[\text{M}+\text{H}]^+$.

10 Compound **240**: ^1H NMR (300 MHz, DMSO-*d*₆) δ 10.93 (s, 1H), 8.33 (dd, J = 2.5, 0.8 Hz, 1H), 8.04 (dd, J = 8.5, 0.8 Hz, 1H), 7.81 (d, J = 7.0 Hz, 1H), 7.72 (dd, J = 8.5, 2.4 Hz, 1H), 7.34 (td, J = 8.0, 6.3 Hz, 1H), 7.27 – 6.96 (m, 4H), 6.93 (dd, J = 2.0, 0.6 Hz, 1H), 6.60 (dd, J = 7.0, 2.0 Hz, 1H), 3.98 (s, 2H), 3.45 (s, 3H); LCMS (ESI) m/z : 338.4 $[\text{M}+\text{H}]^+$.

15 Compound **241**: ^1H NMR (300 MHz, Chloroform-*d*) δ 10.54 (s, 1H), 8.43 – 8.17 (m, 3H), 7.65 – 7.45 (m, 2H), 7.11 (dt, J = 10.2, 8.3 Hz, 1H), 7.03 – 6.82 (m, 2H), 3.95 (s, 2H), 2.85 (s, 3H); LCMS (ESI) m/z : 341.4 $[\text{M}+\text{H}]^+$.

Compound **242**: ^1H NMR (300 MHz, DMSO-*d*₆) δ 10.39 (s, 1H), 9.04 (d, J = 5.0 Hz, 1H), 8.38 (d, J = 2.3 Hz, 1H), 8.19 (d, J = 8.5 Hz, 1H), 7.96 (d, J = 5.0 Hz, 1H), 7.82 (dd, J = 8.5, 2.4 Hz, 1H), 7.25 – 6.88 (m, 3H), 4.01 (s, 2H), 2.78 (s, 3H); LCMS (ESI) m/z : 341.4 $[\text{M}+\text{H}]^+$.

20 Compound **243**: ^1H NMR (300 MHz, Chloroform-*d*) δ 10.54 (s, 1H), 8.43 – 8.20 (m, 3H), 7.57 (d, J = 8.6 Hz, 2H), 7.33 – 7.13 (m, 3H), 7.13 – 7.00 (m, 1H), 3.97 (s, 2H), 2.86 (s, 3H); LCMS (ESI) m/z : 339.3 $[\text{M}+\text{H}]^+$.

Compound **244**: ^1H NMR (300 MHz, Chloroform-*d*) δ 10.44 (s, 1H), 8.95 (d, J = 5.0 Hz, 1H), 8.38 (d, J = 8.5 Hz, 1H), 8.26 (d, J = 2.4 Hz, 1H), 8.09 – 7.92 (m, 1H), 7.60 (d, J = 2.3 Hz, 1H), 7.23 (dd, J = 7.0, 2.1 Hz, 1H), 7.09 (d, J = 8.5 Hz, 2H), 3.96 (s, 2H), 2.86 (s, 3H); LCMS (ESI) m/z : 357.4 $[\text{M}+\text{H}]^+$.

25 Compound **245**: ^1H NMR (500 MHz, MeOD) δ 8.62 (s, 1H), 7.37 – 7.34 (m, 1H), 7.17 – 7.15 (d, J = 7.7 Hz, 1H), 7.13 – 7.11 (d, J = 9.7 Hz, 1H), 7.02 – 7.00 (m, 1H), 4.37 (s, 2H), 3.53 – 3.42 (m, 3H), 3.04 – 2.93 (m, 2H), 2.62 – 2.60 (m, 2H); LCMS (ESI) m/z : 343.1 $[\text{M}+\text{H}]^+$.

30 Compound **246**: ^1H NMR (500 MHz, DMSO-*d*₆) δ 10.43 (s, 1H), 8.24 (d, J = 9.1 Hz, 1H), 7.68 (d, J = 9.1 Hz, 1H), 7.27 (ddd, J = 29.5, 23.6, 12.8 Hz, 4H), 3.38 (s, 3H), 3.21 (t, J = 7.8 Hz, 2H), 3.05 (t, J = 7.8 Hz, 2H), 2.86 (t, J = 8.5 Hz, 2H), 2.54 (t, J = 8.5 Hz, 2H); LCMS (ESI) m/z : 372.1 $[\text{M}+\text{H}]^+$.

Compound **247**: ^1H NMR (500 MHz, DMSO-*d*₆) δ 10.41 (s, 1H), 8.28 (d, J = 9.0 Hz, 1H), 7.70 (d, J = 9.0 Hz, 1H), 6.97 (d, J = 4.0 Hz, 1H), 6.87 (d, J = 3.5 Hz, 1H), 4.42 (s, 2H), 3.38 (s, 2H), 2.85 (t, J = 8.5 Hz, 2H), 2.54 (t, J = 8.5 Hz, 2H); LCMS (ESI) m/z : 364.0 $[\text{M}+\text{H}]^+$.

35 Compound **248**: ^1H NMR (400 MHz, Dimethylsulfoxide-*d*₆) δ 10.62 (s, 1H), 8.67 (s, 1H), 8.29 (s, 1H), 8.02 (d, J = 8 Hz, 1H), 7.98 (d, J = 9.5 Hz, 1H), 7.71 (d, J = 8.5 Hz, 1H), 7.30 (t, J = 6 Hz, 2H), 7.12 (t, J = 8.3 Hz, 2H), 6.44 (t, J = 9.5 Hz, 2H), 3.95 (s, 2H), 3.50 (s, 3H); LCMS (ESI) m/z : 338.1 $[\text{M}+\text{H}]^+$.

40 Compound **249**: ^1H NMR (500 MHz, DMSO-*d*₆) δ 9.52 (s, 1H), 8.20 (d, J = 1.5 Hz, 1H), 7.71 (d, J = 8.6 Hz, 1H), 7.58 (dd, J = 8.6, 2.1 Hz, 1H), 7.43 (d, J = 1.5 Hz, 1H), 7.37 – 7.19 (m, 4H), 6.11 (s, 1H), 4.74 (s, 2H), 4.14 (t, J = 5.3 Hz, 2H), 4.01 – 3.87 (m, 4H); LCMS (ESI) m/z : 368.0 $[\text{M}+\text{H}]^+$.

Compound **250**: ^1H NMR (500 MHz, CDCl_3) δ 8.00 (dd, $J = 29.7, 5.2$ Hz, 2H), 7.45 (dd, $J = 8.6, 2.3$ Hz, 1H), 7.24 – 7.10 (m, 3H), 7.04 (d, $J = 7.1$ Hz, 1H), 6.94 (s, 1H), 4.81 (s, 4H), 4.23 (s, 4H), 3.88 (s, 2H); LCMS (ESI) m/z : 344.0 $[\text{M}+\text{H}]^+$.

Compound **251**: ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 10.05 (s, 1H), 8.33 (s, 1H), 8.08 - 8.06 (d, $J = 8.4$ Hz, 1H), 7.88 (s, 1H), 7.75 - 7.72 (d, $J = 8.6$ Hz, 1H), 7.43 – 7.26 (m, 1H), 7.12 - 7.10 (t, $J = 7.2$ Hz, 2H), 7.04 - 7.01 (t, $J = 8.6$ Hz, 1H), 3.99 (s, 2H), 3.79 (s, 3H), 2.17 (s, 3H); LCMS (ESI) m/z : 353.0 $[\text{M}+\text{H}]^+$.

Compound **252**: ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 10.23 (s, 1H), 9.19 (s, 1H), 8.71 (s, 1H), 8.34 (d, $J = 2.0$ Hz, 1H), 8.17 (d, $J = 8.5$ Hz, 1H), 7.79 (dd, $J = 8.5, 2.0$ Hz, 1H), 7.35 (dd, $J = 14.5, 8.0$ Hz, 1H), 7.12 (t, $J = 7.5$ Hz, 2H), 7.04 (dd, $J = 12.0, 5.5$ Hz, 1H), 3.99 (s, 2H), 2.64 (s, 3H); LCMS (ESI) m/z : 323.1 $[\text{M}+\text{H}]^+$.

Compound **253**: ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 10.42 (s, 1H), 8.23 (d, $J = 9.0$ Hz, 1H), 7.62 (d, $J = 9.0$ Hz, 1H), 7.33–7.21 (m, 5H), 4.26 (s, 2H), 3.38 (s, 3H), 2.85 (t, $J = 8.5$ Hz, 2H), 2.54 (d, $J = 8.5$ Hz, 2H); LCMS (ESI) m/z : 324.1 $[\text{M}+\text{H}]^+$.

Compound **254**: ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 11.06 (s, 1H), 8.22 (d, $J = 8.5$ Hz, 1H), 7.96 (d, $J = 10.0$ Hz, 1H), 7.89 (d, $J = 9.0$ Hz, 1H), 7.45 (s, 1H), 7.38–7.35 (m, 1H), 7.32–7.30 (m, 2H), 7.06 (d, $J = 10.0$ Hz, 1H), 4.45 (s, 2H), 3.62 (s, 3H); LCMS (ESI) m/z : 356.0 $[\text{M}+\text{H}]^+$.

Compound **255**: ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 8.37 (d, $J = 1.6$ Hz, 1H), 7.85 (s, 1H), 7.39 (s, 1H), 7.34 (t, $J = 7.8$ Hz, 1H), 7.28–7.25 (m, 2H), 4.12 (s, 2H), 3.39 (s, 3H), 3.16 (t, $J = 8.4$ Hz, 2H), 2.60 (t, $J = 8.4$ Hz, 2H);

Compound **256**: ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 10.10 (s, 1H), 8.34–8.35 (d, $J = 2.0$ Hz, 1H), 8.04–8.06 (d, $J = 8.5$ Hz, 1H), 7.89–7.91 (d, $J = 10.0$ Hz, 1H), 7.73–7.75 (m, 1H), 7.32–7.34 (m, 2H), 7.22–7.28 (m, 2H), 7.05–7.07 (m, 1H), 4.08–4.09 (t, $J = 3.5$ Hz, 1H), 3.98 (s, 2H); LCMS (ESI) m/z : 381.1 $[\text{M}+\text{H}]^+$.

Compound **257**: ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 10.90 (s, 1H), 8.30 (d, $J = 9.2$ Hz, 1H), 7.93 (d, $J = 10.0$ Hz, 1H), 7.70 (d, $J = 9.2$ Hz, 1H), 7.40–7.26 (m, 3H), 7.08 (d, $J = 10.0$ Hz, 1H), 4.30 (s, 2H), 4.16 (t, $J = 7.2$ Hz, 2H), 1.88–1.79 (m, 2H), 0.93 (t, $J = 7.4$ Hz, 3H); LCMS (ESI) m/z : 384.1 $[\text{M}+\text{H}]^+$.

Compound **258**: ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 10.84 (s, 1H), 8.40–8.41 (d, $J = 2.5$ Hz, 1H), 8.31 (d, $J = 1.5$ Hz, 1H), 8.02–8.03 (d, $J = 8.5$ Hz, 1H), 7.89–7.91 (m, 1H), 7.71–7.73 (m, 1H), 7.32–7.36 (m, 2H), 7.10–7.12 (m, 2H), 7.03 (m, 1H), 6.42–6.46 (d, $J = 10.0$ Hz, 1H), 3.97 (s, 2H), 3.39 (m, 1H); LCMS (ESI) m/z : 364.1 $[\text{M}+\text{H}]^+$.

Compound **259**: ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 11.28 (s, 1H), 8.75 (d, $J = 2.7$ Hz, 1H), 8.40 (d, $J = 9.2$ Hz, 1H), 8.02 (dd, $J = 9.5, 2.7$ Hz, 1H), 7.87 (d, $J = 9.3$ Hz, 1H), 7.34 (t, $J = 8.1$ Hz, 1H), 7.19 (t, $J = 2.2$ Hz, 1H), 7.10 – 6.99 (m, 2H), 6.46 (d, $J = 9.5$ Hz, 1H), 5.39 (s, 2H), 3.52 (s, 3H); LCMS (ESI) m/z : 371.1 $[\text{M}+\text{H}]^+$.

Compound **260**: ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 9.83 (s, 1H), 8.46 (s, 1H), 8.14 (d, $J = 8.5$ Hz, 1H), 7.96 (d, $J = 8.0$ Hz, 1H), 7.34 (dd, $J = 15.6, 8.1$ Hz, 1H), 6.91 (dd, $J = 24.8, 9.7$ Hz, 2H), 6.80 (t, $J = 8.4$ Hz, 1H), 5.13 (s, 2H), 3.37 (s, 3H), 2.86 (t, $J = 8.4$ Hz, 2H), 2.61 – 2.52 (m, 2H).

Compound **261**: ^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 9.84 (s, 1H), 8.46 (d, $J = 1.9$ Hz, 1H), 8.14 (d, $J = 8.5$ Hz, 1H), 7.95 (dd, $J = 8.5, 2.2$ Hz, 1H), 7.33 (t, $J = 8.2$ Hz, 1H), 7.14 (t, $J = 2.1$ Hz, 1H), 7.06 – 6.96

(m, 2H), 5.14 (s, 2H), 3.37 (s, 3H), 2.86 (t, $J = 8.5$ Hz, 2H), 2.53 (t, $J = 8.5$ Hz, 2H); LCMS (ESI) m/z : 373.0 $[M+H]^+$.

Compound **262**: ^1H NMR (500 MHz, DMSO- d_6) δ 10.24 (s, 1H), 8.49 (d, $J = 1.8$ Hz, 1H), 8.20 (d, $J = 8.5$ Hz, 1H), 8.03 – 7.90 (m, 2H), 7.33 (t, $J = 8.2$ Hz, 1H), 7.17 – 6.98 (m, 4H), 5.16 (s, 2H), 3.80 (s, 3H); LCMS (ESI) m/z : 371.1 $[M+H]^+$.

Compound **263**: ^1H NMR (500 MHz, DMSO- d_6) δ 10.63 (s, 1H), 8.69 (d, $J = 2.6$ Hz, 1H), 8.47 (d, $J = 1.9$ Hz, 1H), 8.17 (d, $J = 8.5$ Hz, 1H), 7.95 (ddd, $J = 10.9, 9.0, 2.5$ Hz, 2H), 7.33 (t, $J = 8.2$ Hz, 1H), 7.14 (t, $J = 2.1$ Hz, 1H), 7.06 – 6.97 (m, 2H), 6.44 (d, $J = 9.5$ Hz, 1H), 5.14 (s, 2H), 3.51 (s, 3H); LCMS (ESI) m/z : 370.0 $[M+H]^+$.

Compound **264**: ^1H NMR (400 MHz, DMSO- d_6) δ 10.72 (s, 1H), 8.67 (d, $J = 2.4$ Hz, 1H), 8.47 (d, $J = 1.6$ Hz, 1H), 8.17 (d, $J = 8.4$ Hz, 1H), 7.95 (dd, $J = 9.6, 2.8$ Hz, 1H), 7.91 (dd, $J = 8.8, 2.4$ Hz, 1H), 7.33 (t, $J = 8.2$ Hz, 1H), 7.14 (t, $J = 4.0$ Hz, 1H), 7.04–7.00 (m, 2H), 6.43 (d, $J = 9.6$ Hz, 1H), 5.14 (s, 2H), 4.01–3.95 (m, 2H), 1.28 (t, $J = 7.2$ Hz, 3H); LCMS (ESI) m/z : 384.1 $[M+H]^+$.

Compound **265**: ^1H NMR (500 MHz, DMSO- d_6) δ 9.83 (s, 1H), 8.45 (d, $J = 2.3$ Hz, 1H), 8.17 – 8.09 (m, 1H), 7.95 (dd, $J = 8.6, 2.3$ Hz, 1H), 7.36 (t, $J = 9.1$ Hz, 1H), 7.30 (dd, $J = 6.1, 3.1$ Hz, 1H), 7.08 – 6.98 (m, 1H), 5.12 (s, 2H), 3.37 (s, 3H), 2.86 (t, $J = 8.5$ Hz, 2H), 2.53 (t, $J = 8.5$ Hz, 2H); LCMS (ESI) m/z : 391.1 $[M+H]^+$.

Compound **266**: ^1H NMR (500 MHz, DMSO- d_6) δ 10.64 (s, 1H), 8.69 (d, $J = 2.7$ Hz, 1H), 8.46 (d, $J = 2.3$ Hz, 1H), 8.16 (d, $J = 8.6$ Hz, 1H), 7.99 (dd, $J = 9.5, 2.7$ Hz, 1H), 7.91 (dd, $J = 8.6, 2.4$ Hz, 1H), 7.36 (t, $J = 9.1$ Hz, 1H), 7.30 (dd, $J = 6.1, 3.1$ Hz, 1H), 7.09 – 7.01 (m, 1H), 6.44 (d, $J = 9.5$ Hz, 1H), 5.12 (s, 2H), 3.51 (s, 3H); LCMS (ESI) m/z : 388.0 $[M+H]^+$.

Compound **267**: ^1H NMR (400 MHz, DMSO- d_6) δ 11.17 (s, 1H), 8.72 (d, $J = 2.4$ Hz, 1H), 8.27 (d, $J = 9.6$ Hz, 1H), 8.00 (dd, $J = 9.6, 2.4$ Hz, 1H), 7.62 (d, $J = 9.2$ Hz, 1H), 7.34–7.21 (m, 2H), 6.45 (d, $J = 9.6$ Hz, 1H), 4.34 (s, 2H), 3.51 (s, 3H); LCMS (ESI) m/z : 375.1 $[M+H]^+$.

Compound **268**: ^1H NMR (500 MHz, DMSO- d_6) δ 9.70 (s, 1H), 8.16 (d, $J = 2.5$ Hz, 1H), 8.03 (d, $J = 9.0$ Hz, 1H), 7.69 (s, 1H), 7.59 (dd, $J = 9.0, 3.0$ Hz, 1H), 7.55 (d, $J = 8.0$ Hz, 1H), 7.48 (d, $J = 8.0$ Hz, 1H), 7.38 (t, $J = 8.0$ Hz, 1H), 5.19 (s, 2H), 3.36 (s, 3H), 2.85 (t, $J = 8.5$ Hz, 2H), 2.52 (t, $J = 8.5$ Hz, 2H); LCMS (ESI) m/z : 417.0/419.0 $[M+H]^+$.

Compound **269**: ^1H NMR (500 MHz, DMSO- d_6) δ 9.72 (s, 1H), 8.18 (d, $J = 3.0$ Hz, 1H), 8.05 (d, $J = 9.0$ Hz, 1H), 7.87–7.85 (m, 1H), 7.84 (s, 1H), 7.73 (d, $J = 9.0$ Hz, 1H), 7.60 (dd, $J = 9.0, 3.0$ Hz, 1H), 5.25 (s, 2H), 3.36 (s, 3H), 2.85 (t, $J = 8.5$ Hz, 2H), 2.52 (t, $J = 8.5$ Hz, 2H); LCMS (ESI) m/z : 382.1 $[M+H]^+$.

Compound **270**: ^1H NMR (400 MHz, DMSO- d_6) δ 9.73 (s, 1H), 8.18 (d, $J = 3.2$ Hz, 1H), 8.05 (d, $J = 9.0$ Hz, 1H), 7.87 (dd, $J = 8.4, 2.4$ Hz, 1H), 7.83 (s, 1H), 7.73 (d, $J = 9.6$ Hz, 1H), 7.60 (dd, $J = 9.2, 3.2$ Hz, 1H), 5.24 (s, 2H), 3.35 (s, 3H), 2.85 (t, $J = 8.6$ Hz, 2H), 2.52 (d, $J = 7.0$ Hz, 2H); LCMS (ESI) m/z : 382.0 $[M+H]^+$.

Compound **271**: ^1H NMR (500 MHz, DMSO- d_6) δ 10.46 (s, 1H), 8.27 (d, $J = 9.0$ Hz, 1H), 7.67 (d, $J = 9.0$ Hz, 1H), 7.39 (t, $J = 3.5$ Hz, 1H), 6.97 (t, $J = 3.5$ Hz, 2H), 4.47 (s, 2H), 3.53 (s, 3H), 2.85 (t, $J = 8.5$ Hz, 2H), 2.54 (t, $J = 9.0$ Hz, 2H); LCMS (ESI) m/z : 330.1 $[M+H]^+$.

Compound **272**: ^1H NMR (400 MHz, DMSO- d_6) δ 10.90 (s, 1H), 8.64 (d, $J = 2.4$ Hz, 1H), 8.32 (d, $J = 1.9$ Hz, 1H), 8.08 (d, $J = 8.6$ Hz, 1H), 7.96 (dd, $J = 9.6, 2.5$ Hz, 1H), 7.70 (dd, $J = 8.6, 2.1$ Hz, 1H),

7.35 (d, $J = 6.4$ Hz, 1H), 7.10 (dd, $J = 21.8, 15.3$ Hz, 3H), 6.46 (d, $J = 9.5$ Hz, 1H), 5.55 (d, $J = 7.4$ Hz, 1H), 4.89 (d, $J = 7.2$ Hz, 4H), 3.98 (s, 2H); LCMS (ESI) m/z : 380.0 $[M+H]^+$.

Compound **273**: ^1H NMR (400 MHz, DMSO- d_6) δ 10.90 (s, 1H), 8.64 (d, $J = 2.4$ Hz, 1H), 8.32 (d, $J = 1.9$ Hz, 1H), 8.08 (d, $J = 8.5$ Hz, 1H), 7.96 (dd, $J = 9.6, 2.5$ Hz, 1H), 7.70 (dd, $J = 8.6, 2.3$ Hz, 1H),
5 7.30 (ddd, $J = 22.2, 10.8, 5.7$ Hz, 4H), 6.46 (d, $J = 9.6$ Hz, 1H), 5.67 – 5.46 (m, 1H), 4.89 (d, $J = 7.2$ Hz, 4H), 3.97 (s, 2H); LCMS (ESI) m/z : 396.1 $[M+H]^+$.

Compound **274**: ^1H NMR (500 MHz, DMSO- d_6) δ 9.80 (s, 1H), 8.59 – 8.45 (m, 2H), 8.35 (s, 1H), 8.04 (d, $J = 8.4$ Hz, 1H), 7.88 (s, 1H), 7.79 (d, $J = 6.5$ Hz, 1H), 4.02 (s, 2H), 3.36 (s, 3H), 2.85 (t, $J = 8.5$ Hz, 2H), 2.53 (d, $J = 8.5$ Hz, 2H); LCMS (ESI) m/z : 358.0 $[M+H]^+$.

Compound **275**: ^1H NMR (400 MHz, DMSO- d_6) δ 10.16 (s, 1H), 8.50 (dd, $J = 10.9, 2.0$ Hz, 2H), 8.36 (d, $J = 1.9$ Hz, 1H), 8.08 (d, $J = 8.5$ Hz, 1H), 7.93 (d, $J = 9.7$ Hz, 1H), 7.86 (t, $J = 2.1$ Hz, 1H), 7.79 (dd, $J = 8.5, 2.3$ Hz, 1H), 7.06 (d, $J = 9.7$ Hz, 1H), 4.01 (s, 2H), 3.77 (s, 3H); LCMS (ESI) m/z : 356.1 $[M+H]^+$.

Compound **276**: ^1H NMR (500 MHz, DMSO- d_6) δ 10.66 (s, 1H), 8.68 (d, $J = 2.6$ Hz, 1H), 8.52 (dd, $J = 11.3, 2.0$ Hz, 2H), 8.36 (d, $J = 2.1$ Hz, 1H), 8.05 (d, $J = 8.6$ Hz, 1H), 7.98 (dd, $J = 9.5, 2.7$ Hz, 1H), 7.89 (t, $J = 2.0$ Hz, 1H), 7.78 (dd, $J = 8.6, 2.3$ Hz, 1H), 6.44 (d, $J = 9.5$ Hz, 1H), 4.02 (s, 2H), 3.50 (s, 3H); LCMS (ESI) m/z : 355.0 $[M+H]^+$.

Compound **277**: ^1H NMR (400 MHz, DMSO- d_6) δ 9.73 (s, 1H), 8.85 (d, $J = 8.0$ Hz, 2H), 8.37 (d, $J = 1.6$ Hz, 1H), 8.14 (s, 1H), 8.04 (d, $J = 8.4$ Hz, 1H), 7.79 (dd, $J = 8.4, 2.4$ Hz, 1H), 4.11 (s, 2H), 3.36 (s, 3H), 2.85 (t, $J = 8.4$ Hz, 2H), 2.53 (d, $J = 8.4$ Hz, 2H); LCMS (ESI) m/z : 392.0 $[M+H]^+$.

Compound **278**: ^1H NMR (400 MHz, DMSO- d_6) δ 10.11 (s, 1H), 8.77 (d, $J = 5.2$ Hz, 1H), 8.36 (d, $J = 2$ Hz, 1H), 8.07 (d, $J = 8.4$ Hz, 1H), 7.93 (d, $J = 9.6$ Hz, 1H), 7.77-7.82 (m, 2H), 7.60-7.63 (m, 1H), 7.06 (d, $J = 9.2$ Hz, 1H), 4.24 (s, 2H), 3.78 (s, 3H); LCMS (ESI) m/z : 390.1 $[M+H]^+$.

Compound **279**: ^1H NMR (400 MHz, DMSO- d_6) δ 8.77 (d, $J = 5.2$ Hz, 1H), 8.65 (d, $J = 2$ Hz, 1H), 8.34 (s, 1H), 8.04 (d, $J = 8.8$ Hz, 1H), 7.93-7.99 (m, 1H), 7.71-7.78 (m, 2H), 7.60-7.63 (m, 1H), 6.41 (d, $J = 9.6$ Hz, 1H), 4.22 (s, 2H), 3.48 (s, 3H); LCMS (ESI) m/z : 389.1 $[M+H]^+$.

Compound **280**: ^1H NMR (500 MHz, DMSO- d_6) δ 10.22 (s, 1H), 8.36 (s, 1H), 8.34 - 8.31 (d, $J = 1.9$ Hz, 1H), 8.07-8.06 (d, $J = 8.5$ Hz, 1H), 7.76-7.74 (m, 1H), 7.35-7.33 (m, 1H), 7.12-7.10 (t, $J = 7.9$ Hz, 2H), 7.04-7.01 (m, 5.2 Hz, 1H), 3.99 (s, 2H), 3.85 (s, 3H); LCMS (ESI) m/z : 416.9 $[M+H]^+$.

Compound **281**: ^1H NMR (400 MHz, DMSO- d_6) δ 9.87 (d, $J = 13.2$ Hz, 1H), 7.79 (d, $J = 8.8$ Hz, 1H), 7.71 (d, $J = 2.4$ Hz, 1H), 7.40-7.34 (m, 1H), 7.22-7.16 (m, 3H), 7.08-7.04 (m, 1H), 4.33 (s, 2H), 2.81 (t, $J = 8.8$ Hz, 2H), 2.52-2.49 (m, 5H); LCMS (ESI) m/z : 356.2 $[M+H]^+$.

Compound **282**: ^1H NMR (500 MHz, DMSO- d_6) δ 10.13 (s, 1H), 8.34 (d, $J = 2.0$ Hz, 1H), 8.08 (d, $J = 8.5$ Hz, 1H), 7.95 (d, $J = 10.0$ Hz, 1H), 7.76 (dd, $J = 8.5, 2.5$ Hz, 1H), 7.08 (d, $J = 9.5$ Hz, 1H), 6.91 (s, 1H), 6.87-6.85 (m, 2H), 3.93 (s, 2H), 3.79 (s, 3H), 3.75 (s, 3H); LCMS (ESI) m/z : 385.1 $[M+H]^+$.

Compound **283**: ^1H NMR (400 MHz, DMSO- d_6) δ 10.91 (s, 1H), 8.33 (d, $J = 2.3$ Hz, 1H), 8.15 (s, 1H), 8.00 (d, $J = 8.5$ Hz, 1H), 7.72 (dd, $J = 8.6, 2.4$ Hz, 1H), 7.39 – 7.26 (m, 1H), 7.16 – 7.07 (m, 2H), 7.08 – 6.99 (m, 1H), 3.98 (s, 2H), 3.35 (s, 3H); LCMS (ESI) m/z : 328.1 $[M+H]^+$.

Compound **284**: ^1H NMR (500 MHz, DMSO- d_6) δ 10.75 (s, 1H), 8.71 (d, $J = 1.5$ Hz, 1H), 8.10 (d, $J = 8.0$ Hz, 1H), 7.97-7.93 (m, 2H), 7.93-7.91 (m, 1H), 7.42-7.41 (m, 3H), 7.37-7.34 (m, 1H), 7.30-7.27 (m, 2H), 4.13 (s, 2H), 2.96 (s, 6H); LCMS (ESI) m/z : 394.2 $[M+H]^+$.

Compound **285**: ^1H NMR (500 MHz, DMSO- d_6) δ 9.76 (s, 1H), 8.30 (d, J = 1.5 Hz, 1H), 8.07-8.09 (d, J = 13.5 Hz, 1H), 7.98 (d, J = 2.0 Hz, 1H), 7.76-7.78 (m, 1H), 7.32-7.37 (m, 1H), 7.10-7.13 (m, 2H), 7.01-7.05 (m, 1H), 6.83 (d, J = 2.0 Hz, 1H), 3.98 (s, 2H), 3.86-3.89 (m, 1H), 1.15-1.18 (m, 2H), 1.01-1.05 (m, 2H); LCMS (ESI) m/z : 337.1 $[\text{M}+\text{H}]^+$.

5 Compound **286**: ^1H NMR (500 MHz, DMSO- d_6) δ 10.14 (s, 1H), 7.93 (d, J = 9.7 Hz, 1H), 7.80 (dd, J = 38.0, 5.9 Hz, 2H), 7.44 (s, 1H), 7.35 (ddd, J = 22.5, 15.0, 7.5 Hz, 3H), 7.20 (dd, J = 8.8, 2.0 Hz, 1H), 7.07 (d, J = 9.7 Hz, 1H), 4.35 (s, 2H), 3.77 (s, 3H); LCMS (ESI) m/z : 370.0 $[\text{M}+\text{H}]^+$.

10 Compound **287**: ^1H NMR (500 MHz, DMSO- d_6) δ 10.98 (s, 1H), 8.71 (d, J = 2.5 Hz, 1H), 8.33 (d, J = 2.3 Hz, 1H), 8.10 – 8.02 (m, 2H), 7.89 (t, J = 59.4 Hz, 1H), 7.71 (dd, J = 8.5, 2.4 Hz, 1H), 7.40-7.29 (m, 1H), 7.15 – 7.08 (m, 2H), 7.06 – 6.99 (m, 1H), 6.61 (d, J = 9.8 Hz, 1H), 3.98 (s, 2H); LCMS (ESI) m/z : 374.1 $[\text{M}+\text{H}]^+$.

15 Compound **288**: ^1H NMR (500 MHz, DMSO- d_6) δ 10.87 (s, 1H), 8.28 (d, J = 9.1 Hz, 1H), 7.95 (d, J = 9.6 Hz, 1H), 7.70 (d, J = 9.1 Hz, 1H), 7.36 (s, 1H), 7.29 (d, J = 7.7 Hz, 1H), 7.23 (dd, J = 21.1, 4.6 Hz, 2H), 7.09 (d, J = 9.7 Hz, 1H), 3.81 (s, 3H), 3.22 (dd, J = 8.9, 6.7 Hz, 2H), 3.06 (t, J = 7.9 Hz, 2H); LCMS (ESI) m/z : 370.1 $[\text{M}+\text{H}]^+$.

20 Compound **289**: ^1H NMR (400 MHz, DMSO- d_6) δ 11.19 (s, 1H), 9.19 (d, J = 2.0 Hz, 1H), 9.12 (s, 2H), 8.43 (dd, J = 8.4, 2.4 Hz, 1H), 8.36 (d, J = 2.0 Hz, 1H), 8.13 (d, J = 8.4 Hz, 1H), 7.75 (dd, J = 8.4, 2.4 Hz, 1H), 7.61 (d, J = 8.0 Hz, 1H), 7.37-7.33 (m, 2H), 7.29 – 7.24 (m, 2H), 4.42 (t, J = 5.8 Hz, 2H), 3.99 (s, 2H), 2.67 (t, J = 5.2 Hz, 3H); LCMS (ESI) m/z : 367.0 $[\text{M}+\text{H}]^+$.

Compound **290**: ^1H NMR (500 MHz, DMSO- d_6) δ 11.14-11.15 (d, J = 7.0 Hz, 1H), 8.95 (s, 1H), 8.35 (d, J = 2.0 Hz, 1H), 8.20-8.23 (dd, J = 12.0, 1.5 Hz, 1H), 8.11-8.12 (d, J = 8.5 Hz, 1H), 7.73-7.75 (dd, J = 8.5, 2.0 Hz, 1H), 7.28-7.36 (m, 2H), 7.23-7.27 (m, 2H), 5.46-5.48 (t, J = 6.0 Hz, 1H), 4.64-4.65 (dd, J = 6.0, 1.5 Hz, 2H), 3.98 (s, 2H); LCMS (ESI) m/z : 372.0 $[\text{M}+\text{H}]^+$.

25 Compound **291**: ^1H NMR (500 MHz, DMSO- d_6) δ 10.89 (s, 1H), 8.42-8.46 (m, 2H), 8.14-8.16 (d, J = 10.5 Hz, 1H), 7.88-7.92 (m, 2H), 7.34-7.38 (m, 1H), 7.30-7.34 (m, 1H), 7.13 (m, 1H), 6.99-7.02 (m, 2H), 6.41-6.43 (d, J = 12.0 Hz, 1H), 5.12 (s, 2H), 3.35-3.39 (m, 1H), 1.00-1.02 (d, J = 7.5 Hz, 4H); LCMS (ESI) m/z : 396.1 $[\text{M}+\text{H}]^+$.

30 Compound **292**: ^1H NMR (400 MHz, DMSO- d_6) δ 11.11 (s, 1H), 9.06 (d, J = 2.0 Hz, 1H), 8.49 (d, J = 1.6 Hz, 1H), 8.36 (dd, J = 8.0, 2.4 Hz, 1H), 8.22 (d, J = 8.8 Hz, 1H), 7.94 (dd, J = 8.8, 2.0 Hz, 1H), 7.58 (d, J = 8.0 Hz, 1H), 7.32 (t, J = 8.0 Hz, 1H), 7.14 (t, J = 2.0 Hz, 1H), 7.02 (dd, J = 8.0, 2.0 Hz, 2H), 5.57 (t, J = 6.0 Hz, 1H), 5.15 (s, 2H), 4.63 (d, J = 6.4 Hz, 2H); LCMS (ESI) m/z : 370.1 $[\text{M}+\text{H}]^+$.

35 Compound **293**: ^1H NMR (500 MHz, DMSO- d_6) δ 11.11 (s, 1H), 9.07 (d, J = 2.5 Hz, 1H), 8.49 (d, J = 2.0 Hz, 1H), 8.37 (dd, J = 8.0, 2.5 Hz, 1H), 8.23 (d, J = 8.5 Hz, 1H), 7.94 (dd, J = 8.5, 2.0 Hz, 1H), 7.60 (d, J = 8.0 Hz, 1H), 7.36 (t, J = 9.0 Hz, 1H), 7.32-7.30 (m, 1H), 7.07-7.04 (m, 1H), 5.58 (t, J = 6.0 Hz, 1H), 5.14 (s, 2H), 4.65 (d, J = 6.0 Hz, 2H); LCMS (ESI) m/z : 388.1 $[\text{M}+\text{H}]^+$.

Compound **294**: ^1H NMR (500 MHz, DMSO- d_6) δ 8.67 (s, 1H), 8.05 (d, J = 7.5 Hz, 1H), 7.92 (d, J = 7.5 Hz, 1H), 7.50-7.44 (m, 4H), 7.00 (t, J = 56 Hz, 1H), 4.18 (s, 2H), 3.27-3.19 (m, 2H), 3.17 (s, 3H), 2.48 (t, J = 8.0 Hz, 2H); LCMS (ESI) m/z : 373.1 $[\text{M}+\text{H}]^+$.

40 Compound **295**: ^1H NMR (400 MHz, DMSO- d_6) δ 11.26 (s, 1H), 9.20 (d, J = 1.6 Hz, 1H), 8.51 (dd, J = 8.0, 2.0 Hz, 1H), 8.36 (d, J = 2.0 Hz, 1H), 8.13 (d, J = 8.4 Hz, 1H), 7.84 (d, J = 8.4 Hz, 1H), 7.76

(dd, $J = 8.1, 2.0$ Hz, 1H), 7.36 – 7.33 (m, 2H), 7.29 – 7.24 (m, 2H), 7.06 (t, $J = 54.8$ Hz, 1H), 3.99 (s, 2H); LCMS (ESI) m/z : 374.0 [M+H]⁺.

Compound **296**: ¹H NMR (400 MHz, TFA) δ 8.71 (d, $J = 8.9$ Hz, 1H), 8.58 (s, 1H), 8.18 (d, $J = 8.9$ Hz, 1H), 7.80 – 7.64 (m, 2H), 7.64 – 7.41 (m, 2H), 4.09 (d, $J = 18.2$ Hz, 3H), 3.59 (ddd, $J = 20.6, 13.1, 7.0$ Hz, 6H), 3.34 (t, $J = 8.7$ Hz, 2H); LCMS (ESI) m/z : 371.1 [M+H]⁺.

Compound **297**: ¹H NMR (500 MHz, DMSO-d₆) δ 10.10 (s, 1H), 8.21 (d, $J = 1.9$ Hz, 1H), 8.07 (d, $J = 8.5$ Hz, 1H), 7.95 (d, $J = 9.6$ Hz, 1H), 7.75 (dd, $J = 8.5, 2.3$ Hz, 1H), 7.36 – 7.27 (m, 2H), 7.25 (d, $J = 1.8$ Hz, 1H), 7.19 (d, $J = 7.5$ Hz, 1H), 7.08 (d, $J = 9.6$ Hz, 1H), 3.79 (s, 3H), 2.91 (s, 4H); LCMS (ESI) m/z : 369.1 [M+H]⁺.

Compound **298**: ¹H NMR (500 MHz, MeOD) δ 8.61 (s, 1H), 8.28 (s, 1H), 8.10 (dd, $J = 9.5, 2.6$ Hz, 1H), 8.04 (s, 1H), 7.85 (d, $J = 8.1$ Hz, 1H), 7.31 (t, $J = 7.6$ Hz, 2H), 7.25 – 7.15 (m, 3H), 6.63 (d, $J = 9.5$ Hz, 1H), 3.68 (s, 3H), 2.35 (t, $J = 7.3$ Hz, 2H), 1.70 – 1.51 (m, 2H); LCMS (ESI) m/z : 346.1 [M+H]⁺.

Compound **299**: ¹H NMR (500 MHz, DMSO-d₆) δ 11.15 (s, 1H), 8.93 (d, $J = 2.5$ Hz, 1H), 8.35 (d, $J = 1.5$ Hz, 1H), 8.26 (dd, $J = 2.5$ Hz, 8.5 Hz, 1H), 8.11 (d, $J = 8.5$ Hz, 1H), 7.81 (d, $J = 8.5$ Hz, 1H), 7.74 (dd, $J = 2.5$ Hz, 8.5 Hz, 1H), 7.21–7.38 (m, 4H), 3.99 (s, 2H); LCMS (ESI) m/z : 402.0, 404.0 [M+H]⁺.

Compound **300**: ¹H NMR (500 MHz, DMSO-d₆) δ 10.12 (s, 1H), 8.58 (s, 1H), 8.19 (d, $J = 2.5$ Hz, 1H), 8.04 (d, $J = 9.2$ Hz, 1H), 7.95 (d, $J = 10.0$ Hz, 1H), 7.70 (dd, $J = 8.5, 3.0$ Hz, 1H), 7.28–7.23 (m, 1H), 7.08 (d, $J = 10.0$ Hz, 1H), 6.85 (dd, $J = 8.1, 1.6$ Hz, 1H), 6.80–6.77 (m, 1H), 6.63–6.60 (m, 1H), 3.79 (s, 3H); LCMS (ESI) m/z : 340.1 [M+H]⁺.

Compound **301**: ¹H NMR (500 MHz, DMSO-d₆) δ 10.20 (s, 1H), 8.25 (d, $J = 2.0$ Hz, 1H), 8.15 (d, $J = 9.0$ Hz, 1H), 7.96 (d, $J = 9.5$ Hz, 1H), 7.72 (dd, $J = 9.0, 2.5$ Hz, 1H), 7.25–7.23 (m, 1H), 7.08 (d, $J = 10.0$ Hz, 1H), 6.70 – 6.65 (m, 3H), 3.80 (s, 3H), 3.30 (s, 3H); LCMS (ESI) m/z : 354.1 [M+H]⁺.

Compound **302**: ¹H NMR (500 MHz, DMSO-d₆) δ 10.66 (s, 1H), 8.68 (d, $J = 3.0$ Hz, 1H), 8.23 (d, $J = 2.5$ Hz, 1H), 8.12 (d, $J = 8.5$ Hz, 1H), 8.00 (dd, $J = 9.5, 2.5$ Hz, 1H), 7.70 (dd, $J = 9.5, 3.0$ Hz, 1H), 7.26 – 7.21 (m, 1H), 6.68 – 6.61 (m, 3H), 6.44 (d, $J = 9.5$ Hz, 1H), 3.51 (s, 3H), 3.29 (s, 3H); LCMS (ESI) m/z : 353.0 [M+H]⁺.

Compound **303**: ¹H NMR (500 MHz, DMSO-d₆) δ 10.05 (s, 1H), 8.54 (s, 1H), 8.20 (d, $J = 2.5$ Hz, 1H), 8.04–8.06 (d, $J = 9.0$ Hz, 1H), 7.90–7.92 (d, $J = 10.0$ Hz, 1H), 7.65–7.68 (m, 1H), 7.22–7.26 (m, 1H), 7.05–7.07 (d, $J = 9.0$ Hz, 1H), 6.97–6.99 (m, 2H), 6.83–6.85 (m, 1H), 4.09–4.10 (m, 1H), 1.27–1.28 (m, 2H), 1.01–1.03 (m, 2H); LCMS (ESI) m/z : 382.0 [M+H]⁺.

Compound **304**: ¹H NMR (500 MHz, DMSO-d₆) δ 10.04 (s, 1H), 8.57 (s, 1H), 8.20–8.21 (d, $J = 2.5$ Hz, 1H), 8.04–8.06 (d, $J = 8.5$ Hz, 1H), 7.90–7.92 (d, $J = 9.0$ Hz, 1H), 7.66–7.69 (m, 1H), 7.24–7.26 (m, 1H), 7.05–7.07 (d, $J = 9.5$ Hz, 1H), 6.83–6.85 (d, $J = 8.0$ Hz, 1H), 6.76–6.78 (d, $J = 11.5$ Hz, 1H), 6.59–6.62 (m, 1H), 4.08–4.11 (m, 1H), 1.27–1.28 (m, 2H), 1.00–1.04 (m, 2H); LCMS (ESI) m/z : 366.1 [M+H]⁺.

Compound **305**: ¹H NMR (400 MHz, DMSO-d₆) δ 8.29 (s, 1H), 7.78 (d, $J = 2.7$ Hz, 1H), 7.42 (dd, $J = 9.6, 2.8$ Hz, 1H), 7.31 (t, $J = 8.1$ Hz, 1H), 7.01 (ddd, $J = 22.5, 10.2, 2.0$ Hz, 3H), 6.36 (d, $J = 9.6$ Hz, 1H), 4.70 – 4.60 (m, 1H), 3.78 (dd, $J = 8.7, 5.2$ Hz, 2H), 3.41 (s, 3H), 3.30 – 3.13 (m, 2H), 1.95 (d, $J = 12.0$ Hz, 2H), 1.64 – 1.40 (m, 2H); LCMS (ESI) m/z : 362.0 [M+H]⁺.

Compound **306**: ¹H NMR (500 MHz, DMSO-d₆) δ 7.75 (d, $J = 3.1$ Hz, 1H), 7.38 (dd, $J = 9.8, 3.1$ Hz, 1H), 7.32 (t, $J = 8.2$ Hz, 1H), 7.11 – 7.10 (t, $J = 2.1$ Hz, 1H), 7.03 – 6.94 (m, 2H), 6.36 – 6.34 (d, $J = 9.8$

Hz, 1H), 4.77 – 4.64 (m, 1H), 3.77 - 3.75 (d, J = 55.8 Hz, 2H), 3.43 (s, 1H), 3.39 (s, 3H), 3.36 – 3.19 (m, 1H), 1.99 (s, 2H), 1.64 - 1.62 (d, J = 10.2 Hz, 2H); LCMS (ESI) m/z : 363.1 $[M+H]^+$.

Compound **307**: ^1H NMR (500 MHz, DMSO- d_6) δ 7.47 (d, J = 9.8 Hz, 1H), 7.32 (t, J = 8.2 Hz, 1H), 7.11 (d, J = 2.0 Hz, 1H), 7.04 (d, J = 9.8 Hz, 1H), 7.02 – 6.95 (m, 2H), 4.78 – 4.56 (m, 1H), 3.76 (d, J = 48.0 Hz, 2H), 3.57 (s, 3H), 3.50 – 3.31 (m, 2H), 1.99 (s, 2H), 1.67 (s, 2H); LCMS (ESI) m/z : 364.0 $[M+H]^+$.

Compound **308**: ^1H NMR (500 MHz, DMSO- d_6) δ 8.14 (s, 1H), 7.75(d, J = 2.5 Hz, 1H), 7.39(dd, J_1 = 2.5 Hz, J_2 = 9.0 Hz, 1H), 7.31-7.34(m, 1H), 7.25-7.27(m, 2H), 7.16 (d, J = 8.0 Hz, 1H), 6.33 (d, J = 9.5 Hz, 1H), 4.01-4.04 (m, 2H), 3.39(s, 3H), 2.70(t, J = 12 Hz, 2H), 2.50-2.55(m, 2H), 1.70-1.75(m, 1H), 1.54-1.56 (m, 2H), 1.04-1.12(m, 2H); LCMS (ESI) m/z : 360.1 $[M+H]^+$.

Compound **309**: ^1H NMR (400 MHz, DMSO- d_6) δ 9.22 (s, 1H), 7.61(d, J = 9.6 Hz, 1H), 7.31-7.34(m, 1H), 7.25-7.27(m, 2H), 7.16(d, J = 7.6 Hz, 1H), 6.87 (d, J = 9.6 Hz, 1H), 4.04 – 4.07 (m, 2H), 3.55(s, 3H), 2.72(t, J = 12.4 Hz, 2H), 2.50-2.55 (m, 2H), 1.70-1.76 (m, 1H), 1.52-1.55 (m, 2H), 1.03-1.14(m, 2H); LCMS (ESI) m/z : 361.1 $[M+H]^+$.

Compound **310**: ^1H NMR (400 MHz, DMSO- d_6) δ 8.70 (d, J = 1.2 Hz, 1H), 8.09-8.05 (m, 2H), 7.97-7.95 (m, 1H), 7.12-7.04 (m, 4H), 4.14 (s, 2H), 3.61 (s, 3H); LCMS (ESI) m/z : 357.1 $[M+H]^+$.

Compound **311**: ^1H NMR (400 MHz, DMSO- d_6) δ 10.49 (s, 1H), 8.69 (d, J = 1.6 Hz, 1H), 8.34 (d, J = 2.8 Hz, 1H), 8.04 (d, J = 8.0 Hz, 1H), 7.93-7.91 (m, 1H), 7.79-7.76 (m, 1H), 7.12-7.07 (m, 3H), 6.42 (d, J = 9.6 Hz, 1H), 4.13 (s, 2H), 3.44 (s, 3H); LCMS (ESI) m/z : 356.0 $[M+H]^+$.

Compound **312**: ^1H NMR (400 MHz, DMSO- d_6) δ 9.91 (s, 1H), 8.67 (s, 1H), 8.07 (d, J = 9.6 Hz, 2H), 7.92 (d, J = 7.2 Hz, 1H), 7.45-7.34 (m, 2H), 7.16 (s, 1H), 7.05 (s, 1H), 4.10 (s, 2H), 3.60 (s, 3H); LCMS (ESI) m/z : 357.1 $[M+H]^+$.

Compound **313**: ^1H NMR (400 MHz, DMSO- d_6) δ 10.49 (s, 1H), 8.67 (d, J = 1.6 Hz, 1H), 8.34 (d, J = 2.8 Hz, 1H), 8.04 (d, J = 8.0 Hz, 1H), 7.90-7.88 (m, 1H), 7.79-7.76 (m, 1H), 7.45-7.35 (m, 2H), 7.16-7.13 (m, 1H), 6.42 (d, J = 9.6 Hz, 1H), 4.10 (s, 2H), 3.44 (s, 3H); LCMS (ESI) m/z : 356.0 $[M+H]^+$.

Compound **314**: ^1H NMR (400 MHz, DMSO- d_6) δ 10.59 (t, J = 7.8 Hz, 1H), 8.42 (s, 1H), 8.28 (s, 1H), 8.11 (s, 1H), 8.06 – 8.03 (m, 1H), 7.71 (d, J = 6.8 Hz, 1H), 7.38-7.34 (m, 2H), 7.11 (s, 1H), 3.94 (s, 2H), 3.87 (s, 3H); LCMS (ESI) m/z : 329.0 $[M+H]^+$.

Compound **315**: ^1H NMR (400 MHz, DMSO- d_6) δ 10.61 (s, 1H), 8.43 (s, 1H), 8.32 (d, J = 1.6 Hz, 1H), 8.13 (s, 1H), 8.07 (d, J = 8.8 Hz, 1H), 7.76 (d, J = 8.6 Hz, 1H), 7.10 – 7.03 (m, 3H), 3.98 (s, 2H), 3.88 (s, 3H); LCMS (ESI) m/z : 329.0 $[M+H]^+$.

Compound **316**: ^1H NMR (400 MHz, DMSO- d_6) δ 10.47 (s, 1H), 8.41 (s, 1H), 8.30 (d, J = 1.6 Hz, 1H), 8.10 (d, J = 10.4 Hz, 2H), 7.69 (dd, J = 8.4, 2.0 Hz, 1H), 7.27–7.23 (m, 2H), 7.15 (d, J = 9.6 Hz, 1H), 3.95 (s, 2H), 3.86 (s, 3H); LCMS (ESI) m/z : 345.1 $[M+H]^+$.

Compound **317**: ^1H NMR (400 MHz, DMSO- d_6) δ 12.77 (s, 1H), 7.89(d, J = 9.6 Hz, 1H), 7.37-7.43(m, 1H), 7.05-7.15(m, 4H), 4.11(s, 2H), 3.78(s, 3H); LCMS (ESI) m/z : 423.0 $[M+H]^+$.

Compound **319**: ^1H NMR (400 MHz, DMSO- d_6) δ 11.21 (s, 1H), 8.85 (d, J = 1.2 Hz, 1H), 8.45-8.48 (m, 1H), 8.36 (d, J = 1.2 Hz, 1H), 8.09-8.11 (d, J = 8.4 Hz, 1H), 7.74-7.76 (m, 1H), 7.29-7.36 (m, 2H), 7.23-7.29 (m, 2H), 3.98 (s, 2H); LCMS (ESI) m/z : 376.0 $[M+H]^+$.

Compound **320**: ^1H NMR (400 MHz, DMSO- d_6) δ 11.06 (s, 1H), 9.09 (d, J = 2 Hz, 1H), 8.31-8.43 (m, 2H), 8.13 (d, J = 8.8 Hz, 1H), 7.74 (d, J = 8 Hz, 2H), 7.19-7.39 (m, 4H), 5.51 (d, J = 1.6 Hz, 1H), 4.56 (d, J = 1.2 Hz, 1H), 3.92-4.03 (m, 4H), 1.40 (t, J = 6.8 Hz, 3H); LCMS (ESI) m/z : 394.1 $[\text{M}+\text{H}]^+$.

Compound **321**: ^1H NMR (400 MHz, DMSO- d_6) δ 10.35 (s, 1H), 8.68 (s, 1H), 8.20-8.17 (m, 3H), 8.03 – 8.01 (m, 1H), 7.70 (dd, J = 8.4, 2.0 Hz, 1H), 5.54 (t, J = 5.8 Hz, 1H), 4.67 (d, J = 5.6 Hz, 2H), 2.47 (d, J = 6.8 Hz, 2H), 1.66-1.60 (m, 5H), 1.55–1.48 (m, 1H), 1.23-1.10 (m, 3H), 0.97–0.88 (m, 2H); LCMS (ESI) m/z : 326.2 $[\text{M}+\text{H}]^+$.

Compound **322**: ^1H NMR (400 MHz, DMSO- d_6) δ 9.13 (s, 1H), 7.65(d, J = 10.0 Hz, 1H), 7.30-7.34(m, 2H), 7.24-7.26(m, 2H), 7.15(d, J = 9.0 Hz, 1H), 6.95(d, J = 10.0 Hz, 1H), 3.84(s, 1H), 3.56(s, 3H), 2.50-2.54 (m, 2H), 1.62-1.65 (m, 3H), 1.47-1.52 (m, 4H), 1.15-1.20 (m, 2H); LCMS (ESI) m/z : 375.2 $[\text{M}+\text{H}]^+$.

Compound **323**: ^1H NMR (500 MHz, DMSO- d_6) δ 11.58 (bs, 1H), 9.49(s, 1H), 8.28 (d, J = 2.0 Hz, 1H), 8.07(d, J = 8.5 Hz, 1H), 7.75 (d, J = 8.5 Hz, 1H), 7.52 (dd, J = 7.0, 2.0 Hz, 1H), 7.35(t, J = 9.0 Hz, 1H), 7.30-7.26(m, 1H), 5.90 (s, 1H), 3.95(s, 2H), 3.64(s, 3H); LCMS (ESI) m/z : 361.0 $[\text{M}+\text{H}]^+$.

Compound **324**: ^1H NMR (500 MHz, DMSO- d_6) δ 11.61 (bs, 1H), 9.56(s, 1H), 8.28 (d, J = 2.0 Hz, 1H), 8.06(d, J = 8.5 Hz, 1H), 7.76 (dd, J = 8.5, 1.5 Hz, 1H), 7.39-7.35 (m, 2H), 7.12-7.10(m, 1H), 5.90 (s, 1H), 3.95(s, 2H), 3.64(s, 3H); LCMS (ESI) m/z : 345.1 $[\text{M}+\text{H}]^+$.

Compound **325**: ^1H NMR (500 MHz, DMSO- d_6) δ 11.67 (bs, 1H), 9.95 (s, 1H), 8.33 (d, J = 1.5 Hz, 1H), 8.07(d, J = 9.0 Hz, 1H), 7.89 (dd, J = 8.5, 1.5 Hz, 1H), 7.10-7.04 (m, 3H), 5.93 (s, 1H), 4.00(s, 2H), 3.65(s, 3H); LCMS (ESI) m/z : 345.1 $[\text{M}+\text{H}]^+$.

Compound **326**: ^1H NMR (500 MHz, DMSO- d_6) δ 10.70 (s, 1H), 8.65 (d, J = 2.0 Hz, 1H), 8.17 (d, J = 2.0 Hz, 1H), 8.02 (d, J = 8.5 Hz, 1H), 7.95 (dd, J = 9.5, 2.5 Hz, 1H), 7.69 (dd, J = 8.5, 2.0 Hz, 1H), 6.44 (d, J = 10.0 Hz, 1H), 3.98 (q, J = 7.0 Hz, 2H), 2.47 (d, J = 7.0 Hz, 2H), 1.67-1.60(m, 5H), 1.51-1.47(m, 1H), 1.28 (t, J = 7.0 Hz, 3H), 1.21–1.07 (m, 3H), 0.96–0.89 (m, 2H); LCMS (ESI) m/z : 340.1 $[\text{M}+\text{H}]^+$.

Compound **327**: ^1H NMR (500 MHz, DMSO- d_6) δ 11.28 (s, 1H), 9.23 (d, J = 1.5 Hz, 1H), 8.54 (dd, J = 8.0, 2.0 Hz, 1H), 8.22–8.20 (m, 2H), 8.11 (d, J = 9.0 Hz, 1H), 7.68 (dd, J = 8.5, 2.0 Hz, 1H), 2.48 (d, J = 7.5 Hz, 2H), 1.67-1.60 (m, 5H), 1.52-1.47 (m, 1H), 1.21–1.10 (m, 3H), 0.96–0.89 (m, 2H); LCMS (ESI) m/z : 321.1 $[\text{M}+\text{H}]^+$.

Compound **328**: ^1H NMR (500 MHz, DMSO- d_6) δ 12.49 (s, 1H), 8.47 (d, J = 6.0 Hz, 1H), 8.29 (s, 1H), 8.20 (dd, J = 13.0, 7.5 Hz, 2H), 7.70 (d, J = 8.0 Hz, 1H), 7.36 ((dd, J = 19.0, 9.0 Hz, 2H), 7.12 (s, 1H), 6.60 (t, J = 7.0 Hz, 1H), 3.94 (s, 2H), 3.63 (s, 3H); LCMS (ESI) m/z : 356.0 $[\text{M}+\text{H}]^+$.

Compound **329**: ^1H NMR (500 MHz, DMSO- d_6) δ 12.49 (s, 1H), 8.47 (dd, J = 7.0, 2.0 Hz, 1H), 8.31 (d, J = 2.0 Hz, 1H), 8.22–8.17 (m, 2H), 7.73 (dd, J = 8.5, 2.0 Hz, 1H), 7.08–7.03 (m, 3H), 6.60 (t, J = 7.0 Hz, 1H), 3.97 (s, 2H), 3.63 (s, 3H); LCMS (ESI) m/z : 327.1 $[\text{M}+\text{H}]^+$.

Compound **330**: ^1H NMR (500 MHz, DMSO- d_6) δ 12.48 (s, 1H), 8.46 (dd, J = 7.0, 2.0 Hz, 1H), 8.30 (d, J = 1.5 Hz, 1H), 8.22–8.17 (m, 2H), 7.71 (dd, J = 8.5, 2.0 Hz, 1H), 7.39 – 7.31 (m, 2H), 7.25 (dd, J = 16.0, 8.0 Hz, 2H), 6.60 (t, J = 7.0 Hz, 1H), 3.96 (s, 2H), 3.63 (s, 3H); LCMS (ESI) m/z : 354.1 $[\text{M}+\text{H}]^+$.

Compound **331**: ^1H NMR (400 MHz, DMSO- d_6) δ 12.49 (s, 1H), 8.46 (d, J = 6.4 Hz, 1H), 8.30 (s, 1H), 8.20 (t, J = 8.2 Hz, 2H), 7.71 (d, J = 8.4 Hz, 1H), 7.52 (d, J = 6.8 Hz, 1H), 7.35 (t, J = 9.0 Hz, 1H), 7.30–7.27 (m, 1H), 6.60 (t, J = 6.8 Hz, 1H), 3.95 (s, 2H), 3.63 (s, 3H); LCMS (ESI) m/z : 372.0 $[\text{M}+\text{H}]^+$.

Compound **332**: ^1H NMR (500 MHz, DMSO) δ 12.51 (s, 1H), 8.48–8.46 (m, 1H), 8.29 (s, 1H), 8.21 (d, J = 8.5 Hz, 2H), 7.72–7.70 (m, 1H), 7.35 (dd, J = 14.5, 7.5 Hz, 1H), 7.12 (t, J = 7.5 Hz, 2H), 7.04 (t, J = 8.5 Hz, 1H), 6.63 (t, J = 7.0 Hz, 1H), 4.12 (q, J = 7.0 Hz, 2H), 3.97 (s, 2H), 1.31 (t, J = 7.0 Hz, 3H); LCMS (ESI) m/z : 352.1 $[\text{M}+\text{H}]^+$.

5 Compound **333**: ^1H NMR (500 MHz, DMSO- d_6) δ 11.12 (s, 1H), 8.98 (s, 1H), 8.35 (s, 1H), 8.27–8.29 (d, J = 10 Hz, 1H), 8.11–8.12 (d, J = 8.5 Hz, 1H), 7.73–7.75 (d, J = 8.5 Hz, 1H), 7.33–7.36 (m, 2H), 7.23–7.28 (m, 2H), 7.01–7.07 (m, 1H), 6.47–6.50 (d, J = 17.5 Hz, 1H), 5.74–5.76 (d, J = 11.0 Hz, 1H), 3.98 (s, 2H); LCMS (ESI) m/z : 368.0 $[\text{M}+\text{H}]^+$.

10 Compound **334**: ^1H NMR (500 MHz, DMSO- d_6) δ 10.24 (s, 1H), 8.34 (d, J = 1.9 Hz, 1H), 8.19 – 7.96 (m, 2H), 7.76 (dd, J = 8.5, 2.2 Hz, 1H), 7.34 (dd, J = 7.9, 6.6 Hz, 1H), 7.12 (t, J = 8.3 Hz, 2H), 7.04 (d, J = 1.8 Hz, 1H), 3.99 (s, 2H); LCMS (ESI) m/z : 391.9, 393.9 $[\text{M}+\text{H}]^+$.

Compound **335**: ^1H NMR (400 MHz, DMSO- d_6) δ 10.16 (s, 1H), 8.54 (d, J = 6.4 Hz, 1H), 8.36 (s, 1H), 8.11 (d, J = 8.4 Hz, 1H), 7.72–7.84 (m, 1H), 7.28–7.42 (m, 1H), 6.92–7.18 (m, 4H), 3.99 (s, 2H), 3.54 (s, 3H); LCMS (ESI) m/z : 339.1 $[\text{M}+\text{H}]^+$.

15 Compound **336**: ^1H NMR (500 MHz, DMSO- d_6) δ 8.31 (d, J = 2.5 Hz, 1H), 7.92 (d, J = 8.0 Hz, 1H), 7.85 (dd, J_1 = 2.5 Hz, J_2 = 9.5 Hz, 1H), 7.30–7.33 (m, 1H), 7.24–7.25 (m, 2H), 7.15 (d, J = 7.5 Hz, 1H), 6.38 (d, J = 9.0 Hz, 1H), 3.64–3.68 (m, 1H), 3.47 (s, 3H), 2.49–2.51 (m, 2H), 1.82 (d, J = 11.0 Hz, 2H), 1.65 (d, J = 12.5 Hz, 2H), 1.46–1.50 (m, 1H), 1.24 (dd, J_1 = 10.5 Hz, J_2 = 23.0 Hz, 2H), 1.06 (dd, J_1 = 11.0 Hz, J_2 = 24.5 Hz, 2H); LCMS (ESI) m/z : 359.1 $[\text{M}+\text{H}]^+$.

20 Compound **337**: ^1H NMR (500 MHz, DMSO- d_6) δ 10.69 (s, 1H), 8.68 (d, J = 2.7 Hz, 1H), 8.37 (dd, J = 2.4, 0.9 Hz, 1H), 8.11 (dd, J = 8.7, 0.9 Hz, 1H), 7.97 (dd, J = 9.5, 2.7 Hz, 1H), 7.80 (dd, J = 8.7, 2.3 Hz, 1H), 6.43 (d, J = 9.5 Hz, 1H), 3.50 (s, 3H), 1.62 – 1.50 (m, 1H), 0.95 – 0.85 (m, 2H), 0.79 – 0.71 (m, 2H); LCMS (ESI) m/z : 294.2 $[\text{M}+\text{H}]^+$.

25 Compound **338**: ^1H NMR (500 MHz, DMSO- d_6) δ 10.08 (s, 1H), 8.28 (d, J = 5.1 Hz, 1H), 8.03 (s, 1H), 7.94 (d, J = 9.7 Hz, 1H), 7.45 – 7.35 (m, 2H), 7.33 – 7.27 (m, 2H), 7.12 – 7.03 (m, 2H), 4.03 (s, 2H), 3.78 (s, 3H); LCMS (ESI) m/z : 355.1 $[\text{M}+\text{H}]^+$.

30 Compound **339**: ^1H NMR (500 MHz, DMSO- d_6) δ 8.53 (d, J = 10.0 Hz, 1H), 7.80–7.77 (m, 1H), 7.56–7.52 (m, 1H), 7.38–7.33 (m, 1H), 7.17–7.13 (m, 2H), 7.07–7.03 (m, 1H), 4.04 (s, 2H), 3.69–3.67 (m, 1H), 3.60–3.58 (m, 2H), 3.46 (s, 1H), 3.39–3.37 (m, 1H), 3.28 (s, 1H), 1.18 (s, 3H), 1.05 (s, 3H); LCMS (ESI) m/z : 329.1 $[\text{M}+\text{H}]^+$.

Compound **340**: ^1H NMR (500 MHz, DMSO- d_6) δ 11.93 (s, 1H), 7.66 (s, 1H), 7.64 – 7.52 (m, 3H), 7.36 (s, 1H), 4.24 (s, 2H), 3.35 (s, 3H), 2.82 (t, J = 8.5 Hz, 2H), 2.53 (s, 2H); LCMS (ESI) m/z : 397.0 $[\text{M}+\text{H}]^+$.

35 Compound **341**: ^1H NMR (500 MHz, DMSO- d_6) δ 12.49–11.25 (m, 1H), 7.80 (d, J = 8.0 Hz, 2H), 7.50 (d, J = 7.5 Hz, 2H), 7.36 (s, 1H), 4.23 (s, 2H), 3.35 (s, 3H), 2.82 (t, J = 8.5 Hz, 2H), 2.52 (t, J = 5.3 Hz, 2H); LCMS (ESI) m/z : 354.1 $[\text{M}+\text{H}]^+$.

40 Compound **342**: ^1H NMR (400 MHz, DMSO- d_6) δ 10.52 (s, 1H), 8.66 (d, J = 2.3 Hz, 1H), 8.50 (s, 1H), 8.17 (d, J = 2.6 Hz, 1H), 8.10 – 7.95 (m, 2H), 7.65 (dd, J = 9.0, 2.7 Hz, 1H), 7.24 (t, J = 7.9 Hz, 1H), 6.96 (d, J = 8.1 Hz, 2H), 6.84 (d, J = 7.4 Hz, 1H), 6.44 (d, J = 9.5 Hz, 1H), 3.51 (s, 3H); LCMS (ESI) m/z : 355.0 $[\text{M}+\text{H}]^+$.

Compound **343**: ^1H NMR (500 MHz, DMSO- d_6) δ 11.21 (s, 1H), 7.37 – 7.33 (m, 1H), 7.11-7.03 (m, 3H), 6.82 (d, J = 4.0 Hz, 1H), 6.67 (d, J = 4.0 Hz, 1H), 4.07 (s, 2H), 3.36 (s, 3H), 2.81 (t, J = 8.5 Hz, 2H), 2.51 (t, J = 3.5 Hz, 2H); LCMS (ESI) m/z : 346.1 $[\text{M}+\text{H}]^+$.

Compound **344**: ^1H NMR (400 MHz, DMSO- d_6) δ 11.48 (s, 1H), 9.50 (s, 1H), 8.75 (d, J = 7.2 Hz, 1H), 8.61 (s, 1H), 8.40 (d, J = 1.6 Hz, 1H), 8.13 (d, J = 8.4 Hz, 1H), 7.85 (dd, J = 8.4, 2.0 Hz, 1H), 7.54 (d, J = 7.2 Hz, 1H), 7.37 (dd, J = 14.4, 8.0 Hz, 1H), 7.14 (t, J = 7.6 Hz, 2H), 7.08-7.03 (m, 1H), 4.03 (s, 2H); LCMS (ESI) m/z : 348.1 $[\text{M}+\text{H}]^+$.

Compound **345**: ^1H NMR (500 MHz, DMSO- d_6) δ 12.83 (s, 1H), 7.91 (d, J = 9.5 Hz, 1H), 7.43-7.39 (m, 1H), 7.24-7.21 (m, 2H), 7.14-7.11 (m, 1H), 7.06 (d, J = 10.0 Hz, 1H), 4.43 (s, 2H), 3.79 (s, 3H); LCMS (ESI) m/z : 346.1 $[\text{M}+\text{H}]^+$.

Compound **346**: ^1H NMR (500 MHz, DMSO- d_6) δ 12.88 (s, 1H), 7.92 (d, J = 10.0 Hz, 1H), 7.38-7.35 (m, 2H), 7.27 (d, J = 9.5 Hz, 1H), 7.07 (d, J = 9.5 Hz, 1H), 4.45 (s, 2H), 3.79 (s, 3H); LCMS (ESI) m/z : 380.1 $[\text{M}+\text{H}]^+$.

Compound **347**: ^1H NMR (500 MHz, DMSO- d_6) δ 12.85 (bs, 1H), 7.91 (d, J = 9.5 Hz, 1H), 7.64 (d, J = 6.5 Hz, 2H), 7.41-7.39 (m, 2H), 7.06 (d, J = 9.5 Hz, 1H), 4.42 (s, 2H), 3.78 (s, 3H); LCMS (ESI) m/z : 380.0 $[\text{M}+\text{H}]^+$.

Compound **348**: ^1H NMR (500 MHz, DMSO- d_6) δ 11.05 (s, 1H), 9.07 (s, 1H), 8.34-8.33 (m, 2H), 8.12 (d, J = 8.5 Hz, 1H), 7.73 (dd, J = 9.0, 2.0 Hz, 1H), 7.36 – 7.23 (m, 5H), 4.52 (d, J = 9.0 Hz, 2H), 3.98 (s, 2H), 2.90 (s, 3H), 1.44 (s, 4.2H), 1.29 (s, 4.8H); LCMS (ESI) m/z : 467.0 $[\text{M}+\text{H}]^+$.

Compound **349**: ^1H NMR (400 MHz, DMSO- d_6) δ 10.53 (s, 1H), 8.66 (d, J = 2.4 Hz, 1H), 8.53 (s, 1H), 8.18 (d, J = 2.8 Hz, 1H), 8.04 (d, J = 8.8 Hz, 1H), 8.00 (dd, J = 9.6, 2.8 Hz, 1H), 7.67 (dd, J = 9.2, 2.8 Hz, 1H), 7.28-7.22 (m, 1H), 6.83 (dd, J = 8.0, 1.2 Hz, 1H), 6.78-6.74 (m, 1H), 6.74-6.58 (m, 1H), 6.44 (d, J = 9.2 Hz, 1H), 3.51 (s, 3H); LCMS (ESI) m/z : 339.1 $[\text{M}+\text{H}]^+$.

Compound **350**: ^1H NMR (500 MHz, DMSO- d_6) δ 12.71 (bs, 1H), 8.72 (d, J = 2.5 Hz, 1H), 8.02 (dd, J = 10.0, 2.5 Hz, 1H), 7.62 (dd, J = 7.0, 2.0 Hz, 1H), 7.42-7.36 (m, 2H), 6.46 (d, J = 9.5 Hz, 1H), 4.39 (s, 2H), 3.51 (s, 3H); LCMS (ESI) m/z : 379.1 $[\text{M}+\text{H}]^+$.

Compound **351**: ^1H NMR (500 MHz, DMSO- d_6) δ 10.69 (s, 1H), 9.11 (s, 2H), 7.95 (d, J = 9.7 Hz, 1H), 7.51 – 7.16 (m, 4H), 7.09 (d, J = 9.7 Hz, 1H), 4.22 (s, 2H), 3.81 (s, 3H); LCMS (ESI) m/z : 356.0 $[\text{M}+\text{H}]^+$.

Compound **352**: ^1H NMR (400 MHz, DMSO- d_6) δ 8.48 (s, 1H), 7.63 (d, J = 8.0 Hz, 1H), 7.36–7.31 (m, 2H), 7.19 (dd, J = 9.6, 2.8 Hz, 1H), 7.12-7.01 (m, 3H), 6.72 (d, J = 2.8 Hz, 1H), 6.29 (d, J = 9.6 Hz, 1H), 5.45 (t, J = 5.8 Hz, 1H), 4.12 (d, J = 5.6 Hz, 2H), 3.98 (s, 2H), 3.29 (s, 3H); LCMS (ESI) m/z : 324.1 $[\text{M}+\text{H}]^+$.

Compound **353**: ^1H NMR (400 MHz, DMSO- d_6) δ 12.72 (s, 1H), 8.72 (d, J = 2.4 Hz, 1H), 8.00 (dd, J_1 = 2.8 Hz, J_2 = 9.6 Hz, 1H), 7.42 (dd, J_1 = 8.0 Hz, J_2 = 14.4 Hz, 1H), 7.11-7.21 (m, 3H), 6.47 (d, J = 9.6 Hz, 1H), 4.35 (s, 2H), 3.51 (s, 3H); LCMS (ESI) m/z : 369.0 $[\text{M}+\text{H}]^+$.

Compound **354**: ^1H NMR (400 MHz, DMSO- d_6) δ 11.26 (s, 1H), 9.22 (d, J = 1.6 Hz, 1H), 8.49 (dd, J = 2.4 Hz, 8 Hz, 1H), 8.37 (d, J = 2 Hz, 1H), 8.14 (d, J = 8.4 Hz, 1H), 8.05 (d, J = 8 Hz, 1H), 7.75 (dd, J = 2.4 Hz, 8.4 Hz, 1H), 7.21-7.40 (m, 4H), 3.99 (s, 2H), 2.68 (s, 3H); LCMS (ESI) m/z : 366.1 $[\text{M}+\text{H}]^+$.

Compound **355**: ^1H NMR (400 MHz, DMSO- d_6) δ 10.46 (s, 1H), 8.49 (s, 1H), 8.29 (d, J = 1.6 Hz, 1H), 8.13–8.10 (m, 2H), 7.67 (dd, J = 8.4, 1.6 Hz, 1H), 7.35 (dd, J = 14.4, 7.6 Hz, 1H), 7.13–7.10 (m, 2H),

7.04 (t, $J = 8.6$ Hz, 1H), 4.17 (q, $J = 7.2$ Hz, 2H), 3.96 (s, 2H), 1.39 (t, $J = 7.2$ Hz, 3H); LCMS (ESI) m/z : 325.1 $[M+H]^+$.

Compound **356**: ^1H NMR (400 MHz, DMSO- d_6) δ 10.51 (s, 1H), 8.41 (s, 1H), 8.28 (d, $J = 1.6$ Hz, 1H), 8.11 (s, 1H), 8.07 (d, $J = 8.4$ Hz, 1H), 7.68 (dd, $J = 8.6, 2.0$ Hz, 1H), 7.34 (dd, $J = 14.4, 8.0$ Hz, 1H),
5 7.12–7.09 (m, 2H), 7.05–7.00 (m, 1H), 3.95 (s, 2H), 3.86 (s, 3H); LCMS (ESI) m/z : 311.0 $[M+H]^+$.

Compound **357**: ^1H NMR (500 MHz, DMSO- d_6) δ 10.48 (s, 1H), 8.67 (d, $J = 2.0$ Hz, 1H), 8.34 (d, $J = 2.5$ Hz, 1H), 8.03 (d, $J = 7.5$ Hz, 1H), 7.90–7.88 (m, 1H), 7.78–7.76 (m, 1H), 7.38–7.34 (m, 1H), 7.17–7.12 (m, 2H), 7.07–7.03 (m, 1H), 6.41 (d, $J = 9.5$ Hz, 1H), 4.12 (s, 2H), 3.44 (s, 3H); LCMS (ESI) m/z : 338.0 $[M+H]^+$.

10 Compound **358**: ^1H NMR (500 MHz, DMSO- d_6) δ 9.52 (d, $J = 2.5$ Hz, 1H), 9.17 (d, $J = 2.0$ Hz, 1H), 8.38 (d, $J = 2.0$ Hz, 1H), 8.17 (d, $J = 8.5$ Hz, 1H), 7.78 (dd, $J = 8.5$ Hz, $J = 2.0$ Hz, 1H), 7.34–7.39 (m, 1H), 7.12–7.15 (m, 2H), 7.05 (td, $J = 8.5$ Hz, $J = 2.5$ Hz, 1H), 6.08 (s, 1H), 4.01 (m, 2H); LCMS (ESI) m/z : 366.0 $[M+H]^+$.

15 Compound **359**: ^1H NMR (400 MHz, DMSO- d_6) δ 11.10 (s, 1H), 9.27 (s, 1H), 8.87 (s, 1H), 8.57 (d, $J = 2.4$ Hz, 1H), 8.14 (dd, $J = 9.5, 2.4$ Hz, 1H), 7.38 (dd, $J = 14.4, 7.9$ Hz, 1H), 7.19 (d, $J = 7.3$ Hz, 2H), 7.10 (t, $J = 8.5$ Hz, 1H), 6.52 (d, $J = 9.5$ Hz, 1H), 3.82 (s, 2H), 3.53 (s, 3H); LCMS (ESI) m/z : 339.1 $[M+H]^+$.

20 Compound **360**: ^1H NMR (400 MHz, DMSO- d_6) δ 10.17 (s, 1H), 8.35 (d, $J = 1.9$ Hz, 1H), 8.10 (d, $J = 8.4$ Hz, 1H), 7.96 (d, $J = 9.7$ Hz, 1H), 7.87 (dd, $J = 8.5, 2.2$ Hz, 1H), 7.28 (dt, $J = 24.9, 12.5$ Hz, 1H), 7.08 (d, $J = 9.7$ Hz, 1H), 6.90 – 6.65 (m, 3H), 4.23 (t, $J = 6.6$ Hz, 2H), 3.80 (s, 3H), 3.06 (t, $J = 6.6$ Hz, 2H); LCMS (ESI) m/z : 369.1 $[M+H]^+$.

Compound **361**: ^1H NMR (400 MHz, DMSO- d_6) δ 10.45 (s, 1H), 8.64 (d, $J = 2.4$ Hz, 1H), 8.17 (d, $J = 2.8$ Hz, 1H), 8.05 (d, $J = 9.2$ Hz, 1H), 7.98 (dd, $J = 9.6, 2.4$ Hz, 1H), 7.57–7.54 (m, 2H), 7.45 – 7.42 (m, 3H), 6.43 (d, $J = 9.6$ Hz, 1H), 5.20 (s, 2H), 3.50 (s, 3H); LCMS (ESI) m/z : 370.1 $[M+H]^+$.

25 Compound **362**: ^1H NMR (400 MHz, DMSO- d_6) δ 10.20 (s, 1H), 8.36 (d, $J = 1.9$ Hz, 1H), 8.11 (d, $J = 8.5$ Hz, 1H), 8.00 – 7.81 (m, 2H), 7.36 – 7.19 (m, 2H), 7.08 (d, $J = 9.7$ Hz, 1H), 6.93 (dd, $J = 12.1, 5.1$ Hz, 3H), 4.21 (t, $J = 6.6$ Hz, 2H), 3.80 (s, 3H), 3.06 (t, $J = 6.6$ Hz, 2H); LCMS (ESI) m/z : 351.1 $[M+H]^+$.

30 Compound **363**: ^1H NMR (400 MHz, DMSO- d_6) δ 10.87 (s, 1H), 8.73 (d, $J = 1.6$ Hz, 1H), 8.10–8.13 (m, 2H), 7.91–7.97 (m, 2H), 7.41 (s, 1H), 7.23–7.36 (m, 3H), 4.12 (s, 2H), 3.73 (s, 3H); LCMS (ESI) m/z : 355.1 $[M+H]^+$.

Compound **364**: ^1H NMR (400 MHz, DMSO- d_6) δ 10.32 (s, 1H), 8.94 (d, $J = 4.8$ Hz, 1H), 8.37 (d, $J = 2.4$ Hz, 1H), 8.16 (d, $J = 8.8$ Hz, 1H), 7.72–7.84 (m, 2H), 7.30–7.40 (m, 1H), 6.98–7.17 (m, 3H), 4.07 (s, 3H), 4.00 (s, 2H); LCMS (ESI) m/z : 339.1 $[M+H]^+$.

35 Compound **365**: ^1H NMR (500 MHz, DMSO- d_6) δ 8.43–8.46 (m, 2H), 8.15–8.17 (d, $J = 9.0$ Hz, 1H), 7.89–7.92 (m, 2H), 7.34–7.38 (m, 1H), 7.30–7.31 (m, 1H), 7.03–7.06 (m, 1H), 5.12 (s, 2H), 3.37–3.41 (m, 1H), 1.02–1.03 (d, $J = 5.5$ Hz, 4H); LCMS (ESI) m/z : 414.0 $[M+H]^+$.

40 Compound **366**: ^1H NMR (400 MHz, DMSO- d_6) δ 9.05 (d, $J = 2$ Hz, 1H), 8.34 (d, $J = 2$ Hz, 1H), 8.26 (dd, $J = 2$ Hz, 8.4 Hz, 1H), 8.13 (d, $J = 8.8$ Hz, 1H), 7.73 (dd, $J = 2$ Hz, 8.4 Hz, 1H), 7.41 (d, $J = 8.4$ Hz, 1H), 7.19–7.38 (m, 4H), 4.71 (brs, 1H), 3.98 (s, 2H), 3.78 (t, $J = 6.4$ Hz, 2H), 2.95 (t, $J = 6.4$ Hz, 2H); LCMS (ESI) m/z : 368.1 $[M+H]^+$.

Compound **367**: ^1H NMR (400 MHz, DMSO- d_6) δ 10.12 (s, 1H), 8.56 (s, 1H), 8.19 (d, J = 2.6 Hz, 1H), 8.09 (d, J = 8.9 Hz, 1H), 7.96 (d, J = 9.7 Hz, 1H), 7.69 (dd, J = 8.9, 2.8 Hz, 1H), 7.25 (t, J = 7.9 Hz, 1H), 7.09 (d, J = 9.7 Hz, 1H), 6.99 (d, J = 7.9 Hz, 2H), 6.85 (d, J = 7.1 Hz, 1H), 3.80 (s, 3H); LCMS (ESI) m/z : 356.0 $[\text{M}+\text{H}]^+$.

5 Compound **369**: ^1H NMR (500 MHz, DMSO- d_6) δ 8.31 (d, J = 8.0 Hz, 1H), 7.84 (d, J = 10.0 Hz, 1H), 7.31 (t, J = 8.0 Hz, 1H), 7.05–6.95 (m, 4H), 4.63 (s, 1H), 3.90–3.84 (m, 1H), 3.74 (s, 3H), 1.95–1.93 (m, 2H), 1.80–1.73 (m, 2H), 1.69–1.60 (m, 4H); LCMS (ESI) m/z : 362.0 $[\text{M}+\text{H}]^+$.

10 Compound **370**: ^1H NMR (400 MHz, DMSO- d_6) δ 9.67 (s, 1H), 8.14 (d, J = 2.0 Hz, 1H), 8.01 (d, J = 8.4 Hz, 1H), 7.65 (dd, J = 8.4, 2.4 Hz, 1H), 3.36 (s, 2H), 2.85 (t, J = 8.6 Hz, 2H), 2.53 (d, J = 8.8 Hz, 1H), 2.45 (d, J = 6.8 Hz, 2H), 1.66–1.58 (m, 5H), 1.54–1.43 (m, 1H), 1.24–1.08 (m, 3H), 0.96–0.87 (m, 2H); LCMS (ESI) m/z : 329.2 $[\text{M}+\text{H}]^+$.

15 Compound **371**: ^1H NMR (400 MHz, DMSO- d_6) δ 10.03 (s, 1H), 8.32 (d, J = 1.5 Hz, 1H), 8.09 (d, J = 8.6 Hz, 1H), 7.91 (d, J = 2.2 Hz, 1H), 7.85 (d, J = 8.6 Hz, 1H), 7.38 (ddd, J = 17.0, 9.3, 5.3 Hz, 2H), 7.19 – 7.08 (m, 1H), 6.87 (d, J = 2.3 Hz, 1H), 3.98 (s, 5H); LCMS (ESI) m/z : 329.1 $[\text{M}+\text{H}]^+$.

20 Compound **372**: ^1H NMR (400 MHz, DMSO- d_6) δ 10.33 (s, 1H), 8.70 (d, J = 2.8 Hz, 1H), 8.34 (d, J = 1.9 Hz, 1H), 8.07 (d, J = 8.5 Hz, 1H), 7.75 (dd, J = 8.5, 2.3 Hz, 1H), 7.40 – 7.30 (m, 1H), 7.25 (d, J = 2.4 Hz, 1H), 7.13 (dd, J = 10.8, 4.5 Hz, 2H), 7.04 (d, J = 2.3 Hz, 1H), 3.99 (s, 2H); LCMS (ESI) m/z : 365.0 $[\text{M}+\text{H}]^+$.

25 Compound **373**: ^1H NMR (400 MHz, DMSO- d_6) δ 10.61 (s, 1H), 8.43 (s, 1H), 8.32 (d, J = 1.6 Hz, 1H), 8.13 (s, 1H), 8.07 (d, J = 8.8 Hz, 1H), 7.76 (d, J = 8.6 Hz, 1H), 7.10–7.03 (m, 3H), 3.98 (s, 2H), 3.88 (s, 3H); LCMS (ESI) m/z : 341.0 $[\text{M}+\text{H}]^+$.

30 Compound **374**: ^1H NMR (400 MHz, DMSO- d_6) δ 10.99 (brs, 1H), 9.04 (d, J = 2 Hz, 1H), 8.28–8.38 (m, 2H), 8.13 (d, J = 8.4 Hz, 1H), 7.68–7.80 (m, 2H), 7.19–7.40 (m, 4H), 5.38 (s, 1H), 3.98 (s, 2H), 1.46 (s, 6H); LCMS (ESI) m/z : 382.1 $[\text{M}+\text{H}]^+$.

35 Compound **375**: ^1H NMR (400 MHz, DMSO- d_6) δ 11.08 (s, 1H), 9.08 (s, 1H), 8.42 (dd, J = 8.0, 2.0 Hz, 1H), 8.20 (d, J = 1.6 Hz, 1H), 8.10 (d, J = 8.4 Hz, 1H), 7.71–7.64 (m, 1H), 4.67 (s, 2H), 2.48 (m, 2H), 1.68–1.61 (m, 5H), 1.53–1.48 (m, 1H), 1.24–1.10 (m, 3H), 0.98–0.89 (m, 2H); LCMS (ESI) m/z : 326.2 $[\text{M}+\text{H}]^+$.

40 Compound **376**: ^1H NMR (300 MHz, Chloroform- d) δ 8.55 (d, J = 9.1 Hz, 1H), 8.02 (d, J = 9.7 Hz, 1H), 7.43 (d, J = 9.0 Hz, 1H), 7.31 (d, J = 6.3 Hz, 2H), 7.06 (d, J = 9.7 Hz, 2H), 6.98 (d, J = 2.1 Hz, 2H), 4.36 (s, 2H), 4.16 (d, J = 7.5 Hz, 2H), 1.54 – 1.36 (m, 1H), 0.68 – 0.57 (m, 2H), 0.52 (d, J = 4.9 Hz, 2H); LCMS (ESI) m/z : 380.3 $[\text{M}+\text{H}]^+$.

45 Compound **377**: ^1H NMR (500 MHz, DMSO- d_6) δ 12.17 (s, 1H), 7.37–7.33 (m, 1H), 7.28 (s, 1H), 7.11–7.03 (m, 3H), 4.11 (s, 2H), 3.57 (t, J = 8.7 Hz, 1H), 3.44–3.36 (m, 2H), 2.70 (s, 3H), 2.54 – 2.48 (m, 1H), 2.46–2.41 (m, 1H); LCMS (ESI) m/z : 334.1 $[\text{M}+\text{H}]^+$.

50 Compound **378**: ^1H NMR (400 MHz, DMSO- d_6) δ 11.81 (s, 1H), 7.32 – 7.22 (m, 2H), 7.17 – 7.06 (m, 2H), 6.88 (s, 1H), 3.97 (s, 2H), 3.34 (s, 3H), 2.83 (t, J = 8.5 Hz, 2H), 2.53 (t, J = 8.4 Hz, 2H); LCMS (ESI) m/z : 347.1 $[\text{M}+\text{H}]^+$.

55 Compound **379**: ^1H NMR (500 MHz, DMSO- d_6) δ 11.23 (s, 1H), 8.70 (d, J = 2.6 Hz, 1H), 8.27 (d, J = 9.2 Hz, 1H), 7.96 (dd, J = 9.5, 2.6 Hz, 1H), 7.61 (d, J = 9.5 Hz, 1H), 7.36 – 7.32 (m, 2H), 7.20 – 7.07

(m, 2H), 6.45 (d, $J = 9.5$ Hz, 1H), 4.26 (s, 2H), 3.99 (q, $J = 7.1$ Hz, 2H), 1.29 (t, $J = 7.1$ Hz, 3H); LCMS (ESI) m/z : 353.1 $[M+H]^+$.

Compound **380**: ^1H NMR (400 MHz, Dimethylsulfoxide- d_6) δ 11.96 (s, 1H), 7.84 (d, 1H, $J = 7.6$ Hz), 7.68 (t, 1H, $J = 7.6$ Hz), 7.57 (d, 1H, $J = 7.6$ Hz), 7.47 (d, 1H, $J = 7.6$ Hz), 7.32 (s, 1H), 4.33 (s, 2H), 3.35 (s, 3H), 2.82 (t, 2H, $J = 8.4$ Hz), 2.51 (t, 2H, $J = 8.4$ Hz); LCMS (ESI) m/z : 354.1 $[M+H]^+$.

Compound **381**: ^1H NMR (300 MHz, Chloroform- d) δ 8.56 – 8.40 (m, 1H), 7.91 (s, 1H), 7.48 (dd, $J = 8.0, 2.3$ Hz, 1H), 7.36 – 7.23 (m, 2H), 7.04 – 6.80 (m, 3H), 4.64 (d, $J = 5.6$ Hz, 2H), 3.98 (s, 2H), 3.43 (s, 3H), 3.00 – 2.85 (m, 2H), 2.53 (t, $J = 8.5$ Hz, 2H); LCMS (ESI) m/z : 355.4 $[M+H]^+$.

Compound **382**: ^1H NMR (500 MHz, MeOD) δ 8.36 (d, $J = 5.8$ Hz, 1H), 7.73 (dd, $J = 5.8, 2.1$ Hz, 1H), 7.67 (d, $J = 1.9$ Hz, 1H), 7.34 – 7.25 (m, 2H), 7.25 – 7.15 (m, 2H), 4.09 (s, 2H), 3.45 (s, 3H), 2.91 (t, $J = 8.6$ Hz, 2H), 2.57 (t, $J = 8.6$ Hz, 2H); LCMS (ESI) m/z : 357.1 $[M+H]^+$.

Compound **383**: ^1H NMR (400 MHz, DMSO- d_6) δ 9.69 (s, 1H), 8.27 (d, $J = 2.0$ Hz, 1H), 8.01 (d, $J = 6.8$ Hz, 1H), 7.68–7.70 (m, 1H), 7.16 (s, 4H), 3.90 (s, 4H), 3.36 (s, 3H), 2.82–2.86 (m, 2H), 2.52–2.54 (m, 2H), 1.17 (d, $J = 5.6$ Hz, 6H); LCMS (ESI) m/z : 365.2 $[M+H]^+$.

Compound **384**: ^1H NMR (400 MHz, DMSO- d_6) δ 10.89 (s, 1H), 8.31 (d, $J = 9.0$ Hz, 1H), 7.95 (d, $J = 9.5$ Hz, 1H), 7.72 (d, $J = 9.5$ Hz, 1H), 7.32 (d, $J = 2$ Hz, 1H), 7.28 (s, 1H), 7.19 (d, $J = 9$ Hz, 1H), 7.08 (d, $J = 10$ Hz, 1H), 4.32 (s, 2H), 3.81 (s, 3H); LCMS (ESI) m/z : 374.1 $[M+H]^+$.

Compound **385**: ^1H NMR (500 MHz, DMSO- d_6) δ 11.73 (s, 1H), 9.82 (s, 1H), 7.28 – 7.15 (m, 2H), 6.83 (d, $J = 2.4$ Hz, 1H), 6.72 (dd, $J = 8.4, 2.4$ Hz, 1H), 4.08 (s, 2H), 3.34 (s, 3H), 2.82 (t, $J = 8.5$ Hz, 2H), 2.52 (t, $J = 8.5$ Hz, 2H); LCMS (ESI) m/z : 379.0 $[M+H]^+$.

Compound **386**: ^1H NMR (500 MHz, DMSO- d_6) δ 12.06 (s, 1H), 7.40 – 7.33 (m, 2H), 7.16 – 7.10 (m, 2H), 7.07 (td, $J = 8.5, 2.0$ Hz, 1H), 4.80 (t, $J = 5.0$ Hz, 1H), 4.71 (t, $J = 5.0$ Hz, 1H), 4.15 (s, 2H), 4.09 (t, $J = 5.0$ Hz, 1H), 4.06 – 3.99 (m, 1H), 2.84 (q, $J = 8.4$ Hz, 2H), 2.56 (t, $J = 8.5$ Hz, 2H); LCMS (ESI) m/z : 379.0 $[M+H]^+$.

Compound **387**: ^1H NMR (400 MHz, DMSO- d_6) δ 9.77 (s, 1H), 7.94–7.94 (d, $J = 2.8$ Hz, 1H), 7.54 (d, $J = 1.2$ Hz, 1H), 7.28–7.40 (m, 4H), 4.00 (s, 2H), 3.84 (s, 3H), 3.33 (s, 3H), 2.80–2.84 (t, $J = 6.8$ Hz, 2H), 2.51–2.53 (m, 2H); LCMS (ESI) m/z : 387.1 $[M+H]^+$.

Compound **388**: ^1H NMR (400 MHz, CDCl $_3$) δ = 9.23 (s, 1H), 7.55 (s, 1H), 7.36 – 7.29 (m, 1H), 7.12 (d, $J = 7.7$ Hz, 1H), 7.07 – 6.93 (m, 2H), 4.28 (s, 2H), 3.49 (s, 3H), 3.03 – 2.92 (m, 2H), 2.60 (t, $J = 8.6$ Hz, 2H); LCMS (ESI) 347.1 $[M+H]^+$.

Compound **389**: ^1H NMR (500 MHz, Dimethylsulfoxide- d_6) δ 12.34 (s, 1H), 7.90 (d, $J = 9.7$ Hz, 1H), 7.80 (s, 1H), 7.72 (d, $J = 8.0$ Hz, 1H), 7.65 (d, $J = 7.5$ Hz, 1H), 7.55 (t, $J = 7.5$ Hz, 1H), 7.38 (s, 1H), 7.06 (d, $J = 9.7$ Hz, 1H), 4.21 (s, 2H), 3.77 (s, 3H); LCMS (ESI) 352.0 $[M+H]^+$.

Compound **390**: ^1H NMR (500 MHz, DMSO- d_6) δ 8.38 (d, $J = 8.5$ Hz, 1H), 7.98 (d, $J = 7.9$ Hz, 1H), 7.90 (d, $J = 8.4$ Hz, 1H), 7.78 – 7.71 (m, 1H), 7.60 (t, $J = 7.5$ Hz, 1H), 7.51 – 7.49 (m, 2H), 7.41 (d, $J = 3.5$ Hz, 1H), 6.01 (s, 2H), 2.89 (t, $J = 8.25$ Hz, 5H), 2.31 (t, $J = 8.4$ Hz, 2H); LCMS (ESI) 380.0 $[M+H]^+$.

Compound **391**: ^1H NMR (500 MHz, DMSO- d_6) δ 11.18 (s, 1H), 8.53 (s, 1H), 8.36 – 8.29 (m, 2H), 8.15 – 8.11 (m, 2H), 7.84 – 7.73 (m, 2H), 7.36 (dd, $J = 14.4, 8.0$ Hz, 1H), 7.17 – 6.99 (m, 3H), 4.00 (s, 2H), 3.30 (s, 3H); LCMS (ESI) 385.0 $[M+H]^+$.

Compound **392**: ^1H NMR (500 MHz, DMSO- d_6) δ 9.71 (s, 1H), 8.33 (d, J = 1.7 Hz, 1H), 8.28 (d, J = 1.9 Hz, 1H), 8.02 (d, J = 8.5 Hz, 1H), 7.70 (dd, J = 8.5, 2.2 Hz, 1H), 7.49 (dd, J = 8.0, 2.1 Hz, 1H), 7.20 (d, J = 8.0 Hz, 1H), 3.90 (s, 2H), 3.35 (s, 3H), 2.85 (t, J = 8.5 Hz, 2H), 2.52 (t, J = 8.3 Hz, 2H), 2.05 – 2.02 (m, 1H), 0.92 – 0.84 (m, 4H); LCMS (ESI) m/z 364.1 $[\text{M}+\text{H}]^+$.

5 Compound **393**: ^1H NMR (500 MHz, CH₃OD) δ 8.14 (d, J = 11.9 Hz, 2H), 7.54 (d, J = 8.8 Hz, 1H), 7.30 (ddd, J = 40.7, 24.1, 7.6 Hz, 4H), 4.51 (s, 4H), 4.08 (s, 2H), 3.70 – 3.49 (m, 4H), 2.04 – 1.88 (m, 4H); LCMS (ESI) m/z : 372.1 $[\text{M}+\text{H}]^+$.

10 Compound **394**: ^1H NMR (500 MHz, Dimethylsulfoxide- d_6) δ 11.20 (s, 1H), 8.33 (d, 1H, J = 9.5 Hz), 7.97 (d, 1H, J = 9 Hz), 7.79 (s, 1H), 7.62-7.70 (m, 2H), 7.37-7.56 (m, 3H), 2.17 (s, 3H); LCMS (ESI) m/z : 274.0 $[\text{M}+\text{H}]^+$.

Compound **395**: ^1H NMR (300 MHz, Chloroform- d) δ 8.62 (d, J = 9.1 Hz, 1H), 8.04 (d, J = 9.7 Hz, 1H), 7.49 (d, J = 9.1 Hz, 1H), 7.07 (d, J = 9.7 Hz, 1H), 3.95 (s, 3H), 2.89 (d, J = 7.3 Hz, 2H), 2.15 (m, 1H), 1.00 (d, J = 6.6 Hz, 6H); LCMS (ESI) m/z : 288.2 $[\text{M}+\text{H}]^+$.

15 Compound **396**: ^1H NMR (500 MHz, Dimethylsulfoxide- d_6) δ 9.83 (s, 1H), 8.28 (d, J = 1.7 Hz, 1H), 8.07 (d, J = 8.5 Hz, 1H), 7.79 (dd, J = 8.5, 2.0 Hz, 1H), 4.48 (s, 2H), 3.36 (s, 3H), 2.86 (t, J = 8.5 Hz, 2H), 2.60 – 2.51 (m, 2H), 1.42 (s, 3H), 0.78 (t, J = 5.5 Hz, 2H), 0.45 (q, J = 4.9 Hz, 2H); LCMS (ESI) m/z : 317.2 $[\text{M}+\text{H}]^+$.

20 Compound **397**: ^1H NMR (500 MHz, DMSO- d_6) δ 7.91 (d, J = 2 Hz, 1H), 7.26-7.34 (m, 2H), 6.95-7.09 (m, 3H), 6.71 (t, J = 5.5 Hz, 1H), 6.48 (d, J = 8.5 Hz, 1H), 4.07 (d, J = 6 Hz, 2H), 3.77 (s, 2H), 3.18 (s, 3H), 2.45 (t, J = 8 Hz, 2H), 2.31 (t, J = 8 Hz, 2H); LCMS (ESI) m/z : 327.1 $[\text{M}+\text{H}]^+$.

Compound **398**: ^1H NMR (400 MHz, CDCl₃) δ 8.57 (br s, 1H), 8.46 (br d, J = 4.0 Hz, 1H), 7.74 (br d, J = 7.8 Hz, 1H), 7.34 (br dd, J = 4.8, 7.6 Hz, 1H), 6.60 (br s, 1H), 4.99 (d, J = 1.7 Hz, 2H), 3.46 (s, 3H), 2.99 - 2.92 (m, 2H), 2.61 (br t, J = 8.6 Hz, 2H); LCMS (ESI) m/z : 330.0 $[\text{M}+\text{H}]^+$.

25 Compound **399**: ^1H NMR (500 MHz, CDCl₃) δ 7.33 (dd, J = 14.5, 7.5 Hz, 1H), 7.07 (d, J = 7.5 Hz, 1H), 7.00 (t, J = 7.5 Hz, 2H), 6.74 (s, 1H), 4.03 (s, 2H), 3.49 (s, 3H), 2.97 (t, J = 8.5 Hz, 2H), 2.61 (t, J = 8.5 Hz, 2H); LCMS (ESI) m/z : 331.1 $[\text{M}+\text{H}]^+$.

Compound **400**: ^1H NMR (500 MHz, DMSO- d_6) δ 12.36 (s, 1H), 7.38 – 7.31 (m, 2H), 7.12 – 7.03 (m, 3H), 4.34 – 4.32 (m, 1H), 4.12 (s, 2H), 2.64 (s, 3H), 2.30 – 2.18 (m, 3H), 1.92 – 1.87 (m, 1H); LCMS (ESI) m/z : 334.1 $[\text{M}+\text{H}]^+$.

30 Compound **401**: ^1H NMR (500 MHz, DMSO- d_6) δ 10.21 (s, 1H), 8.82 (d, J = 2.4 Hz, 1H), 8.07 (dd, J = 8.4, 2.5 Hz, 1H), 7.40 – 7.22 (m, 2H), 7.17 – 7.06 (m, 2H), 7.03 (s, 1H), 4.07 (s, 2H), 3.37 (s, 3H), 2.83 (t, J = 8.5 Hz, 2H), 2.52 (d, J = 9.8 Hz, 2H); LCMS (ESI) m/z : 341.1 $[\text{M}+\text{H}]^+$.

35 Compound **402**: ^1H NMR (400 MHz, DMSO- d_6) δ 9.76 (s, 1H), 8.33 (d, J = 2.0 Hz, 1H), 8.06 (d, J = 8.5 Hz, 1H), 7.79 (dd, J = 8.5, 2.3 Hz, 1H), 7.38 (d, J = 1.2 Hz, 1H), 4.27 (s, 2H), 3.36 (s, 3H), 2.85 (t, J = 8.5 Hz, 2H), 2.85 (t, J = 6.8 Hz, 2H), 2.37 (s, 3H); LCMS (ESI) m/z : 344.0 $[\text{M}+\text{H}]^+$.

Compound **403**: ^1H NMR (500 MHz, CH₃OD) δ 8.11 (d, J = 11.3 Hz, 2H), 7.50 (d, J = 8.8 Hz, 1H), 7.30 (ddd, J = 41.7, 24.7, 7.7 Hz, 4H), 4.31 (dd, J = 22.0, 13.1 Hz, 4H), 4.07 (s, 2H), 3.73 (dq, J = 9.1, 5.9 Hz, 1H), 2.23 (s, 3H); LCMS (ESI) m/z : 344.0 $[\text{M}+\text{H}]^+$.

40 Compound **404**: ^1H NMR (400 MHz, DMSO- d_6) δ 12.37 (s, 1H), 8.17-8.19 (d, J = 7.2 Hz, 1H), 7.43-7.45 (d, J = 7.2 Hz, 1H), 7.37-7.39 (m, 2H), 7.13-7.16 (m, 2H), 7.07 (m, 1H), 4.17 (s, 2H), 4.15 (s, 3H); LCMS (ESI) m/z : 345.1 $[\text{M}+\text{H}]^+$.

Compound **405**: ^1H NMR (500 MHz, DMSO- d_6) δ 10.31 (s, 1H), 8.14 (s, 1H), 7.68 (s, 1H), 7.44-7.31 (m, 2H), 7.26 (s, 1H), 7.19 (d, J = 6.5 Hz, 1H), 5.33 (s, 2H), 3.34 (s, 3H), 2.82 (t, J = 8.5 Hz, 2H), 2.48 (d, J = 8.5 Hz, 2H); LCMS (ESI) m/z : 346.1 $[\text{M}+\text{H}]^+$.

Compound **406**: ^1H NMR (400 MHz, DMSO- d_6) δ 11.61 (s, 1H), 7.34 (td, J = 7.9, 6.1 Hz, 1H), 7.12 – 6.99 (m, 3H), 6.93 (s, 1H), 4.00 (s, 2H), 3.34 (s, 3H), 2.84 (t, J = 8.5 Hz, 2H), 2.51 (t, J = 8.5 Hz, 2H); LCMS (ESI) m/z : 347.0 $[\text{M}+\text{H}]^+$.

Compound **407**: ^1H NMR (500 MHz, Dimethylsulfoxide- d_6) δ 11.03 (s, 1H), 7.36 – 7.20 (m, 4H), 3.98 (s, 3H), 3.33 (s, 3H), 2.81 (q, J = 8.9 Hz, 2H), 2.53 (s, 2H); LCMS (ESI) m/z : 347.0 $[\text{M}+\text{H}]^+$.

Compound **408**: ^1H NMR (400 MHz, CDCl_3) δ 10.30 (br s, 1H), 7.33 - 7.27 (m, 1H), 7.10 (d, J = 7.6 Hz, 1H), 7.03 (br d, J = 9.7 Hz, 1H), 6.95 (dt, J = 2.5, 8.5 Hz, 1H), 4.21 (s, 2H), 3.46 (s, 3H), 3.01 (t, J = 8.6 Hz, 2H), 2.71 - 2.57 (m, 2H); LCMS (ESI) m/z : 348.0 $[\text{M}+\text{H}]^+$.

Compound **409**: ^1H NMR (400 MHz, DMSO- d_6) δ 11.48 (s, 1H), 7.38-7.44 (m, 3H), 7.31(s, 1H), 4.30 (s, 2H), 3.39 (s, 3H), 2.79 (t, J = 6.8 Hz, 2H), 2.50-2.53 (m, 2H); LCMS (ESI) m/z : 348.1 $[\text{M}+\text{H}]^+$.

Compound **410**: ^1H NMR (500 MHz, DMSO- d_6) δ 11.25 (s, 1H), 8.71 (d, J = 2.6 Hz, 1H), 8.27 (d, J = 9.2 Hz, 1H), 7.96 (dd, J = 9.5, 2.6 Hz, 1H), 7.64 (d, J = 9.2 Hz, 1H), 7.37 (dd, J = 14.2, 7.8 Hz, 1H), 7.19 – 7.02 (m, 3H), 6.45 (d, J = 9.5 Hz, 1H), 4.27 (s, 2H), 3.99 (q, J = 7.1 Hz, 2H), 1.29 (t, J = 7.1 Hz, 3H); LCMS (ESI) m/z : 353.1 $[\text{M}+\text{H}]^+$.

Compound **411**: ^1H NMR (300 MHz, Chloroform- d) δ 8.46 (s, 1H), 8.39 (s, 1H), 7.96 (d, J = 9.6 Hz, 1H), 7.67 (s, 1H), 7.46 (s, 1H), 7.31 (s, 5H), 7.04 – 6.90 (m, 3H), 6.87 (d, J = 9.6 Hz, 1H), 4.79 (d, J = 5.8 Hz, 2H), 4.03 (s, 2H), 3.87 (s, 3H); LCMS (ESI) m/z : 353.5 $[\text{M}+\text{H}]^+$.

Compound **412**: ^1H NMR (500 MHz, Dimethylsulfoxide- d_6) δ 9.72 (s, 1H), 8.23 (d, J = 1.8 Hz, 1H), 8.06 (d, J = 8.4 Hz, 1H), 7.76 (d, J = 2.2 Hz, 1H), 3.45 (s, 2H), 3.36 (s, 3H), 2.86 (t, J = 8.5 Hz, 2H), 2.54 (d, J = 8.5 Hz, 2H), 2.32 (s, 4H), 1.31 (t, J = 5.5 Hz, 4H), 0.88 (s, 6H); LCMS (ESI) m/z : 358.3 $[\text{M}+\text{H}]^+$.

Compound **413**: ^1H NMR (400 MHz, DMSO- d_6) δ 12.75 (s, 1H), 8.23 (s, 1H), 7.72 (dt, J = 7.6, 1.4 Hz, 1H), 7.71 – 7.59 (m, 2H), 7.54 (tdd, J = 8.4, 2.7, 1.1 Hz, 1H), 3.38 (s, 3H), 2.89 (t, J = 8.5 Hz, 2H), 2.56 (t, J = 8.5 Hz, 2H); LCMS (ESI) m/z : 361.0 $[\text{M}+\text{H}]^+$.

Compound **414**: ^1H NMR (400 MHz, CDCl_3) δ 9.99 (br s, 1H), 7.33 - 7.22 (m, 1H), 7.20 (s, 1H), 7.03 (br d, J = 7.5 Hz, 1H), 6.97 - 6.89 (m, 2H), 4.10 (s, 2H), 3.93 - 3.80 (m, 2H), 2.95 (dt, J = 2.2, 8.6 Hz, 2H), 2.58 (dt, J = 2.2, 8.5 Hz, 2H), 1.25 (dt, J = 2.3, 7.0 Hz, 3H); LCMS (ESI) m/z : 361.1 $[\text{M}+\text{H}]^+$.

Compound **415**: ^1H NMR (400 MHz, DMSO- d_6) δ 10.45 (s, 1H), 8.55 (s, 1H), 8.37-8.38 (m, 2H), 8.15 (d, J = 8.5 Hz, 1H), 8.05 (d, J = 0.5 Hz, 1H), 7.80-7.86 (m, 2H), 7.25-7.38 (m, 4H), 4.00 (s, 2H); LCMS (ESI) m/z : 364.0 $[\text{M}+\text{H}]^+$.

Compound **416**: ^1H NMR (500 MHz, CDCl_3) δ 7.48 (dd, J = 8.0, 1.5 Hz, 1H), 7.26 (dd, J = 8.5, 1.5 Hz, 1H), 7.18-7.10 (m, 3H), 3.50 (s, 3H), 2.99 (t, J = 8.5 Hz, 2H), 2.63 (t, J = 8.5 Hz, 2H); LCMS (ESI) m/z : 365.0 $[\text{M}+\text{H}]^+$.

Compound **417**: ^1H NMR (400 MHz, DMSO- d_6) δ 10.11 (s, 1H), 8.35 (s, 1H), 8.14-8.35 (m, 3H), 7.77-7.79 (m, 1H), 7.33-7.37 (m, 1H), 7.02-7.14 (m, 3H), 3.80 (s, 2H); LCMS (ESI) m/z : 366.1 $[\text{M}+\text{H}]^+$.

Compound **418**: ^1H NMR (500 MHz, Dimethylsulfoxide- d_6) δ 10.51 (brs, 1H), 8.35 (d, 1H, J = 9 Hz), 8.06 (d, 1H, J = 9 Hz), 7.82 (s, 1H), 7.65-7.74 (m, 2H), 7.56 (d, 1H, J = 16.5 Hz), 7.40-7.49 (m, 2H), 3.40 (s, 3H), 2.88 (t, 2H, J = 8.5 Hz), 2.56 (t, 2H, J = 8.5 Hz); LCMS (ESI) m/z : 370.1 $[\text{M}+\text{H}]^+$.

Compound **419**: ^1H NMR (500 MHz, DMSO- d_6) δ 11.84 (s, 1H), 7.25-7.41 (m, 4H), 7.02-7.09 (m, 1H), 6.35 (s, 1H), 3.34 (s, 3H), 2.77-2.86 (m, 2H), 2.50-2.56 (m, 2H), 1.89 (s, 3H); LCMS (ESI) m/z : 377.1 $[\text{M}+\text{H}]^+$.

Compound **420**: ^1H NMR (500 MHz, CDCl $_3$) δ 10.23 (s, 1H), 7.27-7.30 (m, 1H), 7.18 (s, 1H), 7.03 (d, J = 7.5 Hz, 1H), 6.92-6.95 (m, 2H), 4.09 (s, 2H), 4.04 (t, J = 5.5 Hz, 2H), 3.92 (t, J = 5.5 Hz, 2H), 2.93 (t, J = 8.5 Hz, 2H), 2.73 (s, 1H), 2.59 (t, J = 8.5 Hz, 2H); LCMS (ESI) m/z : 377.1 $[\text{M}+\text{H}]^+$.

Compound **421**: ^1H NMR (500 MHz, Dimethylsulfoxide- d_6) δ 10.20 (s, 1H), 8.35 (s, 1H), 8.08 (d, J = 8.5 Hz, 1H), 7.92 (d, J = 9.5 Hz, 1H), 7.76 (dd, J = 8.5, 2.0 Hz, 1H), 7.37-7.33 (m, 1H), 7.12-7.10 (m, 2H), 7.05-7.02 (m, 2H), 5.33-5.30 (m, 1H), 4.00 (s, 2H), 2.63-2.55 (m, 2H), 2.33-2.28 (m, 2H), 1.87-1.80 (m, 2H); LCMS (ESI) m/z : 379.1 $[\text{M}+\text{H}]^+$.

Compound **422**: ^1H NMR (500 MHz, DMSO- d_6) δ 8.38 (d, J = 8.5 Hz, 1H), 7.97 (d, J = 7.7 Hz, 1H), 7.90 (d, J = 8.5 Hz, 1H), 7.78 (d, J = 4.7 Hz, 1H), 7.77-7.73 (m, 1H), 7.61 – 7.58 (m, 1H), 7.52 (d, J = 8.5 Hz, 1H), 7.18 (d, J = 4.7 Hz, 1H), 5.74 (s, 2H), 3.26 (s, 3H), 2.81 (t, J = 8.4 Hz, 2H), 2.36 (t, J = 8.4 Hz, 2H); LCMS (ESI) m/z : 379.4 $[\text{M}+\text{H}]^+$.

Compound **423**: ^1H NMR (500 MHz, DMSO- d_6) δ 11.12 (s, 1H), 8.36 (d, J = 2.0 Hz, 1H), 8.25 – 8.19 (m, 2H), 8.12 (d, J = 8.5 Hz, 1H), 8.06 (d, J = 8.5 Hz, 2H), 7.76 (dd, J = 8.5, 2.4 Hz, 1H), 7.39 – 7.32 (m, 1H), 7.16 – 7.00 (m, 3H), 4.00 (s, 2H), 3.30 (s, 3H); LCMS (ESI) m/z : 385.0 $[\text{M}+\text{H}]^+$.

Compound **424**: ^1H NMR (500 MHz, DMSO- d_6) δ 11.98 (s, 1H), 7.48 (s, 1H), 7.32-7.44 (m, 2H), 7.08-7.25 (m, 3H), 3.35 (s, 3H), 3.18 (s, 3H), 2.78-2.84 (m, 2H), 2.48-2.54 (m, 2H), 1.89 (s, 3H); LCMS (ESI) m/z : 391.0 $[\text{M}+\text{H}]^+$.

Compound **425**: ^1H NMR (400 MHz, DMSO- d_6) δ 9.48 (brs, 1H), 8.35 (s, 1H), 8.29 (d, J = 6 Hz, 1H), 8.11 (d, J = 8.4 Hz, 1H), 7.78 (dd, J = 2 Hz, 8.4 Hz, 1H), 7.29-7.39 (m, 1H), 7.08-7.18 (m, 2H), 6.98-7.07 (m, 1H), 6.95 (d, J = 6 Hz, 1H), 3.99 (s, 2 H); LCMS (ESI) m/z : 325.1 $[\text{M}+\text{H}]^+$.

Compound **426**: ^1H NMR (400 MHz, DMSO- d_6) δ 10.29 (bs, 1H), 8.85 (d, J = 2.4 Hz, 1H), 8.32 (d, J = 1.9 Hz, 1H), 8.02 (t, J = 2.2 Hz, 1H), 7.92 (d, J = 9.7 Hz, 1H), 7.39 – 7.32 (m, 2H), 7.31 – 7.27 (m, 1H), 7.27 – 7.21 (m, 1H), 7.07 (d, J = 9.7 Hz, 1H), 4.01 (s, 2H), 3.79 (s, 3H); LCMS (ESI) m/z : 355.0 $[\text{M}+\text{H}]^+$.

Compound **427**: ^1H NMR (400 MHz, DMSO- d_6) δ 10.48 (s, 1H), 8.65 (d, J = 2.4 Hz, 1H), 8.19 (d, J = 3.2 Hz, 1H), 8.07 (d, J = 8.8 Hz, 1H), 7.98 (dd, J = 9.2, 2.4 Hz, 1H), 7.86 (dd, J = 8.8, 2.4 Hz, 1H), 7.83 (s, 1H), 7.73 (d, J = 10.0 Hz, 1H), 7.57 (dd, J = 8.8, 2.8 Hz, 1H), 6.43 (d, J = 9.6 Hz, 1H), 5.25 (s, 2H), 3.50 (s, 3H); LCMS (ESI) m/z : 379.0 $[\text{M}+\text{H}]^+$.

Compound **428**: ^1H NMR (400 MHz, DMSO- d_6) δ 10.53 (s, 1H), 9.23 (d, J = 1.2 Hz, 1H), 8.58 (dd, J = 8.4, 2.0 Hz, 1H), 8.51 (s, 1H), 8.32 (dd, J = 14.0, 8.0 Hz, 2H), 8.02 (dd, J = 8.4, 2.0 Hz, 1H), 7.37 (t, J = 9.2 Hz, 1H), 7.32 (dd, J = 6.0, 2.8 Hz, 1H), 7.08-7.04 (m, 1H), 5.15 (s, 2H), 3.95 (s, 3H); LCMS (ESI) m/z : 416.0 $[\text{M}+\text{H}]^+$.

Compound **429**: ^1H NMR (400 MHz, DMSO- d_6) δ 11.17 (s, 1H), 9.39 (s, 1H), 8.65 (d, J = 7.2 Hz, 1H), 8.53 (s, 1H), 8.37 (d, J = 2.0 Hz, 1H), 8.12 (d, J = 8.4 Hz, 1H), 7.76 (dd, J = 8.4, 2.0 Hz, 1H), 7.45 – 7.25 (m, 5H), 4.00 (s, 2H); LCMS (ESI) m/z : 364.0 $[\text{M}+\text{H}]^+$.

Compound **430**: ^1H NMR (400 MHz, DMSO- d_6) δ 12.33 (s, 1H), 7.89 (dd, J_1 = 4.0 Hz, J_2 = 9.6 Hz, 1H), 7.69 (s, 1H), 7.31-7.39 (m, 2H), 7.17-7.19 (m, 2H), 7.05-7.09 (m, 2H), 4.62 (s, 2H), 3.78 (s, 3H); LCMS (ESI) m/z : 388.0 $[\text{M}+\text{H}]^+$.

Compound **431**: ^1H NMR (400 MHz, DMSO- d_6) δ 12.66 (bs, 1H), 8.73 (d, J = 1.2 Hz, 1H), 8.00 (dd, J = 9.6, 2.4 Hz, 1H), 7.36 (dt, J = 8.8, 2.4 Hz, 1H), 7.32 (s, 1H), 7.25-7.22 (m, 1H), 6.45 (d, J = 9.2 Hz, 1H), 4.41 (s, 2H), 3.49 (s, 3H); LCMS (ESI) m/z : 379.0 $[\text{M}+\text{H}]^+$.

Compound **432**: ^1H NMR (400 MHz, DMSO- d_6) δ 7.59 (d, J = 9.6 Hz, 1H), 7.30 - 7.28 (t, J = 8.2 Hz, 1H), 7.10 - 7.08 (t, J = 2.1 Hz, 1H), 7.03 - 6.93 (m, 3H), 4.79 - 4.68 (m, 1H), 4.01 - 3.89 (m, 1H), 3.80 (d, J = 14.3 Hz, 1H), 3.65 (s, 3H), 3.46 - 3.44 (m, 2H), 1.98 (s, 2H), 1.63 (s, 2H); LCMS (ESI) m/z : 348.1 $[\text{M}+\text{H}]^+$.

Compound **433**: ^1H NMR (400 MHz, DMSO- d_6) δ 7.83 (d, J = 2.6 Hz, 1H), 7.31 (tdd, J = 20.0, 13.0, 6.9 Hz, 3H), 7.15 (dd, J = 17.6, 8.9 Hz, 2H), 7.05 (t, J = 8.6 Hz, 1H), 6.59 (d, J = 9.0 Hz, 1H), 4.49 (d, J = 5.8 Hz, 2H), 3.34 (s, 3H), 2.87 (t, J = 8.5 Hz, 2H), 2.55 (t, J = 7.5 Hz, 2H); LCMS (ESI) m/z : 357.1 $[\text{M}+\text{H}]^+$.

Compound **434**: ^1H NMR (400 MHz, DMSO- d_6) δ 8.96 (s, 1H), 7.72 (d, J = 10.0 Hz, 1H), 7.29-7.33 (m, 1H), 7.24-7.25 (m, 2H), 7.13 (d, J = 7.6 Hz, 1H), 6.92 (d, J = 10.0 Hz, 1H), 6.82 (d, J = 8.0 Hz, 1H), 3.51 (s, 3H), 3.38-3.42 (m, 1H), 2.48-2.51 (m, 2H), 1.86-1.89 (m, 2H), 1.62-1.65 (m, 2H), 1.48-1.53 (m, 1H), 1.02-1.14 (m, 4H); LCMS (ESI) m/z : 375.1 $[\text{M}+\text{H}]^+$.

Compound **435**: ^1H NMR (400 MHz, DMSO- d_6) δ 9.66-9.75 (m, 1H), 8.37 (d, J = 1.2 Hz, 1H), 8.28 (d, J = 1.6 Hz, 1H), 8.01 (d, J = 8.4 Hz, 1H), 7.69 (dd, J_1 = 2.0 Hz, J_2 = 8.4 Hz, 1H), 7.52 (dd, J_1 = 2.0 Hz, J_2 = 8.4 Hz, 1H), 7.16 (d, J = 8.4 Hz, 1H), 3.92 (s, 2H), 3.34 (s, 3H), 2.83 (t, J = 8.4 Hz, 2H), 2.45-2.56 (m, 2H), 2.40 (s, 3H); LCMS (ESI) m/z : 338.1 $[\text{M}+\text{H}]^+$.

Compound **436**: ^1H NMR (400 MHz, DMSO- d_6) δ 9.69 (s, 1H), 8.27 (d, J = 2.0 Hz, 1H), 8.00 (d, J = 8.4 Hz, 1H), 7.68 (dd, J_1 = 2.4 Hz, J_2 = 8.4 Hz, 1H), 7.23-7.26 (m, 1H), 7.18 (s, 1H), 7.10-7.14 (m, 2H), 5.13 (t, J = 5.6 Hz, 1H), 4.34 (d, J = 5.2 Hz, 2H), 3.93 (s, 2H), 3.35 (s, 3H), 2.84 (t, J = 8.4 Hz, 2H), 2.50-2.53 (m, 2H); LCMS (ESI) m/z : 353.2 $[\text{M}+\text{H}]^+$.

Compound **437**: ^1H NMR (400 MHz, DMSO- d_6) δ 9.71 (s, 1H), 8.29-8.32 (m, 2H), 8.25 (d, J = 1.2 Hz, 1H), 8.02 (d, J = 8.4 Hz, 1H), 7.71 (dd, J_1 = 2.4 Hz, J_2 = 8.4 Hz, 1H), 7.46 (s, 1H), 3.93 (s, 2H), 3.48 (s, 3H), 2.84 (t, J = 8.4 Hz, 2H), 2.48-2.53 (m, 2H), 2.24 (s, 3H); LCMS (ESI) m/z : 338.1 $[\text{M}+\text{H}]^+$.

Compound **438**: ^1H NMR (400 MHz, DMSO- d_6) δ 9.72 (s, 1H), 8.22 (d, J = 2.0 Hz, 1H), 8.02 (d, J = 8.4 Hz, 1H), 7.67 (dd, J_1 = 2.4 Hz, J_2 = 8.8 Hz, 1H), 7.30-7.35 (m, 1H), 7.06-7.10 (m, 2H), 6.99-7.04 (m, 1H), 3.93 (s, 2H), 3.85 (t, J = 4.4 Hz, 1H), 3.19-3.23 (m, 1H), 3.14 (s, 3H), 3.00 (dd, J_1 = 4.8 Hz, J_2 = 10.0 Hz, 1H), 2.40-2.43 (m, 2H), 2.35 (s, 3H), 1.84 (dd, J_1 = 4.4 Hz, J_2 = 13.6 Hz, 1H); LCMS (ESI) m/z : 344.2 $[\text{M}+\text{H}]^+$.

Compound **439**: ^1H NMR (400 MHz, DMSO- d_6) δ 9.83 (s, 1H), 8.23 (d, J = 1.6 Hz, 1H), 7.68-7.72 (m, 2H), 7.63 (s, 1H), 7.50-7.53 (d, J = 10.0 Hz, 1H), 7.12-7.15 (m, 1H), 6.54-6.57 (d, J = 9.2 Hz, 1H), 4.51-4.52 (d, J = 6.4 Hz, 2H), 3.32-3.34 (d, J = 6.0 Hz, 3H), 2.78-2.82 (m, 2H), 2.46-2.48 (m, 2H); LCMS (ESI) m/z : 381.1 $[\text{M}+\text{H}]^+$.

Compound **440**: ^1H NMR (400 MHz, DMSO- d_6) δ 9.97 (s, 1H), 9.71 (s, 1H), 8.32 (d, J = 2.4 Hz, 1H), 8.02 (d, J = 8.4 Hz, 1H), 7.72-7.77 (m, 3H), 7.62 (d, J = 7.6 Hz, 1H), 7.53-7.56 (m, 1H), 4.06 (s, 2H), 3.35 (s, 3H), 2.84 (t, J = 8.4 Hz, 2H), 2.49-2.53 (m, 2H); LCMS (ESI) m/z : 351.1 $[\text{M}+\text{H}]^+$.

Compound **441**: ^1H NMR (400 MHz, TFA) δ 8.80 (d, J = 4.4 Hz, 1H), 8.78 (d, J = 4.8 Hz, 1H), 8.74 (d, J = 2.8 Hz, 1H), 8.42 (d, J = 9.6 Hz, 1H), 8.22 (s, 1H), 8.07 (d, J = 8.0 Hz, 1H), 8.00 (t, J = 9.2 Hz, 2H), 5.85 (s, 2H), 4.58 (s, 3H); LCMS (ESI) m/z : 380.0 $[\text{M}+\text{H}]^+$.

Compound **442**: ^1H NMR (500 MHz, CDCl_3) δ 10.71 (s, 1H), 8.60 – 8.38 (m, 3H), 8.22 (s, 1H), 7.83 (dd, J = 8.8, 1.8 Hz, 1H), 7.48 (d, J = 8.3 Hz, 1H), 4.14 (s, 2H), 3.50 (s, 3H), 2.96 (t, J = 8.6 Hz, 2H), 2.62 (t, J = 8.6 Hz, 2H); LCMS (ESI) m/z : 342.1 $[\text{M}+\text{H}]^+$.

Compound **443**: ^1H NMR (500 MHz, DMSO) δ 10.41 (s, 1H), 9.07 (s, 2H), 7.42 – 7.20 (m, 4H), 4.21 (s, 2H), 3.38 (s, 3H), 2.84 (t, J = 8.5 Hz, 2H), 2.53 (d, J = 8.5 Hz, 2H); LCMS (ESI) m/z : 358.1 $[\text{M}+\text{H}]^+$.

Compound **444**: ^1H NMR (500 MHz, DMSO- d_6) δ 9.68 (s, 1H), 8.21 (d, J = 1.5 Hz, 1H), 8.02 (d, J = 8 Hz, 1H), 7.68-7.74 (m, 1H), 5.77-5.88 (m, 1H), 4.93-5.06 (m, 2H), 3.36 (s, 3H), 2.86 (t, J = 8.5 Hz, 2H), 2.68 (t, J = 7.5 Hz, 2H), 2.51-2.56 (m, 2H), 2.30-2.38 (m, 2H); LCMS (ESI) m/z : 287.1 $[\text{M}+\text{H}]^+$.

Compound **445**: ^1H NMR (500 MHz, DMSO- d_6) δ 9.75 (s, 1H), 8.34 (d, J = 1.5 Hz, 1H), 8.00-8.10 (m, 2H), 7.70-7.81 (m, 2H), 7.65 (d, J = 7.5 Hz, 1H), 4.21 (s, 2H), 3.36 (s, 3H), 2.85 (t, J = 8.5 Hz, 2H), 2.52 (t, J = 8.5 Hz, 2H); LCMS (ESI) m/z : 392.2 $[\text{M}+\text{H}]^+$.

Compound **446**: ^1H NMR (500 MHz, DMSO- d_6) δ 10.08-10.20 (m, 1H), 8.24 (d, J = 2.0 Hz, 1H), 7.98-8.01 (m, 1H), 7.65-7.68 (m, 1H), 7.33 (dd, J_1 = 7.5 Hz, J_2 = 15.0 Hz, 1H), 7.09-7.11 (m, 2H), 7.02-7.05 (m, 1H), 4.29-4.34 (m, 1H), 3.97-3.97 (m, 3H), 3.62 (dd, J_1 = 5.5 Hz, J_2 = 10.5 Hz, 1H), 3.26-3.35 (m, 1H), 3.18-3.24 (m, 3H), 2.45-2.51 (m, 1H), 1.87-1.89 (m, 1H), 1.40 (s, 3H), 1.25-1.28 (m, 6H); LCMS (ESI) m/z : 430.2 $[\text{M}+\text{H}]^+$.

Compound **447**: ^1H NMR (500 MHz, DMSO- d_6) δ 10.20 (s, 1H), 8.23 (d, J = 2.0 Hz, 1H), 8.03 (d, J = 8.5 Hz, 1H), 7.66 (dd, J_1 = 2.0 Hz, J_2 = 9.0 Hz, 1H), 7.32-7.36 (m, 1H), 7.08-7.11 (m, 2H), 7.01-7.05 (m, 1H), 3.94 (s, 2H), 3.85-3.87 (m, 1H), 3.73-3.75 (m, 1H), 3.11 (s, 3H), 3.00-3.03 (m, 1H), 2.90-2.92 (m, 1H), 2.10-2.15 (m, 1H), 2.02-2.05 (s, 1H); LCMS (ESI) m/z : 330.2 $[\text{M}+\text{H}]^+$.

Compound **448**: ^1H NMR (500 MHz, DMSO- d_6) δ 10.27 (s, 1H), 8.34 (d, J = 2.0 Hz, 1H), 8.19 (d, J = 8.5 Hz, 1H), 8.10 (dd, J = 8.5, 4.0 Hz, 1H), 7.91 (t, J = 9.0 Hz, 1H), 7.78 (dd, J = 8.5, 2.0 Hz, 1H), 7.35 (dd, J = 14.5, 8.0 Hz, 1H), 7.14-7.02 (m, 3H), 3.99 (s, 2H), 2.59 (d, J = 3.0 Hz, 3H); LCMS (ESI) m/z : 340.1 $[\text{M}+\text{H}]^+$.

Compound **449**: ^1H NMR (500 MHz, DMSO- d_6) δ 10.51-10.52 (m, 1H), 8.67 (d, J = 2.0 Hz, 1H), 8.39 (d, J = 1.5 Hz, 1H), 8.29 (d, J = 2.0 Hz, 1H), 8.05 (d, J = 8.5 Hz, 1H), 7.98 (dd, J_1 = 2.0 Hz, J_2 = 9.5 Hz, 1H), 7.67 (dd, J_1 = 2.0 Hz, J_2 = 8.5 Hz, 1H), 7.53 (dd, J_1 = 2.0 Hz, J_2 = 8.5 Hz, 1H), 7.18 (d, J = 8.0 Hz, 1H), 6.43 (d, J = 9.0 Hz, 1H), 3.93 (s, 2H), 3.49 (s, 3H), 2.42 (s, 3H); LCMS (ESI) m/z : 335.1 $[\text{M}+\text{H}]^+$.

Compound **450**: ^1H NMR (500 MHz, DMSO- d_6) δ 10.54 (s, 1H), 8.67 (d, J = 2.5 Hz, 1H), 8.31-8.34 (m, 2H), 8.27 (d, J = 1.5 Hz, 1H), 8.06 (d, J = 8.5 Hz, 1H), 7.98 (dd, J_1 = 3.0 Hz, J_2 = 9.5 Hz, 1H), 7.69 (dd, J_1 = 2.0 Hz, J_2 = 8.5 Hz, 1H), 7.47 (s, 1H), 6.43 (d, J = 9.5 Hz, 1H), 3.94 (s, 2H), 3.50 (s, 3H), 2.26 (s, 3H); LCMS (ESI) m/z : 335.1 $[\text{M}+\text{H}]^+$.

Compound **451**: ^1H NMR (500 MHz, DMSO- d_6) δ 10.56 (s, 1H), 8.38 (s, 1H), 8.26 (d, J = 8.5 Hz, 1H), 8.19 (d, J = 8.5 Hz, 1H), 8.11 (d, J = 9.0 Hz, 1H), 7.80 (d, J = 8.0 Hz, 1H), 7.33-7.38 (m, 2H), 7.25-7.29 (m, 2H), 4.00 (s, 2H); LCMS (ESI) m/z : 369.2 $[\text{M}+\text{H}]^+$.

Compound **452**: ^1H NMR (500 MHz, DMSO- d_6) δ 10.63 (s, 1H), 8.69 (d, J = 2.7 Hz, 1H), 8.45 (d, J = 2.3 Hz, 1H), 8.16 (d, J = 8.6 Hz, 1H), 7.99 (dd, J = 9.5, 2.7 Hz, 1H), 7.90 (dd, J = 8.6, 2.4 Hz, 1H), 7.20 – 7.10 (m, 2H), 7.08 – 7.00 (m, 2H), 6.44 (d, J = 9.5 Hz, 1H), 5.08 (s, 2H), 3.51 (s, 3H); LCMS (ESI) m/z : 354.1 $[\text{M}+\text{H}]^+$.

Compound **453**: ^1H NMR (500 MHz, DMSO- d_6) δ 10.70 (s, 1H), 8.68 (d, J = 2.6 Hz, 1H), 8.52 – 8.43 (m, 2H), 8.36 (d, J = 2.0 Hz, 1H), 8.06 – 7.96 (m, 2H), 7.80 (dd, J = 8.6, 2.3 Hz, 1H), 7.71 (d, J = 9.8 Hz, 1H), 6.44 (d, J = 9.5 Hz, 1H), 4.06 (s, 2H), 3.51 (s, 3H); LCMS (ESI) m/z : 339.1 $[\text{M}+\text{H}]^+$.

Compound **454**: ^1H NMR (500 MHz, DMSO- d_6) δ 10.73(s, 1H), 8.49 (dd, J_1 = 9.0 Hz, J_2 = 19.0 Hz, 2H), 8.40 (d, J = 2.0 Hz, 1H), 8.18 (d, J = 8.5 Hz, 1H), 7.82 (dd, J_1 = 2.0 Hz, J_2 = 8.5 Hz, 1H), 7.34–7.38 (m, 2H), 7.26–7.30 (m, 2H), 4.02 (s, 3H), 4.01(s, 2H); LCMS (ESI) m/z : 383.2 $[\text{M}+\text{H}]^+$.

Compound **455**: ^1H NMR (500 MHz, DMSO- d_6) δ 10.76 (s, 1H), 8.32 (s, 1H), 8.02 (d, J = 8.4 Hz, 1H), 7.72 – 7.70 (m, 1H), 7.35 – 7.33 (m, 1H), 7.12 – 7.10 (m, 3H), 7.04 – 7.01 (t, J = 8.9 Hz, 1H), 5.52 (s, 2H), 3.98 (s, 2H), 3.79 (s, 3H), 3.69 (s, 3H); LCMS (ESI) m/z : 447.2 $[\text{M}+\text{H}]^+$.

Compound **456**: ^1H NMR (500 MHz, DMSO- d_6) δ 10.76 (s, 1H), 8.33 (s, 1H), 8.02 (d, J = 8.6 Hz, 1H), 7.72 – 7.70 (d, J = 9.1 Hz, 1H), 7.39 – 7.30 (m, 2H), 7.28 – 7.26 (d, J = 8.1 Hz, 1H), 7.23 – 7.20 (d, J = 7.4 Hz, 1H), 7.13 (d, J = 8.5 Hz, 2H), 6.85 – 6.83 (d, J = 8.6 Hz, 2H), 6.77 (s, 1H), 5.52 (s, 2H), 3.97 (s, 2H), 3.79 (s, 3H), 3.69 (s, 3H); LCMS (ESI) m/z : 463.1 $[\text{M}+\text{H}]^+$.

Compound **457**: ^1H NMR (500 MHz, DMSO- d_6) δ 10.87 (s, 1H), 8.58 (s, 1H), 8.21 (d, J = 2.1 Hz, 1H), 8.12 – 7.92 (m, 2H), 7.86 (dd, J = 9.3, 2.4 Hz, 1H), 7.37 (dd, J = 14.4, 7.8 Hz, 1H), 7.25 – 7.02 (m, 3H), 6.49 (d, J = 9.4 Hz, 1H), 3.77 (s, 2H), 3.50 (s, 3H); LCMS (ESI) m/z : 338.1 $[\text{M}+\text{H}]^+$.

Compound **458**: ^1H NMR (500 MHz, DMSO- d_6) δ 10.91 (s, 1H), 8.29 (d, J = 2.3 Hz, 1H), 8.03 (d, J = 8.5 Hz, 1H), 7.71 (dd, J = 8.5, 2.4 Hz, 1H), 7.39 – 7.28 (m, 1H), 7.16 – 7.06 (m, 2H), 7.06 – 6.99 (m, 1H), 4.63 – 4.53 (m, 1H), 4.44 (t, J = 9.0 Hz, 1H), 4.27 – 4.18 (m, 1H), 3.96 (s, 2H), 2.75 (s, 3H); LCMS (ESI) m/z : 330.1 $[\text{M}+\text{H}]^+$.

Compound **459**: ^1H NMR (500 MHz, DMSO- d_6) δ 11.09 (s, 1H), 8.36 (d, J = 1.8 Hz, 1H), 8.01 (d, J = 8.5 Hz, 1H), 7.75 (dd, J = 8.5, 2.2 Hz, 1H), 7.35 (d, J = 6.4 Hz, 1H), 7.11 (t, J = 7.3 Hz, 2H), 7.04 (s, 1H), 6.27 (s, 1H), 3.99 (s, 2H), 3.71 (s, 3H), 3.44 (s, 3H); LCMS (ESI) m/z : 341.0 $[\text{M}+\text{H}]^+$.

Compound **460**: ^1H NMR (500 MHz, DMSO- d_6) δ 11.13 (s, 1H), 8.37 (d, J = 2.0 Hz, 1H), 8.02 (d, J = 8.5 Hz, 1H), 7.76 (dd, J = 8.5, 2.3 Hz, 1H), 7.35 (dd, J = 9.6, 5.6 Hz, 2H), 7.28 (d, J = 8.3 Hz, 1H), 7.24 (d, J = 7.6 Hz, 1H), 6.32 (s, 1H), 3.99 (s, 2H), 3.74 (s, 3H), 3.48 (s, 3H); LCMS (ESI) m/z : 357.1 $[\text{M}+\text{H}]^+$.

Compound **461**: ^1H NMR (500 MHz, DMSO- d_6) δ 12.65 (bs, 1H), 8.73 (s, 1H), 8.01 (dd, J = 9.5, 3.0 Hz, 1H), 7.41 (dd, J = 14.0, 3.0 Hz, 1H), 7.22–7.19 (m, 2H), 7.12 (td, J = 9.5, 2.0 Hz, 1H), 6.46 (d, J = 9.5 Hz, 1H), 4.40 (s, 2H), 3.51 (s, 3H); LCMS (ESI) m/z : 345.1 $[\text{M}+\text{H}]^+$.

Compound **462**: ^1H NMR (500 MHz, DMSO- d_6) δ 12.65 (bs, 1H), 8.74 (s, 1H), 8.01 (dd, J = 9.5, 3.0 Hz, 1H), 7.45 (s, 1H), 7.41–7.32 (m, 3H), 6.46(d, J = 9.5 Hz, 1H), 4.40 (s, 2H), 3.51 (s, 3H); LCMS (ESI) m/z : 361.1 $[\text{M}+\text{H}]^+$.

Compound **463**: ^1H NMR (500 MHz, DMSO- d_6) δ 12.78 (s, 1H), 10.92 (s, 1H), 8.73 (d, J = 1.5 Hz, 1H), 8.33 (d, J = 2.5 Hz, 1H), 8.18 (d, J = 2.0 Hz, 1H), 8.10 (d, J = 8.5 Hz, 1H), 7.72 (dd, J = 8.5 Hz, J = 2.5 Hz, 1H), 7.33–7.37 (m, 1H), 7.11–7.13 (m, 2H), 7.03 (td, J = 8.5 Hz, 2.0 Hz, 1H), 3.99 (s, 2H); LCMS (ESI) m/z : 365.0 $[\text{M}+\text{H}]^+$.

Compound **464**: ^1H NMR (500 MHz, DMSO- d_6) δ 8.01 (d, J = 2.4 Hz, 1H), 7.50 – 7.48 (m, 1H), 7.31 – 7.30 (t, J = 8.2 Hz, 1H), 7.10 – 7.08 (t, J = 2.1 Hz, 1H), 7.04 – 6.91 (m, 2H), 6.40 (d, J = 9.3 Hz, 1H), 4.86 – 4.60 (m, 1H), 3.79 (s, 2H), 3.46 (s, 3H), 3.40 – 3.25 (m, 2H), 1.97 – 1.95 (m, 2H), 1.69 – 1.48 (m, 2H); LCMS (ESI) m/z : 347.0 $[\text{M}+\text{H}]^+$.

Compound **465**: ^1H NMR (500 MHz, DMSO- d_6) δ 8.35 (d, J = 7.5 Hz, 1H), 7.89 (dd, J_1 = 2.5 Hz, J_2 = 9.5 Hz, 1H), 7.81 (d, J = 7.0 Hz, 1H), 7.31-7.34 (m, 1H), 7.25-7.26 (m, 2H), 7.15 (d, J = 7.0 Hz, 1H), 6.40 (d, J = 9.5 Hz, 1H), 3.89 (dd, J_1 = 3.5 Hz, J_2 = 7.5 Hz, 1H), 3.50 (s, 3H), 2.51-2.61 (m, 2H), 1.72-1.75 (m, 1H), 1.65-1.70 (m, 2H), 1.51-1.55 (m, 2H), 1.41-1.48 (m, 4H); LCMS (ESI) m/z : 359.1 $[\text{M}+\text{H}]^+$.

5 Compound **466**: ^1H NMR (500 MHz, DMSO- d_6) δ 8.36 (d, J = 2.0 Hz, 1H), 8.00 (d, J = 7.5 Hz, 1H), 7.88 (dd, J = 9.5, 2.5 Hz, 1H), 7.31 (t, J = 8.0 Hz, 1H), 7.03-6.93 (m, 3H), 6.39 (d, J = 9.5 Hz, 1H), 4.62 (s, 1H), 3.87 (s, 1H), 3.48 (s, 3H), 1.94 (d, J = 5.0 Hz, 2H), 1.66 (t, J = 11.0 Hz, 6H); LCMS (ESI) m/z : 361.1 $[\text{M}+\text{H}]^+$.

10 Compound **467**: ^1H NMR (500 MHz, DMSO- d_6) δ 9.43 (t, J = 6.5 Hz, 1H), 8.90 (d, J = 2.0 Hz, 1H), 8.39 (d, J = 3.0 Hz, 1H), 8.19 (dd, J = 8.5, 2.0 Hz, 1H), 8.07 (d, J = 8.0 Hz, 1H), 7.97 (dd, J = 9.5, 3.0 Hz, 1H), 7.38 – 7.34 (m, 1H), 7.17 (d, J = 7.5 Hz, 1H), 7.14 (d, J = 10.0 Hz, 1H), 7.08-7.04 (m, 1H), 6.54 (d, J = 9.0 Hz, 1H), 4.52 (d, J = 6.5 Hz, 2H), 3.54 (s, 3H); LCMS (ESI) m/z : 338.0 $[\text{M}+\text{H}]^+$.

15 Compound **468**: ^1H NMR (500 MHz, DMSO- d_6) δ 9.65 (s, 1H), 8.24 (s, 1H), 8.03 (d, J = 8.4 Hz, 1H), 7.76 (d, J = 8.4 Hz, 1H), 3.36 (s, 3H), 2.86 (t, J = 8.5 Hz, 2H), 2.62 – 2.38 (m, 5H), 1.07 – 0.87 (m, 1H), 0.58 – 0.39 (m, 2H), 0.21 (q, J = 4.7 Hz, 2H); LCMS (ESI) m/z : 287.2 $[\text{M}+\text{H}]^+$.

Compound **469**: ^1H NMR (500 MHz, DMSO- d_6) δ 9.70 (s, 1H), 8.33 (d, J = 5.0 Hz, 1H), 8.29 (d, J = 2.0 Hz, 1H), 8.01 (d, J = 8.5 Hz, 1H), 7.75 (dd, J = 8.5, 2.0 Hz, 1H), 7.15 (s, 1H), 7.05 (d, J = 4.5 Hz, 1H), 4.03 (s, 2H), 3.36 (s, 3H), 2.84 (t, J = 8.3 Hz, 2H), 2.52 (t, J = 7.8 Hz, 2H), 2.27 (s, 3H); LCMS (ESI) m/z : 338.2 $[\text{M}+\text{H}]^+$.

20 Compound **470**: ^1H NMR (500 MHz, DMSO- d_6) δ 9.74 (s, 1H), 8.33 (d, J = 2.0 Hz, 1H), 8.03 (d, J = 8.5 Hz, 1H), 7.86 (t, J = 7.5 Hz, 1H), 7.75 (dd, J = 8.5, 2.0 Hz, 1H), 7.49 (d, J = 10.5 Hz, 1H), 7.33 (d, J = 8.0 Hz, 1H), 4.07 (s, 2H), 3.36 (s, 3H), 2.85 (t, J = 8.5 Hz, 2H), 2.53 (d, J = 8.5 Hz, 2H); LCMS (ESI) m/z : 366.1 $[\text{M}+\text{H}]^+$.

25 Compound **471**: ^1H NMR (500 MHz, DMSO- d_6) δ 9.88 (s, 1H), 7.92-7.78 (m, 4H), 7.40-7.26 (m, 4H), 3.88 (s, 2H), 2.78 (t, J = 8.5 Hz, 2H), 2.48 (d, J = 8.5 Hz, 2H); (ESI) m/z : 372.1 $[\text{M}-\text{TFA}+\text{H}]^+$.

Compound **472**: ^1H NMR (500 MHz, DMSO- d_6) δ 9.95 (s, 1H), 8.20 (d, J = 1.9 Hz, 1H), 7.89 (dd, J = 8.8, 2.0 Hz, 1H), 7.66 (d, J = 8.8 Hz, 1H), 7.40 – 7.18 (m, 4H), 4.07 – 3.82 (m, 5H), 3.83 – 3.65 (m, 2H), 2.49 – 2.43 (m, 1H), 1.00 (d, J = 6.2 Hz, 3H); LCMS (ESI) m/z : 346.1 $[\text{M}+\text{H}]^+$.

30 Compound **474**: ^1H NMR (400 MHz, DMSO- d_6) δ 9.76 (s, 1H), 8.67 (d, J = 4 Hz, 1H), 8.36 (s, 1H), 8.05 (d, J = 6.8 Hz, 1H), 7.85 (s, 1H), 7.78-7.80 (m, 2H), 7.60 (d, J = 3.6 Hz, 1H), 4.13 (s, 2H), 3.36 (s, 3H), 2.83-2.86 (m, 2H), 2.52-2.54 (m, 2H); LCMS (ESI) m/z : 392.1 $[\text{M}+\text{H}]^+$.

Compound **475**: ^1H NMR (500 MHz, Dimethylsulfoxide- d_6) δ 10.17 (s, 1H), 9.23 (s, 1H), 8.46 (s, 1H), 7.46 – 7.16 (m, 4H), 4.14 (s, 2H), 3.36 (s, 3H), 2.86 (t, J = 8.4 Hz, 2H), 2.53 (t, J = 8.4 Hz, 2H); LCMS (ESI) m/z : 358.1 $[\text{M}+\text{H}]^+$.

35

Example 239. Characterization Data of Compounds of the Invention

The following compounds were synthesized by methods similar to those described above.

CMPD No.	Characterization Data	
476	LCMS (ESI) m/z: 315.1 [M+H] ⁺ .	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.63 (s, 1H), 9.63 (s, 1H), 8.14 (d, <i>J</i> = 1.8 Hz, 1H), 8.05 (d, <i>J</i> = 8.5 Hz, 1H), 7.73 (dd, <i>J</i> = 8.5, 2.1 Hz, 1H), 5.91 (s, 1H), 3.65 (s, 3H), 2.47 (d, <i>J</i> = 7.1 Hz, 2H), 1.63 (dd, <i>J</i> = 25.7, 11.7 Hz, 5H), 1.54 – 1.44 (m, 1H), 1.22 – 1.08 (m, 3H), 0.92 (q, <i>J</i> = 12.0 Hz, 2H).
477	LCMS (ESI) m/z: 327.1 [M+H] ⁺ .	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 9.76 (s, 1H), 8.19 (s, 1H), 8.06 (d, <i>J</i> = 8.5 Hz, 1H), 7.70 (dd, <i>J</i> = 8.6, 2.0 Hz, 1H), 6.19 (s, 1H), 2.86 (t, <i>J</i> = 8.5 Hz, 2H), 2.54 (d, <i>J</i> = 8.5 Hz, 2H), 2.34 – 2.29 (m, 2H), 2.26–2.25 (m, 2H), 1.66 – 1.44 (m, 6H).
478	LCMS (ESI) m/z: 351.1 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 11.36 (s, 1H), 9.23 (s, 1H), 8.54 (dd, <i>J</i> = 8.1, 1.7 Hz, 1H), 8.39 (s, 1H), 8.21 (d, <i>J</i> = 8.1 Hz, 1H), 8.13 (d, <i>J</i> = 8.5 Hz, 1H), 7.79 (dd, <i>J</i> = 8.5, 1.7 Hz, 1H), 7.17 – 7.00 (m, 3H), 4.01 (s, 2H).
479	LCMS (ESI) for C ₁₉ H ₁₇ ClN ₄ O ₂ [M+H] ⁺ : 369.1	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 11.29 (s, 1H), 9.27 (s, 2H), 8.36 (s, 1H), 8.13 (d, <i>J</i> = 8.5 Hz, 1H), 7.76 (d, <i>J</i> = 8.6 Hz, 1H), 7.45 – 7.15 (m, 4H), 4.66 (s, 2H), 4.01 (s, 2H), 3.40 (s, 3H).
480	LCMS (ESI) m/z: 341.2[M+H] ⁺ .	¹ H NMR (500 MHz, CDCl ₃) δ 8.40(s, 1H), 8.21 – 8.11 (m, 2H), 7.54 (dd, <i>J</i> = 8.5, 2.2 Hz, 1H), 7.05 – 6.83 (m, 4H), 5.57-5.52 (m, 1H), 4.14 (d, <i>J</i> = 4 Hz, 2H), 3.97 (s, 2H), 2.97 (s, 3H).
481	LCMS (ESI) m/z: 338.0[M+H] ⁺ .	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.20 (s, 1H), 9.08 (d, <i>J</i> = 2.0 Hz, 1H), 8.75 (d, <i>J</i> = 1.7 Hz, 1H), 8.53 – 8.31 (m, 2H), 8.11 (d, <i>J</i> = 8.5 Hz, 1H), 7.77 (dd, <i>J</i> = 8.6, 2.3 Hz, 1H), 7.36 (dd, <i>J</i> = 14.4, 8.0 Hz, 1H), 7.13 (t, <i>J</i> = 7.9 Hz, 2H), 7.05 (d, <i>J</i> = 2.5 Hz, 1H), 4.65 (s, 2H), 4.00 (s, 2H).
482	LCMS (ESI) m/z: 364.0[M+H] ⁺ .	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.36 (s, 1H), 9.23 (d, <i>J</i> = 1.9 Hz, 1H), 8.54 (dd, <i>J</i> = 8.1, 2.2 Hz, 1H), 8.41 (d, <i>J</i> = 2.0 Hz, 1H), 8.21 (d, <i>J</i> = 8.1 Hz, 1H), 8.15 (d, <i>J</i> = 8.5 Hz, 1H), 7.85 (dd, <i>J</i> = 8.6, 2.2 Hz, 1H), 7.06 (t, <i>J</i> = 8.0 Hz, 1H), 6.61 (t, <i>J</i> = 2.0 Hz, 1H), 6.57-6.53 (m, 2H), 4.31 (s, 2H).
483	LCMS (ESI) m/z: 354.1[M+H] ⁺ .	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.28 (s, 1H), 9.13 (d, <i>J</i> = 1.8 Hz, 1H), 8.80 (d, <i>J</i> = 1.5 Hz, 1H), 8.48 (d, <i>J</i> = 16.8 Hz, 1H), 8.37 (d, <i>J</i> = 2.0 Hz, 1H), 8.12 (d, <i>J</i> = 8.5 Hz, 1H), 7.80 (dd, <i>J</i> = 8.5, 2.3 Hz, 1H), 7.36 (dd, <i>J</i> = 12.7, 4.7 Hz, 2H), 7.31 – 7.20 (m, 2H), 4.67 (s, 2H), 3.99 (s, 2H).
484	LCMS (ESI) m/z: 341.5 [M+H] ⁺ .	¹ H NMR (300 MHz, Chloroform- <i>d</i>) δ 10.55 (s, 1H), 8.41 – 8.20 (m, 3H), 7.58 (ddd, <i>J</i> = 8.6, 3.0, 0.6 Hz, 2H), 6.81 – 6.57 (m, 3H), 3.97 (s, 2H), 2.86 (s, 3H).
485	LCMS (ESI) m/z: 341.5 [M+H] ⁺ .	¹ H NMR (300 MHz, Chloroform- <i>d</i>) δ 10.42 (s, 1H), 8.95 (d, <i>J</i> = 5.0 Hz, 1H), 8.37 (dd, <i>J</i> = 8.5, 0.8 Hz, 1H), 8.25 (dt, <i>J</i> = 2.5, 0.7 Hz, 1H), 8.01 (dd, <i>J</i> = 5.0, 0.7 Hz, 1H), 7.57 (ddd, <i>J</i> = 8.5, 2.4, 0.6 Hz, 1H), 7.20 – 6.84 (m, 3H), 3.96 (s, 2H), 2.85 (d, <i>J</i> = 0.6 Hz, 3H).
486	LCMS (ESI) m/z: 357.5 [M+H] ⁺ .	¹ H NMR (300 MHz, Chloroform- <i>d</i>) δ 10.17 (s, 1H), 8.83 (d, <i>J</i> = 4.8 Hz, 1H), 8.35 (d, <i>J</i> = 8.5 Hz, 1H), 8.23 (d, <i>J</i> = 2.3 Hz, 1H), 7.85 (dd, <i>J</i> = 4.8, 1.4 Hz, 1H), 7.57 (dd, <i>J</i> = 8.5, 2.4 Hz, 1H), 7.20 – 6.83 (m, 2H), 4.16 (s, 3H), 3.95 (s, 2H).

CMPD No.	Characterization Data	
487	LCMS (ESI) m/z: 370.0 [M+H] ⁺ .	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.57 (s, 1H), 8.80 (s, 1H), 8.37 (d, J = 2.8 Hz, 1H), 8.20 – 7.97 (m, 2H), 7.80 (dd, J = 9.7, 2.9 Hz, 1H), 7.35 (t, J = 8.2 Hz, 1H), 7.18 (t, J = 2.2 Hz, 1H), 7.05 (dd, J = 8.1, 2.1 Hz, 2H), 6.43 (d, J = 9.7 Hz, 1H), 5.33 (s, 2H), 3.45 (s, 3H).
488	LCMS (ESI) m/z: 388.0 [M+H] ⁺ .	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.57 (s, 1H), 8.80 (s, 1H), 8.37 (d, J = 2.8 Hz, 1H), 8.13 (dt, J = 8.1, 4.9 Hz, 2H), 7.79 (dd, J = 9.7, 2.8 Hz, 1H), 7.51 – 7.29 (m, 2H), 7.08 (dt, J = 9.1, 3.5 Hz, 1H), 6.43 (d, J = 9.7 Hz, 1H), 5.31 (s, 2H), 3.45 (s, 3H).
489	LCMS (ESI) m/z: 357.1/359.0 [M+H] ⁺ .	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.60 (bs, 1H), 9.58 (s, 1H), 8.29 (d, J = 2.0 Hz, 1H), 8.07 (d, J = 8.5 Hz, 1H), 7.78 (d, J = 8.5 Hz, 1H), 7.36-7.32 (m, 2H), 7.28-7.23 (m, 2H), 5.90 (s, 1H), 4.02-3.97 (m, 4H), 1.32 (t, J = 7.0 Hz, 3H);
490	LCMS (ESI) m/z: 389.0 [M+H] ⁺ .	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.47 (s, 1H), 9.25 (s, 2H), 8.34 (s, 1H), 8.17 (d, J = 8.4 Hz, 1H), 7.79 (dd, J = 8.5, 2.2 Hz, 1H), 7.44 – 7.26 (m, 1H), 7.13 (dd, J = 12.0, 5.0 Hz, 2H), 7.04 (td, J = 8.7, 2.3 Hz, 1H), 4.00 (s, 2H).
491	LCMS (ESI) m/z: 391.1 [M+H] ⁺ .	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.14 (s, 1H), 9.13 (d, J = 1.5 Hz, 1H), 8.43 (dd, J = 8.0, 2.0 Hz, 1H), 8.36 (d, J = 2 Hz, 1H), 8.13 (d, J = 8.5 Hz, 1H), 7.73-7.78 (m, 2H), 7.22–7.38 (m, 4H), 3.99 (s, 2H), 1.74 (s, 6H).
492	LCMS (ESI) m/z: 365.0 [M+H] ⁺ .	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.43 (s, 1H), 9.24 (d, J = 1.9 Hz, 1H), 8.66 – 8.45 (m, 2H), 8.23 (t, J = 7.5 Hz, 2H), 7.98 (dd, J = 8.6, 2.2 Hz, 1H), 7.34 (t, J = 8.2 Hz, 1H), 7.20 – 6.93 (m, 3H), 5.17 (s, 2H).
493	LCMS (ESI) m/z: 351.1 [M+H] ⁺ .	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.40 (s, 1H), 9.22 (d, J = 1.2 Hz, 1H), 8.62 (dd, J = 8.1, 2.0 Hz, 1H), 8.38 (d, J = 1.9 Hz, 1H), 8.32 (d, J = 8.1 Hz, 1H), 8.19 (d, J = 8.5 Hz, 1H), 7.82 (dd, J = 8.5, 2.2 Hz, 1H), 7.11 – 6.99 (m, 3H), 4.00 (s, 2H).
494	LCMS (ESI) m/z: 355.0/357.0 [M+H] ⁺ .	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 9.25 (s, 2H), 8.35 (d, J = 2.5 Hz, 1H), 8.13 (d, J = 8.5 Hz, 1H), 7.75 (dd, J ₁ = 2.0 Hz, J ₂ = 8.5 Hz, 1H), 7.36-7.33 (m, 2H), 7.28-7.23 (m, 2H), 5.47 (bs, 1H), 4.68 (s, 2H), 3.99 (s, 2H);
495	LCMS (ESI) m/z: 339.1 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.53 (s, 1H), 8.65 (s, 1H), 8.12 – 8.02 (m, 2H), 7.93 – 7.82 (m, 1H), 7.33 – 7.30 (dd, J = 8.3, 5.7 Hz, 2H), 7.14 – 7.10 (t, J = 8.8 Hz, 2H), 7.04 – 7.01 (d, J = 9.9 Hz, 1H), 4.10 (s, 2H), 3.60 (s, 3H).
496	LCMS (ESI) m/z: 338.0 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.47 (s, 1H), 8.64 (s, 1H), 8.33 (d, J = 2.6 Hz, 1H), 8.02 (d, J = 8.0 Hz, 1H), 7.92 – 7.82 (m, 1H), 7.76 – 7.73 (dd, J = 9.7, 2.7 Hz, 1H), 7.32 – 7.30 (dd, J = 8.3, 5.7 Hz, 2H), 7.14 – 7.10 (t, J = 8.8 Hz, 2H), 6.41 (d, J = 9.7 Hz, 1H), 4.06 – 4.03 (d, J = 24.4 Hz, 2H), 3.43 (s, 3H).
497	LCMS (ESI) m/z: 338.0 [M+H] ⁺ .	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.50 (s, 1H), 8.68 (d, J = 5.0 Hz, 1H), 8.35 (d, J = 2.0 Hz, 1H), 8.22 (d, J = 8.5 Hz, 1H), 8.18 (d, J = 0.7 Hz, 1H), 7.81 (dd, J = 8.5, 2.3 Hz, 1H), 7.68 – 7.60 (m, 1H), 7.41 – 7.31 (m, 1H), 7.13 (dd, J = 11.4, 4.8 Hz, 2H), 7.06-7.03 (m, 1H), 4.68 (s, 2H), 4.00 (m, 2H).
498	LCMS (ESI) m/z: 364.0 [M+H] ⁺ .	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.43 (s, 1H), 9.22 (d, J = 1.2 Hz, 1H), 8.62 (dd, J = 8.1, 1.9 Hz, 1H), 8.41 (d, J = 1.6 Hz, 1H), 8.33 (d, J = 8.1 Hz, 1H), 8.21 (d, J = 8.5 Hz, 1H), 7.89 (dd, J = 8.5, 2.0 Hz, 1H), 7.06 (t, J = 8.0 Hz, 1H), 6.70 – 6.46 (m, 4H), 4.31 (s, 2H).

CMPD No.	Characterization Data	
499	LCMS (ESI) m/z: 418.0 [M+H] ⁺ .	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.15 (s, 1H), 9.16 (d, <i>J</i> = 1.8 Hz, 1H), 8.44 (dd, <i>J</i> = 8.4, 2.3 Hz, 1H), 8.36 (d, <i>J</i> = 2.0 Hz, 1H), 8.14 (d, <i>J</i> = 8.5 Hz, 1H), 7.84 (d, <i>J</i> = 8.3 Hz, 1H), 7.75 (dd, <i>J</i> = 8.5, 2.3 Hz, 1H), 7.40 – 7.32 (m, 2H), 7.22-7.28 (m, 2H), 6.76 (s, 1H), 6.39 (s, 1H), 3.99 (s, 2H).
500	LCMS (ESI) m/z: 334.0 [M+H] ⁺ .	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.63 (s, 1H), 9.54 (s, 2H), 8.36 (s, 1H), 8.16 (d, <i>J</i> = 8.4 Hz, 1H), 7.80 (d, <i>J</i> = 8.1 Hz, 1H), 7.35 (dd, <i>J</i> = 14.5, 7.8 Hz, 1H), 7.13 (t, <i>J</i> = 8.6 Hz, 2H), 7.05 (dd, <i>J</i> = 12.7, 4.6 Hz, 1H), 4.00 (s, 2H).
501	LCMS (ESI) m/z: 379.1 [M+H] ⁺ .	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 9.74 (s, 1H), 8.34 (d, <i>J</i> = 1.9 Hz, 1H), 8.09 (d, <i>J</i> = 8.4 Hz, 1H), 7.94 (d, <i>J</i> = 9.7 Hz, 1H), 7.82 – 7.63 (m, 2H), 7.40 – 7.31 (m, 2H), 7.30 – 7.20 (m, 2H), 7.14 (d, <i>J</i> = 9.7 Hz, 1H), 5.92 – 5.68 (m, 2H), 3.98 (s, 2H).
502	LCMS (ESI) m/z: 366.1/368.0 [M+H] ⁺ .	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.42 (s, 1H), 9.22 (d, <i>J</i> = 1.5 Hz, 1H), 8.55 (dd, <i>J</i> = 8.0, 1.5 Hz, 1H), 8.35 (d, <i>J</i> = 1.0 Hz, 1H), 8.30 (d, <i>J</i> = 8.0 Hz, 1H), 8.20 (d, <i>J</i> = 8.5 Hz, 1H), 7.79 (dd, <i>J</i> = 8.0, 1.5 Hz, 1H), 7.36-7.32 (m, 2H), 7.28-7.24 (m, 2H), 3.98 (s, 2H), 2.7 (s, 3H);
503	LCMS (ESI) m/z: 356.0[M+H] ⁺ .	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.25 (s, 1H), 9.13 (s, 1H), 8.79 (s, 1H), 8.48 (s, 1H), 8.37 (d, <i>J</i> = 1.9 Hz, 1H), 8.12 (d, <i>J</i> = 8.5 Hz, 1H), 7.85 – 7.72 (m, 1H), 7.47 – 7.32 (m, 3H), 7.13 (d, <i>J</i> = 1.9 Hz, 1H), 4.68 (s, 2H), 3.98 (s, 2H).
504	LCMS (ESI) m/z: 327.1 [M+H] ⁺ .	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.46 (s, 1H), 9.14 (s, 2H), 8.35 (s, 1H), 8.17 (d, <i>J</i> = 8.3 Hz, 1H), 7.79 (dd, <i>J</i> = 8.5, 2.2 Hz, 1H), 7.46 – 7.30 (m, 1H), 7.13 (dd, <i>J</i> = 12.0, 4.9 Hz, 2H), 7.04 (td, <i>J</i> = 8.7, 2.3 Hz, 1H), 4.00 (s, 2H).
505	LCMS (ESI) m/z: 308.3 [M+H] ⁺ .	¹ H NMR (300 MHz, DMSO- <i>d</i> ₆) δ 11.11 (s, 1H), 8.84 – 8.63 (m, 2H), 8.35 (dd, <i>J</i> = 2.5, 0.8 Hz, 1H), 8.11 (dd, <i>J</i> = 8.4, 0.8 Hz, 1H), 8.01 – 7.82 (m, 2H), 7.83 – 7.48 (m, 4H), 7.35 (td, <i>J</i> = 8.0, 6.3 Hz, 1H), 7.21 – 6.97 (m, 3H), 3.99 (s, 2H).
506	LCMS (ESI) m/z: 349.3 [M+H] ⁺ .	¹ H NMR (300 MHz, Chloroform- <i>d</i>) δ 10.32 (s, 1H), 8.85 (d, <i>J</i> = 4.9 Hz, 1H), 8.42 – 8.31 (m, 1H), 8.27 (dd, <i>J</i> = 2.4, 0.8 Hz, 1H), 7.93 (d, <i>J</i> = 4.9 Hz, 1H), 7.59 (dd, <i>J</i> = 8.5, 2.4 Hz, 1H), 7.39 – 7.21 (m, 2H), 7.09 – 6.80 (m, 3H), 2.46 – 2.28 (m, 1H), 1.33 – 1.11 (m, 4H).
507	LCMS (ESI) m/z: 368.1 [M+H] ⁺ .	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.41 (s, 1H), 9.22 (s, 1H), 8.55 (d, <i>J</i> = 8.0 Hz, 1H), 8.34(s, 1H), 8.31 (d, <i>J</i> = 8.0 Hz, 1H), 8.20 (d, <i>J</i> = 8.5 Hz, 1H), 7.79 (d, <i>J</i> = 8.5 Hz, 1H), 7.39-7.33 (m, 2H), 7.12 (s, 1H), 3.97 (s, 2H), 2.70 (s, 3H); .
508	LCMS (ESI) m/z: 346.1 [M+H] ⁺ .	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.90 (s, 1H), 8.32 (d, <i>J</i> = 2.1 Hz, 1H), 8.15 (s, 1H), 7.99 (d, <i>J</i> = 8.5 Hz, 1H), 7.71 (dd, <i>J</i> = 8.6, 2.3 Hz, 1H), 7.42 – 7.30 (m, 2H), 7.11 (s, 1H), 3.95 (s, 2H), 3.35 (s, 3H).
509	LCMS (ESI) m/z: 346.1 [M+H] ⁺ .	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 10.91 (s, 1H), 8.35 (d, <i>J</i> = 1.5 Hz, 1H), 8.15 (s, 1H), 8.00 (d, <i>J</i> = 8.5 Hz, 1H), 7.75 (dd, <i>J</i> = 8.5, 2.0 Hz, 1H), 7.06 (m, 3H), 3.98 (s, 2H), 3.35 (s, 3H).
510	LCMS (ESI) m/z: 368.1/370.1 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.37 (s, 1H), 8.71 (d, <i>J</i> = 1.6 Hz, 1H), 8.34 (d, <i>J</i> = 2.0 Hz, 1H), 8.21 (d, <i>J</i> = 8.4 Hz, 1H), 8.16 (d, <i>J</i> = 8.0 Hz, 1H), 8.05 (dd, <i>J</i> = 8.0, 2.0 Hz, 1H), 7.78 (dd, <i>J</i> = 8.4, 2.4 Hz, 1H), 7.36 (d, <i>J</i> = 1.6 Hz, 1H), 7.33 (d, <i>J</i> = 7.6 Hz, 1H), 7.28-7.24 (m, 2H), 5.55 (d, <i>J</i> = 4.4 Hz, 1H), 4.93-4.91 (m, 1H), 3.98 (s, 2H), 1.40 (d, <i>J</i> = 6.8 Hz, 3H);

CMPD No.	Characterization Data	
511	LCMS (ESI) m/z: 370.2 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.38 (s, 1H), 8.71 (d, <i>J</i> = 1.6 Hz, 1H), 8.33 (d, <i>J</i> = 2.0 Hz, 1H), 8.21 (d, <i>J</i> = 8.4 Hz, 1H), 8.16 (d, <i>J</i> = 8.0 Hz, 1H), 8.05 (dd, <i>J</i> = 8.0, 2.0 Hz, 1H), 7.78 (dd, <i>J</i> = 8.4, 2.4 Hz, 1H), 7.41-7.33 (m, 2H), 7.14-7.11 (m, 1H), 5.55 (d, <i>J</i> = 4.0 Hz, 1H), 4.95-4.89 (m, 1H), 3.97 (s, 2H), 1.40 (d, <i>J</i> = 6.4 Hz, 3H);
512	LCMS (ESI) m/z: 369.1/371.1 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 8.38-8.35 (m, 2H), 8.18 (d, <i>J</i> = 8.4 Hz, 1H), 8.05 (d, <i>J</i> = 8.4 Hz, 1H), 7.80 (dd, <i>J</i> = 8.4, 2.4 Hz, 1H), 7.37-7.33 (m, 2H), 7.29-7.25 (m, 2H), 5.85 (d, <i>J</i> = 4.0 Hz, 1H), 5.14-5.11 (m, 1H), 4.00 (s, 2H), 1.50 (d, <i>J</i> = 6.4 Hz, 3H); LCMS (ESI) m/z: 369.1/371.1 [M+H] ⁺ .
513	LCMS (ESI) m/z: 370.0[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 11.02 (s, 1H), 9.05 (d, <i>J</i> = 2.0 Hz, 1H), 8.34(t, <i>J</i> = 5.2, 2H), 8.13 (d, <i>J</i> = 8.4Hz, 1H), 7.74-7.67 (m, 1H), 7.63(d, <i>J</i> = 4.0 Hz, 1H), 7.10-7.04(m, 3H), 5.54 (s, 1H), 4.82-4.77 (m, 1H), 3.99 (s, 2H), 1.39 (d, <i>J</i> = 6.0 Hz, 3H).
514	LCMS (ESI) m/z: 370.0[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 11.01 (s, 1H), 9.05 (d, <i>J</i> = 1.8 Hz, 1H), 8.47 – 8.29 (m, 2H), 8.13 (d, <i>J</i> = 8.5 Hz, 1H), 7.73 (dd, <i>J</i> = 8.6, 2.4 Hz, 1H), 7.63 (d, <i>J</i> = 8.2 Hz, 1H), 7.47 – 7.29 (m, 2H), 7.17 – 7.06 (m, 1H), 5.54 (d, <i>J</i> = 4.7 Hz, 1H), 4.88 – 4.65 (m, 1H), 3.97 (s, 2H), 1.39 (d, <i>J</i> = 6.6 Hz, 3H).
515	LCMS (ESI) m/z: 356.1 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.94 (s, 1H), 8.33 (s, 1H), 8.04 (s, 1H), 7.77 (d, <i>J</i> = 40.6 Hz, 2H), 7.37 (s, 2H), 7.03 (d, <i>J</i> = 68.1 Hz, 2H), 6.61 (s, 1H), 3.96 (s, 2H), 3.40 (s, 3H).
516	LCMS (ESI) m/z: 369.1 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.66 (bs, 1H), 8.50 (d, <i>J</i> = 8.4 Hz, 1H), 8.40 (d, <i>J</i> = 2.0 Hz, 1H), 8.36 (d, <i>J</i> = 8.8 Hz, 1H), 8.18 (d, <i>J</i> = 8.8 Hz, 1H), 7.82 (dd, <i>J</i> = 8.4, 2.4 Hz, 1H), 7.42-7.34 (m, 2H), 7.15-7.13 (m, 1H), 3.99 (s, 2H), 2.85 (s, 3H);
517	LCMS (ESI) m/z: 367.0/369.1 [M+H] ⁺	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.75 (s, 1H), 8.50 (d, <i>J</i> = 8.8 Hz, 1H), 8.40 (d, <i>J</i> = 2.0 Hz, 1H), 8.36 (d, <i>J</i> = 8.8 Hz, 1H), 8.18 (d, <i>J</i> = 8.4 Hz, 1H), 7.82 (dd, <i>J</i> = 8.4, 2.4 Hz, 1H), 7.38-7.33 (m, 2H), 7.29-7.25 (m, 2H), 4.01 (s, 2H), 2.85 (s, 3H);.
518	LCMS (ESI) m/z: 405.0 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.47 (s, 1H), 9.25 (s, 2H), 8.34 (s, 1H), 8.17 (d, <i>J</i> = 8.3 Hz, 1H), 7.79 (dd, <i>J</i> = 8.5, 2.1 Hz, 1H), 7.38 (ddd, <i>J</i> = 19.4, 7.6, 5.3 Hz, 2H), 7.13 (d, <i>J</i> = 2.0 Hz, 1H), 3.97 (s, 2H).
519	LCMS (ESI) m/z: 368.0[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 11.02 (s, 1H), 9.05(d, <i>J</i> = 1.6 Hz, 1H), 8.36-8.40 (m, 2H), 8.13 (d, <i>J</i> = 8.4 Hz, 1H), 7.75-7.72 (m, 1H), 7.63 (d, <i>J</i> = 8.0 Hz, 1H), 7.37-7.33(m, 2H), 7.29-7.24 (m, 2H), 5.54 (d, <i>J</i> = 4.4 Hz, 1H),4.81 – 4.78 (m, 1H), 3.98 (s, 2H),1.39 (d, <i>J</i> = 6.8 Hz, 3H).
520	LCMS (ESI) m/z: 368.0[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 11.02 (s, 1H), 9.05(d, <i>J</i> = 1.6 Hz, 1H), 8.36-8.40 (m, 2H), 8.13 (d, <i>J</i> = 8.4 Hz, 1H), 7.75-7.72 (m, 1H), 7.63 (d, <i>J</i> = 8.0 Hz, 1H), 7.37-7.33(m, 2H), 7.29-7.24 (m, 2H), 5.54 (d, <i>J</i> = 4.4 Hz, 1H),4.81 – 4.78 (m, 1H), 3.98 (s, 2H),1.40 (d, <i>J</i> = 6.8 Hz, 3H).
521	LCMS (ESI) m/z: 364.9 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 11.27 (s, 1H), 9.47 (s, 2H), 9.28 (d, <i>J</i> = 9.2 Hz, 1H), 8.95 (d, <i>J</i> = 9.6 Hz, 1H), 8.40 (s, 1H), 8.09 (d, <i>J</i> = 8.0 Hz, 1H), 7.83 (dd, <i>J</i> = 8.5, 2.3 Hz, 1H), 7.38 – 7.33 (m, 2H), 7.30 – 7.28 (m, 2H), 4.01 (s, 2H).

CMPD No.	Characterization Data	
522	LCMS (ESI) m/z: 385.9[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 11.02 (s, 1H), 9.05 (s, 1H), 8.35 (s, 2H), 8.13 (d, <i>J</i> = 8.3 Hz, 1H), 7.73 (d, <i>J</i> = 8.5 Hz, 1H), 7.63 (d, <i>J</i> = 8.0 Hz, 1H), 7.53 (d, <i>J</i> = 7.2 Hz, 1H), 7.42 – 7.20 (m, 2H), 5.55 (s, 1H), 4.80 (d, <i>J</i> = 6.0 Hz, 1H), 3.97 (s, 2H), 1.39 (d, <i>J</i> = 6.4 Hz, 3H).
523	LCMS (ESI) m/z: 371.0 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.02 (s, 1H), 8.33 (d, <i>J</i> = 1.8 Hz, 1H), 8.08 (d, <i>J</i> = 8.4 Hz, 1H), 7.88 (d, <i>J</i> = 1.2 Hz, 1H), 7.75 (dd, <i>J</i> = 8.5, 2.4 Hz, 1H), 7.36 – 7.33 (m, 2H), 7.12 (s, 1H), 3.96 (s, 2H), 3.79 (s, 3H), 2.17 (d, <i>J</i> = 1.1 Hz, 3H).
524	LCMS (ESI) m/z: 371.0 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.07 (s, 1H), 8.35 (d, <i>J</i> = 4.0 Hz, 1H), 8.09 (d, <i>J</i> = 8.5 Hz, 1H), 7.89 (d, <i>J</i> = 1.2 Hz, 1H), 7.78 (dd, <i>J</i> = 8.5, 2.4 Hz, 1H), 7.14 – 6.96 (m, 3H), 3.99 (s, 2H), 3.80 (s, 3H), 2.17 (d, <i>J</i> = 1.1 Hz, 3H).
525	LCMS (ESI) m/z: 352.0 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.43(s, 2H), 8.36(d, <i>J</i> = 2.0 Hz, 1H), 8.12(d, <i>J</i> = 8.4 Hz, 1H), 7.77(dd, <i>J</i> ₁ = 2.0 Hz, <i>J</i> ₂ = 8.4 Hz, 1H), 7.40-7.33(m, 2H), 7.13-7.12(m, 1H), 3.97(s, 2H);
526	LCMS (ESI) m/z: 351.1 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 11.30 (s, 1H), 9.26 (d, <i>J</i> = 2.0 Hz, 1H), 8.76 (d, <i>J</i> = 1.6 Hz, 1H), 8.56-8.59 (q, <i>J</i> = 3.6 Hz, 1H), 7.96-8.14 (m, 3H), 7.08-7.12 (m, 3H), 4.16 (s, 2H).
527	LCMS (ESI) m/z: 399.0 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 11.64 (s, 1H), 9.14 (s, 1H), 8.83 (s, 1H), 8.40 (d, <i>J</i> = 1.9 Hz, 1H), 8.12 (d, <i>J</i> = 8.5 Hz, 1H), 7.78 (dd, <i>J</i> = 8.5, 2.3 Hz, 1H), 7.40 – 7.31 (m, 1H), 7.14 (t, <i>J</i> = 8.0 Hz, 2H), 7.06 (d, <i>J</i> = 8.4 Hz, 1H), 4.01 (s, 2H).
528	LCMS (ESI) m/z: 391.0 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.15 (s, 1H), 8.36 (d, <i>J</i> = 1.9 Hz, 1H), 8.09 (d, <i>J</i> = 8.4 Hz, 1H), 7.95 (d, <i>J</i> = 9.7 Hz, 1H), 7.78 (dd, <i>J</i> = 8.5, 2.3 Hz, 1H), 7.50 – 7.38 (m, 2H), 7.08 (d, <i>J</i> = 9.7 Hz, 1H), 3.97 (s, 2H), 3.79 (s, 3H).
529	LCMS (ESI) m/z: 352.0[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 11.02 (s, 1H), 9.06 (t, <i>J</i> = 8.4 Hz, 1H), 8.40 – 8.33 (m, 2H), 8.13 (d, <i>J</i> = 8.5 Hz, 1H), 7.73 (dd, <i>J</i> = 8.5, 2.3 Hz, 1H), 7.63 (d, <i>J</i> = 8.2 Hz, 1H), 7.41 – 7.27 (m, 1H), 7.20 – 7.09 (m, 2H), 7.06-7.02 (m, 1H), 5.55 (s, 1H), 4.80 (q, <i>J</i> = 6.5 Hz, 1H), 3.99 (s, 2H), 1.40 (d, <i>J</i> = 6.6 Hz, 3H).
530	LCMS (ESI) m/z: 371.1 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.58 (s, 1H), 8.38-8.35 (m, 2H), 8.18 (d, <i>J</i> = 8.8 Hz, 1H), 8.05 (d, <i>J</i> = 8.8 Hz, 1H), 7.80 (dd, <i>J</i> = 8.4, 2.4 Hz, 1H), 7.42-7.34 (m, 2H), 7.15-7.12 (m, 1H), 5.86 (d, <i>J</i> = 4.8 Hz, 1H), 5.13-5.11 (m, 1H), 3.98 (s, 2H), 1.50 (d, <i>J</i> = 6.8 Hz, 3H);
531	LCMS (ESI) m/z: 367.1 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.07 (s, 1H), 8.33 (d, <i>J</i> = 1.9 Hz, 1H), 8.09 (d, <i>J</i> = 8.5 Hz, 1H), 7.79 (s, 1H), 7.76 (dd, <i>J</i> = 8.5, 2.3 Hz, 1H), 7.38 – 7.35 (m, 1H), 7.21 – 7.09 (m, 2H), 7.08 – 7.03 (m, 1H), 3.99 (s, 2H), 3.80 (s, 3H), 2.57 – 2.53 (m, 2H), 1.16 (t, <i>J</i> = 7.4 Hz, 3H).
532	LCMS (ESI) m/z: 357.1 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 12.15 (s, 1H), 8.36 (d, <i>J</i> = 2.0 Hz, 1H), 8.22 (dt, <i>J</i> = 14.0, 6.4 Hz, 3H), 7.78 (dd, <i>J</i> = 8.5, 2.3 Hz, 1H), 7.13 – 7.00 (m, 3H), 3.99 (s, 2H), 3.84 (s, 3H).
533	LCMS (ESI) m/z: 356.1 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.94 (s, 1H), 8.36 (d, <i>J</i> = 2.0 Hz, 1H), 8.06 (d, <i>J</i> = 8.5 Hz, 1H), 7.81 (d, <i>J</i> = 7.0 Hz, 1H), 7.75 (dd, <i>J</i> = 8.5, 2.3 Hz, 1H), 7.14 – 7.00 (m, 3H), 6.95 (d, <i>J</i> = 1.7 Hz, 1H), 6.61 (dd, <i>J</i> = 7.0, 1.9 Hz, 1H), 3.99 (s, 2H), 3.47 (s, 3H).

CMPD No.	Characterization Data	
534	LCMS (ESI) m/z: 358.1 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.40 (s, 1H), 9.21 (d, <i>J</i> = 1.0 Hz, 1H), 8.62 (dd, <i>J</i> = 8.0, 1.9 Hz, 1H), 8.37 (d, <i>J</i> = 1.8 Hz, 1H), 8.32 (d, <i>J</i> = 8.2 Hz, 1H), 8.18 (d, <i>J</i> = 8.5 Hz, 1H), 7.90 (dd, <i>J</i> = 6.2, 2.0 Hz, 1H), 7.81 (dd, <i>J</i> = 8.5, 2.0 Hz, 1H), 7.77 – 7.64 (m, 1H), 7.47 (t, <i>J</i> = 8.0 Hz, 1H), 4.03 (s, 2H).
535	LCMS (ESI) m/z: 358.0 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 11.34 (s, 1H), 9.22 (s, 1H), 8.53 (dd, <i>J</i> = 8.0, 2.0 Hz, 1H), 8.40 (d, <i>J</i> = 2.0 Hz, 1H), 8.20 (d, <i>J</i> = 8.4 Hz, 1H), 8.13 (d, <i>J</i> = 8.8 Hz, 1H), 7.80 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 7.73-7.69 (m, 2H), 7.59 (d, <i>J</i> = 9.6 Hz, 1H), 4.06 (s, 2H);
536	LCMS (ESI) m/z: 358.0 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.41 (s, 1H), 9.22 (dd, <i>J</i> = 2.0, 0.8 Hz, 1H), 8.62 (dd, <i>J</i> = 8.0, 2.0 Hz, 1H), 8.40 (d, <i>J</i> = 2.0 Hz, 1H), 8.32 (dd, <i>J</i> = 8.4, 0.8 Hz, 1H), 8.19 (d, <i>J</i> = 8.4 Hz, 1H), 7.84 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 7.72-7.70 (m, 2H), 7.61-7.58 (m, 1H), 4.06 (s, 2H);
537	LCMS (ESI) m/z: 357.0 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.15 (s, 1H), 8.29 (d, <i>J</i> = 2.1 Hz, 1H), 8.08 (d, <i>J</i> = 8.5 Hz, 1H), 7.95 (d, <i>J</i> = 9.7 Hz, 1H), 7.70 (dd, <i>J</i> = 8.5, 2.2 Hz, 1H), 7.41 (dd, <i>J</i> = 15.4, 8.7 Hz, 1H), 7.29 – 7.19 (m, 1H), 7.06 (dd, <i>J</i> = 13.5, 6.1 Hz, 2H), 3.98 (s, 2H), 3.79 (s, 3H).
538	LCMS (ESI) m/z: 356.0 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.58 (s, 1H), 8.67 (d, <i>J</i> = 2.5 Hz, 1H), 8.27 (s, 1H), 8.11 – 7.89 (m, 2H), 7.73 – 7.58 (m, 1H), 7.41 (dd, <i>J</i> = 15.5, 8.6 Hz, 1H), 7.29 – 7.18 (m, 1H), 7.07 (t, <i>J</i> = 8.3 Hz, 1H), 6.43 (d, <i>J</i> = 9.5 Hz, 1H), 3.96 (s, 2H), 3.50 (s, 3H).
539	LCMS (ESI) m/z: 357.1 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.14 (s, 1H), 8.31 (s, 1H), 8.09 (d, <i>J</i> = 8.5 Hz, 1H), 7.95 (d, <i>J</i> = 9.7 Hz, 1H), 7.73 (d, <i>J</i> = 8.4 Hz, 1H), 7.24 (td, <i>J</i> = 8.9, 4.8 Hz, 2H), 7.19 – 7.00 (m, 2H), 3.99 (s, 2H), 3.79 (s, 3H).
540	LCMS (ESI) m/z: 341.0 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.74 (s, 1H), 8.33 (d, <i>J</i> = 2.0 Hz, 1H), 8.03 (d, <i>J</i> = 8.5 Hz, 1H), 7.71 (dd, <i>J</i> = 8.6, 2.3 Hz, 1H), 7.35 (dd, <i>J</i> = 14.3, 8.0 Hz, 1H), 7.19 (s, 1H), 7.15 – 7.08 (m, 2H), 7.04 (dd, <i>J</i> = 12.0, 5.5 Hz, 1H), 4.41 (s, 2H), 4.04 (s, 3H), 3.98 (s, 2H).
541	LCMS (ESI) m/z: 351.1 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 11.32 (s, 1H), 9.22 (d, <i>J</i> = 1.6 Hz, 1H), 8.53 (dd, <i>J</i> ₁ = 2.0 Hz, <i>J</i> ₂ = 8.4 Hz, 1H), 8.36 (d, <i>J</i> = 2.4 Hz, 1H), 8.20 (dd, <i>J</i> ₁ = 0.4 Hz, <i>J</i> ₂ = 8.0 Hz, 1H), 8.12 (d, <i>J</i> = 8.8 Hz, 1H), 7.75 (dd, <i>J</i> ₁ = 2.4 Hz, <i>J</i> ₂ = 8.8 Hz, 1H), 7.40-7.33 (m, 2H), 7.13-7.10 (m, 1H), 3.97 (s, 2H);
542	LCMS (ESI) m/z: 351.0 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 11.29 (s, 1H), 8.94 (d, <i>J</i> = 5.0 Hz, 1H), 8.53 (s, 1H), 8.37 (d, <i>J</i> = 2.1 Hz, 1H), 8.20 (dd, <i>J</i> = 5.1, 1.7 Hz, 1H), 8.11 (d, <i>J</i> = 8.5 Hz, 1H), 7.76 (dd, <i>J</i> = 8.5, 2.4 Hz, 1H), 7.47 – 7.28 (m, 2H), 7.13 (s, 1H), 3.98 (s, 2H).
543	LCMS (ESI) m/z: 390.0 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.54 (s, 1H), 8.67 (d, <i>J</i> = 2.6 Hz, 1H), 8.33 (d, <i>J</i> = 2.1 Hz, 1H), 8.06 (d, <i>J</i> = 8.5 Hz, 1H), 7.98 (dd, <i>J</i> = 9.5, 2.7 Hz, 1H), 7.72 (dd, <i>J</i> = 8.6, 2.3 Hz, 1H), 7.42 (ddd, <i>J</i> = 12.9, 6.5, 1.8 Hz, 2H), 6.43 (d, <i>J</i> = 9.5 Hz, 1H), 3.95 (s, 2H), 3.50 (s, 3H).
544	LCMS (ESI) m/z: 339.1 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.53 (s, 1H), 8.97 (s, 2H), 8.34 (d, <i>J</i> = 1.6 Hz, 1H), 8.19 (d, <i>J</i> = 8.4 Hz, 1H), 7.80 (dd, <i>J</i> ₁ = 2.0 Hz, <i>J</i> ₂ = 8.4 Hz, 1H), 7.38-7.32 (m, 1H), 7.14-7.11 (m, 2H), 7.04 (td, <i>J</i> ₁ = 2.4 Hz, <i>J</i> ₂ = 8.8 Hz, 1H), 4.68 (s, 2H), 4.00 (s, 2H);

CMPD No.	Characterization Data	
545	LCMS (ESI) m/z: 370.2[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.53 (s, 1H), 10.53 (s, 1H), 8.66 (d, <i>J</i> = 2.6 Hz, 1H), 8.66 (d, <i>J</i> = 2.6 Hz, 1H), 8.31 (d, <i>J</i> = 2.1 Hz, 1H), 8.31 (d, <i>J</i> = 2.1 Hz, 1H), 8.06 (d, <i>J</i> = 8.5 Hz, 1H), 7.98 (dd, <i>J</i> = 9.5, 2.7 Hz, 1H), 7.69 (dd, <i>J</i> = 8.6, 2.4 Hz, 1H), 7.50 – 7.37 (m, 4H), 7.00 (t, <i>J</i> = 56.0 Hz, 1H), 6.43 (d, <i>J</i> = 9.5 Hz, 1H), 4.03 (s, 2H), 4.03 (s, 2H), 3.50 (s, 3H), 3.50 (s, 3H).
546	LCMS (ESI) m/z: 339.0 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 12.12 (s, 1H), 8.33 (d, <i>J</i> = 1.9 Hz, 1H), 8.25 – 8.20 (m, 2H), 8.18 (d, <i>J</i> = 8.5 Hz, 1H), 7.75 (dd, <i>J</i> = 8.5, 2.2 Hz, 1H), 7.35 (dd, <i>J</i> = 14.3, 8.0 Hz, 1H), 7.16 – 7.08 (m, 2H), 7.04 (td, <i>J</i> = 8.6, 2.3 Hz, 1H), 3.98 (s, 2H), 3.83 (s, 3H).
547	LCMS (ESI) m/z: 357.0 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 12.13 (s, 1H), 8.33 (d, <i>J</i> = 2.0 Hz, 1H), 8.22 (q, <i>J</i> = 4.3 Hz, 2H), 8.18 (d, <i>J</i> = 8.5 Hz, 1H), 7.75 (dd, <i>J</i> = 8.5, 2.2 Hz, 1H), 7.42 – 7.29 (m, 2H), 7.15 – 7.07 (m, 1H), 3.96 (s, 2H), 3.84 (s, 3H).
548	LCMS (ESI) m/z: 357.1[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.15 (s, 1H), 8.54 (d, <i>J</i> = 6.5 Hz, 1H), 8.36 (d, <i>J</i> = 1.9 Hz, 1H), 8.11 (d, <i>J</i> = 8.4 Hz, 1H), 7.78 (dd, <i>J</i> = 8.5, 2.3 Hz, 1H), 7.46-7.29 (m, 2H), 7.17-7.08 (m, 1H), 7.04 (d, <i>J</i> = 6.5 Hz, 1H), 3.97 (s, 2H), 3.54 (s, 3H).
549	LCMS (ESI) m/z: 352.0 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.62 (s, 1H), 9.54 (s, 2H), 8.36 (s, 1H), 8.16 (d, <i>J</i> = 8.0 Hz, 1H), 7.79 (dd, <i>J</i> = 8.5, 2.0 Hz, 1H), 7.37 (dt, <i>J</i> = 19.4, 5.6 Hz, 2H), 7.13 (s, 1H), 3.98 (s, 2H).
550	LCMS (ESI) m/z: 363.1 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.54 (s, 1H), 8.66 (d, <i>J</i> = 2.6 Hz, 1H), 8.32 (d, <i>J</i> = 2.0 Hz, 1H), 8.06 (d, <i>J</i> = 8.5 Hz, 1H), 7.98 (dd, <i>J</i> = 9.5, 2.7 Hz, 1H), 7.88 (dd, <i>J</i> = 6.3, 2.2 Hz, 1H), 7.70 (dd, <i>J</i> = 8.0, 2.2 Hz, 2H), 7.47 (t, <i>J</i> = 8.0 Hz, 1H), 6.43 (d, <i>J</i> = 9.0 Hz, 1H), 4.00 (s, 2H), 3.50 (s, 3H).
551	LCMS (ESI) m/z: 357.2 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.14 (s, 1H), 8.30 (t, <i>J</i> = 10.6 Hz, 1H), 8.09 (d, <i>J</i> = 8.5 Hz, 1H), 7.95 (d, <i>J</i> = 9.7 Hz, 1H), 7.72 (dd, <i>J</i> = 8.5, 2.1 Hz, 1H), 7.31 (dt, <i>J</i> = 7.7, 6.8 Hz, 1H), 7.25 – 7.13 (m, 2H), 7.08 (d, <i>J</i> = 9.7 Hz, 1H), 4.06 (s, 2H), 3.79 (s, 3H).
552	LCMS (ESI) m/z: 356.2 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.55 (s, 1H), 8.67 (d, <i>J</i> = 2.5 Hz, 1H), 8.29 (d, <i>J</i> = 1.9 Hz, 1H), 8.07 (d, <i>J</i> = 8.5 Hz, 1H), 7.98 (dd, <i>J</i> = 9.5, 2.6 Hz, 1H), 7.66 (dd, <i>J</i> = 8.6, 2.2 Hz, 1H), 7.42 – 7.25 (m, 1H), 7.24 – 7.08 (m, 2H), 6.43 (d, <i>J</i> = 9.5 Hz, 1H), 4.04 (s, 2H), 3.50 (s, 3H).
553	LCMS (ESI) m/z: 353.1 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.46(s, 1H), 9.17(s, 2H), 8.36(d, <i>J</i> = 2.0 Hz, 1H), 8.20(d, <i>J</i> = 8.4 Hz, 1H), 7.81(dd, <i>J</i> ₁ = 2.0 Hz, <i>J</i> ₂ = 8.4 Hz, 1H), 7.09-7.04(m, 3H), 6.87(dd, <i>J</i> ₁ = 11.6 Hz, <i>J</i> ₂ = 18.0 Hz, 1H), 6.31(d, <i>J</i> = 18.0 Hz, 1H), 5.68(d, <i>J</i> = 10.8 Hz, 1H), 4.00(s, 2H);
554	LCMS (ESI) m/z: 371.0 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.41 (s, 1H), 9.54 – 9.07 (m, 3H), 8.36 (d, <i>J</i> = 1.9 Hz, 1H), 8.17 (d, <i>J</i> = 8.5 Hz, 1H), 7.80 (dd, <i>J</i> = 8.5, 2.2 Hz, 1H), 7.43 – 7.30 (m, 2H), 7.13 (brs, 1H), 3.98 (s, 2H).
555	LCMS (ESI) m/z: 365.1 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 11.54 (s, 1H), 9.65 (s, 1H), 9.26 (s, 1H), 8.73 (s, 1H), 8.40 (s, 1H), 8.12 (d, <i>J</i> = 8.5 Hz, 1H), 7.77 (dd, <i>J</i> = 8.5, 2.3 Hz, 1H), 7.36 (td, <i>J</i> = 8.0, 6.4 Hz, 1H), 7.14 (dd, <i>J</i> = 10.4, 4.3 Hz, 2H), 7.05 (td, <i>J</i> = 8.6, 2.3 Hz, 1H), 4.01 (s, 2H).
556	LCMS (ESI) m/z: 381.0 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 11.53 (s, 1H), 9.64 (s, 1H), 9.26 (s, 1H), 8.73 (s, 1H), 8.40 (d, <i>J</i> = 1.7 Hz, 1H), 8.12 (d, <i>J</i> = 8.5 Hz, 1H), 7.77 (dd, <i>J</i> = 8.5, 2.1 Hz, 1H), 7.42 – 7.32 (m, 2H), 7.31 – 7.22 (m, 2H), 4.01 (s, 2H).

CMPD No.	Characterization Data	
557	LCMS (ESI) m/z: 380.0 [M+H] ⁺ .	¹ H NMR (400 MHz, MeOD- <i>d</i> ₄) δ 8.98 (d, <i>J</i> = 2.0 Hz, 1H), 8.38 – 8.22 (m, 2H), 8.15 (d, <i>J</i> = 8.5 Hz, 1H), 7.90 (d, <i>J</i> = 8.4 Hz, 1H), 7.69 (dd, <i>J</i> = 8.5, 2.3 Hz, 1H), 7.10-7.25 (m, 4H), 4.01 (s, 2H), 1.45 (dd, <i>J</i> = 7.5, 4.4 Hz, 2H), 1.28 (dd, <i>J</i> = 7.5, 4.4 Hz, 2H).
558	LCMS (ESI) m/z: 382.0 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.14 (s, 1H), 8.36 (d, <i>J</i> = 1.7 Hz, 1H), 8.09 (d, <i>J</i> = 8.5 Hz, 1H), 7.95 (d, <i>J</i> = 9.7 Hz, 1H), 7.90 – 7.81 (m, 1H), 7.81 – 7.73 (m, 2H), 7.08 (d, <i>J</i> = 9.7 Hz, 1H), 4.01 (s, 2H), 3.79 (s, 3H).
559	LCMS (ESI) m/z: 357.1 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.49(s, 1H), 8.97(s, 2H), 8.36(d, <i>J</i> = 2.0 Hz, 1H), 8.19(d, <i>J</i> = 8.4 Hz, 1H), 7.81(dd, <i>J</i> ₁ = 2.0 Hz, <i>J</i> ₂ = 8.4 Hz, 1H), 7.06-7.04(m, 3H), 5.63 (t, <i>J</i> = 5.7 Hz, 1H), 4.68(d, <i>J</i> = 6.0 Hz, 2H), 4.00(s, 2H);
560	LCMS (ESI) m/z: 341.0 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.46 (s, 1H), 8.28 (d, <i>J</i> = 2.1 Hz, 1H), 8.09 (d, <i>J</i> = 8.5 Hz, 1H), 7.72 (dd, <i>J</i> = 8.5, 2.2 Hz, 1H), 7.34 (dd, <i>J</i> = 14.3, 8.0 Hz, 1H), 7.18 – 7.09 (m, 2H), 7.06-7.02 (m, 1H), 6.75 (s, 1H), 5.43 (d, <i>J</i> = 5.1 Hz, 1H), 4.55 (d, <i>J</i> = 4.7 Hz, 2H), 3.97 (d, <i>J</i> = 5.8 Hz, 2H), 3.91 (s, 3H).
561	LCMS (ESI) m/z: 371.0 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.12 (s, 1H), 8.34 (d, <i>J</i> = 1.9 Hz, 1H), 8.09 (d, <i>J</i> = 8.5 Hz, 1H), 7.95 (d, <i>J</i> = 9.7 Hz, 1H), 7.75 (dd, <i>J</i> = 8.5, 2.3 Hz, 1H), 7.44 – 7.25 (m, 4H), 7.15 – 6.82(t, <i>J</i> = 56.0 Hz, 1H), 7.10 (d, <i>J</i> = 9.6 Hz, 1H), 4.05 (s, 2H), 3.79 (s, 3H).
562	LCMS (ESI) m/z: 388.9 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.15 (s, 1H), 8.37 (d, <i>J</i> = 1.9 Hz, 1H), 8.10 (d, <i>J</i> = 8.5 Hz, 1H), 7.95 (d, <i>J</i> = 9.7 Hz, 1H), 7.83 – 7.75 (m, 1H), 7.36 (d, <i>J</i> = 12.8 Hz, 2H), 7.28 (d, <i>J</i> = 8.8 Hz, 1H), 7.16-6.88 (m, 2H), 4.06 (s, 2H), 3.79 (s, 3H).
563	LCMS (ESI) m/z: 351.0 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 11.29 (s, 1H), 8.94 (d, <i>J</i> = 5.0 Hz, 1H), 8.53 (s, 1H), 8.37 (d, <i>J</i> = 2.1 Hz, 1H), 8.20 (dd, <i>J</i> = 5.1, 1.7 Hz, 1H), 8.11 (d, <i>J</i> = 8.5 Hz, 1H), 7.76 (dd, <i>J</i> = 8.5, 2.4 Hz, 1H), 7.47 – 7.28 (m, 2H), 7.13 (s, 1H), 3.98 (s, 2H).
564	LCMS (ESI) m/z: 364.1 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.13 (s, 1H), 8.35 (s, 1H), 8.08 (d, <i>J</i> = 8.5 Hz, 1H), 7.95 (d, <i>J</i> = 9.6 Hz, 1H), 7.89 (d, <i>J</i> = 4.7 Hz, 1H), 7.76 (d, <i>J</i> = 8.2 Hz, 1H), 7.70 (s, 1H), 7.47 (t, <i>J</i> = 9.0 Hz, 1H), 7.08 (d, <i>J</i> = 9.6 Hz, 1H), 4.02 (s, 2H), 3.79 (s, 3H).
565	LCMS (ESI) m/z: 356.1 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.54 (s, 1H), 8.67 (d, <i>J</i> = 2.6 Hz, 1H), 8.29 (d, <i>J</i> = 2.0 Hz, 1H), 8.06 (d, <i>J</i> = 8.5 Hz, 1H), 7.98 (dd, <i>J</i> = 9.5, 2.7 Hz, 1H), 7.67 (dd, <i>J</i> = 8.6, 2.2 Hz, 1H), 7.25 (ddd, <i>J</i> = 14.1, 7.1, 3.9 Hz, 2H), 7.14 (td, <i>J</i> = 8.2, 4.5 Hz, 1H), 6.43 (d, <i>J</i> = 9.5 Hz, 1H), 3.97 (s, 2H), 3.50 (s, 3H).
566	LCMS (ESI) m/z: 356.1 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.55 (s, 1H), 8.66 (d, <i>J</i> = 2.6 Hz, 1H), 8.24 (d, <i>J</i> = 1.9 Hz, 1H), 8.05 (d, <i>J</i> = 8.6 Hz, 1H), 7.97 (dd, <i>J</i> = 9.5, 2.7 Hz, 1H), 7.60 (dd, <i>J</i> = 8.5, 2.2 Hz, 1H), 7.38 (t, <i>J</i> = 8.3 Hz, 1H), 7.13 (t, <i>J</i> = 7.9 Hz, 2H), 6.42 (d, <i>J</i> = 9.5 Hz, 1H), 3.99 (s, 2H), 3.49 (s, 3H).
567	LCMS (ESI) m/z: 365.1 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.48 (s, 1H), 8.77-8.78 (d, <i>J</i> = 4.4 Hz, 1H), 8.72 (s, 1H), 8.62 (s, 1H), 8.50-8.51 (d, <i>J</i> = 5.2 Hz, 1H), 8.15-8.17 (d, <i>J</i> = 8.0 Hz, 1H), 7.96-7.99 (m, 1H), 7.52-7.54 (m, 1H), 7.34-7.40 (d, <i>J</i> = 7.2 Hz, 1H), 7.15-7.21(m, 2H), 7.06-7.09(m, 2H), 4.15 (s, 2H), 2.81-2.82 (d, <i>J</i> = 4.8 Hz, 3H).

CMPD No.	Characterization Data	
568	LCMS (ESI) m/z: 353.1 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.45(s, 1H), 9.17(s, 2H), 8.34(d, <i>J</i> = 1.6 Hz, 1H), 8.19(d, <i>J</i> = 8.4 Hz, 1H), 7.78(dd, <i>J</i> ₁ = 2.0 Hz, <i>J</i> ₂ = 8.4 Hz, 1H), 7.40-7.33(m, 2H), 7.14-7.11(m, 1H), 6.87(dd, <i>J</i> ₁ = 11.2 Hz, <i>J</i> ₂ = 17.6 Hz, 1H), 6.31(d, <i>J</i> = 18.0 Hz, 1H), 5.68(d, <i>J</i> = 11.2 Hz, 1H), 3.97(s, 2H);
569	LCMS (ESI) m/z: 336.2 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.56 (s, 1H), 8.80 (s, 1H), 8.37 (d, <i>J</i> = 2.8 Hz, 1H), 8.23 – 8.03 (m, 2H), 7.80 (dd, <i>J</i> = 9.7, 2.8 Hz, 1H), 7.32 (dd, <i>J</i> = 8.6, 7.4 Hz, 2H), 7.19 – 6.90 (m, 3H), 6.43 (d, <i>J</i> = 9.7 Hz, 1H), 5.27 (d, <i>J</i> = 17.1 Hz, 2H), 3.45 (s, 3H).
570	LCMS (ESI) m/z: 366.0[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 11.33 (s, 1H), 8.90 (d, <i>J</i> = 5.0 Hz, 1H), 8.54 (d, <i>J</i> = 0.8Hz, 1H), 8.37 (d, <i>J</i> = 2.1 Hz, 1H), 8.16 (dd, <i>J</i> = 5.0, 1.7 Hz, 1H), 8.12 (d, <i>J</i> = 8.5 Hz, 1H), 7.76 (dd, <i>J</i> = 8.5, 2.3 Hz, 1H), 7.36 (td, <i>J</i> = 8.0, 6.4 Hz, 1H), 7.18 – 7.09 (m, 2H), 7.04 (td, <i>J</i> = 8.4, 2.1 Hz, 1H), 4.00 (s, 2H), 3.93 (s, 3H).
571	LCMS (ESI) m/z: 391.0 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.15 (s, 1H), 8.30 (s, 1H), 8.08 (d, <i>J</i> = 8.5 Hz, 1H), 7.95 (d, <i>J</i> = 9.7 Hz, 1H), 7.69 (d, <i>J</i> = 8.4 Hz, 1H), 7.47 (dd, <i>J</i> = 17.8, 8.8 Hz, 1H), 7.30 (dd, <i>J</i> = 8.5, 4.2 Hz, 1H), 7.08 (d, <i>J</i> = 9.7 Hz, 1H), 4.11 (s, 2H), 3.79 (s, 3H).
572	LCMS (ESI) m/z: 390.0 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.55 (s, 1H), 8.67 (d, <i>J</i> = 2.6 Hz, 1H), 8.27 (d, <i>J</i> = 2.0 Hz, 1H), 8.06 (d, <i>J</i> = 8.5 Hz, 1H), 7.98 (dd, <i>J</i> = 9.5, 2.7 Hz, 1H), 7.63 (dd, <i>J</i> = 8.6, 2.4 Hz, 1H), 7.47 (dd, <i>J</i> = 18.3, 8.5 Hz, 1H), 7.33 – 7.23 (m, 1H), 6.43 (d, <i>J</i> = 9.5 Hz, 1H), 4.09 (s, 2H), 3.50 (s, 3H).
573	LCMS (ESI) m/z: 359.2 [M+H] ⁺ .	¹ H NMR (300 MHz, DMSO- <i>d</i> ₆) δ 10.34 (s, 1H), 8.31 (d, <i>J</i> = 2.9 Hz, 1H), 8.22 (dd, <i>J</i> = 9.1, 1.6 Hz, 1H), 7.97 (dd, <i>J</i> = 9.7, 1.5 Hz, 1H), 7.75 (dt, <i>J</i> = 9.0, 2.2 Hz, 1H), 7.17 – 6.93 (m, 2H), 6.83 (dt, <i>J</i> = 8.6, 2.0 Hz, 2H), 3.80 (s, 3H);
574	LCMS (ESI) m/z: 381.1 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.56 (s, 1H), 8.68 (s, 1H), 8.34 (s, 1H), 8.06 (d, <i>J</i> = 8.5 Hz, 1H), 7.98 (dd, <i>J</i> = 9.5, 2.4 Hz, 1H), 7.90 – 7.80 (m, 1H), 7.73 (m, 2H), 6.43 (d, <i>J</i> = 9.5 Hz, 1H), 3.99 (s, 2H), 3.50 (s, 3H).
575	LCMS (ESI) m/z: 389.0[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 8.34 (d, <i>J</i> = 2.0 Hz, 1H), 8.09 (d, <i>J</i> = 8.5 Hz, 1H), 7.95 (d, <i>J</i> = 9.7 Hz, 1H), 7.75 (dd, <i>J</i> = 8.5, 2.4 Hz, 1H), 7.52 (dd, <i>J</i> = 11.6, 6.0 Hz, 2H), 7.33 (d, <i>J</i> = 11.9 Hz, 1H), 7.18 (t, <i>J</i> = 56.0 Hz, 1H), 7.08 (d, <i>J</i> = 9.7 Hz, 1H), 4.03 (s, 2H), 3.79 (s, 3H).
576	LCMS (ESI) m/z: 351.9 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.79 (s, 1H), 8.63 (d, <i>J</i> = 8.7 Hz, 1H), 8.56 (d, <i>J</i> = 8.7 Hz, 1H), 8.39 (s, 1H), 8.14 (d, <i>J</i> = 8.5 Hz, 1H), 7.81 (dd, <i>J</i> = 8.5, 2.3 Hz, 1H), 7.37 (m, 2H), 7.14 (s, 1H), 3.99 (s, 2H).
577	LCMS (ESI) m/z: 374.9[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.66 (s, 1H), 8.29 (d, <i>J</i> = 14.3 Hz, 1H), 7.90 (d, <i>J</i> = 9.7 Hz, 1H), 7.79 (dd, <i>J</i> = 10.6, 1.6 Hz, 1H), 7.51 – 7.30 (m, 2H), 7.27 – 7.12 (m, 1H), 7.06 (d, <i>J</i> = 9.7 Hz, 1H), 4.04 (s, 2H), 3.78 (s, 3H).
578	LCMS (ESI) m/z: 365.0[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 11.30 (s, 1H), 8.88 (d, <i>J</i> = 4.9 Hz, 1H), 8.81 (d, <i>J</i> = 5.0 Hz, 1H), 8.48 (d, <i>J</i> = 1.0 Hz, 1H), 8.36 (d, <i>J</i> = 2.0 Hz, 1H), 8.14 – 8.06 (m, 2H), 7.75 (dd, <i>J</i> = 8.6, 2.4 Hz, 1H), 7.41 – 7.31 (m, 1H), 7.13 (t, <i>J</i> = 7.0 Hz, 2H), 7.05 (t, <i>J</i> = 8.6 Hz, 1H), 4.00 (s, 2H), 2.85 (d, <i>J</i> = 4.8 Hz, 3H).

CMPD No.	Characterization Data	
579	LCMS (ESI) m/z: 333.1[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 11.24 (s, 1H), 9.31 (s, 1H), 9.20 (s, 1H), 8.83 (d, <i>J</i> = 1.9 Hz, 1H), 8.36 (s, 1H), 8.12 (d, <i>J</i> = 8.5 Hz, 1H), 7.76 (d, <i>J</i> = 8.6 Hz, 1H), 7.36 (dd, <i>J</i> = 14.3, 6.5 Hz, 1H), 7.20 – 7.09 (m, 2H), 7.04 (t, <i>J</i> = 8.6 Hz, 1H), 4.0 (s, 2H).
580	LCMS (ESI) m/z: 356.0[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 11.18 (s, 1H), 9.08 (d, <i>J</i> = 11.2 Hz, 1H), 8.75 (d, <i>J</i> = 11.4 Hz, 1H), 8.39 (dd, <i>J</i> = 25.3, 11.2 Hz, 2H), 8.10 (dd, <i>J</i> = 12.6, 8.5 Hz, 1H), 7.80 (d, <i>J</i> = 9.2 Hz, 1H), 7.04 (s, 3H), 4.65 (d, <i>J</i> = 12.6 Hz, 2H), 3.99 (d, <i>J</i> = 12.4 Hz, 2H).
581	LCMS (ESI) m/z: 341.1 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 11.21 (s, 1H), 9.18 (s, 2H), 8.37 (d, <i>J</i> = 1.9 Hz, 1H), 8.13 (d, <i>J</i> = 8.5 Hz, 1H), 7.77 (dd, <i>J</i> = 8.5, 2.3 Hz, 1H), 7.06 (dd, <i>J</i> = 11.5, 4.5 Hz, 3H), 4.00 (s, 2H), 2.70 (s, 3H).
582	LCMS (ESI) m/z: 370.0 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.63 (s, 1H), 8.64 (d, <i>J</i> = 2.6 Hz, 1H), 8.31 (d, <i>J</i> = 1.9 Hz, 1H), 8.06 (d, <i>J</i> = 8.5 Hz, 1H), 7.94 (dd, <i>J</i> = 9.5, 2.7 Hz, 1H), 7.69 (dd, <i>J</i> = 8.6, 2.4 Hz, 1H), 7.44 – 7.30 (m, 2H), 7.19 – 7.00 (m, 1H), 6.43 (d, <i>J</i> = 9.5 Hz, 1H), 3.97 (dd, <i>J</i> = 13.4, 6.2 Hz, 4H), 1.27 (t, <i>J</i> = 7.1 Hz, 3H).
583	LCMS (ESI) m/z: 370.0 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.64 (s, 1H), 8.65 (d, <i>J</i> = 2.6 Hz, 1H), 8.33 (d, <i>J</i> = 2.0 Hz, 1H), 8.07 (d, <i>J</i> = 8.6 Hz, 1H), 7.94 (dd, <i>J</i> = 9.5, 2.7 Hz, 1H), 7.72 (dd, <i>J</i> = 8.6, 2.4 Hz, 1H), 7.06 (dd, <i>J</i> = 12.9, 4.5 Hz, 3H), 6.43 (d, <i>J</i> = 9.5 Hz, 1H), 4.05 – 3.91 (m, 4H), 1.28 (t, <i>J</i> = 7.1 Hz, 3H).
584	LCMS (ESI) m/z: 337.3 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.23 (s, 1H), 8.48 (t, <i>J</i> = 9.8 Hz, 1H), 8.19 (d, <i>J</i> = 8.6 Hz, 1H), 8.08 – 7.85 (m, 2H), 7.45 – 7.20 (m, 2H), 7.14 – 6.88 (m, 4H), 5.12 (s, 2H), 3.80 (s, 3H).
585	LCMS (ESI) m/z: 361.0 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.61 (s, 1H), 8.37 (dd, <i>J</i> = 5.5, 3.3 Hz, 2H), 8.20 (d, <i>J</i> = 8.9 Hz, 1H), 8.14 (d, <i>J</i> = 8.5 Hz, 1H), 7.79 (dd, <i>J</i> = 8.5, 2.3 Hz, 1H), 7.38 (ddt, <i>J</i> = 14.0, 11.0, 5.3 Hz, 2H), 7.17 – 7.08 (m, 1H), 3.98 (s, 2H).
586	LCMS (ESI) m/z: 359.2 [M+H] ⁺ .	¹ H NMR (300 MHz, DMSO- <i>d</i> ₆) δ 10.34 (s, 1H), 8.37 – 8.30 (m, 1H), 8.30 – 8.16 (m, 1H), 7.96 (d, <i>J</i> = 9.7 Hz, 1H), 7.74 (dd, <i>J</i> = 9.0, 3.0 Hz, 1H), 7.24 (dt, <i>J</i> = 8.7, 2.1 Hz, 1H), 7.09 (d, <i>J</i> = 9.7 Hz, 1H), 6.99 (dt, <i>J</i> = 8.5, 2.3 Hz, 2H), 3.80 (s, 3H);
587	LCMS (ESI) m/z: 358.2 [M+H] ⁺ .	¹ H NMR (300 MHz, DMSO- <i>d</i> ₆) δ 10.66 (s, 1H), 8.67 (d, <i>J</i> = 2.7 Hz, 1H), 8.27 – 8.11 (m, 2H), 7.99 (dd, <i>J</i> = 9.6, 2.7 Hz, 1H), 7.60 (dd, <i>J</i> = 9.0, 3.0 Hz, 1H), 7.47 (dt, <i>J</i> = 10.5, 9.2 Hz, 1H), 7.28 (ddd, <i>J</i> = 11.8, 6.8, 3.0 Hz, 1H), 6.90 (dtd, <i>J</i> = 9.2, 3.3, 1.8 Hz, 1H), 6.44 (d, <i>J</i> = 9.5 Hz, 1H), 3.50 (s, 3H);
588	LCMS (ESI) m/z: 358.3 [M+H] ⁺ .	¹ H NMR (300 MHz, DMSO- <i>d</i> ₆) δ 10.71 (s, 1H), 8.68 (d, <i>J</i> = 2.7 Hz, 1H), 8.28 (dd, <i>J</i> = 3.0, 0.6 Hz, 1H), 8.21 (dd, <i>J</i> = 9.0, 0.7 Hz, 1H), 8.00 (dd, <i>J</i> = 9.6, 2.7 Hz, 1H), 7.69 (dd, <i>J</i> = 9.0, 3.0 Hz, 1H), 7.03 (tt, <i>J</i> = 9.4, 2.3 Hz, 1H), 6.87 – 6.75 (m, 2H), 6.44 (d, <i>J</i> = 9.5 Hz, 1H), 3.57 (s, 3H), 3.50 (s, 3H).
589	LCMS (ESI) m/z: 374.1 [M+H] ⁺ .	¹ H NMR (300 MHz, DMSO- <i>d</i> ₆) δ 10.71 (s, 1H), 8.68 (d, <i>J</i> = 2.6 Hz, 1H), 8.28 (dd, <i>J</i> = 3.0, 0.7 Hz, 1H), 8.21 (dd, <i>J</i> = 9.1, 0.7 Hz, 1H), 8.00 (dd, <i>J</i> = 9.5, 2.7 Hz, 1H), 7.69 (dd, <i>J</i> = 9.1, 3.0 Hz, 1H), 7.22 (dt, <i>J</i> = 8.7, 2.1 Hz, 1H), 7.04 – 6.90 (m, 2H), 6.44 (d, <i>J</i> = 9.5 Hz, 1H), 3.50 (s, 3H);
590	LCMS (ESI) m/z: 357.1[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.16 (s, 1H), 8.55 (d, <i>J</i> = 6.5 Hz, 1H), 8.38 (d, <i>J</i> = 1.9 Hz, 1H), 8.12 (d, <i>J</i> = 8.5 Hz, 1H), 7.81 (dd, <i>J</i> = 8.5, 2.3 Hz, 1H), 7.16 – 6.93 (m, 4H), 4.00 (s, 2H), 3.54 (s, 3H).

CMPD No.	Characterization Data	
591	LCMS (ESI) m/z: 352.1 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.49(s, 1H), 9.43(d, <i>J</i> = 1.6 Hz, 1H), 9.39(d, <i>J</i> = 1.6 Hz, 1H), 8.36(d, <i>J</i> = 2.0 Hz, 1H), 8.13(d, <i>J</i> = 8.8 Hz, 1H), 7.80(dd, <i>J</i> ₁ = 2.4 Hz, <i>J</i> ₂ = 8.4 Hz, 1H), 7.41-7.33(m, 2H), 7.14-7.11(m, 1H), 3.98(s, 2H);
592	LCMS (ESI) m/z: 361.1[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 11.20 (s, 1H), 9.15 (d, <i>J</i> = 1.8 Hz, 1H), 8.92 (d, <i>J</i> = 4.8 Hz, 1H), 8.50 (dd, <i>J</i> = 8.1, 2.1 Hz, 1H), 8.36 (d, <i>J</i> = 1.9 Hz, 1H), 8.13 (dd, <i>J</i> = 8.3, 2.0 Hz, 2H), 7.75 (dd, <i>J</i> = 8.5, 2.3 Hz, 1H), 7.43 – 7.14 (m, 4H), 3.99 (s, 2H), 2.85 (d, <i>J</i> = 4.8 Hz, 3H).
593	LCMS (ESI) m/z: 383.1[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 11.22 (s, 1H), 9.15 (s, 1H), 8.94 (d, <i>J</i> = 4.7 Hz, 1H), 8.50 (d, <i>J</i> = 8.1 Hz, 1H), 8.35 (s, 1H), 8.13 (d, <i>J</i> = 8.0 Hz, 2H), 7.75 (d, <i>J</i> = 8.5 Hz, 1H), 7.37 (dd, <i>J</i> = 18.9, 8.5 Hz, 2H), 7.13 (s, 1H), 3.98 (s, 2H), 2.85 (d, <i>J</i> = 4.5 Hz, 3H).
594	LCMS (ESI) m/z: 350.1 [M+H] ⁺ .	¹ H NMR (400 MHz, CF ₃ COOD) δ 9.01 (s, 1H), 8.81 (s, 1H), 8.46-8.42 (m, 2H), 7.89 (d, <i>J</i> = 8.8 Hz, 1H), 7.55-7.50 (m, 2H), 7.42 (d, <i>J</i> = 8.8 Hz, 1H), 4.67 (q, <i>J</i> = 7.6 Hz, 2H), 4.36 (s, 2H), 1.78 (t, <i>J</i> = 7.2 Hz, 3H);
595	LCMS (ESI) m/z: 348.1 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 11.20 (s, 1H), 9.18 (s, 2H), 8.39 (d, <i>J</i> = 2.4 Hz, 1H), 8.13 (d, <i>J</i> = 8.4 Hz, 1H), 7.79 (dd, <i>J</i> = 8.4, 2.4 Hz, 1H), 7.72-7.69 (m, 2H), 7.60-7.57 (m, 1H), 4.05 (s, 2H), 2.70 (s, 3H);
596	LCMS (ESI) m/z: 387.1 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.06 (s, 1H), 8.36 (s, 1H), 8.10 (d, <i>J</i> = 8.5 Hz, 1H), 7.79 (dd, <i>J</i> = 8.0, 2.1 Hz, 1H), 7.26 (s, 1H), 7.06 – 7.03 (m, 3H), 3.99 (s, 2H), 3.93 (s, 3H), 3.78 (s, 3H).
597	LCMS (ESI) m/z: 369.1[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.11 (s, 1H), 8.32 (d, <i>J</i> = 2.1 Hz, 1H), 8.08 (d, <i>J</i> = 8.5 Hz, 1H), 7.95 (d, <i>J</i> = 9.7 Hz, 1H), 7.74 (dd, <i>J</i> = 8.5, 2.3 Hz, 1H), 7.23 – 7.00 (m, 3H), 6.83-6.77 (m, 1H), 3.95 (d, <i>J</i> = 10.9 Hz, 2H), 3.81 (s, 3H), 3.79 (s, 3H).
598	LCMS (ESI) m/z: 375.2 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.82 (s, 1H), 8.45 (s, 1H), 8.14 (d, <i>J</i> = 8.5 Hz, 1H), 8.02 – 7.77 (m, 1H), 7.37 (dd, <i>J</i> = 19.7, 9.6 Hz, 1H), 7.20 (ddd, <i>J</i> = 12.5, 6.9, 3.0 Hz, 1H), 6.88 (d, <i>J</i> = 9.0 Hz, 1H), 5.10 (s, 2H), 3.37 (s, 3H), 2.86 (t, <i>J</i> = 8.4 Hz, 2H), 2.54 (d, <i>J</i> = 8.5 Hz, 2H).
599	LCMS (ESI) m/z: 355.3 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.23 (s, 1H), 8.48 (d, <i>J</i> = 1.9 Hz, 1H), 8.19 (d, <i>J</i> = 8.4 Hz, 1H), 7.97 (dd, <i>J</i> = 9.1, 3.3 Hz, 2H), 7.35 – 6.85 (m, 5H), 5.10 (s, 2H), 3.80 (s, 3H).
600	LCMS (ESI) m/z: 336.2 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.64 (s, 1H), 8.69 (d, <i>J</i> = 2.1 Hz, 1H), 8.47 (s, 1H), 8.16 (d, <i>J</i> = 8.6 Hz, 1H), 8.06 – 7.79 (m, 2H), 7.31 (t, <i>J</i> = 7.8 Hz, 2H), 7.16 – 6.89 (m, 3H), 6.44 (d, <i>J</i> = 9.5 Hz, 1H), 5.11 (s, 2H), 3.51 (s, 3H).
601	LCMS (ESI) m/z: 394.0[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 11.23 (s, 1H), 8.92 (d, <i>J</i> = 2.1 Hz, 1H), 8.66 (d, <i>J</i> = 2.1 Hz, 1H), 8.38 (d, <i>J</i> = 1.9 Hz, 1H), 8.11 (d, <i>J</i> = 8.5 Hz, 1H), 7.77 (dd, <i>J</i> = 8.5, 2.3 Hz, 1H), 7.22 – 6.86 (m, 3H), 4.00 (s, 2H).
602	LCMS (ESI) m/z: 361.0/363.0 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.28(s, 1H), 9.14(s, 1H), 8.97(s, 1H), 8.35(s, 1H), 8.14(d, <i>J</i> = 8.4 Hz, 1H), 7.79(d, <i>J</i> = 8.4 Hz, 1H), 7.40-7.32(m, 2H), 7.13(bs, 1H), 3.97(s, 2H);
603	LCMS (ESI) m/z: 357.1 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.48(s, 1H), 8.96(s, 2H), 8.33(d, <i>J</i> = 1.6 Hz, 1H), 8.18(d, <i>J</i> = 8.4 Hz, 1H), 7.78(dd, <i>J</i> ₁ = 2.0 Hz, <i>J</i> ₂ = 8.4 Hz, 1H), 7.40-7.32(m, 2H), 7.13-7.10(m, 1H), 5.63 (bs, 1H), 4.68(s, 2H), 3.97(s, 2H);

CMPD No.	Characterization Data	
604	LCMS (ESI) m/z: 371.1 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.47(s, 1H), 9.00(s, 2H), 8.33(d, <i>J</i> = 2.0 Hz, 1H), 8.18(d, <i>J</i> = 8.8 Hz, 1H), 7.78(dd, <i>J</i> ₁ = 2.0 Hz, <i>J</i> ₂ = 8.4 Hz, 1H), 7.40-7.32(m, 2H), 7.13-7.10(m, 1H), 5.66 (d, <i>J</i> = 4.4 Hz, 1H), 4.96-4.93(m, 1H), 1.44 (d, <i>J</i> = 6.4 Hz, 3H), 3.97(s, 2H);
605	LCMS (ESI) m/z: 384.0/386.0 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.99(s, 1H), 9.05(d, <i>J</i> = 2.0 Hz, 1H), 8.33(dd, <i>J</i> ₁ = 2.0 Hz, <i>J</i> ₂ = 8.4 Hz, 2H), 8.12(d, <i>J</i> = 8.4 Hz, 1H), 7.73(dd, <i>J</i> ₁ = 2.4 Hz, <i>J</i> ₂ = 8.4 Hz, 1H), 7.60(d, <i>J</i> = 8.0 Hz, 1H), 7.36-7.32(m, 2H), 7.28-7.23(m, 2H), 5.57(d, <i>J</i> = 4.4 Hz, 1H), 4.77 (m, 1H), 4.66-4.64 (m, 1H), 3.98(s, 2H), 3.73-3.70 (m, 1H), 3.54-3.50 (m, 1H);
606	LCMS (ESI) m/z: 362.1 [M+H] ⁺ .	¹ H NMR (500 MHz, TFA) δ 9.15 (s, 1H), 9.04 (s, 1H), 8.99 (d, <i>J</i> = 9.0 Hz, 1H), 8.62 (d, <i>J</i> = 8.9 Hz, 1H), 8.04 (s, 1H), 8.00 (d, <i>J</i> = 7.2 Hz, 1H), 7.90 (d, <i>J</i> = 8.7 Hz, 1H), 4.87 (s, 2H), 3.68 (s, 3H), 3.61 (s, 3H).
607	LCMS (ESI) m/z: 375.2 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.83 (s, 1H), 8.45 (s, 1H), 8.14 (d, <i>J</i> = 8.5 Hz, 1H), 7.95 (d, <i>J</i> = 8.4 Hz, 1H), 7.31 (dt, <i>J</i> = 8.8, 7.4 Hz, 2H), 7.04 (s, 1H), 5.16 (s, 2H), 3.37 (s, 3H), 2.86 (t, <i>J</i> = 8.5 Hz, 2H), 2.54 (d, <i>J</i> = 8.5 Hz, 2H).
608	LCMS (ESI) m/z: 385.0[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 11.37 (s, 1H), 9.15 (d, <i>J</i> = 1.7 Hz, 1H), 8.76 (d, <i>J</i> = 1.8 Hz, 1H), 8.39 (d, <i>J</i> = 2.1 Hz, 1H), 8.12 (d, <i>J</i> = 8.5 Hz, 1H), 7.79 (dd, <i>J</i> = 8.5, 2.3 Hz, 1H), 7.20 – 6.98 (m, 3H), 4.01 (s, 2H).
609	LCMS (ESI) m/z: 378.1 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.05 (s, 1H), 8.36 (d, <i>J</i> = 2.0 Hz, 1H), 8.09 (d, <i>J</i> = 8.5 Hz, 1H), 7.88 (s, 1H), 7.79 (dd, <i>J</i> = 8.0, 2.3 Hz, 1H), 7.70 – 7.68 (m, 2H), 7.58 (d, <i>J</i> = 9.9 Hz, 1H), 4.05 (s, 2H), 3.79 (s, 3H), 2.17 (s, 3H).
610	LCMS (ESI) m/z: 378.1 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.04 (s, 1H), 8.34 (s, 1H), 8.08 (d, <i>J</i> = 8.5 Hz, 1H), 7.88 – 7.85 (m, 2H), 7.76 (d, <i>J</i> = 8.4 Hz, 1H), 7.69 (d, <i>J</i> = 8.0 Hz, 1H), 7.47 (t, <i>J</i> = 8.0 Hz, 1H), 4.02 (s, 2H), 3.79 (s, 3H), 2.17 (s, 3H).
611	LCMS (ESI) m/z: 359.9[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.56 (s, 1H), 8.66 (s, 1H), 8.30-8.40 (m, 2H), 8.09-8.16 (m, 1H), 7.70-7.81 (m, 1H), 7.30-7.41 (m, 1H), 7.00-7.18 (m, 3H), 3.99 (s, 2H).
612	LCMS (ESI) m/z: 376.0[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 11.44 (s, 1H), 9.41 (d, <i>J</i> = 2.0 Hz, 1H), 9.08 (d, <i>J</i> = 2.0 Hz, 1H), 8.41 (t, <i>J</i> = 14.1 Hz, 1H), 8.13 (d, <i>J</i> = 8.5 Hz, 1H), 7.80 (dd, <i>J</i> = 8.6, 2.3 Hz, 1H), 7.20 – 7.00 (m, 3H), 4.01 (s, 2H).
613	LCMS (ESI) m/z: 351.1[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.54 (s, 1H), 8.67 (d, <i>J</i> = 2.6 Hz, 1H), 8.31 (d, <i>J</i> = 2.0 Hz, 1H), 8.14 – 8.03 (m, 2H), 7.98 (dd, <i>J</i> = 9.5, 2.6 Hz, 1H), 7.69 (dd, <i>J</i> = 8.5, 2.3 Hz, 1H), 6.96 – 6.84 (m, 1H), 6.71 (s, 1H), 6.43 (d, <i>J</i> = 9.5 Hz, 1H), 3.92 (s, 2H), 3.82 (s, 3H), 3.50 (s, 3H).
614	LCMS (ESI) m/z: 364.0 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.16 (s, 1H), 8.33 (d, <i>J</i> = 1.9 Hz, 1H), 8.10 (d, <i>J</i> = 8.5 Hz, 1H), 7.95 (d, <i>J</i> = 9.7 Hz, 1H), 7.89 – 7.80 (m, 1H), 7.74 (dd, <i>J</i> = 11.2, 4.2 Hz, 2H), 7.39 (t, <i>J</i> = 7.7 Hz, 1H), 7.08 (d, <i>J</i> = 9.7 Hz, 1H), 4.08 (s, 2H), 3.79 (s, 3H).
615	LCMS (ESI) m/z: 371.2 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.24 (s, 1H), 8.51 (s, 1H), 8.20 (d, <i>J</i> = 8.4 Hz, 1H), 7.98 (dd, <i>J</i> = 12.4, 5.9 Hz, 2H), 7.45 (d, <i>J</i> = 7.9 Hz, 1H), 7.39 – 7.25 (m, 2H), 7.09 (d, <i>J</i> = 9.7 Hz, 1H), 6.99 (dd, <i>J</i> = 10.6, 4.3 Hz, 1H), 5.23 (s, 2H), 3.80 (s, 3H).

CMPD No.	Characterization Data	
616	LCMS (ESI) m/z: 365.1[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 11.25 (s, 1H), 9.05 (s, 1H), 8.47 (s, 1H), 8.37 (s, 1H), 8.24 – 8.03 (m, 1H), 7.78 (d, <i>J</i> = 8.5 Hz, 1H), 7.06 (dd, <i>J</i> = 14.7, 8.8 Hz, 3H), 4.27 – 3.81 (m, 2H), 2.57 (s, 3H).
617	LCMS (ESI) m/z: 379.0/381.0 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.55(s, 1H), 8.67(d, <i>J</i> = 2.8 Hz, 1H), 8.32(d, <i>J</i> = 2.0 Hz, 1H), 8.06(d, <i>J</i> = 8.4 Hz, 1H), 7.97(dd, <i>J</i> ₁ = 2.8 Hz, <i>J</i> ₂ = 9.6 Hz, 1H), 7.94(d, <i>J</i> = 2.0 Hz, 1H), 7.72-7.62(m, 3H), 8.42(d, <i>J</i> = 9.6 Hz, 1H), 4.00 (s, 2H), 3.49(s, 3H), ;
618	LCMS (ESI) m/z: 379.0/381.0 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.56(s, 1H), 8.67(d, <i>J</i> = 2.4 Hz, 1H), 8.35(d, <i>J</i> = 2.0 Hz, 1H), 8.06(d, <i>J</i> = 8.4 Hz, 1H), 7.97(dd, <i>J</i> ₁ = 2.4 Hz, <i>J</i> ₂ = 9.6 Hz, 1H), 7.90(t, <i>J</i> = 1.6 Hz, 1H), 7.80(t, <i>J</i> = 1.6 Hz, 1H), 7.77-7.72(m, 2H), 6.43(d, <i>J</i> = 9.6 Hz, 1H), 4.01 (s, 2H), 3.49(s, 3H);
619	LCMS (ESI) m/z: 374.1[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 11.07 (s, 1H), 8.80 (d, <i>J</i> = 1.9 Hz, 1H), 8.36 (s, 2H), 8.12 (d, <i>J</i> = 8.5 Hz, 1H), 7.76 (dd, <i>J</i> = 8.5, 2.2 Hz, 1H), 7.22 – 6.96 (m, 3H), 4.00 (s, 2H), 2.41 (s, 3H).
620	LCMS (ESI) m/z: 363.0 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.94 (s, 1H), 8.38 (d, <i>J</i> = 2.0 Hz, 1H), 8.06 (d, <i>J</i> = 8.5 Hz, 1H), 7.81 (d, <i>J</i> = 7.0 Hz, 1H), 7.77 (dd, <i>J</i> = 8.5, 2.3 Hz, 1H), 7.74 – 7.64 (m, 2H), 7.58 (d, <i>J</i> = 9.8 Hz, 1H), 6.94 (d, <i>J</i> = 1.8 Hz, 1H), 6.61 (dd, <i>J</i> = 7.0, 2.0 Hz, 1H), 4.05 (s, 2H), 3.46 (s, 3H).
621	LCMS (ESI) m/z: 327.2 [M+H] ⁺ .	¹ H NMR (300 MHz, Chloroform- <i>d</i>) δ 9.68 (dd, <i>J</i> = 2.4, 1.2 Hz, 1H), 9.48 (dd, <i>J</i> = 5.3, 1.3 Hz, 1H), 8.70 (s, 1H), 8.30 (d, <i>J</i> = 8.5 Hz, 1H), 8.19 (d, <i>J</i> = 2.3 Hz, 1H), 7.93 (dd, <i>J</i> = 5.3, 2.4 Hz, 1H), 7.61 (dd, <i>J</i> = 8.5, 2.4 Hz, 1H), 7.24 – 6.80 (m, 2H), 3.96 (s, 2H).
622	LCMS (ESI) m/z: 327.2 [M+H] ⁺ .	¹ H NMR (300 MHz, Chloroform- <i>d</i>) δ 9.68 (dd, <i>J</i> = 2.4, 1.2 Hz, 1H), 9.48 (dd, <i>J</i> = 5.3, 1.2 Hz, 1H), 8.66 (s, 1H), 8.31 (d, <i>J</i> = 8.5 Hz, 1H), 8.24 – 8.14 (m, 1H), 7.93 (dd, <i>J</i> = 5.3, 2.4 Hz, 1H), 7.62 (dd, <i>J</i> = 8.6, 2.4 Hz, 1H), 6.70 (ddt, <i>J</i> = 10.1, 4.5, 2.3 Hz, 3H), 3.98 (s, 2H).
623	LCMS (ESI) m/z: 352.1 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.46 (s, 1H), 8.55 (d, <i>J</i> = 2.5 Hz, 1H), 8.30 (d, <i>J</i> = 2.1 Hz, 1H), 8.06 (d, <i>J</i> = 8.5 Hz, 1H), 7.93 – 7.88 (m, 1H), 7.69 (dd, <i>J</i> = 8.6, 2.4 Hz, 1H), 7.30-7.36 (m, 1H), 7.10-7.16 (m, 2H), 6.95-7.08 (m, 1H), 3.97 (s, 2H), 3.51 (s, 3H), 2.05 (s, 3H).
624	LCMS (ESI) m/z: 353.1[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 8.33 (d, <i>J</i> = 2.0 Hz, 1H), 8.21 – 8.14 (m, 2H), 7.75 (dd, <i>J</i> = 8.5, 2.3 Hz, 1H), 7.35 (td, <i>J</i> = 8.0, 6.3 Hz, 1H), 7.15 – 7.08 (m, 2H), 7.03 (td, <i>J</i> = 8.4, 2.3 Hz, 1H), 3.98 (s, 2H), 3.78 (s, 3H), 2.40 (s, 3H).
625	LCMS (ESI) m/z: 357.0 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.15 (s, 1H), 8.29 (d, <i>J</i> = 2.1 Hz, 1H), 8.08 (d, <i>J</i> = 8.5 Hz, 1H), 7.95 (d, <i>J</i> = 9.7 Hz, 1H), 7.70 (dd, <i>J</i> = 8.5, 2.2 Hz, 1H), 7.41 (dd, <i>J</i> = 15.4, 8.7 Hz, 1H), 7.29 – 7.19 (m, 1H), 7.06 (dd, <i>J</i> = 13.5, 6.1 Hz, 2H), 3.98 (s, 2H), 3.79 (s, 3H).
626	LCMS (ESI) m/z: 380.0/382.0 [M+H] ⁺ .	¹ H NMR (400 MHz, CDCl ₃) δ 9.47(s, 1H), 8.30(d, <i>J</i> = 8.8 Hz, 1H), 8.20(s, 1H), 8.05(d, <i>J</i> = 9.6 Hz, 1H), 7.55-7.52(m, 2H), 7.40(s, 1H), 7.36(s, 1H), 7.04(d, <i>J</i> = 10.0 Hz, 1H), 3.99 (s, 2H), 3.89(s, 3H);
627	LCMS (ESI) m/z: 334.0[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.95 (s, 1H), 9.29 – 9.16 (m, 2H), 8.72 (d, <i>J</i> = 1.7 Hz, 1H), 8.14 (d, <i>J</i> = 8.0 Hz, 1H), 7.97 (dd, <i>J</i> = 8.0, 2.1 Hz, 1H), 7.45-7.32 (m, 1H), 7.25 – 7.13 (m, 2H), 7.09-7.04 (m, 1H), 4.15 (s, 2H).

CMPD No.	Characterization Data	
628	LCMS (ESI) m/z: 363.1[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 11.08 (s, 1H), 9.01 (d, <i>J</i> = 2.1 Hz, 1H), 8.69 (d, <i>J</i> = 1.9 Hz, 1H), 8.38 (d, <i>J</i> = 2.0 Hz, 1H), 8.26 (d, <i>J</i> = 2.0 Hz, 1H), 8.13 (d, <i>J</i> = 8.5 Hz, 1H), 7.78 (dd, <i>J</i> = 8.6, 2.4 Hz, 1H), 7.74 – 7.66 (m, 2H), 7.62 – 7.55 (m, 1H), 5.49 (s, 1H), 4.62 (s, 2H), 4.05 (s, 2H).
629	LCMS (ESI) m/z: 351.1 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 11.32(s, 1H), 9.22(d, <i>J</i> = 1.6 Hz, 1H), 8.53(dd, <i>J</i> ₁ = 2.4 Hz, <i>J</i> ₂ = 8.4 Hz, 1H), 8.34(d, <i>J</i> = 1.6 Hz, 1H), 8.20(d, <i>J</i> = 8.0 Hz, 1H), 8.12(d, <i>J</i> = 8.4 Hz, 1H), 7.73(dd, <i>J</i> ₁ = 2.4 Hz, <i>J</i> ₂ = 8.4 Hz, 1H), 7.28-7.21(m, 2H), 7.15-7.12(m, 1H), 3.99(s, 2H);
630	LCMS (ESI) m/z: 356.1 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.95 (s, 1H), 8.32 (d, <i>J</i> = 1.5 Hz, 1H), 8.05 (d, <i>J</i> = 8.5 Hz, 1H), 7.81 (d, <i>J</i> = 7.0 Hz, 1H), 7.70 (dd, <i>J</i> = 8.5, 2.0 Hz, 1H), 7.35 – 7.19 (m, 2H), 7.14 (dd, <i>J</i> = 7.8, 3.8 Hz, 1H), 6.94 (d, <i>J</i> = 1.5 Hz, 1H), 6.61 (dd, <i>J</i> = 7.0, 1.8 Hz, 1H), 3.99 (s, 2H), 3.46 (s, 3H).
631	LCMS (ESI) m/z: 389.0[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.72 (s, 1H), 8.91 (d, <i>J</i> = 6.0 Hz, 2H), 8.70 (d, <i>J</i> = 1.6 Hz, 1H), 8.12 (d, <i>J</i> = 8.0 Hz, 1H), 7.96 (dd, <i>J</i> = 8.0, 2.1 Hz, 1H), 7.46-7.34 (m, 1H), 7.25 – 7.12 (m, 2H), 7.09-7.04 (m, 1H), 4.14 (s, 2H).
632	LCMS (ESI) m/z: 393.9 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.90 (s, 1H), 8.56 (s, 1H), 8.33 (d, <i>J</i> = 1.5 Hz, 1H), 8.09 (d, <i>J</i> = 8.5 Hz, 1H), 7.75 (dd, <i>J</i> = 8.5, 1.9 Hz, 1H), 7.35 (dd, <i>J</i> = 14.4, 7.9 Hz, 1H), 7.12 (t, <i>J</i> = 7.4 Hz, 2H), 7.04 (dd, <i>J</i> = 11.9, 5.3 Hz, 1H), 3.98 (s, 2H).
633	LCMS (ESI) m/z: 314.1 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.90 (s, 1H), 9.28 (d, <i>J</i> = 1.7 Hz, 1H), 8.61 (d, <i>J</i> = 1.7 Hz, 1H), 8.32 (s, 1H), 8.14 (d, <i>J</i> = 8.5 Hz, 1H), 7.76 (dd, <i>J</i> = 8.4, 1.9 Hz, 1H), 7.35 (dd, <i>J</i> = 14.3, 7.9 Hz, 1H), 7.23 – 7.08 (m, 2H), 7.04 (t, <i>J</i> = 7.6 Hz, 1H), 3.98 (s, 2H).
634	LCMS (ESI) m/z: 373.0[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.28 (s, 1H), 9.14 (d, <i>J</i> = 1.2 Hz, 1H), 8.97 (d, <i>J</i> = 1.2 Hz, 1H), 8.35 (d, <i>J</i> = 2.0 Hz, 1H), 8.14 (d, <i>J</i> = 8.4 Hz, 1H), 7.79 (dd, <i>J</i> = 8.4, 2.2 Hz, 1H), 7.20 – 7.03 (m, 2H), 6.86 – 6.71 (m, 1H), 3.95 (s, 2H), 3.82 (s, 3H).
635	LCMS (ESI) m/z: 361.0[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.30 (s, 1H), 9.15 (d, <i>J</i> = 1.2 Hz, 1H), 8.97 (d, <i>J</i> = 1.2 Hz, 1H), 8.38 (d, <i>J</i> = 2.0 Hz, 1H), 8.16 (d, <i>J</i> = 8.4 Hz, 1H), 7.82 (dd, <i>J</i> = 8.4, 2.4 Hz, 1H), 7.16 – 6.97 (m, 3H), 4.00 (s, 2H).
636	LCMS (ESI) m/z: 351.1[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.87 (s, 1H), 9.03 (s, 1H), 8.67 (d, <i>J</i> = 10.1 Hz, 1H), 8.34 (s, 1H), 8.12 (d, <i>J</i> = 7.8 Hz, 1H), 7.78 (d, <i>J</i> = 8.4 Hz, 1H), 7.35 (dd, <i>J</i> = 14.4, 7.9 Hz, 1H), 7.19 – 6.96 (m, 3H), 3.99 (s, 2H).
637	LCMS (ESI) m/z: 326.1 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 11.05 (s, 1H), 9.06 (d, <i>J</i> = 1.9 Hz, 1H), 8.36 (dd, <i>J</i> = 8.2, 2.3 Hz, 1H), 8.27 (d, <i>J</i> = 2.2 Hz, 1H), 8.17 (d, <i>J</i> = 8.6 Hz, 1H), 7.74 (dd, <i>J</i> = 8.6, 2.3 Hz, 1H), 7.59 (d, <i>J</i> = 8.2 Hz, 1H), 6.32 (s, 1H), 5.61 (s, 1H), 4.64 (s, 2H), 3.69 (t, <i>J</i> = 5.4 Hz, 2H), 3.60 (t, <i>J</i> = 5.5 Hz, 2H), 2.47 (t, <i>J</i> = 5.4 Hz, 2H), 2.36 (t, <i>J</i> = 5.0 Hz, 2H).
638	LCMS (ESI) m/z: 364.1[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.48 (s, 1H), 9.44 (d, <i>J</i> = 1.2 Hz, 1H), 9.39 (d, <i>J</i> = 1.2 Hz, 1H), 8.37 (d, <i>J</i> = 1.8 Hz, 1H), 8.14 (d, <i>J</i> = 8.4 Hz, 1H), 7.80 (dd, <i>J</i> = 8.5, 2.2 Hz, 1H), 7.12 (m, 2H), 6.80 (m, 1H), 3.95 (s, 2H), 3.82 (s, 3H).

CMPD No.	Characterization Data	
639	LCMS (ESI) m/z: 352.0[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.50 (s, 1H), 9.44 (s, 1H), 9.39 (s, 1H), 8.39 (s, 1H), 8.15 (d, <i>J</i> = 8.4 Hz, 1H), 7.83 (d, <i>J</i> = 8.4 Hz, 1H), 7.05 (d, <i>J</i> = 8.6 Hz, 3H), 4.01 (s, 2H).
640	LCMS (ESI) m/z: 339.0 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.27 (s, 1H), 8.98 (s, 1H), 8.35 (d, <i>J</i> = 1.9 Hz, 1H), 8.07 (d, <i>J</i> = 8.5 Hz, 1H), 7.76 (dd, <i>J</i> = 8.5, 2.2 Hz, 1H), 7.35 (dd, <i>J</i> = 14.3, 8.0 Hz, 1H), 7.13 (t, <i>J</i> = 7.4 Hz, 2H), 7.04 (t, <i>J</i> = 8.6 Hz, 1H), 3.99 (s, 2H).
641	LCMS (ESI) m/z: 364.0[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.16 (s, 1H), 8.33 (d, <i>J</i> = 2.0 Hz, 1H), 8.09 (d, <i>J</i> = 8.5 Hz, 1H), 7.99 – 7.96 (m, 1H), 7.95 (d, <i>J</i> = 9.8 Hz, 1H), 7.89 – 7.81 (m, 1H), 7.74 (dd, <i>J</i> = 8.5, 2.2 Hz, 1H), 7.50 – 7.39 (m, 1H), 7.08 (d, <i>J</i> = 9.7 Hz, 1H), 4.05 (s, 2H), 3.79 (s, 3H).
642	LCMS (ESI) m/z: 341.1 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.41 (s, 1H), 8.28 (d, <i>J</i> = 1.6 Hz, 1H), 7.99 (d, <i>J</i> = 8.8 Hz, 1H), 7.77 (s, 1H), 7.66 (dd, <i>J</i> ₁ = 2.4 Hz, <i>J</i> ₂ = 8.8 Hz, 1H), 7.35 (dd, <i>J</i> ₁ = 7.6 Hz, <i>J</i> ₂ = 14.0 Hz, 1H), 7.10–7.13 (m, 2H), 7.01–7.06 (m, 1H), 3.96 (s, 2H), 3.38 (s, 3H), 3.22 (s, 3H);.
643	LCMS (ESI) m/z: 359.0 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.41 (s, 1H), 8.27 (d, <i>J</i> = 2.0 Hz, 1H), 7.99 (d, <i>J</i> = 8.4 Hz, 1H), 7.77 (s, 1H), 7.65 (dd, <i>J</i> ₁ = 2.0 Hz, <i>J</i> ₂ = 8.4 Hz, 1H), 7.33–7.39 (m, 2H), 7.09–7.12 (m, 1H), 3.93 (s, 2H), 3.38 (s, 3H), 3.22 (s, 3H);
644	LCMS (ESI) m/z: 359.1 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.42 (s, 1H), 8.30 (d, <i>J</i> = 2.0 Hz, 1H), 8.00 (d, <i>J</i> = 8.4 Hz, 1H), 7.78 (s, 1H), 7.69 (dd, <i>J</i> ₁ = 2.0 Hz, <i>J</i> ₂ = 8.4 Hz, 1H), 7.03–7.10 (m, 3H), 3.96 (s, 2H), 3.38 (s, 3H), 3.22 (s, 3H);
645	LCMS (ESI) m/z: 332.1 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.08 (s, 1H), 9.00 (s, 1H), 8.33 (d, <i>J</i> = 1.9 Hz, 1H), 8.04 (d, <i>J</i> = 8.5 Hz, 1H), 7.74 (dd, <i>J</i> = 8.5, 2.3 Hz, 1H), 7.35 (td, <i>J</i> = 8.0, 6.4 Hz, 1H), 7.12 (dd, <i>J</i> = 10.5, 4.4 Hz, 2H), 7.04 (td, <i>J</i> = 8.7, 2.4 Hz, 1H), 3.98 (s, 2H).
646	LCMS (ESI) m/z: 368.1[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.30 (s, 1H), 9.14 (d, <i>J</i> = 1.6 Hz, 1H), 8.97 (d, <i>J</i> = 1.6 Hz, 1H), 8.40 (d, <i>J</i> = 2.0 Hz, 1H), 8.15 (d, <i>J</i> = 8.4 Hz, 1H), 7.84 (dd, <i>J</i> = 8.4, 2.4 Hz, 1H), 7.70–7.72 (m, 2H), 7.58 – 7.61 (m, 1H), 4.01 (s, 2H).
647	LCMS (ESI) m/z: 382.0[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.56 (s, 1H), 8.67 (d, <i>J</i> = 2.5 Hz, 1H), 8.26 (d, <i>J</i> = 2.0 Hz, 1H), 8.06 (d, <i>J</i> = 8.6 Hz, 1H), 7.98 (dd, <i>J</i> = 9.5, 2.5 Hz, 1H), 7.73 (dd, <i>J</i> = 8.7, 2.4 Hz, 1H), 7.44 – 7.24 (m, 2H), 7.09 (brs, 1H), 6.43 (d, <i>J</i> = 9.5 Hz, 1H), 3.50 (s, 3H), 1.31 (s, 4H).
648	LCMS (ESI) m/z: 363.1[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.56 (s, 1H), 8.67 (d, <i>J</i> = 2.6 Hz, 1H), 8.30 (d, <i>J</i> = 2.1 Hz, 1H), 8.07 (d, <i>J</i> = 8.6 Hz, 1H), 8.01 – 7.92 (m, 2H), 7.85 – 7.72 (m, 1H), 7.68 (dd, <i>J</i> = 8.6, 2.3 Hz, 1H), 7.48 – 7.40 (m, 1H), 6.43 (d, <i>J</i> = 9.5 Hz, 1H), 4.03 (s, 2H), 3.50 (s, 3H).
649	LCMS (ESI) m/z: 355.0 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 11.06 (s, 1H), 9.14 (s, 2H), 8.34 (d, <i>J</i> = 2.2 Hz, 1H), 8.11 (d, <i>J</i> = 8.5 Hz, 1H), 7.73 (dd, <i>J</i> = 8.5, 2.3 Hz, 1H), 7.35 (dd, <i>J</i> = 9.4, 6.0 Hz, 2H), 7.30 – 7.20 (m, 2H), 4.00 (s, 3H), 3.98 (s, 2H).
650	LCMS (ESI) m/z: 326.2 [M+H] ⁺ .	¹ H NMR (500 MHz, DMSO- <i>d</i> ₆) δ 11.60 (bs, 1H), 9.58 (s, 1H), 8.29 (d, <i>J</i> = 2.0 Hz, 1H), 8.07 (d, <i>J</i> = 8.5 Hz, 1H), 7.78 (d, <i>J</i> = 8.5 Hz, 1H), 7.36–7.32 (m, 2H), 7.28–7.23 (m, 2H), 5.90 (s, 1H), 4.02–3.97 (m, 4H), 1.32 (t, <i>J</i> = 7.0 Hz, 3H);
651	LCMS (ESI) m/z: 326.2[M+H] ⁺ .	¹ H NMR (300 MHz, Chloroform- <i>d</i>) δ 9.08 – 8.77 (m, 2H), 8.74 (s, 1H), 8.34 (dd, <i>J</i> = 8.6, 0.8 Hz, 1H), 8.15 (dd, <i>J</i> = 2.3, 0.8 Hz, 1H), 7.88 – 7.68 (m, 2H), 7.60 (dd, <i>J</i> = 8.5, 2.4 Hz, 1H), 6.70 (dq, <i>J</i> = 7.2, 3.1, 2.4 Hz, 3H), 3.96 (s, 2H).

CMPD No.	Characterization Data	
652	LCMS (ESI) m/z: 355.0 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.73 (s, 1H), 9.06 (d, <i>J</i> = 3.3 Hz, 1H), 8.99 (d, <i>J</i> = 3.3 Hz, 1H), 8.32 (d, <i>J</i> = 2.0 Hz, 1H), 8.06 (d, <i>J</i> = 8.5 Hz, 1H), 7.71 (dd, <i>J</i> = 8.6, 2.4 Hz, 1H), 7.39 – 7.31 (m, 2H), 7.27 (ddd, <i>J</i> = 13.7, 7.8, 4.3 Hz, 2H), 3.97 (s, 2H), 3.51 (s, 3H).
653	LCMS (ESI) m/z: 383.1[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.15 (s, 1H), 8.29 (d, <i>J</i> = 2.1 Hz, 1H), 8.08 (d, <i>J</i> = 8.6 Hz, 1H), 7.95 (d, <i>J</i> = 9.7 Hz, 1H), 7.79 (dd, <i>J</i> = 8.6, 2.4 Hz, 1H), 7.39 – 7.28 (m, 2H), 7.05-7.12 (m, 2H), 3.79 (s, 3H), 1.32 (s, 4H).
654	LCMS (ESI) m/z: 359.1[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.50 (s, 1H), 9.42 (s, 1H), 9.40 (s, 1H), 8.39 (s, 1H), 8.14 (d, <i>J</i> = 8.4 Hz, 1H), 7.90 (d, <i>J</i> = 5.8 Hz, 1H), 7.82 (d, <i>J</i> = 8.2 Hz, 1H), 7.71 (s, 1H), 7.48 (t, <i>J</i> = 8.8 Hz, 1H), 4.04 (s, 2H).
655	LCMS (ESI) m/z: 359.1[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.51 (s, 1H), 9.44 (d, <i>J</i> = 1.4 Hz, 1H), 9.40 (d, <i>J</i> = 1.4 Hz, 1H), 8.41 (d, <i>J</i> = 2.0 Hz, 1H), 8.15 (d, <i>J</i> = 8.4 Hz, 1H), 7.85 (dd, <i>J</i> = 8.4, 2.4 Hz, 1H), 7.71 (dd, <i>J</i> = 8.0, 2.0 Hz, 2H), 7.66 – 7.53 (m, 1H), 4.06 (s, 2H).
656	LCMS (ESI) m/z: 334.0 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 11.41 (s, 1H), 9.64 (s, 1H), 9.47 (d, <i>J</i> = 5.2 Hz, 1H), 8.41 (s, 1H), 8.14-8.12 (m, 2H), 7.81 (d, <i>J</i> = 8.4 Hz, 1H), 7.73-7.70 (m, 2H), 7.59 (d, <i>J</i> = 9.2 Hz, 1H), 4.06 (s, 2H);
657	LCMS (ESI) m/z: 361.0 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 11.43 (s, 1H), 9.61 (s, 1H), 8.39 (s, 2H), 8.11 (d, <i>J</i> = 8.4 Hz, 1H), 7.80 (d, <i>J</i> = 6.4 Hz, 1H), 7.10 – 7.04 (m, 3H), 4.01 (s, 2H).
658	LCMS (ESI) m/z: 373.0 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.26 (s, 1H), 8.50 (d, <i>J</i> = 2.1 Hz, 1H), 8.20 (d, <i>J</i> = 8.5 Hz, 1H), 8.05 – 7.87 (m, 2H), 7.09 (d, <i>J</i> = 9.7 Hz, 1H), 6.98 – 6.69 (m, 3H), 5.16 (s, 2H), 3.80 (s, 3H).
659	LCMS (ESI) m/z: 377.0[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.30 (s, 1H), 9.15 (s, 1H), 8.97 (s, 1H), 8.38 (d, <i>J</i> = 1.6 Hz, 1H), 8.16 (d, <i>J</i> = 8.4 Hz, 1H), 7.83 (dd, <i>J</i> = 8.8, 2.0 Hz, 1H), 7.26-7.29 (m, 2H), 7.18 (d, <i>J</i> = 10.0, 1H), 4.00 (s, 2H).
660	LCMS (ESI) m/z: 411.1[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.29 (s, 1H), 8.62 (d, <i>J</i> = 2.5 Hz, 1H), 7.98 (dd, <i>J</i> = 9.5, 2.6 Hz, 1H), 7.94 (d, <i>J</i> = 8.8 Hz, 1H), 7.68 (d, <i>J</i> = 2.8 Hz, 1H), 7.35 (t, <i>J</i> = 8.2 Hz, 1H), 7.08 – 7.04 (m, 1H), 7.02 (dd, <i>J</i> = 8.9, 2.9 Hz, 1H), 6.98 (t, <i>J</i> = 2.1 Hz, 1H), 6.89 (dd, <i>J</i> = 8.3, 1.9 Hz, 1H), 6.42 (d, <i>J</i> = 9.5 Hz, 1H), 5.25-5.19 (m, 1H), 4.39 – 4.35 (m, 2H), 3.83 (dd, <i>J</i> = 8.6, 3.9 Hz, 2H), 3.49 (s, 3H).
661	LCMS (ESI) m/z: 368.1[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.51 (s, 1H), 9.44 (d, <i>J</i> = 1.4 Hz, 1H), 9.40 (d, <i>J</i> = 1.4 Hz, 1H), 8.40 (d, <i>J</i> = 2.0 Hz, 1H), 8.15 (d, <i>J</i> = 8.4 Hz, 1H), 7.84 (dd, <i>J</i> = 8.4, 2.4 Hz, 1H), 7.35 – 7.22 (m, 2H), 7.23 – 7.13 (m, 1H), 4.01 (s, 2H).
662	LCMS (ESI) m/z: 352.0 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 11.50 (s, 1H), 9.88 (d, <i>J</i> = 2.1 Hz, 1H), 8.82 (d, <i>J</i> = 2.1 Hz, 1H), 8.40 (d, <i>J</i> = 2.0 Hz, 1H), 8.13 (d, <i>J</i> = 8.5 Hz, 1H), 7.81 (dd, <i>J</i> = 8.5, 2.4 Hz, 1H), 7.22 – 6.90 (m, 3H), 4.01 (s, 2H).
663	LCMS (ESI) m/z: 372.1[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 11.26 (s, 1H), 9.04 (d, <i>J</i> = 1.5 Hz, 1H), 8.47 (d, <i>J</i> = 1.3 Hz, 1H), 8.40 (d, <i>J</i> = 1.8 Hz, 1H), 8.13 (d, <i>J</i> = 8.5 Hz, 1H), 7.80 (dd, <i>J</i> = 8.5, 2.3 Hz, 1H), 7.72-7.69 (m, 2H), 7.59 (d, <i>J</i> = 9.8 Hz, 1H), 4.06 (s, 2H), 2.57 (s, 3H).
664	LCMS (ESI) m/z: 372.9 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.25 (s, 1H), 8.49 (d, <i>J</i> = 2.1 Hz, 1H), 8.19 (d, <i>J</i> = 8.5 Hz, 1H), 8.08 – 7.84 (m, 2H), 7.38 (dd, <i>J</i> = 19.8, 9.4 Hz, 1H), 7.21 (ddd, <i>J</i> = 12.3, 6.6, 2.8 Hz, 1H), 7.09 (d, <i>J</i> = 9.7 Hz, 1H), 6.94 – 6.82 (m, 1H), 5.12 (s, 2H), 3.80 (s, 3H).

CMPD No.	Characterization Data	
665	LCMS (ESI) m/z: 381.1[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 11.09 (s, 1H), 8.80 (d, <i>J</i> = 2.2 Hz, 1H), 8.37 (dd, <i>J</i> = 9.5, 1.9 Hz, 2H), 8.12 (d, <i>J</i> = 8.5 Hz, 1H), 7.78 (dd, <i>J</i> = 8.5, 2.4 Hz, 1H), 7.70 (d, <i>J</i> = 5.3 Hz, 2H), 7.59 (d, <i>J</i> = 9.9 Hz, 1H), 4.05 (s, 2H), 2.41 (s, 3H).
666	LCMS (ESI) m/z: 368.1/370.0 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.36 (s, 1H), 9.10 (d, <i>J</i> = 4.8 Hz, 1H), 8.41 (d, <i>J</i> = 2.0 Hz, 1H), 8.15-8.13 (m, 2H), 7.84 (dd, <i>J</i> = 8.4, 2.4 Hz, 1H), 7.72-7.70 (m, 2H), 7.61-7.58 (m, 1H), 4.07 (s, 2H);
667	LCMS (ESI) m/z: 388.9 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.24 (s, 1H), 8.50 (s, 1H), 8.20 (d, <i>J</i> = 8.6 Hz, 1H), 8.06 – 7.88 (m, 2H), 7.50 (t, <i>J</i> = 8.9 Hz, 1H), 7.20 (dd, <i>J</i> = 11.4, 2.7 Hz, 1H), 7.09 (d, <i>J</i> = 9.7 Hz, 1H), 6.94 (d, <i>J</i> = 11.4 Hz, 1H), 5.15 (s, 2H), 3.80 (s, 3H).
668	LCMS (ESI) m/z: 375.0/377.0 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.42(s,1H), 8.30(d, <i>J</i> = 2.4 Hz, 1H), 8.00(d, <i>J</i> = 8.4 Hz, 1H), 7.77(s,1H), 7.69(dd, <i>J</i> ₁ = 2.4 Hz, <i>J</i> ₂ = 8.4 Hz, 1H), 7.28 (dt, <i>J</i> ₁ = 2.4 Hz, <i>J</i> ₂ = 8.8 Hz, 1H), 7.24-(s, 1H), 7.18-7.15 (m, 1H), 3.96(s, 2H), 3.38(s, 3H),3.22(s, 3H);
669	LCMS (ESI) m/z: 350.1 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 11.40 (s, 1H), 9.64 (s, 1H), 9.47 (d, <i>J</i> = 5.3 Hz, 1H), 8.41 (d, <i>J</i> = 1.7 Hz, 1H), 8.14 (dd, <i>J</i> = 8.3, 3.6 Hz, 2H), 7.90 (s, 1H), 7.80 (t, <i>J</i> = 10.2 Hz, 3H), 4.05 (s, 2H).
670	LCMS (ESI) m/z: 371.2 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.23 (s, 1H), 8.48 (d, <i>J</i> = 1.8 Hz, 1H), 8.19 (d, <i>J</i> = 8.5 Hz, 1H), 7.97 (dd, <i>J</i> = 9.1, 3.4 Hz, 2H), 7.43 – 7.28 (m, 2H), 7.18 – 6.92 (m, 3H), 5.12 (s, 2H), 3.80 (s, 3H).
671	LCMS (ESI) m/z: 396.0[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.27 (s, 1H), 8.51 (s, 1H), 8.21 (d, <i>J</i> = 8.5 Hz, 1H), 7.98 (t, <i>J</i> = 8.4 Hz, 2H), 7.68 – 7.53 (m, 3H), 7.09 (d, <i>J</i> = 9.6 Hz, 1H), 5.23 (s, 2H), 3.80 (s, 3H).
672	LCMS (ESI) m/z: 357.1[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.79 (s, 1H), 8.61 (s, 1H), 8.32 (s, 1H), 8.14 (d, <i>J</i> = 8.4 Hz, 1H), 8.05 (s, 1H), 7.78 (d, <i>J</i> = 8.4 Hz, 1H), 7.05 (dd, <i>J</i> = 14.7, 8.8 Hz, 3H), 3.98 (s, 2H), 3.55 (s, 3H).
673	LCMS (ESI) m/z: 357.1[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 9.78 (s, 1H), 8.62 (s, 1H), 8.30 (s, 1H), 8.13 (d, <i>J</i> = 8.5 Hz, 1H), 8.05 (s, 1H), 7.80 – 7.71 (m, 1H), 7.36 (dd, <i>J</i> = 19.3, 8.6 Hz, 2H), 7.12– 7.04 (m, 1H), 3.95 (s, 2H), 3.55 (s, 3H).
674	LCMS (ESI) m/z: 384.0[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.31 (s, 1H), 9.15 (s, 1H), 8.98 (d, <i>J</i> = 1.2 Hz, 1H), 8.40 (d, <i>J</i> = 1.6 Hz, 1H), 8.16 (d, <i>J</i> = 8.4 Hz, 1H), 7.79-7.91 (m, 4H), 4.05 (s, 2H).
675	LCMS (ESI) m/z: 383.1 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 8.87 (d, <i>J</i> = 4.8 Hz, 1H), 8.82 (d, <i>J</i> = 5.0 Hz, 1H), 8.50 (s, 1H), 8.21 (t, <i>J</i> = 5.6 Hz, 2H), 8.10 (dd, <i>J</i> = 5.0, 1.5 Hz, 1H), 7.63 (d, <i>J</i> = 6.8 Hz, 1H), 7.54 (dd, <i>J</i> = 9.0, 3.0 Hz, 1H), 7.39 (d, <i>J</i> = 7.7 Hz, 1H), 7.27 (d, <i>J</i> = 7.6 Hz, 1H), 7.18 (d, <i>J</i> = 8.1 Hz, 1H), 2.86 (d, <i>J</i> = 4.8 Hz, 3H).
676	LCMS (ESI) m/z: 370.1 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.48 (s, 1H), 8.55 (d, <i>J</i> = 1.9 Hz, 1H), 8.32 (s, 1H), 8.07 (d, <i>J</i> = 8.5 Hz, 1H), 7.91 (s, 1H), 7.72 (dd, <i>J</i> = 8.5, 1.9 Hz, 1H), 7.05 (dd, <i>J</i> = 12.5, 4.6 Hz, 3H), 3.97 (s, 2H), 3.51 (s, 3H), 2.05 (s, 3H).
677	LCMS (ESI) m/z: 374.9[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.50 (s, 1H), 9.44 (s, 1H), 9.40 (s, 1H), 8.42 (s, 1H), 8.15 (s, 1H), 7.94 – 7.74 (m, 4H), 4.06 (s, 2H).
678	LCMS (ESI) m/z: 383.1[M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.39 (s, 1H), 8.78 (d, <i>J</i> = 4.4 Hz, 1H), 8.62 (s, 1H), 8.54 (d, <i>J</i> = 2.5 Hz, 1H), 8.51 (d, <i>J</i> = 5.1 Hz, 1H), 8.23 (d, <i>J</i> = 8.7 Hz, 1H), 7.71 (d, <i>J</i> = 7.7 Hz, 1H), 7.57 – 7.46 (m, 3H), 7.39 (dd, <i>J</i> = 14.9, 7.2 Hz, 2H), 2.82 (d, <i>J</i> = 4.4 Hz, 3H).

CMPD No.	Characterization Data	
679	LCMS (ESI) m/z: 370.1 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.46 (s, 1H), 8.55 (d, <i>J</i> = 2.2 Hz, 1H), 8.30 (s, 1H), 8.06 (d, <i>J</i> = 8.5 Hz, 1H), 7.90 (s, 1H), 7.69 (dd, <i>J</i> = 8.6, 2.1 Hz, 1H), 7.37 (dd, <i>J</i> = 10.6, 8.5 Hz, 2H), 7.12 (s, 1H), 3.94 (s, 2H), 3.51 (s, 3H), 2.05 (s, 3H).
680	LCMS (ESI) m/z: 391.0 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.17 (s, 1H), 8.33 (s, 1H), 8.09 (d, <i>J</i> = 8.5 Hz, 1H), 7.95 (d, <i>J</i> = 9.7 Hz, 1H), 7.73 (dd, <i>J</i> = 8.0, 2.0 Hz, 1H), 7.47 – 7.42 (m, 1H), 7.26 (d, <i>J</i> = 8.9 Hz, 1H), 7.08 (d, <i>J</i> = 9.7 Hz, 1H), 4.14 (s, 2H), 3.79 (s, 3H).
681	LCMS (ESI) m/z: 383.0 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 11.58 (s, 1H), 8.41 (s, 1H), 7.93 (d, <i>J</i> = 8.3 Hz, 1H), 7.80 (dd, <i>J</i> = 8.5, 2.4 Hz, 1H), 7.47 – 7.32 (m, 2H), 7.32 – 7.16 (m, 2H), 4.00 (s, 2H).
682	LCMS (ESI) m/z: 401.0 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 11.82 (s, 1H), 11.36 (s, 1H), 10.35 (s, 1H), 8.36 (d, <i>J</i> = 2.0 Hz, 1H), 7.94 (d, <i>J</i> = 8.0 Hz, 1H), 7.77 (dd, <i>J</i> = 8.0, 2.3 Hz, 1H), 7.35 – 7.30 (m, 2H), 7.28 – 7.23 (m, 2H), 3.99 (s, 2H).
683	LCMS (ESI) m/z: 341.1 [M+H] ⁺ .	¹ H NMR (400 MHz, DMSO- <i>d</i> ₆) δ 10.50 (s, 1H), 9.28 (s, 1H), 8.36 (d, <i>J</i> = 2.0 Hz, 1H), 8.04 (d, <i>J</i> = 8.5 Hz, 1H), 7.77 (dd, <i>J</i> = 8.5, 2.3 Hz, 1H), 7.05 (dd, <i>J</i> = 9.6, 4.4 Hz, 3H), 3.99 (s, 2H).

Example 240. Stearoyl-CoA desaturase (SCD) is the target of the Compounds of the Invention

A. Materials and Methods: Compound Profiling Methods

5 Strains expressing SCD1 or SCD5 as the sole desaturase, the human SCD1 and SCD5 genes were used to evaluate inhibition of SCD1/SCD5 using reduced growth as a surrogate for SCD inhibition. These yeast strains express human SCD1 or SCD5 from a plasmid harbored in a strain in which the yeast *OLE1* gene is deleted.

10 All compound profiling experiments were performed using the same basic protocol. Yeast were cultured using standard techniques in complete synthetic media lacking uracil and containing yeast nitrogen base supplemented with 2% (w/v) glucose (SD-Ura). Starter cultures were inoculated in 3 mL SD-Ura media containing 0.01% tween and 0.2 mM palmitoleic and oleic acid. Cultures were incubated overnight in a 30°C shaker incubator (225 rpm). Saturated morning cultures were centrifuged, washed in SD-Ura media lacking TWEEN-20 and fatty acids, and then diluted 1:20 in fresh SD-Ura media also
15 lacking TWEEN-20 and fatty acids. Cells were grown for 6 h to an OD₆₀₀ (optical density) of ~0.4-0.8 at 30°C with shaking.

Compound stocks (10 mM in 100% DMSO) were arrayed into 384-round well, v-bottom polypropylene plates and diluted according to indicated dilution factors. Compound administration was performed in two separate steps. First, 15 µL of SD-Ura was dispensed into clear 384-well assay plates
20 using a MULTIDROP™ Combi reagent dispenser. The diluted compound stock plates were then applied to the assay plates using an automated workstation (Perkin Elmer JANUS™) outfitted with a 384-pin tool containing slotted pins that deliver 100 nL of compound. The cultures described above were centrifuged and washed with media lacking TWEEN-20 or oleic and palmitoleic acids. Cultures were then resuspended at a 2-fold concentrated OD₆₀₀ of 0.02 (final OD₆₀₀ of 0.001) in SD-Ura. 15 µL of diluted

culture was then dispensed into the pinned assay plate to achieve 30 μ L of the 1x OD₆₀₀ culture (0.01) and a top drug concentration of 33.3 μ M.

After yeast delivery, assay plates were incubated under humidified conditions at 30 °C for 40 h. Yeast growth was monitored by reading the OD₆₀₀ of each well using a microplate reader (Perkin Elmer EnVision™). Data were analyzed as follows. Raw data were processed by background subtracting and converting values to a percent of the nontreated condition for that strain $[(\text{EXP}-0.035)/(\text{DMSO}-0.035) \times 100\%]$.

B. Results

Using the methods described above, the inhibition of SCD1 and SCD5 was tested for compounds of the invention. The results are shown in Table 3.

Table 3. Inhibition of SCD1 and SCD5 by Compounds of the Invention

Compound No.	SCD1 IC50 (μ M)	SCD5 IC50 (μ M)
1	>45.00	5.16
2	>45.00	2.65
3	0.99	0.45
4	1.73	0.58
5	3.34	1.87
6	>45.00	1.02
7	2.07	0.02
8	>45.00	4.20
9	3.04	0.56
10	9.54	0.50
11	2.74	0.08
12	1.60	0.21
13	>45.00	1.54
14	17.28	3.74
15	>45.00	0.45
16	>45.00	13.28
17	>45.00	0.77
18	8.57	1.60
19	>45.00	4.69
20	0.22	0.03
21	>45.00	1.78
22	>45.00	0.46
23	>45.00	2.49
24	10.80	0.29
25	4.03	0.53

Compound No.	SCD1 IC ₅₀ (μ M)	SCD5 IC ₅₀ (μ M)
26	>45.00	1.95
27	>45.00	0.39
28	1.95	0.02
29	11.86	0.05
30	>45.00	3.53
31	6.28	0.05
32	26.43	0.31
33	>45.00	17.98
34	>45.00	0.71
35	>45.00	0.30
36	16.89	0.38
37	10.25	0.05
38	15.66	0.89
39	>45.00	0.92
40	0.11	0.01
41	0.19	0.01
42	2.41	0.08
43	4.06	0.21
44	14.12	0.78
45	15.39	0.43
46	0.06	0.01
47	1.10	0.13
48	0.15	0.01
49	>45.00	21.22
50	1.53	0.02
51	>45.00	1.56
52	8.21	0.13
53	0.28	0.01
54	12.02	0.58
55	1.21	0.16
56	0.02	0.01
57	0.56	0.01
58	>45.00	35.65
59	0.31	0.01
60	4.38	0.65
61	7.52	0.60
62	2.34	2.06

Compound No.	SCD1 IC50 (μ M)	SCD5 IC50 (μ M)
63	0.38	0.32
64	0.56	0.06
65	1.21	0.14
66	1.44	0.01
67	0.44	0.12
68	1.65	0.26
69	>45.00	0.27
70	2.90	0.49
71	>45.00	3.91
72	4.70	0.39
73	8.08	0.17
74	0.25	0.01
75	1.49	0.01
76	0.01	0.01
77	>45.00	6.73
78	>45.00	0.64
79	5.19	0.01
80	27.88	1.57
81	>45.00	2.42
82	>45.00	0.03
83	>45.00	0.42
84	6.66	0.37
85	3.21	0.30
86	9.69	0.07
87	>45.00	0.28
88	0.65	0.02
89	0.11	0.01
90	18.02	0.62
91	0.01	0.01
92	0.11	0.02
93	0.55	0.02
94	0.03	0.01
95	>45.00	0.01
96	1.08	0.13
97	1.10	0.02
98	2.96	0.04
99	0.14	0.01

Compound No.	SCD1 IC50 (μ M)	SCD5 IC50 (μ M)
100	1.74	0.02
101	1.08	0.02
102	10.35	0.08
103	0.16	0.08
104	0.04	0.04
105	>45.00	0.83
106	>45.00	1.24
107	>45.00	1.06
108	7.61	1.40
109	0.37	0.28
110	3.94	0.22
111	0.01	0.01
112	0.01	0.01
113	0.08	0.01
114	0.05	0.01
115	>45.00	0.05
116	0.01	0.01
117	0.63	0.07
118	>45.00	0.44
119	0.01	0.01
120	>45.00	0.03
121	0.02	0.02
122	0.01	0.01
123	>45.00	8.94
124	>45.00	10.05
125	0.01	0.01
126	0.83	0.23
127	3.12	0.22
128	0.18	0.01
129	>45.00	0.05
130	>45.00	0.04
131	0.01	0.01
132	0.01	0.01
133	>45.00	0.23
134	0.09	0.01
135	14.14	0.15
136	1.26	0.49

Compound No.	SCD1 IC ₅₀ (μ M)	SCD5 IC ₅₀ (μ M)
137	0.01	0.01
138	0.55	0.08
139	4.93	0.06
140	0.29	0.01
141	>45.00	0.16
142	>45.00	0.01
143	0.51	0.37
144	0.01	0.01
145	1.71	0.10
146	0.19	0.01
147	0.31	0.04
148	0.01	0.01
149	0.23	0.01
150	0.02	0.01
151	1.34	0.08
152	>45.00	1.99
153	5.30	7.60
154	>45.00	14.64
155	24.70	7.80
156	>45.00	28.15
157	>45.00	6.65
158	10.48	6.19
159	>45.00	8.04
160	>45.00	3.07
161	>45.00	1.64
162	>45.00	1.79
163	>45.00	0.24
164	>45.00	6.22
165	14.15	3.31
166	14.73	9.36
167	25.90	0.93
168	>45.00	1.72
169	>45.00	2.48
170	>45.00	1.07
171	>45.00	0.86
172	2.29	0.37
173	1.72	0.15

Compound No.	SCD1 IC50 (μ M)	SCD5 IC50 (μ M)
174	7.56	0.08
175	>45.00	20.08
176	>45.00	2.66
177	>45.00	5.49
178	6.67	0.77
179	>45.00	1.03
180	6.02	0.91
181	>45.00	1.22
182	>45.00	13.26
183	10.67	1.41
184	>45.00	28.93
185	>45.00	8.59
186	>45.00	12.59
187	>45.00	6.51
188	4.40	0.19
189	>45.00	5.07
190	>45.00	33.00
191	>45.00	2.68
192	11.87	1.31
193	>45.00	2.29
194	>45.00	1.54
195	15.91	2.31
196	5.58	1.56
197	2.75	0.37
198	>45.00	7.18
199	>45.00	5.80
200	>45.00	0.44
201	0.59	0.19
202	0.02	0.02
203	4.24	3.72
204	>45.00	27.91
205	>45.00	29.42
206	3.36	2.51
207	0.09	0.01
208	0.13	0.05
209	1.69	2.45
210	0.38	1.31

Compound No.	SCD1 IC ₅₀ (μ M)	SCD5 IC ₅₀ (μ M)
211	14.56	2.94
212	0.15	0.04
213	0.39	0.38
214	14.54	1.75
215	1.28	4.02
216	0.01	0.02
217	3.69	2.38
218	2.73	0.36
219	1.58	1.35
220	0.66	0.52
221	>45.00	>45.00
222	7.45	2.51
223	>45.00	11.28
224	0.31	0.22
225	2.07	1.96
226	7.27	5.71
227	0.44	0.36
228	0.34	0.32
229	0.14	0.11
230	2.88	3.80
231	8.93	3.17
232	0.14	0.07
233	1.63	0.87
234	6.30	1.44
235	1.88	1.77
236	0.01	0.01
237	7.21	3.20
238	4.06	3.96
239	0.25	0.01
240	4.39	0.31
241	2.03	0.07
242	0.05	0.01
243	0.06	0.01
244	0.01	0.01
245	>45.00	>45.00
246	6.45	1.59
247	>45.00	2.02

Compound No.	SCD1 IC ₅₀ (μ M)	SCD5 IC ₅₀ (μ M)
248	0.20	0.01
249	>45.00	6.75
250	>45.00	9.75
251	>45.00	0.15
252	0.69	0.13
253	>45.00	4.75
254	>45.00	3.53
255	>45.00	4.74
256	0.75	0.04
257	>45.00	4.36
258	3.86	0.18
259	5.37	0.57
260	4.58	0.17
261	1.42	0.05
262	3.98	0.26
263	>45.00	0.17
264	>45.00	8.84
265	23.25	0.35
266	1.85	0.40
267	>45.00	10.56
268	>45.00	3.04
269	>45.00	0.03
270	>45.00	6.88
271	>45.00	14.78
272	>45.00	12.96
273	>45.00	3.25
274	>45.00	0.76
275	>45.00	3.02
276	>45.00	0.95
277	>45.00	13.40
278	39.92	2.03
279	21.48	1.96
280	0.13	0.02
281	>45.00	2.75
282	0.21	0.02
283	2.96	0.27
284	>45.00	4.52

Compound No.	SCD1 IC ₅₀ (μ M)	SCD5 IC ₅₀ (μ M)
285	9.41	1.43
286	4.00	0.24
287	0.86	0.14
288	>45.00	2.52
289	>45.00	9.20
290	0.01	0.01
291	22.53	4.91
292	2.07	0.01
293	0.08	0.04
294	>45.00	0.30
295	22.49	0.34
296	>45.00	0.86
297	>45.00	1.20
298	2.75	0.34
299	>45.00	3.79
300	>45.00	5.60
301	>45.00	5.22
302	>45.00	3.34
303	4.18	0.97
304	>45.00	2.70
305	27.05	6.94
306	3.86	2.11
307	1.17	0.57
308	22.84	3.12
309	0.54	0.05
310	0.14	0.01
311	1.02	0.01
312	1.82	0.03
313	1.86	0.02
314	0.10	0.02
315	0.01	0.01
316	0.01	0.01
317	0.98	0.10
318	0.13	0.05
319	>45.00	0.46
320	>45.00	1.58
321	0.01	0.01

Compound No.	SCD1 IC50 (μ M)	SCD5 IC50 (μ M)
322	12.65	6.07
323	10.68	0.81
324	>45.00	1.13
325	16.45	0.66
326	>45.00	4.71
327	>45.00	1.32
328	1.76	0.01
329	0.10	0.01
330	0.57	0.01
331	0.13	0.01
332	1.68	0.48
333	0.11	0.18
334	>45.00	9.39
335	15.40	0.69
336	>45.00	4.27
337	>45.00	9.87
338	>45.00	16.30
339	>45.00	17.74
340	0.09	0.12
341	>45.00	2.70
342	>45.00	20.94
343	3.14	3.42
344	>45.00	26.31
345	3.95	2.52
346	0.34	0.55
347	0.68	0.71
348	7.37	4.96
349	>45.00	32.30
350	2.60	5.42
351	>45.00	35.45
352	>45.00	35.46
353	1.94	1.36
354	6.78	0.28
355	0.54	0.16
356	0.12	0.04
357	4.06	0.05
358	6.05	0.17

Compound No.	SCD1 IC50 (μ M)	SCD5 IC50 (μ M)
359	18.66	3.27
360	32.56	6.59
361	>45.00	2.63
362	>45.00	14.53
363	3.16	0.13
364	0.71	0.02
365	25.81	4.00
366	0.02	0.02
367	25.84	2.98
368	1.37	0.24
369	>45.00	14.02
370	>45.00	6.65
371	0.12	0.01
372	>45.00	0.77
373	0.30	0.03
374	38.46	7.04
375	0.01	0.01
376	>45.00	>45.00
377	>45.00	>45.00
378	>45.00	>45.00
379	>45.00	>45.00
380	>45.00	>45.00
381	>45.00	>45.00
382	>45.00	>45.00
383	>45.00	>45.00
384	>45.00	>45.00
385	>45.00	>45.00
386	>45.00	>45.00
387	>45.00	>45.00
388	17.63	>45.00
389	>45.00	>45.00
390	>45.00	>45.00
391	1.24	>45.00
392	>45.00	>45.00
393	>45.00	>45.00
394	>45.00	>45.00
395	>45.00	>45.00

Compound No.	SCD1 IC ₅₀ (μ M)	SCD5 IC ₅₀ (μ M)
396	>45.00	>45.00
397	>45.00	>45.00
398	>45.00	>45.00
399	>45.00	>45.00
400	>45.00	>45.00
401	>45.00	>45.00
402	>45.00	>45.00
403	>45.00	>45.00
404	>45.00	>45.00
405	>45.00	>45.00
406	>45.00	>45.00
407	>45.00	>45.00
408	>45.00	>45.00
409	>45.00	>45.00
410	>45.00	>45.00
411	>45.00	>45.00
412	>45.00	>45.00
413	>45.00	>45.00
414	25.02	>45.00
415	>45.00	>45.00
416	>45.00	>45.00
417	>45.00	>45.00
418	>45.00	>45.00
419	>45.00	>45.00
420	>45.00	>45.00
421	>45.00	>45.00
422	>45.00	>45.00
423	>45.00	>45.00
424	>45.00	>45.00
425	>45.00	>45.00
426	>45.00	>45.00
427	>45.00	>45.00
428	>45.00	>45.00
429	>45.00	>45.00
430	>45.00	>45.00
431	1.07	>45.00
432	>45.00	>45.00

Compound No.	SCD1 IC ₅₀ (μ M)	SCD5 IC ₅₀ (μ M)
433	>45.00	>45.00
434	>45.00	>45.00
435	>45.00	>45.00
436	6.24	>45.00
437	>45.00	>45.00
438	>45.00	>45.00
439	>45.00	>45.00
440	>45.00	>45.00
441	>45.00	>45.00
442	>45.00	>45.00
443	>45.00	>45.00
444	>45.00	>45.00
445	>45.00	>45.00
446	>45.00	>45.00
447	>45.00	>45.00
448	>45.00	>45.00
449	>45.00	>45.00
450	>45.00	>45.00
451	1.40	>45.00
452	>45.00	>45.00
453	0.18	>45.00
454	1.93	>45.00
455	>45.00	>45.00
456	>45.00	>45.00
457	>45.00	>45.00
458	>45.00	>45.00
459	>45.00	>45.00
460	>45.00	>45.00
461	>45.00	>45.00
462	>45.00	>45.00
463	>45.00	>45.00
464	>45.00	>45.00
465	>45.00	>45.00
466	>45.00	>45.00
467	>45.00	>45.00
468	>45.00	>45.00
469	>45.00	>45.00

Compound No.	SCD1 IC50 (μ M)	SCD5 IC50 (μ M)
470	>45.00	>45.00
471	>45.00	>45.00
472	>45.00	>45.00
473	>45.00	>45.00
474	NT	NT
475	NT	NT
476	>45.00	7.6
477	>45.00	18
478	2.1	0.019
479	12	0.68
480	3.5	0.23
481	0.12	0.027
482	4.8	0.62
483	0.075	0.017
484	0.53	0.014
485	0.21	0.021
486	7.8	0.11
487	4.6	0.31
488	5.8	0.109
489	>45.00	0.544
490	>45.00	2.2
491	25	6.5
492	>45.00	5.8
493	32	0.043
494	0.01	0.01
495	0.56	0.015
496	0.222	0.01
497	0.01	0.01
498	2.7	5.2
499	10	0.82
500	>45.00	0.01
501	0.01	0.01
502	>45.00	0.01
503	0.012	0.01
504	2.8	0.26
505	NT	NT
506	1.5	0.014

Compound No.	SCD1 IC50 (μ M)	SCD5 IC50 (μ M)
507	0.98	1.2
508	2.6	0.45
509	0.43	0.12
510	0.1	0.077
511	0.143	0.19
512	0.049	0.06
513	0.77	0.17
514	2.6	0.32
515	5.9	0.32
516	0.96	0.77
517	0.18	0.14
518	>45.00	1.7
519	0.88	0.22
520	0.36	0.09
521	2.5	5.3
522	0.36	0.06
523	>45.00	0.11
524	>45.00	0.029
525	>45.00	0.55
526	0.099	0.01
527	>45.00	1.3
528	0.06	0.01
529	1.1	0.67
530	0.16	0.19
531	1.3	0.34
532	0.01	0.01
533	0.22	0.01
534	6	0.2
535	>45.00	0.48
536	1	0.11
537	17	0.49
538	1.6	0.18
539	3.5	0.17
540	0.06	0.01
541	6.6	0.22
542	18	0.01
543	0.037	0.01

Compound No.	SCD1 IC50 (μ M)	SCD5 IC50 (μ M)
544	0.01	0.96
545	0.71	0.1
546	0.32	0.027
547	0.24	0.01
548	>45.00	3
549	>45.00	0.89
550	2.4	0.37
551	>45.00	1.2
552	1.9	0.36
553	NT	NT
554	3.2	8.8
555	0.74	0.01
556	2.3	0.01
557	>45.00	1.9
558	43	0.064
559	0.01	0.01
560	0.25	0.022
561	6.7	0.2
562	1	0.01
563	1.1	0.57
564	1.4	0.062
565	2.7	0.02
566	>45.00	5.6
567	0.01	0.01
568	3.9	0.88
569	>45.00	1.2
570	10	0.43
571	0.52	0.01
572	0.017	0.01
573	>45.00	2.3
574	NT	NT
575	0.37	0.01
576	>45.00	0.4
577	23	6.4
578	>45.00	0.37
579	>45.00	0.74
580	0.019	0.01

Compound No.	SCD1 IC ₅₀ (μ M)	SCD5 IC ₅₀ (μ M)
581	0.68	0.062
582	4.3	0.28
583	NT	NT
584	>45.00	1.2
585	>45.00	0.38
586	>45.00	1.3
587	17	1.1
588	6.2	0.53
589	2.3	0.15
590	30	0.47
591	2.2	0.018
592	>45.00	0.276
593	>45.00	0.43
594	3.1	0.12
595	35	0.42
596	1.08	0.026
597	2.6	0.07
598	39	0.15
599	>45.00	0.94
600	28	1.6
601	>45.00	0.034
602	>45.00	0.066
603	0.01	0.01
604	0.037	0.042
605	0.28	0.32
606	0.61	0.17
607	>45.00	0.58
608	0.91	0.027
609	>45.00	0.284
610	3.4	0.6
611	>45.00	0.371
612	4.4	1.2
613	3.4	0.6
614	>45.00	2.5
615	>45.00	0.079
616	0.522	0.01
617	0.22	0.039

Compound No.	SCD1 IC ₅₀ (μ M)	SCD5 IC ₅₀ (μ M)
618	0.51	0.022
619	28	0.15
620	0.2	0.2
621	0.035	0.025
622	0.023	0.016
623	0.232	0.019
624	>45.00	0.054
625	4.8	0.31
626	>45.00	0.014
627	0.327	0.01
628	0.19	0.03
629	3.3	0.25
630	1.1	0.32
631	0.65	2.2
632	>45.00	0.07
633	1.8	0.27
634	>45.00	0.28
635	>45.00	0.062
636	>45.00	0.142
637	12	8.1
638	3.2	0.098
639	0.49	0.039
640	3.2	1.3
641	>45.00	0.54
642	0.092	0.01
643	0.072	0.01
644	0.042	0.01
645	1.3	0.21
646	>45.00	0.14
647	9.3	2.4
648	>45.00	0.99
649	1.4	0.48
650	0.17	0.056
651	0.09	0.024
652	1.9	0.086
653	>45.00	1.4
654	1.9	0.056

Compound No.	SCD1 IC ₅₀ (μ M)	SCD5 IC ₅₀ (μ M)
655	0.36	0.035
656	0.22	0.11
657	0.01	0.01
658	1.6	0.18
659	0.35	0.055
660	>45.00	8.9
661	0.18	0.01
662	0.3	0.18
663	>45.00	0.039
664	31	0.9
665	>45.00	0.49
666	3.6	0.29
667	>45.00	0.31
668	0.01	0.01
669	0.22	0.073
670	>45.00	1.8
671	>45.00	2
672	0.5	0.42
673	3.1	0.36
674	NT	NT
675	>45.00	12
676	0.083	0.01
677	>45.00	0.079
678	0.32	0.38
679	0.57	0.01
680	2.7	0.025
681	>45.00	2.1
682	0.1	0.2
683	8.1	3.9

"NT" indicates not tested

Other Embodiments

While the present invention has been described with reference to what are presently considered to be the preferred examples, it is to be understood that the invention is not limited to the disclosed examples. To the contrary, the invention is intended to cover various modifications and equivalent arrangements included within the spirit and scope of the appended claims.


All publications, patents and patent applications are herein incorporated by reference in their entirety to the same extent as if each individual publication, patent or patent application was specifically

and individually indicated to be incorporated by reference in its entirety. Where a term in the present application is found to be defined differently in a document incorporated herein by reference, the definition provided herein is to serve as the definition for the term.

Other embodiments are in the claims.

Claims

1. A compound, or pharmaceutically acceptable salt thereof, having the structure of any one of compounds 476-683 in Table 2.
2. A pharmaceutical composition comprising a compound, or pharmaceutically acceptable salt thereof, of claim 1, and a pharmaceutically acceptable excipient.
3. A method of treating a neurological disorder in a subject in need thereof, the method comprising administering an effective amount of a compound, or pharmaceutically acceptable salt thereof, of claim 1 or a pharmaceutical composition of claim 2.
4. A method of inhibiting toxicity in a cell related to a protein, the method comprising administering an effective amount of a compound of claim 1 or a pharmaceutical composition of claim 2.
5. The method of claim 4, wherein the toxicity is α -synuclein-related toxicity.
6. The method of claim 4, wherein the toxicity is ApoE4-related toxicity.
7. The method of any one of claims 4 to 6, wherein the cell is a mammalian neural cell.
8. A method of treating a stearyl-CoA desaturase (SCD)-associated disorder in a subject in need thereof, the method comprising administering an effective amount of a compound, or pharmaceutically acceptable salt thereof, of claim 1 or a pharmaceutical composition of claim 2.
9. The method of claim 8, wherein the SCD-associated disorder is a SCD5-associated disorder.
10. A method of inhibiting SCD5, the method comprising contacting a cell with an effective amount of a compound of claim 1 or a pharmaceutical composition of claim 2.
11. A method of inhibiting SCD1, the method comprising contacting a cell with an effective amount of a compound of claim 1 or a pharmaceutical composition of claim 2.
12. A method of treating a primary brain cancer in a subject in need thereof, the method comprising administering an effective amount of a compound having the structure of **Formula I**:







Formula I,

wherein

R¹ is optionally substituted C₁-C₆ alkyl, optionally substituted C₆-C₁₀ aryl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heteroaryl, or optionally substituted C₂-C₉ heterocyclyl;

L¹ is optionally substituted C₁-C₆ alkylene, optionally substituted C₁-C₆ heteroalkylene, optionally substituted C₂-C₆ alkenylene, optionally substituted C₂-C₆ alkynylene, optionally substituted C₃-C₆

carbocyclylene, , , , , or ;

R^a is H or optionally substituted C₁-C₆ alkyl;

L³ is optionally substituted C₂-C₉ heterocyclylene;

each of X¹, X², X³, and X⁴ is, independently, N or CH;

L² is optionally substituted C₁-C₆ alkylene or optionally substituted C₁-C₆ heteroalkylene; and

R² is optionally substituted C₁-C₆ heteroalkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₂-C₉ heterocyclyl, optionally substituted C₆-C₁₀ aryl, or optionally substituted C₂-C₉ heteroaryl,

or a pharmaceutically acceptable salt thereof.

13. The method of claim 12, wherein the compound, or pharmaceutically acceptable salt thereof, has the structure of any one of compounds 1-475 in Table 1 or any one of compounds 476-683 in Table 2.

14. The method of claim 12 or 13, wherein the primary brain cancer is a glioma.

15. The method of claim 14, wherein the glioma is an astrocytoma.

16. The method of claim 15, wherein the astrocytoma is a glioblastoma.

17. The method of any one of claims 12-16, wherein the cancer is determined or predicted to be resistant to one or more chemotherapeutic agents.

18. The method of any one of claims 12-17, wherein the cancer has failed to respond to one or more chemotherapeutic agents.

19. The method of claim 17 or 18, wherein one or more chemotherapeutic agents is selected from the group of temozolomide, carmustine, bevacizumab, lomustine, everolimus, vincristine, or procarbazine.

20. The method of claim 19, wherein one or more chemotherapeutic agents is temozolomide.

21. The method of any one of claims 12-20, wherein the subject is further administered one or more additional therapeutic interventions.

22. The method of claim 21, wherein one or more additional therapeutic interventions comprises surgery, radiation, and/or one or more additional chemotherapeutic agents.

23. The method of claim 22, wherein one or more additional therapeutic interventions is one or more chemotherapeutic agents.

24. The method of claim 23, wherein one or more chemotherapeutic agents is selected from the group of temozolomide, carmustine, bevacizumab, lomustine, everolimus, vincristine, or procarbazine.

25. The method of claim 24, wherein one or more chemotherapeutic agents is temozolomide.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 20/23913

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☒ Claims Nos.: 7, 17-25
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
--see attached extra sheet--

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-6 and 8-11

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 20/23913

A. CLASSIFICATION OF SUBJECT MATTER

IPC - C07D 261/18; C07D 413/04; C07D 413/10 (2020.01)

CPC - A61K 31/42; A61K 31/4439; A61P 35/00; C07D 261/18; C07D 413/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

See Search History document

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

See Search History document

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

See Search History document

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 2013/0317020 A1 (RUAH et al.) 28 November 2013 (28.11.2013), entire document, especially: pg 23, Table 1, formula 31.	1-6, 8-11
A	US 9,266,832 B2 (GRIFFIOEN et al.) 23 February 2016 (23.02.2016), entire document, especially: col 97-98, Table 1, Cpd 107.	1-6, 8-11
A	PubChem-CID-91412014, Create Date: 17 March 2015 (17.03.2015), pg 2, Fig.	1-6, 8-11
A, P	WO 2019/183587 A1 (YUMANITY THERAPEUTICS INC) 26 September 2019 (26.09.2019), entire document.	1-6, 8-11

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"D" document cited by the applicant in the international application

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

16 July 2020

Date of mailing of the international search report

28 JUL 2020

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-8300

Authorized officer

Lee Young

Telephone No. PCT Helpdesk: 571-272-4300

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.

PCT/US 20/23913

--BOX III - LACK OF UNITY--

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I: Claims 1-6 and 8-11, drawn to a compound, or pharmaceutically acceptable salt thereof, having the structure of any one of compounds 476-683 in Table 2.

Group II: Claims 12-16, drawn to a method of treating a primary brain cancer in a subject in need thereof, the method comprising administering an effective amount of a compound having the structure of Formula I.

Special Technical Features

The inventions listed as Groups I and II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Group I requires a compound having the structure of any one of compounds 476-683 in Table 2, which is not required by Group II.

Group II requires a method of treating a primary brain cancer with a compound having the structure of Formula I, which is not required by Group I.

Shared Common Features

The only feature shared by Groups I and II that would otherwise unify the groups is a disubstituted 6-membered aromatic ring wherein the substituents are separated by 2 positions (i.e. para-substituted). However, this shared technical feature does not represent a contribution over prior art, because the shared technical feature is anticipated by US 2013/0317020 A1 (RUAH et al.). Ruah discloses a disubstituted 6-membered aromatic ring wherein the substituents are separated by 2 positions (i.e. para-substituted) (page 21, Table 1, row 3, compound 24).

As the technical features were known in the art at the time of the invention, this cannot be considered a special technical feature that would otherwise unify the groups. Groups I and II therefore lack unity under PCT Rule 13 because they do not share a same or corresponding special technical feature.

Note reg. item 4: Claims 7 and 17-25 are unsearchable because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).